{"title": "PDF", "author": "PDF", "url": "www.incliva.es/wp-content/uploads/2023/07/Memoria-2021_.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "SCIENTIFIC REPORT 2021 Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico of Valencia INCLIVA Health Research Institute2021\nSCIENTIFIC REPORT\nAvda. Men\u00e9ndez Pelayo, 4 accesorio \u00b7 46010 Valencia (Espa\u00f1a)\nTel. 34 96 197 35 17   Fax 34 96 197 35 40\nwww.incliva. es   incliva@incliva.es\nPublished by:\nFundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de Valencia\nINCLIVA Health Research Institute\nAvd. Men\u00e9ndez Pelayo, 4 Accesorio \u2013 46010 Valencia\nDirection:\nAndr\u00e9s Cervantes Ruip\u00e9rez MD PhD, General Director\nCoordination and writing:\nScientific Management Department\nFundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de Valencia\nINCLIVA Health Research Institute\nDesign: Marta Ballester Collado\nLayout: Antonio G. Valledor1. Introduction     5\n2. INCLIVA origin and structure   9\n 2.1 History    11 \n 2.2  Organizational structure  12\n 2.3  Core facilities   17\n3. INCLIVA global analysis  19\n 3.1  Scientific production global analysis  21\n 3.2  Financial resources  24\n 3.3  Cooperative research networks  28\n 3.4  Knowledge transfer activities  29\n 3.5  Gender perspective  36\n \n4. Scientific activity   43 \n 4.1  Scientific structure  45\n 4.2  Scientific translational programs  46\n  4.2.1 Overweight and cardiovascular and renal risk  46\n  4.2.2 Detection and control of ventricular dysfunction  48\n  4.2.3 Rare Diseases  50\n  4.2.4 Neurological Decline  52\n  4.2.5 Translational Oncology  55\n  4.2.6 Reproductive Medicine  57\n  4.2.7 Ageing and associated diseases  59\n 4.3 Research areas  63\n  4.3.1 Cardiovascular Area  65\n  4.3.2 Oncology Area  96\n  4.3.3 Metabolism Area 126\n  4.3.4 Reproductive Medicine Area 177\n  4.3.5 Associated Clinical Groups 187\n 4.4 Hospital division research area 190\n 4.5  Other scientific contributions from scientific platforms 224\n  4.5.1 Biobank  224\n  4.5.2 Oncology Phase I Oncology Clinical Trials Unit 231\n  4.5.3 Innovation Platform ITEMAS 233\n  4.5.4 Spanish Clinical Research Network (SCReN), Clinical Research  \n   and Clinical Trials of the Clinical Trials Platform (UICEC INCLIVA) 235\n  4.5.5 Precission Medicine Unit 241\n  4.5.6 Bioinformatics and Biostatistics Unit 243\n5. Clinical trials and other studies 247\n 5.1 Activity of the Ethical Committee for investigation with \n  medicinal products (CEIm) 249\n 5.2 Clinical research activity performed by Valencia\n  Cl\u00ednico-Malvarrosa Health Department 251\n6. Initiatives for research promotion 257\n 6.1  Grants for external fellowships 259\n 6.2 Training and teaching activities 261\n7. Communication   263\n 7.1  Highlights   265\n 7.2  Communication Indicators 2021 267\n8. INCLIVA social initiatives 269\n 8.1  Philanthropic projects 274\n 8.2 Private philanthropic donations and acknowledgments 276\n9. Publication list.   279\nINCLIVA SCIENTIFIC REPORT 2021\nindexINCLIVA SCIENTIFIC REPORT 2021intro-\nduc-\ntion7\nINCLIVA SCIENTIFIC REPORT 2021introduction 1It is our pleasure to present this year\u2019s INCLIVA Annual Scientific Report, an appraisal of the scientific \nactivity carried out in 2021 by research groups at the Hospital Cl\u00ednico Universitario de Valencia and \nits Department of Health, as well as the groups of scientific excellence at the Faculty of Medicine and \nDentistry of the University of Valencia and the INCLIVA-affiliated IGENOMIX Foundation. The following \npages show the result of the joint effort of our professionals, which have consolidated INCLIVA as \namong the foremost health research institutes in Spain in 2021, with great international prestige and \nexceptional scientific output. The main milestones reached this year are summarized below.\nFirst and foremost, INCLIVA has obtained a five-year renewed accreditation from the Carlos III Health \nInstitute (ISCIII) as a health research institute after meeting the biomedical health research institute \naccreditation requirements and evaluation criteria set out in articles 4 and 11, respectively, of Royal \nDecree 279/2016, June 24. The members of the Evaluation Committee considered that INCLIVA \n\u201cdemonstrates consolidated governance processes and sustained progress in scientific activity and \ntranslation indicators\u201d. The board members concur that INCLIVA \u201cis a clinical and translational research \ncentre with a solid track record, on good course to adapt to the requirements of the new accreditation \nguide, especially in the areas of impact, transfer and citizen participation\u201d and highlight \u201cthe work being \ncarried out promoting leadership transition via incorporation of young researchers\u201d.\nAs a second notable milestone, INCLIVA Board of Trustees has approved the renewal of the Conselleria \nde Sanidad Universal y Salud P\u00fablica (Universal Healthcare and Public Health) agreement for research \nmanagement at the Clinical Hospital and Department of Health. The first collaboration framework \nagreement between INCLIVA and the Ministry of Health establishing the rules of collaboration between the \nentities to support, promote, manage and facilitate research activity at the Clinical Hospital Department \nof Health was formalized in November 2000. New agreements have subsequently been signed, the \nlatest in 2013 which was extended in 2017 until 2021. In light of the success of this collaboration, both \nentities have signed a new framework agreement.\nThroughout its history, INCLIVA has been committed to quality of life in people with rare diseases; \nindeed, we are the first Health Research Institute in Spain to create a rare diseases research area, and \nhave promoted the creation of the Alliance for Translational Research in Rare Diseases, an initiative \nawarded by the Spanish Federation of Rare Diseases (FEDER). This firm commitment to rare diseases \nresearch has led to the incorporation of FEDER to the INCLIVA Board of Trustees to intensify its line \nof transversal research into these pathologies. This addition also strengthens INCLIVA\u2019s competitive \nadvantage in terms of links with civil society and patients, due to the translational nature of our research.\nRegarding scientific output, our research staff published 834 articles in 2021, with a cumulative \nimpact factor of over 6,000 points. The quality of our scientific output should also be highlighted: around \n80% of published articles are in the first and second quartiles, 20% in the first decile and 21% with an \nimpact factor higher than 7. In addition, 46% of scientific output has involved international collaboration. \nA total of 65 doctoral theses were defended in 2021, 12 of them with European mention.INCLIVA SCIENTIFIC REPORT 20218\nintroduction1INCLIVA continues to consolidate its reputation for high quality, competitive projects, confirming the \nupward trajectory of recent years by obtaining nearly five million euros in funding for 20 new national \nand regional projects.\nOur researchers have also achieved great success in European Commission competitive calls for \nproposals, obtaining nearly 6.4 million euros in accumulated funds for projects in the areas of oncology, \nwomen\u2019s health, microbiology, big data and artificial intelligence, personalized medicine, aging and \nfragility. In other standout activity, we have participated in international networks such as the Big Data \nValue Association (BDVA/DAIRO), the European infrastructure for translational medicine (EATRIS), the \nEuropean high-capacity screening network (EU-OPENSCREEN) and Worldwide innovative networking \n(WIN) in personalized cancer medicine.\nTurning to calls for staff funded by the Carlos III Health Institute, in total, Incliva staff were awarded two \nJoan Rod\u00e9s grants, two R\u00edo Hortega grants, a new Miguel Servet grant, the confirmation of a Miguel \nServet type II grants, and two predoctoral grants in health research. In addition, two national predoctoral \ngrants were obtained (Ministry of Science, Innovation and Universities and Ministry of Universities). \nLikewise, ten grants were awarded from the Department of Innovation, Universities, Science and Digital \nSociety of the Autonomous Public Health Department, and two grants from the Valencian Innovation \nAgency.\nAnother key achievement in 2021 has been formal recognition of a new emerging group working within \nthe priority research lines of cardiovascular, metabolism and organ damage and reproductive medicine.\nRegarding clinical trials, our Drug Research Ethics Committee (CEIm) at the Hospital Cl\u00ednico Universitario \nde Valencia, the first to receive this certification in the Valencian Community and among the first at \na national level, has been a reference committee in 70 of 84 studies since the new legislation was \napproved in 2016, and throughout 2021 it has started 206 of 269 new clinical studies, and is involved \nin 579 of a total of 596 active studies this year.\nIn December 2021, the INCLIVA Innovation Unit (UAI) obtained renewed certification to the \nUNE166002 standard. Another of the Unit\u2019s successes this year has been two newly licensed patents: \n\u201cMaxillo-mandibular prosthesis and manufacturing method\u201d (number ES2525506) in July, and \u201cMass \nspectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from \nsepsis or septic shock (ss) patients\u201d (number EP16382509) in September. In addition, the Ag\u00e8ncia \nValenciana de la Innovaci\u00f3 has approved two innovation agents for the INCLIVA Innovation Unit.\n \nFinally, the institute\u2019s quality and excellence strategy this year has resulted in an important milestone \nfor the Quality and Data Protection Unit, which obtained the certificate of compliance with the \nISO:9001:2015 quality standard for technical and scientific research support services (bioinformatics, \nbiostatistics and high-efficiency liquid chromatography).origin\n&\nstruc-\nture\nINCLIVA SCIENTIFIC REPORT 20212. INCLIVA origin and structure    \n 2.1 History      \n 2.2 Organizational structure     \n  2.2.1. Government structure\n   2.2.1.1 Board of Trustees\n   2.2.1.2 Board of Governors\n   2.2.1.3 General and Scientific Director\n   2.2.1.4 External Scientific Committee\n   2.2.1.5 Internal Scientific Committee\n             Research Commission\n             Innovation Commission \n   2.2.1.6 Ethics Committee for Investigation\n        with Medicinal Products\n  2.2.2. Management structure\n 2.3 Core facilities11\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure 22.1. History\nThe Hospital Cl\u00ednico Universitario of Valencia Research Foundation was constituted in the year 2000 as the first Valencian research \nfoundation affiliated to a public hospital. Ten years later, various centers of excellence in biomedical research from the University of \nValencia and IGENOMIX joined the Foundation through the establishment of specific agreements, and thus INCLIVA Health Research \nInstitute was created.\nINCLIVA\u2019s main aims are to manage the biomedical research carried out by the Hospital Cl\u00ednico Universitario de Valencia and its \nHealth Department, and to encourage teaching and scientific activities, thus improving patient treatment and knowledge sharing.\nIn 2011 INCLIVA was accredited as a Health Research Institute by the Ministry of Science and Innovation thus obtaining preferential \ntreatment from the Carlos III Health Institute, in recognition of its excellence in research.\nDuring 2021 INCLIVA received the official notification of renewal of its accreditation as Health Research Institute for the next five \nyears.\n12\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure22.2. Organizational structure\n2.2.1. Government structure\nThe highest government body in the Foundation, the Board of Trustees is headed by the Regional Minister for Health of the Valencian \nGovernment. This body appoints a Board of Governors \u2013 headed by the Chief Executive Officer of the Health Department \u2013 the General Di-\nrector, the Scientific Director and the Financial Director. These are guided by two Research Committees: the External Scientific Committee \nand the Internal Scientific Committee.\n2.2.1.1 Board of Trustees\nPresident, Ms. Ana Barcel\u00f3 Chico, Regional Minister for Health of \nthe Valencian Government\nVice-president, Mr. \u00c1lvaro Bonet, Chief Executive Officer of the \nHospital Cl\u00ednico Universitario of Valencia and of the Valencia Cl\u00edni-\nco \u2013 Malvarrosa Health Department\nBoard members\n\u2022 Mrs. Mar\u00eda Vicenta Mestre, Distinguished Dean of the University \nof Valencia\n\u2022 Mrs. Concha Andr\u00e9s Sanchis, Autonomous Secretary of Efficien-\ncy and Health Technology of the Conselleria de Sanidad Universal \ny Salud P\u00fablica (Autonomous Public Health Department) of the \nValencian Government\n\u2022 Mr. Javier Burgos Mu\u00f1oz, General Director of Research and \nHigh Sanitary Inspection of the Conselleria de Sanidad Universal \ny Salud P\u00fablica (Autonomous Public Health Department) of the \nValencian Government\n\u2022 Mrs. Emilia Ad\u00e1n Garc\u00eda. President of the Social Council of the \nUniversity of Valencia\n\u2022 Mr. Carlos Sim\u00f3n, Scientific Director of the IGENOMIX Founda-\ntion \n\u2022 Mr. Francisco Javier Chorro, Distinguished Dean of the Faculty of \nMedicine of the University of Valencia\u2022 Mr. Jos\u00e9 Bernardo Noblejas P\u00e9rez, Valencia Chamber of Com -\nmerce\n\u2022 Mrs. Mar\u00eda \u00c1ngela Nieto Toledano, Instituto de Neurociencias \nde Alicante CSIC\n\u2022 Mr. Rafael Alc\u00f3n Traver, President of Bancaja Foundation\n\u2022 Mr. Joaqu\u00edn Santo, Valencian Council of Culture \n\u2022 Mr. Juan L\u00f3pez-Trigo Pich\u00f3, Ca\u00f1ada Blanch Foundation \n\u2022 Mr. Andr\u00e9s Cervantes Ruip\u00e9rez, INCLIVA General Director\n\u2022 Mr. Rub\u00e9n Ventura, Fero Foundation\n\u2022 Mrs. B\u00e1rbara Congost Mir\u00f3n, FEDER representative, Federaci\u00f3n \nEspa\u00f1ola de Enfermedades Raras\nBoard members under own name\n\u2022 Mr. Carlos Pascual\n\u2022 Mr. Joaqu\u00edn Ortega Serrano\n\u2022 Mrs. Ana Lluch Hern\u00e1ndez\n\u2022 Mr. Tom\u00e1s Tr\u00e9nor Puig\n\u2022 Mr. Manuel Delgado Rodr\u00edguez, Board of Trustees Secretary\n2.2.1.2 Board of Governors\n\u2022 Mr. \u00c1lvaro Bonet Pla, Chief Executive Officer of the Hospital Cl\u00edni-\nco Universitario of Valencia and of the Valencia Cl\u00ednico \u2013 Malvar -\nrosa Health Department\n\u2022 Mr. Francisco Javier Chorro, Distinguished Dean of the Faculty of \nMedicine of University of Valencia\u2022 Mr. Andr\u00e9s Cervantes Ruip\u00e9rez, INCLIVA General Director\n\u2022 Mr. Vicente de Juan Mart\u00edn, Financial-Administrative Director\n\u2022 Mrs. Ana Sanmart\u00edn Almenar, Primary Care Director of the Hos -\npital Cl\u00ednico Universitario of Valencia and of the Valencia Cl\u00ednico \n\u2013 Malvarrosa Health Department 13\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure 2\u2022 Mr. Jorge Navarro P\u00e9rez, Medical Director of the Hospital Cl\u00edni-\nco Universitario of Valencia and of the Valencia Cl\u00ednico \u2013 Malvar -\nrosa Health Department \n\u2022 Mr. Javier Burgos Mu\u00f1oz, General Director of Research and \nHigh Sanitary Inspection of the Conselleria de Sanidad Universal \ny Salud P\u00fablica (Autonomous Public Health Department) of the \nValencian Government\n\u2022 Mr. Pascual Medina Bes\u00f3, Coordinator of Central Medical Re-\nsearch Unit of the Faculty of Medicine of University of Valencia\n2.2.1.3 General and Scientific Director\nProfessor Andr\u00e9s Cervantes Ruip\u00e9rez is Full Professor of Medicine at the University of Valencia, Head of the Oncology Service of the \nHospital Cl\u00ednico Universitario of Valencia and Director of the Cancer Area at the INCLIVA Health Research Institute.\nHis training as a resident medical intern took place at the Hospital Cl\u00ednico Universitario of Valencia. After completing this residency, he ob-\ntained a predoctoral fellowship at the Free University Hospital in Amsterdam, where he obtained his Doctorate in the laboratory of cellular \npharmacology, with work on multidrug resistance.\nHis areas of interest and research are gastrointestinal and gynecological cancer, as well as phase I trials and new drugs development.\nAs a clinical researcher in rectal cancer, he has published several papers on the quality of multidisciplinary work as well as on evaluating \nthe quality of mesorectal surgery, how to optimize initial therapy choices and especially, how to treat cancer of the upper third of the rectum.\nHe is the President of the European Society of Medical Oncology (ESMO) since July 2019. \u2022 Mr. Manuel Al\u00f3s, Head of the Pharmacy Service of Hospital Cl\u00ednico \nUniversitario of Valencia and of the Valencia Cl\u00ednico \u2013 Malvarrosa \nHealth Department\n\u2022 Mrs. Marina Soro, President of Ethic Committee for Investigation \nwith medicinal products \n\u2022 Mr. Federico Pallard\u00f3, Professor of the Department of Physiology \nof the University of Valencia\n\u2022 Mr. Carlos Sim\u00f3n, IGENOMIX Foundation\n\u2022 Mrs. Maite S\u00e1enz, Secretary General\n2.2.1.4 External Scientific Committee\n\u2022 Mr. Javier D\u00edez. Professor of Medicine, University of Navarra. \nDirector of the Cardiovascular Sciences Area, Center for Applied \nMedical Research (CIMA). University of Navarra\n\u2022 Mr. Antonio Vidal-Puig. Professor of Molecular Nutrition and \nMetabolism, University of Cambridge. Honorary consultant \nin metabolic medicine. Metabolic research laboratories. \nAddenbrooke\u00b4s Hospital, Cambridge, United Kingdom\n\u2022 Mr. Josep Tabernero. Head of the Medical Oncology Service. Vall \nd\u2019Hebr\u00f3n Hospital.\n\u2022 Mr. Juan Carlos Lacal Sanju\u00e1n. Research Professor at the CSIC. \nInstitute of Biomedical Research, Madrid\u2022 Mr. Manuel Tena Sempere. Professor of University. Department \nof Cell Biology, Physiology and Immunology. University of Cordoba\n\u2022 Mr. M Roser Torra Balcells. Nephrologist, Fundaci\u00f3 Puigvert. \nResearch line in the study of Hereditary Kidney Diseases \n\u2022 Mrs. Laura Saucek. Group leader at VHIO (Oncology Institute \nof the Vall d\u2019Hebron Hospital). Head of Modeling of Anti-\ntumor Therapies in mice. Founder executive director (CEO) at \nPeptomycs SL 14\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure22.2.1.5 Internal Scientific Committee \n\u2022 Mr. Andr\u00e9s Cervantes Ruip\u00e9rez, INCLIVA General Director\n\u2022 Mrs. Ana Sanmart\u00edn Almenar, Primary Care Director of the \nHospital Cl\u00ednico Universitario of Valencia and of the Valencia \nCl\u00ednico \u2013 Malvarrosa Health Department \n\u2022 Mr. Jorge Navarro P\u00e9rez, Medical Director of Hospital Cl\u00ednico \nUniversitario of Valencia and of the Valencia Cl\u00ednico \u2013 Malvarrosa \nHealth Department \n\u2022 Mr. Julio N\u00fa\u00f1ez, Associate Professor of the Department of \nMedicine of the University of Valencia, attached to the Scientific \nDirection\n\u2022 Mr. Vicente Bod\u00ed, Full Professor of the Department of Medicine \nof the University of Valencia\n\u2022 Mr. Josep Red\u00f3n, INCLIVA Emeritus Researcher \n\u2022 Mr. Federico Pallard\u00f3, Full Professor of the Department of \nPhysiology of the University of Valencia\n\u2022 Mrs. Mar\u00eda Jes\u00fas Sanz Ferrando, Full Professor of the \nDepartment of Pharmacology at the University of Valencia\n\u2022 Mrs. Ana Lluch Hern\u00e1ndez, Emeritus Professor of the \nDepartment of Medicine of the University of Valencia\n\u2022 Mrs. Mar\u00eda del Mar Tormo Garc\u00eda, Oncologist at the Hospital \nCl\u00ednico Universitario of Valencia and of the Valencia Cl\u00ednico \u2013 \nMalvarrosa Health Department Hematology Service\nRESEARCH COMMISSION\nPresident:  Mr. Luis Sabater Ort\u00ed, Section Head of the General \nSurgery \nVicepresident: Mr. Julio N\u00fa\u00f1ez Villota, Cardiology Associate Physician\nVocals: \n\u2022 Mrs. Marta Peir\u00f3 Signes, Scientific Subdirector at INCLIVA\n\u2022 Mr. Jaime Signes-Costa, Neumology Service Head\n\u2022 Mrs. Rosa Zaragoz\u00e1 Colom, researcher at INCLIVA\n\u2022 Mr. Vicente Jos\u00e9 Bod\u00ed Peris, Professor of the Department of \nMedicine of the University of Valencia\n\u2022 Mrs. M\u00aa Jos\u00e9 Terol Castera, Hematology and Hemotherapy \nAssociated Physician\n\u2022 Mrs. Gema Mi\u00f1ana Escriv\u00e1, Cardiology Associate Physician\u2022 Mr. Felipe Vilella Mitjana, researcher at INCLIVA\n\u2022 Mrs. Isabel Gabald\u00f3n S\u00e1nchez, Valencia Cl\u00ednico - Malvarrosa \nHealth Department \n\u2022 Mr. David Moro Valdezate, General Sugery Associate Physician\n\u2022 Mrs. Mar\u00eda del Mar Tormo D\u00edaz, Hematology and Hemotherapy \nAssociated Physician\n\u2022 Mrs. Laura Piqueras Ruiz, researcher at INCLIVA\n\u2022 Mrs. Patricia Rosell\u00f3, Pediatrics Associated Physician\n\u2022 Mr. Sergio Mart\u00ednez Herv\u00e1s, Endocrinology and Nutrition \nAssociated Physician\n\u2022 Mrs. Herminia Gonz\u00e1lez Navarro, researcher at INCLIVA\n\u2022 Mrs. Pilar Eroles Asensio, researcher at INCLIVA\n\u2022 Mrs. M\u00aa Cruz Gonz\u00e1lez Villaescusa, Neumology Associate \nPhysician\n\u2022 Mrs. Carmina Montoliu F\u00e9lix, researcher at INCLIVA\n\u2022 Mr. Jos\u00e9 Real Collado, Head of the Endocrinology and Nutrition \nService\n\u2022 Mr. Ra\u00fal G\u00f3mez Gallego, researcher at INCLIVA\n\u2022 Mr. F. Javier Chaves Mart\u00ednez, researcher at INCLIVA\n\u2022 Mr. Daniel Monle\u00f3n Salvad\u00f3, researcher at INCLIVA\n\u2022 Mrs. Desamparados Roda P\u00e9rez, Oncology Associate Physician\n\u2022 Mr. Carlos Tornero Tornero, Head of the Anesthesia/\nReanimation Service\n\u2022 Mrs. Nuria Cabedo Escrig, researcher at INCLIVA\n\u2022 Mrs. Pilar Rentero Garrido, coordinator of Precission Medicine \nUnit\n\u2022 Mrs. Ana Bel\u00e9n Paes, researcher at INCLIVA  \n\u2022 Mr. Jos\u00e9 Luis G\u00f3rriz Teruel, Head of the Nephrology Service \n\u2022 Mr. Antonio Mart\u00ednez Sabater, general supervisor at the Hospital \nCl\u00ednico Universitario de Valencia\n\u2022 Mr. C\u00e9sar R\u00edos Navarro, researcher at INCLIVA  \n\u2022 Mrs. Lorena Peir\u00f3 Chova, researcher at Biobank\nCommission Management Unit : Mrs. Sof\u00eda Galant15\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure 2INNOVATION COMMISSION\nPresident:  Andr\u00e9s Cervantes Ruip\u00e9rez, INCLIVA General Director\nCommission Management: Mrs. Marta del Olmo Zurriaga, Head of UAI\n\u2022 Mr. Vicente de Juan Mart\u00edn, Financial-Administrative Director\n\u2022 Mr. Jorge Navarro P\u00e9rez, Medical Director of Hospital Cl\u00ednico \nUniversitario de Valencia and of the Valencia Cl\u00ednico \u2013 Malvarrosa \nHealth Department\n\u2022 Mrs. Marta Peir\u00f3 Signes, Scientific Subdirector at INCLIVA\n\u2022 Mrs. Maite S\u00e1enz Gonz\u00e1lez, Secretary General at INCLIVA\n\u2022 Mr. Josep Red\u00f3n, INCLIVA Emeritus Researcher \n\u2022 Mr. Enrique Rodr\u00edguez Borja, Clinical researcher with experience \nin the field of innovation\u2022 Mr. Miguel Puche Torres, Clinical researcher with experience in \nthe field of innovation\n\u2022 Mr. Federico Pallard\u00f3 Calatayud, Basic researcher with \nexperience in the field of innovation\n\u2022 Mr. Rub\u00e9n Artero Allepuz, Basic researcher with experience in \nthe field of innovation\n\u2022 Mrs. Consuelo Borr\u00e1s Blasco, Basic researcher with experience \nin the field of innovation\n\u2022 Mr. Felip Vilella Mitjana, Basic researcher with experience in the \nfield of innovation\n\u2022 Mrs. Carolina Mir S\u00e1nchez, Clinical researcher with experience \nin the field of innovation\n\u2022 Mrs. Maite S\u00e1nchez, Clinical researcher with experience in the \nfield of innovation\n2.2.1.6. Ethics Committee for Investigation with Medicinal Products\nPresident : Mrs. Marina Soro Domingo, Head of Section of the \nAnesthesiology and Reanimation Unit\nVice-president: Mr. Esteban Morcillo S\u00e1nchez, Clinical pharma-\ncologist   \nTechnical Secretary: Mr. Julio Palmero Da Cruz, Head of Radio-\ndiagnosis Service\nMembers:\n\u2022 Mr. Manuel Al\u00f3s Almi\u00f1ana, Head of the Pharmacy Department\n\u2022 Mr. Diego V. Cano Blanquer, Hospital Pharmacist\n\u2022 Mr. Jos\u00e9 Luis Trillo Mata, Primary Care Pharmacist\n\u2022 Mrs. M\u00aa Jos\u00e9 Tar\u00edn Blasco, Law Degree \n\u2022 Mr. David Juan L\u00f3pez Ortega, Law Degree \n\u2022 Mrs. Carmen Celda Ortega, Nurse\n\u2022 Mr. Luis Gonz\u00e1lez Luj\u00e1n, Primary Attention doctor\n\u2022 Mr. Joaqu\u00edn Ortega Serrano, Head of the General Surgery Ser-\nvice\n\u2022 Mrs. Patricia Rosell\u00f3 Millet, Specialist of the Pediatrics Depart -\nment\n\u2022 Mr. Ricardo Ruiz Granell, Head of Section of Cardiostimulation of \nCardiology Department\u2022 Mrs. M\u00aa Jes\u00fas Puchades Montesa, Specialist of the Nephrology \nDepartment\n\u2022 Mr. Jos\u00e9 Alejandro P\u00e9rez Fidalgo, Specialist of the Oncology De -\npartment\n\u2022 Mrs. Tania Fleitas Kanonnikoff, Specialist of the Oncology Depart -\nment\n\u2022 Mrs. M\u00aa Luisa Calabuig Mu\u00f1oz, Specialist of the Hematology De -\npartment\n\u2022 Mr. Antonio Pel\u00e1ez Hern\u00e1ndez, Allergy Specialist\n\u2022 Mr. Francisco Das\u00ed Fern\u00e1ndez, Stabilized Miguel Servet Re-\nsearcher \n\u2022 Mr. Luis Miguel Bayo Calaforra, \u201cAmics de la Gent Major\u201d Foun-\ndation\n\u2022 Mr. Rafael Barajas Cenobio, Responsible for Quality and Data \nProtection INCLIVA\nAdministrative Secretary: Mrs. Sof\u00eda Galant,  \nMr. Carlos Ballesteros\nAdministrative: Mrs. Maialen Llopis 16\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure22.2.2. Management structure\nProjects Management\nTraining Event sClinical Trial\nCEIM Technical SecretaryHuman Resources and\nEqualit y\nBillin g\nGeneral Service sRecruitmentAdmission, Archives andCommission\nAreas and \nResearch Groups for Research Suppor t\nResearch Areas\nResearch Groups\nEmerging researcher sBiobank\nGeneral Secretar y\nSupport Unit s Management Are a Research Are aGeneral Directo rBOARD OF GOVERNORSBOARD OF TRUSTEES\nsCentral Medical\nResearch Unit\nCommunication Unit\nComputing UnitQuality and Data Protection UnitScientific Sub-directorate Economical Sub-directorateThe organizational chart, approved at the Board of Trustees, is comprised of two sub-directorates, economical and scientific.\nThe first sub-directorate is in charge of the administrative area, which deals with the financial and administrative matters as well as with \nhuman resource management.\nThe second is in the charge of scientific activity management and innovation. It is responsible for integral scientific management that \nincludes controlling and monitoring clinical trials and research projects, organizing courses, conferences and seminars, and several tasks \nrelated to general administration. Furthermore, it acts as an administrative support to the different affiliated scientific committees and to \nthe Medical Research Central Unit. It comprises the innovation area in charge of quality and planning, innovation management, international \nprograms and scientific and innovative culture promotion (UCCI).\nAdvisory structureGovernment  structureCommission\nPrecission Medici ne17\nINCLIVA SCIENTIFIC REPORT 2021INCLIVA origin and structure 22.3. Core facilities\nINCLIVA PLATFORMS \n\u2022 Biobank\n\u2022 Bioinformatics Unit\n\u2022 Precission Medicine Unit\n\u2022 Cytogenetics LaboratoryRESEARCH SUPPORT PLATFORMS\n\u2022 Cell Culture Unit\n\u2022 Flow Cytometric Unit\n\u2022 Multigenic Analysis Unit\n\u2022 Confocal Microscopy Unit\n\u2022 Sequenom Platform\n\u2022 Laboratory of Molecular Imaging and Metabolomics\n\u2022 Animal Housing and Experimental Operating Theaters Unit\n\u2022 Proteomics Unit \n\u2022 Small Animals PET/CT Camera and Laboratory for Radioactive \nIsotopes\n\u2022 Personal Autonomy, Dependence and Severe Mental Disorders \nAssessment UnitADMINISTRATIVE AREA: \n\u2022 Financial Director: Vicente de Juan\n\u2022 Budget Control and Economic Management: Consuelo L\u00f3pez\n\u2022 Human Resources and Equality Unit: Ruth Cano, Anabel Gil, \nLuc\u00eda Toledo\n\u2022 Invoicing and Project Justify: Vera Mar\u00edn, Karen Iglesias, M\u00aa \nPilar Boix\n\u2022 Accounting: M\u00aa Jos\u00e9 Rosal\u00e9n\n\u2022 Records Unit: Alicia Belenguer\n\u2022 Purchasing Unit: Isabel Gomis\n\u2022 General Services Unit: Cristina Garc\u00eda\n\u2022 Receptionists: Inmaculada Montalt, Alicia Gumiel\nSCIENTIFIC MANAGEMENT AREA:\n\u2022 Scientific Subdirector and Project Management: Marta Peir\u00f3\n\u2022 Scientific Culture Unit: Mercedes Navarro\n\u2022 International projects Unit: Ana Ferrer, Ana Duarte, Eugenia \nFlores\n\u2022 Innovation Management Unit: Marta de Olmo, Carlos Guerre-\nro\n\u2022 Clinical Trials Management Unit: Dolores Iglesias, Laura Silla\u2022 Clinical Trials Platform: Dolores Iglesias, Ana Portol\u00e9s, Merce-\ndes Peris, Mireya Ferrandis, Carlos Peris\n\u2022 Training and Events Unit: Cristina Garc\u00eda, Mercedes Navarro, \nClara Soriano\n\u2022 CEIm Administrative Management: Sof\u00eda Galant, Maialen Llo-\npis, Carlos Ballesteros\n\u2022 Data Quality and Protection: Rafael Barajas, Mar\u00eda Dom\u00ednguez\n\u2022 Scientific Production Unit: Patricia Ma\u00f1as\n\u2022 Communication: Alexandra Mu\u00f1oz\nCOMPUTING UNIT:\n\u2022 Head of Information Systems and High Performance Compu-\nting: Miguel Herreros\n\u2022 IT system administrator and programmer: Enrique Herreras\n\u2022 Computer technician: Joan Josep Bruno Ram\u00edrez\nSECRETARY GENERAL\n\u2022 Head: Maite Saenz\n\u2022 Technician: Lorena Munueraglobal\nanaly-\nsis\nINCLIVA SCIENTIFIC REPORT 20213. Global analysis\n 3.1 Scientific production global analysis     \n 3.2 Financial resources\n 3.3 Cooperative research networks\n 3.4 Knowledge transfer activities\n  3.4.1 Knowledge transfer to the National Health System \n  3.4.2. Innovation and Knowledge transfer\n   3.4.2.1 Intellectual Assets\n   3.4.2.2 Competitive innovation\n   3.4.2.3 Entrepreneurship\n 3.5 Gender perspective\n 21\nINCLIVA SCIENTIFIC REPORT 2021global analysis 33.1 Scientific production global analysis\nAs in previous years, INCLIVA continued in 2021 with the upward trend \nin the quality of scientific production. The number of publications this year \nis 834, with a cumulative impact factor of 6.028,392 which translates \ninto an average impact factor 7,228.\nThe following figures depict the number and quality of the published ma -\nnuscripts expressed in terms of total and average impact factor.\nPublications indexed\nCumulative impact factor858834\n584\n550596\n2020 2021 2 017 2018 2019\n53566028\n36193861\n3454\n2020 2021 2 017 2018 2019834\n6.028,392\n7,228\n178\n171Publications\nCumulative\nImpact Factor\nAverage\nImpact Factor\nPublications\nwith IF >7\nFirst decline\npublications22\nINCLIVA SCIENTIFIC REPORT 2021global analysis39%\n12%\n20%59%Q1\nQ2\nQ3\nQ4The distribution by quartiles within their thematic categories is shown below. In 2021, about 80% of the papers that were published in in-\ndexed journals belong to the first and second quartiles of their corresponding thematic categories:\nQuartile distribution\nOriginal articles Q1 Original articles D1The number and percentage of scientific publications according to category are:\nCategory Value\nArticles 691\nCase reports 7\nCorrections 7\nEditorials 43\nLetters 39\nReviews 54\nCardiovascular            Oncology            Metabolism            Reproductive            Hospital divisions1%1%5%5%6%\nThe percentage of originals in first decile and first quartile publications in 2021 are:\n21%\n23%\n35%5%16%82%\n20%\n24%\n34%6%16%23\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3Another key performance indicator is the leadership role in scientific publications. The chart below shows the number of published \narticles in which INCLIVA researchers sign as corresponding author, first and last author.One of the main success factors for a biomedical research institution has to do with its potential to establish high level scientific \ncollaborations. The percentage of national and international collaborations which led to scientific output in 2021 is listed below.\nCollaborations\nLeadership in scientific production15%\n46%\n39%\n276328400\n300\n200\n100\n0\nCorrespondig author First author Last authorNational collaborations\nInternational collaborations\nOnly INCLIVA GROUPS\n33524\nINCLIVA SCIENTIFIC REPORT 2021global analysis302.000.0004.000.0006.000.0008.000.00010.000.00012.000.00014.000.00016.000.0003.2. Financial resources\nINCLIVA\u2019s funding during 2021 totaled \u20ac14.930.802. The funds raised from competitive sources were still higher than the average of \nrecent years.\nFunding source in the indicated period is shown below.\nThe remaining income corresponds to private sources of funding, clinical trial revenues and grants among others. The graph below shows \nthis distribution of the year 2021.14.930.802\n7.101.402\n7.685.5928.268.804\n9.832.90810.006.078\n10.447.574\n2014        2015        2016        2017       2018        2019        2020        202113.869.796\n45% 6.769.731\n53%2021\n7.869.3322% 277.479 0% 14.25902.285.7144.571.4296.857.1439.142.85711.428.57113.714.28616.000.000\n2014 2015 2016 2017 2018 2019 2020 202114.259\n8589\n4310\n551826.385\n37.747\n52.566\n51.511277.479\n289.884\n386.438\n488.777465.322\n531.233\n555.051\n432.6747.869.332\n6.852.035\n5.578.227\n5.138.1214.856.751\n4.456.763\n4.203.612\n3.260.752 6.769.731 6.719.289\n4.478.600 4.373.662 4.484.450\n3.243.061\n2.874.3633.356.465\nPrivate Contracts Grants Donations Other Incom e25\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3The analysis of the income obtained by the Foundation in its last fiscal year (2021) is shown in the table.\nINCOME AMOUNT OVERHEADS TOTAL\nTURNOVER 5.599.768,99 1.169.961,81 6.769.730,80\nDONATIONS 232.963,98 44.515,41 277.479,39\nGRANTS 6.027.004,40 605.345,44 6.632.349,84\nCAPITAL GRANTS 1.236.982,27 1.236.982,27\nFINANCIAL 48,56 48,56\nEXTRAORDINARY 14.210,84 14.210,84\nTOTAL INCOME 13.110.979,04 1.819.822,66 14.930.801,70\nAlso used as a source of information the Annual Accounts of 2021 approved by the Board of Trustees of the Foundation and audited by \nthe General Intervention of the Generalitat Valenciana (through the audit firm Fides Auditores) the information of the expenses executed is \nprovided, with the explanation of the use of the corresponding indirect costs.\nEXPENSES TOTAL\nCASH FUNDING 92.334,78\nSUPPLIES 1.747.409,47\nOTHER FUNCIONAL EXPENSES (ACTIVITY) 2.118.040,25\nSTAFF COSTS 6.506.567,54\nOTHER FUNCIONAL EXPENSES (STRUCTURAL) 389.718,04\nEXTRAORDINARY EXPENSES 27.927,92\nINVENTORY ITEM DONATION EXPENSES 54.454,56\nAMORTIZATION OF FIXED ASSETS 1.452.750,11\nTOTAL EXPENSES 12.389.202,6726\nINCLIVA SCIENTIFIC REPORT 2021global analysis3Finally, this is the balance sheet of the foundation in official format, extracted from the Annual Accounts of 2021:\nASSETSFISCAL YEAR FISCAL YEAR\n2021 2020\nA) NON-CURRENT ASSETS 16.571.327,92 16.160.931,24\nI. Intangible assets 2.453.753,52 2.561.187,29\n2. Concessions 2.443.818,38 2.534.050,18\n3. Patents, licences, trademarks and similar rights 6.057,50 6.485,80\n5. Computer Software 3.877,64 20.651,31\nIII. Investment property 6.946.953,82 7.742.393,94\n2. Technical facilities and other tangible fixed assets 6.946.953,82. 7.742.393,94\nVI. Deferred tax assets 7.170.620,58 5.857.350,01\n1. Other government loans 4.242.885,23 3.088.778,55\n2. Other loans from private entities 786.533,37 741.115,03\n3. Other European Union loans 2.141.201,98 2.027.456,43\nB) CURRENT ASSETS 26.406.646,77 22.201.492,96\nIII. Trade and other receivables 5.341.276,58 5.267.161,86\nIV. Current Investments in group companies and associates 7.121.236,16 9.349.331,29\n6. Other government loans  7.121.236,16 9.349.331,29\nVI. Prepayments for current assets 2.416,00 2.416,00\n5. Other financial assets 2.416,00 2.416,00\nVIII. Cash and cash equivalents 13.941.718,03 7.582.583,81\n1. Cash 13.941.718,03 7.582.583,81\n TOTAL ASSETS (A + B) 42.977.974,69 38.362.424,2027\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3EQUITY AND LIABILITIESFISCAL YEAR FISCAL YEAR\n2021 2020\nA) EQUITY 18.989.637,34 17.280.263,01\nA-1) Capital and reserves without valuation adjustments 12.113.586,20 9.571.987,17\nI. Endowments 617.482,67 617.482,67\nII Reserves 8.954.504,50 6.205.402,21\n2. Other reserves 6.205.402,21\nIV. Profit/(loss) for the period 2.541.599,03 2.749.102,29\nA-3) Grants, donations or gifts and legacies received 6.876.051,14 7.708.275,84\nB) NON-CURRENT LIABILITIES 6.151.112,04 5.663.916,99\nII. Non-current payables 6.151.112,04 5.663.916,99\n5. Other financial liabilities 6.151.112,04 5.663.916,99\nC) CURRENT LIABILITIES 17.837.225,31 15.418.244,20\nII Current provisions 403.165,16 321.709,00\nIII. Current payables 11.170.599,37 10.692.015,95\n5. Other financial liabilities 11.170.599,37 10.692.015,95\nV. Beneficiaries-Creditors 1.330.461,39 496.560,76\nVI. Trade creditors and other accounts payable 4.865.913,38 3.864.247,50\n1. Suppliers 169.342,41 80.828,77\n3. Other payables 145.589,02 174.449,32\n4. Personnel (salaries payable) -0,80 737,12\n6. Public entities, other 4.550.982,75 3.608.232,29\n7. Advances from customers 67.086,01 43.710,99\nTOTAL NET WORTH AND LIABILITIES (A + B + C) 42.977.974,69 38.362.424,2028\nINCLIVA SCIENTIFIC REPORT 2021global analysis33.3 Cooperative research networks\nThe Carlos III Health Institute develops \u2013 through the General Subdirection of Networks and Centers for the Cooperative Research \u2013 the \ncreation of stable research network structures such as CIBER (Network of Centres for Biomedical Research). INCLIVA participates in this \nresearch structure through its associated groups.\nThe following table shows the participation in scientific networks according to the prioritized research area, the center and its principal \ninvestigator.\nCIBER\nResearch Area INCLIVA PI Scientific Network Reference\nCardiovascularMr. Jos\u00e9 Tom\u00e1s Real Collado CIBERdem CB07/08/0018\nMrs. Empar Lurbe i Ferrer CIBERobn CB06/03/0039\nMr. Francisco Javier Chorro Gasc\u00f3 CIBERcv CB16/11/00486\nMr. Juan Sanchis For\u00e9s CIBERcv CB16/11/00420\nMetabolism and \nOrgan DamageMr. Esteban Morcillo S\u00e1nchez CIBERres CB06/06/0027\nMr. Federico V. Pallard\u00f3 Calatayud CIBERrer CB06/07/0073\nMr. Julio Sanju\u00e1n Arias CIBERsam CB07/09/006\nMr. Rafael Tabar\u00e9s Seisdedos CIBERsam CB07/09/0021\nMr. Jos\u00e9 Vi\u00f1a Ribes CIBERfes CB16/10/00435\nOncologyMr. Andr\u00e9s Cervantes Ruip\u00e9rez CIBERonc CB16/12/00473\nMrs. Rosa Noguera Salv\u00e1 CIBERonc CB16/12/0048429\nINCLIVA SCIENTIFIC REPORT 2021global analysis 33.4 Knowledge transfer activities\nINCLIVA Health Research Institute is fully committed to transfer the knowledge created both to the National Health System and to the \nindustrial sector in order to fulfil its organizational mission.\n3.4.1 Knowledge transfer to the National Health System \nClinical guidelines and consensus documents are one of the best indicators of knowledge transfer from research to clinical practice. The \nfollowing table shows the guidelines published in indexed journals in which authors affiliated with INCLIVA have participated. Of these clinical \npractice guidelines, 4 have been implemented in the IIS health centers.\nClinical guidelines IF\n7 86,496\n1. Vogel A, Martinelli E, ESMO Guidelines Commite. Updated treatment recommendations for hepatocellular carcinoma (HCC) from \nthe ESMO Clinical Practice Guidelines. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: \n33716105. IF: 32,976\n2. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, \nHasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, \nPeters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up \nof patients with localised colon cancer. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. \nPMID: 34411693. IF: 32,976\n3. Stergiou GS, Palatini P, Parati G, O\u2019Brien E, Januszewicz A, Lurbe E, Persu A, Mancia G, Kreutz R. 2021 European Society of Hyperten-\nsion practice guidelines for office and out-of-office blood pressure measurement. Journal of Hypertension. 2021 Jul 1;39(7):1293-\n1302. doi: 10.1097/HJH.0000000000002843. PMID: 33710173. IF: 4,844\n4. Kreutz R, Dobrowolski P, Prejbisz A, Algharably EAEH, Bilo G, Creutzig F, Grassi G, Kotsis V, Lovic D, Lurbe E, Modesti PA, Pappaccogli \nM, Parati G, Persu A, Polonia J, Rajzer M, de Timary P, Weber T, Weisser B, Tsioufis K, Mancia G, Januszewicz A. Lifestyle, psycholo-\ngical, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. \nJournal of Hypertension. 2021 Jun 1;39(6):1077-1089. doi: 10.1097/HJH.0000000000002770. PMID: 33395152. IF: 4,844\n5. Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Kiesel L, Lopes P, Pines A, van Trotsenburg \nM, Lambrinoudaki I, Rees M. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS \nclinical guide. Maturitas. 2021 Jun;148:55-61. doi: 10.1016/j.maturitas.2021.04.005. PMID: 33896654. IF: 4,342\n6. Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio M, Barretina-Ginesta M, Gon-\nzalez-Martin A. SEOM clinical guideline in ovarian cancer (2020). Clinical & Translational Oncology. 2021 May;23(5):961-968. doi: \n10.1007/s12094-020-02545-x. PMID: 33515422. IF: 3,405\n7. Belvis R, Irimia P, Seijo-Fernandez F, Paz J, Garcia March G, Santos-Lasaosa S, Latorre G, Gonzalez-Oria C, Rodriguez R, Pozo-Rosich \nP, Lainez Andr\u00e9s J. Neuromodulation in headache and craniofacial neuralgia: guidelines from the Spanish Society of Neurology and \nthe Spanish Society of Neurosurgery. Neurologia. 2021;36(1):61-79. doi: 10.1016/j.nrl.2020.04.022. PMID: 32718873. IF: 3,10930\nINCLIVA SCIENTIFIC REPORT 2021global analysis3Consensus documents IF\n3 7,906\n1. Martin. Garcia A, Mitroi C, Mazon Ramos P, Garcia Sanz R, Virizuela J, Arenas M, Egocheaga Cabello I, Albert D, Anguita Sanchez M, \nArrarte Esteban V, Ayala de la Pena F, Bonanand Lozano C, Castro A, Castro Fernandez A, Cordoba R, Cosin-Sales J, Chaparro-Munoz \nM, Dalmau R, Drak Hernandez Y, Deiros Bronte L, Diez-Villanueva P, Escobar Cervantes C, Fernandez Redondo C, Garcia Rodriguez \nE, Lozano T, Marco Vera P, Martinez Monzonis A, Mesa D, Oristrell G, Palma Gamiz J, Pedreira M, Reinoso-Barbero L, Rodriguez I, \nSerrano Antolin J, Toral B, Torres Royo L, Velasco Del Castillo S, Vicente-Herrero T, Zatarain-Nicolas E, Tamargo J, Lopez Fernandez \nT. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, \nSEHH, SEMG, AEEMT, AEEC, and AECC. Revista Espa\u00f1ola de Cardiolog\u00eda (English ed.). 2021 May;74(5):438-448. doi: 10.1016/j.\nrec.2020.11.020. PMID: 33712348. IF: 4,753\n2. Cilleruelo Ramos A, Figueroa Almanzar S, Lopez Castro R, Martinez Hernandez N, Mezquita Perez L, Moreno Casado P, Zabaleta \nJimenez J. Spanish Society of Thoracic Surgery (SECT) consensus document. Long-term follow-up for operated patients with lung can -\ncer. Cirugia Espanola. 2021 Sep 11:S0009-739X(21)00250-5. doi: 10.1016/j.ciresp.2021.08.003. PMID: 34521509. IF: 1,653\n3. Moral L, Asensi Monzo M, Julia Benito J, Ortega Casanueva C, Paniagua Calzon N, Perez Garcia M, Rodriguez Fernandez-Oliva \nC, Sanz Ortega J, Valdesoiro Navarrete L, Valverde-Molina J. Pediatric asthma: the REGAP consensus. Anales de Pediatria 2021 \nAug;95(2):125.e1-125.e11. doi: 10.1016/j.anpede.2021.02.007. PMID: 34353777. IF: 1,5\nIntitutional Documents IF\n1 6,54\n1. Jimenez-Labaig P, Pacheco-Barcia V, Cebria A, Galvez F, Obispo B, Paez D, Quilez A, Quintanar T, Ramchandani A, Remon J, Rogado \nJ, Sanchez D, Sanchez-Canovas M, Sanz-Garcia E, Sesma A, Tarazona N, Cotes A, Gonzalez E, Bosch-Barrera J, Fernandez A, Felip \nE, Vera R, Rodriguez-Lescure A, Elez E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the \nCOVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021 Jul 26;6(4):100215. doi: 10.1016/j.\nesmoop.2021.100215. PMID: 34325108. IF: 6,54\nPosition statements IF\n2 7,722\n1. Rees M, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Geukes M, Godfrey A, Goulis DG, Griffiths A, Hardy C, Hickey \nM, Hirschberg AL, Hunter M, Kiesel L, Jack G, Lopes P, Mishra G, Oosterhof H, Pines A, Riach K, Shufelt C, van Trotsenburg M, Weiss \nR, Lambrinoudaki I. Global consensus recommendations on menopause in the workplace: a European Menopause and Andropause \nSociety (EMAS) position statement. Maturitas. 2021 Sep;151:55-62. doi: 10.1016/j.maturitas.2021.06.006. PMID: 34274202. \nIF: 4,342\n2. Peixoto Vasco R, Reid J, Lopes H, Prikazsky V, Siepmann I, Martin-Moreno JM, Middleton J. ASPHER Statement: deja vu?. Planning for \nthe Covid-19 third wave and planning for the winter 2021-22. International Journal of Public Health. 2021 Aug 23;66:1604361. doi: \n10.3389/ijph.2021.1604361. PMID: 34497482. IF: 3,3831\nINCLIVA SCIENTIFIC REPORT 2021global analysis 33.4.2. Innovation and Knowledge transfer \nOne of the main objectives of INCLIVA is the development of translational research, that is, research that transports scientific knowledge \ninto clinical practice. To achieve this objective, multidisciplinary collaboration between basic and clinical researchers is necessary, so that \nthe discoveries generated can be taken as products or processes capable of effectively improving the diagnosis, treatment and, in conclu-\nsion, the quality of life of the patient.\nThe Innovation Unit of INCLIVA gives support in this translational process, detecting ideas, evaluating them and facilitating their access \nto the market. This process that goes from the identification of a wide range of ideas to the market launch of those selected products or \nservices through different phases is known as an innovation funnel.\nThe breakdown of the INCLIVA innovation funnel in 2021 is the following:\nInnovation Funnel ITC Health Device Pharma Bio Imaging Organizational Total\nDetection 3 4 0 6 0 3 16\nAssessment 1 3 3 12 1 1 21\nDevelopment 1 2 2 3 0 0 8\nTransfer 1 1 2 4 0 0 8\nMarket 2 2 1 3 1 2 11\nInnovation Funnel\n25\n20\n15\n10\n5\n0\nDetection Assesment Transfer Market Development32\nINCLIVA SCIENTIFIC REPORT 2021global analysis33.4.2.1 Intellectual Assets\nThe protection of knowledge is the first step to move scientific findings and ideas from researchers to the industry and the most common \nway to protect technologies that are new, inventive and have industrial application are patents. Research institutions can exploit the patents \nthey hold by licensing them to companies.\nA large part of the results derived from the research activity, generated by the research staff in the field of their teaching and research \nfunctions, are capable of being protected by means of some of the forms of protection of industrial or intellectual property.\nINCLIVA counts on 13 active patents applications in 2021. During this year INCLIVA has obtained the license of two patents. The next plot \nsummarizes the current status of these protected inventions.\nPatents Licensed\nSeeking partnering2013 2016 2 017 2018 2019 2020 202114\n12\n10\n8\n6\n4\n2\n0\nDuring 2021, 4 patents have been applied. The following graph summarizes the status of patent applications by territory\nPatent applications by territory\nES\nEP\nUS\nOTHERS4\n39\n533\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3The following family patents were active on 2021:\nInvention Priority number IP/% INCLIVA Status\n2021. Use of Musashi 2 (msi2) as therapeutic target for the \ntreatment of the characteristic myopathy of type 1 myotonic \ndystrophyEP21382133 5% EP\n2021. Antitumor agent based on Ruthenium (III) P202130624 40% ES\n2021. APC protein for the detection and prediction of septic \nshockEP21382173 10% EP\n2021. Epigenetic signature for the diagnosis and prognosis of \nSpitzoid cutaneous melanocytic tumorsEP21382569 66,67% EP\n2019. Moxifloxacin for use in the treatment of spinal muscular \natrophyES201930436 23% PCT\n2019. Oropharyngeal obturation device ES20190003 100% PCT\n2018. Injectable material for the regeneration of the articular \ncartilage ES201830730 29% PCT\n2018.  In vitro method for the prediction of response to \nchemotherapy in triple negative breast cancer patientsEP18382390.5 58,3% EP\n2017. Prenylated benzopyranes as PPAR agonists P201731470 40% PCT\n2016. Mass spectrometry-based methods for the detection of \ncirculating histones h3 and h2b in plasma from sepsis or septic \nshock (ss) patientsEP16382509.4 6%EU, USA, JP, CN, CA \n(Licensed)\n2016. Intramedullary fixation device P201631220 2,5%EU, EEUU, Brasil \n(Licensed)\n2016. Device for the exo-prosthetisation of limbs and other \npercutaneous applicationsP201631218 2,5%EU, EEUU\n(Licensed)\n2013. Maxillomandibular prosthesis and production method ES20130030734 33,33% Licensed34\nINCLIVA SCIENTIFIC REPORT 2021global analysis33.4.2.2 Competitive innovation\n In order to develop the innovation ideas, INCLIVA submit proposals to autonomic, national and international founding calls. During 2021, \n10 projects were granted for a total of \u20ac1.029.373,57.\nINNOVATION COMPETITIVE PROJECTS OF 2021 TOTAL ( \u20ac) OF 2021\nValorizaci\u00f3n e internacionalizaci\u00f3n de HistShock, un test IVD para el diagn\u00f3stico y pron\u00f3stico de la sepsis y el \nshock s\u00e9ptico (FIPSE)\u20ac 30.000\nUso de moduladores de microRNAs como terapias experimentales en distrofia miot\u00f3nica de tipo 1 (GVA-APOTIP) \u20ac 36.000\nMejora del diagn\u00f3stico del c\u00e1ncer colorrectal (QUIBIM) (GVA-APOTIP) \u20ac 8.600\nDesarrollo precl\u00ednico de gapmers contra una nueva diana terap\u00e9utica en Distrofia Miot\u00f3nica tipo 1 (DM1) \n(DTS-ISCIII)\u20ac 127.600\nValidaci\u00f3n de test basados en p\u00e9ptidos marcados isot\u00f3picamente y espectrometr\u00eda de masas para la \ncuantificaci\u00f3n de histonas circulantes y prote\u00edna APC (DTS-ISCIII)\u20ac 122.100\nPreservaci\u00f3n de \u00f3rganos de trasplante (ri\u00f1\u00f3n y coraz\u00f3n). Proyecto de CPI (CDTI-AINIA) \u20ac 169.491,70\n2 Agentes de innovaci\u00f3n (AVI-Promoci\u00f3n Talento) \u20ac 250.677,62\nSistema de visi\u00f3n Artificial aumentada para la caracterizaci\u00f3n molecular y morfol\u00f3gica del C\u00e1ncer de piel \n(SAMUEL) (AVI-Estrat\u00e9gico)\u20ac 176.999,4\nSistema inteligente de apoyo a la toma de decisiones cl\u00ednicas en medicina de precisi\u00f3n (OGMIOS) (AVI-Estrat\u00e9gico) \u20ac 107.904,85\nTotal \u20ac 1.029.373,5735\nINCLIVA SCIENTIFIC REPORT 2021global analysis 33.4.2.3 Entrepreneurship\nWhen the knowledge generated in INCLIVA is disruptive and the researches willing to exploit it by themselves, the knowledge transfer is \ndirect, thanks to the creation of a new venture (also known as a spin-off or start-up) based on such knowledge with the support of INCLIVA.\nINCLIVA counts with the following companies officially recognized as spin-offs:\nEpidesase S.L.    \nCompany created in 2014 as a result of a project led by researchers from INCLIVA and the Center for \nResearch in Biomedicine Network (CIBER) in the area of Rare Diseases to transfer knowledge in the field of \nepigenetics and biomedical sciences at the service of society.\nFounding year: 2014\nINCLIVA entrepreneurial team: Mr. Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez and Mr. Federico Pallard\u00f3\nhttp://www.epidisease.com/\nSequencing Multiplex S.L.     \nCompany created in 2013, which was born from the idea of generating solutions for research and clinical \napplications, using as a basis the introduction of new techniques and advanced genetic platforms, mainly next-\ngeneration sequencing (NGS).\nFounding year: 2013\nINCLIVA entrepreneurial team: Mr. Javier Chaves\nhttps://www.seqplexing.com/es\nNela BioDynamics S.L.\nThe company arises from the results of a Final Master Thesis in Biomedical Engineering, which lead to the \nobtaining of two patents on a novel intramedullary fixation system for joint endoprostheses, nails for fractures \nand exoprostheses; and a percutaneous ostomy collar. Both patents are currently licensed to the spin-off itself.\nFouding year: 2020 \nINCLIVA entrepreneurial team: Mr. Jos\u00e9 Exp\u00f3sito Ollero\nhttp://www.nelabiodynamics.com/\nArtHex Biotech S.L.\nCompany created in 2020 at the University of Valencia that develops advanced RNA treatments against ge -\nnetic diseases. ARTHEx Biotech\u2019s mission is to find effective treatments for unmet medical needs. The first \nobjective of the company will be to investigate anti-microRNAs for the treatment of myotonic dystrophy type 1 \n(DM1).\nFouding year: 2020 \nINCLIVA entrepreneurial team: Mr. Rub\u00e9n Artero\nhttp://www.arthexbiotech.com/\nITEMAS PLATFORM\nINCLIVA has the status of Adhered Center of the ITEMAS Platform of the IDIBELL Node. INCLIVA is part of the Alliance for Health Inno -\nvation and Industrialization of the Mediterranean Axis (AIISEM) coordinated by the IDIBELL Foundation and created by the following institu -\ntions: IIS La Fe, FISABIO, IDIBELL, ISABIAL, IISPV, IdISBa, IDIAP and IMIB. AIISEM nodes meet once a month, both the Technical Commission \nand the Strategic Commission. The Alliance has a 3-year Action or Work Plan divided into 5 key objectives.\n36\nINCLIVA SCIENTIFIC REPORT 2021global analysis3Research Staff3.5 Gender perspective\nAs part of its commitment to contribute towards guaranteeing real equality between women and men, INCLIVA\u2019s Board of Trustees has \napproved the II INCLIVA Equality Plan (2020-2024) following approval by the Equality Committee. Through INCLIVA\u2019s II Equality Plan, the \ndifferent planned actions will be implemented throughout its four-year duration following the timeline established for each one.\nCurrently, 73.37% of INCLIVA employees are women. The data corresponding to activity in 2021 is as follows:\nTotal cost of INCLIVA staff 2021\nMen \u20ac1,732,501.38\nWomen \u20ac4,774,066.16\nTOTAL \u20ac6,506,567.54\nA total of 148 employees joined INCLIVA in 2021, of whom 75.68% are women. The percentage of women hired has increased every \nyear for the last three years.\nThe following graphs differentiate between personnel hired for administration tasks and research staff:\n\u2022 Women comprise 88.57% of staff contracted to carry out administration tasks and 69.89% of those who carry out research tasks  \n\u2022 Within the administrative area, 84.62% of Managerial/Technician positions are women and 100% of Auxiliary and Nursing staff con -\ntracts are for women \n\u2022 In research, 96.30% of those hired as Nursing staff, 75% of Administrative staff and 64.03% of Research staff are women.Total cost of INCLIVA Staff 2021Men 27%\n4\n10\n5022\n26893\n1526\n27Women 73%\nAdministrarive Staff\n30\n20\n10\n0\n150\n100\n50\n0Auxiliary\nResearch staffManagerial/Technician\nNursing\nMen              Women              TotalSubordinate staff\nAdministrative staff0\n53\n206 6\n13937\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3Distribution by contract type\nThe breakdown of contracts granted to women is shown in the following graphs:\n\u2022 87.50% of permanent contracts for administration tasks and 58.33% of permanent contracts for research tasks are for women.\n\u2022 88.89% of temporary contracts for research tasks and 70.69% of temporary contracts for research tasks are for women.\n\u2022 in administration: 77.42% of contracts for women are temporary contracts. Of these, 68.18% are contracts to carry out Managerial/\nTechnician tasks and 100% for Auxiliary and Subordinate staff jobs. Fixed contracts for women within the administration are 100% for \npositions such as Managerial/Technician.\n\u2022 in research: 94.62% of contracts awarded to women are temporary contracts. Of these, 96.63% of temporary contracts for research \ntasks, 96.15% of temporary contracts for nursing tasks and 80% for research administration tasks are for women.\n7\n615\n0 022\n6\nShared parental leave\nMaternity/paternity leave was requested by only 9 employees throughout 2021: 3 by men, 6 by women.\nOrganizational structure\nUnlike within our staff structure, women are clearly underrepresented in governing bodies and scientific committees. The distribution of \neach is summarized below:\nMen Women Total 2021\nBoard of Trustees 14 7 21\nBoard of Governors 10 3 13\nExternal Scientific Committee 5 2 7\nInternal Scientific Committee 6 4 10\nResearch Committe 15 18 33\nInnovation Committe 10 5 15\nEthical Committee in Clinical Research 15 9 24\nResearch areas 4 0 4\nScientific translational programs 11 3 14\nResearch Groups 34 16 50Administrative Staff - women\n25\n20\n15\n10\n5\n0\nAuxiliary Managerial/Technician\nPermanent contracts             Temporary contracts            TotalSubordinate staff3 338\nINCLIVA SCIENTIFIC REPORT 2021global analysis3Breakdown of Research Group staff\nA total of 636 researchers belong to consolidated, emerging and associated research groups, and whose EURAXESS profile distribution \nis as follows. Distribution by group of research staff in 2021:\nDistribution by group of research staff hired with public funding in 2021\nResearch projects\nThroughout 2021, competitive tendering began for 20 new public projects, making a total of 129 currently active public projects under \ncompetitive tender. The Principal Investigators are distributed as shown in the table. In total, 33.33% of regional projects are led by women, \ncompared with 36.67% of national projects and 7.69% of international projects.\nMen Women Total 2021\nAutonomous Regions 17 8 24\nNational 57 33 90\nInternational/European 12 1 13\nClinical studies and trials\nA total of 396 new studies and 207 new clinical trials have been conducted throughout 2021. The tables below indicate the distribution \nof Principal Investigators, and number of male and female evaluators.\nMen Women Total 2021\nStudies presented 217 179 396\nSubmitted Essays 106 101 207\nEvaluators 14 8 2280\n70\n60\n50\n40\n30\n20\n10\n0\n250\n200\n150\n100\n50\n0R1\nR1R2\nR2R3\nR3R4\nR4Staff\nStaffMen\nWomen\nPublic financed\nprofiles 2021\nMen\nWomen\nResearch\nprofiles 202119\n06 448\n8797153\n39654926\n10\n1\n33513\n17451367\n12616220236\n1\n849\n621739\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3Transfer to the Productive Sector\nCalls for proposals, innovation awards and patent portfolios during 2021 are distributed by gender as shown in the table:\nMen Women Total 2021\nExternal calls for innovation proposals requested in 2021 12 4 16\nPatents in portfolio (IPs that have co-ownership of a patent) 11 9 20\nVlc-Biocl\u00ednic Applications 2021 14 16 30\nVlc-Biocl\u00ednic Concessions 2021 6 7 13\nApplicants for Innovation Awards 2021 11 19 30\nBibliometric analysis: Biomedical Research Institute (IIS) corresponding author, first and last author\nOf the 834 INCLIVA publications in 2021, the distribution of men to women according to the relevant position of signature (first, last or \ncorresponding author) is 13.39% for female researchers and 34.14% for male researchers.\nTraining Activities\nIn total, 1,703 people participated in training activities carried out during 2021. According to registration questionnaires, 73% of parti-\ncipation was female (1,250) and 24% male (411), the question being left blank in the remaining 3%. In 79% of activities, participation was \nmainly female.\nTitle Date Scope Activity Type Modality Hours Participants Men Women\nBiomedical Research \non Pain with a Gender \nPerspective03/08/2021 RegionalINCLIVA\nSeminarOnline 1 21 4 17\nWith equality you \nalways win \n(1st session)03/10/2021 LocalTraining\nDayOnline 3 10 2 8\nColloquium on Valen-\ncian Researchers\u2019 \nVision of Science09/24/2021 LocalInformative\nOpen\nDayMixed, \nface-to-face/\nonline1 9 0 9\nWith Equality You \nAlways Win  \n(2nd session)10/20/2021 LocalTraining\nDayOnline 2 17 3 14\n1. Colloquium on Valencian Researchers\u2019 Vision of Science\nThe Mediterranean Researchers\u2019 Night (MEDNIGHT 2021) is a project conceived under the umbrella of European Researchers\u2019 Night. \nThe objective is to show the public the importance of science and research developed in Mediterranean countries -emphasizing the role of \nwomen in this area- and seeking to address the issues shared by Mediterranean society.40\nINCLIVA SCIENTIFIC REPORT 2021global analysis3The MEDNIGHT project brings together a consortium of 13 institutions from Greece, Cyprus, the Valencian Community and the Murcia \nRegion and is funded by the European Commission as part of the Marie Sklodowska-Curie actions programme (grant agreement no. \n101036107).\nYouTube link: https://youtu.be/90Jk-ugCJX4\nParticipant Profile: of the 8 responses received, 75% were from women (6 responses) and 25% from men (2 responses). The profes -\nsional profile comprised 25% technical research staff, 12.5%   IP from consolidated groups, 12.5%   predoctoral research staff, 12.5%   \npostdoctoral research staff, 12.5%   management, administration and service staff, 25% others.\n2. With equality you always win (2 sessions)\nThe goals of this information day were to:\n\u2022 Include the gender perspective in INCLIVA research projects.\n\u2022 Disseminate key concepts on equality adapted to the work area.\n\u2022 Make resources available to disaggregate data and statistics by sex.\n\u2022 Provide resources and practical strategies to apply inclusive language in writing.\n\u2022 Set guidelines and recommendations to contribute to real equality in research.\nTraining material was provided.\nParticipant profile in 1st session: of the 10 responses received, 80% were from women (8 responses) and 20% from men (2 responses). \nThe professional profile comprised 40% PI from Emerging Groups, 20% management staff, 10% emerging research staff, 10% manage -\nment, administrative and services staff, 10% nursing staff, 10% others.\nParticipant profile in 2nd session: of the 17 responses received, 82.4% were from women (14 responses) and 17.6% from men (3 \nresponses). The professional profile comprised 35.3% management, administrative and services staff, 23.5% predoctoral research staff, \n11.8% technical research staff, 5.9% PI Consolidated Group, 5.9% nursing staff, 5.9% principal research staff, 11.8% others.\n3. Biomedical Research on Pain with a Gender Perspective\nSeminar given by Dr. Ana Peir\u00f3, Professor of Pharmacology at the Miguel Hern\u00e1ndez University of Elche and researcher at the ISABIAL \nInstitute.\nYouTube link: https://youtu.be/-MAaVHQ8j28\nParticipant Profile: of the 21 responses received, 81% were from women (17 responses) and 19% from men (4 responses). The profes -\nsional profile comprised 28.6% administrative and services staff, 19% medical staff, 14.3% research staff, 33% others.\nExternal stays\nOf a total of 8 external stays, 3 were granted to women, while of the 17 external stays funded by INCLIVA, 9 were women. In total, 48% \nof stays were completed by women.41\nINCLIVA SCIENTIFIC REPORT 2021global analysis 3Internal Stays\nOf a total of 5 internal stays, 3 were granted to women, entailing 60% of total internal stays.\nTraining placements\nThe classification and distribution by gender of training placements in 2021 is shown in the following table:\nMen Women Total 2021\nSecondary school and vocational training placements 3 19 22\nBachelor\u2019s placements 10 40 50\nMaster\u2019s placements 1 10 11\nBachelor\u2019s final project (TFG) agreements (including INCLIVA Calls) 2 7 9\nMaster\u2019s final project (TFM) agreements (including INCLIVA Calls) 2 12 14\nTotal 21 88 109\nDoctoral theses\nBelow is a breakdown by gender of the 65 doctoral theses defended or supervised by INCLIVA research staff. 70.83% of predoctoral \nresearchers who defended their thesis in 2021 were women, and 32.22% of those supervising the theses defended in 2021 were women.\nMen Women Total 2021\nINCLIVA Doctoral students 7 17 24\nINCLIVA Doctoral Supervisors 61 29 90scien-\ntific\nactivi-\nty\nINCLIVA SCIENTIFIC REPORT 2021   \n4. Scientific activity\n 4.1 Scientific structure\n 4.2 Scientific translational programs\n  4.2.1 Overweight and cardiovascular and renal risk\n  4.2.2 Detection and control of ventricular dysfunction\n  4.2.3 Rare Diseases\n   4.2.4 Neurological Decline\n  4.2.5 Translational Oncology\n  4.2.6 Reproductive Medicine\n  4.2.7 Ageing and associated diseases\n 4.3. Research areas\n  4.3.1 Cardiovascular Area\n  4.3.2 Oncology Area\n   4.3.3 Metabolism Area \n  4.3.4 Reproductive Medicine Area\n 4.4. Hospital divisions research areas\n 4.5 Other scientific contributions from scientific platforms\n  4.5.1 Biobank\n  4.5.2 Oncology Phase I Oncology Clinical Trials unit \n  4.5.3 Innovation Platform ITEMAS \n  4.5.4 Spanish Clinical Research Network (SCReN), \n   Clinical Research and Clinical Trials of the Clinical \n   Trials Platform (UICEC INCLIVA)\n  4.5.5 Precission Medicine Unit  \n  4.5.6 Bioinformatic and Biostatistics Unit45\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.1 Scientific structure\nINCLIVA articulates its research in 4 areas of research, 7 scientific programs, 4 platforms and one \nassociated clinical group.\nAreas of research constitute the basis on which to articulate  \nthe scientific work of the groups:\n\u2022 Research area in cardiovascular\n\u2022 Research area in oncology\n\u2022 Research area in metabolism and organ damage\n\u2022 Research area in reproductive medicine\n\u2022 Associated clinical group\nScientific programs are aimed at specific diseases from  \na translational perspective:\n\u2022 Program in Overweight and cardiovascular and renal risk\n\u2022 Program in Detection and control of ventricular dysfunction\n\u2022 Program in Rare Diseases\n\u2022 Program in Neurological Decline\n\u2022 Program in Translational Oncology\n\u2022 Program in Reproductive Medicine\n\u2022 Program in Aging and associated diseases\nPlatforms are based on the provision of research services  \nto the whole institute:\n\u2022  Central Unit for Medical Research (UCIM)\n\u2022  Biobank\n\u2022  Precission Medicine Unit\n\u2022  Bioinformatics and Biostatistics Unit   46\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.2 Scientific translational programs\n4.2.1 Overweight and cardiovascular and renal risk                \nObesity and overweight is a field in which new strategies are developed both for prevention and treatment with the use of tradi-\ntional resources and the new technologies. The present program is focused on the study of pathology on the first stages of obesity \n(overweight with or without metabolic syndrome) integrating different clinical and experimental research studies.\nCoordinators:  Dr. Jos\u00e9 Tom\u00e1s Real and Dr. Josep Redon i Mas\nObjectives: \n\u2022 To deepen in the early alterations, mechanisms and biomar-\nkers that contribute to the development of obesity, vascular \nand renal alterations as a complication, from its fetal, biologi -\ncal, genetic and environmental origins\n\u2022 To know potential signaling pathways susceptible to be thera-\npeutic targets\n\u2022 Early application of new technologies for the prevention and \ntreatment of obesity and vascular and renal alterations in \noverweight subjects\nResearch lines: \n\u2022 To identify early vascular and renal changes in overweight sub-\njects and in animal models\n\u2022 To study the state, mechanisms of vascular inflammation and \nendothelial injury in overweight and animal models\n\u2022 To analyze the relationship of \u201c-omic\u201d markers (genomic, epi -\ngenetic and metabolomic) with obesity and vascular and renal \nalterations in overweight and animal models\n\u2022 Interaction of biomarkers (biological, genomic and metabolic) \nand intervention in progression to obesity and vascular and \nrenal complicationsClinical groups:\n\u2022 Research Group on the Study of Cardiometabolic and Renal \nRisk (Dr. Josep Red\u00f3n i Mas)\n\u2022 Cardiometabolic Research Group on Primary Care (Dr. Jorge \nNavarro P\u00e9rez)\n\u2022 Research Group on the Study of Cardiovascular Risk in Chil-\ndren and Adolescents (Dr. Empar Lurbe i Ferrer)\n\u2022 Research Group on Oxidative Pathology (Dr. Guillermo S\u00e1ez \nTormo)\n\u2022 Research Group on Cardiometabolic Risk (Dr. Jos\u00e9 Tom\u00e1s \nReal Collado)\nExperimental groups:\n\u2022 Research Group on Endothelial Cells (LINCE) (Dr. Carlos Herme-\nnegildo Caudevilla, Dr. Susana Novella del Campo)\n\u2022 Research Group on Molecular Imaging and Metabolomics (Dr. \nDaniel Monle\u00f3n Salvad\u00f3)\n\u2022 Research Group on Inflammation (Dr. Esteban Morcillo S\u00e1n-\nchez, Dr. M\u00aa Jes\u00fas Sanz Ferrando)\n\u2022 Research Group on Genetics of Osteoporosis (Dr. Miguel \u00c1ngel \nGarc\u00eda P\u00e9rez)\n\u2022 Genomics and Diabetes Unit (Dr. Felipe Javier Chaves Mart\u00ednez)\n\u2022 Molecular biology of renal and vascular dysfunction (Dr. Raquel \nCort\u00e9s Vergaz)47\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4OVERWEIGHT AND CARDIOVASCULAR AND RENAL RISK\nOBJECTIVES ACTIONSSTATE\nAchievePartially \nachievedNot \nachieved\nMetabolic, vascular and renal evaluation of \noverweight patients (children and adults)X\nCharacterization of the relationship bet-\nween overweight and vascular inflammation \n/ endothelial functionX\nIdentification of molecular markers that re -\nlate overweight with its associated diseases\u2022 Metabolomic measurements (80 spectral \nfeatures) of 3 cohorts (4500 subjects) for \nassociations between obesity, associated \ndiseases and morbidities and early altera -\ntions of metabolism. Focus on the metabolic \ninteraction between host and gut microbiota. \nCohorts: R\u00edo Hortega (general population), \nAWHS (working population) and PIANCAVA-\nLLO (obese and morbid obese) X\nIdentification of metabolomic markers that \nrelate overweight with its associated mor-\nbidities\u2022 Metabolomic measurements (80 spectral \nfeatures) of 3 cohorts (4500 subjects) for \nassociations between obesity, associated \ndiseases and morbidities and early altera -\ntions of metabolism. Focus on the metabolic \ninteraction between host and gut microbiota. \nCohorts: R\u00edo Hortega (general population), \nAWHS (working population) and PIANCAVA-\nLLO (obese and morbid obese)X\nDevelopment of new early detection sys -\ntems for obesity and its associated compli-\ncations\u2022 Metabolomic measurements (80 spectral \nfeatures) of 3 cohorts (4500 subjects) for \nassociations between obesity, associated \ndiseases and morbidities and early altera -\ntions of metabolism. Focus on the metabolic \ninteraction between host and gut microbiota. \nCohorts: R\u00edo Hortega (general population), \nAWHS (working population) and PIANCAVA-\nLLO (obese and morbid obese)X\nIdentification of molecular targets of obesity \nand its associated complications and deve -\nlopment of new therapiesX48\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Coordinators: Dr. Francisco J. Chorro Gasc\u00f3, Dr. Vicente Bod\u00ed \n Peris and Dr. Juan Sanchis For\u00e9s \nObjectives:\n\u2022 Electrical remodeling: experimental studies on the protective \neffect against the arrhythmic vulnerability of modifications of \nthe signaling pathways\n\u2022 Ventricular remodeling: evaluation of the role of microvascular \ndamage, prediction of postinfarction clinical evolution\n\u2022 Biomarkers: clinical studies aimed at the validation of biomar-\nkers related to the degradation of components of the extra-\ncellular matrix\nResearch lines:\n\u2022 Characterization of the direct electrophysiological effects of \nthe active metabolite of sacubitril\n\u2022 Study of the modifications of the electrophysiological effects of \noverload sharp mechanics\n\u2022 Analysis of the protective effects produced by chronic treat-\nment with inhibitors\n\u2022 Mechanisms involved in the deterioration of systolic function, \nfibrosis and the inducibility of arrhythmias\n\u2022 Development of useful working instruments in the study of car-\ndiac electrophysiology\n\u2022 Basic research related to ischemia and myocardial infarction\n\u2022 Prospective and multicenter registry (Hospital Cl\u00ednico Univer -\nsitario de Valencia and Hospital Cl\u00ednic de Barcelona and Hospi-\ntal Vall d\u2019Hebr\u00f3n de Barcelona) of patients\n\u2022 Prognostic value of geriatric conditions in older patients ad-\nmitted for acute coronary syndromeClinical groups: \n\u2022 Research Group on Clinical Cardiology (Dr. Juan Sanchis For\u00e9s)\n\u2022 Research Group on Cardiac Experimental Electrophysiology \n(Dr. Francisco Javier Chorro Gasc\u00f3)\n\u2022 Research Group on Heart Failure (Dr. Julio N\u00fa\u00f1ez Villota)\n\u2022 Group on Translational Research in Ischemic Heart Disease \n(Dr. Vicente Bod\u00ed Peris)\n\u2022 Cardiometabolic Research Group on Primary Care (Dr. Jorge \nNavarro P\u00e9rez)\n\u2022 Research Group in Care. INVESTENF-INCLIVA (Dr. M\u00aa Jos\u00e9 \nGastaldo Zaragoza)\nExperimental groups: \n\u2022 Research Group on Endothelial Cells (LINCE) (Dr. Carlos Her-\nmenegildo Caudevilla, Dr. Susana Novella del Campo)\n\u2022 Research Group on Molecular Imaging and Metabolomics (Dr. \nDaniel Monle\u00f3n Salvad\u00f3)\n\u2022 Research Group on Inflammation (Dr. Esteban Morcillo S\u00e1n -\nchez, Dr. M\u00aa Jes\u00fas Sanz Ferrando)\n\u2022 Research Group on Nuclear Receptors in Cardiometabolic \nPathology (Dr. Laura Piqueras Ruiz)4.2.2 Detection and control of ventricular dysfunction\nThe program focuses on the study of the pathophysiological mechanisms involved in myocardial ischemic damage, on its \nstructural, functional and electrophysiological repercussions on the evaluation of diagnostic tools and markers and prognoses and \non the study of new therapeutic approaches that may help to prevent their adverse consequences.\nIt is a truly and translational research program that capitalizes the synergies between clinical and experimental research groups \nand also includes specialists in cardiac imaging techniques and technological development experts. The multidisciplinary approach \nextends the possibilities of collaboration between groups, strengthens those already existing and incorporates other groups into \nthe activities of the program. Innovation through the development of analytical tools (imaging techniques such as cardiac magnetic \nresonance, cardiac electrical signals or cartographic techniques), allows the generalize of patents in the field of technological \ndevelopment.49\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4MYOCARDIAL ISCHAEMIA INJURY DETECTION AND CONTROL OF VENTRICULAR DYSFUNCTION\nOBJECTIVES ACTIONSSTATE\nAchievePartially \nachievedNot \nachieved\nStudy of the basic mechanisms involved in \nmyocardial damage\u2022 Oxidative stress during reperfusion in acute \nmyocardial infarction\n\u2022 Neoangiogenesis, the appearance of micro-\nvascular obstruction and impaired function \nsystolic\n\u2022 Deregulation of the immune system in acute \nmyocardial infarctionX\nX\nX\nDiagnosis through new RM tools \u2022 RM micro-image for the development of com -\nbinations of RM sequences without contrast\n\u2022 Analysis of myocardial textures\n\u2022 Offline evaluation of myocardial tension\n\u2022 CMR for risk stratification and decision ma -\nking in STEMI\n\u2022 Stress CMR for risk stratification and deci-\nsion making in chronic coronary syndromesX \nX\nX \n \nX \nX\nPrediction through new biomarkers \u2022 Definition of new serological indicators with \nNMR-S to predict DR and fibrosis\n\u2022 Serum CA125, galectin-1 and galectin-3 \nmarkersX \nX\nPrevention \u2022 DR prevention through multiple antioxidant \ntreatment\n\u2022 Prevention of deterioration of systolic \nfunction, fibrosis and arrhythmiasX\nX50\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.2.3 Rare Diseases\nThe program\u2019s main objectives are to improve the diagnosis and current treatments of rare diseases (RDs). To this end, we will \nproceed to identify and validate rare disease biomarkers for which we do not have effective diagnostic and/or prognostic indicators. \nOn the other hand, new therapeutic strategies will be developed to treat these diseases. Human and animal model samples will be \nused to understand the molecular basis of disease, evaluate the activity of candidate drugs, and discover new biomarkers.\nThe program seeks to fill the gap between basic research and commercial development of diagnostic systems and treatments, so \nit aims to transfer this knowledge to companies to transform biomedical knowledge into products and services that improve human \nhealth. With these objectives, contacts with biotechnology and pharmaceutical companies have been established. On the other hand, \nthe program aims to disseminate its findings to society to get feedback about actual patients\u2019 needs.\nCoordinators: Dr. Francisco Das\u00ed Fern\u00e1ndez and Dr. Federico  \n Pallard\u00f3 Calatayud \nObjectives:\n\u2022 Development of cell models derived from cells of patients diag-\nnosed with the RDs being studied obtained either through the \ngenetic manipulation of healthy cells to mimic the mutations as-\nsociated with these diseases or from animal models in order to \nimprove the knowledge of the pathophysiology of each disease\n\u2022 Discover new therapeutic targets and propose new pharmaco-\nlogical strategies for the treatment of these pathologies\n\u2022 Promote collaboration with services of the Clinical Hospital in-\nvolved in the treatment of these RDs, emphasizing primary care \nto improve its diagnostic potential\n\u2022 Development of new diagnostic and prognostic methods\n\u2022 Development of \u201comics\u201d technologies to advance research in \nRRDD\nResearch lines:\n\u2022 Study of the physiopathology of rare neuromuscular diseases\n\u2022 Epigenetic regulation of neonatal sepsis\n\u2022 Pathophysiology of telomeres\n\u2022 Pathophysiology of alpha-1 antitrypsin deficiency, primary cili-\nary dyskinesia, childhood interstitial diseases and Prader-Willi \nsyndrome\n\u2022 Genetic and epigenetic modifiers in Friedreich\u2019s ataxia\n\u2022 Gene therapy for the treatment of rare respiratory diseases\n\u2022 Design and testing of new biomarkers for rare diseases\n\u2022 Characterization of the cellular and molecular mechanisms \nassociated with the pathology of neuromuscular diseases like \nMyotonic Dystrophy and Friedreich\u2019s ataxia and identification \nof molecular targets for the development of new therapiesClinical groups: \n\u2022 Research Group on Respiratory Diseases (Dr. Jaime Signes-\nCosta Mi\u00f1ana)\nExperimental groups: \n\u2022 Research Group on Translational Genomics (Dr. Rub\u00e9n D Ar -\ntero Allepuz)\n\u2022 Research Group on Rare Respiratory Diseases (RRD) (Dr. \nFrancisco Das\u00ed Fern\u00e1ndez)\n\u2022 Research Group on Cellular and Organic Physiopathology of \nOxidative Stress (Dr. Federico V. Pallard\u00f3 Calatayud)\n\u2022 Research Group on Molecular Imaging and Metabolomics (Dr. \nDaniel Monle\u00f3n Salvad\u00f3)\nClinical Services Associated to the Program:\n\u2022 Department of Pediatrics\n\u2022 Department of Pneumology\n\u2022 Department of Traumatology and Orthopedic Surgery51\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4RARE DISEASES\nOBJECTIVESSTATE\nCOMMENTS\nAchievePartially \nachievedNot \nachieved\nExtension to PCT phase of the European  \npatent \u201cMass spectrometry-based methods \nfor the detection of circulating histones H3 \nand H2B in plasma from sepsis or septic \nshock (ss) patients\u201d (PCT/EP2017/078362)X EP, US, CA, JP y CN\nAcquisition of budget and resources from \ndifferent programs X VLC-Bioclinic 2017 (2 projects), Plan Nacional \nI+D+i Mineco (1 project, 2016-2019), AES \n2016 (2 projects, 2017-2019), Fundaci\u00f3n \nRam\u00f3n Areces (1 project, 2017-2019), AES \n2017 (1 project, 2018-2019), Valencian So -\nciety of Pneumology (2 projects), Grifols S.A. \n(1 project)\nCarry out teaching and outreach activities X \u2022 Subject \u201cEnfermedades Raras\u201d: Medicine \ndegree (UV)\n\u2022 Master course in Biomedical Research \n\u2022 Master \u201cEnfermedades raras\u201d\n\u2022 2nd edition of the on-line course \u201cIntro-\nducci\u00f3n a las EE.RR: investigaci\u00f3n y aten-\nci\u00f3n cl\u00ednica\u201d\n\u2022 Introducction to rare diseases, Program of \nthe University of Valencia La Nau Gran\nAlliance for translational research in rare  \ndiseasesX Feder Funding52\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.2.4 Neurological Decline\nInflammation, which is associated with many chronic diseases (diabetes, liver cirrhosis, etc.), aging or major surgeries, leads to neu-\nroinflammation and brain alterations that eventually lead to cognitive and functional impairment. This deterioration reduces the quality \nof life and increases the risk of accidents, falls, fractures and adverse consequences, which implies an increase in hospitalizations and \nthe use of public resources.\nCognitive and functional impairment associated with aging and many chronic diseases is one of the most important challenges in order \nto improve the quality of life of the population and secure the sustainability of health systems. Early detection and treatment and prevention \nof cognitive and functional impairment would improve the quality of life of the elderly or with chronic diseases and reduce the demand for \nresources to the health system, improving its sustainability. Therefore, it is necessary to design new approaches to address these challen-\nges, based on advances in knowledge on mechanisms, early diagnosis, prevention and treatment of cognitive and functional impairment.\nCoordinators: Dr. Carmina Montoliu F\u00e9lix and Dr. Vicente Felipo Orts\nObjectives:\n\u2022 Characterize the alterations in inflammation, neuroinflam-\nmation, neurotransmission, function and brain structure as -\nsociated with the appearance of cognitive and functional im-\npairment\n\u2022 Characterize cognitive and functional disturbances in detail\n\u2022 Identify biomarkers for the early detection of cognitive and \nfunctional impairment\n\u2022 Identify the mechanisms by which: \na) peripheral inflammation leads to neuroinflammation\nb) neuroinflammation leads to functional, structural and neuro-\ntransmission alterations in the brain\nc) brain disorders lead to cognitive and functional impairment\n\u2022 Identify therapeutic targets to reverse or prevent cognitive and \nfunctional impairment\n\u2022 Design and test new therapeutic procedures to reverse or pre-\nvent cognitive and functional impairment\nResearch lines:\n\u2022 Develop new early diagnostic procedures for cognitive and \nfunctional impairment\n\u2022 Try to transfer the new diagnostic procedures developed to \nclinical practice\n\u2022 Evaluate in patients the efficacy and usefulness of new thera-\npeutic procedures to prevent or reverse cognitive and function-\nal impairment that has been effective in animal models\n\u2022 Transfer to clinical practice the new validated therapeutic pro -\nceduresClinical groups: \n\u2022 Research Group on the Study of Cardiometabolic and Renal \nRisk (Dr. Josep Red\u00f3n i Mas)\n\u2022 Research Group on Anesthesiology and Reanimation (Dr. Ma-\nrina Soro Domingo, Dr. Ernesto Pastor Mart\u00ednez, Dr. Rafael \nBadenes Quiles)\n\u2022 Research Group on Cardiometabolic Risk (Dr. Jos\u00e9 Real Tom\u00e1s)\nExperimental groups: \n\u2022 Research Group on Neurological Impairment (Dr. Carmina \nMontoliu F\u00e9lix)\n\u2022 Research Group on Personal Autonomy, Dependence and Se-\nvere Mental Disorders (TMAP) (Dr. Rafael Tabar\u00e9s Seisdedos, \nDr. Gabriel Selva Vera)\n\u2022 Research Group on Aging and Physical Activity (Dr. Jos\u00e9 Vi\u00f1a \nRibes, Dr. Ana Lloret Alca\u00f1iz)\n\u2022 Research Group on Inflammation (Dr. Esteban Morcillo S\u00e1n -\nchez, Dr. M\u00aa Jes\u00fas Sanz Ferrando)\nClinical Services Associated to the Program:\n\u2022 Department of Digestive Medicine (Dr. Miguel M\u00ednguez P\u00e9rez, \nDr. Amparo Escudero Garc\u00eda)\n\u2022 Department of Neurophysiology (Dr. Paula Cases Berg\u00f3n)\nUniversity Department Associated with the Program:\n\u2022 Biology Unit. Department of Pathology (Dr. Concepci\u00f3n L\u00f3pez \nGin\u00e9s)53\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4NEUROLOGICAL DECLINE\nOBJECTIVESSTATE\nCOMMENTS\nAchievePartially \nachievedNot \nachieved\n1. Characterize the alterations in inflam-\nmation, neuroinflammation, neurotransmis -\nsion, function and brain structure associa -\nted with the appearance of cognitive and \nfunctional impairmentX We analysed the presence of neuroinflammation \nin post-mortem samples of the cerebellum from \npatients died with different grades of liver disease, \nfrom mild steatohepatitis to cirrhosis. \nWe are analysing alterations in neural connectivity \nby functional magnetic resonance imaging.\n2. Characterize cognitive and functional dis-\nturbances in detailX Gait, balance, hand strength and motor speed per -\nformance were evaluated in cirrhotic patients.\nEvaluation and characterization of sensory thres-\nholds was also performed by quantitative sensory \ntesting using a CASE IV.\nWe are characterizing cognitive and functional \ndisturbances in patients with other pathologies: \nNASH (non-alcoholic steatohepatitis), diabetes \nmellitus, schizophrenia, bipolar disorder, and post-\nsurgery patients.\nWe are better characterizing executive functions \nin cirrhotic patients by computerized tests.\n3. Identify biomarkers for the early detec -\ntion of cognitive and functional impairmentX We are studying the altered genes in peripheral \nblood cells and the involved pathways associated \nwith the appearance of cognitive impairment; we \nare characterizing the changes in inflammation \nand metabolites associated to cognitive impair-\nment.\nWe are performing an integrated multiomics \nanalysis to identify biomarkers of cognitive and \nfunctional impairment.\nWe are characterizing eye movements in patients \nwith different pathologies: cirrhosis, NASH, and \ndiabetes mellitus.54\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44. Identify the mechanisms by which: \na) peripheral inflammation leads to neuroin-\nflammation \nb) neuroinflammation leads to functional, \nstructural and neurotransmission altera-\ntions in the brain \nc) brain disorders lead to cognitive and \nfunctional impairmentX We have identified alterations of the immune sys -\ntem associated with the appearance of neurologi -\ncal alterations in cirrhotic patients with MHE. \nWe have identified, in animal models, mechanisms \nby which peripheral inflammation induces neuroin-\nflammation, and how this alters neurotransmis -\nsion and cognitive and motor function.\nWe have shown that there is a dysregulation in the \nurea cycle in non-alcoholic fatty liver disease.\nWe are analyzing the role of exosomes as me-\ndiators of neuroinflammation and of alterations \nin neurotransmission and cognitive and motor \nfunction in animal models of MHE. \n5. Identify therapeutic targets to reverse or \nprevent cognitive and functional impairmentX We have identified several therapeutic targets in \nanimal models of MHE.\n6. Design and test new therapeutic proce -\ndures to reverse or prevent cognitive and \nfunctional impairmentX We are testing the effect of treatments on cogni-\ntive impairment and immunophenotype in patients \nto reverse or prevent cognitive and functional im-\npairment. \nWe have designed several treatments that impro-\nve cognitive and motor function in animal models.\n7. Programme activity: Seminars of the \nNeurological Impairment ProgramX Seminars are scheduled for the third Thursday of \neach month. Time: 13:30h55\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.2.5 Translational Oncology\nThe translational oncology program called \u201cIdentification of oncogenic biomarkers: mechanisms and clinical implications, detection in \nnon-invasive samples, omics analysis\u201d tries to apply to the clinical practice the genomic screening in patients tumors.\nIts main objective is to evaluate the dynamics of the disease through non-invasive biopsies in order to detect minimal residual disea-\nse, early onset of markers after surgery and patient response to different treatments.\nThe high heterogeneity of cancer results in inefficiency of treatments, even when they are directed against specific molecular tar-\ngets. The low availability of tumor specimens makes genomic studies difficult.\nIn this sense, the use of liquid biopsies would facilitate the serial collection of samples to carry out molecular analysis and would \nguarantee a minimum risk for the patient. Thus improving the follow-up and allowing a dynamic understanding of the evolution of the \ngenomic parameters of the patient.\nThis point of view benefits the National Health System as a whole since it allows the application of more specific treatments to \npatients, thus avoiding those that would have been less effective, reducing hospitalization and improving life expectancy and quality \nthereof. It could also prevent generalized treatments, secondary toxicities and rapid treatment adequacy responses.\nFinally, it would improve the inclusion of patients in clinical trials which are stratified by molecular mutations.\n\u2022 Research Group of Innovative Diagnostic and Therapeutical \nDevelopments in Solid Tumors - InDeST (Dr. Andr\u00e9s Cervantes \nRuip\u00e9rez)\n\u2022 Research Group on Hematopoietic Transplantation (Dr. Car-\nlos Solano Vercet)\n\u2022 Research Group on Myeloid Neoplasms (Dr. Mar Tormo D\u00edaz)\n\u2022 Research Group on Lymphoproliferative Disorders (Dr. M\u00aa \nJos\u00e9 Terol Caster\u00e1)\n\u2022 Translational Research Group on Pediatric Solid Tumors (Dr. \nSamuel Navarro Fos, Dr. Rosa Noguera Salv\u00e1)\nClinical Services Associated to the Program\n\u2022 Department of Radiology\n\u2022 Department of Pathological Anatomy\n\u2022 Central Laboratory \n\u2022 Department of Pharmacy\n\u2022 Department of Urology\nAssociated program platforms:\n\u2022 Biobank\n\u2022 Precission Medicine Unit\n\u2022 Bioinformatics and Biostatistics UnitCoordinator: Dr. Andr\u00e9s Cervantes Ruip\u00e9rez\nObjectives:\n\u2022 Identification of diagnostic biomarkers that help the early iden-\ntification of patients\n\u2022 Identification of biomarkers of resistance to treatment or relapses\n\u2022 Development of functional models mimetic to the characteris-\ntics of the patient\n\u2022 Development of decision support systems through data analysis\nResearch lines:\n\u2022 Liquid biopsy as a diagnostic tool\n\u2022 Functional models of organoids, murine and 3D bioprinted for \nthe study of resistance and drug screening\n\u2022 Integration of molecular and image data for the development \nof decision support systems\n\u2022 Promote the development and implementation of programs in \nadvanced therapies, particularly, CAR-T cells cell therapy and \nother models\n\u2022 Continuous improvement of the inclusion of patients in clinical \ntrials, in coordination with primary care\nClinical Groups:\n\u2022 Research Group on Breast Cancer Biology (Dr. Ana Lluch Her-\nn\u00e1ndez, Dr. Pilar Eroles Asensio)56\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4TRANSLATIONAL ONCOLOGY\nOBJECTIVES ACTIONSSTATE\nAchievePartially \nachievedNot \nachieved\nIdentify biomarkers \u2022 Clinical recruitment-characterization and \nstorage Biobank-Data Management\n\u2022 Subclassify tumours according to their pro-\nfile\n\u2022 Identify biomarkers of inflammation / angio -\ngenesis; miRs-detox from oxidative stress\n\u2022 Perform comprehensive omics data analysis \nwith search of altered routes using Biology \nof systemsX \nX \nX \nX\nValidate promising biomarkers / mechanis -\ntic analysis\u2022 Proof of concept on commercial cell lines\n\u2022 Establishment of cell lines with patient tu-\nmours\n\u2022 Establishment of tumours in mouse models \n(xenografts)\n\u2022 IHC antibodies in FFPE to validate expression \n/ western blot in cell lines / xenotumoursXX\n \nX \nX\nDetect biomarkers in liquid biopsies to mo-\nnitor disease progression (BEAMing PCR)\u2022 Start on biopsies of patients with advanced \ndisease or disease progression\n\u2022 Implement technology optimized for initial \ndetection, detection of residual disease, and \ndisease evolution and response to treatmentX \nX57\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.2.6 Reproductive Medicine\nThis program comprises two main lines:\n1. Molecular characterization at single-cell resolution of the human uterus as a basis for both understanding uterus health and \ndisease, and improving diagnosis, monitoring and new therapies.\n2. Study of maternal-embryonic communication mechanisms and their impact on reproductive health.\nCoordinators: Dr. Carlos Sim\u00f3n Vall\u00e9s and Dr. Felipe Vilella  \n Mitjana\nObjectives:\n\u2022 To create comprehensive reference map at single-cell resolu -\ntion of the human uterus\n\u2022 To study the origin of fibroids at the single-cell level\n\u2022 To study the origin of late gestational pathology focuses on \ndecidualization deficiency\n\u2022 To establish the maternal-fetal communication mechanisms \nbefore embryo implantation\n\u2022 To provide early diagnosis and treatment of endometriosis \nand endometrial cancer\n\u2022 To study the molecular mediators in hormone-dependent on -\ncogenesis in endometrium and ovary\n\u2022 To establish a success strategy in the implementation of phy-\nsical activity to reduce the risk of chronic disease in women\nResearch lines:\n\u2022 Study of endometrial receptivity and cell map of the human \nuterus. Previous research in our laboratory using microarray \ntechnology has established a transcriptomic signature of hu-\nman endometrial receptivity\n\u2022 Maternal-fetal communication\n\u2022 Role of the endometrial microbiome in reproduction\n\u2022 Early diagnosis of preeclampsia and other complications of \npregnancy\n\u2022  Study at the single-cell level of the origin of uterine fibroids\n\u2022 Early diagnosis and treatment of endometriosis and endome-\ntrial cancer\n\u2022 Molecular factors involved in the initiation and progression of \nhormone-dependent tumours in the endometrium and ovary\n\u2022 Implementation of physical activity as a strategy to improve \nhealth indicators in womenClinical groups:\n\u2022 Research Group on Women Health (Dr. Antonio Cano S\u00e1n -\nchez)\n\u2022 Research Group on Endometriosis and Endometrial Cancer \nTherapies (Dr. Ra\u00fal G\u00f3mez Gallego)\nExperimental groups:\n\u2022 Research Group on Maternal Fetal Communication (Dr. Felip \nVilella Mitjana)\n\u2022 Research Group on Reproductive Medicine (Dr. Carlos Sim\u00f3n \nVall\u00e9s)\n\u2022 Emergent researcher (Dr. Aymara Mas Perucho)\nClinical Services Associated to the Program\n\u2022 Department of Gynaecology and Obstetrics\n\u2022 Department of Microbiology58\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4ENDOMETRIAL RECEPTIVITY AND EMBRYO VIABILITY\nOBJECTIVESSTATE\nACTIONS\nAchievePartially \nachievedNot \nachieved\nAdvance in the understanding of the mecha-\nnisms that regulate maternal-fetal commu -\nnication X\nProject is ongoing.\nResults published\n Single cell resolving molecular characteri-\nzation of the human uterus with its implica-\ntions for health and diseaseX\nProject is ongoing.\nResults published\nSingle cell study of the origin of fibroids XProject is ongoing\nStudy of resistance to decidualization at the \norigin of late gestational diseaseX\nProject is ongoing\nEarly diagnosis and treatment of endometri-\nosis and endometrial cancerX\nProject is ongoing\nMolecular mediators in hormone-dependent \noncogenesis in endometrium and ovaryX\nProject is ongoing\nSuccess strategy in the implementation of \nphysical activity to reduce the risk of chronic \ndisease in womenX\nProject is ongoing59\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.2.7 Ageing and associated diseases\nThis program has the priority of improving the quality of life of the elderly and promoting longevity as much as possible. The aging po-\npulation is a challenge for current health systems since the population over 65 years old contributes, in a very significant percentage, \nto health expenditure. As life expectancy increases, so do age-associated diseases.\nIn this context, the concept of \u201chealthspan\u201d (quality of life) has emerged. The program is formed by many researchers and health \nprofessionals who consider that efforts to extend life at the expense of causing a severe physical or psychic disability are undesirable \nand, on the contrary, they should focus on lengthening the part of life during which we are able to maintain autonomy, independence, \nproductivity, and well-being.\nA central guiding idea in this program is that people who achieve exceptional longevity (i.e., centenarians) serve as a model of satisfac -\ntory aging. On the other hand, it is considered that the most problematic expression of the population aging is the clinical condition of \nfrailty since an important part of the people over 65 and older fulfill several frailty criteria. Approximately one-fourth of people over the \nage of 85 are estimated to be frail. Frailty is a geriatric syndrome characterized by increased vulnerability to external aggressions as a \nresult of an alteration in the physiological reserves of multiple systems, leading to difficulties in maintaining homeostasis. The program \ntries to identify specific molecular targets to be able to intervene concretely and rationally to improve the quality of life of the elderly.\nFor this, INCLIVA has an enormous advantage because of the great integration that exists, by proximity and interests, between the \nHospital Cl\u00ednico Universitario de Valencia and the Faculty of Medicine of the University of Valencia. This framework allows intense co-\nllaboration between basic research groups, that analyze possible biomarkers associated with healthy aging, frailty, or age-associated \ndiseases and clinical research groups that provide biological human samples and, on the other hand, can transfer to the patient those \nstudies that have been successfully developed at the bench.\nIn addition to this, INCLIVA has registered the first and only Spanish Group for the Study of Centenarians, which includes research \ngroups working in this field distributed in different Spanish communities.\nCoordinators: Dr. Jos\u00e9 Vi\u00f1a Ribes, Dr. Consuelo Borr\u00e1s Blasco,  \n Dr. Mar\u00eda Carmen G\u00f3mez Cabrera\nObjectives: \n\u2022 Determination of oxidative stress and inflammation parame-\nters associated with healthy aging, frailty, and age-associated \ndiseases\n\u2022 Determination of genetic biomarkers (microRNAs, mRNAs, \nand SNPs) associated with healthy aging, frailty, and age-\nassociated diseases\n\u2022 Determination of epigenetic biomarkers associated with \nhealthy aging, frailty, and age-associated diseases\n\u2022 Determination of metabolomic biomarkers associated with \nhealthy aging, frailty, and age-associated diseases\n\u2022 Protocols of physical exercise and other healthy life interven -\ntions for the treatment and prevention of frailtyResearch topics:\n\u2022 Biomarkers of aging\n\u2022 Mechanisms of aging with special attention to exceptional \naging: centenarians\n\u2022 Healthy aging: frailty and prevention of disability\n\u2022 Intervention for successful aging: physical exercise, nutrition, \nmolecular interventions (extracellular vesicles)\n\u2022 Age-associated diseases: cardiovascular and neurodegenera -\ntive diseases\n\u2022 Mitochondrial implications in age-associated frailty \n\u2022 Skeletal muscle repair, exercise, frailty, and sarcopenia\n\u2022 Regenerative medicine in aging and age-associated diseases60\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4AGING AND AGE-ASSOCIATED DISEASES\nOBJECTIVES ACTIONS STATE\nAchieve Partially \nachievedNot \nachieved\nDetermination of pa-\nrameters of oxidative \nstress and inflamma-\ntion associated with \naging healthy, frailty \nand diseases associat-\ned with aging (mainly \ncardiovascular and \nneurodegenerative)\u2022 Oxidative signature of cerebrospinal fluid from mild cognitive impairment \nand Alzheimer disease patients\n\u2022 Reductive Stress: A new concept in Alzheimer\u2019s Disease\n\u2022 Global, regional, and national age-sex-specific mortality and life expectan-\ncy, 1950-2017: a systematic analysis for the Global Burden of Disease \n\u2022 Glucose 6-P dehydrogenase delays the onset of frailty by protecting aga-\ninst muscle damage\n\u2022 Frailty Is Associated with Oxidative Stress in Older Patients with Type 2 \nDiabetes\n\u2022 Redox-related biomarkers in physical exercise\n\u2022 Project: CIBER de Fragilidad y envejecimiento (CIBERfes)\n\u2022 Project: Evolution-Age-Gender-Lifestyle-Environment: mitocondrial fitness \nmapping\nThesis title: Role of p16ink4a and bmi-1 in oxidative stress-induced prema -\nture senescence in human dental pulp stem cells\nThesis title: Regulation of antioxidant defenses in the prevention of skeletal \nmuscle deconditioningXClinical research groups:\n\u2022 Research Group on the Study of Cardiometabolic and Renal \nRisk (Dr. Josep Red\u00f3n i Mas)\n\u2022 Cardiometabolic Research Group on Primary Care (Dr. Jorge \nNavarro P\u00e9rez)\n\u2022 Research Group on Clinical Cardiology (Dr. Juan Sanchis For\u00e9s)\n\u2022 Research Group on Oxidative Pathology (Dr. Guillermo S\u00e1ez \nTormo)\n\u2022 Research Group on Women Health (Dr. Antonio Cano S\u00e1n -\nchez)\n\u2022 Group on Translational Research in Ischemic Heart Disease \n(Dr. Vicente Bod\u00ed Peris)Experimental research groups\n\u2022 Research Group on Neurological Impairment (Dr. Carmina \nMontoliu F\u00e9lix)\n\u2022 Research Group on Endothelial Cells (LINCE) (Dr. Carlos Her-\nmenegildo Caudevilla, Dr. Susana Novella del Campo)\n\u2022 Research Group on Exercise, Nutrition and Healthy Lifestyle \n(Dr. M\u00aa Carmen G\u00f3mez Cabrera)\n\u2022 Research Group on Healthy Aging (Dra. Consuelo Borr\u00e1s \nBlasco)\n\u2022 Research Group on Aging and Physical Activity (Dr. Jos\u00e9 Vi\u00f1a \nRibes)\n\u2022 Research Group on Cellular and Organic Physiopathology of \nOxidative Stress (Dr. Federico V. Pallard\u00f3 Calatayud)\n\u2022 Research Group on Inflammation (Dr. Esteban Morcillo S\u00e1n -\nchez, Dr. M\u00aa Jes\u00fas Sanz Ferrando)\n\u2022 Research Group on Genetics of Osteoporosis (Dr. Miguel \u00c1n-\ngel Garc\u00eda P\u00e9rez)61\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Determination of ge -\nnetic biomarkers (mi-\ncroRNAs, mRNAs and \nSNPs) associated with \nhealthy aging, frailty \nand diseases associa -\nted with aging (mainly \ncardiovascular and neu-\nrodegenerative)\u2022 In Search of \u2018Omics\u2019-Based Biomarkers to Predict Risk of Frailty and Its \nConsequences in Older Individuals: The FRAILOMIC \n\u2022 Human exceptional longevity: transcriptome from centenarians is distinct \nfrom septuagenarians and reveals a role of Bcl-xL in successful aging.\nAging (Albany NY)\n\u2022 A translational approach from an animal model identifies CD80 as a can -\ndidate gene for the study of bone phenotypes in postmenopausal women \n\u2022 Centenarians maintain miRNA biogenesis pathway while it is impaired in \noctogenarians. Mechanisms of ageing and development\nThesis title: Transcript\u00f3mica en centenarios: un ejemplo de envejecimiento \nsatisfactorioX\nDetermination of epi -\ngenetic biomarkers \nassociated with healthy \naging, frailty and disea-\nses associated with \naging (mainly cardiovas-\ncular and neurodegene -\nrative)\u2022 Epigenetic biomarkers for human sepsis and septic shock: insights from \nimmunosuppression\n\u2022 Epigenetic regulation in the pathogenesis of Sj\u00f6gren syndrome and rheu -\nmatoid arthritis\n\u2022 Exercise training as a modulator of epigenetic events in prostate tumors\n\u2022 Implementing precission medicine in human frailty through epigenetic \nbiomarkers\n\u2022 Epigenetic biological age in mice models in aging and frailtyX\nDetermination of me-\ntabolomic biomarkers \nassociated with healthy \naging, frailty and disea-\nses associated with \naging (mainly cardiovas-\ncular and Neurodege -\nnerative)\u2022 Sex differences in age-associated Type 2 Diabetes in rats-role of estro-\ngens and oxidative stressX62\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Physical exercise proto-\ncols for the prevention \nof frailty\u2022 A multicomponent exercise intervention that reverses frailty and impro-\nves cognition, emotion, and social networking in the Community-Dwelling \nFrail Elderly\n\u2022 Exercise training as a drug to treat age associated frailty\n\u2022 Copenhagen consensus statement 2019: physical activity and ageing\n\u2022 Muscle repair after physiological damage relies on nuclear migration for \ncellular reconstruction\nProject: Novel multidomain therapeutic interventions to delay frailty and di-\nsability. Identification of molecular mechanisms with translational relevance\nProject: Personalized physical exercise as an intervention to reverse disa-\nbility in older adults living in residences (RESIFIT)\nThesis title: A multicomponent exercise program to prevent frailty, and for \ncognitive, emotional, and social improvement in frail elderly people\nThesis title: Moderate overexpression of glucose-6-phosphate dehydroge -\nnase improves healthspan in mice. Implications in skeletal muscle regene -\nration\nThesis title: Impact of long-term physical exercise on neuroprotection in \nmiddle-aged subjects: study of the molecular mechanisms involvedX63\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.3. Research areas\n2500\n2000\n1500\n1000\n500\n0350\n300\n250\n200\n150\n100\n50\n01586,983 1811,316 2166,006\n240,7401157,404\n26,068211219309\n41232\n7\nCardiovascular Oncology Metabolism Reproductive\nMedicineHospital\ndivisionsAssociated\nClinical Group\nNumber of publications Impact factorINCLIVA Health Research Institute has four research areas in order to organize its scientific activity. Despite their independence, they \nhave a common objective: meeting health needs and improving R&D&i system.\nTheir main aim is to establish a common reference framework to promote collaboration between INCLIVA attached researchers.\nEach of the lines counts on the participation of one or several advisers from the External Scientific Committee. These lines are led by the \nfollowing coordinators:\nCardiovascular Area\n\u2022 Coordinator: Dr. Francisco Javier Chorro Gasc\u00f3\n\u2022 Mission:  to contribute to the study of different aspects of cardiovascular disease (CVD) from its origins to its consequences\nOncology Area\n\u2022 Coordinator: Dr. Andr\u00e9s Cervantes Ruip\u00e9rez\n\u2022 Mission:  to contribute to the study of different aspects of oncological diseases, at the stage of diagnosis and molecular characteriza-\ntion and selection of specific molecular targets of therapeutic interest\nMetabolism and Organic Damage Area\n\u2022 Coordinator: Dr. Jos\u00e9 Vi\u00f1a Ribes\n\u2022 Mission:  to contribute to the study of the etiology, pathophysiology and diagnosis mechanisms or treatment of various metabolic \ndiseases; or those that generate organ damage as a fundamental link of its trigger action\nReproductive Medicine Area\n\u2022 Coordinator: Dr. Carlos Sim\u00f3n Vall\u00e9s\n\u2022 Mission: to advance in knowledge of human reproduction for translational application, improving the efficiency of assisted reproduc -\ntion treatment and reducing adverse effects\nScientific production analysis by research area\nThe following charts and figures summarize the main scientific activity indicators of the four areas of research and the other divisions \nfrom Hospital Cl\u00ednico de Valencia.64\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Since there are some scientific articles which are shared by two or more areas, it is worth mentioning that the sum of publications by area \nexceeds INCLIVA\u2019s total scientific output. Additionally, the next tables shows scientific publications distribution by area in terms of number \nof articles and impact factor.\n21%\n21%\n30%4%23%1%Relative distribution of publications\nCardiovascular Oncology Metabolism Reproductive Hospital divisions Associated Clnical Group23%\n26%31%3%17 %0%IF distribution65\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.3.1 Cardiovascular area\nGroups\nResearch Group on Cardiometabolic Risk\nGenomics and Diabetes Unit\nResearch Group on Cardiac Experimental Electrophysiology\nResearch Group on Endothelial Cells (LINCE)\nResearch Group on Clinical Cardiology\nResearch Group on the Study of Cardiovascular Risk in Children and Adolescents\nCardiometabolic Research Group on Primary Care\nResearch Group on the Study of Cardiometabolic and Renal Risk\nResearch Group on Vascular Function\nResearch Group on Pedriatric Nutrition\nGroup on Translational Research in Ischemic Heart Disease\nResearch Group on Heart Failure\n211\nNumber of  \narticlesIF\n1586.983IF\n7.521Average83\nCorresponding  \nauthor105\nNational  \ncollaborations60\nInternational \ncollaborations\n35\nD163\nFirst  \nauthor84\nLast  \nauthor114\nQ153\nQ2\noriginal articles letters editorial review case reports1817911366\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Researchers by categoriesResearch Group on Cardiometabolic Risk\nConsolidated group\nLeading Researcher, R4\nJos\u00e9 Tom\u00e1s Real Collado\nHospital. University\nEstablished Researchers, R3\nFrancisco Javier Ampudia Blasco. Hospital. University\nJuan Francisco Ascaso Gimilio. University\nMiguel Civera Andr\u00e9s. Hospital. University\nEmerging Researcher, R2\nSergio Mart\u00ednez Herv\u00e1s. University\nRecognised Researcher, R2\nMarta Peir\u00f3 Signes. INCLIVA. CIBERdem\nFirst Stage Researchers, R1\nBlanca Alabad\u00ed Pardi\u00f1es. INCLIVA\nM\u00edriam Moriana Hern\u00e1ndez. INCLIVA\nStaff. Collaborating Researchers\nAna Palanca Palanca. Hospital\nEsther Benito Casado. CIBERdem\nStaff. Nurse \nPilar Aguilar Santaisabel. HospitalGroup members\nTeam involved in2 3 2 1 3\nResearchers financed by \ncompetitive public calls or networks\nR4\n2 1 2\nStrategic aims\nIn terms of scientific activity of the research group during 2021, our group is participating in the development of three competitive \nand multidisciplinary research projects that include the following aims:\n\u2022 Project: Immunopharmacological modulation of the systemic inflammation associated to metabolic disorders. Search for new \ntherapeutic targets and synthesis of novel drugs\n\u2022 Project: Study of new inflammatory and angiogenic mechanisms associated to severe morbid obesity\n\u2022 Project: Role of the inflammatory processes in metabolic diseases and associated complications\nMain lines of research \n\u2022 Role of inflammatory axes in the modulation of metabolic and vascular dysfunctions in obesity, insulin resistance and diabetes \n\u2022 Primary dyslipidemias: molecular mechanisms, insulin resistance and novel therapeutic targets \n\u2022 Ageing, frailty, sarcopenia and neurodegeneration in people with diabetes \n\u2022 New diabetes technologies \n\u2022 Pharmacogenetic-based personalized treatment in diabetes \n\u2022 Applying Big Data and Artificial Intelligence technologies to analyse cardiovascular risk in dyslipidemia and diabetes R1 R2 R3 R4 STAFF\nR2 STAFF R167\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4\u2022 Adipokines, inflammatory axes, new therapeutic targets and cardiovascular risk in metabolic fatty liver disease \n\u2022 Body composition analysis \n- effect of body composition analysis, vascular risk and treatment in people with diabetes \n- impact of body composition analysis on prognosis, quality of life and therapeutic response in onco-haematological patients\nSELECTED PUBLICATIONS\n1. Perez-Hernandez J, Riffo-Campos A, Ortega A, Martinez-\nArroyo O, Perez-Gil D, Olivares D, Solaz E, Martinez F, \nMartinez-Hervas S, Chaves F, Redon J, Cortes R. Urinary- \nand plasma-derived exosomes reveal a distinct MicroRNA \nsignature associated with albuminuria in hypertension. \nHypertension. 2021 Mar 3;77(3):960-971. doi: 10.1161/\nHYPERTENSIONAHA.120.16598. PMID: 33486986. IF: \n10,19\n2. Danne T, Edelman S, Frias J, Ampudia-Blasco F, Banks P, \nJiang W, Davies M, Sawhney S. Efficacy and safety of adding \nsotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized \ninsulin therapy in adults with type 1 diabetes and baseline \nBMI \u226527 kg/m2. Diabetes, Obesity & Metabolism. 2021 \nMar;23(3):854-860. doi: 10.1111/dom.14271. PMID: \n33289297. IF: 6,577\n3. Wilmot EG, Close KL, Jurisic-Erzen D, Bruttomesso D, \nAmpudia-Blasco FJ, Bosnyak Z, de Climens AR, Bigot G, \nPeters AL, Renard E, Berard L, Calliari LE, Seufert J. Patient-\nreported outcomes in adults with type 1 diabetes in global \nreal-world clinical practice: the SAGE study. Diabetes, Obesity \n& Metabolism. 2021 Aug;23(8):1892-1901. doi: 10.1111/\ndom.14416. PMID: 33914401. IF: 6,577IF 17\nNumber of  \narticles 83.818IF\n4.904Average6\nCorresponding  \nauthor6\nNational  \ncollaborations4\nInternational \ncollaborations\n4. Herrero-Cervera A, Espinos-Estevez C, Martin-Vano S, \nTaberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, \nMartinez-Hervas S, Gonzalez-Navarro H. Dissecting abdominal \naortic aneurysm is aggravated by genetic inactivation of \nLIGHT (TNFSF14). Biomedicines. 2021 Oct 22;9(11):1518. \ndoi: 10.3390/biomedicines9111518. PMID: 34829747. IF: \n6,081\n5. Aguilar-Ballester M, Hurtado-Genoves G, Taberner-Cortes \nA, Herrero-Cervera A, Martinez-Hervas S, Gonzalez-Navarro \nH. Therapies for the treatment of cardiovascular disease \nassociated with Type 2 Diabetes and Dyslipidemia. International \nJournal of Molecular Sciences. 2021 Jan 11;22(2):660. doi: \n10.3390/ijms22020660. PMID: 33440821. IF: 5,923\nRESEARCH PROJECTS AND GRANTS  \nFOR RESEARCH \nReference: PI19/00169\nTitle: Papel de los procesos inflamatorios en las enfermedades \nmetab\u00f3licas y en las complicaciones asociadas\nPrincipal Investigator: Herminia Gonz\u00e1lez and Sergio Mart\u00ednez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER PUBLICATIONSEmerging Researcher \nSergio Mart\u00ednez Herv\u00e1s\nThe line of research is based lipid metabolism, inflammation, fatty liver, insulin resistance, and diabetes and its associated \ncomplications.68\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Beneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget: \u20ac159.720\nReference: PI18/00209\nTitle: Identificaci\u00f3n de nuevos mecanismos implicados en la \nangiog\u00e9nesis e inflamaci\u00f3n en pacientes obesos. Modulaci\u00f3n por \nligandos de receptores nucleares constitutivos de androstano\nPrincipal Investigator: Laura Piqueras Ruiz and Jos\u00e9 Tomas Real \nCollado\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER \nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal budget: \u20ac173.332,50\nReference: CB07/08/0018\nTitle: CIBER de Diabetes y Enfermedades Metab\u00f3licas Asociadas \n(CIBERdem)\nPrincipal Investigator: Juan F. Ascaso Gimilio and Jos\u00e9 Tomas \nReal Collado\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER \nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2008-Reference: SAF2017-89714-R\nTitle: Modulaci\u00f3n farmacol\u00f3gica del sistema inmune como diana \nclave en la prevenci\u00f3n de la enfermedad cardiovascular asociada a \ndesordenes metab\u00f3licos. S\u00edntesis de f\u00e1rmacos novedosos\nPrincipal Investigator: M\u00aa Jes\u00fas Sanz Ferrando and Juan F. \nAscaso Gimilio\nFunding Body: Ministerio de Econom\u00eda y Competitividad\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget: \u20ac205.700\nReference: PROMETEO/2019/032\nTitle: Una aproximaci\u00f3n translacional desde la cl\u00ednica a la \nexperimentaci\u00f3n animal: estudio del papel del eje CCL11/CCR3 y \nla inflamaci\u00f3n eosinof\u00edlica en la patolog\u00eda cardiovascular asociada a \ndes\u00f3rdenes metab\u00f3licos\nPrincipal Investigator: M\u00aa Jes\u00fas Sanz Ferrrando (Jos\u00e9 Tom\u00e1s, \nSergio Mart\u00ednez as collaborating researchers)\nFunding Body: Conselleria de Educaci\u00f3n Cultura y Deporte\nBeneficiary Institution: Universidad de Valencia\nDuration: 2020-2023\nTotal budget: \u20ac211.73669\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Leading Researcher, R4\nFelipe Javier Chaves Mart\u00ednez \nINCLIVA\nEstablished Researcher, R3\nJes\u00fas Rodr\u00edguez D\u00edaz. University\nRecognised Researchers, R2\nAna B\u00e1rbara Garc\u00eda Garc\u00eda. CIBER\nIrene Andr\u00e9s Blasco. INCLIVA\nJos\u00e9 Miguel Juanes T\u00e9bar. INCLIVA\nRoberto Gozalbo Rovira. University\nFirst Stage Researchers, R1\nAzahara M\u00aa Fuentes Trillo. INCLIVA\nCristina Santiso Bell\u00f3n. University\nFran Lara Hern\u00e1ndez. INCLIVA \nM\u00aa Elena Quiroz Rodr\u00edguez. INCLIVA\nNazaret Pe\u00f1a Gil. University\nRebeca Melero Valverde. INCLIVA\nSoraya Garc\u00eda Sorribes. INCLIVA\nStaff. Collaborating Researcher\nIris Manzano Blasco. INCLIVAGroup membersGenomics and Diabetes Unit  \nConsolidated group\nResearchers by categories\n4 7 1\nResearchers financed by \ncompetitive public calls or networks\nR4\n1 7 21 1\nStrategic aims\n\u2022 Identify genetic and environmental factors involved in the development of type 2 diabetes and related diseases\n\u2022 Identify alterations of methylation and hydroxymethylation in relation to the development of type 2 diabetes and its potential use \nas biomarkers\n\u2022 Identify genetic causes of rare diseases: Abeta, ATA and hereditary forms of hypercholesterolemias not caused by known genes\n\u2022 Study of environmental factors involved in the development of diseases of high cardiovascular risk, especially type 2 diabetes \nand associated organic damage\n\u2022 Development of fast and easy procedures for SARS-CoV2 (COVID19) detection and characterization (including the analysis of \nthe main human genetic variations involved in COVID19)\nMain lines of research \n\u2022 Identification of frequent and rare functional variants involved in high cardiovascular risk disease development and their \ninteraction with environmental factors\n\u2022 Genotyping and/or sequencing of complete rotavirus and norovirus genomes. Human genotype study of FUT2 and FUT3 genes \nrelated to viral genotypes and their relationship with intestinal microbiota\n\u2022 Analysis of methylated and hydroxymethylated regions in the genome in patients with specific phenotypes at baseline compared \nwith phenotypes present five years later, as pertains to type 2 diabetesR1 R2 R3 R4 STAFF\nR2 R4 R170\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\n5. Gozalbo-Rovira R, Santiso-Bellon C, Buesa J, Rubio-del-Campo \nA, Vila-Vicent S, Munoz C, Yebra M, Monedero V, Rodriguez-\nDiaz J. Microbiota depletion promotes human rotavirus \nreplication in an adult mouse model. Biomedicines. 2021 Jul \n20;9(7):846. doi: 10.3390/biomedicines9070846. PMID: \n34356911. IF: 6,081\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  COV20/00279\nTitle:  Detecci\u00f3n y caracterizaci\u00f3n r\u00e1pida de COVID19 y del \npaciente\nPrincipal Investigator:  Felipe Javier Chaves Mart\u00ednez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac175.000\nReference:  PI17/00544\nTitle:  Identificaci\u00f3n de variantes gen\u00e9ticas protectoras frente al \ndesarrollo de diabetes tipo 2 en octogenarios\nPrincipal Investigator:  Felipe Javier Chaves Mart\u00ednez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac196.020IF 19\nNumber of  \narticles98.304IF\n5.173Average7\nCorresponding  \nauthor14\nNational  \ncollaborations1\nInternational \ncollaborations\u2022 Monitoring and molecular characterization of chronic lymphocytic leukaemia and study of molecular markers\n\u2022 Identification of relationships between different genes, essential metals and pollutants in relation to type 2 diabetes and related \ntraits\nSELECTED PUBLICATIONS\n1. Rubio-Del-Campo A, Gozalbo-Rovira R, Moya-Gonzalvez E, \nAlberola J, Rodriguez-Diaz J, Yebra M. Infant gut microbiota \nmodulation by human milk disaccharides in humanized \nmicrobiome mice. Gut Microbes. 2021 Jan-Dec;13(1):1-20. \ndoi: 10.1080/19490976.2021.1914377. PMID: \n33938391. IF: 10,245\n2. Perez-Hernandez J, Riffo-Campos A, Ortega A, Martinez-\nArroyo O, Perez-Gil D, Olivares D, Solaz E, Martinez F, \nMartinez-Hervas S, Chaves F, Redon J, Cortes R. Urinary- \nand plasma-derived exosomes reveal a distinct MicroRNA \nsignature associated with albuminuria in hypertension. \nHypertension. 2021 Mar 3;77(3):960-971. doi: 10.1161/\nHYPERTENSIONAHA.120.16598. PMID: 33486986. IF: \n10,19\n3. Alonso SP, Valdes S, Maldonado-Araque C, Lago A, Ocon P, \nCalle A, Castano L, Delgado E, Menendez E, Franch-Nadal J, \nGaztambide S, Girbes J, Chaves F, Garcia-Serrano S, Garcia-\nEscobar E, Fernandez-Garcia JC, Olveira G, Colomo N, Rojo-\nMartinez G. Thyroid hormone resistance index and mortality \nin euthyroid subjects: Di@bet.es study. European Journal of \nEndocrinology. 2021 Dec 1;186(1):95-103. doi: 10.1530/\nEJE-21-0640. PMID: 34735370. IF: 6,664\n4. Maldonado-Araque C, Valdes S, Badia-Guillen R, Lago-\nSampedro A, Colomo N, Garcia-Fuentes E, Gutierrez-Repiso C, \nGoday-Arno A, Calle-Pascual A, Castano L, Castell C, Delgado \nAlvarez E, Menendez Torre E, Franch-Nadal J, Gaztambide \nS, Girbes J, Chaves Mart\u00ednez F, Soriguer F, Rojo-Martinez \nG. Iodine deficiency and mortality in spanish adults. Di@bet.\nes study. Thyroid. 2021 Jan;31(1):106-114. doi: 10.1089/\nthy.2020.0131. PMID: 32781944. IF: 6,56871\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference:  AGL2017-84165-C2-2-R\nTitle: Descifrando las interacciones entre la microbiota intestinal/\nvirus ent\u00e9ricos/hospedador: bases para proteger frente a la \ndiarrea viral\nPrincipal Investigator:  Jes\u00fas Rodr\u00edguez D\u00edaz\nFunding Body: Ministerio de Econom\u00eda y Hacienda\nBeneficiary Institution:  Universidad de Valencia \nDuration: 2018-2021\nTotal budget:  \u20ac133.100\nReference: AEST/2020/041 \nTitle: Desarrollo de un sistema r\u00e1pido y econ\u00f3mico para la \ndetecci\u00f3n de pat\u00f3genos causantes de gastroenteritis infecciosas \nmediante EOSAL\nPrincipal Investigator: Jes\u00fas Rodr\u00edguez D\u00edaz\nFunding Body: Conselleria de Educaci\u00f3n Cultura y Deporte \nBeneficiary Institution:  Universidad de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac40.000 THESIS\nThesis title: Mgviz: desarrollo e integraci\u00f3n de m\u00e9todos de an\u00e1lisis \ny visualizaci\u00f3n de datos gen\u00f3micos en biomedicina\nDoctoral candidate: Jos\u00e9 Miguel Juanes Tebar\nDirector(s):  Felipe Javier Chaves Mart\u00ednez, Pablo Mar\u00edn Garc\u00eda, \nVicente Arnau Llombart \nDate of the defense:  22/03/2021\nGrade:  Sobresaliente \u201ccum laude\u201d72\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Cardiac Experimental Electrophysiology  \nConsolidated group\nLeading Researcher, R4\nFrancisco Javier Chorro Gasc\u00f3 \nHospital. University \nAntonio M. Alberola Aguilar. University\nLuis Such Belenguer. University\nRecognised Researchers, R2\nGerm\u00e1n Parra Giraldo. University\nIrene del Canto Serrano. INCLIVA\nIsabel Trapero Gimeno. University\nLuis Such Miquel. University\nManuel Zarzoso Mu\u00f1oz. University\nFirst Stage Researchers, R1\n\u00d3scar Juli\u00e1n Arias Mutis. CIBER\nPatricia Genov\u00e9s Mart\u00ednez. CIBERGroup members\nStrategic aims\n\u2022 Publication of the results obtained on using the 1,4-benzothiazepine derivative JTV-519 to modify the proarrhythmogenic \nmanifestations of mechanoelectric feedback and continuation of the programmed experimental series to analiyze the effects \nof KN-93, carvedilol and analogues, late Na+ current inhibitors and the Nitric Oxide carrier S-nitrosoglutathione\n\u2022 Continuation of the analysis of the effects of modifications of the basic electrophysiological properties on the processes \ninvolved in the induction and maintenance of ventricular fibrillation\n\u2022 Analysis of the electrophysiological effects of chronic physical exercise and its protective effect against arrhythmias, the \ninfluence of the cardiac nervous system and mitochondrial oxidative stress and the involvement of the IKATP current\n\u2022 Development of instruments for recording, processing and analysing cardiac electrophysiological signals obtained with \nmapping systems\n\u2022 Progressive development of the experimental series aimed to study the mechanisms involved in the deterioration of the \nsystolic function, fibrosis and the inducibility of arrhythmias in a chronic model of infarction\n\u2022 Progressive development of an experimental model of metabolic syndrome to analyze the electrophysiological modifications \nand the inducibility of cardiac arrhythmias\nMain lines of research \n\u2022 Myocardial stretching: analysis of electrophysiological changes induced by mechanical stretching. Autocrine/paracrine \ninfluences and study of protective actions by means of drugs\n\u2022 Clinical and basic research on heart failure: role of calcium homeostasis in arrhythmogenesis. Study on the effects of drugs \nacting on intracellular Ca2+ dynamics\n\u2022 Analysis of the effects of modifications in basic electrophysiological properties on the processes involved in induction and \nmaintenance of ventricular fibrillationResearchers by categories\nTeam involved in5 2 3\nResearchers financed by \ncompetitive public calls or networks\nR4\n1 2R1 R2 R4\nR2 R173\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4ejection fraction status in patients with acute heart failure. \nJournal of Cardiac Failure. 2021 Oct;27(10):1090-1098. \ndoi: 10.1016/j.cardfail.2021.06.020. PMID: 34273477. IF: \n5,712\n5. de Dios E, Rios-Navarro C, Perez-Sole N, Gavara J, Marcos-\nGarces V, Forteza M, Oltra R, Vila J, Chorro F, Bodi V. \nOverexpression of genes involved in lymphocyte activation \nand regulation are associated with reduced CRM-\nderived cardiac remodelling after STEMI. International \nImmunopharmacology. 2021 Mar 4;95:107490. doi: \n10.1016/j.intimp.2021.107490. PMID: 33677257. IF: \n4,932\n \nRESEARCH PROJECTS AND GRANTS  \nFOR RESEARCH\nReference: CB16/11/00486\nTitle: CIBER Cardiovascular\nPrincipal Investigator:  Francisco Javier Chorro Gasc\u00f3\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2017-\u2022 Study of electrophysiological effects of chronic physical activity by: a) analysis of the protection against arrhythmias or scientific \nactivity facilitation of its reversion; b) study of the influence of heart\u2019s nervous system and mitochondrial oxidative stress; and c) \nanalysis of the effects on the electrical instability induced by myocardial ischemia and the implication of IKATP current\n\u2022 Development and extension of tools for the registration, processing and analysing of cardiac electrophysiological signals based \non multielectrodes and optical mapping systems able to analyze voltage and calcium signals\n\u2022 Study of mechanisms involved in the deterioration of the systolic function, fibrosis and the inducibility of arrhythmias in a \nchronic model of infarction\n\u2022 Study of electrophysiological modifications and inducibility of cardiac arrhythmias in an experimental model of metabolic \nsyndrome\nPUBLICATIONS\nIF 24\nNumber of  \narticles124.007IF\n5.166Average2\nCorresponding  \nauthor14\nNational  \ncollaborations4\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Palau P, Seller J, Dominguez E, Sastre C, Ramon JM, \nEspriella R, Santas E, Minana G, Bodi V, Sanchis J, Valle A, \nChorro FJ, Llacer P, Bayes-Genis A, Nunez J. Effect of beta-\nblocker withdrawal on functional capacity in heart failure \nand preserved ejection fraction. Journal of the American \nCollege of Cardiology. 2021 Nov 23;78(21):2042-2056. doi: \n10.1016/j.jacc.2021.08.073. PMID: 34794685. IF: 24,094\n2. Nunez J, de la Espriella R, Minana G, Santas E, Llacer P, Nunez \nE, Palau P, Bodi V, Chorro F, Sanchis J, Lupon J, Bayes-Genis \nA. Antigen carbohydrate 125 as a biomarker in heart failure: \na narrative review. European Journal of Heart Failure. 2021 \nSep;23(9):1445-1457. doi: 10.1002/ejhf.2295. PMID: \n34241936. IF: 15,534\n3. Nunez J, Lorenzo M, Minana G, Palau P, Monmeneu JV, Lopez-\nLereu MP, Gavara J, Marcos-Garces V, Rios-Navarro C, Perez \nN, de Dios E, Nunez E, Sanchis J, Chorro FJ, Bayes-Genis A, \nBodi V. Sex differences on new-onset heart failure in patients \nwith known or suspected coronary artery disease. European \nJournal of Preventive Cardiology. 2021 Dec 29;28(15):1711-\n1719. doi: 10.1093/eurjpc/zwab078. PMID: 33970216. IF: \n7,084\n4. Santas E, Minana G, Palau P, De La Espriella R, Lorenzo M, \nNunez G, Sanchis J, Chorro FJ, Bayes-Genis A, Nunez J. Right \nheart dysfunction and readmission risk across left ventricular 74\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Reference:  PI18/01620\nTitle:  Modificaci\u00f3n de los efectos pro-arr\u00edtmicos inducidos por la \nsobrecarga mec\u00e1nica o el remodelado ventricular\nPrincipal Investigator:  Francisco Javier Chorro Gasc\u00f3\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac129.470\nReference: PROMETEO/2018/078\nTitle: Mecanismos protectores frente a la muerte cardiaca \ns\u00fabita de causa arr\u00edtmica\nPrincipal Investigator: Francisco Javier Chorro Gasc\u00f3\nFunding body: Conselleria de Educaci\u00f3n Cultura y Deporte\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n del Hospital \nCl\u00ednico Universitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac275.859,02\nTitle:  Resonancia magn\u00e9tica card\u00edaca de estr\u00e9s con vasodilatadores \npara predecir la mortalidad a largo plazo en un amplio registro \nretrospectivo de pacientes con cardiopat\u00eda isqu\u00e9mica conocida o \nsospechada\nPrincipal Investigator: Vicent Bod\u00ed Peris (Francisco J Chorro \nGasc\u00f3 as collaborating researcher)\nFunding body: Sociedad Espa\u00f1ola de Cardiolog\u00eda\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n del Hospital \nCl\u00ednico Universitario de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac15.000THESIS\nThesis title: Estudio de la funci\u00f3n mioc\u00e1rdica en la enfermedad \nrenal cr\u00f3nica avanzada y en la terapia de sustituci\u00f3n renal\nDoctoral candidate: Joana Melero Lloret\nDirector(s):  Francisco Javier Chorro Gasc\u00f3, Carlos Joaqu\u00edn \nSoriano Navarro\nDate of the defense:  26/03/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title:  Cambios en la activaci\u00f3n electromiogr\u00e1fica de \nla musculatura de codo en sujetos sanos comparada con la \nactivaci\u00f3n muscular en sujetos con tendinopat\u00eda y la influencia de \nla aplicaci\u00f3n de punci\u00f3n seca en la misma\nDoctoral candidate: Fredy Hanna\nDirector(s): Yasser Alakhdar Mohmara, Antonio Alberola Aguilar\nDate of the defense: 23/04/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title:  Efectos de la inhibici\u00f3n de la desacetilaci\u00f3n de las \nhistonas en el remodelado post-infarto del sustrato arritmog\u00e9nico\nDoctoral candidate: Patricia Genov\u00e9s Mart\u00ednez\nDirector(s): Francisco Javier Chorro Gasc\u00f3, Luis Such Belenguer, \nIrene Del Canto Serrano\nDate of the defense: 27/04/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Efectos electrofisiol\u00f3gicos intr\u00ednsecos del ejercicio \nf\u00edsico cr\u00f3nico sobre el miocardio ventricular norm\u00f3xico y tras \nisquemia regional aguda: implicaci\u00f3n del canal Katp. Estudio en \ncoraz\u00f3n aislado de conejo\nDoctoral candidate: Nathalia Gallego Rojas \nDirector(s): Juan Guerrero Mart\u00ednez, Germ\u00e1n Parra Giraldo, Luis \nSuch Belenguer\nDate of the defense: 22/07/2021\nGrade:  Sobresaliente \u201ccum laude\u201d75\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Leading Researchers, R4\nCarlos Hermenegildo Caudevilla \nUniversity\nSusana Novella del Campo\nUniversity\nRecognised Researchers, R2\nDaniel Bernardo P\u00e9rez Cremades. University\nElena Monsalve Villalba. UniversityGroup members\nhttp://www.uv.es/lince/SP/index.htmlResearch Group on Endothelial Cells (LINCE)  \nConsolidated group\nStrategic aims\n\u2022 To analyze the levels of selected miRNA of acute myocardial infarction patients included in the studies of PI19/01714\n\u2022 To analyze the role of estrogen receptors on the regulation of miRNA by estradiol\n\u2022 To tune the experimental surgical procedure of AMI in the SAMR1/SAMP8 murine senesence model, which will allow us to \nevaluate the vascular effect of aging and sex and to verify that the change in expression of some miRNA observed in humans \nwith AMI is reproduced\n\u2022 To incorporate new pre and postdoctoral researchers to our group\nMain lines of research \n\u2022 Sex differences in cardiovascular research\n\u2022 Vascular effects of sex hormones\n\u2022 Identification of new sex hormone-regulated signaling pathways in endothelium\n\u2022 Identification and characterization of estradiol-regulated miRNA in endothelium and acute myocardial infarction murine model\n\u2022 Interaction of sex hormones with pro-atherogenic factorsResearchers by categories\nResearchers financed by \ncompetitive public calls or networks\nR4\n12 2R2 R4\nR2\nPUBLICATIONS\nIF 4\nNumber of  \narticles31.635IF\n7.908Average1\nCorresponding  \nauthor0\nNational  \ncollaborations3\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Becker-Greene D, Li H, P\u00e9rez-Cremades D, Wu W, Bestepe \nF, Ozdemir D, Niosi CE,  Aydogan C, Orgil D, Feinberg MW, \nIcli B. MiR-409-3p targets a MAP4K3-ZEB1-PLGF signaling \naxis and controls brown adipose tissue angiogenesis and insulin resistance. Cellular and Molecular Life Sciences. \n2021 Dec;78(23):7663-7679. doi: 10.1007/s00018-021-\n03960-1. IF: 9,26176\nINCLIVA SCIENTIFIC REPORT 2021scientific activity42. Perez-Cremades D, Paes A, Vidal-Gomez X, Mompeon A, \nHermenegildo C, Novella S. Regulatory network analysis \nin estradiol-treated human endothelial cells. International \nJournal of Molecular Sciences. 2021 Jul 30;22(15):8193. \ndoi: 10.3390/ijms22158193. PMID: 34360960. IF: 5,923\n3. Ni H, Haemmig S, Deng Y, Chen J, Simion V, Yang D, Sukhova \nG, Shvartz E, Wara AKMK, Cheng HS, P\u00e9rez-Cremades \nD, Assa C, Sausen G, Zhuang R, Dai Q, Feinberg MW. A \nsmooth muscle cell-enriched long noncoding RNA regulates \ncell plasticity and atherosclerosis by interacting with serum \nresponse factor. Arteriosclerosis, Thrombosis, and Vascular \nBiology. 2021 Sep;41(9):2399-2416. doi: 10.1161/\nATVBAHA.120.315911. IF: 8,311\n4. Yang Y, Haemmig S, Zhou H, P\u00e9rez-Cremades D, Sun X, \nChen L, Li J, Haneo-Mejia H, Yang T, Hollan I, Feinberg MW. \nMethotrexate attenuates vascular inflammation through an \nadenosine-microRNA-dependent pathway. Elife. 2021 Jan \n8;10:e58064. doi: 10.7554/eLife.58064. IF: 8,140\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: COST Action CA17129\nTitle:  Catalysing transcriptomics research in cardiovascular \ndisease\nPrincipal Investigator: Yvan Devaux (Susana Novella as \ncollaborating researcher)\nFunding body: European Commission\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nReference: PI19/01714\nTitle:  Regulaci\u00f3n dependiente de sexo y estr\u00f3genos en el s\u00edndrome \ncoronario agudo e impacto funcional en\u00a0 c\u00e9lulas endoteliales \nhumanas. Nuevos\u00a0biomarcadores\u00a0para prevenci\u00f3n primaria\nPrincipal Investigator: Carlos Hermenegildo y Susana Novella\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal Budget: \u20ac159.720Reference:  AICO/2020/030\nTitle:  Repercusi\u00f3n en la funci\u00f3n vascular de miRNA regulados por \nestr\u00f3genos\nPrincipal Investigator: Susana Novella del Campo\nFunding body:  Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary institution:  Universidad de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac40.000\n 77\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Clinical Cardiology\nConsolidated group\nLeading Researcher, R4\nJuan Sanchis For\u00e9s \nHospital. University \nEstablished Researcher, R3\nVicente Ruiz Ros. Hospital. University\nRecognised Researchers, R2\nAnna Mollar Fern\u00e1ndez. INCLIVA\nSergio Garc\u00eda Blas. Hospital\nFirst Stage Researchers, R1\nErnesto Valero Picher. Hospital\nJessika Ariadnna Gonz\u00e1lez D\u2019 Gregorio. Hospital. INCLIVA\nStaff. Collaborating Researcher\nAgust\u00edn Fern\u00e1ndez Cisnal. Hospital\nStaff. Nurses\nGeorgina Zaharia. INCLIVAGroup members\nStrategic aims\n\u2022 Publication of manuscripts in high IF journals\n\u2022 CIBER Cardiovascular\n\u2022 Development of FIS projects\nMain lines of research \n\u2022 Research line in heart failure:\n- Beta blocker treatment withdrawal in patients with heart failure with preserved systolic function and evidence of chronotropic \nincompetence\n- Short-term effects of dapagliflozin on peak oxygen consumption in type 2 diabetic patients with heart failure with reduced \nsystolic function\n\u2022 Research line in acute coronary syndrome: randomized comparison between invasive and conservative strategies in frail elderly \npatients with non-ST-segment elevation myocardial infarction (MOSCA-FRAIL)\n\u2022 Investigation line in interventional cardiology: effect of changes in antigen carbohydrate 125 levels before percutaneous aortic \nvalve prosthesis implant on prognosis after implantationResearchers by categories\nTeam involved in2 1 2 1 2\nResearchers financed by \ncompetitive public calls or networks\nR4\n1 1R1 R2 R3 R4 STAFF\nR2 R1\nPUBLICATIONS\nIF 46\nNumber of  \narticles235.466IF\n5.118Average8\nCorresponding  \nauthor30\nNational  \ncollaborations7\nInternational \ncollaborations78\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4SELECTED PUBLICATIONS\n1. Palau P, Seller J, Dominguez E, Sastre C, Ramon JM, \nEspriella R, Santas E, Minana G, Bodi V, Sanchis J, Valle A, \nChorro FJ, Llacer P, Bayes-Genis A, Nunez J. Effect of beta-\nblocker withdrawal on functional capacity in heart failure \nand preserved ejection fraction. Journal of the American \nCollege of Cardiology. 2021 Nov 23;78(21):2042-2056. doi: \n10.1016/j.jacc.2021.08.073. PMID: 34794685. IF: 24,094\n2. Nunez J, de la Espriella R, Minana G, Santas E, Llacer P, Nunez \nE, Palau P, Bodi V, Chorro F, Sanchis J, Lupon J, Bayes-Genis \nA. Antigen carbohydrate 125 as a biomarker in heart failure: \na narrative review. European Journal of Heart Failure. 2021 \nSep;23(9):1445-1457. doi: 10.1002/ejhf.2295. PMID: \n34241936. IF: 15,534\n3. Lam C, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi \nE, Ezekowitz J, Hernandez A, O\u2019Connor C, Roessig L, Patel \nM, Pieske B, Anstrom K, Armstrong P, VICTORIA Study Grp. \nClinical outcomes and response to vericiguat according to \nindex heart failure event: insights from the VICTORIA trial. \nJAMA Cardiology. 2021 Jun 1;6(6):706-712. doi: 10.1001/\njamacardio.2020.6455. PMID: 33185650. IF: 14,676\n4. Nunez J, Lorenzo M, Minana G, Palau P, Monmeneu JV, Lopez-\nLereu MP, Gavara J, Marcos-Garces V, Rios-Navarro C, Perez \nN, de Dios E, Nunez E, Sanchis J, Chorro FJ, Bayes-Genis A, \nBodi V. Sex differences on new-onset heart failure in patients \nwith known or suspected coronary artery disease. European \nJournal of Preventive Cardiology. 2021 Dec 29;28(15):1711-\n1719. doi: 10.1093/eurjpc/zwab078. PMID: 33970216. \nIF: 7,084\n5. De Luca G, Cercek M, Jensen LO, et al. Impact of renin-\nangiotensin system inhibitors on mortality during the COVID \nPandemic among STEMI patients undergoing mechanical \nreperfusion: insight from an international STEMI registry. \nBiomedicine & Pharmacotherapy. 2021 Jun;138:111469. \ndoi: 10.1016/j.biopha.2021.111469. PMID: 3374052. IF: \n6,529RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI18/01138\nTitle:  Efecto de la modificaci\u00f3n de los niveles de ant\u00edgeno \ncarbohidrato 125 antes del implante de pr\u00f3tesis valvular a\u00f3rtica \npercut\u00e1nea sobre el pron\u00f3stico tras el implante\nPrincipal Investigator: Juan Sanchis For\u00e9s\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal budget:  \u20ac57.475\nReference: CB16/11/00420\nTitle:  CIBER Cardiovascular\nPrincipal Investigator:  Juan Sanchis For\u00e9s\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER \nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2017-\nReference: AP-2021-016\nTitle:  BREIC: Identificaci\u00f3n de biomarcadores del eje coraz\u00f3n-\nmicrobiota-sistema inmune por RMN para la estratificaci\u00f3n de \npacientes con insuficiencia cardiaca\nPrincipal Investigator: Vannina Gonz\u00e1lez Marrachelli and Anna \nMollar Fern\u00e1ndez\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution:  Universidad de Valencia - INCLIVA\nDuration: 2021-202279\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on the Study of Cardiovascular Risk in Children and Adolescents  \nConsolidated group\nLeading Researcher, R4\nEmpar Lurbe i Ferrer \nUniversity \nEstablished Researchers, R3\nFrancisco Aguilar Bacallado. University\nIsabel Torr\u00f3 Dom\u00e9nech. University\nRecognised Researcher, R2\nJulio \u00c1lvarez Pitti. University\nFirst Stage Researchers, R1\nAna de Blas Zapata. University\nNuria Garc\u00eda Carbonell. University\nRafael G\u00f3mez Zafra. University\nStaff. Collaborating Researcher\nJuan Jos\u00e9 Alc\u00f3n S\u00e1ez. University \nStaff. Technician\nFrancisco Ponce Zan\u00f3n. CIBERobnGroup members\nStrategic aims\n\u2022 The iPEDITEC Unit brings healthcare workers into daily contact with engineers developing software for signal capture through \nmobile devices. Studying the psychological parameters that facilitate personalized therapy has been a priority aim during \n2021, resulting in improved treatment of obese pediatric patients in the Unit\n\u2022 The PAIDO Program is focused on personalized medical care extended through initiatives involving family, educators, \nnutritionists, physical education teachers and other social agents. Treatment goes beyond the hospital setting to include the \nchild\u00b4s environment and personal sphere and is supported by state-of the art artificial intelligence technologies\n\u2022 To improve the knowledge of fetal life and postnatal growth on the development of cardiometabolic risk factors early in life. \nThe KITE cohort is a prospective study starting at birth and assessing the determinants of cardiometabolic risk factors in \nthe first decades of life. Omics data from umbilical cord are available and the analysis of the interaction between clinical data \nand omics may help to introduce actions in critical periods of life and the potential contribution to reduce cardiometabolic \ndisease later in life. Mrs. Lurbe is the coordinator of the new document of the European Guidelines on Arterial Hypertension \nin Children and Adolescents\nMain lines of research \n\u2022 New technologies applied to the detection of congenital heart diseases and sepsis in asymptomatic newborn babies\n\u2022 Childhood obesity: new insights in the personalized treatment: study of the cardiorespiratory capacity\n\u2022 New technologies applied to the treatment of obesity: physical exercise preventing and treating obesity\n\u2022 Arterial hypertension in children and adolescents\n\u2022 Cardiovascular and renal risk in diabetesResearchers by categories\nTeam involved in3 1 2 1 3\nResearchers financed by \ncompetitive public calls or networks\nR4\n1R1 R2 R3 R4 STAFF\nSTAFF\nStaff. Administrative assistant\nChristine Deutsch. INCLIVA80\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Beneficiary Institution:  Universidad de Valencia\nDuration: 2020-2024\nTotal budget:  \u20ac700.000\nReference: PI20/00269\nTitle: Impacto del peso al nacer y el patr\u00f3n de crecimiento \nen los factores de riesgo cardiometab\u00f3lico en adolescentes \npostpuberales: aproximaci\u00f3n cl\u00ednica y molecular\nPrincipal Investigator: Empar Lurbe i Ferrer\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget:  \u20ac174.845\nReference:  PI17/01517\nTitle: Programaci\u00f3n fetal y desarrollo postnatal en hijos de \nmadres obesas: modulaci\u00f3n por la alimentaci\u00f3n en el primer a\u00f1o \nde vida\nPrincipal Investigator:  Empar Lurbe i Ferrer\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac170.005\nReference:  CB06/03/0039\nTitle:  Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBER) de \nFisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn)\nPrincipal Investigator: Empar Lurbe i Ferrer\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Consorcio Hospital General Universitario \nde Valencia\nDuration: 2006-PUBLICATIONS\nIF 11\nNumber of  \narticles48.776IF\n4.434Average5\nCorresponding  \nauthor2\nNational  \ncollaborations9\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Lurbe E, Ingelfinger J. Developmental and early life origins of \ncardiometabolic risk factors: novel findings and implications. \nHypertension. 2021 Feb;77(2):308-318. doi: 10.1161/\nHYPERTENSIONAHA.120.14592. PMID: 33390043. IF: \n10,19\n2. Stabouli S, Erdine S, Suurorg L, Jankauskiene A, Lurbe E. \nObesity and eating disorders in children and adolescents: the \nbidirectional link. Nutrients. 2021 Nov 29;13(12):4321. doi: \n10.3390/nu13124321. PMID: 34959873. IF: 5,717\n3. Drozdz D, Alvarez-Pitti J, Wojcik M, Borghi C, Gabbianelli \nR, Mazur A, Herceg-Cavrak V, Gonzalez Lopez-Valcarcel B, \nBrzezinski M, Lurbe E, Wuehl E. Obesity and cardiometabolic \nrisk factors: from childhood to adulthood. Nutrients. 2021 \nNov 22;13(11):4176. doi: 10.3390/nu13114176. PMID: \n34836431. IF: 5,717\n4. Falkner B, Lurbe E. Primary hypertension beginning in \nchildhood and risk for future cardiovascular disease. Journal \nof Pediatrics. 2021 Nov;238:16-25. doi: 10.1016/j.\njpeds.2021.08.008. PMID: 34391765. IF: 4,406\n5. Falkner B, Lurbe E. The USPSTF call to inaction on blood \npressure screening in children and adolescents. Pediatric \nNephrology. 2021 Jun;36(6):1327-1329. doi: 10.1007/\ns00467-021-04926-y. PMID: 33449211. IF: 3,714\nRESEARCH PROJECTS AND GRANTS  \nFOR RESEARCH\nReference:  COST CA19115\nTitle:  Network for blood pressure research in children and \nadolescents. HyperChildNET\nPrincipal Investigator:  Empar Lurbe i Ferrer\nFunding Body: European Commision\u2022 Early origins of cardiometabolic risk factors assessed in a prospective study starting at birth (Cohort KITE)\n\u2022 HyperChildNET: European Network for Research on Blood Pressure in Children and Adolescents81\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Cardiometabolic Research Group on Primary Care  \nConsolidated group\nLeading Researcher, R4\nJorge Navarro P\u00e9rez \nUniversity. Cl\u00ednico-Malvarrosa Health Departament \nEstablished Researchers, R3\nAlvaro Bonet Pl\u00e0. Cl\u00ednico-Malvarrosa Health Department\nCarolina Mir S\u00e1nchez. University. Cl\u00ednico-Malvarrosa Health Department\nRuth Us\u00f3 Talamantes. Cl\u00ednico-Malvarrosa Health Department\nStaff. Collaborating Researchers\nCarlos Momparler Mart\u00ednez. Cl\u00ednico-Malvarrosa Health Department\nCarmina Mart\u00ednez Vernia. Cl\u00ednico-Malvarrosa Health Departament\nEnrique Guinot Mart\u00ednez. Cl\u00ednico-Malvarrosa Health Departament\nIrene Marco Moreno. Cl\u00ednico-Malvarrosa Health Departament\nIsabel Gabald\u00f3n S\u00e1nchez. Cl\u00ednico-Malvarrosa Health Departament\nJos\u00e9 Luis Trillo Mata. Hospital\nM\u00aa Jos\u00e9 Puchades Company. Cl\u00ednico-Malvarrosa Health Department\nMarisa G\u00f3mez Arnedo. Cl\u00ednico-Malvarrosa Health Departament\nNidia Ruiz Varea. Cl\u00ednico-Malvarrosa Health Department\nPablo Sabater Arnaldos. Cl\u00ednico-Malvarrosa Health Departament\nPilar Botija Yag\u00fce. Cl\u00ednico-Malvarrosa Health Departament\nPilar Roca Navarro. University. Cl\u00ednico-Malvarrosa Health Department\nRuth Uribes Fillol. Cl\u00ednico-Malvarrosa Health Departament\nTom\u00e1s S\u00e1nchez Ruiz. University. Cl\u00ednico-Malvarrosa Health Departament\nVibiana Blanco Alvarado. Cl\u00ednico-Malvarrosa Health Departament\nVictoria Gosalbes Soler. Cl\u00ednico-Malvarrosa Health DepartmentGroup members\nR4\nStrategic aims\n\u2022 Consolidation of various lines of cardiometabolic research\n\u2022 Consolidation of a network of partners in the area of \nprimary careResearchers by categories\n3 1 16R3 R4 STAFF\nIF 12\nNumber of  \narticles37.918IF\n3.159Average2\nCorresponding  \nauthor9\nNational  \ncollaborations1\nInternational \ncollaborationsPUBLICATIONSMain lines of research \n\u2022 Cardiovascular population studies (ESCARVAL, Big data \nstudies)\n\u2022 Studies monitoring cardiovascular risk factors (ADAMPA)82\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI16/02130\nTitle: Impacto de la auto-medici\u00f3n y el auto-ajuste de la medicaci\u00f3n \nantihipertensiva en el control de la hipertensi\u00f3n arterial. Un \nensayo cl\u00ednico pragm\u00e1tico: estudio ADAMPA\nPrincipal Investigator: Jorge Navarro P\u00e9rez and Jos\u00e9 Sanf\u00e9lix-\nGenov\u00e9s\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2017-2021\nTotal Budget: \u20ac86.515\nTHESIS\nThesis title: Efectividad de una intervenci\u00f3n de automanejo de la \nhipertensi\u00f3n arterial en la mejora de la inercia terap\u00e9utica y la \nadherencia a los medicamentos antihipertensivos. Ensayo cl\u00ednico \npragm\u00e1tico ADAMPA\nDoctoral candidate: Irene Marco Moreno \nDirector(s):  Gabriel Sanf\u00e9lix, Salvador Peir\u00f3 Moreno, Jose San \nF\u00e9lix Genov\u00e9s \nDate of the defense:  28/04/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: An\u00e1lisis de los determinantes socioecon\u00f3micos \ny de la morbilidad del Departamento de Salud Valencia Cl\u00ednico-\nMalvarrosa. Desarrollo de un \u00edndice de privaci\u00f3n poblacional \nintegrado\nDoctoral candidate: Pilar Botija Yag\u00fce\nDirector(s):  Ruth Us\u00f3 Talamantes, Jorge Navarro P\u00e9rez, M\u00aa de \nlas Mercedes Botija Yag\u00fce \nDate of the defense: 30/11/2021\nGrade: Sobresaliente \u201ccum laude\u201dSELECTED PUBLICATIONS\n1. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon \nS, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, \nPena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, \nCano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella \nGonzalez I. Ten-year assessment of a cancer fast-track \nprogramme to connect primary care with oncology: reducing \ntime from initial symptoms to diagnosis and treatment \ninitiation. ESMO Open. 2021 May 11;6(3):100148. doi: \n10.1016/j.esmoop.2021.100148. PMID: 33989988. IF: \n6,54\n2. Domingo O, Alberto G, Ana Maria C, Jorge N, Vicente \nG, Quesada-Rico Jose A, Pomares-Gomez Francisco J, \nAdriana L, Concepcion C. Hospital admissions trends for \nsevere hypoglycemia in diabetes patients in Spain, 2005 \nto 2015. Diabetes Research and Clinical Practice. 2021 \nJan;171:108565. doi: 10.1016/j.diabres.2020.108565. \nPMID: 33242511. IF: 5,602\n3. Uso-Talamantes R, Gonzalez-de-Julian S, Diaz-Carnicero J, \nSauri-Ferrer I, Trillo-Mata J, Carrasco-Perez M, Navarro-\nPerez J, Gorriz J, Vivas-Consuelo D, Redon J. Cost of Type \n2 diabetes patients with chronic kidney disease based on \nreal-world data: an observational population-based study in \nSpain. International Journal of Environmental Research and \nPublic Health. 2021 Sep 18;18(18):9853. doi: 10.3390/\nijerph18189853. PMID: 34574782. IF: 3,39\n4. Soriano-Maldonado C, Lopez-Pineda A, Orozco-Beltran \nD, Quesada JA, Alfonso-Sanchez JL, Pallares-Carratala \nV, Navarro-Perez J, Gil-Guillen VF, Martin-Moreno JM, \nCarratala-Munuera C. Gender differences in the diagnosis \nof dyslipidemia: ESCARVAL-GENERO. International Journal \nof Environmental Research and Public Health. 2021 Nov \n25;18(23):12419. doi: 10.3390/ijerph182312419. \nPMID: 34886144. IF: 3,39\n5. Carratala-Munuera C, Lopez-Pineda A, Orozco-Beltran D, \nQuesada J, Alfonso-Sanchez J, Pallares-Carratala V, Soriano-\nMaldonado C, Navarro-Perez J, Gil-Guillen V, Martin-Moreno \nJ. Gender inequalities in diagnostic inertia around the \nthree most prevalent cardiovascular risk studies: protocol \nfor a population-based cohort study. International Journal \nof Environmental Research and Public Health. 2021 Apr \n12;18(8):4054. doi: 10.3390/ijerph18084054. PMID: \n33921396. IF: 3,3983\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on the Study of Cardiometabolic and Renal Risk  \nConsolidated group\nLeading Researcher, R4\nJosep Red\u00f3n i Mas \nINCLIVA\nEstablished Researchers, R3\nM\u00aa Jos\u00e9 Forner Giner. Hospital. University\nM\u00aa Jos\u00e9 Galindo Puerto. Hospital. University\nM\u00aa Jos\u00e9 Garc\u00eda-Fuster Gonz\u00e1lez-Alegre. Hospital\nEmerging Researcher, R2\nRaquel Cort\u00e9s Vergaz. INCLIVA\nRecognised Researcher, R2\nAna Ortega Guti\u00e9rrez. INCLIVA\nDavid Mart\u00ed Aguado. Hospital\nFirst Stage Researchers, R1\nAdri\u00e1n Ruiz Hern\u00e1ndez. Hospital. University\nMar\u00eda Grau P\u00e9rez. INCLIVA\nOlga Mart\u00ednez Arroyo. INCLIVA\nStaff. Collaborating Researchers\nElena Solaz Moreno. Hospital\nJavier D\u00edaz Carnicero. INCLIVA\nJos\u00e9 Miguel Calder\u00f3n Terol. INCLIVAGroup members\nEmerging Researcher\nRaquel Cort\u00e9s Vergaz\nThe main objective of this new field of research is to study the molecular mechanisms associated with the development of early kidney \ndamage due to hypertension and diabetes, focusing on the characterization of extracellular vesicles and their roles as intercellular media-\ntors. In addition, a new line of research has been opened in kidney damage associated with systemic lupus erythematosus, autoimmune \ndisease, and the role of extracellular vesicles as diagnostic, prognostic and monitoring biomarkers of disease activityStaff. Nurse\nLaura Cantero Mil\u00e1n. Hospital\nStaff. Technicians\nAntonio Fern\u00e1ndez Gim\u00e9nez. INCLIVA \n\u00d3scar Calaforra Juan. CIBERobn\nNoem\u00ed Dolz Gilba. INCLIVA\nStaff. Administrative assistant\nChristine Deutsch. INCLIVA Researchers by categories\n3 3 3 1 8\nResearchers financed by \ncompetitive public calls or networks\nR4\n2 1 1R1 R2 R3 R4 STAFF\nR2 STAFF R1\nStrategic aims\n\u2022 To start-up the laboratory for the analysis of podocytes (identification, cultivation and phenotyping) and its derivatives: micro-\nRNA, exosomes\n\u2022 To identify a circulating and exosomal non-coding RNA - mRNA interaction networks associated to renal damage progression\n\u2022 The integration of metabolomics and genomics in the study of factors related to the development of kidney damage\n\u2022 Development of studies for noninvasive hemodynamic characterization in vascular pathology \n\u2022 Analysis of morbidity and mortality linked to the presence of hypertension and renal injury\n\u2022 Development of in vitro studies of platelet and leukocyte adhesion in venous thromboembolism\n\u2022 Genetic studies related to obesity and overweight and venous thromboembolism\n\u2022 Development of phase III and IV clinical trials84\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44. Corma Gomez A, Macias J, Morano L, Rivero A, Tellez F, Rios \nMJ, Santos M, Serrano M, Palacios R, Merino D, Real LM, \nDe Los Santos I, Vera Mendez FJ, Galindo MJ, Pineda JA. \nLiver stiffness-based strategies predict absence of variceal \nbleeding in cirrhotic HCV-infected patients with and without \nHIV-coinfection after sustained virological response. Clinical \nInfectious Diseases. 2021 Mar 1;72(5):e96-e102. doi: \n10.1093/cid/ciaa1726. PMID: 33211801. IF: 9,079\n5. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda \nC, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, \nPerez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-\nGarcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, \nMarti-Bonmati L. Digital pathology: accurate technique for \nquantitative assessment of histological features in metabolic-\nassociated fatty liver disease. Alimentary Pharmacology & \nTherapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/\napt.16100. PMID: 32981113. IF: 8,171PUBLICATIONS\nSELECTED PUBLICATIONS\n1. NCD Risk Factor Collaboration. Worldwide trends in \nhypertension prevalence and progress in treatment and control \nfrom 1990 to 2019: a pooled analysis of 1201 population-\nrepresentative studies with 104 million participants. Lancet. \n2021 Sep 11;398(10304):957-980. doi: 10.1016/S0140-\n6736(21)01330-1. PMID: 34450083, IF: 79,321\n2. Perez-Hernandez J, Riffo-Campos A, Ortega A, Martinez-\nArroyo O, Perez-Gil D, Olivares D, Solaz E, Martinez F, \nMartinez-Hervas S, Chaves F, Redon J, Cortes R. Urinary- \nand plasma-derived exosomes reveal a distinct microRNA \nsignature associated with albuminuria in hypertension. \nHypertension. 2021 Mar 3;77(3):960-971. doi: 10.1161/\nHYPERTENSIONAHA.120.16598. PMID: 33486986, IF: \n10,19\n3. Carrero, A, Berenguer J, Hontanon V, Guardiola JM, Navarro \nJ, von Wichmann MA, Tellez MJ, Quereda C, Santos I, Sanz \nJ, Galindo MJ, Hernandez Quero J, Jimenez Sousa MA, \nPerez Latorre L, Bellon JM, Resino S, Esteban H, Martinez E, \nGonzalez Garcia J. Effects of HCV eradication on bone mineral \ndensity in HIV/HCV coinfected patients. Clinical Infectious \nDiseases. 2021 Oct 5;73(7):e2026-e2033. doi: 10.1093/\ncid/ciaa1396. PMID: 32930720. IF: 9,079IF 38\nNumber of  \narticles351.977IF\n9.262Average11\nCorresponding  \nauthor16\nNational  \ncollaborations10\nInternational \ncollaborationsMain lines of research \n\u2022 Analysis of podocytes -renal proximal tubular epithelial cell communication as key player in kidney damage progression (miRNAs \nand exosomes)\n\u2022 Impact of cardiovascular risk factors and renal function in absolute morbidity and mortality in high-risk population and in the \ngeneral population\n\u2022 Inflammation and oxidative stress in the development of cardiovascular disease\n\u2022 Genomics, proteomics and metabolomics of early cardiometabolic and renal disorders\n\u2022 Impact of environmental toxins (metals) in cardiometabolic risk\n\u2022 Identification of polymorphisms and related to the control of BMI and waist circumference and the risk of obesity genes\n\u2022 Venous thrombosis in young patients: factors associated with its development\n\u2022 The relationship between risk of venous thromboembolic disease and arteriosclerosis\n\u2022 Molecular mechanisms associated with activity changes and renal damage development in systemic lupus erythematosus85\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: 945097-WELLBASED\nTitle:  WELLBASED. Improving health, wellbeing and equality by \nevidenced-based urban policies for tackling energy poverty\nPrincipal Investigator:  Josep Red\u00f3n i Mas\nFunding body: European Commission\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2025\nTotal budget:  \u20ac395.250\nReference: 780495 - BigMedilytics\nTitle:  Big Data for Medical Analytics\nPrincipal Investigator:  Josep Red\u00f3n i Mas\nFunding body: European Commission\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac1.062.136,25\nReference: 785815 - BigData@Heart\nTitle: Big Data for Better Hearts\nPrincipal Investigator: Josep Red\u00f3n i Mas\nFunding body: European Commission\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2017-2022 \nTotal budget:  \u20ac386.250 (Contribution EC: 100%)\nReference: PI19/01796\nTitle: Implicaciones experimentales y cl\u00ednicas del complejo \nproteico rabphilin-rab\u00a0en da\u00f1o renal en la diabetes mellitus tipo 2\nPrincipal Investigator: Josep Red\u00f3n i Mas\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget:  \u20ac196.020Reference: PI18/01405\nTitle:  Perfil de microRNAs exosomales y su valor pron\u00f3stico a \nlargo plazo en el lupus eritematoso sist\u00e9mico. Asociaci\u00f3n con \nmarcadores establecidos de da\u00f1o renal\nPrincipal Investigator: Raquel Cort\u00e9s Vergaz \nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac111.320\nTitle:  Estudio multic\u00e9ntrico de precisi\u00f3n diagn\u00f3stica para \ncuantificar y caracterizar la fibrosis de la enfermedad hep\u00e1tica \nmetab\u00f3lica mediante patolog\u00eda digital avanzada\nPrincipal Investigator:  David Mart\u00edn Aguado\nFunding body: Sociedad Valenciana de Patolog\u00eda Digestiva\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac5.000\nTitle: CoVIHd: incidencia y severidad de COVID-19 en personas \nVIH-positivas en TAR en Espa\u00f1a\nPrincipal Investigator: M\u00aa Jos\u00e9 Galindo Puerto\nFunding body: Janssen - Cilag S.A.\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal budget:  \u20ac22.500\nTHESIS\nThesis title:  Estudio prospectivo multic\u00e9ntrico de precisi\u00f3n \ndiagn\u00f3stica de los biomarcadores de imagen en las hepatopat\u00edas \ncr\u00f3nicas difusas\nDoctoral candidate: David Mart\u00ed Aguado\nDirector(s): Luis Mart\u00ed Bonmat\u00ed, Miguel \u00c1ngel Serra Desfilis \nDate of the defense:  29/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d86\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Vascular Function  \nConsolidated group\nLeading Researcher, R4\nJos\u00e9 M\u00aa Vila Salinas \nUniversity\nEstablished Researcher, R3\nM\u00aa Dolores Mauricio Avi\u00f1\u00f3. University\nMart\u00edn Aldasoro Celaya. University\nV\u00edctor Manuel V\u00edctor Gonz\u00e1lez. UniversityGroup members\nStrategic aims\n\u2022 Vascular changes associated with different pathologies\n\u2022 Regulation of blood flow\nMain lines of research \n\u2022 Characterization of alterations in the control of vascular tone and endothelial function induced by aging\n\u2022 The effects of exercise training on the vascular response\n\u2022 Vascular and extravascular effects of ranolazine\n\u2022 Improvement of insulin vascular effects by ranolazine\n\u2022 Vascular effects of nanoparticles\nderived cardiac remodelling after STEMI. International \nImmunopharmacology. 2021 Mar 4;95:107490. doi: \n10.1016/j.intimp.2021.107490. PMID: 33677257. IF: \n4,932\n3. Correa-Ghisays P, Sanchez-Orti JV, Balanza-Martinez V, \nSelva-Vera G, Vila-Frances J, Magdalena-Benedito R, Victor \nVM, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde \nJ, San-Martin C, Crespo-Facorro B, Tabares-Seisdedos R. \nTransdiagnostic neurocognitive deficits in patients with \ntype 2 diabetes mellitus, major depressive disorder, bipolar PUBLICATIONS\nIF 9\nNumber of  \narticles42.967IF\n4.774Average3\nCorresponding  \nauthor6\nNational  \ncollaborations0\nInternational \ncollaborationsResearchers by categories\n3 1R3 R4\nSELECTED PUBLICATIONS\n1. Guerra-Ojeda S, Marchio P, Gimeno-Raga M, Arias-Mutis \nO, San-Miguel T, Valles S, Aldasoro M, Vila J, Zarzoso M, \nMauricio M. PPARgamma as an indicator of vascular function \nin an experimental model of metabolic syndrome in rabbits. \nAtherosclerosis. 2021 Aug 5;332:16-23. doi: 10.1016/j.\natherosclerosis.2021.08.006. PMID: 34375909. IF: 5,162\n2. de Dios E, Rios-Navarro C, Perez-Sole N, Gavara J, Marcos-\nGarces V, Forteza M, Oltra R, Vila J, Chorro F, Bodi V. \nOverexpression of genes involved in lymphocyte activation \nand regulation are associated with reduced CRM-87\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4disorder, and schizophrenia: a 1-year follow-up study. Journal \nof Affective Disorders. 2021 Dec 26;300:99-108. doi: \n10.1016/j.jad.2021.12.074. PMID: 34965401. IF: 4,839\n4. Jorda A, Aldasoro M, Aldasoro C, Valles S. Inflammatory \nchemokines expression variations and their receptors in APP/\nPS1 mice. Journal of Alzheimers Disease. 2021;83(3):1051-\n1060. doi: 10.3233/JAD-210489. PMID: 34397415. IF: \n4,472\n5. Rios-Navarro C, Daugbouche-Rubio N, Gavara J, de Dios E, \nPerez N, Vila JM, Chorro FJ, Ruiz-Sauri A, Bodi V. Ischemia-\nreperfusion injury to coronary arteries: comprehensive \nmicroscopic study after reperfused myocardial infarction. \nAnnals of Anatomy. 2021 Nov;238:151785. doi: 10.1016/j.\naanat.2021.151785. PMID: 34144157. IF: 2,698\nTHESIS\nThesis title: Estudio de los mecanismos de estr\u00e9s oxidativo, \nactivaci\u00f3n del inflamasoma NLRP3 y las interacciones leucocito-\nendotelio en la diabetes: efectos del papel de la empagliflozina\nDoctoral candidate: Francesca Iannantuoni\nDirector(s):  V\u00edctor Manuel V\u00edctor Gonz\u00e1lez, Milagros Rocha \nBarajas \nDate of the defense: 22/06/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award:  European PhD\nThesis title: Study of mitochondrial dynamics and function \nand autophagy and their relationship with cardiovascular \ncomplications in Type 2\nDoctoral candidate: Ar\u00e1nzazu Mart\u00ednez de Mara\u00f1\u00f3n Peris\nDirector(s):  V\u00edctor Manuel V\u00edctor Gonz\u00e1lez, Milagros Rocha \nBarajas, Miguel Mart\u00ed Cabrera \nDate of the defense: 20/12/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award:  European PhD88\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Pedriatric Nutrition  \nConsolidated group\nLeading Researcher, R4\nCecilia Mart\u00ednez Costa \nHospital. University\nJavier Buesa G\u00f3mez\nHospital. University\nEstablished Researchers, R3\nElena Crehu\u00e1 Gaudiza. Hospital. University\nFrancisco N\u00fa\u00f1ez G\u00f3mez. Hospital. University\nJavier Esta\u00f1 Capell. Hospital. University\nLaura Mart\u00ednez Rodr\u00edguez. Hospital\nRecognised Researcher, R2\nAna Paula Grattarola. INCLIVA\nFirst Stage Researcher, R1\nAlba Peret\u00f3 Moll. Hospital\nAna Barr\u00e9s Fern\u00e1ndez. Hospital\nAna Delgado Vicente. Hospital\n\u00c1ngel Vicente Valls Ar\u00e9valo. Hospital\nCarlos S\u00e1enz de Juano Petit. Hospital\nIsidro Robredo Garc\u00eda. INCLIVA\nLaura N\u00fa\u00f1ez Mart\u00ednez. Hospital\nStaff. Collaborating Researchers\nInmaculada Tarazona Casany. Hospital\nJos\u00e9 Vicente Arcos Machancoses. HospitalGroup members\nStrategic aims\nCardiovascular area:\n\u2022 Study of metabolome and microbiome in obese children with/without insulin resistance before and after personalized \nnutritional intervention and physical exercise\nArea of human milk:\n\u2022 Characterization of mother-infant microbiome in term and preterm infants. Influence of perinatal variables\nArea of hospital malnutrition and artificial nutrition:\n\u2022 Validation of the pediatric screening tools for detecting the risk of malnutrition linked to chronic disease and pediatric \nhospitalizationResearchers by categories\n1 4 7 2 2R1 R2 R3 R4 STAFF89\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Main lines of research \nCardiovascular area:\n\u2022 Analysis of microbiota in obese children before and after intervention\n\u2022 Analysis of metabolome in obese children with/without insulin resistance\n\u2022 Monitoring exercise and energy consumption in obese schoolchildren and teenagers to adjust nutritional intervention\nArea of human milk:\n\u2022 Analysis of nutritional and bioactive components in human milk: influence of genotype FUT2 on oligosaccharides\n\u2022 Analysis of mother-fetal microbiome in term and preterm infants. Influence of delivery mode, maternal diet and development. \nImpact on host response and intestinal function\nArea of hospital malnutrition and artificial nutrition:\n\u2022 Validation of the pediatric screening tools for detecting the risk of malnutrition\n\u2022 Multicenter study of acceptance and quality of life in children treated with home enteral nutrition\nPUBLICATIONS\nIF 27\nNumber of  \narticles103.417IF\n3.83Average3\nCorresponding  \nauthor17\nNational  \ncollaborations3\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Costa R, Bueno F, Albert E, Torres I, Carbonell-Sahuquillo \nS, Barres-Fernandez A, Sanchez D, Padron C, Colomina J, \nLazaro Carreno M, Breton-Martinez J, Martinez-Costa C, \nNavarro D. Upper respiratory tract SARS-CoV-2 RNA loads in \nsymptomatic and asymptomatic children and adults. Clinical \nMicrobiology and Infection. 2021 Dec;27(12):1858.e1-1858.\ne7. doi: 10.1016/j.cmi.2021.08.001. PMID: 34384874. IF: \n8,067\n2. Cannon J, Bonifacio J, Bucardo F, Buesa J, Bruggink L, Chan \nM, Fumian T, Giri S, Gonzalez M, Hewitt J, Lin J, Mans J, \nMunoz C, Pan C, Pang X, Pietsch C, Rahman M, Sakon N, \nSelvarangan R, Browne H, Barclay L, Vinje J. Global trends \nin norovirus genotype distribution among children with \nacute gastroenteritis. Emerging Infectious Diseases. 2021 \nMay;27(5):1438-1445. doi: 10.3201/eid2705.204756. \nPMID: 33900173. IF: 6,883\n3. Cortes-Macias E, Selma-Royo M, Martinez-Costa C, Collado MC. \nBreastfeeding practices influence the breast milk microbiota \ndepending on pre-gestational maternal BMI and weight gain \nover pregnancy. Nutrients. 2021 Apr 30;13(5):1518. doi: \n10.3390/nu13051518. PMID: 33946343. IF: 5,7174. Mangas-Sanchez C, Garriga-Garcia M, Serrano-Nieto MJ, \nGarcia-Romero R, Alvarez-Beltran M, Crehua-Gaudiza E, \nMunoz-Codoceo R, Suarez-Cortina L, Vicente-Santamaria S, \nMartinez-Costa C, Diaz-Martin JJ, Bousono-Garcia C, Gonzalez-\nJimenez D. Vitamin D status in pediatric and young adult cystic \nfibrosis patients. Are the new recommendations effective?. \nNutrients. 2021 Dec 9;13(12):4413. doi: 10.3390/\nnu13124413. PMID: 34959965. IF: 5,717\n5. Selma-Royo M, Garc\u00eda Mantrana I, Calatayud M, Parra-\nLlorca A, Martinez Costa C, Collado M. Maternal diet during \npregnancy and intestinal markers are associated with \nearly gut microbiota. European Journal of Nutrition. 2021 \nApr;60(3):1429-1442. doi: 10.1007/s00394-020-02337-\n7. PMID: 32728880. IF: 5,614\n 90\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Reference:  AP-2021-004\nT\u00edtulo:  NEODIAG-VR: Realidad virtual para la formaci\u00f3n \nmultidisciplinar en neonatolog\u00eda\nPrincipal Investigator: Jes\u00fas Gimeno Sancho, Javier Esta\u00f1 Capell\nFunding body: Universidad de Valencia - INCLIVA\nBeneficiary institution:  Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac4.655\nTHESIS\nThesis title:  Efecto de la intervenci\u00f3n nutricional en escolares y \nadolescentes con obesidad con y sin resistencia a la insulina\nDoctoral candidate: Ana Paula Grattarola \nDirector(s): Francisco N\u00fa\u00f1ez G\u00f3mez, Cecilia Mart\u00ednez Costa\nDate of the defense: 11/01/2021\nGrade:  Sobresaliente \u201ccum laude\u201dRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: PI19/00354\nT\u00edtulo:  Efectividad de la vacunaci\u00f3n antigripal y antineumoc\u00f3cica \npara prevenir la hospitalizaci\u00f3n en personas menores de 65 a\u00f1os \nque presentan condiciones de riesgo\nPrincipal Investigator: \u00c1ngela Dom\u00ednguez Garc\u00eda (Francisco \nN\u00fa\u00f1ez as collaborating researcher)\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Universidad de Barcelona\nDuration: 2019-2022\nTotal budget:  \u20ac220.220\nReference:  PCIN-2017-117\nTitle: Obesidad materna y disfunci\u00f3n cognitiva en la descendencia: \npapel causa-efecto de la microbiota intestinal y prevenci\u00f3n \ndiet\u00e9tica temprana\nPrincipal Investigator: Consuelo Borr\u00e1s Blasco (Cecilia Mart\u00ednez \nCosta as collaborating researcher)\nFunding body: Ministerio de Econom\u00eda y Competitividad\nBeneficiary institution:  Universidad de Valencia\nDuration: 2017-2022\nTotal budget:  \u20ac143.00091\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Group on Translational Research in Ischemic Heart Disease  \nConsolidated group\nLeading Researcher, R4\nVicente Bod\u00ed Peris\nHospital. University\nEstablished Researcher, R3\nAmparo Ruiz Saur\u00ed. University\nRecognised Researchers, R2\nClara Bonanad Lozano. Hospital. University. INCLIVA\nJos\u00e9 Gavara Do\u00f1ate. INCLIVA\nFirst Stage Researchers, R1\nC\u00e9sar R\u00edos Navarro. INCLIVA\nElena de Dios Lluch. University\nV\u00edctor Marcos Garc\u00e9s. HospitalGroup members\nStrategic aims\n\u2022 From our research experience from the last years in the clinical and experimental field related to ischemic cardiopathy, our \ncurrent goal is to focus into a translational approach\n\u2022 In 2021 we continued elucidating the pathophysiology of microvascular injury in the context of reperfused STEMI as well as \ntherapeutic opportunities to its repair\n\u2022 We have also developed new tools to study patients with ST-segment elevation myocardial infarction using cardiac magnetic \nresonance imaging\nMain lines of research \n\u2022 Prospective registry of patients with first ST-segment elevation myocardial infarction studied with cardiac magnetic resonance \nimaging at acute and chronic phases\n\u2022 Multicenter registry of patients with chronic coronary syndrome studied with stress cardiac magnetic resonance imaging\n\u2022 Porcine and mice model of experimental myocardial ischemia and myocardial infarction. To achieve a better understanding of \nthe pathophysiology of ischemia, necrosis, fibrosis, angiogenesis, and reperfusion injury and test new novel therapeutic avenues\n\u2022 Involvement in several large international multicenter clinical trials in the field of acute coronary syndromes\nPUBLICATIONS\nIF 48\nNumber of  \narticles506.045IF\n10.542Average16\nCorresponding  \nauthor25\nNational  \ncollaborations12\nInternational \ncollaborationsResearchers by categories\n2 1 3 1 3\nResearchers financed by \ncompetitive public calls or networks\nR4\n1 3R1 R2 R3 R4 STAFF\nR2 R1\nStaff. Collaborating Researcher\nJoaquim C\u00e0noves Femenia. Hospital. University\nPaolo Racugno. Hospital\nStaff. Nurse\nNerea P\u00e9rez Sol\u00e9. INCLIVA92\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI20/00637\nTitle:  Resoluci\u00f3n de la obstrucci\u00f3n microvascular tras un \ninfartodemiocardio: evaluaci\u00f3n de las consecuencias estructurales \ny cl\u00ednicas y b\u00fasqueda de nuevas opciones terap\u00e9uticas \nPrincipal Investigator: Vicent Bod\u00ed Peris and Clara Bonanad \nLozano \nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac129.470\nReference: PROMETEO/2021/008\nTitle: A multidisciplinary study to advance in the understanding of \nthe basic mechanisms and clinical implications of microvascular \nobstruction after acute myocardial infarction. Exploration of novel \ndiagnostic and therapeutic opportunities\nPrincipal Investigator: Vicente Bod\u00ed Peris\nFunding Body:  Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital \nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2024\nTotal Budget: \u20ac435.929\nTitle: Resonancia magn\u00e9tica card\u00edaca de estr\u00e9s con \nvasodilatadores para predecir la mortalidad a largo plazo en \nun amplio registro retrospectivo de pacientes con cardiopat\u00eda \nisqu\u00e9mica conocida o sospechada\nPrincipal Investigator: Vicente Bod\u00ed Peris\nFunding Body: Sociedad Espa\u00f1ola de Cardiolog\u00eda\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2022\nTotal Budget: \u20ac15.000SELECTED PUBLICATIONS\n1. Nunez J, Lorenzo M, Minana G, Palau P, Monmeneu JV, Lopez-\nLereu MP, Gavara J, Marcos-Garces V, Rios-Navarro C, Perez \nN, de Dios E, Nunez E, Sanchis J, Chorro FJ, Bayes-Genis A, \nBodi V. Sex differences on new-onset heart failure in patients \nwith known or suspected coronary artery disease. European \nJournal of Preventive Cardiology. 2021 Dec 29;28(15):1711-\n1719. doi: 10.1093/eurjpc/zwab078. PMID: 33970216. \nIF: 7,084\n2. de Dios E, Rios-Navarro C, Perez-Sole N, Gavara J, Marcos-\nGarces V, Forteza M, Oltra R, Vila J, Chorro F, Bodi V. \nOverexpression of genes involved in lymphocyte activation \nand regulation are associated with reduced CRM-\nderived cardiac remodelling after STEMI. International \nImmunopharmacology. 2021 Mar 4;95:107490. doi: \n10.1016/j.intimp.2021.107490. PMID: 33677257. IF: \n4,932\n3. Gavara J, Marcos-Garces V, Lopez-Lereu, MP, Monmeneu JV, \nRios-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldon A, \nCanoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez \nE, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-\nPalomares JF, Ortiz-Perez JT, Bodi V. Magnetic resonance \nassessment of left ventricular ejection fraction at any time \npost-infarction for prediction of subsequent events in a large \nmulticenter STEMI Registry. Journal of Magnetic Resonance \nImaging. 2021 Jun 16. doi: 10.1002/jmri.27789. PMID: \n34137478. IF: 4,813\n4. Gabaldon-Perez A, Marcos-Garces V, Gavara J, Rios-Navarro \nC, Minana G, Bayes-Genis A, Husser O, Sanchis J, Nunez \nJ, Chorro F, Bodi V. Coronary revascularization and long-\nterm survivorship in chronic coronary syndrome. Journal of \nClinical Medicine. 2021 Feb 5;10(4):610. doi: 10.3390/\njcm10040610. PMID: 33562869. IF: 4,241\n5. Rios-Navarro C, Daugbouche-Rubio N, Gavara J, de Dios E, \nPerez N, Vila JM, Chorro FJ, Ruiz-Sauri A, Bodi V. Ischemia-\nreperfusion injury to coronary arteries: comprehensive \nmicroscopic study after reperfused myocardial infarction. \nAnnals of Anatomy. 2021 Nov;238:151785. doi: 10.1016/j.\naanat.2021.151785. PMID: 34144157. IF: 2,69893\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Heart Failure \nEmerging group\nLeading Researcher, R4\nJulio N\u00fa\u00f1ez Villota\nHospital. University\nRecognised Researchers, R2\nEnrique Santas Olmeda. Hospital\nGemma Mi\u00f1ana Escriv\u00e1. Hospital. University\nPatricia Palau Sampio. Hospital. University\nFirst Stage Researchers, R1\nAna Bel\u00e9n Paes Mart\u00ed. INCLIVA\nRaquel Heredia Cambra. University. CIBER\nStaff. Collaborating Researcher\nRafael de la Espriella Juan. Hospital\nRaquel Heredia Cambra. INCLIVA\nStaff. Nurses\nAlberto Ram\u00edrez S\u00e1iz. INCLIVA\nAna Mart\u00ednez \u00c1lvarez. INCLIVA\nJos\u00e9 Manuel Civera G\u00f3mez. INCLIVA\nStaff. Technician\nAdriana Conesa Bona. INCLIVAGroup members\nStrategic aims\n\u2022 Phenotypic characterization of heart failure syndrome\n\u2022 Deepen into pathophysiological mechanisms in the different phenotypes of the disease\n\u2022 Development of tools to improve the diagnostic process of heart failure\n\u2022 Risk stratification in patients with acute and chronic heart failure\n\u2022 Evaluation of different therapeutic and monitoring strategies that allow improving the prognosis of heart failure\nMain lines of research \n\u2022 Effect on functional capacity of withdrawal of beta-blockers in patients with heart failure and preserved ejection fraction and \nchronotropic incompetence\n\u2022 Myocardial effects of iron repletion\n\u2022 Prevalence and clinical implications of frailty in heart failure\n\u2022 Usefulness of the carbohydrate antigen 125 marker in the evaluation of congestion and a guide to titrate diuretic treatment\n\u2022 Effect of dapagliflozin on functional capacity in patients with heart failure and reduced ejection fraction\n\u2022 Utility of continuous ambulatory peritoneal dialysis in the treatment of patients with heart failure and reduced ejection fraction\n\u2022 Usefulness of intrarenal Doppler to evaluate intrarenal congestion and its clinical significanceResearchers by categories\n2 3 1 6\n1Researchers financed by \ncompetitive public calls or networks\n2R1 R2 R4 STAFF\nSTAFF R194\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4SELECTED PUBLICATIONS\n1. Palau P, Seller J, Dominguez E, Sastre C, Ramon JM, \nEspriella R, Santas E, Minana G, Bodi V, Sanchis J, Valle A, \nChorro FJ, Llacer P, Bayes-Genis A, Nunez J. Effect of beta-\nblocker withdrawal on functional capacity in heart failure \nand preserved ejection fraction. Journal of the American \nCollege of Cardiology. 2021 Nov 23;78(21):2042-2056. doi: \n10.1016/j.jacc.2021.08.073. PMID: 34794685. IF: 24,094\n2. Wettersten N, Horiuchi Y, van Veldhuisen D, Ix J, Mueller \nC, Filippatos G, Nowak R, Hogan C, Kontos M, Cannon C, \nMueller G, Birkhahn R, Taub P, Vilke G, Duff S, McDonald K, \nMahon N, Nunez J, Briguori C, Passino C, Maisel A, Murray \nP. Decongestion discriminates risk for one-year mortality in \npatients with improving renal function in acute heart failure. \nEuropean Journal of Heart Failure. 2021 Jul;23(7):1122-\n1130. doi: 10.1002/ejhf.2179. PMID: 33788989. IF: \n15,534\n3. Nunez J, Lorenzo M, Minana G, Palau P, Monmeneu JV, Lopez-\nLereu MP, Gavara J, Marcos-Garces V, Rios-Navarro C, Perez \nN, de Dios E, Nunez E, Sanchis J, Chorro FJ, Bayes-Genis A, \nBodi V. Sex differences on new-onset heart failure in patients \nwith known or suspected coronary artery disease. European \nJournal of Preventive Cardiology. 2021 Dec 29;28(15):1711-\n1719. doi: 10.1093/eurjpc/zwab078. PMID: 33970216. \nIF: 7,084\n4. De La Espriella Juan R, Bayes-Genis A, Revuelta E, Mi\u00f1ana \nEscriva G, Santas Olmeda E, Llacer P, Garcia Blas S, \nFern\u00e1ndez Cisnal A, Bonanad Lozano C, Ventura S, Sanchez \nR, Bod\u00ed Peris V, Cordero A, Facila De La Esperanza R, Mollar \nFernandez A, Sanchis Fores J, Improve-Hf Investigators, \nNu\u00f1ez Villota J. sST2 and diuretic efficiency in acute heart \nfailure and concomitant renal dysfunction. Journal of \nCardiac Failure. 2021 Apr;27(4):427-434. doi: 10.1016/j.\ncardfail.2020.10.002. PMID: 33038531. IF: 5,712\n5. Santas E, Minana G, Palau P, De La Espriella R, Lorenzo M, \nNunez G, Sanchis J, Chorro FJ, Bayes-Genis A, Nunez J. Right \nheart dysfunction and readmission risk across left ventricular ejection fraction status in patients with acute heart failure. \nJournal of Cardiac Failure. 2021 Oct;27(10):1090-1098. \ndoi: 10.1016/j.cardfail.2021.06.020. PMID: 34273477. IF: \n5,712\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI20/00392\nTitle:  Congesti\u00f3n renal e ninsuficiencia cardiaca aguda y s\u00edndroma \ncardiorenal: valoraci\u00f3n no invasiva mediante doppler vascular \nrenal\nPrincipal Investigator: Julio N\u00fa\u00f1ez Villota\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget:  \u20ac94.834\nReference: PI17/01426\nTitle: Retirada del tratamiento betabloqueante en pacientes \ncon insuficiencia card\u00edaca con funci\u00f3n sist\u00f3lica preservada e \nincompetencia cronotr\u00f3pica. Efecto sobre la capacidad funcional\nPrincipal Investigator: Julio N\u00fa\u00f1ez Villota\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac127.050\nReference: PI17/01736\nTitle: Comparaci\u00f3n aleatoria entre las estrategias invasivas y \nconservadoras en pacientes ancianos fr\u00e1giles con infarto de \nmiocardio sin elevaci\u00f3n del segmento ST (MOSCA-FRAIL)\nPrincipal Investigator:  Gemma Mi\u00f1ana Escriv\u00e1PUBLICATIONS\nIF 59\nNumber of  \narticles542.591IF\n9.196Average21\nCorresponding  \nauthor30\nNational  \ncollaborations17\nInternational \ncollaborations95\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Funding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2022\nTotal budget:  \u20ac70.180\nTitle: Resonancia magn\u00e9tica card\u00edaca de estr\u00e9s con \nvasodilatadores para predecir la mortalidad a largo plazo en \nun amplio registro retrospectivo de pacientes con cardiopat\u00eda \nisqu\u00e9mica conocida o sospechada\nPrincipal Investigator: Vicent Bod\u00ed Peris (Julio N\u00fa\u00f1ez Villota as \ncollaborating researcher)\nFunding Body: Sociedad Espa\u00f1ola de Cardiolog\u00eda\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac15.000\nReference: AP-2021-019\nTitle: HISTONATTR: Efecto de la activaci\u00f3n de TLR por medio de \nsus ligandos sobre la polarizaci\u00f3n de macr\u00f3fagos hacia M1 y su \nfunci\u00f3n citocida frente a las c\u00e9lulas madre de glioblastoma\nPrincipal Investigator: Carlos Rom\u00e1 Mateo and Enrique Santas \nOlmeda\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution: Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac4.750\nTHESIS\nThesis title: Cambios en el contenido mioc\u00e1rdico de hierro tras la \nadministraci\u00f3n de hierro intravenoso (MYOCARDIAL -IRON)\nDoctoral candidate: Ingrid Cardells Beltr\u00e1n \nDirector(s):  Julio N\u00fa\u00f1ez Villota, Gema Mi\u00f1ana Escriv\u00e1 \nDate of the defense: 24/09/2021\nGrade: Sobresaliente \u201ccum laude\u201d96\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.3.2 Oncology area\nGroups\nResearch Group on Histopathology and Tissue Engineering\nResearch Group on Central Nervous System Tumors\nResearch Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST\nResearch Group on Breast Cancer Biology\nResearch Group on Skin Cancer\nTranslational Research Group on Pediatric Solid Tumors\nResearch Group on Hematopoietic Transplantation\nResearch Group on Lymphoproliferative Disorders\nResearch Group on Myeloid Neoplasms\nResearch Group on Molecular Imaging and Metabolomics\n219\nNumber of  \narticlesIF\n1811.316IF\n8.27Average68\nCorresponding  \nauthor100\nNational  \ncollaborations85\nInternational \ncollaborations\n50\nD149\nFirst  \nauthor72\nLast  \nauthor139\nQ128\nQ2\noriginal articles letters editorial review case reports corrections176221182297\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Histopathology and Tissue Engineering  \nConsolidated group\nLeading Researcher, R4\nCarmen Carda Batalla. University\nAmando Peydr\u00f3 Olaya. University\nAntonio Silvestre Mu\u00f1oz. Hospital. University\nManuel Mata Roig. University\nEstablished Researchers, R3\nAntonio Fons Font. University\nCarlos Tejerina Botella. Hospital. University\nFrancisco Forriol Brocal. Hospital\nGenaro Gal\u00e1n Gil. Hospital. University\nJos\u00e9 Javier Mart\u00edn de Llano. University\nMari Fe M\u00ednguez Rey. Hospital. University\nMar\u00eda Sancho-Tello Valls. University\nMiguel Puche Torres. Hospital. University\nRosa Mar\u00eda Cibri\u00e1n Ortiz de Anda. University\nRecognised Researcher, R2\nLara Mili\u00e1n Medina. University\nMar\u00eda Oliver Ferr\u00e1ndiz. University \nRub\u00e9n Salvador Clavell. University\nFirst Stage Researchers, R1\n\u00c1ngel Aguilar Hern\u00e1ndez. Hospital\nGiovanna Foschini Mart\u00ednez. Hospital\nIrene Monle\u00f3n Guinot. University\nZakaria Oguir. HospitalGroup members\nStrategic aims\nThe group obtained funding to continue working on to the line of Tissue Engineering with new projects: \n\u2022 Bone regeneration in prosthetic implants. Biological processes conditioned by age and gende. Design of new biomaterials\n\u2022 Biomimetic microgels for the study of the tumor microenvironment (TME) and the mesenchymal epithelial transition (EMT) in \nlung cancer \n\u2022 Cartilage and bone regeneration techniques and their application in pathologies\nMain lines of research \nRegenerative Medicine:\n\u2022 Study of articular cartilage regeneration\n\u2022 Study of bone regeneration. Effect of age and gender on the regeneration processResearchers by categories\n3 9 4 4 3R1 R2 R3 R4 STAFF\nStaff. Collaborating Researcher\nIgnacio Peregr\u00edn Nevado. Hospital \nJavier Alc\u00e1cer Fern\u00e1ndez-Coronado. University\nTeresa Sagrado Vives. University98\nINCLIVA SCIENTIFIC REPORT 2021scientific activity45. Reula A, Pitarch-Fabregat J, Milara J, Cortijo J, Mata-Roig M, \nMilian L, Armengot M. High-Speed video microscopy for primary \nciliary dyskinesia diagnosis: a study of ciliary motility variations \nwith time and temperature. Diagnostics (Basel). 2021 Jul \n20;11(7):1301. doi: 10.3390/diagnostics11071301. \nPMID: 34359383. IF: 3,706\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PID2019-106099RB-C42 \nTitle:  Microgeles biomim\u00e9ticos para el estudio del microentorno \ndel tumor (TME) y la transici\u00f3n epitelio mes\u00e9nquima (EMT) en \nc\u00e1ncer de pulm\u00f3n \nPrincipal Investigator: Manuel Mata Roig and Jos\u00e9 Javier Mart\u00edn \nde Llano\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n \nBeneficiary Institution: Universidad de Valencia\nDuration: 2020-2023 \nTotal Budget: \u20ac151.250\nTitle:  Cell-free approach for articular cartilage regeneration using \nautologous and synthetic microspheres as supporting biomaterial \n(JOINTCART)\nPrincipal Investigator: Jos\u00e9 Luis G\u00f3mez Ribelles (Carmen Carda \nBatalla, Mar\u00eda Sancho-Tello, Manuel Mata Roig, Jos\u00e9 Javier Mart\u00edn \nde Llano, Lara Mili\u00e1n Medina as collaborating researchers)PUBLICATIONS\nIF 24\nNumber of  \narticles86.878IF\n3.619Average3\nCorresponding  \nauthor19\nNational  \ncollaborations1\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Oliver-Ferrandiz M, Milian L, Sancho-Tello M, de Llano J, \nRoca F, Martinez-Ramos C, Carda C, Mata M. Alginate-\nagarose hydrogels improve the in vitro differentiation of \nhuman dental pulp stem cells in chondrocytes. A histological \nstudy. Biomedicines. 2021 Jul 17;9(7):834. doi: 10.3390/\nbiomedicines9070834. PMID: 34356898. IF: 6,081\n2. Milian L, Sancho-Tello M, Roig-Soriano J, Foschini G, Mart\u00ednez-\nHern\u00e1ndez NJ, M\u00e1s-Estell\u00e9s J, Ruiz-Sauri A, Zurriaga \nJ, Carda C, Mata M. Optimization of a decellularization \nprotocol of porcine tracheas. Long-term effects of \ncryopreservation. A histological study. International Journal \nof Artificial Organs. 2021 Dec;44(12):998-1012. doi: \n10.1177/03913988211008912. PMID: 33863248. IF: \n1,595\n3. Salvador-Clavell R, Mart\u00edn de Llano JJ, Mili\u00e1n L, Oliver M, \nMata M, Carda C, Sancho-Tello M. Chondrogenic potential \nof human dental pulp stem cells cultured as microtissues. \nStem Cells International. 2021 Sep 7;2021:7843798. doi: \n10.1155/2021/7843798. PMID: 34539791. IF: 5,443\n4. Mart\u00ednez-Hern\u00e1ndez NJ, Mas-Estell\u00e9s J, Mili\u00e1n-Medina L, \nMart\u00ednez-Ramos C, Cer\u00f3n-Navarro J, Galbis-Caravajal J, Roig-\nBataller A, Mata-Roig M. A Standardised approach to the \nbiomechanical evaluation of tracheal grafts. Biomolecules. \n2021 Oct 5;11(10):1461. doi: 10.3390/biom11101461. \nPMID: 34680094. IF: 4,879\u2022 Study of the use of dental pulp cells as precursors in regenerative therapies\n\u2022 Study of regeneration of dental and periodontal tissues\n\u2022 Study of tumor microenvironment using biomimetic microgels\nHistopathology:\n\u2022 Study of ciliary pathology99\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Funding Body:  Ministerio de Econom\u00eda y Competitividad - CIBER-\nBBN\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia and  Universidad de Valencia\nDuration: 2018-2021\nTotal Budget: \u20ac59.241,25\nReference: PROMETEO/2020/069 \nTitle:  Regeneraci\u00f3n \u00f3sea en implantopr\u00f3tesis. Procesos \nbiol\u00f3gicos condicionados por la edad y el g\u00e9nero. Dise\u00f1o de \nnuevos biomateriales (ROMEN) \nPrincipal Investigator: Carmen Carda Batalla \nFunding Body: Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary Institution: Universidad de Valencia\nDuration: 2020-2023 \nTotal Budget: \u20ac235.145\nTHESIS\nThesis title:  Regeneraci\u00f3n de cart\u00edlago mediante el uso de c\u00e9lulas \nmadre de pulpa dental humanas (HDPSCS)\nDoctoral candidate: Mar\u00eda Oliver Ferr\u00e1ndiz\nDirector(s): Manuel Mata Roig, Jos\u00e9 Javier Mart\u00edn De Llano\nDate of the defense:  04/03/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title:  Efectos de la estimulaci\u00f3n mec\u00e1nica sobre c\u00e9lulas \nmadre aplicado a la regeneraci\u00f3n de cart\u00edlago\nDoctoral candidate: Rub\u00e9n Salvador Clavell\nDirector(s): Jos\u00e9 Javier Mart\u00edn De Llano, Mar\u00eda del Carmen \nCarda Batalla, Mar\u00eda Sancho-Tello Valls\nDate of the defense:  04/03/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: Comportamiento periodontal de restauraciones de \nrecubrimiento completo sobre preparaciones dentarias sin l\u00ednea \nde terminaci\u00f3n: estudio cl\u00ednico prospectivo a 6 a\u00f1os\nDoctoral candidate: Blanca Serra Pastor\nDirector(s):  Antonio Fons Font, Rub\u00e9n Agust\u00edn Panadero, M\u00aa \nFernanda Sol\u00e1 Ruiz\nDate of the defense: 23/04/2021\nGrade: Sobresaliente \u201ccum laude\u201dThesis title: An\u00e1lisis de la correlaci\u00f3n entre la exploraci\u00f3n f\u00edsica \ny los hallazgos en la resonancia magn\u00e9tica en pacientes con \ndisfunci\u00f3n de la articulaci\u00f3n temporo-mandibular\nDoctoral candidate: \u00c1lvaro Sada Malumbres\nDirector(s): Miguel Puche Torres, Mario F Mu\u00f1oz Guerra\nDate of the defense: 08/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title:  Estudio de las malformaciones vasculares evaluadas \na lo largo de una d\u00e9cada en un hospital de referencia con un \ncomit\u00e9 multidisciplinar\nDoctoral candidate: Andrea Est\u00e9banez Corrales\nDirector(s): Jos\u00e9 Mar\u00eda Mart\u00edn Hern\u00e1ndez, Miguel Puche Torres\nDate of the defense: 17/06/2021\nGrade:  Sobresaliente \u201ccum laude\u201d100\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Central Nervous System Tumors  \nConsolidated group\nLeading Researcher, R4\nMiguel Cerd\u00e1 Nicol\u00e1s \nHospital. University\nEstablished Researchers, R3\nConcepci\u00f3n L\u00f3pez Gin\u00e9s. University\nJavier Meg\u00edas Vericat. University\nPedro Rold\u00e1n Bad\u00eda. Hospital. University\nTeresa San Miguel D\u00edez. University\nRecognised Researchers, R2\nLisandra Mu\u00f1oz Hidalgo. University\nPablo Cerd\u00e1 Dur\u00e1n. University\nStaff. Technician\nLara Navarro Cerver\u00f3. UniversityGroup members\nR1\n7\nStrategic aims\nClinical-pathological study of 40 patients affected by primary glioblastoma according to established protocol\n\u2022 Short-cell cultures and their viability analysis have been performed. Analysis by FISH of EGFR status and freezing of the \ndifferent passes according to established methodology\n\u2022 The study of the proteomic analysis of the 40 tumors (frozen samples) by Western Blott according to established \nmethodology has been completed\nExperimental study:\n\u2022 Spheres (neurospheres) have been elaborated from different cell lines and cell cultures of glioblastoma, characterizing and \nanalyzing their behavior\n\u2022 Analysis of cultures subjected to silencing and overexpression by transfection of miRNAs by the lipofection method\n\u2022 Analysis of cell cultures in hypoxia situation, analyzing their characteristics and behavior before silencing and overexpression \nby transfection of selected miRNAs in hypoxia situation and in the different amplification status of the EGFR\n\u2022 The pilot study of viability and effectiveness of xenotransplantation in nude mice has been completed with the achievement \nof neoplasias under study\nMain lines of research \n\u2022 Primary GBM. Amplification status of EGFR and angiogenic/infiltrative phenotype. Molecular networks responsible for tumor \nmodulation and reprogramming processes\n\u2022 Role of microRNA in the regulation of EGFR-dependent signaling pathways in high-grade astrocytic gliomas\n\u2022 Development of a model for analyzing the modulation of microRNA gene activity in cell cultures of primary GBM and GBM \ncell lines\n\u2022 Development of a model of population analysis and spatial distribution of these neoplasms\n\u2022 Metabolomics and microvascular environment characterization of aggressive human glioma by DCE-MRI and genetic study \nof biopsiesResearchers by categories\n2 4 1 1R2 R3 R4 STAFF101\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: GV/2020/048\nTitle: Estudio de la angiog\u00e9nesis en el glioblastoma y su asociaci\u00f3n \ncon inflamaci\u00f3n y agresividad en tumores humanos y en cultivo in \nvitro. Introducci\u00f3n a la patolog\u00eda digital e integraci\u00f3n con datos \n\u00f3micos\nPrincipal Investigator: Teresa San Miguel D\u00edez\nFunding body: Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary institution:  Universidad de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac12.420\nReference: AP-2021-001\nTitle: LIGAM1: Efecto de la activaci\u00f3n de TLR por medio de sus \nligandos sobre la polarizaci\u00f3n de macr\u00f3fagos hacia M1 y su \nfunci\u00f3n citocida frente a las c\u00e9lulas madre de glioblastoma\nPrincipal Investigator: Javier Meg\u00edas Vericat and Andrea \nCabrera Pastor\nFunding body: Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary institution: Universidad de Valencia - INCLIVA\nDuration: 2021\nTotal Budget: \u20ac4.607,5\nTHESIS\nThesis title: Biocompatibilidad y bioactividad de nuevos materiales \npara odontolog\u00eda regenerativa\nDoctoral candidate: Francisco Javier Rodr\u00edguez Lozano\nDirector(s): Leopoldo Forner Lozano, Mar\u00eda del Carmen Llena \nPuy, Concepci\u00f3n L\u00f3pez Gines\nDate of the defense:  03/12/2021\nGrade: Sobresaliente \u201ccum laude\u201dPUBLICATIONS\nIF 6\nNumber of  \narticles28.687IF\n4.781Average0\nCorresponding  \nauthor5\nNational  \ncollaborations1\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Gimenez-Garzo C, Fiorillo A, Ballester-Ferre M, Gallego J, \nCasanova-Ferrer F, Urios A, Benlloch S, Marti-Aguado D, San-\nMiguel T, Tosca J, Rios M, Monton C, Durban L, Escudero-\nGarcia D, Aparicio L, Felipo V, Montoliu C. A new score unveils \na high prevalence of mild cognitive impairment in patients with \nnonalcoholic fatty liver disease. Journal of Clinical Medicine. \n2021 Jun 25;10(13):2806. doi: 10.3390/jcm10132806. \nPMID: 34202269. IF: 4,241\n2. Rega D, Aiko M, Penaranda N, Urios A, Gallego J, Gimenez-\nGarzo C, Casanova F, Fiorillo A, Cabrera-Pastor A, San-Miguel \nT, Ipiens C, Escudero-Garcia D, Tosca J, Monton C, Ballester \nM, Ballester J, Aparicio L, Rios M, Durban L, Mir A, Kosenko \nE, Cases P, Felipo V, Montoliu C. Patients with minimal \nhepatic encephalopathy show altered thermal sensitivity \nand autonomic function. Journal of Clinical Medicine. 2021 \nJan 11;10(2):E239. doi: 10.3390/jcm10020239. PMID: \n33440769. IF: 4,241\n3. Rodriguez-Lozano F, Lopez-Garcia S, Garcia-Bernal D, Sanz \nJ, Lozano A, Pecci-Lloret M, Melo M, Lopez-Gines C, Forner \nL. Cytocompatibility and bioactive properties of the new \ndual-curing resin-modified calcium silicate-based material \nfor vital pulp therapy. Clinical Oral Investigations. 2021 \nAug;25(8):5009-5024. doi: 10.1007/s00784-021-03811-\n0. PMID: 33638052. IF: 3,573\n4. Guerra-Ojeda S, Marchio P, Gimeno-Raga M, Arias-Mutis \nO, San-Miguel T, Valles S, Aldasoro M, Vila J, Zarzoso M, \nMauricio M. PPARgamma as an indicator of vascular function \nin an experimental model of metabolic syndrome in rabbits. \nAtherosclerosis. 2021 Aug 5;332:16-23. doi: 10.1016/j.\natherosclerosis.2021.08.006. PMID: 34375909. IF: 5,162\n5. Sanz J, Rodriguez-Lozano F, Lopez-Gines C, Monleon D, Llena \nC, Forner L. Dental stem cell signaling pathway activation \nin response to hydraulic calcium silicate-based endodontic \ncements: a systematic review of in vitro studies. Dental \nMaterials. 2021 Apr;37(4):e256-e268. doi: 10.1016/j.\ndental.2021.01.025. PMID: 33573840. IF: 5,304102\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group of Innovative Diagnostic and Therapeutical  \nDevelopments in Solid Tumors - InDeST  \nConsolidated group\nLeading Researcher, R4\nAndr\u00e9s Cervantes Ruip\u00e9rez \nHospital. University\nEstablished Researchers, R3\nDesamparados Roda P\u00e9rez. Hospital\nGerardo L\u00f3pez Rodas. University\nEmerging researchers, R2\nNoelia Tarazona Llavero. Hospital\nTania Fleitas Kanonnikoff. Hospital\nRecognised Researchers, R2 \nAmelia Insa Moll\u00e1. Hospital\nFrancisco Gimeno Valiente. INCLIVA\nJose A. P\u00e9rez Fidalgo. Hospital. University\nJosefa Castillo Aliaga. University\nMaider Ibarrola Villava. INCLIVA\nMar\u00eda Carolina Mart\u00ednez Ciarpaglini. Hospital. University\nSusana Rosell\u00f3 Keranen. Hospital\nValentina Gambardella. Hospital\nFirst Stage Researchers, R1 \nFederica Papaccio. ESMO \nFernanda Guti\u00e9rrez Bravo. INCLIVA \nGema Bruixola Campos. Hospital\nJorge Mart\u00edn Aranda. INCLIVA \nJos\u00e9 Francisco Gonz\u00e1lez Mu\u00f1oz. INCLIVA\nLorena Alarc\u00f3n Molero. University\nManuel Cabeza Segura. INCLIVA\nMarisol Huerta \u00c1lvaro. Hospital\nPaloma Mart\u00edn Martorell. Hospital\nRoberto Tebar Mart\u00ednez. AECC\nStaff. Collaborating Researcher\nClara Alfaro Cervell\u00f3. Hospital. University\nStaff. Technicians \nAlba Viala Monle\u00f3n. Hospital\nAm\u00e9rica Bueno G\u00f3mez. INCLIVA\nAna Ferrer Mart\u00ednez. INCLIVA\nBeatriz L\u00f3pez Montero. INCLIVAGroup members\nBlanca Garc\u00eda Mic\u00f3. INCLIVA \nCarlos Peris Casilda. INCLIVA\nCristina Mongort Sanchis. INCLIVA\nGuillermo Moret Peir\u00f3. INCLIVA\nHelen Manzaneda L\u00f3pez. INCLIVA\nIgnacio Casta\u00f1o L\u00f3pez. INCLIVA\nLaura Olivares Ord\u00f3\u00f1ez. INCLIVA \nM\u00aa Carmen Mart\u00ednez L\u00f3pez. INCLIVA\nM\u00aa Elena Dur\u00e9ndez S\u00e1ez. INCLIVA\nM\u00aa Pilar Natividad L\u00f3pez. INCLIVA\nSergio Romero Alcaide. INCLIVA\nZahara Garz\u00f3n Lloria. INCLIVA\nStaff. Nurses \nAna Ruiz Qu\u00edlez. INCLIVA\nCelia Mart\u00ednez Ridaura. INCLIVA\nCristina Jord\u00e1 Guerola. INCLIVA \nEstela Contel Mart\u00ednez. INCLIVA\nGloria Corredor Agull\u00f3. INCLIVA\nInma Blasco Blasco. University\nLuna Porta Campos. INCLIVA\nVer\u00f3nica Babiano Su\u00e1rez. INCLIVA\nVer\u00f3nica Garc\u00eda Oliver. INCLIVATeam involved inResearchers by categories\n10 10 1 2 33\nResearchers financed by \ncompetitive public calls or networks\nR4\n5 4 4R1 R2 R4 R3 STAFF\nR2 STAFF R1103\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Staff. Administrative assistants \nAna Vercher Grau. INCLIVA\nCarla Gil Ferri. INCLIVA\nElena Jim\u00e9nez Mart\u00ed. University\nEnrique Castell\u00f3 Moreno. INCLIVA Gabriela P\u00e9rez Garrity. INCLIVA\nMireia Tom\u00e0s i Giner. INCLIVA\nPaula Petruskevicius Fern\u00e1ndez. INCLIVA\nEmerging Researchers\nNoelia Tarazona Llavero\nOur scientific interests are based on the use of liquid biopsy with the use of circulating tumor DNA in plasma to detect minimal residual di-\nsease and its association with survival, identify mechanisms of progression and resistance to therapy and identify new therapeutic targets. \nLikewise, the use of circulating tumor cells to characterize minimal residual disease and the establishment of organoids from the tumor \nand circulating tumor cells of patients with localized colon cancer and the study of new biomarkers\nTania Fleitas Kanonnikoff\nOur scientific interests are based on the understanding of the tumor immune microenvironment of Gastric Cancer. Moreover, we are \nalso focused on the study of the clinical-epidemiological-molecular characteristics of patients with young gastric tumors under 50 years of \nage, the study of the clinical-pathological-molecular characteristics of patients diagnosed with advanced Her2-positive Gastric C resistant to \ntrastuzumab and the observational study of the clinical-epidemiological-molecular characteristics of patients diagnosed with gastric cancer \nfrom European and Latin American cohortsStrategic aims\nOur group aims to improve the patient\u2019s life through the development of new diagnostic and therapeutic methods. In addition \nto this main goal, we intend to implement strategies to facilitate the development of precission medicine in solid tumors with \ninnovative therapeutic approaches and provide knowledge on how to approach precission medicine in colorectal and gastric \ncancer from different points such as molecular classification, the use of predictive biomarkers and new therapeutic approaches.\nMain lines of research\n\u2022 To develop first-in-human Phase I trials of antineoplastic agents with innovative designs\n\u2022 To develop liquid biopsies (ctDNA, cmicroRNAs) for early diagnosis, monitoring and the prediction of therapeutic effects in \npatients with gastro-intestinal malignancies\n\u2022 To use the latest technologies to improve our knowledge of the molecular and genetic causes of cancer\n\u2022 To implement the use of organoids (3D cell cultures) from patients as functional models, in order to understand the \nunderlaying causes of tumorigenesis and to test the appropriateness of the treatments\nPUBLICATIONS\nIF 56\nNumber of  \narticles621.677IF\n11.101Average16\nCorresponding  \nauthor14\nNational  \ncollaborations30\nInternational \ncollaborations104\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4SELECTED PUBLICATIONS\n1. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, \nMishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua \nC, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, \nLordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu \nA, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO \nClinical Practice Guidelines for the diagnosis treatment and follow-\nup of patients with localised colon cancer. Annals of Oncology. 2021 \nDec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. \nPMID: 34411693. IF: 32,976\n2. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, \nSimonelli M, Cosman R, van der Westhuizen A, Atkinson V, \nCarpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le \nRhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, \nMan M, Gandhi L, Avsar E, Melisi D. First-in-human phase I study of \na next-generation, oral, transforming growth factor-beta receptor \n1 inhibitor, LY3200882 in patients with advanced cancer. Clinical \nCancer Research. 2021 Dec 15;27(24):6666-6676. doi: \n10.1158/1078-0432.CCR-21-1504. PMID: 34548321. IF: \n12,531\n3. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, \nMonton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. \nRadiomics and radiogenomics in head and neck squamous cell \ncarcinoma: potential contribution to patient management and \nchallenges. Cancer Treatment Reviews. 2021 Sep;99:102263. \ndoi: 10.1016/j.ctrv.2021.102263. PMID: 34343892. IF: \n12,111\n4. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo \nJM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, \nBruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini \nC, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, \nMonton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-\nMartorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-\nTrejos S, Cervantes A, Roda D. Molecular profiling of advanced \nsolid tumours. The impact of experimental molecular-matched \ntherapies on cancer patient outcomes in early-phase trials: the \nMAST study. British Journal of Cancer. 2021 Oct;125(9):1261-\n1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820. \nIF: 7,64\n5. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, \nGambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo \nJ. Epigenetic mechanisms are involved in the oncogenic \nproperties of ZNF518B in colorectal cancer. Cancers. 2021 \nMar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: \n33801071. IF: 6,639\n \n RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: 825832 \u2013 LEGACy\nTitle:  CeLac and European consortium for a personalized \nmedicine approach to Gastric Cancer\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal Budget: \u20ac3.577.431,27 (INCLIVA: \u20ac638.315)\nReference:  ICI20/00009\nTitle: Investigaci\u00f3n Cl\u00ednica Independiente\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2024\nTotal Budget: \u20ac1.039.970\nReference: PI18/01508\nTitle:  Macr\u00f3fagos asociados al tumor, angiog\u00e9nesis tumoral \ny resistencia a las terapias en C\u00e1ncer G\u00e1strico Difuso fenotipo \nMesenquimal\nPrincipal Investigator: Tania Carolina Fleitas Kanonnikoff and \nDesamparados Roda P\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal Budget: \u20ac99.220\nReference:  PI18/01909\nTitle:  Medicina personalizada en pacientes con c\u00e1ncer colorrectal \nlocalizado: abordaje multi\u00f3mico de la Enfermedad M\u00ednima Residual \nen biopsia l\u00edquida y modelos de organoides\nPrincipal Investigator:  Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal Budget: \u20ac141.570\nReference:  PT20/00100\nTitle:  Clinical Research Platform\nPrincipal Investigator:  Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER105\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Beneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget: \u20ac199.650\nReference:  PT17/0017/0003\nTitle: Clinical Research and Trials Platform\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac266.475\nReference:  CB16/12/00473 \nTitle:  Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer \n(CIBERonc)\nPrincipal Investigator:  Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2017-\nReference: GV/2020/189\nTitle: Estudio de la carga tumoral ganglionar y el budding tumoral \ncomo factores pron\u00f3sticos el c\u00e1ncer colorrectal en estadios \nlocalizados \nPrincipal Investigator: M\u00aa Carolina Mart\u00ednez Ciarpaglini \nFunding Body: Conselleria de Educaci\u00f3n Cultura y Deporte \nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac16.000 \nTitle: Tumor microenvironment-derived factors in localized colon \ncancer: clinical impact and therapeutic implications\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal budget:  \u20ac992.996\nTitle: Organoides derivados de pacientes (PDOs) para personalizar \nel tratamiento en reca\u00eddas de c\u00e1ncer de colon (CC) localizado \nmediante secuenciaci\u00f3n del exoma completo y del DNA gen\u00f3mico\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: Digestive Tumors Treatment Group (TTD)\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2020-2022\nTotal budget:  \u20ac40.000\nTitle: Utilidad de la biopsia l\u00edquida y organoides en el manejo y \ntratamiento de adenocarcinoma de p\u00e1ncreas: hacia una medicina \nde precisi\u00f3n\nPrincipal Investigator: Maider Ibarrola Villava\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal Budget: \u20ac100.000\nTitle: Carcionog\u00e9nesis colorrectal: la interacci\u00f3n el microambiente \ntumoral y las c\u00e9lulas madre. Impacto en el tratamiento \npersonalizado\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2023\nTotal budget: \u20ac130.000\nTitle: Secuenciaci\u00f3n del exoma completo del DNA tumoral \ncirculante y DNA gen\u00f3mico para aumentar la sensibilidad en la \ndetecci\u00f3n de la enfermedad m\u00ednima residual y abrir nuevas v\u00edas \npara la medicina personalizada en c\u00e1ncer de colon localizado\nPrincipal Investigator: Noelia Tarazona Llavero \nFunding Body: Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM)\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac20.000 \nTitle:  Mecanismos moleculares y heterogeneidad tumoral \nasociados a la resistencia primaria y adquirida al tratamiento \ncont rastuzumab en c\u00e1ncer g\u00e1strico (CG) o de la uni\u00f3n gastro-\nesof\u00e1gica (CUGE)\nPrincipal Investigator: Tania Carolina Fleitas Kanonnikoff \nFunding Body: Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica \n(SEOM) \nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac9.096\nReference: PI-2021-007\nTitle:  DIRUGEN: Dise\u00f1o e investigaci\u00f3n de nuevos compuestos de 106\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4THESIS\nThesis title: Multi-omic characterization of advanced colorectal \ncancer patients derived organoids in the context of Precission \nMedicine\nDoctoral candidate: Federica Papaccio\nDirector(s): Andr\u00e9s Cervantes Ruip\u00e9rez, Josefa Castillo Aliaga\nDate of the defense:  23/12/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhDrutenio (III) basados en biomol\u00e9culas como potenciales agentes \nantitumorales\nPrincipal Investigator: Francisco Jos\u00e9 Mart\u00ednez Lillo and Tania \nFleitas Kanonnikoff \nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution:  Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac19.000 \nReference: AP-2021-008\nTitle:  PROTORGANOIDE: Medicina personalizada y de precisi\u00f3n a \ntrav\u00e9s del an\u00e1lisis prote\u00f3mico de organoides\nPrincipal Investigator: Manuel Mart\u00edn S\u00e1nchez del Pino and \nJosefa Castillo Aliaga \nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution: Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac4.750 107\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Breast Cancer Biology \nConsolidated group\nLeading Researchers, R4\nAna Lluch Hern\u00e1ndez \nUniversity\nPilar Eroles Asensio\nINCLIVA\nEstablished Researchers, R3\nAntonio Millet Serrano. University\nIsabel Chirivella Gonz\u00e1lez. Hospital. University\nOctavio Burgues Gasi\u00f3n. Hospital. University\nRecognised Researchers, R2\nBego\u00f1a Bermejo De Las Heras. Hospital. University\nBego\u00f1a Pineda Merlo. University\nDiego Soriano Mena. Hospital\nEduardo Tormo Mart\u00edn. CIBERONC \nElvira Buch Villa. Hospital\nJuan Miguel Cejalvo And\u00fajar. Hospital\nMar\u00eda Teresa Mart\u00ednez Mart\u00ednez. Hospital\nFirst Stage Researchers, R1\nAna Caterina Lameirinhas. AECC \nAnna Adam-Artigues. AECC \nCristina Hernando Meli\u00e1. Hospital\nIris Garrido Cano. CIBER \nJuan Jos\u00e9 Mart\u00ednez Pretel. INCLIVA \nSandra Torres Ruiz. INCLIVA\nStaff. Collaborating Researcher\nEsther Jord\u00e1 Sorolla. Hospital. UniversityGroup members\nStaff. Technicians\nElisa Alonso Yuste. INCLIVA\nJ\u00falia Soler Flores. INCLIVA\nStaff. Nurses \nCristina T\u00e9bar S\u00e1nchez. INCLIVA\nPatricia Mart\u00ednez Belenguer. INCLIVA\nSilvia Coret Sinisterra. INCLIVA\nSara Rodr\u00edguez Pestano. INCLIVA\nStaff. Administrative assistant\nCristina Parrilla Mu\u00f1oz. Hospital\nYolanda De La Cruz Robles. INCLIVAResearchers by categories\n3 7 6 2 9\nResearchers financed by \ncompetitive public calls or networks\nR4\n2 1 5R2 R1 R3 R4 STAFF\nR2 R4 R1\nStrategic aims\nResistance to treatments:\n\u2022 Evaluation of the recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models\nMetastatic setting:\n\u2022 Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and \nbiomarker assessment substudy\n\u2022 Analysis of postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes108\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\nIF 38\nNumber of  \narticles475.522IF\n12.513Average7\nCorresponding  \nauthor9\nNational  \ncollaborations22\nInternational \ncollaborationsER+ breast cancer:\n\u2022 Evaluation of the outcomes of single versus double hormone receptor-positive breast cancer\n\u2022 Description that the ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program \nsensitive to CDK4/6 inhibitors\n\u2022 Design of adjuvant endocrine therapy for premenopausal breast cancer\nBreast cancer in very young women:\n\u2022 Identification of miR124-2 as a survival biomarker by methylation deregulation of its promoters\n\u2022 Review of breast cancer in pregnant patients\nPrognostic and prediction:\n\u2022 Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer\n\u2022 Evaluation of the pathologic complete response rate to neoadjuvant chemotherapy in triple negative breast cancer subtypes\n\u2022 Study of the incidence, characteristics, and prevention of the alopecia following adjuvant docetaxel\n\u2022 Molecular characterization of oligometastatic breast cancer patients\nMain lines of research\n\u2022 Evaluation of microRNAs and mRNAs differentially expressed after chemotherapy treatment\n\u2022 Involvement of miRNAs and other epigenetic regulations in breast cancer processes\n\u2022 Role of tumor heterogeneity and dynamic reprogramming of tumor cell resistance to anti-HER2 therapy\n\u2022 Evaluation of the involvement of stem cells and epithelial mesenchymal transition in the mechanisms of resistance to treatment \nin HER2 + breast cancer\n\u2022 Primary and secondary resistance in HER2 + breast cancer: search for new treatments\n\u2022 Interaction between estrogen receptors, tumor angiogenesis and breast cancer metabolism\n\u2022 Molecular and Clinical characterization of breast tumors from very young women\n\u2022 The role of AXL in trastuzumab-resistant breast cancer\n2. Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, \nGelber R, de Azambuja E, Fielding A, Balmana J, Domchek S, \nGelmon K, Hollingsworth S, Korde L, Linderholm B, Bandos H, \nSenkus E, Suga J, Shao Z, Pippas A, Nowecki Z, Huzarski T, Ganz \nP, Lucas P, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler \nR, Steger G, Costantino J, Arahmani A, Wolmark N, McFadden \nE, Karantza V, Lakhani S, Yothers G, Campbell C, Geyer C, \nOlympiA Clinical Trial Steering. Adjuvant olaparib for patients \nwith BRCA1- or BRCA2-mutated breast cancer. New England \nJournal of Medicine. 2021 Jun 24;384(25):2394-2405. doi: \n10.1056/NEJMoa2105215. PMID: 34081848. IF: 91,245SELECTED PUBLICATIONS\n1. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain \nKS, Hayes DF, Lin UN, Perez EA, Goldstein LJ, Chia SKL, \nDhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly \nCM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, \nLee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, \nFerrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, \nTripathy D, Pusztai L, Hortobagyi GN. 21-Gene assay to inform \nchemotherapy benefit in node-positive breast cancer. New \nEngland Journal of Medicine. 2021 Dec 16;385(25):2336-\n2347. doi: 10.1056/NEJMoa2108873. PMID: 34914339. \nIF: 91,245109\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 43. Perez-Garcia JM, Gebhart G, Ruiz Borrego M, Stradella \nA, Bermejo B, Schmid P, Marme F, Escriva-de-Romani S, \nCalvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc \nF, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-\nCordero M, Malfettone A, Cortes J, Llombart-Cussac \nA. Chemotherapy de-escalation using an F-18-FDG-PET-\nbased pathological response-adapted strategy in patients \nwith HER2-positive early breast cancer (PHERGain): a \nmulticentre, randomised, open-label, non-comparative, \nphase 2 trial. Lancet Oncology. 2021 Jun;22(6):858-\n871. doi: 10.1016/S1470-2045(21)00122-4. PMID: \n34019819. IF: 41,316\n4. Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, \nCiruelos E, Munoz M, Bermejo B, Margeli M, Anton A, Kahan \nZ, Csoszi T, Casas M, Murillo L, Morales S, Alba E, Gal-Yam \nE, Guerrero-Zotano A, Calvo L, Haba-Rodriguez J, Ramos M, \nAlvarez I, Garcia-Palomo A, Bartlett C, Koehler M, Caballero \nR, Corsaro M, Huang X, Garcia-Saenz J, Chacon J, Swift C, \nThallinger C, Gil-Gil M. Palbociclib in combination with endocrine \ntherapy versus capecitabine in hormonal receptor-positive, \nhuman epidermal growth factor 2-negative, aromatase \ninhibitor-resistant metastatic breast cancer: a phase III \nrandomised controlled trial-PEARL. Annals of Oncology. 2021 \nApr;32(4):488-499. doi: 10.1016/j.annonc.2020.12.013. \nPMID: 33385521. IF: 32,976\n5. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall \nD, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez \nL, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch \nA, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, \nAlbanell J. Preclinical and clinical characterization of fibroblast-\nderived neuregulin-1 on trastuzumab and pertuzumab activity \nin HER2-positive breast cancer. Clinical Cancer Research. \n2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-\n0432.CCR-20-2915. PMID:34385295. IF: 12,531\nRESEARCH PROJECTS AND GRANTS  \nFOR RESEARCH\nReference: 965231-REBECCA\nTitle:  REsearch on BrEast Cancer induced chronic conditions \nsupported by Causal Analysis of multi-source data\nPrincipal Investigator: Aristotelio Panepistimio Thessalonikis \n(Cristina Hernando as collaborating researcher)\nFunding Body: European Commission\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2025\nTotal budget:  \u20ac466.125Reference: PI18/01219\nTitle: Caracterizaci\u00f3n y repercusi\u00f3n terap\u00e9utica de la ecolog\u00eda de \nc\u00e1ncer de mama HER2 positivo\nPrincipal Investigator:  Pilar Eroles Asensio\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget: \u20ac112.530\nReference:  PI18/00817\nTitle:  Caracterizaci\u00f3n molecular del c\u00e1ncer de mama gestacional\nPrincipal Investigator: Juan de la Haba Rodr\u00edguez (Bego\u00f1a \nBermejo as collaborating researcher)\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Biom\u00e9dica de \nC\u00f3rdoba (FIBICO)\nDuration: 2019-2021\nTotal budget:  \u20ac146.159,53\nTitle:  Disecci\u00f3n multidiciplinar de los mecanismos de resistencia \na quimioterapia en c\u00e1ncer de mama triple negativo: un paso hacia \nuna mejor atenci\u00f3n cl\u00ednica\nPrincipal Investigator: Juan Miguel Cejalvo And\u00fajar\nFunding Body: Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer\nBeneficiary institution:  CIBERONC/Fundaci\u00f3n Investigaci\u00f3n \nHospital Cl\u00ednico Universitario de Valencia\nDuration: 2021-2023\nTotal budget: \u20ac268.500\nTitle: Disecci\u00f3n multidisciplinar de los mecanismos de resistencia \na quimioterapia en c\u00e1ncer de mama triple negativo: un paso hacia \nuna mejor atenci\u00f3n cl\u00ednica\nPrincipal Investigator: \u00c1ngel R Nebreda (Juan Miguel Cejalvo as \ncollaborating researcher)\nFunding Body: Instituto de Investigaci\u00f3n Biom\u00e9dica-IRB\nBeneficiary institution:  CIBERONC/Fundaci\u00f3n Investigaci\u00f3n \nHospital Cl\u00ednico Universitario de Valencia\nDuration: 2021-2026\nTotal budget:  \u20ac268.500\nTitle: An\u00e1lisis del papel de la v\u00eda aurora kinasa-p53 como potencial \nmarcador predictivo y dianas terap\u00e9uticas en c\u00e1ncer de mama \ntriple negativo\nPrincipal Investigator: Bego\u00f1a Pineda Merlo\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a110\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Beneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac120.000\nTitle: Diferencias entre el perfil gen\u00f3mico en mujeres j\u00f3venes \nmenores de 35 a\u00f1os con respecto al c\u00e1ncer de mama de \nmujeres mayores\nPrincipal Investigator: M\u00aa Teresa Mart\u00ednez Mart\u00ednez\nFunding Body: Fundaci\u00f3n Sandra Ibarra\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac10.500\nTitle:  Hemopach versus drenaje axilar para un mejor control del \nseroma post linfadenectom\u00eda axilar. Estudio cl\u00ednico aleatorizado, \ncontrolado, multic\u00e9ntrico\nPrincipal Investigator: Elvira Buch Villa\nFunding Body: Asociaci\u00f3n Espa\u00f1ola de Cirujanos\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget: \u20ac10.000\nTitle: Factores pron\u00f3sticos y predictivos en c\u00e1ncer de mama \noligometast\u00e1sico que identifiquen pacientes en las que el \ntratamiento local sobre la met\u00e1stasis aumente su supervivencia: \nBeneficio del estadio NED (no evidencia de enfermedad)\nPrincipal Investigator: Juan Miguel Cejalvo And\u00fajar\nFunding Body:  METAPREMIOS 1. Asociaci\u00f3n de C\u00e1ncer de Mama \nMetast\u00e1tico\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020- 2022\nTotal budget:  \u20ac16.500Title: Dimerizacion de AXL -HER2 como mecanismo de resistencia \nadquirida a la terapia anti-HER2 en c\u00e1ncer de mama HER2+: un \npaso hacia la medicina de precisi\u00f3n\nPrincipal Investigator:  Juan Miguel Cejalvo And\u00fajar\nFunding Body: ADAMED\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget:  \u20ac18.000\nTHESIS \nThesis title: Estudio de las alteraciones gen\u00e9ticas asociadas \ncon la resistencia al tratamiento neoadyuvante de deprivaci\u00f3n \nestrog\u00e9nica en c\u00e1ncer de mama\nDoctoral candidate: \u00c1ngel Luis Guerrero Zotano \nDirector(s): Jos\u00e9 Antonio L\u00f3pez Guerrero, Vicente Guillem Porta, \nAna Lluch Hern\u00e1ndez\nDate of the defense: 21/01/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Involvement of EZH2-MYC loop and SALL4 in \nepithelial-mesenchymal transition (EMT) and trastuzumab \nresistance process in HER2+ breast cancer\nDoctoral candidate: Chaudhuri Birlipta Pattanayak Pattanayak\nDirector(s):  Pilar Eroles Asensio, Juan Miguel Cejalvo And\u00fajar\nDate of the defense: 26/02/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: Role of miR-99a-5p in breast cancer: translating \nmolecular findings into clinical tool\nDoctoral candidate: Iris Garrido Cano\nDirector(s): Pilar Eroles Asensio, Ram\u00f3n Mart\u00ednez M\u00e1\u00f1ez \nDate of the defense: 17/12/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD111\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Skin Cancer  \nConsolidated group\nLeading Researcher, R4\nJos\u00e9 Carlos Monteagudo Castro \nHospital. University\nRecognised Researchers, R2\nAndrea Est\u00e9banez Corrales. Hospital\nJos\u00e9 M\u00aa Mart\u00edn Hern\u00e1ndez. Hospital. University\nLiria Terr\u00e1dez M\u00e1s. Hospital. University\nFirst Stage Researchers, R1\nAna\u00efs Moscard\u00f3 Navarro. University\nAndr\u00e9s Mosquera Zamudio. INCLIVA\nEsmeralda Silva D\u00edaz. HospitalGroup members\nStrategic aims\n\u2022 Transcriptomic identification of miRNA-205 target genes potentially involved in metastasis and survival of cutaneous \nmalignant melanoma\n\u2022 Search for a genetic and/or epigenetic signature which permit a more precise diagnosis and prediction of the metastatic \npotential of ambiguous melanocytic lesions, and particularly of spitzoid tumors\n\u2022 Identification of circulating miRNAs which may serve as prognostic and/or staging biomarkers in patients with primary \ncutaneous melanoma\nMain lines of research\n\u2022 Prognostic value of intratumoral and circulatind microRNAs in melanoma tumor progression and clinical outcome\n\u2022 Improvement by circulating biomarkers of melanoma staging schedule at the time of diagnosis\n\u2022 Machine learning in the study of whole slide digitized images of spitzoid melanocytic tumors for diagnosis and prognosis \nimprovement\n\u2022 Evaluation of long- and short-term morphological changes in melanocytic nevi in a digitized dermoscopic unitResearchers by categories\n3 5 1 3\nResearchers financed by \ncompetitive public calls or networks\nR4\n1R2 R1 R4 STAFF\nR1Santiago Guillen Climent. University\nSilvia P\u00e9rez Deb\u00e9n. INCLIVA\nStaff. Collaborating researcher\nBeatriz S\u00e1nchez Sendra. INCLIVA\nIn\u00e9s Escandell Gonz\u00e1lez. University\nJaime Agust\u00ed Mart\u00ednez. INCLIVA\nPUBLICATIONS\nIF 20\nNumber of  \narticles71.524IF\n3.576Average6\nCorresponding  \nauthor7\nNational  \ncollaborations2\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Monteagudo C, Funez R, Sanchez-Sendra B, Gonzalez-Munoz \nJF, Nieto G, Alfaro-Cervello C, Murgui A, Barr R. Cutaneous \nlymphadenoma is a distinct trichoblastoma-like lymphoepithelial tumor with diffuse androgen receptor immunoreactivity, \nnotch1 ligand in reed-sternberg-like cells, and common \nEGFR somatic mutations. American Journal of Surgical 112\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Reference: PI20/00094\nTitle: An\u00e1lisis combinado por Inteligencia Artificial de marcadores \nepigen\u00e9ticos e im\u00e1genes microsc\u00f3picas digitalizadas de \ntumores melanoc\u00edticos ambiguos para optimizar su clasificaci\u00f3n \ndiagn\u00f3stica y pron\u00f3stica\nPrincipal Investigator:  Jos\u00e9 Carlos Monteagudo Castro\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac220.220\nReference: PI17/02019\nTitle:  Estudio del valor del patr\u00f3n de metilaci\u00f3n y variaciones \ndel n\u00famero de copias del genoma para determinar el grado de \nmalignidad en los tumores melanoc\u00edticos de potencial maligno \nincierto\nPrincipal Investigator: Jos\u00e9 Carlos Monteagudo Castro\nFunding body: Instituto de Salud Carlos III - Cofinanced FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal Budget: \u20ac99.220\nTitle: Estudio de factores pron\u00f3sticos en pacientes con linfomas \ncut\u00e1neos de c\u00e9lulas T (LCCT)\nPrincipal Investigator: \u00c1ngeles Revert (Esmeralda Silva as \nfunded researcher)\nFunding body: Janssen-Cilag\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac22.500\nTitle: Estudio de las malformaciones vasculares evaluadas a lo \nlargo de una d\u00e9cada en un hospital de referencia con comit\u00e9 \nmultidisciplinario\nPrincipal Investigator: \u00c1ngeles Revert (Andrea Est\u00e9banez as \nfunded researcher)\nFunding body: Janssen-Cilag\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac22.500Pathology. 2021 Oct 1;45(10):1382-1390. doi: 10.1097/\nPAS.0000000000001727. PMID: 34232601. IF: 6,394\n2. Sanchez-Velazquez A, Bauer-Alonso A, Estrach T, Vega-Diez \nD, Garcia-Muret P, Haya L, Penate Y, Acebo E, Fernandez de \nMisa R, Blanes M, Suh-Oh HJ, Izu R, Silva-Diaz E, Sarriugarte \nJ, Roman-Curto C, Botella-Estrada R, Mateu-Puchades A, \nPrieto-Torres L, Morillas V, Morillo M, Sanchez-Caminero P, \nCalzado L, Perez-Ferriols A, Perez A, Dominguez JD, Navedo \nM, Muniesa C, Combalia A, Arroyo-Andres J, Descalzo MA, \nGarcia-Doval I, Ortiz-Romero PL. Patients with Primary \nCutaneous Lymphoma are at risk for severe COVID-19. Data \nfrom the Spanish Primary Cutaneous Lymphoma Registry. \nJournal of the European Academy of Dermatology and \nVenereology. 2021 Oct;35(10):e624-e626. doi: 10.1111/\njdv.17430. PMID: 34062018. IF: 6,166\n3. Est\u00e9banez A, Verd\u00fa-Amor\u00f3s J, Silva E, Velasco R, Cuesta \nA, Monteagudo C, Mart\u00edn JM. Kutane und systemische \nver\u00e4nderungen mit \u00e4hnlichkeiten zum omenn-syndrom bei \nheterozygoter mutation im RAG2-Gen. Journal der Deutschen \nDermatologischen Gesellschaft. 2021 Jun;19(6):906-908. \ndoi: 10.1111/ddg.14383_g. PMID: 34139086. IF: 5,584\n4. Del Amor R, Launet L, Colomer A, Moscardo A, Mosquera-\nZamudio A, Monteagudo C, Naranjo V. An attention-based \nweakly supervised framework for spitzoid melanocytic \nlesion diagnosis in whole slide images. Artificial Intelligence \nin Medicine. 2021 Nov;121:102197. doi: 10.1016/j.\nartmed.2021.102197. PMID: 34763799. IF: 5,326\n5. Estebanez A, Puche-Torres M, Garcia J, Cunat A, Canales M, \nFelix M, Campos S, Canada J, Hernandez J. Characteristics of \nmucocutaneous vascular malformations drawn from a decade \nof a multidisciplinary committee experience. Dermatologic \nTherapy. 2021 Sep;34(5):e15074. doi: 10.1111/dth.15074. \nPMID: 34338412. IF: 2,851\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: 860627- H2020 - Marie Sk odowska-Curie Innovative \nTraining Networks \nTitle:  Cloud Artificial Intelligence for pathology-CLARIFY\nPrincipal Investigator: Jos\u00e9 Carlos Monteagudo Castro\nFunding body: European Commission\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration:  2019-2023\nTotal Budget: \u20ac252.000113\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Translational Research Group on Pediatric Solid Tumors  \nConsolidated group\nLeading Researchers, R4\nSamuel Navarro Fos\nHospital. University\nRosa Noguera Salv\u00e1\nUniversity\nRecognised Researchers, R2\nInmaculada Noguera Salv\u00e1. University\nM\u00aa Amparo L\u00f3pez Carrasco. CIBERONC\nRebeca Burgos Panadero. INCLIVA\nSabina Sanegre Sans. CIBERONC\nFirst Stage Researchers, R1\nEzequiel Monferrer Garzar\u00e1n. AECC\nIsaac Vieco Mart\u00ed. INCLIVAGroup members\nStrategic aims\n\u2022 Genomic heterogeneity in neuroblastoma (NB), especially in MYCN amplification\n\u2022 Xenotransplant models of NB\n\u2022 Importance of extracellular matrix and vascularization in NB\n\u2022 Morphological and molecular analysis of neuroblastic and malignant infantile skeletal tumors\nMain lines of research\n\u2022 Genetic analysis in neuroblastoma. At the European level, we participate in the establishment of a uniform nomenclature, \nand standard practices and quality validation studies, essential to obtain and maintain high quality in genetic results used \nfor therapeutic stratification\n\u2022 Identification of new genetic factors with prognostic value in neuroblastic and malignant infantile skeletal and soft tissue tumors\n\u2022 Histopathologic studies of the expression of diagnostic and prognostic markers in solid pediatric tumors\n\u2022 Tumor microenvironments in low prevalence tumors\n\u2022 Preclinical models. Obtaining and characterizing cell lines in vivo and in vitro (2D and 3D) from fresh neuroblastic and \nmalignant infantile solid tumor material\nPUBLICATIONS\nIF 12\nNumber of  \narticles114.903IF\n9.575Average5\nCorresponding  \nauthor6\nNational  \ncollaborations6\nInternational \ncollaborationsTeam involved inResearchers by categories\n2 4 2\nResearchers financed by \ncompetitive public calls or networks\nR4\n2 2R1 R2 R4\nR1 R2114\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4patient outcome. International Journal of Molecular \nSciences. 2021 Aug 30;22(17):9423. doi: 10.3390/\nijms22179423. PMID: 34502329. IF: 5,923\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI20/01107 \nTitle: Neuroblastoma: estrategias mecanoterap\u00e9uticas basadas en \nmodelos 3D y tumores derivados de pacientes con microambiente \nrico en vitronectina \nPrincipal Investigator:  Rosa Noguera Salv\u00e1\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget:  \u20ac232.320\nReference: CB16/12/00484   \nTitle:  CIBER Oncolog\u00eda\nPrincipal Investigator: Rosa Noguera Salv\u00e1\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Universidad de Valencia\nDuration: 2017-\nTotal budget:  \u20ac250.000\nTitle: Identification and validation of targeted and immune therapies, \npreclinical models and markers of therapeutic response in \nperipheral neuroblastic tumours\nPrincipal Investigator: Rosa Noguera Salv\u00e1\nFunding body:  Asociaci\u00f3n de familiares y amigos de pacientes con \nNeuroblastoma \nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2017-2021\nTotal budget:  \u20ac203.000\nTitle: Identificaci\u00f3n de nuevas dianas terap\u00e9uticas relacionadas \ncon la matriz extracelular de los sarcomas \u201cEwing-like\u201d: estudio \nmorfo-molecular\nPrincipal Investigator: Rosa Noguera Salv\u00e1 and Enrique de \u00c1lava\nFunding body: Fundaci\u00f3n CRIS\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2019-2022\nTotal budget: \u20ac60.000SELECTED PUBLICATIONS\n1. Bellini A, Potschger U, Bernard V, Lapouble E, Baulande \nS, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts \nDR, Bhalshankar J, Bown N, de Preter K, Clement N, \nCombaret V, Font de Mora J, George SL, Jimenez I, Jeison \nM, Marques B, Martinsson T, Mazzocco K, Morini M, \nMuhlethaler-Mottet A, Noguera R, Pierron G, Rossing M, \nTaschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz \nW, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis \nJ, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, \nTweddle DA, Ladenstein R, Schleiermacher G. Frequency \nand prognostic impact of alk amplifications and mutations \nin the European Neuroblastoma Study Group (SIOPEN) \nHigh-Risk Neuroblastoma Trial (HR-NBL1). Journal of \nClinical Oncology. 2021 Oct 20;39(30):3377-3390. doi: \n10.1200/JCO.21.00086. PMID: 34115544. IF: 44,544\n2. Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-\nLagares A, Jacome MA, Salguero-Aranda C, Garcia Ros D, \nDavidson B, Lopez R, Melero I, Navarro S, Ramon y Cajal S, \nde Alava E, Matias-Guiu X, Noguera R. Characterizing the \ninvasive tumor front of aggressive uterine adenocarcinoma \nand leiomyosarcoma. Frontiers in Cell and Developmental \nBiology. 2021 Jun 3;9:670185. doi: 10.3389/\nfcell.2021.670185. PMID: 34150764. IF: 6,684\n3. Lopez-Carrasco A, Berbegall A, Martin-Vano S, Blanquer-\nMaceiras M, Castel V, Navarro S, Noguera R. Intra-\ntumour genetic heterogeneity and prognosis in high-risk \nneuroblastoma. Cancers. 2021 Oct 15;13(20):5173. doi: \n10.3390/cancers13205173. PMID: 34680323. IF: 6,639\n4. Gamble L, Purgato S, Henderson M, Di Giacomo S, Russell \nA, Pigini P, Murray J, Valli E, Milazzo G, Giorgi F, Cowley \nM, Ashton L, Bhalshankar J, Schleiermacher G, Rihani A, \nVan Maerken T, Vandesompele J, Speleman F, Versteeg \nR, Koster J, Eggert A, Noguera R, Stallings R, Tonini G, \nFong K, Vaksman Z, Diskin S, Maris J, London W, Marshall \nG, Ziegler D, Hogarty M, Perini G, Norris M, Haber M. A \nG316A polymorphism in the ornithine decarboxylase \ngene promoter modulates mycn-driven childhood \nneuroblastoma. Cancers. 2021 Apr 9;13(8):1807. doi: \n10.3390/cancers13081807. PMID: 33918978. IF: \n6,639\n5. Machado I, Nieto Morales MG, Cruz J, Lavernia J, Giner \nF, Navarro S, Ferrandez A, Llombart-Bosch A. Solitary \nfibrous tumor: integration of clinical, morphologic, \nimmunohistochemical and molecular findings in risk \nstratification and classification may better predict 115\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference: 12/2019-P2Y01D\nTitle:  Espacio intercelular: Bioimagen microsc\u00f3pica, Fase II\nPrincipal Investigator: Rosa Noguera Salv\u00e1\nFunding body: Fundaci\u00f3n Neuroblastoma\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2019-2021\nTotal budget: \u20ac90.000116\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Hematopoietic Transplantation  \nConsolidated group\nLeading Researcher, R4\nCarlos Solano Vercet \nHospital. University\nDavid Navarro Ortega\nHospital. University\nRecognised Researchers, R2\nJos\u00e9 Luis Pi\u00f1ana S\u00e1nchez. Hospital\nMar\u00eda Jos\u00e9 Remigia Pellicer. Hospital\nPaula Amat Mart\u00ednez. Hospital. University\nRafael Hernani Morales. Hospital\nEmerging Researcher, R2\nEliseo Alejandro Albert Vicent. Hospital \nEstela Gim\u00e9nez Quiles. Hospital\nFirst Stage Researchers, R1\nAriadna P\u00e9rez Mart\u00ednez. Hospital\nIgnacio Torres Fink. Hospital\nStaff. Collaborating Researchers\nAna Benzanqu\u00e9n Vallejos. Hospital\nRosa Goterris Viciedo. Hospital\nStaff. Nurses \nAna Miralles Whitehead. INCLIVA\nElisa N\u00fa\u00f1ez Biota. INCLIVAGroup members\nStrategic aims\n\u2022 Translational research on biology and treatment of graft-versus-host disease after allogeneic transplantation of hematopoietic \nprogenitor cells\n\u2022 Infection and immune reconstitution after haematopoietic transplant\n\u2022 Creation of a Multidisciplinary Unit of Advanced Therapies-CART in Hospital Cl\u00ednico Universitario de Valencia - INCLIVA\n\u2022 Design and implementation of an outpatient programme in hematopoetic transplant and cellular therapy\nMain lines of research\n\u2022 Translational research on complications of allogeneic hematopoietic transplantation: graft-versus-host disease\n\u2022 Infection and immune reconstitution after hematopoietic transplantation\n\u2022 Translational research of alloreactivity in the context of new modalities of allogeneic transplantation from compatible and \nincompatible alternative donors (haploidentical transplant)\n\u2022 Clinical application of gene and cellular therapy using CAR-T and other immune effector cells\n\u2022 Scientific and logistical implications of the implementation of a transplant programme in the outpatient settingStaff. Technicians\nDiana Campos Beltr\u00e1n. INCLIVA\nElena Ferrer Mart\u00ednez del Peral. INCLIVA\nM\u00aa Pilar Ortiz Gavil\u00e1n. INCLIVAResearchers by categories\n6 2 2 7\nResearchers financed by \ncompetitive public calls or networks\nR4\n2 1R2 R1 R4 STAFF\nR2 R1117\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44. Hernani R, Sancho A, Amat P, Hernandez-Boluda J, Perez \nA, Pinana J, Carretero C, Goterris R, Gomez M, Saus A, \nFerrer B, Teruel A, Terol M, Solano C. CAR-T therapy in solid \ntransplant recipients with post-transplant lymphoproliferative \ndisease: case report and literature review. Current Research \nin Translational Medicine. 2021 Jul 22;69(4):103304. doi: \n10.1016/j.retram.2021.103304. PMID: 34303899. IF: \n4,513\n5. Amat P, Lopez-Corral L, Goterris R, Perez A, Lopez O, Heras \nI, Arbona C, Viguria MC, Hernandez-Boluda JC, Martinez-\nRuiz F, Martinez A, Solano C. Biomarker profile predicts \nclinical efficacy of extracorporeal photopheresis in steroid-\nresistant acute and chronic graft-vs-host disease after \nallogenic hematopoietic stem cell transplant. Journal of \nClinical Apheresis. 2021 Oct;36(5):697-710. doi: 10.1002/\njca.21918. PMID: 34185332. IF: 2,821\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: TTVGuideTX\nTitle:  Personalisation of immunosuppression by monitoring viral \nload post kidney transplantation - a randomised controlled phase \nII trial\nPrincipal Investigator: David Navarro Ortega\nFunding body: European Commission\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de ValenciaSELECTED PUBLICATIONS\n1. Lopez M, Chiner-Oms A, Garcia de Viedma D, et al. The first \nwave of the COVID-19 epidemic in Spain was associated with \nearly introductions and fast spread of a dominating genetic \nvariant. Nature Genetics. 2021 Oct;53(10):1405-1414. doi: \n10.1038/s41588-021-00936-6. PMID: 34594042. IF: \n38,33\n2. Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, \nAl Zahrani M, Apperley J, Berceanu A, Bofarull RM, Calbacho \nM, Ciceri F, Lopez-Corral L, Crippa C, Fox ML, Grassi A, Jimenez \nMJ, Demir SK, Kwon M, Llamas C, Lorenzo JL, Mielke S, \nOrchard K,Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo \nA, Kroger N, Pinana JL, Styczynski J. COVID-19 and stem cell \ntransplantation; results from an EBMT and GETH multicenter \nprospective survey. Leukemia. 2021 Oct;35(10):2885-2894. \ndoi: 10.1038/s41375-021-01302-5. PMID: 34079042. IF: \n11,528\n3. Solano Vercet C, Vazquez L, Gimenez Quiles E, De La Camara \nR, Albert Vicent E, Rovira M, Espigado I, Calvo C, Lopez-Jimenez \nJ, Suarez-Lledo M, Chinea A, Esquirol A, Perez Martinez A, \nBermudez A, Saldana R, Heras I, Gonzalez-Huerta A, Torrado \nT, Bautista G, Batlle M, Jimenez S, Vallejo C, Barba P, Cuesta \nM, Pinana J, Navarro Ortega D. Cytomegalovirus DNAemia \nand risk of mortality in allogeneic hematopoietic stem cell \ntransplantation: analysis from the Spanish Hematopoietic \nTransplantation and Cell Therapy Group. American Journal of \nTransplantation. 2021 Jan;21(1):258-271. doi: 10.1111/\najt.16147. PMID: 32812351. IF: 8,086PUBLICATIONS\nIF 57\nNumber of  \narticles301.211IF\n5.284Average32\nCorresponding  \nauthor37\nNational  \ncollaborations9\nInternational \ncollaborationsEmerging Researchers\nEstela Gim\u00e9nez Quiles\nThe main objective is the study of the dynamics of the composition and of the viral load of the main components of the human plasma \nvirome as a predictor of functional immunity in the context of allogeneic transplantation of hematopoietic progenitors\nEliseo Alejandro Albert Vicent\nThe main objective is the study of infection in immunosuppressed patients, particularly in Cytomegalovirus and Alphatorquevirus infection \nin patients undergoing allogeneic hematopoietic stem cell transplantation118\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Duration: 2021-2026\nTotal budget: \u20ac85.625\nReference: PI18/01473\nTitle:  Inmunobiolog\u00eda de la infusi\u00f3n de linfocitos del donante con \ndepleci\u00f3n ex vivo de linfocitos T CD45RA+ en pacientes con alto \nriesgo de infecci\u00f3n viral tras TPH alog\u00e9nico\nPrincipal Investigator: Carlos Solano Vercet\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021 \nTotal budget:  \u20ac123.420\nReference: PI18/00127\nTitle: Virolog\u00eda e inmunolog\u00eda de la infecci\u00f3n por el citomegalovirus \n(CMV) en el paciente con neoplasia hematol\u00f3gicas en la era de las \nnuevas bioterapias\nPrincipal Investigator: David Navarro Ortega\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac111.320\nReference:  PI17/01097\nTitle: Score integrado de factores inmunol\u00f3gicos y genot\u00edpicos \nde predicci\u00f3n del riesgo y evoluci\u00f3n de la infecci\u00f3n por CMV en \npacientes con trasplante renal\nPrincipal Investigator: Mar\u00eda Jos\u00e9 Remigia Pellicer\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2022\nTotal budget: \u20ac32.670\nReference: ICI21/00016\nTitle: Terapia celular combinada para pacientes COVID-19 de alto \nriesgo de mortalidad (DECODE-19)\nPrincipal Investigator: Bernat Soria Escoms (Carlos Solano as \ncollaborating researcher)\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2024\nTotal budget: \u20ac459.800 Reference:  GV/2020/188\nTitle: Anellovirus y Pegivirus un posible marcador del estado neto \nde inmunosupresi\u00f3n: evaluaci\u00f3n en el trasplante alog\u00e9nico de \nprogenitores hematopoy\u00e9ticos\nPrincipal Investigator: Estela Gim\u00e9nez Quiles\nFunding body: Conselleria de Educaci\u00f3n Cultura y Deporte\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac16.000\nTitle: Inmunobiolog\u00eda de la infusi\u00f3n de linfocitos del donante con \ndepleci\u00f3n ex vivo de linfocitos T CD45RA+ en pacientes con alto \nriesgo de infecci\u00f3n viral tras TPH alog\u00e9nico\nPrincipal Investigator:  Carlos Solano Vercet\nFunding body: Janssen - Cilag S.A.\u00a0\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal budget:  \u20ac22.500\nTitle: Torquetenovirus en terapia CAR-T: predicci\u00f3n del riesgo de \ns\u00edndrome de liberaci\u00f3n de citocinas y diagn\u00f3stico diferencial con \ninfecci\u00f3n\nPrincipal Investigator:  Rafael Hernani Morales\nFunding body:  Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia-\nGilead\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget:  \u20ac60.000\nReference: AP178182020\nTitle: Estudio de la inmunidad y Creaci\u00f3n de un Banco Nacional \nde Terapia Celular Adoptiva de donantes de linfocitos que han \nsuperado COVID-19. Ensayo cl\u00ednico Fase I multic\u00e9ntrico para \nevaluar la seguridad de la infusi\u00f3n de c\u00e9lulas natural killer como \nterapia adoptiva en casos pacientes con neumon\u00eda y/o linfopenia \ndebido al coronavirus SARS-CoV-2 (RELEASE)\nPrincipal Investigator: Cristina Eguizabal (Carlos Solano as \ncollaborating researcher)\nFunding body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia, IIS Biocruces Bizkaia-CVTTH, Hospital La \nPaz-IDIPAZ, Centro de Transfusiones de Madrid, Hospital General \nde Alicante119\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Duration: 2020-2021\nTotal budget: \u20ac100.000\nReference: BIO21/COV/030\nTitle:  Estudio de la inmunidad y Creaci\u00f3n de un Banco Nacional \nde Terapia Celular Adoptiva de donantes de linfocitos que han \nsuperado COVID-19. Ensayo cl\u00ednico Fase I multic\u00e9ntrico para \nevaluar la seguridad de la infusi\u00f3n de c\u00e9lulas natural killer como \nterapia adoptiva en casos pacientes con neumon\u00eda y/o linfopenia \ndebido al coronavirus SARS-CoV-2 (RELEASE)\nPrincipal Investigator: Cristina Eguizabal (Carlos Solano as \ncollaborating researcher)\nFunding body: Fundaci\u00f3n Vasca de Innovaci\u00f3n e investigaci\u00f3n \nSanitarias (BIOEFF)\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac99.935\nReference: PI-2021-004\nTitle: TECO: Validaci\u00f3n de dos sistemas biosensor para la diagnosis \nsimult\u00e1nea de COVID19 y otros pat\u00f3genos a\u00e9reos\nPrincipal Investigator: David Gim\u00e9nez Romero (Estela Gim\u00e9nez \nQuiles as collaborating researcher)\nFunding body: Universidad de Valencia - INCLIVA\nBeneficiary institution:  Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac19.000THESIS\nThesis title: Par\u00e1metros biol\u00f3gicos predictivos de la infecci\u00f3n \nactiva precoz por Citomegalovirus en el trasplante alog\u00e9nico de \nprecursores hematopoy\u00e9ticos\nDoctoral candidate: Alberto Talaya Pe\u00f1alver \nDirector(s): David Navarro Ortega\nDate of the defense: 26/05/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title:  Estudio de la enfermedad residual m\u00ednima en \npacientes con mieloma m\u00faltiple en muy buena respuesta parcial \no completa convencional mediante citometr\u00eda de flujo de alta \nsensibilidad y la medici\u00f3n de cadenas mediante la t\u00e9cnica Hevylite\nDoctoral candidate: Mar\u00eda Jos\u00e9 Remigia Pellicer\nDirector(s): Javier De la Rubia Comos, Amparo Sempere Talens, \nCarlos Solano Vercet\nDate of the defense:  04/06/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: Factores predictivos de desarrollo y evoluci\u00f3n de \ninfecci\u00f3n activa por citomegalovirus en el trasplante alog\u00e9nico de \nprecursores hematopoy\u00e9ticos\nDoctoral candidate: V\u00edctor Vinuesa Velasco\nDirector(s): David Navarro Ortega\nDate of the defense: 08/09/2021\nGrade: Sobresaliente \u201ccum laude\u201d120\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Lymphoproliferative Disorders  \nConsolidated group\nLeading Researcher, R4\nM\u00aa Jos\u00e9 Terol Caster\u00e1 \nHospital. University\nEstablished Researcher, R3\nAntonio Ferr\u00e1ndez Izquierdo. Hospital. University\nRecognised Researchers, R2\nAna Isabel Teruel Casa\u00fas. Hospital. University\nBlanca Ferrer Lores. Hospital\nStaff. Collaborating Researchers\nAlicia Serrano Alcal\u00e1. INCLIVA\nEdelmira Mart\u00ed S\u00e1ez. Hospital\nRaimundo Cervera Vidal. INCLIVAGroup members\nStrategic aims\n\u2022 During the year 2021, we were able to deepen the knowledge of the role of the NOTCH1/FBXW7/PI3K/PTEN/AKT \nsignaling pathway in the progression of Chronic Lymphocytic Leukemia B (CLL-B) to advanced forms. Thus, in the cell lines \nand in the patient\u2019s primary cells, we observed a variation in the number of gene copies by both FISH and PCRq in the \nNOTCH1, FBXW7 and PTEN genes, with an inverse relationship between NOTCH1 and FBXW7/PTEN\n\u2022 A second objective has been to analyze the clinical significance of the rearrangements of MYC, BCL-2 and BCL-6 in diffuse \nlarge cell lymphoma. We have been able to verify that patients with concomitant C-MYC and BCL-2 protein expression \npresent a worse prognosis in terms of SLP and Sg than the rest\n\u2022 Thirdly, during 2021, the study of the mutational status of IgVH in CLL and its prognostic impact in a wide series of patients \nhas been implemented. New molecular markers (mutations TP53, BIRC3, MYD88, NOTCH1 and SF3B1) have also been \nstudied in CLL by new generation sequencing techniques. In addition, we have continued the collaboration in the GENOMA \nCLL sequencing project, with a clinical-evolutionary update\n\u2022 Finally, we have expanded our participation in clinical research projects in CLL, refractory lymphomas and multiple myeloma, \nboth with the incorporation of new drugs and in the design and development of new therapeutic options\nMain lines of research\n\u2022 Analysis of the interactions of CLL cells with their cellular microenvironment: further study of the intracellular mechanisms \ntriggered by VEGF. Analysis of the possible correlation with CXCR4/CCR7 cytokines pathway. Transactivation mechanisms \nof the aforementioned receptors\n\u2022 Role of the NOTCH1/FBXW7/PI3K/PTEN/AKT signaling pathway in the progression of Chronic Lymphocytic Leukemia \nB (CLL -B) to advanced forms: pathway molecular profile analysis in 100 patients with CLL-B of primary cells obtained at \ndiagnosis and at the time of the progression, analyzing for this, the presence of mutations and number of copies of DNA, \ngene expression, FISH and (RT-PCR)Researchers by categories\n1 2 1 6R3 R2 R4 STAFF\nStaff. Nurses \nEsther Lozano Garc\u00eda. INCLIVA\nJuan Ram\u00f3n de Moya Romero. Hospital. University\nMercedes Bou Moreno. INCLIVA121\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 14\nNumber of  \narticles79.735IF\n5.695Average0\nCorresponding  \nauthor11\nNational  \ncollaborations0\nInternational \ncollaborations\nPena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, \nCano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella \nGonzalez I. Ten-year assessment of a cancer fast-track \nprogramme to connect primary care with oncology: reducing \ntime from initial symptoms to diagnosis and treatment \ninitiation. ESMO Open. 2021 May 11;6(3):100148. doi: \n10.1016/j.esmoop.2021.100148. PMID: 33989988. IF: \n6,54\n5. Jimenez I, Tazon-Vega B, Abrisqueta P, Nieto JC, Bobillo S, \nPalacio-Garcia C, Carabia J, Valdes-Mas R, Munuera M, \nPuigdefabregas L, Parra G, Esteve-Codina A, Franco-Jarava C, \nIacoboni G, Terol MJ, Garcia-Marco JA, Crespo M, Bosch F. \nImmunological and genetic kinetics from diagnosis to clinical \nprogression in chronic lymphocytic leukemia. Biomarker \nResearch. 2021 May 20;9(1):37. doi: 10.1186/s40364-\n021-00290-z. PMID: 34016160. IF: 6,148SELECTED PUBLICATIONS\n1. Moreno C, Munoz C, Terol MJ, Hernandez-Rivas JA, Villanueva \nM. Restoration of the immune function as a complementary \nstrategy to treat Chronic Lymphocytic Leukemia effectively. \nJournal of Experimental & Clinical Cancer Research. 2021 \nOct 15;40(1):321. doi: 10.1186/s13046-021-02115-1. \nPMID: 34654437. IF: 11,161\n2. Puig N, Hernandez MT, Rosinol L, Gonzalez E, de Arriba F, Oriol \nA, Gonzalez-Calle V, Escalante F, de la Rubia J, Gironella M, \nRios R, Garcia-Sanchez R, Arguinano JM, Alegre A, Martin J, \nGutierrez NC, Calasanz MJ, Martin ML, Couto MC, Casanova \nM, Arnao M, Perez-Persona E, Garzon S, Gonzalez MS, Martin-\nSanchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel \nAI, Cortes-Rodriguez M, Paiva B, Cedena MT, San-Miguel JF, \nLahuerta JJ, Blade J, Niesvizky R, Mateos MV. Lenalidomide \nand dexamethasone with or without clarithromycin in patients \nwith multiple myeloma ineligible for autologous transplant: \na randomized trial. Blood Cancer Journal. 2021 May \n21;11(5):101. doi: 10.1038/s41408-021-00490-8. PMID: \n34021118. IF: 11,037\n3. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda \nC, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, \nPerez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-\nGarcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, \nMarti-Bonmati L. Digital pathology: accurate technique for \nquantitative assessment of histological features in metabolic-\nassociated fatty liver disease. Alimentary Pharmacology & \nTherapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/\napt.16100. PMID: 32981113. IF: 8,171\n4. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon \nS, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, \u2022 Study of the rearrangements of bcl-2, bcl-6 and MYC in diffuse large cell lymphoma: clinical significance and correlation with \nimmunohistochemical expression using FISH and IHQ techniques\n\u2022 Study of new molecular markers (mutations of IgVH, TP53, BIRC3, MYD88, NOTCH1 and SF3B1) in CLL: conventional versus \nNGS techniques. Implication in clonal evolution associated with tumor progression\n\u2022 New therapeutic options for CLL/MM patients who are resistant to chemoimmunotherapy122\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Myeloid Neoplasms  \nConsolidated group\nLeading Researcher, R4\nMar Tormo D\u00edaz\nHospital. University\nJuan Carlos Hern\u00e1ndez Boluda\nHospital. University\nRecognised Researchers, R2\nCarlos Carretero M\u00e1rquez. Hospital\nMarisa Calabuig Mu\u00f1oz. Hospital\nMontserrat G\u00f3mez Calafaz. Hospital\nFirst Stage Researcher, R1\nIrene Pastor Gal\u00e1n. Hospital\nStaff. Collaborating Researcher\nEva Villam\u00f3n Ribate. INCLIVA\nIv\u00e1n Mart\u00edn Castillo. INCLIVA\nStaff. Nurse\nAlicia Borrero Abarca. INCLIVAGroup members\nStrategic aims\n\u2022 Analyse of the risk factors for thrombosis in myelofibrosis \n\u2022 Analyse patients diagnosed with myelodysplasticsyndromes with 20q deletion and del(20q). Assess the incidence, prognostic \nvalue and impact on response to azacitidine of azacitidine\n\u2022 Analyse in patients diagnosed of acute myeloid leukemias and del(7q) the incidence, prognostic value and potential as a \ntherapeutic target of chromosomal deletions of the EZH2 gene and of genetic mutations alterations and other genetic \nmutations\nMain lines of research\n\u2022 Study of mechanisms involved in leukemic transformation in myeloproliferative neoplasms\n\u2022 Study of risk factors for thrombosis in myelofibrosis\n\u2022 Study of acute myeloid leukemias with 7q deletion\n\u2022 Study of myelodysplastic syndromes with 20q deletion and del(20q)\n\u2022 Collaborative studies with the CETLAM group (LMA, SMD), PETHEMA (LLA, LMA), the Spanish Philadelphia-negative chronic \nmyeloproliferative disorders group (GEMFIN), the Spanish LMC group (GELMC) and the Spanish SMD group (GESMD)Researchers by categories\n3 1 2 3R2 R1 R4 STAFF123\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 37\nNumber of  \narticles283.959IF\n8Average3\nCorresponding  \nauthor19\nNational  \ncollaborations18\nInternational \ncollaborations\nGarcia-Hernandez C, Garcia-Gutierrez V, Palomino A, Ferrer-\nMarin F, Isabel Mata-Vazquez M, Moreto A, Magro E, Murillo \nI, Alonso-Dominguez J, Maria Guerra J, Guerrero L, Maria \nRaya J, Perez-Encinas M, Carreno-Tarragona G, Fox L, Pastor \nGalan I, Bellosillo B, Hernandez Boluda J, MPN Spanish Grp \nGemfin. Cytoreductive treatment in patients withCALR-mutated \nessential thrombocythaemia: a study comparing indications \nand efficacy among genotypes from the Spanish Registry of \nEssential Thrombocythaemia. British Journal of Haematology. \n2021 Mar;192(6):988-996. doi: 10.1111/bjh.16988. PMID: \n32745264. IF: 6,998\n5. Martin I, Villamon E, Abellan R, Calasanz M, Irigoyen A, Sanz G, \nSuch E, Mora E, Gutierrez M, Collado R, Garcia-Serra R, Vara \nM, Blanco M, Oiartzabal I, Alvarez S, Bernal T, Granada I, Xicoy \nB, Jerez A, Calabuig M, Diez R, Gil A, Diez-Campelo M, Solano \nC, Tormo M, Spanish Grp Myelodysplastic Syn. Myelodysplastic \nsyndromes with 20q deletion: incidence, prognostic value and \nimpact on response to azacitidine of ASXL1 chromosomal \ndeletion and genetic mutations. British Journal of Haematology. \n2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. PMID: \n34296432. IF: 6,998\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle:  Inmunobiolog\u00eda de la infusi\u00f3n de linfocitos del donante con \ndepleci\u00f3n ex vivo de linfocitos T CD45RA+ en pacientes con alto \nriesgo de infecci\u00f3n viral tras TPH alog\u00e9nico\nPrincipal Investigator: Carlos Solano Vercet and Eva Villam\u00f3n \nRibate\nFunding body: Janssen - Cilag S.A. \nBeneficiary Insitution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2021\nTotal Budget: \u20ac22.500SELECTED PUBLICATIONS\n1. Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, \nGenesca E, Barba P, Ribera J, Garcia Cadenas I, Moreno \nM, Martinez-Carballeira D, Torrent A, Martinez-Sanchez P, \nMonsalvo S, Gil C, Tormo M, Artola M, Cervera M, Gonzalez-\nCampos J, Rodriguez-Medina C, Bermudez A, Novo A, Soria \nB, Coll R, Amigo M, Lopez A, Fernandez Martin R, Serrano J, \nMercadal S, Cladera A, Gimenez-Conca A, Penarrubia M, Abella \nE, Vall-Llovera F, Hernandez-Rivas J, Garcia A, Bergua Burgues \nJ, de Rueda B, Sanchez-Sanchez M, Serrano A, Calbacho M, \nAlonso Vence N, Mendez-Sanchez J, Garcia-Boyero R, Olivares \nM, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, \nOrfao A. Chemotherapy or allogeneic transplantation in high-\nrisk philadelphia chromosome-negative Adult Lymphoblastic \nLeukemia. Blood. 2021 Apr 8;137(14):1879-1894. doi: \n10.1182/blood.2020007311. PMID: 33150388. IF: 22,113\n2. Hernandez Boluda J, Pereira A, Kroeger N, Beelen D, Robin \nM, Bornhaeuser M, Angelucci E, Vitek A, Blau I, Niittyvuopio \nR, Finke J, Cornelissen J, Passweg J, Dreger P, Petersen E, \nKanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, \nCzerw T, McLornan D, Yakoub-Agha I. Determinants of survival \nin myelofibrosis patients undergoing allogeneic hematopoietic \ncell transplantation. Leukemia. 2021 Jan;35(1):215-224. \ndoi: 10.1038/s41375-020-0815-z. PMID: 32286544. IF: \n11,528\n3. Hernandez-Boluda JC, Pereira A, Kroger N, Cornelissen \nJJ, Finke J, Beelen D, de Witte M, Wilson K, Platzbecker U, \nSengeloev H, Blaise D, Einsele H, Sockel K, Kruger W, Lenhoff \nS, Salaroli A, Martin H, Garcia-Gutierrez V, Pavone V, Alvarez-\nLarran A, Raya JM, Zinger N, Gras L, Hayden P, Czerw T, \nMcLornan D, Yakoub-Agha I. Allogeneic hematopoietic cell \ntransplantation in older myelofibrosis patients: a study of the \nChronic Malignancies Working Party of EBMT and the Spanish \nMyelofibrosis Registry. American Journal of Hematology. 2021 \nOct 1;96(10):1186-1194. doi: 10.1002/ajh.26279. PMID: \n34152630. IF: 10,047\n4. Alvarez-Larran A, Angona A, Andrade-Campos M, Soledad \nNoya M, Teresa Gomez-Casares M, Cuevas B, Caballero G, 124\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Molecular Imaging and Metabolomics  \nConsolidated group\nLeading Researcher, R4\nDaniel Monle\u00f3n Salvad\u00f3. University. INCLIVA\nRecognised Researchers, R2\nAntonio Pell\u00edn Carcel\u00e9n. University\nJos\u00e9 Manuel Morales Tatay. University\nMercedes Pardo Tendero. University\nVannina Gonz\u00e1lez Marrachelli. University\nFirst Stage Researchers, R1\nGeraldine Rocha Correal. University\nMar\u00eda Mart\u00edn Grau. University\nPilar Casanova Terol. University\nSerena Pisoni. University\nStaff. Collaborating Researcher\nItziar P\u00e9rez Terol. INCLIVAGroup members\nStrategic aims\n\u2022 Identify new metabolomic markers of tumor aggressiveness in brain cancer\n\u2022 Identify new markers of myocardial infarction\n\u2022 Identify new metabolomic cardiovascular risk markers based on the microbiota-host interaction\nMain lines of research\n\u2022 Tumor metabolism through metabolic profiles in biopsies, biofluids and cells (brain cancer, glioblastoma multiforme, prostate, \nbladder)\n\u2022 Metabolic profiles in the progression of cardiometabolic risk modulated by the microbiota-host interaction\n\u2022 Metabolic profiles of healthy aging vs frailty\n\u2022 MRI microimaging study of porcine cardiac tissue samples to develop new detection methods\nPUBLICATIONS\nIF 6\nNumber of  \narticles30.096IF\n5.016Average1\nCorresponding  \nauthor3\nNational  \ncollaborations1\nInternational \ncollaborationsResearchers by categories\n4 4 1 2\nResearchers financed by \ncompetitive public calls or networks\nR4\n2 3 1R2 R1 R4 STAFF\nR2 R1 R4\nStaff. Technicians\nPatricia Almud\u00e9ver Folch. University125\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Duration: 2021-2022\nTotal Budget: \u20ac4.750\nReference: PCIN-2017-117\nTitle: Obesidad materna y disfunci\u00f3n cognitiva en la descendencia: \npapel causa-efecto de la microbiota intestinal y prevenci\u00f3n \ndiet\u00e9tica temprana\nPrincipal Investigator: Consuelo Borr\u00e1s Blasco (Daniel Monle\u00f3n \nSalvad\u00f3, Vannina Gonz\u00e1lez Marrachelli, Jos\u00e9 Manuel Morales \nTatay as collaborating researchers)\nFunding Body: Ministerio de Econom\u00eda, Industria y Competitividad\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2017-2022\nTotal Budget: \u20ac143.000\n \nReference: PID2020-113839RB-I00\nTitle: Efecto del tratamiento con ves\u00edculas extracelulares de \nc\u00e9lulas madre de grasa de ratones j\u00f3venes sobre par\u00e1metros de \nenvejecimiento y fragilidad en ratones de edad avanzada\nPrincipal Investigator: Consuelo Borr\u00e1s Blasco (Vannina \nGonz\u00e1lez Marrachelli as collaborating researcher)\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary Institution:  Universidad de Valencia\nDuration: 2021-2024\nTotal Budget: \u20ac181.500\nReference:  PID2019-108973RB-C22\nTitle: Metabolomic study of mechanisms for Se-related diabetes \nand insulin resistance\nPrincipal Investigator: Daniel Monle\u00f3n Salvad\u00f3\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary Institution: Universidad de Valencia\nDuration: 2020-2023\nTotal Budget: \u20ac140.000\nTHESIS\nThesis title: Estudio metabol\u00f3mico de la interacci\u00f3n hu\u00e9sped-\nmicrobiota intestinal en la enfermedad cardiometab\u00f3lica. \nDetecci\u00f3n temprana, prevenci\u00f3n y tratamiento\nDoctoral candidate: Mar\u00eda Mercedes Pardo Tendero\nDirector(s): Daniel Monle\u00f3n Salvad\u00f3, Vannina Gonz\u00e1lez Marrachelli \nDate of the defense:  25/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhDSELECTED PUBLICATIONS\n1. Pallares-Carratala V, Quesada J, Orozco-Beltran D, Amigo-\nGrau N, Lopez-Pineda A, Fernandez Gimenez A, Gil-Guillen \nV, Correig X, Masana L, Monle\u00f3n Salvad\u00f3 D, Red\u00f3n Mas J, \nPascual R, Carratala-Munuera C. Whole-exome sequencing, \nEGFR amplification and infiltration patterns in human \nglioblastoma. American Journal of Cancer Research. 2021 \nJan;75(1):e13610. doi: 10.1111/ijcp.13610. IF: 6,166\n2. Sanz J, Rodriguez-Lozano F, Lopez-Gines C, Monleon D, Llena \nC, Forner L. Dental stem cell signaling pathway activation \nin response to hydraulic calcium silicate-based endodontic \ncements: a systematic review of in vitro studies. Dental \nmaterials. 2021 Apr;37(4):e256-e268. doi: 10.1016/j.\ndental.2021.01.025. PMID: 33573840. IF: 5,304\n3. Gambini J, Gimeno-Mallench L, Olaso-Gonzalez G, Mastaloudis \nA, Traber M, Monleon D, Borras C, Vina J. Moderate red \nwine consumption increases the expression of longevity-\nassociated genes in controlled human populations and extends \nlifespan in drosophila melanogaster. Antioxidants. 2021 \nFeb 16;10(2):301. doi: 10.3390/antiox10020301. PMID: \n33669360. IF: 6,312\n4. Mollar A, Marrachelli V, Nunez E, Monleon D, Bodi V, Sanchis \nJ, Navarro D, Nunez J. Bacterial metabolites trimethylamine \nN-oxide and butyrate as surrogates of small intestinal bacterial \novergrowth in patients with a recent decompensated heart \nfailure. Scientific reports. 2021 Mar 17;11(1):6110. doi: \n10.1038/s41598-021-85527-5. PMID: 33731747. IF: 4,379\n5. Borras C, Abdelaziz KM, Diaz A, Gambini J, Jove M, Lopez-Grueso \nR, Mas-Bargues C, Monleon D, Pamplona R, Vina J. Lifelong \nsoya consumption in males does not increase lifespan but \nincreases health span under a metabolic stress such as type \n2 diabetes mellitus. Mechanisms of Ageing and Development. \n2021 Dec;200:111596. doi: 10.1016/j.mad.2021.111596. \nPMID: 34774606. IF: 5,432\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: AP-2021-016\nTitle:  BREIC: Identificaci\u00f3n de biomarcadores del eje coraz\u00f3n-\nmicrobiota-sistema inmune por RMN para la estratificaci\u00f3n de \npacientes con insuficiencia cardiaca\nPrincipal Investigator: Vannina Gonz\u00e1lez Marrachelli and Anna \nMollar Fern\u00e1ndez \nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution: Universidad de Valencia - INCLIVA126\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.3.3 Metabolism area\nGroups\nResearch Group on Genetics of Osteoporosis\nResearch Group on Neurological Impairment\nResearch Group on Inflammation\nResearch Group on Oxidative Pathology\nResearch Group on Psychiatry and Neurodegenerative Diseases\nResearch Group on Respiratory Diseases\nResearch Group on Tissular Biochemistry\nResearch Group on Aging and Physical Activity\nResearch Group on Anesthesiology and Reanimation\nResearch Group on Translational Genomics\nResearch Group on General and Digestive Surgery\nResearch Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP)\nResearch Group on Cellular and Organic Physiopathology of Oxidative Stress\nResearch Group on Inflammation: Metabolism and Organic Damage line\nResearch group on Metabolic Diseases\nResearch Group on Rare Respiratory Diseases (RRD)\nResearch Group on Healthy Aging\nResearch Group on Exercise, Nutrition and Healthy Lifestyle\nResearch Group on Epigenomics and Translational Epigenetics\n309\nNumber of  \narticlesIF\n2166.006IF\n7.009Average105\nCorresponding  \nauthor124\nNational  \ncollaborations128\nInternational \ncollaborations\n62\nD174\nFirst  \nauthor105\nLast  \nauthor188\nQ175\nQ2\noriginal articles letters editorial review case reports corrections266892423127\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Genetics of Osteoporosis\nConsolidated group\nLeading Researcher, R4\nMiguel \u00c1ngel Garc\u00eda P\u00e9rez. University\nEstablished Researcher, R3\nDami\u00e1n Mifsut Miedes. Hospital. University\nFirst Stage Researcher, R1\nClara Mar\u00eda Pertusa Vi\u00f1uales. INCLIVA\nStaff. Collaborating Researcher\nRosa Mar\u00eda Aliaga Corach\u00e1n. UniversityGroup members\nStrategic aims\nDuring 2021 our group has continued its studies on the genetics of osteoporosis, carrying out functional approaches for the \nidentification of candidate genes and conducting allelic association studies to bone phenotypes and also to cardiovascular risk \nphenotypes such as arterial hypertension.\nWith respect to the candidate genes studied, our interest has focused on genes related to arginine metabolism and epigenetic \nmechanisms.\nIn addition, during this year we have continued the characterization of the fragility fracture by studying its metabolome and \ncertain cytokines and serum miRNAs as possible biomarkers.\nMain lines of research \n\u2022 Identification of genes and polymorphisms associated with bone and cardiovascular phenotypes, mainly related to epigenetic \nmechanisms, to immune system and to the metabolism of arginine\n\u2022 Identification of genes and miRNAs differentially expressed in bone fracture due to fragility\n\u2022 Analysis of metabolome and cytokines in bone fracture and low bone mineral density\n\u2022 Functional characterization by genetic techniques of polymorphisms associated with bone and cardiovascular phenotypes\n\u2022 Identification of genetic, biochemical and cytomic biomarkers in patients with the Idic15\nPUBLICATIONS\nIF 5\nNumber of  \narticles18.723IF\n3.744Average2\nCorresponding  \nauthor3\nNational  \ncollaborations0\nInternational \ncollaborationsResearchers by categories\n1 1 1 1\nResearchers financed by \ncompetitive public calls or networks\nR4\n1R1 R3 R4 STAFF\nR1128\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : 826640\nTitle: Evidence-Based Guidance to Scale-up Integrated Care in \nEurope (VIGOUR)\nPrincipal Investigator: Simon Robinson (Miguel \u00c1ngel Garc\u00eda \nP\u00e9rez as collaborating researcher)\nFunding Body: Consumers, Health, Agriculture and Food Executive \nAgency\nBeneficiary Institution: Universidad de Valencia\nDuration: 2019-2021\nTotal budget: \u20ac3.046.024,67\nReference: PI17/01875\nTitle: Osteoporosis y fractura \u00f3sea: identificaci\u00f3n de genes \nasociados y evaluaci\u00f3n del papel del metabolismo de la arginina\nPrincipal Investigator: Miguel \u00c1ngel Garc\u00eda P\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac99.220SELECTED PUBLICATIONS\n1. Rodriguez-Collell J, Mifsut D, Ruiz-Sauri A, Rodriguez-Pino \nL, Gonzalez-Soler E, Valverde-Navarro A. Improving the \ncementation of the tibial component in knee arthroplasty: \na study of four techniques in the cadaver. Bone & Joint \nResearch. 2021 Aug;10(8):467-473. doi: 10.1302/2046-\n3758.108.BJR-2020-0524.R1. PMID: 34340533. IF: 5,853\n2. Pertusa C, Tarin JJ, Cano A, Garcia-Perez MA, Mifsut D. Serum \nmicroRNAs in osteoporotic fracture and osteoarthritis: a \ngenetic and functional study. Scientific Reports. 2021 Sep \n29;11(1):19372. doi: 10.1038/s41598-021-98789-w. \nPMID: 34588560. IF: 4,379\n3. Zolfaroli I, Ortiz E, Garcia-Perez M, Hidalgo-Mora J, Tarin \nJ, Cano A. Positive association of high-density lipoprotein \ncholesterol with lumbar and femoral neck bone mineral density \nin postmenopausal women. Maturitas. 2021 May;147:41-46. \ndoi: 10.1016/j.maturitas.2021.03.001. PMID: 33832646. \nIF: 4,342\n4. Dudenko D, Gomez R, Garcia-Perez M, Tarin J, Cano A. \nBazedoxifene increases the proliferation of human arterial \nendothelial cells but does not affect the expression of \ncyclins A, B, and D1 and of p27(Kip1). Gynecological \nEndocrinology. 2021 Mar;37(3):269-272. doi: \n10.1080/09513590.2021.1876653. PMID: 33480311. \nIF: 2,26\n5. Cano-Marquina AJ, Garcia-Perez MA, Tarin JJ, Maceira \nAM, Cosin-Sales J, Cano A. Variants translating reduced \nexpression of the beta estrogen receptor gene were \nassociated with increased carotid intima media thickness: \na cross-sectional study in late postmenopausal women. \nMedicine. 2021 Jun 11;100(23):e26216. doi: 10.1097/\nMD.0000000000026216. PMID: 34115005. IF: 1,889129\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Neurological Impairment\nConsolidated group\nLeading Researcher, R4\nCarmina Montoliu F\u00e9lix \nINCLIVA. University\nEstablished Researchers, R3\nAmparo Escudero Garc\u00eda. Hospital. University\nJos\u00e9 Ballester Fayos. Hospital\nJos\u00e9 Luis Le\u00f3n Guijarro. Hospital\nRoberto Aliaga M\u00e9ndez. Hospital\nRecognised Researchers, R2\nAmparo Uri\u00f3s Lluch. INCLIVA\nAndrea Cabrera Pastor. INCLIVA. University\nCristina Mont\u00f3n Rodr\u00edguez. Hospital\nJoan Tosca Cuquerella. Hospital\nMar\u00eda Pilar Ballester Ferrer. Hospital. INCLIVA\nNicol\u00e1s Pe\u00f1aranda Sarmiento. Hospital\nPaloma Lluch Garc\u00eda. Hospital. University\nPaula Cases Berg\u00f3n. Hospital\nRut Victorio Mu\u00f1oz. Hospital\nFirst Stage Researchers, R1\nAlessandra Fiorillo. INCLIVA\nCristina Ipiens Escuer. INCLIVAGroup members\nStrategic aims\n\u2022 Evaluation of cognitive and motor alterations in patients with liver cirrhosis and minimal hepatic encephalopathy (MHE)\n\u2022 To characterize the inflammatory processes and create a bioinformatic model of the molecular and cellular events of the \nimmune system associated to the onset of MHE. Assess its utility to predict or diagnose MHE\n\u2022 To analyse cerebral alterations: visual evoked potentials; neuronal connectivity using functional magnetic resonance\n\u2022 Analysis of alterations in thermal and mechanical sensitivity and in peripheral nerve conduction velocity\n\u2022 Assess the utility of the analysis of eye movements for early diagnosis of MHE\n\u2022 Assess the effects of rifaximin treatment on the alterations analysed in the above objectives \n\u2022 To identify procedures based on above results, which improve diagnosis of MHE\nMain lines of research \nMain Line of research: Characterization of neurological and cerebral alterations in patients with minimal hepatic encephalopathy \n(MHE). Mechanisms: Contribution of inflammation. Diagnostic and therapeutic implications. Sublines: \n\u2022 Characterization of cognitive, functional and cerebral alterations in patients with minimal hepatic encephalopathy\n\u2022 Characterize alterations in inflammation, neuroinflammation, brain function and structure associated with the onset of MHE\n\u2022 Identify biomarkers for the early detection of mild cognitive impairment in MHEDalia Rega Caballero. INCLIVA\nFranc Casanova Ferrer. INCLIVA\nJuan Jos\u00e9 Gallego Roig. INCLIVA\nStaff. Collaborating Researchers\nMika Aiko. Hospital\nStaff. Nurses \nClara Barber\u00e1 Fuset. Hospital\nMar\u00eda Jes\u00fas Campa Santiago. Hospital \nNuria Casas\u00fas Moya. Hospital\nPilar Aguilar Santaisabel. Hospital\nStaff. Technicians\nAlberto Sabio Palomares. INCLIVA\nAlejandra Hern\u00e1ndez Hern\u00e1ndez. University. INCLIVA\nConsuelo Miguel Moreno. Hospital\nLaura Puchades Lanza. INCLIVAResearchers by categories\n4 9 1 9 5\nResearchers financed by \ncompetitive public calls or networks\nR4 R4\n2 3R2 R3 R4 STAFF R1\nR2 R1130\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\nIF 11\nNumber of  \narticles51.209IF\n4.655Average2\nCorresponding  \nauthor3\nNational  \ncollaborations2\nInternational \ncollaborations\u2022 To assess the effects of rifaximin treatment and new treatments: mechanisms involved\n\u2022 Identification and modelling of molecular and cellular events of the immune response associated to the appearance of \nminimal hepatic encephalopathy in cirrhotic patients\n\u2022 To assess the usefulness of eye movement analysis for the early diagnosis of MHE\n\u2022 Research on cognitive and motor alterations in patients with non-alcoholic fatty liver disease showing mild cognitive \nimpairment (MCI)\n5. Ballester M, Lluch P, Gomez C, Capilla M, Tosca J, Marti-\nAguado D, Guijarro J, Minguez M. Transjugular intrahepatic \nportosystemic shunt reduces hospital care burden in patients \nwith decompensated cirrosis. Internal and Emergency \nMedicine. 2021 Sep;16(6):1519-1527. doi: 10.1007/\ns11739-020-02602-x. PMID: 33400160. IF: 3,397\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: Role of extracellular vesicles, metabolome and altered in-\ntercellular communication in the induction of minimal hepatic \nencephalopathy: mechanisms, therapeutic and diagnostic impli-\ncations\nPrincipal Investigator:  Andrea Cabrera Pastor\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2024\nTotal budget:  \u20ac40.000\nReference: PI18/00150\nTitle: Caracterizaci\u00f3n de las alteraciones neurol\u00f3gicas y cere -\nbrales en pacientes con encefalopat\u00eda hep\u00e1tica m\u00ednima. Contribu-\nci\u00f3n de la inflamaci\u00f3n. Implicaciones diagn\u00f3sticas y terap\u00e9uticas\nPrincipal Investigator:  Carmina Montoliu F\u00e9lix\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac171.820SELECTED PUBLICATIONS\n1. Tosca J, Villagrasa R, Sanahuja A, Sanchez A, Trejo G, Herreros \nB, Pascual I, Mas P, Pena A, Minguez M. Caustic ingestion: \ndevelopment and validation of a prognostic score. Endoscopy. \n2021 Aug;53(8):784-791. doi: 10.1055/a-1297-0333. \nPMID: 33096569. IF: 10,093\n2. Rubio T, Felipo V, Tarazona S, Pastorelli R, Escudero-Garcia \nD, Tosca J, Urios A, Conesa A, Montoliu C. Multi-omic \nanalysis unveils biological pathways in peripheral immune \nsystem associated to minimal hepatic encephalopathy \nappearance in cirrhotic patients. Scientific Reports. 2021 \nJan 21;11(1):1907. doi: 10.1038/s41598-020-80941-7. \nPMID: 33479266. IF: 4,379\n3. Rega D, Aiko M, Penaranda N, Urios A, Gallego J, Gimenez-\nGarzo C, Casanova F, Fiorillo A, Cabrera-Pastor A, San-Miguel \nT, Ipiens C, Escudero-Garcia D, Tosca J, Monton C, Ballester \nM, Ballester J, Aparicio L, Rios M, Durban L, Mir A, Kosenko \nE, Cases P, Felipo V, Montoliu C. Patients with minimal \nhepatic encephalopathy show altered thermal sensitivity \nand autonomic function. Journal of Clinical Medicine. 2021 \nJan 11;10(2):E239. doi: 10.3390/jcm10020239. PMID: \n33440769. IF: 4,241\n4. Gimenez-Garzo C, Fiorillo A, Ballester-Ferre M, Gallego J, \nCasanova-Ferrer F, Urios A, Benlloch S, Marti-Aguado D, San-\nMiguel T, Tosca J, Rios M, Monton C, Durban L, Escudero-\nGarcia D, Aparicio L, Felipo V, Montoliu C. A new score unveils \na high prevalence of mild cognitive impairment in patients with \nnonalcoholic fatty liver disease. Journal of Clinical Medicine. \n2021 Jun 25;10(13):2806. doi: 10.3390/jcm10132806. \nPMID: 34202269. IF: 4,41131\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference:  PROMETEO/2018/051\nTitle:  Mecanismos moleculares y cerebrales de las alteraciones \ncognitivas y motoras en hiperamonemia y encefalopat\u00eda hep\u00e1tica. \nlmplicaciones terap\u00e9uticas y diagn\u00f3sticas\nPrincipal Investigator: Vicente Felipo Orts (Carmina Montoliu \nF\u00e9lix as collaborating researcher)\nFunding body: Conselleria de Educaci\u00f3n\nBeneficiary institution: Centro de Investigaci\u00f3n Pr\u00edncipe Felipe \n(CIPF)\nDuration: 2018-2021\nTotal budget:  \u20ac289.194,57\nTitle: Identification and modelling of molecular and cellular events \nof the immune response associated to the appearance of minimal \nhepatic encephalopathy in cirrhotic patients\nPrincipal Investigator: Carmina Montoliu F\u00e9lix\nFunding body: Fundaci\u00f3n Ram\u00f3n Areces \nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal budget: \u20ac129.600\nTitle:  Adhesi\u00f3n al programa de detecci\u00f3n de Displasia y C\u00e1ncer \ncolorrectal en la Enfermedad Inflamatoria Intestinal\nPrincipal Investigator:  M\u00aa Pilar Ballester Ferr\u00e9\nFunding body: Sociedad Valenciana de Patolog\u00eda Digestiva\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac5.000\nTitle:  LIGAM1: Efecto de la activaci\u00f3n de TLR por medio de sus \nligandos sobre la polarizaci\u00f3n de macr\u00f3fagos hacia M1 y su \nfunci\u00f3n citocida frente a las c\u00e9lulas madre de glioblastoma\nPrincipal Investigator: Javier Meg\u00edas Vericat and Andrea Cabre -\nra Pastor\nFunding body: Universidad de Valencia - INCLIVA\nBeneficiary institution:  Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac4.067,5\nTitle:  Estudio multic\u00e9ntrico de precisi\u00f3n diagn\u00f3stica para cuantifi-\ncar y caracterizar la fibrosis de la Enfermedad Hep\u00e1tica Metab\u00f3li-\nca mediante patolog\u00eda digital avanzada\nPrincipal Investigator: David Mart\u00edn Aguado (Amparo Escudero \nGarc\u00eda as collaborating researcher)Funding body: Sociedad Valenciana de Patolog\u00eda Digestiva\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac5.000\nTitle: Estudio nacional en enfermedad inflamatoria intestinal so-\nbre determinantes gen\u00e9ticos y ambientales (Estudio ENEIDA)\nPrincipal Investigator:  Miguel M\u00ednguez P\u00e9rez\nFunding body: Janssen - Cilag S.A. \nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal budget:  \u20ac22.500\nTHESIS\nThesis title: Caracterizaci\u00f3n del deterioro neurol\u00f3gico y la \nrespuesta al tratamiento con rifaximina en pacientes con \nencefalopat\u00eda hep\u00e1tica m\u00ednima\nDoctoral candidate: Mar\u00eda Pilar Ballester Ferr\u00e9 \nDirector(s): Carmina Montoliu F\u00e9lix, Desamparados Escudero \nGarc\u00eda, Miguel \u00c1ngel Serra Desf\u00edlis \nDate of the defense: 08/01/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Estudio epidemiol\u00f3gico retrospectivo de 10 a\u00f1os \nde los enfermos con virus C diagnosticados en el servicio de \nMedicina Digestiva del Hospital Cl\u00ednico Universitario de Valencia\nDoctoral candidate: Laura Puchades Lanza \nDirector(s): Miguel \u00c1ngel Serra Desfilis, Desamparados Escudero \nGarc\u00eda \nDate of the defense:  28/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Impacto de la inmunosuppresi\u00f3n y otros factores \nde riesgo en el desarrollo de infecciones en pacientes con \nenfermedad inflamatoria intestinal: estudio caso-control\nDoctoral candidate: Natalia Garc\u00eda Gimeno \nDirector(s):  Miguel M\u00ednguez P\u00e9rez, Francisco Mora Miguel, Joan \nTosca Cuquerella\nDate of the defense: 05/11/2021\nGrade:  Sobresaliente \u201ccum laude\u201d132\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Inflammation\nConsolidated group\nLeading Researchers, R4\nEsteban Morcillo S\u00e1nchez \nHospital. University\nMar\u00eda Jes\u00fas Sanz Ferrando\nUniversity\nEstablished Researcher, R3\nDiego Cort\u00e9s Mart\u00ednez. University\nEmerging Researcher, R2\nNuria Cabedo Escrig. INCLIVA. University\nRecognised Researcher, R2\nPatrice Gomes Marques. INCLIVA\nFirst Stage Researchers, R1\nCarlos Villarroel Vicente. University\nElena Domingo P\u00e9rez. University\nMar\u00eda Le\u00f3n T\u00e9llez. INCLIVA\nStaff. Technician\nLaura Vila Das\u00ed. INCLIVAGroup members\nStrategic aims\n\u2022 Study of intracellular mucin MUC1 in lung fibrosis\n\u2022 Study of the anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /\n\u03b22-adrenoceptor agonist (MABA) in COPD patients\n\u2022 Study of MUC1 deficiency in corticosteroid insensitivity in asthma\n\u2022 Study of the systemic inflammation associated to Primary Hypercholesterolemia and Metabolic Syndrome\n\u2022 Study of the CCL11/CCR3 axis in Primary Hypercholesterolemia and atherosclerosis\n\u2022 Study of the impact of PCSK9 blockade in the systemic inflammation associated to Familial Hypercholesterolemia\n\u2022 Synthesis of new dual PPAR\u03b1/\u03b3 agonists and pharmacology study in ob/ob mice\n\u2022 Synthesis of new dual LXR/PPAR\u03b1/\u03b3 agonists and pharmacology study in ob/ob mice\nMain lines of research \n\u2022 Pharmacological modulation of chronic inflammation and remodeling in the context of chronic obstructive pulmonary disease, \nasthma and idiopathic pulmonary fibrosis\n\u2022 Study of the vascular inflammation induced by different risk factors of atherosclerosis: metabolic syndrome, primary and familial \nhypercholesterolemia. Effect of PCSK9 inhibitors in the systemic inflammation associated to familial hypercholesterolemia\n\u2022 Synthesis of new dual PPAR\u03b1/\u03b3  agonists to be used in the control of cardiometabolic disorders\n\u2022 Synthesis of new dual LXR/PPAR\u03b1/\u03b3 agonists to be used in the control of cardiometabolic disordersResearchers by categories\n1 2 1 2 3\nResearchers financed by \ncompetitive public calls or networks\nR4 R4 R4\n1 1 3R3 R4 STAFF R2 R1\nR2 STAFF R1\nTeam involved in133\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Emerging Researcher\nNuria Cabedo Escrig\nIn the field of medicinal chemistry, the research is focused on the development of new synthetic molecules, analogues of natural pro -\nducts, with potential effect to regulate lipid metabolism, glucose homeostasis, dopaminergic pathway and inflammatory processes in order \nto treat cardiometabolic disorders and neurological diseases. We are working in the hit-to-lead strategy on therapeutic targets such as \nperoxisome proliferator activating receptors (PPAR), liver X receptors (LXR), dopaminergic receptors, and pro-inflammatory cytokines\nPUBLICATIONS\nIF 14\nNumber of  \narticles95.051IF\n6.789Average5\nCorresponding  \nauthor2\nNational  \ncollaborations4\nInternational \ncollaborations\nPrevalence and risk factors for delirium in critically ill patients \nwith COVID-19 (COVID-D): a multicentre cohort study. Lancet. \nRespiratory Medicine. 2021; 9(3): 239-250. doi: 10.1016/\nS2213-2600(20)30552-X. PMID: 33428871. IF: 30,7\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitulo: The William Harvey International Translational Research \nAcademy (WHRI-ACADEMY)   \nInvestigadora principal: M\u00e1rta Korbonits (Mar\u00eda Jes\u00fas Sanz \nFerrando as collaborating researcher)\nEntidad financiadora: FP7 Marie Curie Actions\nInstituci\u00f3n beneficiaria: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2015-\nTotal Budget: \u20ac6.500.000 \nReference: PI18/01450\nTitle:  Desarrollo qu\u00edmico y farmacol\u00f3gico de nuevos f\u00e1rmacos \n\u201cmultidiana\u201d en el tratamiento de la diabetes mellitus tipo 2 y la \nenfermedad cardiovascular asociada\nPrincipal Investigator: Nuria Cabedo Escrig\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal Budget: \u20ac61.710 SELECTED PUBLICATIONS\n1. Collado A, Domingo E, Marques P, Perello E, Mart\u00ednez-Herv\u00e1s \nS, Piqueras L, Ascaso JF, Real JT, Sanz MJ. Oral unsaturated \nfat load impairs postprandial systemic inflammation \nin primary hypercholesterolemia patients. Frontiers in \nPharmacology. 2021 Apr 20;12:656244. doi: 10.3389/\nfphar.2021.656244. PMID: 33959024. IF: 5,81\n2. Marques P, Piqueras L, Sanz MJ. An updated overview of \ne-cigarette impact on human health. Respiratory Research. \n2021 May 18;22(1):151. doi: 10.1186/s12931-021-\n01737-5. PMID: 34006276. IF: 5,631\n3. Milara J, Ballester B, Safont M, Artigues E, Escriva J, Morcillo \nE, Cortijo J. MUC4 is overexpressed in idiopathic pulmonary \nfibrosis and collaborates with transforming growth factor \nbeta inducing fibrotic responses. Mucosal Immunology. 2021 \nMar;14(2):377-388. doi: 10.1038/s41385-020-00343-w. \nPMID: 32887938. IF: 7,313\n4. Villarroel-Vicente C, Gutierrez-Palomo S, Ferri J, Cortes D, \nCabedo N. Natural products and analogs as preventive agents \nfor metabolic syndrome via peroxisome proliferator-activated \nreceptors: an overview. European Journal of Medicinal \nChemistry. 2021 Oct 5;221:113535. doi: 10.1016/j.\nejmech.2021.113535. PMID: 33992930. IF: 6,514\n5. Pun B, Badenes R, Heras La Calle G, Orun O, Chen W, Raman \nR, Simpson B, Wilson-Linville S, Hinojal Olmedillo B, Vallejo de la \nCueva A, van der Jagt M, Navarro Casado R, Leal Sanz P, Orhun \nG, Ferrer Gomez C, Nunez Vazquez K, Pineiro Otero P, Taccone \nF, Gallego Curto E, Caricato A, Woien H, Lacave G, O\u2019Neal \nH, Peterson S, Brummel N, Girard T, Ely E, Pandharipande \nP, COVID-19 Intensive Care International Study Group. 134\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Reference: CB06/06/0027\nTitle: CIBER Enfermedades Respiratorias (CIBERes)\nPrincipal Investigator: Esteban Morcillo S\u00e1nchez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Universidad de Valencia\nDuration: 2007-\nReference: PID2020-120336RB-I00\nTitle:  Modulaci\u00f3n de la inflamaci\u00f3n metab\u00f3lica en la prevenci\u00f3n \nde la patolog\u00eda cardiovascular: Identificaci\u00f3n de nuevas dianas \nterap\u00e9uticas y desarrollo de f\u00e1rmacos novedosos\nPrincipal Investigator: Mar\u00eda Jes\u00fas Sanz Ferrando\nFunding Body: Ministerio de Ciencia, Innovaci\u00f3n y Universidades\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2024\nTotal Budget: \u20ac290.400Reference: SAF2017-89714-R \nTitle: Modulaci\u00f3n farmacol\u00f3gica del sistema inmune como diana \nclave en la prevencion de la enfermedad cardiovascular asociada \na des\u00f3rdenes metab\u00f3licos. S\u00edntesis de f\u00e1rmacos novedosos\nPrincipal Investigator: Juan F. Ascaso and Mar\u00eda Jes\u00fas Sanz \nFerrando\nFunding body: Ministerio de Econom\u00eda y Competitividad\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac205.700\nReference: PROMETEO/2019/032\nTitle:  Una aproximaci\u00f3n translacional desde la cl\u00ednica a la \nexperimentaci\u00f3n animal: Estudio del papel del eje CCL11/CCR3 y \nla inflamaci\u00f3n eosinof\u00edlica en la patolog\u00eda cardiovascular asociada \na des\u00f3rdenes metab\u00f3licos\nPrincipal Investigator: Mar\u00eda Jes\u00fas Sanz Ferrando\nFunding body: Conselleria de Educaci\u00f3n Cultura y Deporte\nBeneficiary institution: Universidad de Valencia\nDuration: 2020-2023\nTotal budget:  \u20ac211.736135\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Oxidative Pathology\nConsolidated group\nLeading Researcher, R4\nGuillermo S\u00e1ez Tormo \nUniversity\nEstablished Researchers, R3\nAntonio Iradi Casal. University\nEulalia Alonso Iglesias. University\nRecognised Researchers, R2\nLeticia Bag\u00e1n Deb\u00f3n. University\nPedro Gargallo Bayo. UniversityGroup members\nStrategic aims\n\u2022 To study the role of Mediterranean diet on hemodynamics, endotelial function, abdominal adiposity and gene expression in \npatients at high cardiovascular risk has been studied\n\u2022 To monitor the morbidly obese patients in terms of anthropometric changes, metabolic and oxidative stress markers before \nand after dietary intervention, exercise and bariatric surgery\n\u2022 To analyze in the role of DNA damage and different markers of oxidative stress in order to validate the modified base 8-oxo-\ndG as a possible tumor marker at high cardiovascular risk\nMain lines of research\n\u2022 Study of the role of OS as a physiopathological mechanism of cardiometabolic diseases\n\u2022 Study of DNA damage and repair signaling routes in patients with cardiovascular evolution pathologies, in order to identify \ngrades of expression in different genes\n\u2022 Study of OS role in the pathology of neoplastic diseases, as well as the possible validation of their molecular oxidative products \nas clinical markersR1\n2\nPUBLICATIONS\nIF 11\nNumber of  \narticles50.691IF\n4.608Average1\nCorresponding  \nauthor10\nNational  \ncollaborations1\nInternational \ncollaborationsResearchers by categories\n2 2 1R2 R3 R4136\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4THESIS\nThesis title: Effects of elastic-based exercise interventions on \noxidative stress, bone health, body composition, neuromuscular \nstrength and physical function in older women: training intensity \nand modality as key exercise\nDoctoral candidate: Pedro Gargallo Bayo\nDirector(s):  Juan Carlos Colado S\u00e1nchez, Guillermo S\u00e1ez Tormo\nDate of the defense: 15/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD\nThesis title: Estudio de la sialometr\u00eda en un grupo de 103 \npacientes con s\u00edndrome de Sj\u00f6gren y su relaci\u00f3n con los criterios \ndiagn\u00f3sticos establecidos en esta enfermedad autoinmune\nDoctoral candidate: Carlos Alvari\u00f1o Mart\u00edn \nDirector(s): Jose Vicente Bag\u00e1n Sebasti\u00e1n, Leticia Bag\u00e1n Deb\u00f3n\nDate of the defense: 29/07/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: Determinaci\u00f3n de los polimorfismos del receptor de \nla vitamina D en ni\u00f1os asm\u00e1ticos al\u00e9rgicos a los \u00e1caros del polvo\nDoctoral candidate: Sara Ferrer Suay\nDirector(s): Miguel Tortajada Girbes, Eulalia Alonso Iglesias, Pilar \nCodo\u00f1er Franch\nDate of the defense: 10/12/2021\nGrade: Sobresaliente \u201ccum laude\u201dSELECTED PUBLICATIONS\n1. Alcala M, Bolado V, Sanchez-Vera I, Clapes S, Dasi F, Saez G, \nCarrera E, Alvarez-Gallego F, Loeken M, Viana M. Prevention \nof teratogenesis in pregnancies of obese rats by vitamin E \nsupplementation. Antioxidants. 2021 Jul 23;10(8):1173. doi: \n10.3390/antiox10081173. PMID: 34439421. IF: 6,312\n2. Acevedo-Leon D, Monzo-Beltran L, Gomez-Abril S, Estan-Capell \nN, Camarasa-Lillo N, Perez-Ebri M, Escandon-Alvarez J, Alonso-\nIglesias E, Santaolaria-Ayora M, Carbonell-Moncho A, Ventura-\nGayete J, Pla L, Martinez-Bisbal M, Martinez-Manez R, Bagan-\nDebon L, Vina-Almunia A, Martinez-Santamaria M, Ruiz-Luque \nM, Alonso-Fernandez J, Banuls C, Saez G. The Effectiveness \nof glutathione redox status as a possible tumor marker in \ncolorectal cancer. International Journal of Molecular Sciences. \n2021 Jun 8;22(12):6183. doi: 10.3390/ijms22126183. \nPMID: 34201191. IF: 5,923\n3. Herreros-Pomares A, Llorens C, Soriano B, Bagan L, Moreno \nA, Calabuig-Farinas S, Jantus-Lewintre E, Bagan J. Differentially \nmethylated genes in proliferative verrucous leukoplakia \nreveal potential malignant biomarkers for oral squamous \ncell carcinoma. Oral Oncology. 2021 May;116:105191. doi: \n10.1016/j.oraloncology.2021.105191. PMID: 33657465. \nIF: 5,337\n4. Herreros-Pomares A, Llorens C, Soriano B, Zhang F, \nGallach S, Bagan L, Murillo J, Jantus-Lewintre E, Bagan J. \nOral microbiome in Proliferative Verrucous Leukoplakia \nexhibits loss of diversity and enrichment of pathogens. \nOral Oncology. 2021 Sep;120:105404. doi: 10.1016/j.\noraloncology.2021.105404. PMID: 34225130. IF: 5,337\n5. Dualde P, Leon N, Sanchis Y, Corpas-Burgos F, Fernandez SF, \nHernandez CS, Saez G, Perez-Zafra E, Mora-Herranz A, Pardo \nO, Coscolla C, Lopez A, Yusa V. Biomonitoring of phthalates, \nbisphenols and parabens in children: exposure, predictors \nand risk assessment. International Journal of Environmental \nResearch and Public Health. 2021 Aug 24;18(17):8909. doi: \n10.3390/ijerph18178909. PMID: 34501500. IF: 3,39137\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Psychiatry and Neurodegenerative Diseases \nConsolidated group\nLeading Researcher, R4\nJulio Sanju\u00e1n Arias \nHospital. University\nEstablished Researchers, R3\nEduardo Jes\u00fas Aguilar Garc\u00eda-Iturrospe. Hospital. University\nJuan Nacher Rosell\u00f3. University\nMar\u00eda Dolores Molt\u00f3 Ruiz. University\nRecognised Researchers, R2\nCarlos Ca\u00f1ete Nicol\u00e1s. Hospital. University\nEsther Lorente Rovira. Hospital\nFrancisco Olucha Bordonau. University\nGraci\u00e1n Garc\u00eda Mart\u00ed. CIBERSAM\nJos\u00e9 Carlos Gonz\u00e1lez Piqueras. Hospital. University\nMar\u00eda Jos\u00e9 Escart\u00ed Fabra. Hospital\nMarien Gadea Domenech. University\nMarta P\u00e9rez Rando. University\nMiguel Hern\u00e1ndez Viadel. Hospital. University\nOlga Mar\u00eda Rivero Mart\u00edn. INCLIVA\nFirst Stage Researchers, R1 \nLuc\u00eda Bonet Mora. University \nJavier David Lluesma. University \nJon I\u00f1aki Etxeandia Pradera. Hospital\nJulia Alcaide Pozo. UniversityGroup members\nStrategic aims\n\u2022 Elaboration of a mobile application associated to the Clinical Records to improve adherence to the treatment of patients with \nfirst episode psychosis\n\u2022 Publication of Results of Gene-Environmental interaction First Episode Psychosis projects\n\u2022 Development of new techniques to diagnosis psychosis by fMRI and machine learning approach\n\u2022 Development of animal models in severe mental disorder and neurodegenerative diseases\n\u2022 Models of prediction of response in first psychotic episodes\n\u2022 Identification of genetic and epigenetic modifiers and molecular targets in Friedreich\u2019s Ataxia\nMain lines of research\n\u2022 Identifying risk polymorphisms in psychosis and affective disorders\n\u2022 Epigenetic studies (functional expression) of candidate genes in psychosis and mental illness\n\u2022 Study on animal models in serious mental illnessResearchers by categories\n3 10 1 6 4\nResearchers financed by \ncompetitive public calls or networks\nR4 R4\n5 1 2R2 R3 R4 STAFF R1\nSTAFF R2 R1\nTeam involved in\nStaff. Collaborating Researchers\nH\u00e9ctor Carceller Cerd\u00e1. University\nPatrycja Klimczak. University\nStaff. Nurse\nBlanca Ll\u00e0cer Iborra. CIBERSAM\nStaff. Technician\nCarlos Casillas Serra. INCLIVA\nStaff. Administrative assistant\nJulen Santiago Agrediano. INCLIVA\nVirginia G\u00f3mez Soriano. INCLIVA138\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\nIF 44\nNumber of  \narticles230.321IF\n5.234Average10\nCorresponding  \nauthor16\nNational  \ncollaborations26\nInternational \ncollaborations\nM, Sanjuan J, Santos J, Arrojo M, Del-Ben C, Menezes P, Selten \nJ, Jones P, Jongsma H, Kirkbride J, Rutten B, van Os J, Murray \nR, Gayer-Anderson C, Morgan C. Perceived major experiences \nof discrimination, ethnic group, and risk of psychosis in a six-\ncountry case-control study. Psychological Medicine. 2021 \nMar 2;1-9. doi: 10.1017/S0033291721000453. PMID: \n33648622. IF: 7,723\n5. Cuesta M, Lecumberri P, Moreno-Izco L, Lopez-Ilundain J, Ribeiro \nM, Cabada T, Lorente-Omenaca R, de Erausquin G, Garcia Marti \nG, Sanjuan Arias J, Sanchez-Torres A, Gomez M, Peralta V. \nMotor abnormalities and basal ganglia in first-episode psychosis \n(FEP). Psychological Medicine. 2021 Jul;51(10):1625-1636. \ndoi: 10.1017/S0033291720000343. PMID: 32114994. \nIF: 7,723\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI20/00473\nTitle:  Estudio longitudinal de una cohorte representativa: superando \nla heterogeneidad cl\u00ednica y biol\u00f3gica en primeros episodios \npsic\u00f3ticos\nPrincipal Investigator: Julio Sanju\u00e1n Arias\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget: \u20ac68.970SELECTED PUBLICATIONS\n1. Velthorst E, Mollon J, Murray R, et al. Cognitive functioning \nthroughout adulthood and illness stages in individuals with \npsychotic disorders and their unaffected siblings. Molecular \nPsychiatry. 2021 Aug;26(8):4529-4543. doi: 10.1038/\ns41380-020-00969-z. PMID: 33414498. IF: 15,992\n2. Fernandez Garcia-Agudo L, Steixner-Kumar AA, Curto Y, \nBarnkothe N, Hassouna I, Jahne S, Butt UJ, Grewe K, Weber \nMS, Green K, Rizzoli S, Nacher J, Nave KA, Ehrenreich H. \nBrain erythropoietin fine-tunes a counterbalance between \nneurodifferentiation and microglia in the adult hippocampus. \nCell Reports. 2021 Aug 24;36(8):109548. doi: 10.1016/j.\ncelrep.2021.109548. PMID: 34433021. IF: 9,423\n3. Ajnakina O, Rodriguez V, Quattrone D, di Forti M, Vassos E, \nArango C, Berardi D, Bernardo M, Bobes J, de Haan L, Del-\nBen CM, Gayer-Anderson C, Jongsma HE, Lasalvia A, Tosato \nS, Llorca PM, Menezes PR, Rutten BP, Santos JL, Sanjuan J, \nSelten JP, Szoke A, Tarricone I, D\u2019Andrea G, Richards A, Tortelli \nA, Velthorst E, Jones PB, Arrojo Romero M, La Cascia C, \nKirkbride JB, van Os J, O\u2019Donovan M, Murray RM. Duration of \nuntreated psychosis in first-episode psychosis is not associated \nwith common genetic variants for major psychiatric conditions: \nresults from the multi-center EU-GEI Study. Schizophrenia \nBulletin. 2021 Oct 21;47(6):1653-1662. doi: 10.1093/\nschbul/sbab055. PMID: 33963865. IF: 9,306\n4. Misra S, Gelaye B, Williams D, Koenen K, Borba C, Quattrone \nD, Di Forti M, Tripoli G, La Cascia C, La Barbera D, Ferraro L, \nTarricone I, Berardi D, Lasalvia A, Tosato S, Szoke A, Llorca P, \nArango C, Tortelli A, de Haan L, Velthorst E, Bobes J, Bernardo \u2022 Generating Studing models of neurodegenerative diseases (Friedreich Ataxia) on invertebrate animals (Drosophila)\n\u2022 Study of mutations in monogenic neurodegenerative diseases\n\u2022 Identifying genetic and environmental risk factors in affective and psychotic disorders\n\u2022 Identifying abnormal patterns in neuroimaging (morphometry, functional, spectroscopy) in psychotic patients\n\u2022 Design and coordination of clinical, genetic and neuroimaging data bases oriented to performing multicenter projects\n\u2022 Development of interactive systems for improving therapeutic adherence\n\u2022 Study on the efficiency of psycho-social intervention techniques in serious mental illness139\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference:  CB07/09/0006\nTitle:  CIBER de Investigaci\u00f3n en Salud Mental (CIBERsam)\nPrincipal Investigator:  Juan Nacher Rosell\u00f3\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Universidad de Valencia\nDuration: 2008-\nReference: RTI2018-098269-B-I00\nTitle: La matriz extracelular cerebral en la depresi\u00f3n: de modelos \nanimales a pacientes\nPrincipal Investigator: Juan Salvador Nacher Rosell\u00f3\nFunding body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary institution:  Universidad de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac217.800\nReference:  PROMETEO/2020/024\nTitle: Desarrollo de nuevos marcadores biol\u00f3gicos y nuevas \nestrategias terap\u00e9uticas para el diagn\u00f3stico y el tratamiento de la \npsicosis \nPrincipal Investigator: Julio Sanju\u00e1n Arias\nFunding Body: Conselleria de Educaci\u00f3n, Cultura y Deporte\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2023\nTotal budget:  \u20ac174.588\nTHESIS\nThesis title: Estudio de la plasticidad estructural en enfermedades \npsiqui\u00e1tricas con modelos animales\nDoctoral candidate: Clara Bueno Fern\u00e1ndez \nDirector(s): Juan Salvador Nacher Rosello, Esther Castillo G\u00f3mez\nDate of the defense: 09/03/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Papel de n\u00facleo incertus en el reconocimiento social \na trav\u00e9s de sus conexiones en el cerebro de rata\nDoctoral candidate: Cristina Garc\u00eda D\u00edaz\nDirector(s): Francisco Olucha Bordonau \nDate of the defense: 29/03/2021\nGrade: Sobresaliente \u201ccum laude\u201dThesis title: Continuous neuronal integration in the cerebral \ncortex of rodents and humans\nDoctoral candidate: Simona Coviello \nDirector(s): Juan Salvador Nacher Rosello, Esther Castillo G\u00f3mez \nDate of the defense:  30/03/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD\nThesis title: Eficacia de un programa de rehabilitaci\u00f3n de las \nfunciones atencionales mediante tareas competitivas multijugador. \nEstudio cl\u00ednico, neurofisiol\u00f3gico y neuroanat\u00f3mico en pacientes con \nictus\nDoctoral candidate: M\u00aa Dolores Navarro P\u00e9rez\nDirector(s): Roberto Llor\u00e9ns Rodr\u00edguez, Mar\u00eda Engracia Gadea \nDom\u00e8nech, Enrique Noe Sebasti\u00e1n \nDate of the defense: 25/05/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: Hospitalizaci\u00f3n Domiciliaria en Salud Mental: eficacia \ny viabilidad\nDoctoral candidate: Elvira Ferrando Aparicio \nDirector(s): Eduardo Jes\u00fas Aguilar Garc\u00eda Iturrospe, Francisca \nSilvestre Pascual\nDate of the defense:  07/07/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Tears as powerful visual communication signals: a \nsociobiological approach\nDoctoral candidate: Alfonso Ignacio Pic\u00f3 Peris\nDirector(s):  Mar\u00eda Engracia Gadea Dom\u00e8nech\nDate of the defense: 13/07/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: REMINDCARE: una aplicaci\u00f3n para primeros \nepisodios psic\u00f3ticos integrada en la pr\u00e1ctica cl\u00ednica diaria\nDoctoral candidate: Luc\u00eda Bonet Mora \nDirector(s):  Julio Sanjuan Arias \nDate of the defense: 16/07/2021\nGrade:  Sobresaliente \u201ccum laude\u201d140\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Respiratory Diseases\nConsolidated group\nLeading Researcher, R4\nJaime Signes-Costa Mi\u00f1ana\nHospital \nEstablished Researchers, R3\nJes\u00fas Sancho Chinesta. Hospital\nJos\u00e9 Franco Serrano. Hospital. University\nM\u00aa Cruz Gonz\u00e1lez Villaescusa. Hospital\nM\u00aa Luisa Briones Urtiaga. Hospital\nRecognised Researchers, R2\nCarmen Mu\u00f1oz Esteban. Hospital \nFrancisco Carri\u00f3n Valero. Hospital. University\nJos\u00e9 Lu\u00eds D\u00edaz Cordob\u00e9s. Hospital\nM\u00aa Bel\u00e9n Safont Mu\u00f1oz. Hospital\nPilar Ba\u00f1uls Polo. Hospital\nFirst Stage Researchers, R1\nIrene Bocigas Hu\u00e9scar. Hospital\nNieves Navarro Soriano. Hospital\nPaola Lisseth Ord\u00f3\u00f1ez G\u00f3mez. Hospital\nSantos Ferrer Espinosa. Hospital\nStaff. Collaborating Researchers\nAlba Mulet Arabi. Hospital\nAlejandro Ochoa Alvarado. Hospital\nAna Ferrer Pons. Hospital\nAndrea Ballester F\u00e9rriz. Hospital\nAntonio Herrera Cuadros. INCLIVA\nAntonio Quezada Reynosa. Hospital\nCristina Rosario Mart\u00edn. Hospital\nElena Gim\u00e9nez Civera. INCLIVA\nElvira Bond\u00eda Real. Hospital\nEnric Bur\u00e9s Sales. Hospital\nErick Monclou Garz\u00f3n. Hospital\nHeidi Mora Bastida. Hospital\nJulia Tarras\u00f3 Castillo. Hospital\nLuc\u00eda Fern\u00e1ndez Presa. Hospital\nManuela Mar\u00edn Gonz\u00e1lez. Hospital\nMariam Garc\u00eda Alfaro. Hospital\nNatividad Blasco Angulo. INCLIVA\nPablo Royo Sim\u00f3. UniversityGroup members Researchers by categories\n4 5 1 18 4R2 R3 R4 STAFF R1141\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 42. Abraham W, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, \nDesai A, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett J, \nNicholls S, Redon J, Schenkenberger I, Silva-Cardoso J, Stork \nS, Krzysztof Wranicz J, Savarese G, Brueckmann M, Jamal \nW, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali \nA, Anker S. Underlying heart diseases and acute COVID-19 \noutcomes. European Heart Journal. 2021;28(2):202-214. \ndoi: 10.5603/CJ.a2020.0183. PMID: 33346365. IF: \n29,983SELECTED PUBLICATIONS\n1. Marconi V, Ramanan A, de Bono S, Kartman C, Krishnan V, \nLiao R, Piruzeli M, Goldman J, Alatorre-Alexander J, de Cassia \nPellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, \nCrowe B, Reis P, Zhang X, Adams D, Ely E, COV-BARRIER Study \nGroup. Efficacy and safety of baricitinib for the treatment \nof hospitalised adults with COVID-19 (COV-BARRIER): a \nrandomised, double-blind, parallel-group, placebo-controlled \nphase 3 trial. Lancet Respiratory Medicine. 2021; 9(12): \n1407-1418. doi: 10.1016/S2213-2600(21)00331-3. \nPMID: 34480861. IF: 30,7Strategic aims\n\u2022 Study of respiratory complications in patients with neuromuscular diseases. Utility of mechanical ventilation and other \nrespiratory supports\n\u2022 Implication of early diagnosis of obstructive airway diseases in the prognosis and follow-up of patients. Emphysema early \ndetection program. Program for early detection of Alpha 1 Antitrypsin Deficiency\n\u2022 Early follow-up program for COPD with exacerbator phenotype \n\u2022 Severe Asthma control program\n\u2022 Control of respiratory disorders during sleep as prevention of cardiovascular risk factors \n\u2022 Early diagnosis of idiopathic interstitial respiratory diseases (IPF) and secondary diseases (drug toxicity and post-BMT)\nMain lines of research \n\u2022 Usefulness of non-invasive ventilation in the weaning process of patients with prolonged mechanical ventilation\n\u2022 Improve the effectiveness of mechanically assisted cough procedures in patients with ALS, as well as the precission of the \nclinical tools available to evaluate frontotemporal dementia in them\n\u2022 Study in smokers of the early stages of COPD. GOLD classification paradigm 0\n\u2022 Identify cardiac morphological changes in patients with sleep-disordered breathing and ischemic heart disease treated with \nCPAP\n\u2022 Follow-up of patients admitted for bilateral COVID19 pneumonia: changes in pulmonary function tests for the early diagnosis \nof pulmonary fibrotic sequelae\n\u2022 Study of oxidative stress and inflammatory mechanisms underlying acute lung damage caused by SARS-CoV-2\nPUBLICATIONS\nIF 27\nNumber of  \narticles190.992IF\n7.073Average5\nCorresponding  \nauthor7\nNational  \ncollaborations13\nInternational \ncollaborations142\nINCLIVA SCIENTIFIC REPORT 2021scientific activity43. Asano T, Boisson B, Onodi F, et al. X-linked recessive TLR7 \ndeficiency in ~1% of men under 60 years old with life-\nthreatening COVID-19. Science Immunology. 2021 Aug \n19;6(62):eabl4348. doi: 10.1126/sciimmunol.abl4348. \nPMID: 34413140. IF: 17,727\n4. Becerra-Munoz V, Nunez-Gil I, Eid C, Aguado M, Romero \nR, Huang J, Mulet Arabi A, Ugo F, Rametta F, Liebetrau C, \nAparisi A, Fernandez-Rozas I, Viana-Llamas M, Feltes G, Pepe \nM, Moreno-Rondon L, Cerrato E, Raposeiras-Roubin S, Alfonso \nE, Carrero-Fernandez A, Buzon-Martin L, Abumayyaleh M, \nGonzalez A, Ortiz A, Macaya C, Estrada V, Fernandez-Perez C, \nGomez-Doblas J. Clinical profile and predictors of in-hospital \nmortality among older patients admitted for COVID-19. Age \nand Ageing. 2021 Feb 26;50(2):326-334. doi: 10.1093/\nageing/afaa258. PMID: 33201181. IF: 10,668\n5. Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies \nneutralizing type I IFNs are present in ~4% of uninfected \nindividuals over 70 years old and account for ~20% of COVID-19 \ndeaths. Science Immunology. 2021 Aug 19;6(62):eabl4340. \ndoi: 10.1126/sciimmunol.abl4340. PMID: 34413139. IF: \n17,727\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: COV20/01209\nTitle:  Cambios en los test de funci\u00f3n pulmonar en pacientes con \nneumon\u00eda por COVID19\nPrincipal Investigator: Jaime Signes-Costa Mi\u00f1ana\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac73.500\nTitle: Evaluaci\u00f3n de la atenci\u00f3n con compasi\u00f3n en el \u00e1mbito \nsanitario: traducci\u00f3n y validaci\u00f3n en la poblaci\u00f3n espa\u00f1ola de un \ninstrumento centrado en el paciente. Estudio multic\u00e9ntrico\nPrincipal Investigator: Jos\u00e9 Luis D\u00edaz Cordob\u00e9s\nFunding body:  Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary institution: Universidad de Valencia\nDuration: 2019-2021Title:  Valoraci\u00f3n de la demencia frontotemporal y su repercusi\u00f3n \nen el proceso de toma de decisiones terap\u00e9uticas en pacientes \ncon esclerosis lateral amiotr\u00f3fica. Estudio Longitudinal\nPrincipal Investigator: Jaime Signes-Costa Mi\u00f1ana\nFunding body:  Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda \nTor\u00e1cica (SEPAR)\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac9.000\nTitle: GOLD 0-DLCO 1. Una mirada m\u00e1s all\u00e1 de la obstrucci\u00f3n. \u00bfEs \nsuficiente la espirometr\u00eda en el screening de EPOC?\nPrincipal Investigator:  Cruz Gonz\u00e1lez Villaescusa\nFunding body: Sociedad Valenciana de Neumolog\u00eda (SVN)\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal Budget: \u20ac12.000\nTitle:  Impacto cl\u00ednico asistencial de la creaci\u00f3n de circuitos de \nderivaci\u00f3n precoz en fibrosis pulmonar idiop\u00e1tica\nPrincipal Investigator:  Bel\u00e9n Safont Mu\u00f1oz\nFunding body: Sociedad Valenciana de Neumolog\u00eda (SVN)\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2025\nTotal Budget: \u20ac12.000143\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Tissular Biochemistry\nConsolidated group\nLeading Researcher, R4\nJuan R. Vi\u00f1a Ribes. University\nTeresa Barber Ballester. University\nEstablished Researchers, R3\nElena Ruiz Garc\u00eda-Trevijano. University\nLuis Torres Asensi. University\nRosa Zaragoz\u00e1 Colom. University\nStaff. Technicians\nCarmen Picher Latorre. University\nConcha Garc\u00eda de Mier. University\nSonia Company Hern\u00e1ndez. UniversityGroup members\nStrategic aims\n\u2022 Vitamin A deficiency impairs several tissues, including lungs and liver. Alteration in the extracellular matrix is being studied \nin rats with chronic VAD\n\u2022 To study the role of nuclear calpains in breast cancer cell lines. CAPN2 modulates P-cofilin levels and impairs cell division\n\u2022 Calpains also seem to control cellular differentiation, their role in this process is being assessed in adipocytes and osteoblasts \ndifferentiation in vitro. To study the role of calpains 1, 2 and 3 as key mediators of hormones and Ca2+ metabolism in \nosteoblast differentiation and platelet abnormalities in LGMD patients\nMain lines of research\n\u2022 Mammalian tissues metabolism and its regulation\n\u2022 Role of calpains in proliferation and differentiation processes\n\u2022 Vitamin A deficiency induces oxidative stress in several tissues including lung and liver\n\u2022 Epigenetic biomarkers and exome sequencing in limb-girdle muscular dystrophies\nPUBLICATIONS\nIF 3\nNumber of  \narticles15.584IF\n5.194Average1\nCorresponding  \nauthor0\nNational  \ncollaborations2\nInternational \ncollaborationsResearchers by categories\n3 2 3R3 R4 STAFF144\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PROMETEOII/2018/167\nTitle: Estudios tridimensionales de ductos mamarios para \ndeterminar el papel de las calpa\u00ednas en la remodelaci\u00f3n del tejido \nmamario. Implicaciones biom\u00e9dicas\nPrincipal Investigator:  Juan Vi\u00f1a Ribes\nFunding Body: Conselleria de Educaci\u00f3n, Cultura y Deporte\nBeneficiary Institution:  Universidad de Valencia\nDuration: 2018-2021\nTotal Budget: \u20ac201.920,20\nReference: OTR-2019-19499INVES\nTitle: Molecular mechanisms in the development of scoliosis in \nlimb-girdle muscular dystrophies\nPrincipal Investigator: Juan Vi\u00f1a Ribes \nFunding Body: Fundaci\u00f3n Ram\u00f3n Areces\nBeneficiary Institution:  Universidad de Valencia\nDuration: 2019-2021\nTotal Budget: \u20ac121.176SELECTED PUBLICATIONS\n1. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, \nGambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo \nJ. Epigenetic mechanisms are involved in the oncogenic \nproperties of ZNF518B in colorectal cancer. Cancers. 2021 \nMar 21;13(6):1433. doi: 10.3390/cancers13061433. \nPMID: 33801071. IF: 6,639\n2. Peterson DR, Hawkins RA, Vina JR. Editorial: organization \nand functional properties of the blood-brain Barrier. Frontiers \nin Physiology. 2021 Dec 2;12:796030. doi: 10.3389/\nfphys.2021.796030. PMID: 34925076. IF: 4,566\n3. Rodriguez-Fernandez L, Company S, Zaragoza R, Vina J, \nGarcia-Trevijano E. Cleavage and activation of LIM kinase 1 as a \nnovel mechanism for calpain 2-mediated regulation of nuclear \ndynamics. Scientific Reports. 2021 Aug 11;11(1):16339. \ndoi: 10.1038/s41598-021-95797-8. PMID: 34381117. IF: \n4,379145\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Aging and Physical Activity\nConsolidated group\nLeading Researcher, R4\nJos\u00e9 Vi\u00f1a Ribes \nUniversity\nEstablished Researchers, R3\nAna Lloret Alca\u00f1iz. University\nConsolaci\u00f3n Garc\u00eda Lucerga. University\nEva Serna Garc\u00eda. University\nRecognised Researchers, R2\nJos\u00e9 Vi\u00f1a Almunia. University\nPaloma Monllor Taltavull. University\nEmerging Researcher, R2\nAna Lloret Alca\u00f1iz. University\nFirst Stage Researcher, R1\n\u00c1ngela Garc\u00eda Correas. University\nStaff. Administrative assistant\nCristina Am\u00e9zcua Garc\u00eda. INCLIVAGroup members\nStrategic aims\n\u2022 Regenerative medicine in aging \n\u2022 Identification of physical training as a drug to treat age-related frailty \n\u2022 Prove that G6PD protects against oxidative damage and improves lifespan in mice \n\u2022 Reducing stress: a new concept in disease Alzheimer\u2019s\nMain lines of research\n\u2022 Aging: identification of genes associated with aging, particularly genes that are specific in centenary people. Implication of the \nestrogens and phytoestrogens in the prevention of age-related damage\n\u2022 Physical activity: identification of the molecular mechanisms by which physical activity is good for health. Identification of the \nmechanisms by which physical activity and antioxidant supplements help preventing primary and secondary sarcopenia in \nboth human and animal studies. Identification of the best exercise intervention to delay and to treat frailty in humans \n\u2022 Physiopathology of the Alzheimer\u2019s disease: identification of the mechanisms by which free radicals, originators of the \noxidative stress are used to unleash cell signals that lead to cell death in Alzheimer diseaseResearchers by categories\n3 2 1 1 1R2 R3 R4 STAFF R1\nTeam involved inResearchers financed by \ncompetitive public calls or networks\n1R1146\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Principal Investigator: Jos\u00e9 Vi\u00f1a Ribes and Leocadio Rodr\u00edguez \nMa\u00f1as\nFunding Body: European Commission \nBeneficiary Institution: CIBER (Fundaci\u00f3n Investigaci\u00f3n Hospital \nCl\u00ednico Universitario de Valencia as Third Party)\nDuration: 2019-2024\nTotal Budget: \u20ac273.720  \nReference: AC20/00026\nTitle:  Combining vitamin E-functionalized CHOcolate with physical \nexercise to reduce the risK of protein energy malnutrition in pre-\ndementia AGEd people. ERA-HDHL Call for Joint Transnational \nResearch Proposals on Development of targeted nutrition for \nprevention of undernutrition for older adults (PREVNUT)\nPrincipal Investigator: Jos\u00e9 Vi\u00f1a Ribes \nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Universidad de Valencia\nDuration: 2021-2023\nTotal budget:  \u20ac169.098\nReference: CB16/10/00435\nTitle:  CIBER de Fragilidad y envejecimiento (CIBERfes)\nPrincipal Investigator: Jos\u00e9 Vi\u00f1a Ribes\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Universidad de Valencia\nDuration: 2017-\nReference: PID2019-110906RB-100\nTitle:  Nuevas intervenciones terap\u00e9uticas multidominio para \nretrasar la fragilidad y la discapacidad. Identificaci\u00f3n de mecanismos \nmoleculares con relevancia traslacional\nPrincipal Investigator: Jos\u00e9 Vi\u00f1a Ribes and Consuelo G\u00f3mez \nCabrera \nFunding Body: Ministerio de Econom\u00eda y Competitividad\nBeneficiary Institution:  Universidad de Valencia\nDuration: 2020-2023\nTotal budget:  \u20ac270.000SELECTED PUBLICATIONS\n1. Gambini J, Gimeno-Mallench L, Olaso-Gonzalez G, Mastaloudis \nA, Traber M, Monleon D, Borras C, Vina J. Moderate red \nwine consumption increases the expression of longevity-\nassociated genes in controlled human populations and extends \nlifespan in drosophila melanogaster. Antioxidants. 2021 \nFeb 16;10(2):301. doi: 10.3390/antiox10020301. PMID: \n33669360. IF: 6,312\n2. Gomez-Cabrera C, Carretero A, Millan-Domingo F, Garcia-\nDominguez E, Correas AG, Olaso-Gonzalez G, Vina J. Redox-\nrelated biomarkers in physical exercise. Redox Biology. 2021 \nJun;42:101956. doi: 10.1016/j.redox.2021.101956. PMID: \n33811000. IF: 11,799\n3. Villafranca-Faus M, Esteban Vila-Martin M, Esteve D, Merino E, \nTeruel-Sanchis A, Cervera-Ferri A, Martinez-Ricos J, Lloret A, \nLanuza E, Teruel-Marti V. Integrating pheromonal and spatial \ninformation in the amygdalo-hippocampal network. Nature \nCommunications. 2021 Sep 6;12(1):5286. doi: 10.1038/\ns41467-021-25442-5. PMID: 34489431. IF: 14,919\n4. Arc-Chagnaud C, Salvador-Pascual A, Garcia-Dominguez E, \nOlaso-Gonzalez G, Correas A, Serna E, Brioche T, Chopard A, \nFernandez-Marcos P, Serrano M, Serrano A, Munoz-Canoves \nP, Sebastia V, Vina J, Carmen Gomez-Cabrera M. Glucose 6-P \ndehydrogenase delays the onset of frailty by protecting against \nmuscle damage. Journal of Cachexia Sarcopenia and Muscle. \n2021 Dec;12(6):1879-1896. doi: 10.1002/jcsm.12792. \nPMID: 34704386. IF: 12,91\n5. Duro-Castano A, Borras C, Herranz-Perez V, Blanco-Gandia \nM, Conejos-Sanchez I, Arminan A, Mas-Bargues C, Ingles M, \nMinarro J, Rodriguez-Arias M, Garcia-Verdugo J, Vina J, Vicent \nM. Targeting Alzheimer\u2019s disease with multimodal polypeptide-\nbased nanoconjugates. Science Advances. 2021 Mar \n26;7(13):eabf9180. doi: 10.1126/sciadv.abf9180. PMID: \n33771874. IF: 14,136\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: DIABFRAIL-LATAM-825546\nTitle: Scaling-up of and evidence-based intervention programme \nin older people with Diabetes and Frailty in LatinAmericaPUBLICATIONS\nIF 24\nNumber of  \narticles150.514IF\n6.271Average6\nCorresponding  \nauthor13\nNational  \ncollaborations8\nInternational \ncollaborations147\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference:  PROMETEO/2019/097 \nTitle: Diferencias de fragilidad entre g\u00e9neros: evaluaci\u00f3n de \nbiomarcadores y estrategias de intervenci\u00f3n \nPrincipal Investigator:  Jos\u00e9 Vi\u00f1a Ribes\nFunding Body: Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary Institution: Universidad de Valencia\nDuration: 2020-2023\nTotal budget:  \u20ac189.391\nTHESIS\nThesis title: Influencia del procesamiento de la leche humana \ndonada sobre la microbiota intestinal, la expresi\u00f3n gen\u00f3mica y el \nequilibrio oxidativo en reci\u00e9n nacidos pret\u00e9rmino menores de 32 \nsemanas de edad gestacional\nDoctoral candidate: Anna Parra Llorca \nDirector(s): M\u00e1ximo Vento, Mar\u00eda Carmen Collado Amores, Eva \nSerna Garc\u00eda\nDate of the defense: 23/02/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD\nThesis title: An\u00e1lisis de la anchura de la cortical vestibular \nen dientes anteriores maxilares y en la planificaci\u00f3n virtual de \nimplantes mediante tomograf\u00edas computarizadas de hazc\u00f3nico\nDoctoral candidate: Julio Rojo Sanchis \nDirector(s): David Pe\u00f1arrocha Oltra, Jose Vi\u00f1a Almunia\nDate of the defense: 30/04/2021\nGrade:  Sobresaliente \u201ccum laude\u201d148\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Researchers by categoriesResearch Group on Anesthesiology and Reanimation\nConsolidated group\nLeading Researcher, R4\nCarlos Tornero Tornero\nHospital. University\nEstablished Researchers, R3\nArmando Maruenda Paulino. University\nGerardo Aguilar Aguilar. Hospital\nMarina Soro Domingo. Hospital. University\nRafael Badenes Quiles. Hospital. University\nRecognised Researchers, R2\nAna Mugarra Llopis. Hospital\nAndrea Guti\u00e9rrez Valc\u00e1rcel. Hospital\nBenigno Escamilla Ca\u00f1ete. Hospital\nJorge Ordu\u00f1a Valls. Hospital \nMar Garzando Civera. Hospital\nMar\u00eda Luisa Garc\u00eda P\u00e9rez. Hospital. University\nRosa Herrera Castro. Hospital \nFirst Stage Researchers, R1\nBlanca Arocas Chicote. Hospital\nStaff. Collaborating Researchers\nAntonio Guillen Ba\u00f1uelos. Hospital\nCristina Cris\u00e1n Ovidiu. Hospital\nErnesto Pastor Mart\u00ednez. HospitalGroup members\nStrategic aims\n\u2022 The effects of advanced monitoring and drugs on hemodynamic management in patients undergoing surgery\n\u2022 Open Lung Approach for the Acute Respiratory Distress Syndrome\n\u2022 Study and development of methods of detection of infections\n\u2022 Development of new strategies and drugs for pain treatment\nMain lines of research\n\u2022 Oxidative stress and protection of organs in ischemia-reperfusion surgery\n\u2022 Ventilatory and pharmacological strategies to decrease organ damage in the lungs associated with mechanical ventilation \nin healthy and injured lungs\n\u2022 Development of hemodynamic monitoring and its application in the field of patients undergoing surgery or admitted to critical \ncare units\n\u2022 Study and development of methods of detection of infections, especially fungal and virological, and how to prevent themwww.anestesiaclinicovalencia.orgWeb4 7 1 14 1R2 R3 R4 STAFF R1\nEstefan\u00eda Gracia Ferr\u00e1ndiz. Hospital\nJos\u00e9 Antonio Carbonell L\u00f3pez. Hospital\nLaura Reviriego Agudo. Hospital\nLiliana Patricia Henao Guerrero. Hospital\nLuis Robert S\u00e1nchez. Hospital\nMar\u00eda Jos\u00e9 Parra Gonz\u00e1lez. Hospital\nMar\u00eda Luisa Laredo Alc\u00e1zar. Hospital\nMario de Fez Barber\u00e1. Hospital\nPaola Valls Montero. Hospital \nStaff . Nurses \nAlicia Garc\u00eda Vigara. INCLIVA\nStaff. Administrative assistant\nNuria Bargues Mart\u00edn. INCLIVA149\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4of a multicenter study. Journal of Clinical Anesthesia. 2021 \nNov;74:110378. doi: 10.1016/j.jclinane.2021.110378. \nPMID: 34144497. IF: 9,452\n4. Padilla M, Coll E, Fernandez-Perez C, Pont T, Ruiz A, Perez-\nRedondo M, Oliver E, Atutxa L, Mancino JM, Daga D, Minambres \nE, Moya J, Vidal B, Duenas-Jurado JM, Mosteiro F, Rodriguez-\nSalgado A, Fernandez-Garcia E, Lara R, Hernandez-Marrero D, \nEstebanez B, Rodriguez-Ferrero ML, Barber M, Garcia-Lopez \nF, Andres A, Santiago C, Zapatero A, Badenes R, Carrizosa \nF, Blanco JJ, Bernal JL, Elola FJ, Vidal C, Terron C, Castro  P, \nComas J, Dominguez-Gil B. Improved short-term outcomes of \nkidney transplants in controlled donation after the circulatory \ndetermination of death with the use of normothermic regional \nperfusion. American Journal of Transplantation. 2021 \nNov;21(11):3618-3628. doi: 10.1111/ajt.16622. PMID: \n33891793. IF: 8,086\n5. COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-\nCoV-2 vaccination modelling for safe surgery to save lives: \ndata from an international prospective cohort study. Bristish \nJournal of Surgery. 2021 Sep 27;108(9):1056-1063. doi: \n10.1093/bjs/znab101. PMID: 33761533. IF: 6,939\u2022 Study and development of therapeutic drug monitoring (TDM) to describe antimicrobials pharmacokinetics (PK) and \ndetermination of minimum inhibitory concentration (MIC)\n\u2022 Development of new strategies and drugs for pain treatment\n\u2022 Development of new strategies and monitoring for Traumatic Brain Injury\n\u2022 Neurocritical patients\n\u2022 Delirium\n\u2022 Critically ill patients with COVID-19\n\u2022 Organ donation\n\u2022 Using PK/PD to optimize antibiotic dosing for critically ill patients\n\u2022 Sepsis and septic shock management\nPUBLICATIONS\nIF 42\nNumber of  \narticles272.621IF\n6.49Average\n11\nCorresponding  \nauthor6\nNational  \ncollaborations34\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Robba C, Graziano F, Rebora P, Elli F, Giussani C, Oddo M, \nMeyfroidt G, Helbok R, Taccone F, Prisco L, Vincent J, Suarez \nJ, Stocchetti N, Citerio G, SYNAPSE-ICU Investigators. \nIntracranial pressure monitoring in patients with acute \nbrain injury in the intensive care unit (SYNAPSE-ICU): an \ninternational, prospective observational cohort study. Lancet \nNeurology. 2021 Jul;20(7):548-558. doi: 10.1016/S1474-\n4422(21)00138-1. PMID: 34146513. IF: 44,182\n2. Pun B, Badenes R, Heras La Calle G, Orun O, Chen W, Raman \nR, Simpson B, Wilson-Linville S, Hinojal Olmedillo B, Vallejo \nde la Cueva A, van der Jagt M, Navarro Casado R, Leal \nSanz P, Orhun G, Ferrer Gomez C, Nunez Vazquez K, Pineiro \nOtero P, Taccone F, Gallego Curto E, Caricato A, Woien H, \nLacave G, O\u2019Neal H, Peterson S, Brummel N, Girard T, Ely \nE, Pandharipande P, COVID-19 Intensive Care International \nStudy Group. Prevalence and risk factors for delirium in \ncritically ill patients with COVID-19 (COVID-D): a multicentre \ncohort study. Lancet. Respiratory Medicine. 2021; 9(3): \n239-250. doi: 10.1016/S2213-2600(20)30552-X. PMID: \n33428871. IF: 30,7\n3. Zorrilla-Vaca A, Stone A, Ripolles-Melchor J, Abad-Motos A, \nRamirez-Rodriguez J, Galan-Menendez P, Mena G, Grant M, \nSpanish Perioperative Audit Res Ne, Spanish Perioperative \nAudit Res Ne, Spanish Perioperative Audit Res Ne. \nInstitutional factors associated with adherence to enhanced \nrecovery protocols for colorectal surgery: secondary analysis 150\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: COV20/00096\nTitle:  Sedaci\u00f3n con sevoflurano en pacientes con S\u00edndrome de \ndistr\u00e9s respiratorio causado por la infecci\u00f3n COVID19\nPrincipal Investigator: Rafael Badenes Quiles\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac21.500\nReference: PI19/00141  \nTitle:  Modelos de estratificaci\u00f3n y predicci\u00f3n en pacientes con \ninsuficiencia respiratoria aguda hipox\u00e9mica con t\u00e9cnicas de \ninteligencia artificial y aprendizaje autom\u00e1tico \nPrincipal Investigator: Jes\u00fas Villar Hern\u00e1ndez (Marina Soro as \ncollaborating researcher)\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Doctor \nNegr\u00edn\nDuration: 2020-2022\nTotal budget:  \u20ac62.920\nReference: PI18/01611\nTitle:  Reducci\u00f3n de complicaciones postoperatorias pulmonares \nmediante una estrategia ventilatoria perioperatoria de apertura \npulmonar individualizada en pacientes intervenidos de cirug\u00eda \ntor\u00e1cica\nPrincipal Investigator: Carlos Mar\u00eda Ferrando Ortol\u00e1 (Francisco \nJavier Belda, Marina Soro, Jos\u00e9 Garc\u00eda de la Asunci\u00f3n as \ncollaborating researchers)\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac134.007,50\nTitle:  Ensayo cl\u00ednico randomizado: hemoabsorci\u00f3n con cytosorb \nvs pr\u00e1ctica cl\u00ednica habitual para analizar su efecto sobre \nbiomarcadores de da\u00f1o renal en la donaci\u00f3n en asistolia \ncontrolada con ECMO\nPrincipal Investigator: Rafael Badenes Quiles\nEntidad financiadora: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2020-2022\nTotal budget:  \u20ac65.000\nReference: SUBCOVERWD-19\nTitle:  Severity subgroup discovery and classification on COVID-19 \nreal world data through machine learning and data quality \nassessment\nPrincipal Investigator: Rafael Badenes Quiles\nFunding body: CRUE-Banco Santander\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac15.000\nTHESIS\nThesis title: Cerebrospinal fluid glucose and lactate concentrations \nafter traumatic brain injury\nDoctoral candidate: Angels Lozano Roig\nDirector(s):  Rafael Badenes Quiles, Armando Maruenda Paulino, \nFabio Silvio Taccone\nDate of the defense: 30/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Delirium en pacientes cr\u00edticos con infecci\u00f3n por \nSARS-CoV-2\nDoctoral candidate: Carolina Ferrer G\u00f3mez\nDirector(s):  Rafael Badenes Quiles, Jos\u00e9 de Andr\u00e9s Ib\u00e1\u00f1ez\nDate of the defense: 19/11/2021\nGrade: Sobresaliente \u201ccum laude\u201d151\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Translational Genomics\nConsolidated group\nLeading Researcher, R4\nRub\u00e9n D. Artero Allepuz. University\nManuel P\u00e9rez Alonso. University\nEstablished Researcher, R3\nArturo L\u00f3pez Castel. University\nRecognised Researchers, R2\nAriadna Bargiela Sch\u00f6nbrunn. University\nEstefan\u00eda Cerro Herreros. University\nPiotr Konieczny. University\nRaquel P\u00e9rez G\u00f3mez. University\nFirst Stage Researchers, R1\n\u00c1gueda Bl\u00e1zquez Bernal. University \nIrene Gonz\u00e1lez Mart\u00ednez. University\nJorge Patricio Espinosa Espinosa. University\nMar\u00eda Sabater Arc\u00eds. University\nNatalia Mariel Riedel Bistoco. University\nNerea Moreno Cervera. University\nSarah Overby. University\nStaff. Technicians\nAndrea Garc\u00eda Rey. INCLIVA\nIv\u00e1n Gimeno Mart\u00ednez. INCLIVAGroup members\nStrategic aims\nDuring 2021 the group has accomplished the publishing of scientific studies based on the main research strategy of looking for \nnew drug candidates for neuromuscular (DM and SMA) rare diseases, but also on more prevalent diseases as those related with \nkidney pathologies. At the same time, it has been established a solid relationship with the spin-off Arhtex Biotech S.L. on the basis \nof several research contracts, on its goal of developing promising molecules with therapeutic potential in DM. The group has been \nawarded with Prometeo funds as \u201cExcellent Research group\u201d involving researchers also from Biodonostia, Biosensors_IBEC and \nIQAC-CSIC. Also significant, our PhD student, Sarah Overby, was one of the recipients for the renowned Grants from Myotonic \nFoundation.\nMain lines of research\n\u2022 Using miRNAs as therapeutic targets in myotonic dystrophy (DM)\n\u2022 Discovery, development, and repurposing of drugs for the treatment of DM\n\u2022 Study of the molecular causes of muscle atrophy, heart dysfunction, and CNS degeneration in DM\n\u2022 Study of the molecular mechanisms associated with spinal muscular atrophy and search for potential therapies\n\u2022 Understanding human podocyte function through Drosophila nephrocytes\n\u2022 Drosophila modeling of limb girdle muscular dystrophy subtype 1F (LGMD1F)Networks\nhttp://www.uv.es/gt/\nhttps://twitter.com/GenomicsLab_UV\nhttps://vimeo.com/user103005442\nhttps://twitter.com/MPAlonso\nhttps://twitter.com/RubenArtero3Researchers by categories\n1 7 2 4 2\nResearchers financed by \ncompetitive public calls or networks\n1 1 6R3 R1 R4 R2 STAFF\nR2 STAFF R1\n152\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Beneficiary Insitution : IIS Biocruces\nDuration: 2018-2022\nTotal Budget: \u20ac500.000\nReference:  PI19/01796\nTitle: Implicaciones experimentales y cl\u00ednicas del complejo proteico \nRabphilin-Rab en da\u00f1o renal en la diabetes mellitus tipo 2\nPrincipal Investigator: Josep Red\u00f3n i Mas (Arturo L\u00f3pez Castel \nas collaborating researcher) \nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia                                                                                                                               \nDuration: 2020-2022\nTotal budget:  \u20ac196.020\nReference:  DTS19/00128\nTitle: Desarrollo precl\u00ednico de un f\u00e1rmaco innovador para Distrofia \nMiot\u00f3nica\nPrincipal Investigator:  Rub\u00e9n Artero Allepuz\nFunding Body: Instituto de Salud Carlos III - Cofinanced FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia                                                                                                                               \nDuration: 2020-2022\nTotal budget:  \u20ac111.100\nReference : RTI2018-094599-B-I00\nTitle: Comprensi\u00f3n de las causas moleculares de la atrofia \nmuscular en distrofia miot\u00f3nica tipo 1\nPrincipal Investigator : Rub\u00e9n Artero Allepuz\nFunding Body: Ministerio de Ciencia, Innovaci\u00f3n y Universidades\nBeneficiary Institution : Universidad de Valencia\nDuration: 2019-2021\nTotal budget : \u20ac185.000\nReference:  INNVA1/2021/44\nTitle: Reposicionamiento de un f\u00e1rmaco para atrofia muscular \nespinal\nPrincipal Investigator:  Rub\u00e9n Artero AllepuzPUBLICATIONS\nIF 11\nNumber of  \narticles86.2IF\n7.84Average7\nCorresponding  \nauthor6\nNational  \ncollaborations2\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Klionsky D, Abdel-Aziz A, Abdelfatah S, et al. Guidelines for the \nuse and interpretation of assays for monitoring autophagy \n(4th edition). Autophagy. 2021 Jan;17(1):1-382. doi: \n10.1080/15548627.2020.1797280. PMID: 33634751. \nIF: 16,016\n2. Fernandez-Garibay X, Ortega MA, Cerro-Herreros E, Comelles \nJ, Martinez E, Artero R, Fernandez-Costa JM, Ramon-Azcon J. \nBioengineered in vitro 3D model of myotonic dystrophy type 1 \nhuman skeletal muscle. Biofabrication. 2021 Apr 26;13(3). doi: \n10.1088/1758-5090/abf6ae. PMID: 33836519. IF: 9,954\n3. Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-Garcia \nJ, Vilchez J, Artero R. Musashi-2 contributes to myotonic \ndystrophy muscle dysfunction by promoting excessive \nautophagy through miR-7 biogenesis repression. Molecular \nTherapy-Nucleic Acids. 2021 Aug 19;25:652-667. doi: \n10.1016/j.omtn.2021.08.010. PMID: 34589284. IF: 8,886\n4. Cerro-Herreros E, Gonzalez-Martinez I, Moreno N, Espinosa-\nEspinosa J, Fernandez-Costa JM, Colom-Rodrigo A, Overby \nSJ, Seoane-Miraz D, Poyatos-Garcia J, Vilchez JJ, Lopez de \nMunain A, Varela MA, Wood MJ, Perez-Alonso M, Llamusi B, \nArtero R. Preclinical characterization of antagomiR-218 as a \npotential treatment for myotonic dystrophy. Molecular Therapy. \nNucleic Acids. 2021 Jul 29;26:174-191. doi: 10.1016/j.\nomtn.2021.07.017. PMID: 34513303. IF: 8,886\n5. Blazquez-Bernal A, Fernandez-Costa JM, Bargiela A, Artero R. \nInhibition of autophagy rescues muscle atrophy in a LGMDD2 \nDrosophila model. FASEB Journal. 2021 Oct;35(10):e21914. \ndoi: 10.1096/fj.202100539RR. PMID: 34547132. IF: 5,191\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : CA17103 COST-DARTER\nTitle: COST: European Cooperation in Science and Technology, \nDelivery of Antisense RNA Therapeutics (DARTER) \nPrincipal Investigator: Virginia Arechavala (Rub\u00e9n Artero Allepuz \nas Co-IP)\nFunding Body: European Commission153\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Funding Body: Agencia Valenciana de la Innovaci\u00f3n-AVI Generalitat \nValenciana \nBeneficiary Institution : Universidad de Valencia\nDuration: 2021-2023\nTotal budget:  \u20ac487.727\nReference:  PROMETEO/2020/081\nTitle: Uso de moduladores de microRNAs como terapias \nexperimentales en distrofia miot\u00f3nica de tipo 1\nPrincipal Investigator:  Rub\u00e9n Artero Allepuz\nFunding Body: Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary Institution : Universidad de Valencia\nDuration: 2020 - 2023\nTotal budget:  \u20ac193.051\nReference:  CI21-00135\nTitle: Valorization of the repurposing of two drug candidates for \nspinal muscular atrophy\nPrincipal Investigator:  Rub\u00e9n Artero Allepuz\nFunding Body: Fundaci\u00f3 Banc\u00e0ria La Caixa\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia                                                                                                                               \nDuration: 2021-2023\nTotal budget:  \u20ac100.000\nReference:  HR17-00268\nTitle:  TATAMI (TherApeutic TArgeting of MIrnas) therapeutic \ntargeting of MBNL microRNAs as innovative treatments for \nmyotonic dystrophy\nPrincipal Investigator:  Rub\u00e9n Artero Allepuz\nFunding Body: Fundaci\u00f3 Banc\u00e0ria La Caixa\nBeneficiary Institution : Universidad de Valencia\nDuration: 2018-2021\nTotal budget:  \u20ac997.023Title:  Restoration of MBNL proteins through miRNA blocking as \nDM1 therapy\nPrincipal Investigator:  Rub\u00e9n Artero Allepuz\nFunding Body: Myotomic Distrophy Foundation\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia                                                                                                                               \nDuration: 2020-2021\nTotal budget:  \u20ac48.000\nReference:  PI-2021-008\nTitle:  miR-OA: Inhibidores de miRNAs como terapia en osteoartritis\nPrincipal Investigator:  Rub\u00e9n Artero Allepuz\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution : Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget:  \u20ac19.000\nReference:  GV/2021/014\nTitle:  Caracterizaci\u00f3n de la contribuci\u00f3n de MSI2 a la atrofia \nmuscular de DM1 utilizando nuevos modelos celulares y murinos\nPrincipal Investigator:  Ariadna Bargiela Sch\u00f6nbrunn\nFunding Body:  Conselleria de Innovaci\u00f3n, Universidades, Ciencia \ny Sociedad Digital\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal budget: \u20ac10.000154\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on General and Digestive Surgery\nConsolidated group\nLeading Researcher, R4\nJoaqu\u00edn Ortega Serrano\nHospital. University\nEstablished Researchers, R3\nAlejandro Esp\u00ed Mac\u00edas. Hospital. University\nLuis Sabater Ort\u00ed. Hospital. University\nRecognised Researchers, R2\nDavid Casado Rodrigo. Hospital\nDavid Moro Valdezate. Hospital. University\nDimitri Dorcaratto. Hospital. University\nElena Mu\u00f1oz Forner. Hospital. University\nEstefan\u00eda Garc\u00eda Botello. Hospital. University\nFernando L\u00f3pez Mozos. Hospital. University\nJos\u00e9 Mart\u00edn Ar\u00e9valo. Hospital. University\nJulio Calvete Chornet. Hospital. University\nMarina Garc\u00e9s Albir. Hospital. University\nNorberto Cassinello Fern\u00e1ndez. Hospital. University\nRaquel Alfonso Ballester. Hospital\nRoberto Mart\u00ed Obiol. Hospital\nVicente Pla Mart\u00edn. Hospital\nFirst Stage Researchers, R1\nCarlos Le\u00f3n Espinoza. Hospital\nGemma Bellver Lobato. Hospital\nIsabel Mora Oliver. Hospital\nMar\u00eda Lape\u00f1a Rodr\u00edguez. HospitalGroup members\nStrategic aims\n\u2022 Research about the incidence of pandemic COVID19 on surgery\n\u2022 Development of 3D modelling for hepatic and pancreatic tumours\n\u2022 Research about the influence of postoperative complications on the oncologic outcome of metastatic disease\n\u2022 Development of a protocol for the outpatient treatment of hyperparathyroidism\n\u2022 Research about the revisional techniques within the bariatric surgery\nMain lines of research\n\u2022 Coloproctology: quality standards for coloproctology, 3D endorectal ultrasound, sacral neuromodulation and perianal fistula \nsurgeryResearchers by categories\n2 13 1 5 6R2 R3 R4 STAFF R1\nLeticia P\u00e9rez Santiago. Hospital\nM\u00aa Carmen Fern\u00e1ndez Moreno. Hospital\nStaff. Collaborating Researchers\nElena Mart\u00ed Cu\u00f1at. Hospital\nMarcos Adrianz\u00e9n Vargas. Hospital\nMar\u00eda Eugenia Barrios Carvajal. Hospital\nRosa Mart\u00ed Fern\u00e1ndez. Hospital\nVicente L\u00f3pez Flor. Hospital155\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 45. Fernandez Moreno M, P\u00e9rez Santiago L, Mart\u00ed Fernandez R, \nLe\u00f3n Espinoza C, Ortega Serrano J. Is laparoscopic approach still \na risk factor for post-appendectomy intra-abdominal abscess?. \nJournal of Trauma and Acute Care Surgery. 2021 Jan \n1;90(1):163-169. doi: 10.1097/TA.0000000000002957. \nPMID: 33003018. IF: 3,313\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  PI19/00250\nTitle: Anastomosis pancre\u00e1tica tras duodenopancreatectom\u00eda \ncef\u00e1lica: pancreatogastrostom\u00eda versus anastomosis de Blumgart. \nEstudio prospectivo, aleatorizado y multic\u00e9ntrico\nPrincipal  Investigator: Luis Sabater Ort\u00ed\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal  Budget:  \u20ac85.910\nReference:  PI20/00008\nTitle: Transecci\u00f3n pancre\u00e1tica asistida por radiofrecuencia vs \nendograpadora. TRANSPAIRE. Ensayo cl\u00ednico en fase III\nPrincipal  Investigator: Patricia S\u00e1nchez Vel\u00e1zquez (Dimitri \nDorcaratto, Marina Garc\u00e9s, Elena Mu\u00f1oz and Luis Sabater as \ncollaborating researchers)PUBLICATIONS\nIF 42\nNumber of  \narticles294.949IF\n7.022Average16\nCorresponding  \nauthor16\nNational  \ncollaborations12\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Lopez-Lopez V, Gomez-Perez B, de Vicente E, Jimenez-Galanes \nS, Mora-Oliver I, Sabater L, Huber T, Lang H, Brusadin R, \nLopez Conesa A, Melendez R, Castro Santiago MJ, Ferreras \nD, Crespo MJ, Cayuela V, Robles-Campos R. Next-generation \nthree-dimensional modelling software for personalized \nsurgery decision-making in perihilar cholangiocarcinoma: \nmulticentre study. British Journal of Surgery. 2021 Dec \n1;108(12):e394-e395. doi: 10.1093/bjs/znab320. PMID: \n34542590. IF: 6,939\n2. Garcia Fadrique A, Estevan Estevan R, Sabater Orti L. ASO visual \nabstract: quality standards for surgery of colorectal peritoneal \nmetastasis after cytoreductive surgery and hyperthermic \nintraperitoneal chemotherapy. Annals of Surgical Oncology. \n2021 Dec;28(Suppl 3):647. doi: 10.1245/s10434-021-\n10681-z. PMID: 34432194. IF: 5,344\n3. Pla Mart\u00ed V, Martin Arevalo J, Moro Valdezate D, Garcia Botello \nS, Mora Oliver I, Gadea Mateo R, C\u00f3zar Lozano C, Esp\u00ed Macias \nA. Impact of the novel powered circular stapler on risk of \nanastomotic leakage in colorectal anastomosis: a propensity \nscore-matched study. Techniques in Coloproctology. 2021 \nMar;25(3):279-284. doi: 10.1007/s10151-020-02338-y. \nPMID: 32914268. IF: 3,781\n4. Garcia-Botello S, Garces-Albir M, Espi-Macias A, Moro-\nValdezate D, Pla-Marti V, Martin-Arevalo J, Ortega-Serrano J. \nSphincter damage during fistulotomy for perianal fistulae and \nits relationship with faecal incontinence. Langenbecks Archives \nof Surgery. 2021 Nov;406(7):2497-2505. doi: 10.1007/\ns00423-021-02307-5. PMID: 34468863. IF: 3,445\u2022 Hepato-bilio-pancreatic surgery: acute pancreatitis, gene transfection, pancreatic-duodenectomy\n\u2022 Endocrine surgery: laparoscopic adrenal tumors, parathyroid adenomas intraoperative localization, ambulatory surgery in \nhyperparathyroidism\n\u2022 Bariatric surgery: pathophysiology of postoperative changes after bariatric surgery\n\u2022 Breast surgery: fibrin sealants in seroma. Selective sentinel node biopsy. Axilla assessment in DCIS\n\u2022 Gastroesophageal surgery: mutations in GIST tumors, overexpression of HER2 and HER3 in gastric tumors, perioperative \nQT in advanced gastric cancer, preoperative gastric arteries embolization in esophageal surgery, PIPAC technique in \ncarcinomatosis surgery156\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Funding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Instituto Hospital del Mar de Investigaciones \nM\u00e9dicas. IMIM\nDuration: 2021-2023\nTotal  Budget:  \u20ac75.020\nTitle: Utilidad de la biopsia l\u00edquida y organoides en el manejo y \ntratamiento de adenocarcinoma de p\u00e1ncreas: hacia una medicina \nde precisi\u00f3n\nPrincipal  Investigator: Maider Ibarrola Villava (Luis Sabater and \nMarina Garc\u00e9s as collaborating researchers)\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal  Budget:  \u20ac100.000\nTitle: Proyecto RENACI\nPrincipal  Investigator: Mario Serradilla Mart\u00edn (Luis Sabater Ort\u00ed \nas collaborating researcher)\nFunding Body: Asociaci\u00f3n Espa\u00f1ola de Cirujanos\nBeneficiary institution: Hospital Universitario Miguel Servet de \nZaragoza\nDuration: 2020-2022157\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Personal Autonomy, Dependence and Severe Mental \nDisorders (TMAP)  \nConsolidated group\nLeading Researcher, R4\nRafael Tabar\u00e9s Seisdedos. University\nManuel G\u00f3mez Beneyto. University\nEstablished Researchers, R3\nFerr\u00e1n Catal\u00e1 L\u00f3pez. INCLIVA\nGabriel Selva Vera. Hospital. University\nInmaculada Fuentes Dur\u00e1. University\nJos\u00e9 Salazar Fraile. INCLIVA\nManuel Gir\u00f3n Gim\u00e9nez. INCLIVA\nMikel Munarriz Ferrandis. INCLIVA\nPatricia Correa Ghisays. University\nRecognised Researchers, R2\nConstanza San Mart\u00edn Valenzuela. University\nDiego Mac\u00edas Saint-Geroms. INCLIVA\nJaume For\u00e9s Martos. INCLIVAGroup members\nStrategic aims\n\u2022 Contribute to the prevention of signs of frailty and cognitive and functional impairment in populations at risk\n\u2022 Favor the identification of biomarkers and endophenotypes associated with cognitive deficits and functional impairment in \npeople with severe mental disorders and other chronic diseases that occur with deterioration in these areas\n\u2022 Understand the unexpected associations between apparently different diseases such as Cancer and diseases of the Central \nNervous System\n\u2022 Continue studies of the increased burden of disease due to mental disorders and neurological diseases such as dementia\n\u2022 Participate in expert groups to reach consensus on nutritional medicine and other clinical practices in modern psychiatry\nMain lines of research\n\u2022 Validation and identification of neurocognitive endophenotypes in severe mental disorder \n\u2022 Identification of biomarkers in severe mental disorder \n\u2022 Epidemiology and disability associated with severe mental disorder \n\u2022 Direct and inverse multimorbidity in patients with complex diseases such as central nervous system disorders, cancer or \nmetabolic diseases \n\u2022 Global Burden of Disease studies \n\u2022 Nutritional Psychiatry \n\u2022 Transdiagnostic cognitive impairment, pre-frailty or frailty, and decreased social functioning in severe mental disorder and \nother diseases with chronic development \n\u2022 COVID-19 pandemic and neurocognition, frailty, and social functioning in severe mental disorder and other diseases with \nchronic developmentResearchers by categories\n7 3 2 1R2 R3 R4 R1\nTeam involved in\nFirst Stage Researchers, R1\nJoan Vicent S\u00e1nchez Ort\u00ed. INCLIVA158\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\nIF 25\nNumber of  \narticles334.274IF\n13.37Average7\nCorresponding  \nauthor10\nNational  \ncollaborations14\nInternational \ncollaborations\nFunctional Capacity Tool (VRFCAT) para su uso en Espa\u00f1a\nPrincipal Investigator: Rosa Ayesa Arriola (Patricia Correa as \ncollaborating researcher)\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Instituto de Investigaci\u00f3n \nMarqu\u00e9s de Valdecilla (IDIVAL)\nDuration: 2021-2023\nTotal budget:  \u20ac87.120\nReference : CB07/09/0021\nTitle: CIBER de Enfermedades Mentales (CIBERSAM)\nPrincipal  Investigator: Rafael Tabar\u00e9s Seisdedos\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution : CIBERSAM\nDuration: 2015-\nReference : UV-INV-AE-1554362\nTitle: Estigma social hacia personas con diagn\u00f3stico de esquizofrenia \nen estudiantes universitarios: PREVAL\nPrincipal  Investigator: Rafael Tabar\u00e9s Seisdedos\nFunding Body: Universidad de Valencia\nBeneficiary institution : Universidad de Valencia\nDuration: 2021-2022\nTotal budget:  \u20ac7.510\nReference : UV-INV-AE19-1199985\nTitle: Evaluaci\u00f3n de un programa de musicoterapia en pacientes \ncon trastorno mental grave\nPrincipal  Investigator: Inmaculada Fuentes Dur\u00e1\nFunding Body: Universidad de Valencia\nBeneficiary institution : Universidad de Valencia\nDuration: 2020-2021\nTotal budget:  \u20ac6.930\nReference : 201904DMC\nTitle: Drug safety and effectiveness network methods and SELECTED PUBLICATIONS\n1. GBD 2019 Under-5 Mortality Collaborators. Global, regional, \nand national progress towards Sustainable Development \nGoal 3.2 for neonatal and child health: all-cause and cause-\nspecific mortality findings from the Global Burden of Disease \nStudy 2019. Lancet. 2021 Sep 4;398(10303):870-905. doi: \n10.1016/S0140-6736(21)01207-1. PMID: 34416195. IF: \n79,321\n2. Global Burden Dis Hlth Financing. Tracking development \nassistance for health and for COVID-19: a review of \ndevelopment assistance, government, out-of-pocket, and other \nprivate spending on health for 204 countries and territories, \n1990-2050. Lancet. 2021 Oct 9;398(10308):1317-1343. \ndoi: 10.1016/S0140-6736(21)01258-7. PMID: 34562388. \nIF: 79,321\n3. Kinyoki D, Osgood-Zimmerman A, Bhattacharjee N, Kassebaum \nN, Hay S, Local Burden Dis Anaemia Collab. Anemia prevalence \nin women of reproductive age in low- and middle-income \ncountries between 2000 and 2018. Nature Medicine. 2021 \nOct;27(10):1761-1782. doi: 10.1038/s41591-021-01498-\n0. PMID: 34642490. IF: 53,44\n4. GBD 2019 Resp Tract Canc Collab. Global, regional, and \nnational burden of respiratory tract cancers and associated \nrisk factors from 1990 to 2019: a systematic analysis for \nthe Global Burden of Disease Study 2019. Lancet Respiratory \nMedicine. 2021 Sep;9(9):1030-1049. doi: 10.1016/S2213-\n2600(21)00164-8. PMID: 34411511. IF: 30,7\n5. Ayesa-Arriola R, Miguel-Corredera M, de la Foz Ortiz-Garcia \nV, Neergaard KD, Correa-Ghisays P, Setien-Suero E, Crespo-\nFacorro B. Education and long-term outcomes in first episode \npsychosis: 10-year follow-up study of the PAFIP cohort. \nPsychological Medicine. 2021 May 6;1-12. doi: 10.1017/\nS0033291721001112. PMID: 33952364. IF: 7,723\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : PI20/00066 \nTitle: Adaptaci\u00f3n y validaci\u00f3n de la bater\u00eda cognitiva Brief Assessment \nof Cognition App (BAC App) y del Virtual Reality Assessment of 159\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4apllications group in indirect comparisons (DSEN MAGIC) Team\nPrincipal Investigator: Hutton B, Moher D, Straus SE, Wells G \n(Ferr\u00e1n Catal\u00e1 as collaborating researcher)\nFunding Body: Canadian Institutes of Health Research/Drug \nSafety and Effectiveness Network\nBeneficiary institution : CIBERSAM\nDuration: 2019-2023\nTotal budget:  \u20ac2.875.010,8\nTHESIS\nThesis title: Efectos de un programa de intervenci\u00f3n psicoeducativa \nen la calidad de vida de los/las pacientes durante sus tratamientos \nde Reproducci\u00f3n Asistida\nDoctoral candidate: Ruth Elizabeth Abad Villavicencio \nDirector(s): Inmaculada Fuentes Dur\u00e1, Carmen Das\u00ed Vivo, M\u00f3nica \nRomeu Villarroya  \nDate of the defense: 21/05/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Epidemiological and molecular associations between \ncentral nervous system disorders and cancer\nDoctoral candidate: Jaume For\u00e9s M\u00e1rtos\nDirector(s): Rafael Tabar\u00e9s Seisdedos, Ferr\u00e1n Catal\u00e1 L\u00f3pez, \nJoan Climent Bataller\nDate of the defense: 21/07/2021\nGrade: Sobresaliente \u201ccum laude\u201d160\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Cellular and Organic Physiopathology of Oxidative Stress  \nConsolidated group\nLeading Researcher, R4\nFederico V. Pallard\u00f3 Calatayud \nUniversity\nEstablished Researchers, R3\nCarlos Rom\u00e1 Mateo. University\nJos\u00e9 Manuel Torres Ib\u00e1\u00f1ez. University\nPilar Gonz\u00e1lez Cabo. University. CIBER\nEmerging Researcher, R2\nJuan Antonio Navarro Langa. INCLIVA\nRecognised Researchers, R2\nMarta Seco Cervera. CIBER\nNoelia Benet\u00f3 Gand\u00eda. CIBER\nFirst Stage Researchers, R1\nConcepci\u00f3n Garc\u00e9s D\u00edaz. University\nLaura Rodr\u00edguez Robles. CIBER\nTamara Lape\u00f1a Luz\u00f3n. University. CIBER\nVicent Beltr\u00e1n Beltr\u00e1n. CIBERGroup members\nStrategic aims\n\u2022 Remarkable achievements are the extension to PCT phase of the European patent \u201cMass spectrometry-based methods for the \ndetection of circulating histones H3 and H2B in plasma from sepsis or septic shock (ss) patients\u201d (PCT/EP2017/078362)\n\u2022 Development of new therapies for the treatment of neuromuscular diseases\n\u2022 Development of new therapies for the treatment of neurodegenerative diseases\nMain lines of research\n\u2022 Pathophysiology of Friedreich\u2019s Ataxia and other neuromuscular diseases\n\u2022 Development of new therapeutic strategies for Friedreich\u2019s Ataxia\n\u2022 Development of new biomarkers in both adult and neonatal sepsis\n\u2022 Epigenetic regulation in the pathophysiology of rare diseases\n\u2022 Epigenetic regulation of immunosuppression events in patients from Intensive Care Units\nResearchers by categories\n3 3 4 1\nResearchers financed by \ncompetitive public calls or networks\n1 2 4R2 R3 R1 R4\nR3 R2 R1\nTeam involved in\nEmerging Researcher\nJuan Antonio Navarro Langa\nOur scientific interests are focused on deciphering the programmed death mechanism followed by cells in Friedreich\u00b4s Ataxia patients \nusing Drosophila melanogaster models. With Filippo Santorelli (University of Pisa), he is establishing a translational platform using Droso-\nphila to model hereditary spastic paraplegia161\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 18\nNumber of  \narticles105.824IF\n5.879Average8\nCorresponding  \nauthor6\nNational  \ncollaborations4\nInternational \ncollaborations\nReference: CB06/07/0073\nTitle: CIBER de Enfermedades Raras (CIBERer)\nPrincipal Investigator: Federico V. Pallard\u00f3 Calatayud\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Universidad de Valencia\nDuration: 2007-\nTitle: S\u00edndrome de CANVAS: diagn\u00f3stico precoz y modelo \nfisiopatol\u00f3gico mediante iPSC\nPrincipal  Investigator: Pilar Gonz\u00e1lez Cabo\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : CIBER de Enfermedades Raras (CIBERer)\nDuration: 2021-2022\nTotal  budget: \u20ac75.020\nReference: ACCI-CIBERER 2019-22\nTitle: Degradaci\u00f3n de la huntingtina mediante ubiquibodies de \ncam\u00e9lidos\nPrincipal Investigator: Pilar Gonz\u00e1lez Cabo (CoIP)\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: CIBER de Enfermedades Raras (CIBERer)\nDuration: 2020-2022\nTotal  budget: \u20ac49.700\nReference: ACCI-CIBERER 2018\nTitle: Edici\u00f3n G\u00e9nica del Gen FXN mediante el Sistema CRISPR/\nCas9 en linfocitos de pacientes con Ataxia de Friedreich\nPrincipal Investigator: Pilar Gonz\u00e1lez Cabo\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  CIBER de Enfermedades Raras (CIBERer)\nDuration: 2019-2021\nTotal  budget: \u20ac39.750\nReference: PID2020-115190RB-I00\nTitle: Relacionando cofilina, una prote\u00edna de uni\u00f3n a actina, con \nla desregulaci\u00f3n del calcio: un enfoque de precisi\u00f3n para el \ntratamiento de la Ataxia de FriedreichSELECTED PUBLICATIONS\n1. Garcia-Gimenez J, Garces C, Roma-Mateo C, Pallardo F. Oxidative \nstress-mediated alterations in histone post-translational \nmodifications. Free Radical Biology & Medicine. 2021 Jul;170:6-\n18. doi: 10.1016/j.freeradbiomed.2021.02.027. PMID: \n33689846. IF: 7,376\n2. Lorente-Pozo S, Navarrete P, Garz\u00f3n MJ, Lara-Cant\u00f3n I, Beltr\u00e1n-\nGarc\u00eda J, Osca-Verdegal R, Mena-Moll\u00e1 S, Garc\u00eda-L\u00f3pez E, \nVento M, Pallard\u00f3 FV, Garc\u00eda-Gim\u00e9nez JL. DNA methylation \nanalysis to unravel altered genetic pathways underlying early \nonset and late onset neonatal sepsis. A pilot study. Frontiers \nin Immunology. 2021 Feb 15;12:622599. doi: 10.3389/\nfimmu.2021.622599. PMID: 33659006. IF: 7,561\n3. Pallardo Calatayud F, Pagano G, Rodriguez Melguizo L, Gonz\u00e1lez \nCabo P, Lyakhovich A, Trifuoggi M. Friedreich Ataxia: current \nstate-of-the-art, and future prospects for mitochondrial-focused \ntherapies. Translational Research. 2021 Mar;229:135-141. \ndoi: 10.1016/j.trsl.2020.08.009. PMID: 32841735. IF: 7,012\n4. Roma-Mateo C, Garcia-Gimenez J. Oxidative stress and rare \ndiseases: from molecular crossroads to therapeutic avenues. \nAntioxidants. 2021 Apr 16;10(4):617. doi: 10.3390/\nantiox10040617. PMID: 33923815. IF: 6,312\n5. Fatmi A, Chabni N, Cernada M, Vento M, Gonzalez-Lopez M, Aribi \nM, Pallardo FV, Garcia-Gimenez JL. Clinical and immunological \naspects of microRNAs in neonatal sepsis. Biomedicine & \nPharmacotherapy. 2021 Nov 19;145:112444. doi: 10.1016/j.\nbiopha.2021.112444. PMID: 34808550. IF: 6,529\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI19/01084\nTitle: Nuevas terapias en Ataxia de\u00a0Friedreich \nPrincipal  Investigator: Federico V. Pallard\u00f3 Calatayud\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal  budget: \u20ac93.170162\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Principal  Investigator: Pilar Gonz\u00e1lez Cabo\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary institution: CIBER de Enfermedades Raras (CIBERer)\nDuration: 2021-2023\nTotal  budget: \u20ac196.300\nReference: PID2020-119127RA-I00\nTitle: Citotoxicidad mediada por macromol\u00e9culas nucleares: \nmecanismos moleculares y potencial para el desarrollo de \nbiomarcadores de sepsis y choque s\u00e9ptico\nPrincipal  Investigator: Carlos Rom\u00e1 Mateo\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary Institution : Universidad de Valencia\nDuration: 2021-2024\nTotal  budget: \u20ac121.000\nReference: RTC2019-006825-1  \nTitle: Potencial de la leriglitazona para el tratamiento de \nenfermedades asociadas a la acumulaci\u00f3n de hierro, distrofias y \nenfermedades neuromusculares\nPrincipal Investigator: Pilar Gonz\u00e1lez Cabo \nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary institution: CIBER de Enfermedades Raras (CIBERer)\nDuration: 2020-2023\nTotal  budget: \u20ac505.061 \nReference: CDEI-04/20-C\nTitle:  Drosophila melanogaster as model to study the impact of \nferroptosis in Friedreich\u00b4s Ataxia\nPrincipal  Investigator: Juan Antonio Navarro Langa\nFunding Body: Conselleria de Sanidad Universal y Salud P\u00fablica\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2023\nTotal  budget: \u20ac246.500\nReference:  PROMETEO 2018/135\nTitle:  From genes to therapy in neurodegenerative and \nneuromuscular disorders\nPrincipal Investigator: Federico V. Pallard\u00f3 Calatayud\nFunding Body:  Conselleria de Educaci\u00f3n, Investigaci\u00f3n, Cultura y \nDeporte\nBeneficiary Institution : Universidad de Valencia\nDuration: 2018-2021\nTotal  Budget:  \u20ac310.506Reference:  90/C/2020\nTitle: Therapeutical strategies for cystinuria\nPrincipal  Investigator: Federico V. Pallard\u00f3 Calatayud\nFunding Body: Marat\u00f3 TV3\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal  budget: \u20ac35.580\nReference:  AP-2021-009\nTitle: NATAX: Nanozimas como aproximaci\u00f3n terap\u00e9utica para el \ntratamiento del estr\u00e9s oxidativo en la Ataxia de Friedreich\nPrincipal  Investigator: Jos\u00e9 Vicente Ros Lis and Federico V. \nPallard\u00f3 Calatayud\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution : Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal  budget: \u20ac4.750\nReference:  AP-2021-014\nTitle: FlyAvatar: Drosophila melanogaster como herramienta de \ndiagn\u00f3stico molecular para la Paraparesia Esp\u00e1stica Hereditaria \n7 (HSP7)\nPrincipal  Investigator: M\u00aa Jos\u00e9 Mart\u00ednez Sebasti\u00e1n and Juan \nAntonio Navarro Langa\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution : Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal  budget: \u20ac4.750\nReference:  AP-2021-019\nTitle: HISTONATTR: Efecto de la activaci\u00f3n de TLR por medio de \nsus ligandos sobre la polarizaci\u00f3n de macr\u00f3fagos hacia M1 y su \nfunci\u00f3n citocida frente a las c\u00e9lulas madre de glioblastoma\nPrincipal  Investigator: Carlos Rom\u00e1 Mateo and Enrique Santas \nOlmeda\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Institution : Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal  budget: \u20ac4.750163\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4THESIS\nThesis title:  Modelo celular a partir de IPSC de la enfermedad \nCharcot-Marie-Tooth causada por la ausencia de GDAP1\nDoctoral candidate: Mar\u00eda \u00c1ngeles Le\u00f3n Rodr\u00edguez  \nDirector(s): Jos\u00e9 Manuel Torres Ib\u00e1\u00f1ez\nDate of the defense: 16/04/2021  \nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Prote\u00ednas nucleares y otros mediadores de inflamaci\u00f3n \nen pacientes en shock s\u00e9ptico sometidos a terapias de reemplazo \nrenal\nDoctoral candidate: M\u00f3nica Crespo G\u00f3mez\nDirector(s): Manuel Cervera Montes, Federico V. Pallard\u00f3 \nCalatayud, Carlos Rom\u00e1 Mateo \nDate of the defense: 25/06/2021\nGrade: Sobresaliente \u201ccum laude\u201d164\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Inflammation: Metabolism and Organic Damage line\nEmerging group\nLeading Researcher, R4\nLaura Piqueras Ruiz\nUniversity. INCLIVA\nFirst Stage Researchers, R1\nLuisa Mar\u00eda Hueso Soler. INCLIVA \nRebeca Ortega Herr\u00e1iz. INCLIVA\nStaff. Collaborating Researcher\nMireia L\u00f3pez Riera. INCLIVAGroup members\nStrategic aims\n\u2022 Identification of new mechanisms involved in angiogenesis and inflammation in obese patients:\n- Study and characterization of the role of the CCR4 receptor and its ligands CCL17/TARCE, CCL22/MDC and CKLF1 in \nangiogenesis and inflammation associated with obesity and in response to bariatric surgery\n- Characterization of the role of constitutive nuclear receptors for androstane (CAR) in endothelial dysfunction and angiogenesis \nassociated with obesity and in response to bariatric surgery\n\u2022 Identification of new mechanisms involved in angiogenesis and inflammation in acute myocardial infarction. Role of the \nantiangiogenic isoform VEGF165b:\n- Determination of VEGF-A165b levels in patients with STEMI and its relationship with microvascular obstruction\n- To study the effects of the neutralization of the VEGF-165b isoform in a mouse model with acute myocardial infarction\n\u2022 Study of the role of the SGLT2 transporter in the development of abdominal aortic aneurysm:\n- To evaluate the effect of empagliflozin, an SGLT2 inhibitor, in an animal model of abdominal aortic aneurysm and to investigate \nthe possible anti-inflammatory effect of empagliflozin on endothelial dysfunction\nMain lines of research\n\u2022 Identification of new mechanisms involved in angiogenesis and inflammation in obese patients. Role of CCR4 chemokine \nreceptor ligands and constitutive nuclear androstane receptors\n\u2022 Identification of new mechanisms involved in angiogenesis and inflammation in acute myocardial infarction. Role of the \nantiangiogenic isoform VEGF165b\n\u2022 Study of the SGLT2 transporter in the development of abdominal aortic aneurysmResearchers by categories\n2 1 1\nResearchers financed by \ncompetitive public calls or networks\n1 1 1R1 R4 STAFF\nSTAFF R4 R1\nPUBLICATIONS\nIF 8\nNumber of  \narticles38.299IF\n4.787Average4\nCorresponding  \nauthor1\nNational  \ncollaborations0\nInternational \ncollaborations165\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4SELECTED PUBLICATIONS\n1. Ortega R, Hueso L, Benito E, Ortega J, Civera M, Sanz M, Real \nJ, Piqueras L. The nuclear retinoid-related orphan receptor \nRORalpha controls adipose tissue inflammation in patients \nwith morbid obesity and diabetes. International Journal of \nObesity. 2021 Jul;45(7):1369-1381. doi: 10.1038/s41366-\n021-00787-5. PMID: 33637954. IF: 5,095\n2. Ascaso P, Palanca A, Martinez-Hervas S, Sanz MJ, Ascaso \nJF, Piqueras L, Real JT. Peripheral blood levels of CXCL10 \nare a useful marker for diabetic polyneuropathy in subjects \nwith type 2 diabetes. International Journal of Clinical Practice. \n2021 Aug;75(8):e14302. doi: 10.1111/ijcp.14302. PMID: \n33930221. IF: 2,503\n3. Rios Navarro C, Hueso Soler L, Diaz Cuevas A, Marcos \nGarc\u00e9s V, Bonanad Lozano C, Ruiz Sauri A, Vila Salinas J, \nSanz Ferrando M, Chorro Gasc\u00f3 F, Piqueras Ruiz L, Bod\u00ed \nPeris V. Role of antiangiogenic VEGF-A165b in angiogenesis \nand systolic function after reperfused myocardial infarction. \nRevista Espanola de Cardiologia (English ed.). 2021 \nFeb;74(2):131-139. doi: 10.1016/j.rec.2020.03.013. \nPMID: 32474003. IF: 4,753\n4. Lopez-Riera M, Ortega R, Hueso L, Montesinos MC, Gomez-\nCabrera MC, Sanz MJ, Real JT, Piqueras L. Activation of \nthe constitutive androstane receptor inhibits leukocyte \nadhesiveness to dysfunctional endothelium. International \nJournal of Molecular Sciences. 2021 Aug 27;22(17):9267. \ndoi: 10.3390/ijms22179267. PMID: 34502180. IF: 5,923\n5. Herrero-Cervera A, Espinos-Estevez C, Martin-Vano S, \nTaberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, \nMartinez-Hervas S, Gonzalez-Navarro H. Dissecting abdominal \naortic aneurysm is aggravated by genetic inactivation of \nLIGHT (TNFSF14). Biomedicines. 2021 Oct 22;9(11):1518. \ndoi: 10.3390/biomedicines9111518. PMID: 34829747. IF: \n6,081\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  PI18/00209\nTitle:  Identificaci\u00f3n de nuevos mecanismos implicados en la \nangiog\u00e9nesis e inflamaci\u00f3n en pacientes obesos. Modulaci\u00f3n por \nligandos de receptores nucleares constitutivos de androstano\nPrincipal Investigator: Laura Piqueras Ruiz and Jos\u00e9 Tomas Real \nCollado\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de ValenciaDuration: 2019-2021\nTotal Budget: \u20ac173.332,50\nReference: CDEI-04/20-A\nTitle: Plan GenT\nPrincipal Investigator:  Laura Piqueras Ruiz\nFunding body: Conselleria de Sanitat\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2023\nTotal Budget: \u20ac253.000166\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Metabolic Diseases\nEmerging group\nLeading Researcher, R4\nHerminia Gonz\u00e1lez Navarro\nINCLIVA. University\nRecognised Researcher, R2\nAlida Taberner Cort\u00e9s. INCLIVA\nFirst Stage Researchers, R1\nGema Hurtado Genov\u00e9s. INCLIVA\nMar\u00eda Aguilar Ballester. INCLIVA\nSusana Mart\u00edn Va\u00f1\u00f3. INCLIVAGroup members\nStrategic aims\n\u2022 Identification of new cellular plasticity mechanisms involved in plaque stability\n\u2022 Identification of new immune populations associated with liver metabolic complications\n\u2022 Effect of dapagliflozin on the development of atherosclerosis in murine models of insulin resistance\nMain lines of research\n\u2022 Study of the effect of inflammatory mediators of the lymphotoxin family and their receptors on the development of fatty liver \nassociated with insulin resistance\n\u2022 Study of the cytokine LIGHT in the stability of the plaque during the progression of atherosclerosis through the use of animal \nmodels with gain and loss of function \n\u2022 Characterization of immune populations in human metabolic complicationsResearchers by categories\n1 3 1 1\nResearchers financed by \ncompetitive public calls or networks\n1 3R2 R1 R4 STAFF\nR4 R1\nPUBLICATIONS\nIF 6\nNumber of  \narticles34.397IF\n5.732Average2\nCorresponding  \nauthor4\nNational  \ncollaborations0\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. De la Rosa A, Gomez-Cabrera M, Vinue A, Gonzalez-Navarro \nH, Sanchez-Andres J, Vina J. Overexpression of glucose 6 \nphosphate dehydrogenase preserves mouse pancreatic \nbeta cells function until late in life. Free Radical Biology & \nMedicine. 2021 Feb 20;164:149-153. doi: 10.1016/j.\nfreeradbiomed.2020.12.439. PMID: 33418115. IF: 7,3762. Lopez-Carrasco A, Berbegall A, Martin-Vano S, Blanquer-\nMaceiras M, Castel V, Navarro S, Noguera R. Intra-tumour \ngenetic heterogeneity and prognosis in high-risk neuroblastoma. \nCancers. 2021 Oct 15;13(20):5173. doi: 10.3390/\ncancers13205173. PMID: 34680323. IF: 6,639\n3. Herrero-Cervera A, Espinos-Estevez C, Martin-Vano S, Staff. Technician\nAndrea Herrero Cervera. INCLIVA167\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference: CDEI0420B \nTitle: Plan GenT\nPrincipal Investigator:  Herminia Gonz\u00e1lez Navarro \nFunding Body: Conselleria de Sanitat\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2023\nTotal Budget: \u20ac253.000\nTitle: Papel de la v\u00eda de se\u00f1alizaci\u00f3n mediada por LIGHT en el \nfenotipo y la reprogramaci\u00f3n celular en la placa de ateroma\nPrincipal Investigator: Herminia Gonz\u00e1lez Navarro\nFunding Body: Sociedad Espa\u00f1ola de arteriosclerosis/Fundaci\u00f3n \nEspa\u00f1ola de arteriosclerosis\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal Budget: \u20ac12.000\nTHESIS\nThesis title: Efecto de la dapagliflozina en la aterosclerosis \ndiab\u00e9tica y caracterizaci\u00f3n de un modelo murino de EHNA \ninducido por dieta \nDoctoral candidate: Aida Taberner Cort\u00e9s\nDirector(s): Herminia Gonz\u00e1lez Navarro \nDate of the defense: 11/11/2021\nGrade: Sobresaliente \u201ccum laude\u201dTaberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, \nMartinez-Hervas S, Gonzalez-Navarro H. Dissecting abdominal \naortic aneurysm is aggravated by genetic inactivation of LIGHT \n(TNFSF14). Biomedicines. 2021 Oct 22;9(11):1518. doi: \n10.3390/biomedicines 9111518. PMID: 34829747. IF: \n6,081\n4. Aguilar-Ballester M, Hurtado-Genoves G, Taberner-Cortes A, \nHerrero-Cervera A, Martinez-Hervas S, Gonzalez-Navarro \nH. Therapies for the treatment of cardiovascular disease \nassociated with Type 2 Diabetes and Dyslipidemia. International \nJournal of Molecular Sciences. 2021 Jan 11;22(2):660. doi: \n10.3390/ijms22020660. PMID: 33440821. IF: 5,923\n5. Burgos-Panadero R, El Moukhtari SH, Noguera I, Rodriguez-\nNogales C, Martin-Vano S, Vicente-Munuera P, Canete A, \nNavarro S, Blanco-Prieto MJ, Noguera R. Unraveling the \nextracellular matrix-tumor cell interactions to aid better \ntargeted therapies for neuroblastoma. International Journal of \nPharmaceutics. 2021 Aug 28;608:121058. doi: 10.1016/j.\nijpharm.2021.121058. PMID: 34461172. IF: 5,875\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  CA17129 \nTitle:  Catalysing transcriptomics research in cardiovascular \ndisease\nPrincipal Investigator: Yvan DEVAUX (Herminia Gonz\u00e1lez \nNavarro as collaborating researcher)\nFunding Body: European Commission\nInstituci\u00f3n beneficiaria: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nReference:  PI19/00169\nTitle: Papel de los procesos inflamatorios en las enfermedades \nmetab\u00f3licas y en las complicaciones asociadas\nPrincipal Investigator: Herminia Gonz\u00e1lez Navarro and Sergio \nMart\u00ednez Herv\u00e1s\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal Budget: \u20ac159.720168\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4\nRare\nRespirato ry\nDiseases\nResearc h\nGroupResearch Group on Rare Respiratory Diseases (RRD)\nEmerging group\nLeading Researcher, R4\nFrancisco Das\u00ed Fern\u00e1ndez\nINCLIVA. University\nEstablished Researcher, R3\nSelene Valero Moreno. University\nRecognised Researcher, R2\nSilvia Castillo Corull\u00f3n. Hospital. University\nFirst Stage Researchers, R1\nDaniel Pellicer Roig. INCLIVA\nLuc\u00eda Ba\u00f1uls Soto. INCLIVA\nMar\u00eda Magall\u00f3n Serrano. INCLIVA\nStaff. Collaborating Researcher\nM\u00aa Mercedes Navarro Garc\u00eda. INCLIVAGroup members\nStrategic aims\n\u2022 We have shown that NK and lymphocytes B express and secrete alpha-1 antitrypsin\n\u2022 We have discovered a group of miRNAs that could be used for the diagnosis and prognosis of alpha-1 antitrypsin deficiency. \nWe are currently validating these results using an external cohort\n\u2022 A new method based on oxidative stress markers to identify patients with Primary Ciliary Dyskinesia has been set up\n\u2022 We have set up the high-speed video method to identify patients with Primary Ciliary Dyskinesia\n\u2022 We have shown that hypoxia modifies neutrophil degranulation and enhances oxidative damage in alpha-1 antitrypsin \ndeficiency patients\nMain lines of research\n\u2022 The group is currently conducting active basic research on two rare respiratory diseases (RRDs); Alpha-1 Antitrypsin \nDeficiency (AATD) and primary ciliary dyskinesia (PCD)\n\u2022 The specific lines of action of the group are:\n- To characterize the molecular mechanisms (especially those aspects related to REDOX regulation) involved in the \ndevelopment of disease in AATD and PCD\n- To evaluate the diagnostic and/or prognostic value of circulating nucleic acids in plasma/serum\n- Development of cellular models from cells of patients with RRD, which allow research in these diseases\n- To develop new therapeutic strategies based on gene therapy\n- To generate social awareness of RRD, through the scientific dissemination of biomedical advances and social and health \npolicies aimed at improving the quality of life of patientsResearchers by categories\n1 3 1 1 1\nResearchers financed by \ncompetitive public calls or networks\n1 1R2 R1 R3 R4 STAFF\nR1 R4\nTeam involved in169\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 13\nNumber of  \narticles48.893IF\n3.761Average5\nCorresponding  \nauthor8\nNational  \ncollaborations3\nInternational \ncollaborations\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI17/01250\nTitle: Estudio del efecto de la hipoxia en la degranulaci\u00f3n, \nproducci\u00f3n de citoquinas y perfil oxidativo de neutr\u00f3filos de \npacientes con d\u00e9ficit de alfa-1 antitripsina\nPrincipal  Investigator: Francisco Das\u00ed Fern\u00e1ndez\nFunding Body: Instituto de Salud Carlos III -  Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal  budget: \u20ac99.220\nTitle: Estudio de los microRNAs circulantes como biomarcadores \npron\u00f3sticos en pacientes con d\u00e9ficit de alfa-1 antitripsina. Un \nenfoque funcional\nPrincipal Investigator:  Francisco Das\u00ed Fern\u00e1ndez\nFunding body: Sociedad Valenciana de Neumolog\u00eda\nBeneficiary institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget: \u20ac6.000 \nTitle: Estudio de la utilidad cl\u00ednica de los exosomas plasm\u00e1ticos en \nla discinesia ciliar primaria\nPrincipal Investigator:  Francisco Das\u00ed Fern\u00e1ndez\nFunding body: Sociedad Valenciana de Neumolog\u00eda\nBeneficiary institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2023\nTotal budget: \u20ac12.000 SELECTED PUBLICATIONS\n1. Alcala M, Bolado V, Sanchez-Vera I, Clapes S, Dasi F, Saez G, \nCarrera E, Alvarez-Gallego F, Loeken M, Viana M. Prevention \nof teratogenesis in pregnancies of obese rats by vitamin E \nsupplementation. Antioxidants. 2021 Jul 23;10(8):1173. doi: \n10.3390/antiox10081173. PMID: 34439421. IF: 6,312\n2. Baz-Redon N, Rovira-Amigo S, Paramonov I, Castillo Corullon S, \nCols Roig M, Antolin M, Garcia Arumi E, Torrent-Vernetta A, De \nMir Messa I, Gartner S, Iglesias Serrano I, Caballero-Rabasco M, \nAsensio De La Cruz O, Vizmanos-Lamotte G, Martin De Vicente \nC, Martinez-Colls M, Reula Martin A, Escribano Montaner A, \nDas\u00ed Fern\u00e1ndez F, Armengot Carceller M, Polverino E, Amengual \nPieras E, Amaro-Rodriguez R, Garrido-Pontnou M, Tizzano E, \nCamats-Tarruella N, Fernandez-Cancio M, Moreno-Galdo A. \nImplementation of a gene panel for genetic diagnosis of primary \nciliary dyskinesia. Archivos de Bronconeumologia. 2021 \nMar;57(3):186-194. doi: 10.1016/j.arbres.2020.02.010. \nPMID: 32253119. IF: 4,872\n3. Ruiz-Duque B, Banuls L, Reinoso-Arija R, Carrasco-Hernandez \nL, Caballero-Eraso C, Dasi F, Lopez-Campos JL. Methodologies \nfor the determination of blood Alpha1 antitrypsin levels: a \nsystematic review. Journal of Clinical Medicine. 2021 Oct \n31;10(21):5132. doi: 10.3390/jcm10215132. PMID: \n34768650. IF: 4,241\n4. Magallon M, Carrion A, Banuls L, Pellicer D, Castillo S, Bondia \nS, Navarro-Garcia M, Gonzalez C, Dasi F. Oxidative stress and \nendoplasmic reticulum stress in rare respiratory diseases. \nJournal of Clinical Medicine. 2021 Mar 18;10(6):1268. doi: \n10.3390/jcm10061268. PMID: 33803835. IF: 4,241\n5. Reula A, Pellicer D, Castillo S, Magallon M, Armengot M, Herrera \nG, O\u2019Connor J, Banuls L, Navarro-Garcia M, Escribano A, Dasi \nF. New laboratory protocol to determine the oxidative stress \nprofile of human nasal epithelial cells using flow cytometry. \nJournal of Clinical Medicine. 2021 Mar 11;10(6):1172. doi: \n10.3390/jcm10061172. PMID: 33799667. IF: 4,241170\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Healthy Aging \nEmerging group\nLeading Researcher, R4\nConsuelo Borr\u00e1s Blasco \nUniversity\nEstablished Researcher, R3\nJuan Gambini Buch\u00f3n. University\nRecognised Researchers, R2\nAna D\u00edaz Cuevas. University \nCristina Mas Bargues. University \nMar Dromant Jarque. INCLIVA\nMarta Ingl\u00e9s de la Torre. UniversityGroup members\nStrategic aims\n\u2022 To know the molecular mechanisms involved in aging and frailty processes\n\u2022 To develop possible methods to evaluate them\n\u2022 To develop appropriate intervention strategies\n\u2022 To determine an index of quality of life in experimental animals\n\u2022 To develop human imaging biomarkers for the diagnosis of frailty\n\u2022 To study interventions to delay aging and prevent frailty:\n- Therapy with small extracellular vesicles\n- Role of the antiapoptotic gene Bcl-xL\nMain lines of research\n\u2022 Development of a quality of life index (healthy aging) in experimental animals (derived from intervention studies in aging)\n\u2022 Development of image biomarkers in the diagnosis of frailty:\n-  Fragility biomarkers based on ultrasound image analysis (echointensity, fractals, textures)\n\u2022 Interventions for healthy aging:\n-  Stem cell derived extracellular medicine (based on previous studies on stem cells and senescence)\n-  Study of Bcl-xL as a longevity gene (based on previous studies in centenarians)Researchers by categories\n4 2 1 1\nResearchers financed by \ncompetitive public calls or networks\n1R2 R1 R3 R4\nR1\nPUBLICATIONS\nIF 23\nNumber of  \narticles117.557IF\n5.111Average5\nCorresponding  \nauthor11\nNational  \ncollaborations7\nInternational \ncollaborationsFirst Stage Researchers, R1\nAurora Rom\u00e1n Rodr\u00edguez. University \nJorge Sanz Ros. University171\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Beneficiary Institution: Universidad de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac169.098\nReference: PID2020-113839RB-I00\nTitle: Efecto del tratamiento con ves\u00edculas extracelulares de \nc\u00e9lulas madre de grasa de ratones j\u00f3venes sobre par\u00e1metros de \nenvejecimiento y fragilidad en ratones de edad avanzada\nPrincipal Investigator: Consuelo Borr\u00e1s Blasco\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary Institution: Universidad de Valencia\nDuration: 2021-2024\nTotal Budget: \u20ac181.500\nReference: PCIN-2017-117\nTitle: Obesidad materna y disfunci\u00f3n cognitiva en la descendencia: \npapel causa-efecto de la microbiota intestinal y prevenci\u00f3n \ndiet\u00e9tica temprana\nPrincipal Investigator: Consuelo Borr\u00e1s Blasco\nFunding Body: Ministerio de Econom\u00eda, Industria y Competitividad\nBeneficiary Institution: Universidad de Valencia\nDuration: 2017-2022\nTotal Budget: \u20ac143.000\nTHESIS\nThesis title: Eficacia de la terapia manual en pacientes con \nmigra\u00f1a\nDoctoral candidate: Elena Mu\u00f1oz G\u00f3mez\nDirector(s): Marta Ingl\u00e9s De La Torre, Gemma Victoria Esp\u00ed L\u00f3pez\nDate of the defense: 23/04/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD\nThesis title: Transcript\u00f3mica en centenarios: un ejemplo de \nenvejecimiento satisfactorio\nDoctoral candidate: Mar Dromant Jarque\nDirector(s): Marta Ingl\u00e9s De La Torre, Consuelo Borr\u00e1s Blasco, \nJos\u00e9 Vi\u00f1a Ribes\nDate of the defense: 21/12/2021\nGrade: Sobresaliente \u201ccum laude\u201dSELECTED PUBLICATIONS\n1. Mas-Bargues C, Borras C. Importance of stem cell culture \nconditions for their derived extracellular vesicles therapeutic \neffect. Free Radical Biology & Medicine. 2021 May 20;168:16-\n24. doi: 10.1016/j.freeradbiomed.2021.03.028. PMID: \n33781893. IF: 7,376\n2. Gambini J, Gimeno-Mallench L, Olaso-Gonzalez G, Mastaloudis \nA, Traber M, Monleon D, Borras C, Vina J. Moderate red \nwine consumption increases the expression of longevity-\nassociated genes in controlled human populations and \nextends lifespan in Drosophila melanogaster. Antioxidants. \n2021 Feb 16;10(2):301. doi: 10.3390/antiox10020301. \nPMID: 33669360. FI: 6,312\n3. Borras C, Ferrando M, Ingles M, Gambini J, Lopez-Grueso \nR, Edo R, Mas-Bargues C, Pellicer A, Vina J. Estrogen \nreplacement therapy induces antioxidant and longevity-related \ngenes in women after medically induced menopause. Oxidative \nMedicine and Cellular Longevity. 2021 Sep 9;2021:8101615. \ndoi: 10.1155/2021/8101615. PMID: 34539974. IF: \n6,543\n4. Duro-Castano A, Borras C, Herranz-Perez V, Blanco-Gandia \nM, Conejos-Sanchez I, Arminan A, Mas-Bargues C, Ingles \nM, Minarro J, Rodriguez-Arias M, Garcia-Verdugo J, Vina J, \nVicent M. Targeting Alzheimer\u2019s disease with multimodal \npolypeptide-based nanoconjugates. Science Advances. 2021 \nMar 26;7(13):eabf9180. doi: 10.1126/sciadv.abf9180. \nPMID: 33771874. IF: 14,136\n5. Borras C, Abdelaziz KM, Diaz A, Gambini J, Jove M, Lopez-\nGrueso R, Mas-Bargues C, Monleon D, Pamplona R, Vina \nJ. Lifelong soya consumption in males does not increase \nlifespan but increases health span under a metabolic stress \nsuch as type 2 diabetes mellitus. Mechanisms of Ageing \nand Development. 2021 Dec;200:111596. doi: 10.1016/j.\nmad.2021.111596. PMID: 34774606. IF: 5,432\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: AC20/00026\nTitle: Combining vitamin E-functionalized CHOcolate with physical \nexercise to reduce the risK of protein energy malnutrition in pre-\ndementia AGEd people. ERA-HDHL Call for Joint Transnational \nResearch Proposals on Development of targeted nutrition for \nprevention of undernutrition for older adults (PREVNUT)\nPrincipal Investigator: Jos\u00e9 Vi\u00f1a Ribes (Consuelo Borr\u00e1s Blasco \nas collaborating researcher)\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER172\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Exercise, Nutrition and Healthy Lifestyle\nEmerging group\nLeading Researcher, R4\nM\u00aa Carmen G\u00f3mez Cabrera\nUniversity\nRecognised Researchers, R2\nAitor Carretero Mart\u00ednez. INCLIVA\nGloria Olaso Gonz\u00e1lez. University\nFirst Stage Researchers, R1\nEsther Garc\u00eda Dom\u00ednguez. University\nFernando Mill\u00e1n Domingo. UniversityGroup members\nStrategic aims\n\u2022 Role of nicotinamide riboside (NR) and Urolithin A (UroA) as mitotherapeutics for the reversal of energy collapse associated \nwith aging\n\u2022 Role of \u03b2-hydroxybutyrate on the loss of muscle mass associated with aging\n\u2022 Effect of an intervention with protein and vitamin supplementation in synergy with a multicomponent program of physical \nexercise in the reversal of frailty\n\u2022 Effect of glucosamine supplementation on physical performance\n\u2022 Evaluation of the neuroprotective effect of ketogenic diets (intermittent fasting and carbohydrate-free diet)\n\u2022 High intensity interval exercise in the prevention and treatment of frailty\n\u2022 Study of the effect of the activation of glucose 6 phosphate dehydrogenase with different intervention strategies in the \nprevention of frailty\nMain lines of research\nUsing molecular approaches in animal and human models, this group aims to establish the basic mechanisms modulated by \nexercise and nutrition to transfer them through clinical trials to the improvement of the quality of life in humans. The research \nlines of the Exercise, Nutrition and Healthy Lifestyle Research Group include the study of:\n\u2022 Cell signaling in skeletal muscle during physical exercise\n\u2022 Oxidative stress associated with physical exercise and the effect of the administration of antioxidants\n\u2022 The mechanisms involved in muscle atrophy with special attention to the study of the importance of oxidative stress in the \nloss of muscle mass, both in clinical and preclinical models\n\u2022 The benefits of physical exercise and nutritional interventions to ensure healthy aging with special attention to the treatment \nof various pathologies associated with aging, especially Alzheimer\u2019s disease, senile sarcopenia and frailtyResearchers by categories\n2 2 1\nResearchers financed by \ncompetitive public calls or networks\n1R1 R2 R4\nR1\nPUBLICATIONS\nIF 13\nNumber of  \narticles127.052IF\n9.773Average3\nCorresponding  \nauthor3\nNational  \ncollaborations8\nInternational \ncollaborations173\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference: PID2019-110906RB-100\nTitle: Nuevas intervenciones terap\u00e9uticas multidominio para \nretrasar la fragilidad y la discapacidad. Identificaci\u00f3n de mecanismos \nmoleculares con relevancia traslacional\nPrincipal Investigator: Jos\u00e9 Vi\u00f1a Ribes and Consuelo G\u00f3mez \nCabrera \nFunding Body: Ministerio de Econom\u00eda y Competitividad\nBeneficiary Institution : Universidad de Valencia\nDuration: 2020-2023\nTotal budget: \u20ac270.000\nReference: 45/UPB/20\nTitle: Redes de Investigaci\u00f3n en ciencias del deporte: EXERNET. \nRed de ejercicio f\u00edsico y salud\nPrincipal Investigator: Jos\u00e9 Antonio Casaj\u00fas (M\u00aa Carmen G\u00f3mez-\nCabrera as collaborating researcher)\nFunding Body: Ministerio de Cultura y Deporte\nBeneficiary Institution : Universidad de Valencia\nDuration: 2021-2022\nTotal Budget: \u20ac8.000                                           \nReference: PROMETEO/2019/097\nTitle: Diferencias de fragilidad entre g\u00e9neros: evaluaci\u00f3n de \nbiomarcadores y estrategias de intervenci\u00f3n\nPrincipal Investigator: Jos\u00e9 Vi\u00f1a Ribes (M\u00aa Carmen G\u00f3mez \nCabrera as collaborating researcher)\nFunding Body: Generalitat Valenciana \nBeneficiary Institution : Universidad de Valencia\nDuration: 2020-2023\nTotal Budget: \u20ac189.391                                           \nReference: 0551_PSL_6_E\nTitle: Ejercicio f\u00edsico personalizado como intervenci\u00f3n para \nrevertir la discapacidad en adultos mayores que viven en \nresidencias (RESIFIT)\nPrincipal Investigator: M\u00aa Carmen G\u00f3mez-Cabrera\nFunding Body: Fundaci\u00f3n General CSIC \nBeneficiary Institution : Universidad de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac24.000                                           SELECTED PUBLICATIONS\n1. Roman W, Pinheiro H, Pimentel M, Segales J, Oliveira L, Garcia-\nDominguez E, Gomez-Cabrera M, Serrano A, Gomes E, Munoz-\nCanoves P. Muscle repair after physiological damage relies \non nuclear migration for cellular reconstruction. Science. \n2021 Oct 15;374(6565):355-359. doi: 10.1126/science.\nabe5620. PMID: 34648328. IF: 47,728\n2. Arc-Chagnaud C, Salvador-Pascual A, Garcia-Dominguez E, \nOlaso-Gonzalez G, Correas A, Serna E, Brioche T, Chopard A, \nFernandez-Marcos P, Serrano M, Serrano A, Munoz-Canoves \nP, Sebastia V, Vina J, Carmen Gomez-Cabrera M. Glucose 6-P \ndehydrogenase delays the onset of frailty by protecting against \nmuscle damage. Journal of Cachexia Sarcopenia and Muscle. \n2021 Dec;12(6):1879-1896. doi: 10.1002/jcsm.12792. \nPMID: 34704386. IF: 12,91\n3. Gomez-Cabrera C, Carretero A, Millan-Domingo F, Garcia-\nDominguez E, Correas AG, Olaso-Gonzalez G, Vina J. Redox-\nrelated biomarkers in physical exercise. Redox Biology. 2021 \nJun;42:101956. doi: 10.1016/j.redox.2021.101956. \nPMID: 33811000. IF: 11,799\n4. De la Rosa A, Gomez-Cabrera M, Vinue A, Gonzalez-Navarro \nH, Sanchez-Andres J, Vina J. Overexpression of glucose 6 \nphosphate dehydrogenase preserves mouse pancreatic \nbeta cells function until late in life. Free Radical Biology & \nMedicine. 2021 Feb 20;164:149-153. doi: 10.1016/j.\nfreeradbiomed.2020.12.439. PMID: 33418115. IF: 7,376\n5. Alabadi B, Civera M, De la Rosa A, Martinez-Hervas S, Gomez-\nCabrera MC, Real JT. Frailty is associated with oxidative \nstress in older patients with Type 2 Diabetes. Nutrients. 2021 \nNov 9;13(11):3983. doi: 10.3390/nu13113983. PMID: \n34836238. IF: 5,717\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: DIABFRAIL-LATAM-825546\nTitle: Scaling-up of and evidence-based intervention programme \nin older people with Diabetes and Frailty in LatinAmerica\nPrincipal Investigator: Leocadio Rodr\u00edguez Ma\u00f1as (M\u00aa Carmen \nG\u00f3mez Cabrera as collaborating researcher)\nFunding Body: European Commission \nBeneficiary Institution: CIBER (Fundaci\u00f3n Investigaci\u00f3n Hospital \nCl\u00ednico Universitario de Valencia as Third Party)\nDuration: 2019-2024\nTotal Budget: \u20ac273.720  174\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Epigenomics and Translational Epigenetics\nAsociated group\nLeading Researcher, R4\nJos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nUniversity. CIBER\nEstablished Researchers, R3\nCarmela Aguado Velasco. INCLIVA\nNieves Carbonell Monle\u00f3n. Hospital\nSalvador Mena Moll\u00e1. University\nFirst Stage Researcher, R1\nJes\u00fas Beltr\u00e1n Garc\u00eda. INCLIVA\nRebeca Osca Verdegal. INCLIVAGroup members\nStrategic aims\nDeepen the characterization of the epigenetic mechanisms that give phenotypic variability in human diseases, and that can give \nrise to diagnostic and prognostic biomarkers that can be implemented in precission medicine:\n\u2022 Identification of epigenetic mechanisms and biomarkers in Rare Diseases \n\u2022 Identification of epigenetic biomarkers in sepsis and neonatal sepsis\n\u2022 Comprehension of the mechanisms mediating the heterogeneity and complexity of sepsis by generating new organoid \nmodels\nMain lines of research\n\u2022 Identification of biomarkers for diagnosis, prognosis and monitoring of therapies in sepsis and septic shock \n\u2022 Identification of molecular mechanisms related to epigenetic dysregulation and oxidative stress in rare diseases\n\u2022 Artificial intelligence for improved criticall-ill patient management using epigenetic biomarkers\n\u2022 Organoids as models to evaluate tissue damage mediated by circulating histones Researchers by categories\n2 3 1R1 R3 R4\nPUBLICATIONS\nIF 12\nNumber of  \narticles76.495IF\n6.374Average4\nCorresponding  \nauthor6\nNational  \ncollaborations2\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Beltran Garcia J, Osca Verdegal R, Nacher Sendra E, Cardona \nMonzonis A, Sanchis Gomar F, Carbonell N, Pallardo FV, \nLavie CJ, Garcia Gimenez JL. Role of non-coding RNAs as \nbiomarkers of deleterious cardiovascular effects in sepsis. \nProgress in Cardiovascular Diseases. 2021;68:70-77. doi: Researchers financed by \ncompetitive public calls or networks\n2 1R1 R4\n10.1016/j.pcad.2021.07.005. PMID: 34265333. IF: 8,194\n2. Roma-Mateo C, Garcia-Gimenez J. Oxidative stress and rare \ndiseases: from molecular crossroads to therapeutic avenues. \nAntioxidants. 2021 Apr 16;10(4):617. doi: 10.3390/\nantiox10040617. PMID: 33923815. IF: 6,312175\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Universitario de Valencia\nDuration: 2020-2023\nTotal  budget: \u20ac100.000\nTitle: Validaci\u00f3n de microRNAs circulantes como biomarcadores \nde pron\u00f3stico y evoluci\u00f3n cl\u00ednica en Ataxia de Friedreich. Hacia la \nmedicina de precisi\u00f3n en las Enfermedades Raras\nPrincipal  Investigator: Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Asociaci\u00f3n Espa\u00f1ola de Ataxias\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal  budget: \u20ac6.000\nTitle: Valorizaci\u00f3n e internacionalizaci\u00f3n de HistShock, un test IVD \npara el diagn\u00f3stico y pron\u00f3stico de la sepsis y el shock s\u00e9ptico\nPrincipal  Investigator: Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Fundaci\u00f3n para la Innovaci\u00f3n y Prospectiva en \nSalud en Espa\u00f1a (FIPSE)\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal  budget: \u20ac30.000\nReference:  UV-19-INV_AE19\nTitle: iTKI, Biosensor de monitorizaci\u00f3n para la respuesta TKI en \nc\u00e1ncer de pulm\u00f3n EGFR mutante\nPrincipal  Investigator: Salvador Mena Moll\u00e1\nFunding Body: Universidad de Valencia\nBeneficiary Institution : Universidad de Valencia\nDuration: 2020-2021\nTotal  budget: \u20ac6.300\nReference:  InmunoDx\nTitle: iTKI, Biosensor de monitorizaci\u00f3n para la respuesta TKI en \nc\u00e1ncer de pulm\u00f3n EGFR mutante\nPrincipal  Investigator: Salvador Mena Moll\u00e1\nFunding Body:  UV-La Fe 2020 Programa Acciones Preparatorias\nBeneficiary Institution : Universidad de Valencia\nDuration: 20213. Osca-Verdegal R, Beltran-Garcia J, Pallardo FV, Garcia-\nGimenez JL. Role of microRNAs as biomarkers in sepsis-\nassociated encephalopathy. Molecular Neurobiology. 2021 \nSep;58(9):4682-4693. doi: 10.1007/s12035-021-02445-3. \nPMID: 34160774. IF: 5,59\n4. Garcia-Gimenez J, Garces C, Roma-Mateo C, Pallardo F. Oxidative \nstress-mediated alterations in histone post-translational \nmodifications. Free Radical Biology & Medicine. 2021 \nJul;170:6-18. doi: 10.1016/j.freeradbiomed.2021.02.027. \nPMID: 33689846. IF: 7,376\n5. Lorente-Pozo S, Navarrete P, Garz\u00f3n MJ, Lara-Cant\u00f3n I, \nBeltr\u00e1n-Garc\u00eda J, Osca-Verdegal R, Mena-Moll\u00e1 S, Garc\u00eda-L\u00f3pez \nE, Vento M, Pallard\u00f3 FV, Garc\u00eda-Gim\u00e9nez JL. DNA methylation \nanalysis to unravel altered genetic pathways underlying early \nonset  and late onset neonatal sepsis. A Pilot Study. Frontiers \nin Immunology. 2021 Feb 15;12:622599. doi: 10.3389/\nfimmu.2021.622599. PMID: 33659006. IF: 7,561\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI19/00994\nTitle: Biomarcadores epigen\u00e9ticos en sepsis y su implicaci\u00f3n en \ninmunosupresi\u00f3n y futuras comorbilidades en supervivientes\nPrincipal  Investigator: Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Universidad de Valencia\nDuration: 2020-2022\nTotal  budget: \u20ac111.320 \nReference:  INNVA1/2020/85\nTitle:  Valorizaci\u00f3n, estrategia de protecci\u00f3n y transferencia de un \nm\u00e9todo de diagn\u00f3stico y pron\u00f3stico de la sepsis y el shock s\u00e9ptico\nPrincipal  Investigator: Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Agencia Valenciana de Innovaci\u00f3n\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal  budget: \u20ac110.670\nTitle:  Identificaci\u00f3n de biomarcadores mediante el uso de las \n\u00f3micas y la Inteligencia Artificial para el diagn\u00f3stico y el pron\u00f3stico \nde la sepsis neonatal\nPrincipal  Investigator: Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nEntidad financiadora: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico 176\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Total  budget: \u20ac4.000\nTHESIS\nThesis title: B\u00fasqueda de MIARNS en fluido crevicular gingival: \nexpresi\u00f3n diferencial en sujetos con periodontitis cr\u00f3nica \navanzada\nDoctoral candidate: Pedro Jos\u00e9 Almi\u00f1ana Pastor\nDirector(s): Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez, Jos\u00e9 Vicente Bag\u00e1n \nSebasti\u00e1n, Andr\u00e9s L\u00f3pez Rold\u00e1n \nDate of the defense: 04/03/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title: Influencia de factores epigen\u00e9ticos en el desarrollo \nde la escoliosis idiop\u00e1tica del adolescente\nDoctoral candidate: Pedro Antonio Rubio Belmar \nDirector(s): Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez, Teresa Bas Hermida\nDate of the defense: 27/05/2021\nGrade: Sobresaliente \u201ccum laude\u201d177\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.3.4 Reproductive medicine area\nGroups\nResearch Group on Women Health\nResearch Group on Reproductive Medicine\nResearch Group on Therapies Against Endometriosis and Endometrial Cancer\nResearch Group on Maternal Fetal Communication\n41\nNumber of  \narticlesIF\n240.74IF\n5.871Average19\nCorresponding  \nauthor10\nNational  \ncollaborations20\nInternational \ncollaborations\n17\nD116\nFirst  \nauthor23\nLast  \nauthor32\nQ12\nQ2\n282921\noriginal articles letters editorial review corrections178\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Women Health  \nConsolidated group\nLeading Researcher, R4\nAntonio Cano S\u00e1nchez. Hospital. University\nJuan Jos\u00e9 Tar\u00edn Folgado. University\nRecognised Researchers, R2\nAna Mart\u00ednez Aspas. Hospital. University\nCelia Bauset Castell\u00f3. Hospital\nEster Ortiz Murillo. Hospital\nGemma Arribas Ferriol. Hospital\nIrene Zolfaroli. Hospital\nJuan Jos\u00e9 Hidalgo Mora. Hospital\nStaff. Collaborating Researchers\nAitana Monllor Tormos. Hospital\nLaura Carbonell L\u00f3pez. Hospital\nRoc\u00edo Belda Montesinos. Hospital\nStaff. Nurses\nAlicia Garc\u00eda Vigara. HospitalGroup members\nStrategic aims\nThe group is positioned in the field of healthy ageing, particularly in what relates women, with special interest to frailty, where it \nhas collaborated in the support of INCLIVA in the project ADVANTAGE. We have collaborated to position the reference site of the \nValencia Region within EIPAHA, the partnership of the European Commission. Moreover, we have participated in the application \nto different European projects with groups from different European countries, including an application to the Maire Curie grants\nMain lines of research\n\u2022 In healthy ageing in the female we are continuing our interest on osteoporosis but also have added frailty and functional decline\n\u2022 The group is consolidating the CARMEN cohort (see the EIPAHA commitment tracker, https://ec.europa.eu/eip/ageing/ \ncommitments-tracker/a3/integrated-care-and-ict-reduce-frailty-and-chronic-diseases-ageing-women_en)\n\u2022 There is a new area of interest on the use of ICT to promote women\u2019s health with regard to endometriosis:\n- To analyze the role of microRNA and vascularization regulators and pain mechanisms. Role of the TNF cytokine family\n- To analyze the initial atherogenesis and selective estrogen receptor modulatorsResearchers by categories\n6 2 4R2 R4 STAFF\nPUBLICATIONS\nIF 16\nNumber of  \narticles58.487IF\n3.655Average5\nCorresponding  \nauthor5\nNational  \ncollaborations6\nInternational \ncollaborations179\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Reference:  826640\nTitle:  Evidence-Based Guidance to Scale-up Integrated Care in \nEurope VIGOUR\nPrincipal Investigator: Antonio Cano S\u00e1nchez\nFunding body: Consumers, Health, Agriculture and Food Executive \nAgency\nBeneficiary institution: Universidad de Valencia\nDuration: 2019-2021\nTotal budget: \u20ac3.046.025SELECTED PUBLICATIONS\n1. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon \nS, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, \nPena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, \nCano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella \nGonzalez I. Ten-year assessment of a cancer fast-track \nprogramme to connect primary care with oncology: reducing \ntime from initial symptoms to diagnosis and treatment \ninitiation. ESMO Open. 2021 May 11;6(3):100148. doi: \n10.1016/j.esmoop.2021.100148. PMID: 33989988. IF: \n6,54\n2. Tejada M, Santos-Llamas A, Fernandez-Ramirez M, Tarin J, \nCano A, Gomez R. A reassessment of the therapeutic potential \nof a dopamine receptor 2 Agonist (D2-AG) in endometriosis by \ncomparison against a standardized antiangiogenic treatment. \nBiomedicines. 2021 Mar 8;9(3):269. doi: 10.3390/\nbiomedicines9030269. PMID: 33800198. IF: 6,081\n3. Nilsson A, Cano A, Bergens O, Kadi F. Randomized controlled \ntrial for promotion of healthy eating in older adults by increasing \nconsumption of plant-based foods: effect on inflammatory \nbiomarkers. Nutrients. 2021 Oct 24;13(11):3753. doi: \n10.3390/nu13113753. PMID: 34836009. IF: 5,717\n4. Pertusa C, Tarin JJ, Cano A, Garcia-Perez MA, Mifsut D. Serum \nmicroRNAs in osteoporotic fracture and osteoarthritis: a \ngenetic and functional study. Scientific Reports. 2021 Sep \n29;11(1):19372. doi: 10.1038/s41598-021-98789-w. \nPMID: 34588560. IF: 4,379\n5. Zolfaroli I, Ortiz E, Garcia-Perez M, Hidalgo-Mora J, Tarin \nJ, Cano A. Positive association of high-density lipoprotein \ncholesterol with lumbar and femoral neck bone mineral density \nin postmenopausal women. Maturitas. 2021 May;147:41-46. \ndoi: 10.1016/j.maturitas.2021.03.001. PMID: 33832646. \nIF: 4,342\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  AC19/00084\nTitle:  Patrones diet\u00e9ticos en poblaci\u00f3n europea senescente: \nacercamiento multidisciplinar para combatir las enfermedades \nmetab\u00f3licas ligadas a sobrepreso. Proyecto Eurodiet\nPrincipal Investigator: Antonio Cano S\u00e1nchez\nFunding body: European Commission\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget: \u20ac27.225180\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Reproductive Medicine  \nConsolidated group\nLeading Researcher, R4\nCarlos Sim\u00f3n Vall\u00e9s\nUniversity. IGENOMIX Foundation\nEmerging researcher, R2\nAymara Mas Perucho. INCLIVA\nRecognised Researchers, R2\nAntonio D\u00edez Juan. IGENOMIX Foundation\nBeatriz Ros\u00f3n Burgo. INCLIVA \nCarlos Lozano Asencio. IGENOMIX Foundation\nCarmen Garc\u00eda Pascual. IGENOMIX Foundation\nCarmen Rubio Lluesa. IGENOMIX Foundation\nDavid Blesa Jarque. IGENOMIX Foundation \nDiana Valbuena Perilla. IGENOMIX Foundation\nInmaculada Moreno Gimeno. IGENOMIX Foundation\nMiguel Mil\u00e1n S\u00e1nchez. IGENOMIX Foundation\nNandakumar Venkatesan. University\nTamara Garrido G\u00f3mez. IGENOMIX Foundation\nFirst Stage Researchers, R1\nAlba Machado L\u00f3pez. IGENOMIX Foundation\nBruno Tos\u00f3n. INCLIVA\nClaudia Abell\u00e1n Orihuela. INCLIVA\nIrene Mu\u00f1oz Blat. INCLIVA\nNerea Castillo Marco. IGENOMIX Foundation\nPaula Punz\u00f3n Jim\u00e9nez. INCLIVAGroup members\nStrategic aims\n\u2022 Our activity predominantly involves research in the field of Reproductive Medicine and women\u2019s health, with a particular focus \non factors that cause infertility, and other gynecological and obstetric pathologies\n\u2022 One of our aims is the characterization at single cell resolution of the human uterus, that will provide unprecedented insight \nat transcriptomic, genomic and spatial changes of this important female organ not only throughout the menstrual cycle but \nalso across lifespan. The comparison in healthy and diseased conditions are also in the scope\nMain lines of research\n\u2022 Adult stem cells in the human endometrium: we have identified the existence of human endometrial stem cells, and we have \ndemonstrated the therapeutic potential of autologous bone marrow CD133+ stem cells in the treatment of non-curable \nendometrial pathologies such as Asherman\u2019s syndrome or endometrial atrophyResearchers by categories\n12 1 6 3\nResearchers financed by \ncompetitive public calls or networks\n4 4R2 R4 R1 STAFF\nR2 R1\nStaff. Technicians\nMarta G\u00e1lvez Diezma. IGENOMIX Foundation\nMarta Gonzalez Monfort. IGENOMIX Foundation\nRoberto Alonso Valero. IGENOMIX Foundation181\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 23\nNumber of  \narticles161.815IF\n7.035Average14\nCorresponding  \nauthor4\nNational  \ncollaborations13\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Capalbo A, Poli M, Riera-Escamilla A, Shukla V, Kudo Hoffding \nM, Krausz C, Hoffmann E, Simon Valles C. Preconception \ngenome medicine: current state and future perspectives \nto improve infertility diagnosis and reproductive and health \noutcomes based on individual genomic data. Human \nReproduction Update. 2021 Feb 19;27(2):254-279. doi: \n10.1093/humupd/dmaa044. PMID: 33197264. IF: 15,61\n2. Capalbo A, Poli M, Rienzi L, Girardi L, Patassini C, Fabiani \nM, Cimadomo D, Benini F, Farcomeni A, Cuzzi J, Rubio C, \nAlbani E, Sacchi L, Vaiarelli A, Figliuzzi M, Findikli N, Coban O, \nBoynukalin FK, Vogel I, Hoffmann E, Livi C, Levi-Setti PE, Ubaldi \nFM, Simon C. Mosaic human preimplantation embryos and \ntheir developmental potential in a prospective, non-selection \nclinical trial. American Journal of Human Genetics. 2021 Dec \n2;108(12):2238-2247. doi: 10.1016/j.ajhg.2021.11.002. \nPMID: 34798051. IF: 11,025\n3. Ravel J, Moreno Gimeno I, Simon Valles C. Bacterial vaginosis \nand its association with infertility, endometritis, and pelvic inflammatory disease. American Journal of Obstetrics and \nGynecology. 2021 Mar;224(3):251-257. doi: 10.1016/j.\najog.2020.10.019. PMID: 33091407. IF: 8,661\n4. Garrido-Gomez T, Castillo-Marco N, Clemente-Ciscar M, \nCordero T, Munoz-Blat I, Amadoz A, Jimenez-Almazan J, \nMonfort-Ortiz R, Climent R, Perales-Marin A, Simon C. \nDisrupted PGR-B and ESR1 signaling underlies defective \ndecidualization linked to severe preeclampsia. eLife. 2021 \nOct 28;10:e70753. doi: 10.7554/eLife.70753. PMID: \n34709177. IF: 8,14\n5. Vilella F, Wang W, Moreno I, Roson B, Quake S, Simon C. Single-\ncell RNA Sequencing of SARS-CoV-2 cell entry factors in the \npreconceptional human endometrium. Human Reproduction. \n2021 Sep 18;36(10):2709-2719. doi: 10.1093/humrep/\ndeab183. PMID: 34329437. IF: 6,918\u2022 The embryo viability: nowadays the selection of embryo is based solely on morphological parameters, which doesn\u2019t guarantee \nits genetic viability. We aim to develop a non-invasive approach based on molecular techniques to identify euploid embryos\n\u2022 Study of endometrial receptivity and performe the Cell Atlas of the human uterus: we discovered the transcriptomic signature \nof human endometrial receptivity. Now, we are part of the International Human Cell Atlas initiative to create the first human \ncell atlas of the uterus\n\u2022 The endometrial microbiome in human reproduction: our research group has described the existence of the endometrial \nmicrobiome and its clinical implications on the reproductive outcome. We investigate the impact of uterine microbiome \ndysbiosis and its clinical impact\n\u2022 The maternal implication in the origin of pre-eclampsia: our research has provided evidence that endometrial decidualization \nresistance is implicated in the origin of this disease. This finding offers a new perspective based on the maternal contribution \nto gestation, aiming to develop a tool that will diagnose pre-eclampsia\n\u2022 Molecular diagnosis of myometrial tumors: our previous work has demonstrated the genomic differential characterization \nof myomas and leiomyosarcomas. We aim to shift the diagnostic and therapeutic focus of uterine leiomyomas and \nleiomyosarcomas through genomic characterization\nEmerging Researcher\nAymara Mas Perucho \nThe main objective of this research is focused on understanding those factors that contribute to the pathophysiology of myometrial \ntumors at the molecular level.182\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : 874867 - HUTER\nTitle: Human Uterus Cell Atlas\nPrincipal Investigator : Carlos Sim\u00f3n Vall\u00e9s\nFunding Body: European Commission\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget : \u20ac4.118.942,50\nReference : PI20/00942\nTitle: Desarrollo de un modelo predictivo para el diagn\u00f3stico \ndiferencial temprano de leiomiomas y leiomiosarcomas uterinos\nPrincipal  Investigator: Aymara Mas Perucho\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget : \u20ac99.825\nReference : PI19/01659\nTitle: An\u00e1lisis transcript\u00f3mico a nivel de c\u00e9lula \u00fanica y tejido \nendometrial completo del fallo en decidualizaci\u00f3n presente en \npacientes con preeclampsia severa\nPrincipal  Investigator: Tamara Garrido G\u00f3mez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget : \u20ac93.170\nReference : RTI2018-094946-B-I00\nTitle: Contribuci\u00f3n maternal en la patog\u00e9nesis de enfermedades \ngestacionales tard\u00edas como la preeclampsia\nPrincipal Investigator : Carlos Sim\u00f3n Vall\u00e9s\nFunding Body: Ministerio de Ciencia, Innovaci\u00f3n y Universidades\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal budget : \u20ac254.100Reference : PROMETEO/2018/161\nTitle: Medicina regenerativa del \u00fatero humano: desde la terapia \ncelular a la creaci\u00f3n del \u00f3rgano mediante bioingenier\u00eda\nPrincipal  Investigator: Carlos Sim\u00f3n Vall\u00e9s\nFunding Body: Conselleria de Educaci\u00f3n, Cultura y Deporte\nBeneficiary institution : Universidad de Valencia\nDuration: 2018-2021\nTotal  budget : \u20ac297.066,67\nReference : PI-2021-010\nTitle: CellStats: Desarrollo de un modelo estad\u00edstico para la \nevaluaci\u00f3n de cambios poblacionales en datos transcript\u00f3micos \nde c\u00e9lula \u00fanica del endometrio humano\nPrincipal Investigator: Guillermo Ayala Gallego and Beatriz Ros\u00f3n \nBurgo\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary institution : Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal budget : \u20ac16.150\nTHESIS\nThesis title: Decidualizaci\u00f3n defectuosa durante y despu\u00e9s de un \nembarazo con preeclampsia revela la contribuci\u00f3n materna en la \netiolog\u00eda de la enfermedad\nDoctoral candidate:  Laura Rubert Torr\u00f3\nDirector(s): Alfredo Perales Mar\u00edn, Carlos Sim\u00f3n Vall\u00e9s, Tamara \nGarrido G\u00f3mez\nDate of the defense: 08/02/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title: Analysis of the endometrial microbiome and its \nimpact on human reproduction\nDoctoral candidate:  Iolanda  Garc\u00eda Grau\nDirector(s): Carlos Sim\u00f3n Vall\u00e9s, Inmaculada Moreno Gimeno, \nJose Remoh\u00ed Gim\u00e9nez \nDate of the defense: 11/06/2021\nGrade:  Sobresaliente \u201ccum laude\u201d183\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Therapies Against Endometriosis and Endometrial Cancer  \nEmerging group\nLeading Researcher, R4\nRa\u00fal G\u00f3mez Gallego\nUniversity\nRecognised Researcher, R2\nMiguel \u00c1ngel Tejada Gir\u00e1ldez. INCLIVA\nFirst Stage Researchers, R1\nAna Isabel Santos Llamas. INCLIVA\nV\u00edctor Rodr\u00edguez Garc\u00eda. UniversityGroup members\nStrategic aims\n\u2022 To refine the development of homologous and heterologous animal models initiated in the laboratory so that they allow to \nreproduce endometriosis in a more physiological way, reflecting the pain and infertility associated with it in order to achieve \ngreater transferability of the findings in these to the clinic\n\u2022 On these optimized endometriosis animal models, evaluate whether immunomodulatory compounds, such as those currently \nmarketed for clinical use in the non-hormonal treatment of osteoporosis, are effective in the remission of pain as well as in \nthe improvement of fertility\n\u2022 To narrow down the molecular mechanisms involved in improving the parameters under study in order to refine therapeutic \ntargets\n\u2022 To evaluate the clinical feasibility of early non-invasive diagnosis of endometriosis through the combined analysis of multiple \nbiomarkers\nMain lines of research\n\u2022 Dysregulation of the angiogenic component in the appearance and maintenance of endometriosis\n\u2022 Development of animal models of pain and infertility associated with endometriosis and testing of the therapeutic role of \nimmunomodulators in them\n\u2022 Early non-invasive diagnosis of endometriosis through combined analysis of multiple biomarkers\nPUBLICATIONS\nIF 5\nNumber of  \narticles27.506IF\n5.501Average1\nCorresponding  \nauthor2\nNational  \ncollaborations1\nInternational \ncollaborationsResearchers by categories\n2 1 1\nResearchers financed by \ncompetitive public calls or networks\n1 1R1 R2 R4\nR4 R1184\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4SELECTED PUBLICATIONS\n1. Ruiz-Cantero M, Gonzalez-Cano R, Tejada M, Santos-Caballero \nM, Perazzoli G, Nieto F, Cobos E. Sigma-1 receptor: a drug \ntarget for the modulation of neuroimmune and neuroglial \ninteractions during chronic pain. Pharmacological Research. \n2021 Jan;163:105339. doi: 10.1016/j.phrs.2020.105339. \nPMID: 33276102. IF: 7,658\n2. Nunez-Badinez P, De Leo B, Laux-Biehlmann A, Hoffmann \nA, Zollner T, Saunders P, Simitsidellis I, Charrua A, Cruz \nF, Gomez R, Tejada M, McMahon S, Lo Re L, Barthas F, \nVincent K, Birch J, Meijlink J, Hummelshoj L, Sweeney P, \nArmstrong J, Treede R, Nagel J. Preclinical models of \nendometriosis and interstitial cystitis/bladder pain syndrome: \nan Innovative Medicines Initiative-PainCare initiative to \nimprove their value for translational research in pelvic pain. \nPain. 2021 Sep 1;162(9):2349-2365. doi: 10.1097/j.\npain.0000000000002248. PMID: 34448751. IF: 6,961\n3. Tejada M, Santos-Llamas A, Fernandez-Ramirez M, Tarin J, \nCano A, Gomez R. A reassessment of the therapeutic potential \nof a dopamine receptor 2 Agonist (D2-AG) in endometriosis by \ncomparison against a standardized antiangiogenic treatment. \nBiomedicines. 2021 Mar 8;9(3):269. doi: 10.3390/\nbiomedicines9030269. PMID: 33800198. IF: 6,081\n4. Gonzalez-Cano R, Ruiz-Cantero M, Santos-Caballero M, \nGomez-Navas C, Tejada M, Nieto F. Tetrodotoxin, a potential \ndrug for neuropathic and cancer pain relief?. Toxins. 2021 \nJul 12;13(7):483. doi: 10.3390/toxins13070483. PMID: \n34357955. IF: 4,546\n5. Dudenko D, Gomez R, Garcia-Perez M, Tarin J, Cano A. \nBazedoxifene increases the proliferation of human arterial \nendothelial cells but does not affect the expression of \ncyclins A, B, and D1 and of p27(Kip1). Gynecological \nEndocrinology. 2021 Mar;37(3):269-272. doi: \n10.1080/09513590.2021.1876653. PMID: 33480311. \nIF: 2,26\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: 777500- IMI-PainCare\nTitle:  Improving the care of patients suffering from acute or \nchronic pain\nPrincipal Investigator: Ra\u00fal G\u00f3mez Gallego\nFunding body: European Commission\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2023\nTotal budget:  \u20ac257.066,25Reference:  PI20/01835\nTitle:  Evaluaci\u00f3n del potencial papel terap\u00e9utico de la inhibici\u00f3n de \nRANK en modelos optimizados de dolor e infertilidad asociados a \nendometriosis\nPrincipal Investigator: Ra\u00fal G\u00f3mez Gallego\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal budget: \u20ac98.010\nReference:  PI17/02329\nTitle:  Papel de los agonistas dopamin\u00e9rgicos en el dolor e \ninfertilidad asociados a endometriosis en modelos animales de \nnueva generaci\u00f3n\nPrincipal Investigator: Ra\u00fal G\u00f3mez Gallego\nFunding body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal budget: \u20ac111.320\nReference:  FIPSE 3724-20\nTitle:  Diagn\u00f3stico precoz no invasivo de endometriosis mediante \nan\u00e1lisis de nuevos biomarcadores a trav\u00e9s de machine learning\nPrincipal Investigator: Ra\u00fal G\u00f3mez Gallego\nFunding body: Fundaci\u00f3n para la Innovaci\u00f3n y Prospectiva en \nSalud en Espa\u00f1a FIPSE\nBeneficiary institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal budget: \u20ac30.000185\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Research Group on Maternal Fetal Communication  \nEmerging group\nLeading Researcher, R4\nFelipe Vilella Mitjana. IGENOMIX Foundation. INCLIVA\nEstablished Researcher, R3\nFrancisco Raga Baixauli. Hospital. University\nRecognised Researcher, R2\nDavid Bolumar Recuero. University\nFirst Stage Researcher, R1\nJavier Gonz\u00e1lez Fern\u00e1ndez. University\nStaff. Technician\nAna Ochando Fern\u00e1ndez. IGENOMIX FoundationGroup members\nStrategic aims\n\u2022 Project origin of diseases: functional capacity of miRNAs secreted into endometrial fluid in obese and type 2 diabetic patients \nto determine if they are capable of modifying mouse embryos transcriptomically and/or epigenetically\n\u2022 Project Transcriptomic and epigenetic modifications in human embryos: obtain the target genes of miRNA miR-30d in \nhuman embryos to have a list of regions potentially susceptible to methylation. These regions will be used to design the PCRs \nof the bisulfite regions by miSeq sequencing\n\u2022 Project Function of DNA and RNA contained in extracellular vesicles secreted by the human endometrium on the pre-\nimplantation embryo: it has been described that the endometrial fluid is secreted by a series of populations of extracellular \nvesicles (apoptotic bodies, microvesicles and exosomes) that represent a conveyance. We propose that these vesicles \ncontain biomolecules of different natures, specifically focusing on the different types of RNAs and DNA, and that their \ncomposition in these chemical species varies throughout the menstrual cycle and depending on the subpopulation of \nvesicles that is analyzed\nMain lines of research\n\u2022 Study of endometrial receptivity, search for new minimally invasive methods for predicting endometrial receptivity\n\u2022 Maternal-Fetal Communication\nPUBLICATIONS\nIF 3\nNumber of  \narticles22.908IF\n7.636Average1\nCorresponding  \nauthor1\nNational  \ncollaborations2\nInternational \ncollaborationsResearchers by categories\n1 1 1 1 1\nResearchers financed by \ncompetitive public calls or networks\n1 1R3 R2 R1 R4 STAFF\nR4 R1186\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4SELECTED PUBLICATIONS\n1. Vilella F, Wang W, Moreno I, Roson B, Quake S, Simon C. Single-\ncell RNA Sequencing of SARS-CoV-2 cell entry factors in the \npreconceptional human endometrium. Human Reproduction. \n2021 Sep 18;36(10):2709-2719. doi: 10.1093/humrep/\ndeab183. PMID: 34329437. IF: 6,918\n2. Vilella F, Wang W, Moreno I, Quake SR, Simon C. Understanding \nthe human endometrium in the 21st century. American Journal \nof Obstetrics and Gynecology. 2021 Jul;225(1):1-2. doi: \n10.1016/j.ajog.2021.04.224. PMID: 34023092. IF: 8,661\n3. Vilella F, Simon C. Reproductive medicine, as seen through single-\ncell glasses. Fertility and Sterility. 2021 Feb;115(2):296-297. \ndoi: 10.1016/j.fertnstert.2020.11.034. PMID: 33386110. \nIF: 7,329\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : 874867 - HUTER\nTitle: Human Uterus Cell Atlas\nPrincipal  Investigator: Carlos Sim\u00f3n Vall\u00e9s (Felip Vilella Mitjana \nas collaborating researcher)\nFunding Body: European Commission\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal budget: \u20ac4.118.942,50\nReference : PI18/00957\nTitle: Funci\u00f3n del ADN y ARN contenido en ves\u00edculas extracelulares \nsecretadas por el endometrio humano sobre el embri\u00f3n pre-\nimplantatorio\nPrincipal  Investigator: Felip Vilella Mitjana\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal  budget : \u20ac135.520187\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.3.5 Associated Clinical Groups\nGroup\nResearch Group in Care. INVESTENF-INCLIVA\n7\nNumber of  \narticlesIF\n26,068IF\n3,724Average1\nCorresponding  \nauthor6\nNational  \ncollaborations1\nInternational \ncollaborations\n0\nD10\nFirst  \nauthor1\nLast  \nauthor3\nQ12\nQ2\n4 32\noriginal articles reviews corrections188\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Research Group on Research in Care. INVESTENF-INCLIVA  \nClinical Associated group\nLeading Researcher, R4\nM\u00aa Jos\u00e9 Gastaldo Zaragoz\u00e1. Hospital\nRecognised Researchers, R2\nAntonio Mart\u00ednez Sabater. Hospital. University\nIv\u00e1n Juli\u00e1n Rochina. Hospital. University \nMontserrat Ca\u00f1abate Ros. Hospital. University\nPablo Garc\u00eda Molina. University\nFirst Stage Researcher, R1\nEvelin Balaguer L\u00f3pez. Hospital. University\nStaff. Nurses\nAd\u00e1n \u00c1lvarez Ordiales. Hospital. University\nAna Bela Espinosa Briones. Hospital\nAna Gancedo Herrero. Hospital\nConcepci\u00f3n Mateo Orrios. Hospital\nEva Mar\u00eda P\u00e9rez Lafuente. Hospital\nLaura Pla Marzo. INCLIVA\nM\u00aa \u00c1ngeles Montal Navarro. University\nM\u00aa Carmen Barber\u00e1 Ventura. Hospital\nM\u00aa Carmen Rodr\u00edguez Dolz. Hospital. University\nM\u00aa Concepci\u00f3n Rodrigo Ruiz. Hospital\nM\u00aa Dolores Cantero L\u00f3pez. Hospital\nM\u00aa Gabriela Chova Mallent. Hospital\nM\u00aa Jes\u00fas Zafra Pir\u00e9s. Hospital\nM\u00aa Luisa Mu\u00f1oz Illescas. Hospital\nM\u00aa Pilar Bernab\u00e9u Adri\u00e1n. HospitalGroup members\nStrategic aims\n\u2022 Contribute with scientific nursing evidence to improve pediatric nursing care \n\u2022 Conduct research in pediatric nursing to disseminate new knowledge \n\u2022 Work for the Quality and Safety of pediatric nursing care\nMain lines of research\n\u2022 Child and adolescent health care \n\u2022 Skin care and skin integrity \n\u2022 Mental Health Care \n\u2022 Care in aging, fragility and chronicityResearchers by categories\n4 1 1 20R2 R1 R4 STAFF\nM\u00aa Victoria Orej\u00f3n Lagunas. Hospital\nMireia S\u00e1nchez Morcillo. Hospital\nNuria Garrido Zafra. Hospital\nSonia Mora Navarro. Hospital\nStaff. Technician\nDavid Palanca Broseta. Hospital189\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 10\nNumber of  \narticles35.767IF\n3.576Average2\nCorresponding  \nauthor8\nNational  \ncollaborations2\nInternational \ncollaborations\nSELECTED PUBLICATIONS\n1. Zamora-Sanchez J, Zabaleta-del-Olmo E, Fernandez-Bertolin S, \nGea-Caballero V, Julian-Rochina I, Perez-Tortajada G, Amblas-\nNovellas J. Profiles of frailty among older people users of a \nhome-based primary care service in an urban area of Barcelona \n(Spain): an observational study and cluster analysis. Journal of \nClinical Medicine. 2021 May 13;10(10):2106. doi: 10.3390/\njcm10102106. PMID: 34068296. IF: 4,241\n2. Zamora-Sanchez J, Zabaleta-del-Olmo E, Gea-Caballero V, \nJulian-Rochina I, Perez-Tortajada G, Amblas-Novellas J. \nConvergent and discriminative validity of the Frail-VIG index with \nthe EQ-5D-3L in people cared for in primary health care. BMC \nGeriatrics. 2021 Apr 13;21(1):243. doi: 10.1186/s12877-\n021-02186-x. PMID: 33849481. IF: 3,921\n3. Sanchis-Sanchez E, Lluch-Girbes E, Guillart-Castells P, Georgieva \nS, Garcia-Molina P, Blasco J. Effectiveness of mechanical \ndiagnosis and therapy in patients with non-specific chronic \nlow back pain: a literature review with meta-analysis. Brazilian \nJournal of Physical Therapy. 2021;25(2):117-134. doi: \n10.1016/j.bjpt.2020.07.007. PUBMED: 32773288. IF: \n3,377\n4. Cabellos-Garcia A, Martinez-Sabater A, Diaz-Herrera M, Gea-\nCaballero V, Castro-Sanchez E. Health literacy of patients on oral \nanticoagulation treatment- individual and social determinants \nand effect on health and treatment outcomes. BMC Public \nHealth. 2021 Jul 9;21(1):1363. doi: 10.1186/s12889-021-\n11259-w. PMID: 34243749. IF: 3,295\n5. Garcia-Molina P, Roig Casasus S, Sanchis-Sanchez E, Balaguer-\nLopez E, Ruescas-Lopez M, Blasco JM. Evaluation of interface \npressure and temperature management in five wheelchair \nseat cushions and their effects on user satisfaction. Journal \nof Tissue Viability. 2021 Aug;30(3):402-409. doi: 10.1016/j.\njtv.2021.05.004. PMID: 34052087. IF: 2,932RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  AP-2021-015\nTitle: VISUALSKIN: Dise\u00f1o de dispositivo cl\u00ednico para la evaluaci\u00f3n \ndel riesgo de lesi\u00f3n en la piel en personas encamadas o usuarias \nde silla de ruedas\nPrincipal Investigator: Julio Martos Torres and Pablo Garc\u00eda \nMolina\nFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary institution:  Universidad de Valencia - INCLIVA \nDuration: 2021-2022\nTotal Budget: \u20ac4.750190\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Groups\nDepartment of Anesthesiology\nDepartment of Biochemistry and Clinical Analysis\nArrhythmia and Cardiac Pacing Unit\nDepartment of Cardiology\nDepartment of Cardiovascular Surgery\nDepartment of Dentistry\nDepartment of Dermatology\nDepartment of Digestive Medicine\nDepartment of Endocrinology\nDepartment of Family and Community Medicine\nDepartment of General Surgery\nDepartment of Gynecology and Obstetrics \nDepartment of Hematology and Hemotherapy\nDepartment of Home Hospitalization\nDepartment of Infectious Diseases \nDepartment of Intensive Medicine\nDepartment of Internal Medicine \nDepartment of Maxillofacial Surgery\nDepartment of Medical Emergency \nDepartment of Medical Oncology \nDepartment of Microbiology\nDepartment of Nephrology\nDepartment of Neurology\nDepartment of Neurosurgery\nDepartment of Nuclear Medicine\nDepartment of Ophthalmology\nDepartment of Otorhinolaryngology\nDepartment of Pathological Anatomy\nDepartment of Pediatric Surgery\nDepartment of Pediatrics\nDepartment of Pharmacy\nDepartment of Plastic Surgery\nDepartment of Psychiatry\nDepartment of Radiologic Diagnosis\nDepartment of Radiotherapy\nDepartment of Rehabilitation\nDepartment of Thoracic Surgery\nDepartment of Traumatology and Orthopedic Surgery\nDepartment of Urology\nTeaching and Dissemination of Knowledge Unit4.4 Hospital division research area191\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4232\nNumber of  \narticlesIF\n1157.404IF\n4.988Average48\nCorresponding  \nauthor123\nNational  \ncollaborations42\nInternational \ncollaborations\n28\nD166\nFirst  \nauthor41\nLast  \nauthor99\nQ138\nQ2\n17919121663\noriginal articles letters editorial review case reports corrections192\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Department of Anesthesiology\nStrategic aims\n\u2022 The effects of advanced monitoring and drugs on hemodynamic management in patients undergoing surgery\n\u2022 Open Lung Approach for the Acute Respiratory Distress Syndrome\n\u2022 Study and development of methods of detection of infections\n\u2022 Development of new strategies and drugs for pain treatment\nMain lines of research\n\u2022 Oxidative stress and protection of organs in ischemia-reperfusion surgery\n\u2022 Ventilatory and pharmacological strategies to decrease organ damage in the lungs associated with mechanical ventilation \nin healthy and injured lungs\n\u2022 Development of hemodynamic monitoring and its application in the field of patients undergoing surgery or admitted to critical \ncare units\n\u2022 Study and development of methods of detection of infections, especially fungal and virological, and how to prevent them\n\u2022 Study and development of therapeutic drug monitoring (TDM) to describe antimicrobials pharmacokinetics (PK) and \ndetermination of minimum inhibitory concentration (MIC)\n\u2022 Development of new strategies and drugs for pain treatment\n\u2022 Development of new strategies and monitoring for Traumatic Brain Injury\nPUBLICATIONS\nIF 3\nNumber of  \narticles14.761IF\n4.92Average1\nCorresponding  \nauthor2\nNational  \ncollaborations1\nInternational \ncollaborations\nmanagement and postoperative outcomes in enhanced \nrecovery colorectal surgery: secondary analysis of POWER \ntrial. Minerva Anestesiologica. 2021 Jan;87(1):13-25. doi: \n10.23736/S0375-9393.20.14589-9. PMID: 33538417. \nIF: 3,051\n3. Castro SM, Belda Nacher FJ, Navarro CD, Puig Bernabeu J. A \nBench Evaluation of Eight Home-Care Ventilators. Respiratory \nCare. 2021 Oct;66(10):1531-1541. doi: 10.4187/\nrespcare.08650. PMID: 34552013. IF: 2,558SELECTED PUBLICATIONS\n1. Zorrilla-Vaca A, Stone A, Ripolles-Melchor J, Abad-Motos A, \nRamirez-Rodriguez J, Galan-Menendez P, Mena G, Grant M, \nSpanish Perioperative Audit Res Ne, Spanish Perioperative \nAudit Res Ne, Spanish Perioperative Audit Res Ne. \nInstitutional factors associated with adherence to enhanced \nrecovery protocols for colorectal surgery: Secondary analysis \nof a multicenter study. Journal of Clinical Anesthesia. 2021 \nNov;74:110378. doi: 10.1016/j.jclinane.2021.110378. \nPMID: 34144497. IF: 9,542\n2. Serrano A, Diaz-Cambronero O, Melchor-Ripolles J, Abad-\nGurumeta A, Ramirez-Rodriguez J, Martinez-Ubieto J, \nSanchez-Merchante M, Rodriguez R, Jorda L, Gil-Trujillo S, \nCabellos-Olivares M, Bordonaba-Bosque D, Aldecoa C, POWER \nGrp, POWER Group, POWER Group. Neuromuscular blockade 193\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Biochemistry and Clinical Analysis\nStrategic aims\nDevelopment of strategies for laboratory test requesting appropriateness with electronic request system in online communication \nwith the Medical Services of the Cl\u00ednico-Malvarrosa Health Department\nMain lines of research\n\u2022 Group-specific: managing laboratory test requests and patient safety through electronic requests \n\u2022 Laboratory Service staff research is carried out in collaboration collaboration with the following clinical research groups: \nClinical Cardiology (ischemic heart disease and heart failure), Cardiometabolic Risk and Diabetes (lipid metabolism and \ninsulin resistance) Clinical Hematology (Minimal Residual Disease), Infant Gastroenterology (Inflammatory Bowel Disease), \nPublic Health and Digestive System (Stratification of the priority of colonoscopy using the SOH test in the Colorectal Cancer \nScreening Program)\nPUBLICATIONS\nIF 13\nNumber of  \narticles49.046IF\n3.772Average3\nCorresponding  \nauthor4\nNational  \ncollaborations0\nInternational \ncollaborations\nJ. Clinical history and detectable troponin concentrations below \nthe 99th percentile for risk stratification of patients with chest \npain and first normal troponin. Journal of Clinical Medicine. \n2021 Apr 20;10(8):1784. doi: 10.3390/jcm10081784. \nPMID: 33923925. IF: 4,241\n5. De La Espriella Juan R, Nu\u00f1ez Benito E, Ll\u00e0cer P, Garcia Blas S, \nVentura Haro S, N\u00fa\u00f1ez J, S\u00e1nchez R, Facila De La Esperanza R, \nVaquer Santamaria J, Bod\u00ed Peris V, Santas Olmeda E, Mi\u00f1ana \nEscriva G, Mollar Fernandez A, N\u00fa\u00f1ez Mar\u00edn G, Chorro Gasc\u00f3 \nF, G\u00f3rriz Teruel J, Sanchis Fores J, Bay\u00e9s-Genis A, Nu\u00f1ez \nVillota J. Early urinary sodium trajectory and risk of adverse \noutcomes in acute heart failure and renal dysfunction. Revista \nEspanola de Cardiologia (English ed.). 2021 Jul;74(7):616-\n623. doi: 10.1016/j.rec.2020.06.004. PMID: 32624444. \nIF: 4,753SELECTED PUBLICATIONS\n1. Rodriguez-Borja E, Pozo-Giraldez A, Diaz-Gimenez M, Hervas-\nRomero A, Corchon-Peyrallo A, Vinyals-Bellido I, Carratala-\nCalvo A. Decision support system through automatic \nalgorithms and electronic request in diagnosis of anaemia \nfor primary care patients. Biochemia Medica. 2021 Jun \n15;31(2):020702. doi: 10.11613/BM.2021.020702. \nPMID: 33927552. IF: 2,313\n2. Pozo-Giraldez A, Rodriguez-Borja E, Diaz-Gimenez M, Carratala-\nCalvo A, Magro-Pose P, Perez-Griera J. Discordant SOX-1 \nantibodies results in paraneoplastic Lambert-Eaton syndrome \ndiagnosis by the clinical laboratory. Clinical Biochemistry. 2021 \nNov;97:82-84. doi: 10.1016/j.clinbiochem.2021.08.004. \nPMID: 34450126. IF: 3,281\n3. Estal R, Bustos B, Simo G, Farinos J, Navarro I, de Miquel V, \nSanchez R, Marco V, Ros M, Suela S, Estrada R. MicroRNAs \nexpression associated with aggressive clinicopathological \nfeatures and poor prognosis in primary cutaneous \nmelanomas. Melanoma Research. 2021 Feb 1;31(1):18-\n26. doi: 10.1097/CMR.0000000000000709. PMID: \n33234848. IF: 3,599\n4. Fernandez-Cisnal A, Valero E, Garcia-Blas S, Pernias V, Pozo A, \nCarratala A, Gonzalez J, Noceda J, Minana G, Nunez J, Sanchis 194\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Arrhythmia and Cardiac Pacing Unit\nStrategic aims\n\u2022 Our Unit has received the Excellence Credit in the Program \u201cAtrial Fibrillation Ablation\u201d from the Spanish Society of Cardiology\n\u2022 The multicentre project \u201cLeft atrial geometry and outcome in atrial fibrillation ablation, LAGO-AF\u201d has been concluded. First \nresults have been published\nMain lines of research\n\u2022 Collaboration in the national prospective observational study on Crioballoon ablation of atrial fibrillation (RECABA)\n\u2022 Leading and Collaboration in the registry on sleep alterations in patiens with pacemakers\n\u2022 Leading a multicenter prospective study on ablation of typical atrial flutter without radioscopy and guided by electrogram \namplitudes\nPUBLICATIONS\nIF 5\nNumber of  \narticles25.442IF\n5.088Average1\nCorresponding  \nauthor2\nNational  \ncollaborations3\nInternational \ncollaborations\non the incidence of implantable cardioverter-defibrillator \ntherapies. Revista Espanola de Cardiologia (english Ed.). 2021 \nApr;74(4):296-302. doi: 10.1016/j.rec.2020.06.017. PMID: \n32773348. IF: 4,753\n4. Rodriguez-Manero M, Baluja A, Hernandez J, Munoz C, Calvo D, \nFernandez-Armenta J, Garcia-Fernandez A, Zorio E, Arce-Leon \nA, Sanchez-Gomez J, Mosquera-Perez I, Arias M, Diaz-Infante \nE, Exposito V, Jimenez-Ramos V, Teijeira E, Canadas-Godoy M, \nGuerra-Ramos J, Oloriz T, Basterra N, Sousa P, Elices-Teja J, \nGarcia-Bolao I, Gonzalez-Juanatey J, Brugada R, Gimeno J, \nBrugada J, Arbelo E. Validation of multiparametric approaches \nfor the prediction of sudden cardiac death in patients with \nBrugada syndrome and electrophysiological study. Revista \nEspanola de Cardiologia (english Ed.). 2021 Aug 31:S1885-\n5857(21)00223-1. doi: 10.1016/j.rec.2021.07.007. PMID: \n34479845. IF: 4,753\n5. Ferrero-de-Loma-Osorio A, Cozar R, Garcia-Alberola A, Valles \nE, Barrera A, Toquero J, Ormaetxe J, Sanchez J, Ruiz-Granell \nR, Amador P, Rubio J, Marti-Amor J, Pascual P, Molina I, \nMartinez-Alday J, RECABA Investigators. Primary results of \nthe Spanish cryoballoon ablation registry: acute and long-term \noutcomes of the RECABA study. Scientific Reports. 2021 \nAug 26;11(1):17268. doi: 10.1038/s41598-021-96655-3. \nPMID: 34446764. IF: 4,379SELECTED PUBLICATIONS\n1. Rodriguez-Manero M, Jorda P, Hernandez J, Munoz C, Grima \nE, Garcia-Fernandez A, Canadas-Godoy M, Jimenez-Ramos \nV, Oloriz T, Basterra N, Calvo D, Perez-Alvarez L, Arias \nM, Exposito V, Aleman A, Diaz-Infante E, Guerra-Ramos J, \nFernandez-Armenta J, Arce-Leon A, Sanchez-Gomez J, Sousa \nP, Garcia-Bolao I, Baluja A, Campuzano O, Sarquella-Brugada \nG, Martinez-Sande J, Gonzalez-Juanatey J, Gimeno J, Brugada \nJ, Arbelo E. Long-term prognosis of women with Brugada \nsyndrome and electrophysiological study. Heart Rhythm. 2021 \nMay;18(5):664-671. doi: 10.1016/j.hrthm.2020.12.020. \nPMID: 33359877. IF: 6,343\n2. Viola G, Stabile G, Bandino S, Rossi L, Marrazzo N, Pecora \nD, Bottoni N, Solimene F, Schillaci V, Scaglione M, Ocello \nS, Baiocchi C, Santoro A, Donzelli S, De Ruvo E, Lavalle C, \nSanchez-Gomez J, Pastor J, Grandio P, Ferraris F, Castro A, \nRebellato L, Marchese P, Adao L, Primo J, Barra S, Casu G. \nSafety, efficacy, and reproducibility of cavotricuspid isthmus \nablation guided by the ablation index: acute results of the FLAI \nstudy. Europace. 2021 Feb 5;23(2):264-270. doi: 10.1093/\neuropace/euaa215. PMID: 33212484. IF: 5,214\n3. Loughlin G, Datino T, Arenal A, Ruiz Granell R, Sanchez Gomez J, \nPerez L, Martinez-Ferrer J, Alzueta J, Perez-Lorente F, Vinolas \nX, Fidalgo Andres M, Fernandez de la Concha J. Predictors \nof adoption and impact of evidence-based programming 195\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : PI-2021-015\nTitle: RECONST_ECG: Evaluaci\u00f3n del proceso de reconstrucci\u00f3n \nde un electrocardiograma de 12 derivaciones a partir de 3 en \ncondiciones ambulatorias\nPrincipal Investigator: Javier Calpe Maravillas and Ricardo Ruiz \nGranellFunding Body: Universidad de Valencia - INCLIVA\nBeneficiary Insitution : Universidad de Valencia - INCLIVA\nDuration: 2021-2022\nTotal Budget: \u20ac8.712\nDepartment of Cardiology\nPUBLICATIONS\nIF 21\nNumber of  \narticles79.504IF\n3.785Average2\nCorresponding  \nauthor13\nNational  \ncollaborations3\nInternational \ncollaborations\n4. Lorenzo M, Palau P, Llacer P, Dominguez E, Ventura B, \nNunez G, Minana G, Solsona J, Santas E, De La Espriella R, \nBodi V, Nunez E, Sanchis J, Bayes-Genis A, Nunez J. Clinical \nutility of antigen carbohydrate 125 for planning the optimal \nlength of stay in acute heart failure. European Journal of \nInternal Medicine. 2021 Oct;92:94-99. doi: 10.1016/j.\nejim.2021.05.037. PMID: 34130879. IF: 4,487\n5. Gabaldon-Perez A, Marcos-Garces V, Gavara J, Rios-Navarro \nC, Minana G, Bayes-Genis A, Husser O, Sanchis J, Nunez \nJ, Chorro F, Bodi V. Coronary Revascularization and long-\nterm survivorship in chronic coronary syndrome. Journal of \nClinical Medicine. 2021 Feb 5;10(4):610. doi: 10.3390/\njcm10040610. PMID: 33562869. IF: 4,241SELECTED PUBLICATIONS\n1. Nunez J, Lorenzo M, Minana G, Palau P, Monmeneu JV, Lopez-\nLereu MP, Gavara J, Marcos-Garces V, Rios-Navarro C, Perez \nN, de Dios E, Nunez E, Sanchis J, Chorro FJ, Bayes-Genis A, \nBodi V. Sex differences on new-onset heart failure in patients \nwith known or suspected coronary artery disease. European \nJournal of Preventive Cardiology. 2021 Dec 29;28(15):1711-\n1719. doi: 10.1093/eurjpc/zwab078. PMID: 33970216. \nIF: 7,084\n2. Santas E, Minana G, Palau P, De La Espriella R, Lorenzo M, \nNunez G, Sanchis J, Chorro FJ, Bayes-Genis A, Nunez J. Right \nheart dysfunction and readmission risk across left ventricular \nejection fraction status in patients with acute heart failure. \nJournal of Cardiac Failure. 2021 Oct;27(10):1090-1098. \ndoi: 10.1016/j.cardfail.2021.06.020. PMID: 34273477. IF: \n5,712\n3. Gavara J, Marcos-Garces V, Lopez-Lereu, MP, Monmeneu JV, \nRios-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldon A, \nCanoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez \nE, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-\nPalomares JF, Ortiz-Perez JT, Bodi V. Magnetic resonance \nassessment of left ventricular ejection fraction at any time \npost-infarction for prediction of subsequent events in a large \nmulticenter STEMI Registry. Journal of Magnetic Resonance \nImaging. 2021 Jun 16. doi: 10.1002/jmri.27789. PMID: \n34137478. IF: 4,813196\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Department of Cardiovascular Surgery\nDepartment of DentistryPUBLICATIONS\nPUBLICATIONSIF\nIF4\n1Number of  \narticles\nNumber of  \narticles15.474\n4.379IF\nIF3.868\n4.379Average\nAverage0\n0Corresponding  \nauthor\nCorresponding  \nauthor4\n1National  \ncollaborations\nNational  \ncollaborations0\n0International \ncollaborations\nInternational \ncollaborations3. Gonzalez-Barbeito M, Arribas J, Vazquez A, Carnero M, \nSarralde J, Cal-Purrinos N, Canovas S, Maroto L, Gutierrez \nF, Hornero F, Bautista-Hernandez V. Risk factors for \npostoperative pacemaker implantation after rapid deployment \naortic valve replacement: results from the RADAR Registry. \nAdvances in Therapy. 2021 Apr;38(4):1832-1842. doi: \n10.1007/s12325-021-01622-z. PMID: 33665760. IF: \n3,845\n4. Fletcher-Sanfeliu D, Garcia-Granero A, Domenech Dolz A, \nPellino G, Orbis F, Arroyo A, Valverde-Navarro A, Sabater Orti L, \nMartin-Gonzalez I. Surgical anatomy applied to transperitoneal \napproaches of the abdominal aorta and visceral trunks. \nDynamic article. Cirugia Espanola. 2021 Oct;99(8):562-571. \ndoi: 10.1016/j.cireng.2021.08.002. PMID: 34538636. IF: \n1,653\nCoV-2. Scientific Reports. 2021 Dec 22;11(1):24392. doi: \n10.1038/s41598-021-03461-y. PMID: 34937855. IF: \n4,379SELECTED PUBLICATIONS\n1. Viana D, Marcos-Garces V, Blas S, Fores J, Romano J, Baena \nJ, Giner M, Suarez N, Chorro F, Fornas F. Immunoglobulin \nG4-related aortitis and severe aortic valve stenosis \ntreated with transcatheter aortic valve replacement and \nimmunosuppression. Canadian Journal of Cardiology. 2021 \nNov;37(11):1873-1876. doi: 10.1016/j.cjca.2021.07.015. \nPMID: 34333027. IF: 5,223\n2. Carnero-Alcazar M, Maroto-Castellanos L, Hernandez-\nVaquero D, Lopez-Menendez J, Hornero Sos F, Silva-Guisasola \nJ, Cobiella-Carnicer J, Perez-Camargo D, Alvarez-de Arcaya \nM, Campelos-Fernandez P, Elvira-Martinez C. Isolated aortic \nvalve replacement in Spain: national trends in risks, valve \ntypes, and mortality from 1998 to 2017. Revista Espanola \nde Cardiologia (english Ed.). 2021 Aug;74(8):700-707. doi: \n10.1016/j.rec.2020.06.008. PMID: 32800747. IF: 4,753\nSELECTED PUBLICATIONS\n1. Ferrer MD, Sanchez Barrueco A, Martinez-Beneyto Y, Mateos-\nMoreno MV, Ausina-Marquez V, Garcia-Vazquez E, Puche-\nTorres M, Forner Giner MJ, Campos Gonzalez A, Santillan \nCoello JM, Alcala Rueda I, Villacampa Auba JM, Cenjor \nEspanol C, Lopez Velasco A, Santolaya Abad D, Garcia-Esteban \nS, Artacho A, Lopez-Labrador X, Mira A. Clinical evaluation \nof antiseptic mouth rinses to reduce salivary load of SARS-197\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Dermatology\nStrategic aims\n\u2022 To continue making a biobank of melanoma patients\nMain lines of research\n\u2022 Melanocytic tumors. Malignant Melanoma: study of cytokines involved in tumor growth\n\u2022 Hemangiomas\n\u2022 Contact dermatitis\n\u2022 Alopecia\n\u2022 Psoriasis: application of new molecules in treatment\nPUBLICATIONS\nIF 15\nNumber of  \narticles40.851IF\n2.723Average9\nCorresponding  \nauthor5\nNational  \ncollaborations0\nInternational \ncollaborations\n4. Benavent M, Fernandez I, Negrete E, Gullon G, Roldan F. \nDouble nail of the second toe: a case report with sonographic \nand radiological correlation. Pediatric Dermatology. 2021 \nNov;38(6):1588-1589. doi: 10.1111/pde.14830. PMID: \n34647639. IF: 1,588\n5. Porcar Saura S, Guillen Climent S, Pinazo Canales M, \nMonteagudo C. Melanocytic hyperactivation simulating \nan acral lentiginous melanoma in a patient with parkinson \ndisease treated by levodopa. American Journal of \nDermatopathology. 2021 Mar 1;43(3):238-241. doi: \n10.1097/DAD.0000000000001807. PMID: 33595233. \nIF: 1,533SELECTED PUBLICATIONS\n1. Perandones-Gonzalez H, Dominguez-Santas M, Fernandez-\nDomper L, Agud-De D, Boixeda P. Ex vivo dermoscopy \nin demodicosis. Journal of the American Academy of \nDermatology. 2021 Jul 27;S0190-9622(21)02180-0. doi: \n10.1016/j.jaad.2021.07.031 PMID: 34329644. IF: 11,257\n2. Estebanez A, Puche-Torres M, Garcia J, Cunat A, Canales M, \nFelix M, Campos S, Canada J, Hernandez J. Characteristics \nof mucocutaneous vascular malformations drawn from \na decade of a multidisciplinary committee experience. \nDermatologic Therapy. 2021 Sep;34(5):e15074. doi: \n10.1111/dth.15074. PMID: 34338412. IF: 2,851\n3. Porcar Saura S, Garc\u00eda V\u00e1zquez A, Ramon Quiles M. \nParaneoplastic acrokeratosis (Bazex syndrome). Medicina \nClinica. 2021 Feb 12;156(3):154. doi: 10.1016/j.\nmedcli.2019.12.016. PMID: 32197862. IF: 1,725\nDepartment of Digestive Medicine \nStrategic aims\n\u2022 Update of protocols and clinical guidelines of the Department\n\u2022 It has been possible to consolidate the relationship of the Unit of Inflammatory Bowel Disease of our Department with the \nnetwork of National Units, through collaborative studies that have been published in international journals of category Q1 \nand Q3198\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Main lines of research\n\u2022 On the section of gastroenterology, to continue the studies on digestive hemorrhage, acute pancreatitis, inflammatory bowel \ndisease, motion sickness and digestive benign anorectal pathology\n\u2022 On the hepatology division to continue the analysis of hepatic encephalopathy, the nonalcoholic, epidemiological, therapeutic \nand immunoprophylaxis on Hepatitis Virus steatohepatitis. Also hepatocellular damage and nitric oxide and liver tumors\n\u2022 About endoscopy division: study on the therapeutic dilatation, the ecoendoscopia diagnostics and therapeutics, ampulectomia, \ndiverticulotomy of Zencker and digestive prostheses\nPUBLICATIONS\nIF 16\nNumber of  \narticles95.781IF\n5.986Average2\nCorresponding  \nauthor10\nNational  \ncollaborations1\nInternational \ncollaborations\n4. Calafat M, Manosa M, Ricart E, Nos P, Iglesias-Flores E, Vera \nI, Lopez-SanRoman A, Guardiola J, Taxonera C, Minguez \nM, Martin-Arranz MD, de Castro L, de Francisco R, Rivero \nM, Garcia-Planella E, Calvet X, Garcia-Lopez S, Marquez L, \nGomollon F, Barrio J, Esteve M, Munoz F, Gisbert JP, Gutierrez \nA, Hinojosa J, Arguelles-Arias F, Busquets D, Bujanda L, Perez-\nCalle JL, Sicilia B, Merino O, Martinez P, Bermejo F, Lorente \nR, Barreiro-de Acosta M, Rodriguez C, Garcia-Sepulcre MF, \nMonfort D, Canete F, Domenech E. Risk of immunomediated \nadverse events and loss of response to infliximab in elderly \npatients with inflammatory bowel disease. A cohort study \nof the ENEIDA registry. Journal of Crohn\u2019s & Colitis. 2021 \nDec 3;jjab213. doi: 10.1093/ecco-jcc/jjab213. PMID: \n34864947. IF: 9,071\n5. Chaparro M, Garre A, Iborra M, Sierra M, Barreiro-de \nAcosta M, Fernandez-Clotet A, de Castro L, Bosca-Watts M, \nCasanova M, Lopez-Garcia A, Lorente R, Rodriguez C, Carbajo \nA, Arroyo M, Gutierrez A, Hinojosa J, Martinez-Perez T, Villoria \nA, Bermejo F, Busquets D, Camps B, Canete F, Mancenido \nN, Monfort D, Navarro-Llavat M, Perez-Calle J, Ramos L, \nRivero M, Angueira T, Camo P, Carpio D, Garcia-de-la-Filia \nI, Gonzalez-Munoza C, Hernandez L, Huguet J, Morales V, \nSicilia B, Vega P, Vera I, Zabana Y, Nos P, Suarez Alvarez P, \nCalvino-Suarez C, Ricart E, Hernandez V, Minguez M, Marquez \nL, Hervias Cruz D, Rubio Iturria S, Barrio J, Gargayo-Puyuelo \nC, Frances R, Hinojosa E, Del Moral M, Calvet X, Algaba A, \nAldeguer X, Guardiola J, Manosa M, Pajares R, Piqueras \nM, Garcia-Bosch O, Lopez Serrano P, Castro B, Lucendo A, SELECTED PUBLICATIONS\n1. de-Madaria E, Sanchez-Marin C, Carrillo I, Vege S, Chooklin \nS, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Marta K, Kamal A, \nLauret-Brana E, Barbu S, Nunes V, Ruiz-Rebollo M, Garcia-\nRayado G, Lozada-Hernandez E, Pereira J, Negoi I, Espina S, \nHollenbach M, Litvin A, Bolado-Concejo F, Vargas R, Pascual \nMoreno I, Singh V, Mira J. Design and validation of a patient-\nreported outcome measure scale in acute pancreatitis: the \nPAN-PROMISE study. Gut. 2021 Jan;70(1):139-147. doi: \n10.1136/gutjnl-2020-320729. PMID: 32245906. IF: \n23,059\n2. Tosca J, Villagrasa R, Sanahuja A, Sanchez A, Trejo G, Herreros \nB, Pascual I, Mas P, Pena A, Minguez M. Caustic ingestion: \ndevelopment and validation of a prognostic score. Endoscopy. \n2021 Aug;53(8):784-791. doi: 10.1055/a-1297-0333. \nPMID: 33096569. IF: 10,093\n3. Chaparro M, Garre A, Mesonero F, Rodriguez C, Barreiro-\nde Acosta M, Martinez-Cadilla J, Arroyo M, Mancenido \nN, Sierra-Ausin M, Vera-Mendoza I, Casanova M, Nos P, \nGonzalez-Munoza C, Martinez T, Bosca Watts M, Calafat \nM, Busquets D, Girona E, Llao J, Martin-Arranz M, Piqueras \nM, Ramos L, Suris G, Bermejo F, Carbajo A, Casas-Deza D, \nFernandez-Clotet A, Garcia M, Ginard D, Gutierrez-Casbas A, \nHernandez L, Lucendo A, Marquez L, Merino-Ochoa O, Rancel \nF, Taxonera C, Lopez Sanroman A, Rubio S, Domenech E, \nGisbert J. Tofacitinib in ulcerative colitis: real-world evidence \nfrom the ENEIDA Registry. Journal of Crohn\u2019s & Colitis. 2021 \nJan 13;15(1):35-42. doi: 10.1093/ecco-jcc/jjaa145. PMID: \n32969471. IF: 9,071199\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Endocrinology \nPUBLICATIONS\nIF 1\nNumber of  \narticles6.514IF\n6.514Average0\nCorresponding  \nauthor1\nNational  \ncollaborations0\nInternational \ncollaborations\nChemistry. 2021 Oct 5;221:113535. doi: 10.1016/j.\nejmech.2021.113535. PMID: 33992930. IF: 6,514SELECTED PUBLICATIONS\n1. Villarroel-Vicente C, Gutierrez-Palomo S, Ferri J, Cortes D, \nCabedo N. Natural products and analogs as preventive agents \nfor metabolic syndrome via peroxisome proliferator-activated \nreceptors: an overview. European Journal of Medicinal Montoro M, Castro Ortiz E, Mesonero F, Garcia-Planella \nE, Fuentes D, Bort I, Delgado-Guillena P, Arias L, Iglesias A, \nCalvo M, Esteve M, Domenech E, Gisbert J. Effectiveness and \nsafety of ustekinumab in ulcerative colitis: real-world evidence \nfrom the ENEIDA registry. Journal of Crohn\u2019s & colitis. 2021 \nNov 8;15(11):1846-1851. doi: 10.1093/ecco-jcc/jjab070. \nPMID: 33860795. IF: 9,071\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: Estudio nacional en enfermedad inflamatoria intestinal \nsobre determinantes gen\u00e9ticos y ambientales (Estudio ENEIDA)\nPrincipal  Investigator: Miguel M\u00ednguez P\u00e9rez\nFunding Body: Janssen-Cilag\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac22.500\nTitle: Influencia de la actividad inflamatoria en la funci\u00f3n anorrectal \nde los pacientes con Enfermedad Inflamatoria Intestinal\nPrincipal  Investigator: Ana Sanahuja Mart\u00ednez\nFunding Body: Sociedad Valenciana de Patolog\u00eda Digestiva\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac5.000THESIS\nThesis title: Impacto de la inmunosuppresi\u00f3n y otros factores \nde riesgo en el desarrollo de infecciones en pacientes con \nenfermedad inflamatoria intestinal: estudio caso-control\nDoctoral candidate:  Natalia Alicia Garc\u00eda Gimeno \nDirector(s): Miguel M\u00ednguez P\u00e9rez, Joan Tosca Cuquerella, \nFrancisco Mora Miguel\nDate of the defense: 05/11/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nThesis title:  Fracaso renal agudo en pancreatitis aguda: \nprevalencia, factores asociados, evoluci\u00f3n cl\u00ednica y utilidad de la \ncistatina C\nDoctoral candidate:  Paola V\u00e1zquez Fern\u00e1ndez\nDirector(s): Francisco Mora Miguel, Isidro Antonio Torregrosa \nMaicas, Isabel Pascual Moreno\nDate of the defense: 22/11/2022\nGrade:  Sobresaliente \u201ccum laude\u201d200\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Department of Family and Community Medicine\nDepartment of General Surgery PUBLICATIONS\nPUBLICATIONSIF\nIF1\n11Number of  \narticles\nNumber of  \narticles1.137\n45.314IF\nIF1.137\n4.119Average\nAverage0\n2Corresponding  \nauthor\nCorresponding  \nauthor1\n2National  \ncollaborations\nNational  \ncollaborations0\n1International \ncollaborations\nInternational \ncollaborationsOct;53(8):102063. doi: 10.1016/j.aprim.2021.102063. \nPMID: 34044187. IF: 1,137\n4. Pla-Marti V, Martin-Arevalo J, Moro-Valdezate D, Garcia-\nBotello S, Perez-Santiago L, Lapena-Rodriguez M, Bauza-\nCollado M, Huerta M, Rosello-Keranen S, Espi-Macias A. \nPrognostic implications of surgical specimen quality on the \noncological outcomes of open and laparoscopic surgery in \nmid and low rectal cancer. Langenbeck\u2019s Archives of Surgery. \n2021 Oct 30. doi: 10.1007/s00423-021-02351-1. PMID: \n34716825. IF: 3,445\n5. Fernandez Moreno M, P\u00e9rez Santiago L, Mart\u00ed Fernandez \nR, Le\u00f3n Espinoza C, Ortega Serrano J. Is laparoscopic \napproach still a risk factor for post-appendectomy intra-\nabdominal abscess?. Journal of Trauma and Acute Care \nSurgery. 2021 Jan 1;90(1):163-169. doi: 10.1097/\nTA.0000000000002957. PMID: 33003018. IF: 3,313SELECTED PUBLICATIONS\n1. Huerta O, Cubero I, Gutierrez A, Gonzalez M. Does primary care \nintervention have an impact in the place of death for patients \nin a palliative care program?. Atencion Primaria. 2021 \nSELECTED PUBLICATIONS\n1. Perez Santiago L, Cassinello Fernandez N, Alfonso Ballester \nR, Diaz Exposito R, Moscardo Navarro A, Ortega Serrano J. \nIntraoperative scintigraphy with portable gamma camera \nfor the localization of interaortocaval paraganglioma. Clinical \nNuclear Medicine. 2021 Nov 1;46(11):e543-e547. doi: \n10.1097/RLU.0000000000003717. PMID: 34183502. \nIF: 7,794\n2. GlobalSurg Collaborative, Only G, COVIDSurg Collaborative. \nSARS-CoV-2 vaccination modelling for safe surgery to save \nlives: data from an international prospective cohort study. \nBritish Journal of Surgery. 2021 Sep 27;108(9):1056-1063. \nPMID: 33761533. IF: 6,939\n3. Pla Mart\u00ed V, Martin Arevalo J, Moro Valdezate D, Garcia Botello \nS, Mora Oliver I, Gadea Mateo R, C\u00f3zar Lozano C, Esp\u00ed Macias \nA. Impact of the novel powered circular stapler on risk of \nanastomotic leakage in colorectal anastomosis: a propensity \nscore-matched study. Techniques in Coloproctology. 2021 \nMar;25(3):279-284. doi: 10.1007/s10151-020-02338-y. \nPMID: 32914268. IF: 3,781201\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Gynecology and Obstetrics\nDepartment of Hematology and HemotherapyPUBLICATIONS\nPUBLICATIONSIF\nIF2\n3Number of  \narticles\nNumber of  \narticles7.808\n23.039IF\nIF3.904\n7.679Average\nAverage1\n0Corresponding  \nauthor\nCorresponding  \nauthor1\n3National  \ncollaborations\nNational  \ncollaborations0\n0International \ncollaborations\nInternational \ncollaborations2. Tejada M, Santos-Llamas A, Fernandez-Ramirez M, Tarin J, \nCano A, Gomez R. A reassessment of the therapeutic potential \nof a dopamine receptor 2 Agonist (D2-AG) in endometriosis by \ncomparison against a standardized antiangiogenic treatment. \nBiomedicines. 2021 Mar 8;9(3):269. doi: 10.3390/\nbiomedicines9030269. PMID: 33800198. IF: 6,081SELECTED PUBLICATIONS\n1. Monzo-Miralles A, Martin-Gonzalez V, Smith-Ballester S, \nIglesias-Miguel V, Cano A. The RANKL/RANK system in \nfemale reproductive organ tumors: a preclinical and clinical \noverview. Advances in Clinical and Experimental Medicine. \n2021 Sep;30(9):879-883. doi: 10.17219/acem/140422. \nPMID: 34435475. IF: 1,727\nStrategic aims\n\u2022 To maintain translational research in the lines prioritized: Myeloid Neoplasms, Lymphoid Neoplasms, Coagulopathies, Stem \nCell Trasplant and Cellular Therapy\n\u2022 To favor the research collaboration between clinical hematologists and basic investigators \n\u2022 To develop research projects using experimental models (for GvHD, and Advanced Therapies)   \n\u2022 To increase the number of clinical trials and research projects in Advanced Therapies\n\u2022 To develop Cellular Therapies in the laboratory throughout colaboration with the Department of Pharmacy and the INCLIVA-\nIIS La Fe- Centro de Transfusiones CV consortium\n\u2022 To enhance new research lines in Thrombophilia, Coagulopathies and Thrombopathies\n\u2022 To improve the impact factor in publications resulting from our research and cooperative projects\nMain lines of research\n\u2022 Hematopoietic Transplantation and Cellular Therapy\n\u2022 Lymphoproliferative Disorders\n\u2022 Myeloid Neoplasms \n\u2022 Hemostasis and Thrombosis202\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4SELECTED PUBLICATIONS\n1. Huerta O, Cubero I, Gutierrez A, Gonzalez M. Does primary care \nintervention have an impact in the place of death for patients \nin a palliative care program?. Atencion Primaria. 2021 \nDepartment of Infectious DiseasesDepartment of Home Hospitalization\nPUBLICATIONSPUBLICATIONS\nIFIF\n21\nNumber of  \narticlesNumber of  \narticles\n5.3861.137\nIFIF\n2.6931.137\nAverageAverage\n00\nCorresponding  \nauthorCorresponding  \nauthor\n11\nNational  \ncollaborationsNational  \ncollaborations\n00\nInternational \ncollaborationsInternational \ncollaborationsleukaemia undergoing treatment with ibrutinib. British Journal \nof Haematology. 2021 Nov;195(4):637-641. doi: 10.1111/\nbjh.17732. PMID: 34402042. IF: 6,998\n3. Hernani R, Sancho A, Amat P, Hernandez-Boluda J, Perez \nA, Pinana J, Carretero C, Goterris R, Gomez M, Saus A, \nFerrer B, Teruel A, Terol M, Solano C. CAR-T therapy in solid \ntransplant recipients with post-transplant lymphoproliferative \ndisease: case report and literature review. Current Research \nin Translational Medicine. 2021 Jul 22;69(4):103304. doi: \n10.1016/j.retram.2021.103304. PMID: 34303899. IF: \n4,513\nresistant Escherichia coli and Klebsiella spp. from blood cultures. \nEuropean Journal of Clinical Microbiology & Infectious Diseases. \n2021 Sep;40(9):1925-1932. doi: 10.1007/s10096-021-\n04251-0. PMID: 33876385. IF: 3,267Oct;53(8):102063. doi: 10.1016/j.aprim.2021.102063. \nPMID: 34044187. IF: 1,137SELECTED PUBLICATIONS\n1. Alvarez-Larran A, Diaz-Gonzalez A, Such E, Mora E, Andrade-\nCampos M, Garcia-Hernandez C, Gomez-Casares M, \nGarcia-Gutierrez V, Carreno-Tarragona G, Garrote M, \nFernandez-Ibarrondo L, Cervera J, Bellosillo B, Cervantes \nF, Hernandez-Boluda J, MPN Spanish Group (GEMFIN). \nGenomic characterization of patients with polycythemia \nvera developing resistance to hydroxyurea. Leukemia. 2021 \nFeb;35(2):623-627. doi: 10.1038/s41375-020-0849-2. \nPMID: 32372025. IF: 11,528\n2. De la Asuncion C, Terol M, Saus A, Olea B, Gimenez E, Albert \nE, Lopez-Jimenez J, Andreu R, Garcia D, Fox L, Remigia M, \nAmat P, Solano C, Navarro D. Cytomegalovirus-specific T-cell \nimmunity and DNAemia in patients with chronic lymphocytic \nSELECTED PUBLICATIONS\n1. Torres I, Albert E, Gimenez E, Olea B, Valdivia A, Pascual T, Huntley \nD, Sanchez D, Costa RM, Pinto C, Oltra R, Colomina J, Navarro D. \nPerformance of a MALDI-TOF mass spectrometry-based method \nfor rapid detection of third-generation oxymino-cephalosporin-203\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Intensive Medicine \nMain lines of research\n\u2022 Plasma histones and septic shock. Immunosuppression in Critical Patient\n\u2022 Local ICU epidemiology. Multiresistant bacteria surveillance\n\u2022 COVID19 pneumonia. Severe ARDS\n\u2022 Bacterial and opportunistic co-infections in a patient with severe COVID19 pneumonia\n\u2022 Benefit of corticosteroids in the Severe ARDS\n\u2022 Severe community pneumococcal fine IV-V pneumonia\nPUBLICATIONS\nIF 11\nNumber of  \narticles72.788IF\n6.617Average0\nCorresponding  \nauthor5\nNational  \ncollaborations2\nInternational \ncollaborations\nGarcia-Gimenez J, Montoya A, Roma-Mateo C. Comparative \nanalysis of chromatin-delivered biomarkers in the monitoring \nof sepsis and septic shock: a pilot study. International Journal \nof Molecular Sciences. 2021 Sep 14;22(18):9935. doi: \n10.3390/ijms22189935. PMID: 34576097. IF: 5,923\n4. De Dios E, Rios-Navarro C, Perez-Sole N, Gavara J, Marcos-\nGarces V, Forteza M, Oltra R, Vila J, Chorro F, Bodi V. \nOverexpression of genes involved in lymphocyte activation \nand regulation are associated with reduced CRM-\nderived cardiac remodelling after STEMI. International \nImmunopharmacology. 2021 Mar 4;95:107490. doi: \n10.1016/j.intimp.2021.107490. PMID: 33677257. IF: \n4,932\n5. Sancho J, Ferrer S, Lahosa C, Posadas T, Bures E, Banuls \nP, Fernandez-Presa L, Royo P, Blasco M, Signes-Costa J. \nTracheostomy in patients with COVID-19: predictors and \nclinical features. European Archives of Oto-Rhino-Laryngology. \n2021 Oct;278(10):3911-3919. doi: 10.1007/s00405-\n020-06555-x. PMID: 33386436. IF: 2,503SELECTED PUBLICATIONS\n1. Pun B, Badenes R, Heras La Calle G, Orun O, Chen W, Raman \nR, Simpson B, Wilson-Linville S, Hinojal Olmedillo B, Vallejo \nde la Cueva A, van der Jagt M, Navarro Casado R, Leal \nSanz P, Orhun G, Ferrer Gomez C, Nunez Vazquez K, Pineiro \nOtero P, Taccone F, Gallego Curto E, Caricato A, Woien H, \nLacave G, O\u2019Neal H, Peterson S, Brummel N, Girard T, Ely \nE, Pandharipande P, COVID-19 Intensive Care International \nStudy Group. Prevalence and risk factors for delirium in \ncritically ill patients with COVID-19 (COVID-D): a multicentre \ncohort study. Lancet Respiratory Medicine. 2021; 9(3): \n239-250. doi: 10.1016/S2213-2600(20)30552-X. PMID: \n33428871. IF: 30,7\n2. Beltran Garcia J, Osca Verdegal R, Nacher Sendra E, Cardona \nMonzonis A, Sanchis Gomar F, Carbonell N, Pallardo FV, \nLavie CJ, Garcia Gimenez JL. Role of non-coding RNAs as \nbiomarkers of deleterious cardiovascular effects in sepsis. \nProgress in Cardiovascular Diseases. 2021;68:70-77. doi: \n10.1016/j.pcad.2021.07.005. PMID: 34265333. IF: 8,194\n3. Beltran-Garcia J, Manclus J, Garcia-Lopez E, Carbonell \nN, Ferreres J, Rodriguez-Gimillo M, Garces C, Pallardo F, 2. Clar J, Oltra MR, Benavent R, Pinto C, Ruiz A, Sanchez MT, Noceda \nJ, Redon J, Forner MJ. Prognostic value of diagnostic scales in \ncommunity-acquired sepsis mortality at an emergency service. Prognosis in community-adquired sepsis. BMC Emergency \nMedicine. 2021 Dec 18;21(1):161. doi: 10.1186/s12873-\n021-00532-1. PMID: 34922448. IF: 2,119204\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI19/00994\nTitle:  Biomarcadores epigen\u00e9ticos en sepsis y su implicaci\u00f3n en \ninmunosupresi\u00f3n y futuras comorbilidades en supervivientes\nPrincipal Investigator: Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez (Jos\u00e9 Ferreres \nand Ainhoa L\u00e1zaro as collaborating researchers)\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Universidad de Valencia\nDuration: 2020-2022\nTotal budget:  \u20ac111.320Reference: PID2019-108973RB-C22\nTitle:  Metabolomic study of mechanism for Se-related diabetes \nand insulin resistance\nPrincipal Investigator: Daniel Monle\u00f3n Salvad\u00f3 (M\u00f3nica Garc\u00eda \nSim\u00f3n as collaborating researcher)\nFunding Body: Ministerio de Ciencia e Innovaci\u00f3n\nBeneficiary Institution: Universidad de Valencia\nDuration: 2020-2023\nTotal budget:  \u20ac181.500\nDepartment of Internal Medicine\nPUBLICATIONS\nIF 6\nNumber of  \narticles18.123IF\n3.02Average0\nCorresponding  \nauthor3\nNational  \ncollaborations0\nInternational \ncollaborations\nautoinyecciones intramusculares. Revista Espanola de \nQuimioterapia. 2021 Aug;34(4):393-395. doi: 10.37201/\nreq/024.2021. PMID: 34049434. IF: 1,553\n5. Perez Catalan I, Roig Marti C, Cubides Montenegro A, Cardenal \nAlvarez A, Guerrero Jimenez F, Albiol Vinals P, Uso Blasco J. \nPrognostic utility of the qSOFA scale in patients admitted to an \nInternal Medicine service due to infectious diseases. Revista \nChilena de Infectologia. 2021 Feb;38(1):31-36. doi: 10.4067/\nS0716-10182021000100031. PMID: 33844790. IF: 0,52\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: Diagn\u00f3stico de infecci\u00f3n por clostridioides difficile mediante \nan\u00e1lisis de metaboloma fecal\nPrincipal  Investigator: Rosa Oltra Sempere\nFunding Body: Sociedad Valenciana de Medicina Interna\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac3.000SELECTED PUBLICATIONS\n1. Rodriguez-Bano J, Pachon J, Carratala J, et al. Treatment \nwith tocilizumab or corticosteroids for COVID-19 patients \nwith hyperinflammatory state: a multicentre cohort study \n(SAM-COVID-19). Clinical microbiology and infection. 2021 \nFeb;27(2):244-252. doi: 10.1016/j.cmi.2020.08.010. PMID: \n32860964. IF: 8,067\n2. Torres I, Albert E, Gimenez E, Olea B, Valdivia A, Pascual T, Huntley \nD, Sanchez D, Costa RM, Pinto C, Oltra R, Colomina J, Navarro D. \nPerformance of a MALDI-TOF mass spectrometry-based method \nfor rapid detection of third-generation oxymino-cephalosporin-\nresistant Escherichia coli and Klebsiella spp. from blood cultures. \nEuropean Journal of Clinical Microbiology & Infectious Diseases. \n2021 Sep;40(9):1925-1932. doi: 10.1007/s10096-021-\n04251-0. PMID: 33876385. IF: 3,267\n3. Clar J, Oltra MR, Benavent R, Pinto C, Ruiz A, Sanchez MT, \nNoceda J, Redon J, Forner MJ. Prognostic value of diagnostic \nscales in community-acquired sepsis mortality at an emergency \nservice. Prognosis in community-adquired sepsis. BMC \nEmergency Medicine. 2021 Dec 18;21(1):161. doi: 10.1186/\ns12873-021-00532-1. PMID: 34922448. IF: 2,119\n4. Sanchez Ramos D, Pinto Pla C, De Gracia Leon A, Colomina \nRodriguez J. Complicacion infecciosa poco frecuente tras 205\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Medical EmergencyDepartment of Maxillofacial Surgery\nPUBLICATIONSPUBLICATIONS\nIFIF\n22\nNumber of  \narticlesNumber of  \narticles\n6.363.222\nIFIF\n3.181.611\nAverageAverage2\nCorresponding  \nauthorCorresponding  \nauthor\n11\nNational  \ncollaborationsNational  \ncollaborations\n0 00\nInternational \ncollaborationsInternational \ncollaborations\nJ. Clinical history and detectable troponin concentrations \nbelow the 99th percentile for risk stratification of patients SELECTED PUBLICATIONS\n1. Fernandez-Cisnal A, Valero E, Garcia-Blas S, Pernias V, Pozo A, \nCarratala A, Gonzalez J, Noceda J, Minana G, Nunez J, Sanchis Strategic aims\n\u2022 Innovation in personalised prosthesis for maxillofacial reconstruction\n\u2022 Traslational research project for the development of implants with high added value through additive manufacturing\n\u2022 Innovation in throat pack\nMain lines of research\n\u2022 Cost-effectiveness analysis on the management of oral surgery processes in patients with severe dependence and/or \npluryphatological chronicles with comorbilities: proposal for a new organizational model of care\n\u2022 Radiological evaluation of predictive factors of access to pterygopalatine fossa\n\u2022 Research on materials involved in bone regeneration\n\u2022 Research on materials involved in nerve repair\n\u2022 Proyect: Mandibular Condylar Hyperplasia: Impact of Bone SPECT on Therapeutic Decision. Proposal of a decision algorithm\nSELECTED PUBLICATIONS\n1. Botella Casas G, Cassinello Fernandez N, Perez Santiago L, \nAlfonso Ballester R, Ortega Serrano J. Influence of carotid \nanatomy anomaly in rescue surgery due to relapse of papillary \nthyroid cancer. Cirugia espa\u00f1ola. 2021 Sep 7;S0009-\n739X(21)00256-6. doi: 10.1016/j.ciresp.2021.08.006. \nPMID: 34507819. IF: 1,6532. Torres-Gaya J, Bosca-Ramon A, Marques-Mateo M, \nValverde-Navarro A, Garcia-San Segundo M, Puche-\nTorres M. Temporomandibular joint arthrocentesis \nguided by ultrasonography: an anatomical study. Journal \nof Stomatology, Oral and Maxillofacial Surgery. 2021 \nSep;122(4):e27-e31. doi: 10.1016/j.jormas.2021.03.002. \nPMID: 33706027. IF: 1,596206\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4with chest pain and first normal troponin. Journal of Clinical \nMedicine. 2021 Apr 20;10(8):1784. doi: 10.3390/\njcm10081784. PMID: 33923925. IF: 4,241\n2. Clar J, Oltra MR, Benavent R, Pinto C, Ruiz A, Sanchez \nMT, Noceda J, Redon J, Forner MJ. Prognostic value of \ndiagnostic scales in community-acquired sepsis mortality \nat an emergency service. Prognosis in community-adquired \nsepsis. BMC Emergency Medicine. 2021 Dec 18;21(1):161. \ndoi: 10.1186/s12873-021-00532-1. PMID: 34922448. \nIF: 2,119THESIS\nThesis title:  Study of the microrna expression profile dysregulation \nby hydrogen on the retinal pigment epithelium cells: role of MIR-\n205-5P\nDoctoral candidate: Mar\u00eda Oltra Sanchis\nDirector(s): Jorge Miguel Barcia Gonz\u00e1lez, Francisco Javier \nRomero G\u00f3mez\nDate of the defense: 27/01/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD\nDepartment of Medical Oncology\nPUBLICATIONS\nIF 11\nNumber of  \narticles76.129IF\n6.92Average1\nCorresponding  \nauthor3\nNational  \ncollaborations3\nInternational \ncollaborations\ntherapies on cancer patient outcomes in early-phase \ntrials: the MAST study. British Journal of Cancer. 2021 \nOct;125(9):1261-1269. doi: 10.1038/s41416-021-\n01502-x. PMID: 34493820. IF: 7,64\n4. Adam-Artigues A, Garrido-Cano I, Carbonell-Asins JA, \nLameirinhas A, Simon S, Ortega-Morillo B, Martinez MT, \nHernando C, Constancio V, Burgues O, Bermejo B, Henrique \nR, Lluch A, Jeronimo C, Eroles P, Cejalvo JM. Identification of \na two-MicroRNA signature in plasma as a novel biomarker \nfor very early diagnosis of breast cancer. Cancers. 2021 Jun \n7;13(11):2848. doi: 10.3390/cancers13112848. PMID: \n34200463. IF: 6,639\n5. Mu\u00f1oz Langa J, Jimenez-Fonseca P, Carmona-Bayonas A, de \nCastro E, Perez-Segura P, Canovas M, Gomez D, Moran L, de \nTejada M, Segui E, Lopez G, Adrian S, Campos M, Olmos V, \nPortero B, Moyano M, Crespo J, Sanchez L, Rebollo M, Rivas \nP, Altozano J, Lescure A, Munoz-Martin A. Rationale, design \nand methodology of TESEO study: a registry of thrombosis \nand neoplasia of SEOM (Spanish Society of Medical Oncology). \nClinical & Translational Oncology. 2021 Apr;23(4):799-811. \ndoi: 10.1007/s12094-020-02472-x. PMID: 32789772. IF: \n3,405SELECTED PUBLICATIONS\n1. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, \nMonton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes \nA. Radiomics and radiogenomics in head and neck \nsquamous cell carcinoma: potential contribution to patient \nmanagement and challenges. Cancer Treatment Reviews. \n2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. \nPMID: 34343892. IF: 12,111\n2. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, \nBermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez \nR. Nanoporous anodic alumina-based sensor for miR-99a-\n5p detection as an effective early breast cancer diagnostic \ntool. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: \n10.1021/acssensors.0c02222. PMID: 33599490. IF: \n7,711\n3. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona \nN, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-\nMartinez R, Viala A, Bruixola G, Hernando C, Blasco I, \nPapaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-\nGarcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, \nRosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, \nInsa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, \nCervantes A, Roda D. Molecular profiling of advanced solid \ntumours. The impact of experimental molecular-matched 207\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Microbiology\nStrategic aims\n\u2022 We have identified rotavirus and norovirus genotypes infecting populations studied in Valencia during recent years\n\u2022 We have characterized the most common phenotypes of histo-blood antigens (secretory, Lewis and ABO antigens) in \nchildren infected with rotavirus\n\u2022 Isolation in culture of human enteroids from norovirus strains\nMain lines of research\n\u2022 Phylogenetic analysis of polymerase and capsid genes sequences of norovirus strains in patients with acute gastroenteritis \nand chronic infections in immunocompromised patients\n\u2022 Study of association between histo-blood antigens (HBGA) of patients infected with different rotavirus and norovirus \ngenotypes\n\u2022 Anti-adhesive effect of human milk oligosaccharides against rotavirus and norovirus\n\u2022 Human norovirus replication in enteroids\nPUBLICATIONS\nIF 26\nNumber of  \narticles115.573IF\n4.445Average2\nCorresponding  \nauthor15\nNational  \ncollaborations0\nInternational \ncollaborations\nNavarro D. Upper respiratory tract SARS-CoV-2 RNA loads in \nsymptomatic and asymptomatic children and adults. Clinical \nMicrobiology and Infection. 2021 Dec;27(12):1858.e1-1858.\ne7. doi: 10.1016/j.cmi.2021.08.001. PMID: 34384874. IF: \n8,067\n4. Salmeron P, Vinado B, Arando M, Alcoceba E, Romero B, \nMenendez B, Bernal S, Idigoras P, Colomina J, Martin-Saco \nG, Leal-Negredo A, Torreblanca A, Martinez O, Serra-Pladevall \nJ. Neisseria gonorrhoeae antimicrobial resistance in Spain: \na prospective multicentre study. Journal of Antimicrobial \nChemotherapy. 2021 May 12;76(6):1523-1531. doi: \n10.1093/jac/dkab037. PMID: 33569588. IF: 5,79\n5. Fernandez-Ruiz M, Olea B, Gimenez E, Laguna-Goya R, Trujillo \nH, Caravaca-Fontan F, Gutierrez E, Lopez-Medrano F, Remigia \nM, Almendro-Vazquez P, Polanco N, Gonzalez E, Ruiz-Merlo T, \nParra P, San Juan R, Andres A, Navarro D, Aguado J. SARS-\nCoV-2-specific cell-mediated immunity in kidney transplant \nrecipients recovered from COVID-19. Transplantation. \n2021 Jun 1;105(6):1372-1380. doi: 10.1097/\nTP.0000000000003672. PMID: 33729741. IF: 4,939SELECTED PUBLICATIONS\n1. Fernandez-Ruiz M, Olea B, Almendro-Vazquez P, Gimenez E, \nMarcacuzco A, San Juan R, Justo I, Calvo-Pulido J, Garcia-\nSesma A, Manrique A, Caso O, Cambra F, Talayero P, \nLopez-Medrano F, Remigia MJ, Ruiz-Merlo T, Parra P, Paz-\nArtal E, Jimenez C, Loinaz C, Navarro D, Laguna-Goya R, \nAguado JM. T cell-mediated response to SARS-CoV-2 in \nliver transplant recipients with prior COVID-19. American \nJournal of Transplantation. 2021 Aug;21(8):2785-2794. doi: \n10.1111/ajt.16708. PMID: 34092033. IF: 8,086\n2. Albert Vicent E, Torres Fink I, Bueno Ferrando F, Huntley \nPascual D, Molla E, Fernandez-Fuentes M, Mart\u00ednez L\u00f3pez M, \nPoujois Gisbert S, Forqu\u00e9 Rodr\u00edguez L, Valdivia Piqueres A, \nSolano De La Asunci\u00f3n C, Ferrer Dot J, Colomina Rodr\u00edguez \nF, Navarro Ortega D. Field evaluation of a rapid antigen test \n(Panbio\u2122 COVID-19 Ag Rapid Test Device) for COVID-19 \ndiagnosis in primary healthcare centers. Clinical Microbiology \nand Infection. 2021 Mar;27(3):472.e7-472.e10. doi: \n10.1016/j.cmi.2020.11.004. PMID: 33189872. IF: 8,067\n3. Costa R, Bueno F, Albert E, Torres I, Carbonell-Sahuquillo \nS, Barres-Fernandez A, Sanchez D, Padron C, Colomina J, \nLazaro Carreno M, Breton-Martinez J, Martinez-Costa C, 208\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4THESIS\nThesis title:  Vigilancia de la susceptibilidad antibi\u00f3tica y \ncaracterizaci\u00f3n genot\u00edpica de aislados de Neisseria Gonorrhoeae \nen la Comunidad Valenciana: proyecto multic\u00e9ntrico GONOvig\nDoctoral candidate: Aleix Borja Fabregat Bolufer\nDirector(s): Javier Colomina Rodr\u00edguez\nDate of the defense: 26/02/2021\nGrade: Sobresaliente \u201ccum laude\u201dThesis title: Desarrollo de un dispositivo m\u00e9dico tipo \u201cpoint of \ncare\u201d para la detecci\u00f3n r\u00e1pida de infecci\u00f3n urinaria y sensibilidad \nantibi\u00f3tica en pa\u00edses en v\u00edas de desarrollo\nDoctoral candidate: Jorge Jover Garc\u00eda\nDirector(s): Javier Colomina Rodr\u00edguez\nDate of the defense: 12/03/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nDepartment of Nephrology \nStrategic aims\n\u2022 To work together with cardiology Department in order to explore new developments in treatment of cardio-renal syndrome \nby peritoneal dialysis\n\u2022 Diabetic kidney disease: risk factors and progression. Diabetic kidney disease in dialysis patients\n\u2022 To analyze risk factors for developing hyperkalemia and the adherence to the current treatments \n\u2022 To establish the picture of the renal problems detected in Oncology and Hematology patients: kidney damage in the onco-\nhematologic patients\n\u2022 To analyze the incidence of acute kidney injury in hospitalized patients\nMain lines of research\n\u2022 Treatment of cardio-renal syndrome by peritoneal dialysis\n\u2022 Diabetic kidney disease and chronic kidney disease: risk factors and progression and proteinuria development. Diabetic \nkidney disease in dialysis patients\n\u2022 Hyperkalemia and chronic kidney disease\n\u2022 Onco-nephrology: kidney damage in the oncologic patient\n\u2022 Biomarkers of acute kidney injury\nPUBLICATIONS\nIF 28\nNumber of  \narticles168.082IF\n6.002Average8\nCorresponding  \nauthor14\nNational  \ncollaborations12\nInternational \ncollaborations\n2. Neuen B, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, \nCannon C, Charytan D, Edwards R, Gorriz J, Jardine M, Levin \nA, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler D, \nMahaffey K, Heerspink H. Effects of canagliflozin on serum \npotassium in people with diabetes and chronic kidney disease: \nthe CREDENCE trial. European Heart Journal. 2021 Dec \n21;42(48):4891-4901. doi: 10.1093/eurheartj/ehab497. \nPMID: 34423370. IF: 29,983SELECTED PUBLICATIONS\n1. Heerspink H, Sjostrom C, Jongs N, Chertow G, Kosiborod M, \nHou F, McMurray J, Rossing P, Correa-Rotter R, Kurlyandskaya \nR, Stefansson B, Toto R, Langkilde A, Wheeler D, DAPA-CKD \nTrial Comm Investigators. Effects of dapagliflozin on mortality \nin patients with chronic kidney disease: a pre-specified analysis \nfrom the DAPA-CKD randomized controlled trial. European \nHeart Journal. 2021 Mar 31;42(13):1216-1227. doi: \n10.1093/eurheartj/ehab094. PMID: 33792669. IF: 29,983209\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 43. Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, \nMcMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, \nStefansson BV, Langkilde AM, Wheeler DC, Heerspink HJL. \nEffects of dapagliflozin in stage 4 chronic kidney disease. \nJournal of the American Society of Nephrology. 2021 \nSep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. \nPMID: 34272327. IF: 10,121\n4. Waijer S, de Vries S, Busch R, Xie D, Gansevoort R, Hou F, \nGorriz J, Laverman G, De Nicola L, Pascual J, Provenzano M, \nPergola P, Tang S, Wanner C, Zaoui P, Parving H, de Zeeuw D, \nHeerspink H. Large between-patient variability in EGFR decline \nbefore clinical trial enrollment and impact on atrasentan\u2019s \nefficacy - a post-hoc analysis from the SONAR Trial. Journal of \nthe American Society of Nephrology. 2021 Nov;32(11):2731-\n2734. doi: 10.1681/ASN.2021040498. PMID: 34417318. \nIF: 10,121\n5. Bushinsky D, Raggi P, Bover J, Ketteler M, Bellasi A, Rodriguez \nM, Sinha S, Garg R, Perello J, Gold A, Chertow G, CaLIPSO \nInvestigators. Effects of myo-inositol hexaphosphate (SNF472) \non bone mineral density in patients receiving hemodialysis: an \nanalysis of the randomized, placebo-controlled CaLIPSO study. \nClinical Journal of the American Society of Nephrology. 2021 \nMay 8;16(5):736-745. doi: 10.2215/CJN.16931020. \nPMID: 33835939. IF: 8,237\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: Comparaci\u00f3n de dos tipos de dializadores (PMMA vs. \nPolisulfona) sobre la extracci\u00f3n de citocinas en pacientes en \nhemodi\u00e1lisis con infecci\u00f3n por COVID 19. Estudio prospectivo\nPrincipal Investigator : M\u00aa Jes\u00fas Puchades Montesa\nFunding Body: Sociedad Valenciana de Nefrolog\u00eda\nBeneficiary Institution : Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac3.500\nTitle: Implicaciones de las alteraciones del metabolismo \u00f3seo-\nmineral en la mortalidad en pacientes en di\u00e1lisis peritoneal. \nProyecto de Big Data: estudio que incluye todos los datos \nanal\u00edticos de nuestra unidad en los \u00faltimos 10 a\u00f1os\nPrincipal Investigator : Elisa P\u00e9rez Bernat\nFunding Body: Sociedad Valenciana de Nefrolog\u00eda\nBeneficiary Institution : Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac3.500Title: Estudio longitudinal, randomizado, cruzado sobre el efecto \ndel uso de I-SGLT2 en la diuresis, natriuriesis y en la ultrafiltraci\u00f3n \ny eliminaci\u00f3n peritoneal de sodio en pacientes con di\u00e1lisis \nperitoneal\nPrincipal Investigator : Marco Montomoli\nFunding Body: Sociedad Valenciana de Nefrolog\u00eda\nBeneficiary Institution : Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac3.500\nTitle: Respuesta a vacunaci\u00f3n anti SARS-COV2 en pacientes en \nterapia renal sustitutiva\nPrincipal Investigator : Nayama Panizo Gonz\u00e1lez\nFunding Body: Sociedad Valenciana de Nefrolog\u00eda\nBeneficiary Institution : Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac3.500\nReference : BCM-PD-02-INT\nTitle: Iniciativa sobre la evoluci\u00f3n de los pacientes con Di\u00e1lisis-DP\nPrincipal Investigator: Alfonso Miguel Carrasco (Miguel \nGonz\u00e1lez Rico and M\u00aa Jes\u00fas Puchades Montesa as collaborating \nresearchers)\nFunding Body: Fresenius medical care\nBeneficiary Institution : Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2015-2021\nTotal Budget: \u20ac2.940210\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Department of Neurology \nPUBLICATIONS\nIF 11\nNumber of  \narticles39.481IF\n3.589Average1\nCorresponding  \nauthor6\nNational  \ncollaborations3\nInternational \ncollaborations\noutcomes in a cohort of patients with primary progressive \nmultiple sclerosis (UPPMS study). Multiple Sclerosis and \nRelated Disorders. 2021 Feb 23;50:102860. doi: 10.1016/j.\nmsard.2021.102860. PMID: 33647591. IF: 4,339\n4. Santos Garcia D, Blazquez-Estrada M, Calopa M, Escamilla-\nSevilla F, Freire E, Garcia Ruiz P, Grandas F, Kulisevsky J, Lopez-\nManzanares L, Martinez Castrillo J, Mir P, Pagonabarraga J, \nPerez-Errazquin F, Salom J, Tijero B, Valldeoriola F, Yanez R, \nAviles A, Luquin M. Present and Future of Parkinson\u2019s Disease \nin Spain: PARKINSON-2030 Delphi Project. Brain Sciences. \n2021 Jul 31;11(8):1027. doi: 10.3390/brainsci11081027. \nPMID: 34439646. IF: 3,394\n5. Pozo-Giraldez A, Rodriguez-Borja E, Diaz-Gimenez M, Carratala-\nCalvo A, Magro-Pose P, Perez-Griera J. Discordant SOX-1 \nantibodies results in paraneoplastic Lambert-Eaton syndrome \ndiagnosis by the clinical laboratory. Clinical Biochemistry. 2021 \nNov;97:82-84. doi: 10.1016/j.clinbiochem.2021.08.004. \nPMID: 34450126. IF: 3,281SELECTED PUBLICATIONS\n1. Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee \nBC, Lavall\u00e9e PC, Mahagne MH, Meseguer E, Nighoghossian \nN, Steg PG, Vicaut \u00c9, Bruckert E, Treat Stroke to Target \nInvestigators. Impact of lower versus higher LDL cholesterol \ntargets on cardiovascular events after ischemic stroke in \npatients with diabetes. Diabetes. 2021 Aug;70(8):1807-\n1815. doi: 10.2337/db21-0302. PMID: 33980690. IF: \n9,461\n2. Gallardo V, Alpuente A, Cerda-Company X, Torres-Ferrus M, Del \nRio M, Lainez J, Leira R, Trochet J, Pozo-Rosich P. The impact \nof a digital platform on migraine patient-centered outcome \nresearch. Evaluation of midolordecabeza.org, a headache \nwebsite in Spanish. Headache. 2021 Oct;61(9):1403-1410. \ndoi: 10.1111/head.14225. PMID: 34601726. IF: 5,887\n3. Perez-Miralles F, Prefasi D, Garcia-Merino A, Ara J, Izquierdo \nG, Meca-Lallana V, Gascon-Gimenez F, Martinez-Gines M, \nRamio-Torrenta L, Costa-Frossard L, Fernandez O, Moreno-\nGarcia S, Medrano N, Maurino J, Casanova B. Short-term data \non disease activity, cognition, mood, stigma and employment \nDepartment of Neurosurgery\nPUBLICATIONS\nIF 5\nNumber of  \narticles9.893IF\n1.978Average1\nCorresponding  \nauthor2\nNational  \ncollaborations2\nInternational \ncollaborations\n10.1016/j.nrl.2020.04.022. PMID: 32718873. IF: 3,109\n2. Martorell-Llobregat C, Gonzalez-Lopez P, Luna E, Asensio-\nAsensio M, Jadraque-Rodriguez R, Garcia-March G, Moreno-\nLopez P. The role of vagus nerve stimulation in the treatment \nof refractory epilepsy: clinical outcomes and impact on quality SELECTED PUBLICATIONS\n1. Belvis R, Irimia P, Seijo-Fernandez F, Paz J, Garcia March \nG, Santos-Lasaosa S, Latorre G, Gonzalez-Oria C, Rodriguez \nR, Pozo-Rosich P, Lainez Andr\u00e9s J. Neuromodulation in \nheadache and craniofacial neuralgia: guidelines from the \nSpanish Society of Neurology and the Spanish Society \nof Neurosurgery. Neurologia. 2021;36(1):61-79. doi: 211\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Nuclear Medicine\nStrategic aims\n\u2022 Comparison of low energy and medium energy collimators in the quantitative assessment of 123I-MIBG cardiac sympathetic \ninnervation imaging\n\u2022 Quantitation vs visual assessment of 99mTc-DPD cardiac uptake in patients with suspected cardiac amyloidosis\n\u2022 Evaluation of left ventricular dysynchrony by Gated SPECT myocardial perfusion in the evaluation of cardiac resynchronization \ntherapy\n\u2022 Radioguided surgery by intraoperative scintigraphy with portable gamma camera in patients with primary hyperparathyroidism \nand not conclusive pre-surgical scintigraphy\nMain lines of research\n\u2022 Radioguided occult lesion localization of pulmonary nodules in video-assisted thoracic surgery\n\u2022 Sentinel Lymph Node detection in patients with breast cancer and positive axillary Lymph Node after neoadjuvant \nchemotherapy\n\u2022 Evaluation of left ventricular dyssynchrony by Gated SPECT myocardial perfusion in patients with cardiac resynchronization \ntherapy\n\u2022 Response assessment at one year after 131i treatment in patients with grave\u2019s disease and multinodular goiter\n\u2022 Diagnosis and follow-up of hyperplasia of the mandibular condyles by bone SPECTof life. Neurologia. 2021 Jun 1;S2173-5808(21)00073-0. \ndoi: 10.1016/j.nrleng.2019.04.004. PMID: 34088638. IF: \n3,109\n3. D\u2019Andrea M, Mongardi L, Fuschillo D, Musio A, Commodaro C, \nQuilis-Quesada V, Tosatto L. Vermian subtentorial arteriovenous \nmalformation supplied by the artery of Wollschlaeger and \nWollschlaeger. Clinical Neurology and Neurosurgery. 2021 \nJul;206:106670. doi: 10.1016/j.clineuro.2021.106670. \nPMID: 34015698. IF: 1,876\n4. Gallardo F, Bustamante J, Martin C, Garcia A, Feldman \nS, Pastor F, Orellana M, Rubino P, Quesada V. Intra- and \nextradural anterior clinoidectomy: anatomy review and surgical \ntechnique step by step. Surgical and Radiologic Anatomy. \n2021 Aug;43(8):1291-1303. doi: 10.1007/s00276-021-\n02681-1. PMID: 33495868. IF: 1,246\n5. Garc\u00eda Oriola G, Real Pe\u00f1a L, Pastor Escartin F, Talamantes \nEscriba F. Merkel cell carcinoma spinal metastases in a \nimmunosuppressed patient: clinical case. Neurocirugia. \n2021;32(1):44-48. doi: 10.1016/j.neucir.2020.01.004. \nPMID: 32234286. IF: 0,553THESIS\nThesis title: Exposici\u00f3n de la oliva bulbar mediante los abordajes \nFAR lateral y retrosigmoideo bajo. An\u00e1lisis comparativo de la \nsuperficie expuesta y \u00e1ngulo de ataque\nDoctoral candidate: Pau Capilla Guasch\nDirector(s): Jos\u00e9 Manuel Gonz\u00e1lez Darder, Vicent Quilis Quesada\nDate of the defense: 02/07/2021\nGrade:  Sobresaliente \u201ccum laude\u201d\nThesis title:  Estudio biomec\u00e1nico y correlaci\u00f3n cl\u00ednica de los \nsistemas de artrodesis cervical anterior caja-placa\nDoctoral candidate: F\u00e9lix Pastor Escart\u00edn\nDirector(s): Manuel Gonz\u00e1lez Darder, Jos\u00e9 Florindo Bartolom\u00e9 \nG\u00f3mez, Vicent Quilis Quesada \nDate of the defense: 24/09/2021\nGrade:  Sobresaliente \u201ccum laude\u201d212\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\nIF 5\nNumber of  \narticles49.411IF\n9.882Average1\nCorresponding  \nauthor2\nNational  \ncollaborations2\nInternational \ncollaborations\n3. Perez Santiago L, Cassinello Fernandez N, Alfonso Ballester \nR, Diaz Exposito R, Moscardo Navarro A, Ortega Serrano J. \nIntraoperative scintigraphy with portable gamma camera for the \nlocalization of interaortocaval paraganglioma. Clinical Nuclear \nMedicine. 2021 Nov 1;46(11):e543-e547. doi: 10.1097/\nRLU.0000000000003717. PMID: 34183502. IF: 7,794\n4. Goni-Girones E, Fuertes-Cabero S, Blanco-Saiz I, Casans-Tormo \nI, San Miguel P, Martin-Gil J, Sampol-Bas C, Abreu-Sanchez P, \nDiaz-Exposito R, Vidal-Sicart S. Radioguided surgery in primary \nhyperparathyroidism: a review of the different available techniques. \nRevista Espanola de Medicina Nuclear e Imagen Molecular. \n2021;40(1):57-66. doi: 10.1016/j.remn.2020.11.003. PMID: \n33386282. IF: 1,359\n5. Casans-Tormo I, Alcala-Lopez J, Espinet-Coll C, Pubul-Nunez \nV, Martinez-Rodriguez I. 18 F-FDG PET/CT in cardiovascular \ninfection and inflammation. Revista Espanola de Medicina Nuclear \ne Imagen Molecular. 2021;40(6):397-408. doi: 10.1016/j.\nremnie.2021.09.008. PMID: 34627726. IF: 1,359SELECTED PUBLICATIONS\n1. Einstein AJ, Shaw LJ, Hirschfeld C, Williams MC, Villines TC, Better \nN, Vitola JV, Cerci R, Dorbala S, Raggi P, Choi AD, Lu B, Sinitsyn V, \nSergienko V, Kudo T, N\u00f8rgaard BL, Maurovich-Horvat P, Campisi \nR, Milan E, Louw L, Allam AH, Bhatia M, Malkovskiy E, Goebel B, \nCohen Y, Randazzo M, Narula J, Pascual TNB, Pynda Y, Dondi \nM, Paez D, the INCAPS COVID Investigators Group. International \nImpact of COVID-19 on the Diagnosis of Heart Disease. Journal \nof the American College of Cardiology. 2021 Jan 19;77(2):173-\n185. doi: 10.1016/j.jacc.2020.10.054. PMID: 33446311. IF: \n24,094\n2. Hirschfeld C, Shaw L, Williams M, Lahey R, Villines T, Dorbala S, \nChoi A, Shah N, Bluemke D, Berman D, Blankstein R, Ferencik \nM, Narula J, Winchester D, Malkovskiy E, Goebel B, Randazzo \nM, Lopez-Mattei J, Parwani P, Vitola J, Cerci R, Better N, Raggi \nP, Lu B, Sergienko V, Sinitsyn V, Kudo T, Norgaard B, Maurovich-\nHorvat P, Cohen Y, Pascual T, Pynda Y, Dondi M, Paez D, Einstein \nA, INCAPS-COVID Investigators Grp. Impact of COVID-19 on \ncardiovascular testing in the united states versus the rest of the \nworld. JACC-Cardiovascular Imaging. 2021 Sep;14(9):1787-\n1799. doi: 10.1016/j.jcmg.2021.03.007. PMID: 34147434. \nIF: 14,805\nDepartment of Ophthalmology\nPUBLICATIONS\nIF 3\nNumber of  \narticles8.955IF\n2.985Average1\nCorresponding  \nauthor2\nNational  \ncollaborations0\nInternational \ncollaborations\nOrtega-Usobiaga J, Saornil-Alvarez M, Cuadrado A, Aramburu \nG, Carduch A, Coma J, Delpech S, Carceles J, Sanchez J, \nSanchez P, Castano M, Puente A, Garcia-Layana A, Spanish \nOphthalmology Soc. Recommendations for ophthalmologic \npractice during the easing of COVID-19 control measures. SELECTED PUBLICATIONS\n1. Gegundez-Fernandez J, Llovet-Osuna F, Fernandez-Vigo J, del \nBarrio J, Pablo-Julvez L, Munoz-Negrete F, Zarranz-Ventura J, \nde la Colina J, Silva V, Jimenez-Alfaro I, Calonge-Cano M, Galindo-\nFerreiro A, Castillo-Gomez A, Mantolan-Sarmiento C, Duch-\nSamper A, de Toledo-Elizalde J, Duch-Mestres F, Elies-Amat D, 213\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Acta Ophthalmologica. 2021 Nov;99(7):e973-e983. doi: \n10.1111/aos.14752. PMID: 33433050. IF: 3,761\n2. Gargallo-Benedicto A, P\u00e9rez-Torregrosa V, Clemente-Tom\u00e1s \nR, Duch-Samper AM. Dual corneal involvement by endotelial \nand epitelial corneal dystrophies in Steinert\u00b4s disease: a case \nof triple dystrophy. European Journal of Ophthalmology. 2021 \nMar;31(2):NP23-NP26. doi: 10.1177/1120672119872374. \nPMID: 31476892. IF: 2,597\n3. Vidal Oliver L, Lopez Montero A, Gil Hernandez I, Garcia Ibor \nF, Vela Bernal S, Duch Samper AM. Monitoring therapy in \nanterior necrotizing scleritis with inflammation with anterior \nsegment optical coherence tomography. European Journal \nof Ophthalmology. 2021 Dec 6;11206721211065564. doi: \n10.1177/11206721211065564. PMID: 34866457. IF: \n2,597THESIS\nThesis title: An\u00e1lisis cuantitativo, mediante OCT y Angio-OCT,del \ngrosor coroideo y flujo vascular retiniano y su relaci\u00f3n con el \nespesor de las capas de fibras nerviosas y c\u00e9lulas ganglionares \nmaculares en pacientes con Esclerosis M\u00faltiple\nDoctoral candidate:  Marta Cerd\u00e1 Ib\u00e1\u00f1ez\nDirector(s): Antonio Miguel Duch Samper, Laura Manfreda \nDom\u00ednguez\nDate of the defense: 27/10/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nDepartment of Otorhinolaryngology\nStrategic aims\n\u2022 Publication of the results of the clinical trial of the Osia transcutaneous osseointegrated implant in mixed hypoacusia\n\u2022 Completion of the study of the results of unilateral cochlear implantation with the Oticon Neuro System implant\nMain lines of research\n\u2022 Experience of using a Nadia Link Cros device compared to Nadia CI in users of unilateral cochlear implants\n\u2022 Publication of the study of the results of unilateral cochlear implantation with the Oticon Neuro System implant\n\u2022 Oticon Medical Ponto Osteintegrated Implant Clinical Results\nPUBLICATIONS\nIF 4\nNumber of  \narticles15.155IF\n3.788Average1\nCorresponding  \nauthor2\nNational  \ncollaborations0\nInternational \ncollaborations\n2. Marco-Pitarch R,  Selva-Garcia M, Plaza-Espin A, Puertas-Cuesta \nJ, Agustin-Panadero R, Fernandez-Julian E, Marco-Algarra \nJ, Fons-Font A. Dimensional analysis of the upper airway in \nobstructive sleep apnea syndrome patients treated with \nmandibular advancement device: a bi and three-dimensional \nevaluation. Journal of Oral Rehabilitation. 2021 Aug;48(8):927-\n936. doi: 10.1111/joor.13176. PMID: 33977548. IF: 3,837\n3. Armengot Carceller M, Gomez-Gomez M, Garcia-Navalon C, \nDomenech-Campos E, Munoz-Fernandez N, Miguel A, Marco SELECTED PUBLICATIONS\n1. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon \nS, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, \nPena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, \nCano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella \nGonzalez I. Ten-year assessment of a cancer fast-track \nprogramme to connect primary care with oncology: reducing \ntime from initial symptoms to diagnosis and treatment initiation. \nESMO Open. 2021 May 11;6(3):100148. doi: 10.1016/j.\nesmoop.2021.100148. PMID: 33989988. IF: 6,54214\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Department of Pathological Anatomy\nPUBLICATIONS\nIF 5\nNumber of  \narticles19.117IF\n3.823Average0\nCorresponding  \nauthor2\nNational  \ncollaborations0\nInternational \ncollaborations\nR. Folliculotropic mycosis fungoides with flexural eruptive \ncysts and comedones in a 14-year-old boy. American Journal \nof Dermatopathology. 2021 Sep 1;43(9):656-658. doi: \n10.1097/DAD.0000000000001958. PMID: 33989213. \nIF: 1,533\n5. Marti-Fernandez R, Cassinello-Fernandez N, Palomares-\nCasasus S, Gomez-Adrian J, Ferrandez-Izquierdo A. \nDiffuse lipomatosis of the thyroid gland. American \nSurgeon. 2021 Jun 27:31348211029848. doi: \n10.1177/00031348211029848. PMID: 34180266. IF: \n0,668SELECTED PUBLICATIONS\n1. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda \nC, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, \nPerez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-\nGarcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, \nMarti-Bonmati L. Digital pathology: accurate technique for \nquantitative assessment of histological features in metabolic-\nassociated fatty liver disease. Alimentary Pharmacology & \nTherapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/\napt.16100. PMID: 32981113. IF: 8,171\n2. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, \nGambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes \nA, Ibarrola-Villava M. Circulating tumor DNA detection by \nDigital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: \na systematic review. Cancers. 2021 Feb 27;13(5):994. doi: \n10.3390/cancers13050994. PMID: 33673558. IF: 6,639\n3. Mart\u00ed Fernandez R, Garces Albir M, Ballester Ferre M, \nDorcaratto D, Villagrasa Manzano R, Mu\u00f1oz Forner E, G\u00f3mez \nAdri\u00e1n J, Sanchiz Soler V, Sabater Orti L, Ortega Serrano \nJ. Surgical treatment of an intraductal papillary mucinous \nneoplasm of the biliary tract diagnosed by SpyGlass\u00ae. \nRevista Espanola de Enfermedades Digestivas. 2021 \nJan;113(1):45-47. doi: 10.17235/reed.2020.7122/2020. \ndoi: 10.17235/reed.2020.7122/2020. PMID: 33054282. \nIF: 2,086\n4. Roca-Gines J, Alfaro-Cervello C, Sanchez-Arraez J, Torres-\nNavarro I, Navarro-Mira MA, Monteagudo C, Botella-Estrada Algarra J, Palop-Cervera M, Pinero A. Effects of omalizumab \ntreatment in patients with recalcitrant nasal polyposis and \nmild asthma: a multicenter retrospective study. American \nJournal of Rhinology & Allergy. 2021 Jul;35(4):516-524. doi: \n10.1177/1945892420972326. PMID: 33153272. IF: \n2,467\n4. Pla-Gil I, Redo M, Perez-Carbonell T, Martinez-Beneyto P, \nAlborch M, Ventura A, Monteagudo E, Ribas I, Algarra J. Clinical performance assessment of a new active \nosseointegrated implant system in mixed hearing loss: \nresults from a prospective clinical investigation. Otology & \nNeurotology. 2021 Aug 1;42(7):e905-e910. doi: 10.1097/\nMAO.0000000000003116. PMID: 33710155. IF: 2,311215\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Pediatric Surgery\nPUBLICATIONS\nIF 1\nNumber of  \narticles1.5IF\n1.5Average0\nCorresponding  \nauthor1\nNational  \ncollaborations0\nInternational \ncollaborations\n10.1016/j.anpedi.2020.06.012. PMID: 32703582. IF: \n1,5SELECTED PUBLICATIONS\n1. Martinez Gomez M, L\u00f3pez S\u00e1iz A, Ferrer Gonzalez J, Pin \nArboledas G. Meckel\u2019s double diverticulum. About a case. \nAnales de pediatr\u00eda. 2021 Apr;94(4):268-269. doi: \nDepartment of Pediatrics\nPUBLICATIONS\nIF 15\nNumber of  \narticles50,961IF\n3.397Average4\nCorresponding  \nauthor8\nNational  \ncollaborations1\nInternational \ncollaborations\nFerrando S, Anton-Gamero M, Carrasco Hidalgo-Barquero \nM, Fernandez-Escribano A, Fernandez-Maseda M, Espinosa \nL, Oliet A, Vicente A, Ariceta G, Santos F, RenalTubeGroup. \nPhenotypic characterization of X-linked hypophosphatemia \nin pediatric Spanish population. Orphanet Journal of Rare \nDiseases. 2021 Feb 27;16(1):104. doi: 10.1186/s13023-\n021-01729-0. PMID: 33639975. IF: 4,123\n4. Rubio-San-Simon A, Alvaro R, Ribelles A, Heredia A, Guerra-\nGarcia P, Verdu-Amoros J, Andres M, Canete A, Rives S, \nPerez-Martinez A, Mora J, Patino-Garcia A, Lassaleta A, Llort \nA, Ramirez M, Mata C, Gallego S, Martin-Broto J, Cruz O, La \nMadrid A, Solano P, Romera I, Fernandez-Teijeiro A, Bautista F, \nMoreno L. The paediatric cancer clinical research landscape \nin Spain: a 13-year multicentre experience of the new agents \ngroup of the Spanish Society of Paediatric Haematology and \nOncology (SEHOP). Clinical & Translational Oncology. 2021 \nDec;23(12):2489-2496. doi: 10.1007/s12094-021-\n02649-y. PMID: 34076861. IF: 3,405\n5. Breton-Martinez J, Alcolea A, Quintero-Garcia D, Mendez-\nEchevarria A, Ramos E, Bueno F, Colomina J, Mari-Lopez J, \nCrehua-Gaudiza E, Garcia-Rodriguez J, Martinez-Costa C. \nNon-wild-type cryptococcosis in a child with multivisceral SELECTED PUBLICATIONS\n1. Costa R, Bueno F, Albert E, Torres I, Carbonell-Sahuquillo S, \nBarres-Fernandez A, Sanchez D, Padron C, Colomina J, Lazaro \nCarreno M, Breton-Martinez J, Martinez-Costa C, Navarro D. \nUpper respiratory tract SARS-CoV-2 RNA loads in symptomatic \nand asymptomatic children and adults. Clinical Microbiology \nand Infection. 2021 Dec;27(12):1858.e1-1858.e7. doi: \n10.1016/j.cmi.2021.08.001. PMID: 34384874. IF: 8,067\n2. Burkhardt B, Taj M, Garnier N, Minard-Colin V, Hazar V, \nMellgren K, Osumi T, Fedorova A, Myakova N, Verdu-Amoros J, \nAndres M, Kabickova E, Attarbaschi A, Chiang A, Bubanska E, \nDonska S, Hjalgrim L, Wachowiak J, Pieczonka A, Uyttebroeck \nA, Lazic J, Loeffen J, Buechner J, Niggli F, Csoka M, Krivan \nG, Palma J, Burke G, Beishuizen A, Koeppen K, Mueller S, \nHerbrueggen H, Woessmann W, Zimmermann M, Balduzzi \nA, Pillon M. Treatment and outcome analysis of 639 relapsed \nnon-hodgkin lymphomas in children and adolescents and \nresulting treatment recommendations. Cancers. 2021 Apr \n25;13(9):2075. doi: 10.3390/cancers13092075. PMID: \n33923026. IF: 6,639\n3. Rodriguez-Rubio E, Gil-Pena H, Chocron S, Madariaga L, de la \nCerda-Ojeda F, Fernandez-Fernandez M, de Lucas-Collantes \nC, Gil M, Luis-Yanes M, Vergara I, Gonzalez-Rodriguez J, 216\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4organ transplant who owned bird pets. Transplant Infectious \nDisease. 2021 Jun;23(3):e13558. doi: 10.1111/tid.13558. \nPMID: 33386674. IF: 2,228\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: Sistema inteligente de apoyo a latoma de decisiones cl\u00ednicas \nen medicina de precisi\u00f3n\nPrincipal  Investigator: Jaime Verd\u00fa Amor\u00f3sFunding Body: Agencia Valenciana de la Innovaci\u00f3n-AVI Generalitat \nValenciana \nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac107.904,85\nDepartment of Pharmacy\nStrategic aims\n\u2022 Implementation of a new therapeutical drug monitoring system in a clinical analytical laboratory for pharmacokinetic control \nof antibiotic, antifungal and antineoplastic agents in the hospitalized patient, with the aim of optimal and rational use of \npharmacological treatment \n\u2022 Study of pharmacokinetics of caspofungin in patients under hemodiafiltration. Study approved by the Agencia Espa\u00f1ola del \nMedicamento y Productos Sanitarios with code MER-CAS-2013-01\n\u2022 Observational Study of population pharmacokinetic model of voriconazole in allogeneic stem cell transplantation. Study \napproved by the Agencia Espa\u00f1ola del medicamento y Productos Sanitarios with code CSV-VOR-2014-01\n\u2022 Study of pharmacokinetics of Ceftolozane in critical patients. Study pending of approval by the Agencia Espa\u00f1ola del \nMedicamento y Productos Sanitarios with code CEFT-TCRR-2017\n\u2022 Study of Physico-chemical stability of a new mycophenolate mofetil intravenous solution in polypropilene infusion bag at \ndifferent storage conditions\n\u2022 Study of Physico-chemical stability of a new ophthalmic eyedrop formulation at different storage conditions\nMain lines of research\n\u2022 Implementation of a new therapeutical drug monitoring system in a clinical analytical laboratory for pharmacokinetic control \nof antibiotic, antifungal and antineoplastic agents in the hospitalized patient, with the aim of optimal and rational use of \npharmacological treatment \n\u2022 Study of pharmacokinetics of caspofungin in patients under hemodiafiltration. Study approved by the Agencia Espa\u00f1ola del \nMedicamento y Productos Sanitarios with code MER-CAS-2013-01\n\u2022 Observational Study of population pharmacokinetic model of voriconazole in allogeneic stem cell transplantation. Study \napproved by the Agencia Espa\u00f1ola del medicamento y Productos Sanitarios with code CSV-VOR-2014-01\n\u2022 Study of pharmacokinetics of Ceftolozane in critical patients. Study pending of approval by the Agencia Espa\u00f1ola del \nMedicamento y Productos Sanitarios with code CEFT-TCRR-2017\n\u2022 Study of Physico-chemical stability of a new mycophenolate mofetil intravenous solution in polypropilene infusion bag at \ndifferent storage conditions\n\u2022 Study of Physico-chemical stability of a new ophthalmic eyedrop formulation at different storage conditions\n\u2022 Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections \nin critically ill patients on continuous venovenous haemodiafiltration \n\u2022 Cost effectiveness analysis of direct-acting antiviral therapy for treatment-of patients with chronic HCV infection217\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4PUBLICATIONS\nIF 2\nNumber of  \narticles7.547IF\n3.773Average0\nCorresponding  \nauthor1\nNational  \ncollaborations0\nInternational \ncollaborations\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle: Impact of continuous veno-venous hemodiafltration on dosing \nof antibiotics in critically ill patients\nPrincipal Investigator: Rafael Ferriols Lisart (Carlos Ezquer Gar\u00edn \nas collaborating researcher)\nFunding Body: Janssen - Cilag S.A. \nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac22.500SELECTED PUBLICATIONS\n1. Lopez A, Alos Almi\u00f1ana M, Peris J. Health outcomes and \nprimary adherence to secondary prevention treatment after \nst-elevation myocardial infarction: a spanish cohort study. \nJournal of Cardiovascular Translational Research. 2021 \nApr;14(2):308-316. doi: 10.1007/s12265-020-10045-0. \nPMID: 32557320. IF: 4,132\n2. Sancho J, Ferrer S, Bures E, Diaz JL, Torrecilla T, Signes-Costa \nJ, Servera E. Effect of one-year dextromethorphan/quinidine \ntreatment on management of respiratory impairment in \namyotrophic lateral sclerosis. Respiratory Medicine. 2021 Jul \n7;186:106536. doi: 10.1016/j.rmed.2021.106536. PMID: \n34260979. IF: 3,415\nDepartment of Plastic Surgery\nDepartment of PsychiatryPUBLICATIONS\nPUBLICATIONSIF\nIF1\n4Number of  \narticles\nNumber of  \narticles2.851\n11.249IF\nIF2.851\n2.812Average\nAverage0\n1Corresponding  \nauthor\nCorresponding  \nauthor1\n2National  \ncollaborations\nNational  \ncollaborations0\n1International \ncollaborations\nInternational \ncollaborationsa decade of a multidisciplinary committee experience. \nDermatologic Therapy. 2021 Sep;34(5):e15074. doi: \n10.1111/dth.15074. PMID: 34338412. IF: 2,851SELECTED PUBLICATIONS\n1. Estebanez A, Puche-Torres M, Garcia J, Cunat A, Canales M, \nFelix M, Campos S, Canada J, Hernandez J. Characteristics \nof mucocutaneous vascular malformations drawn from 218\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4systematic review. Psychopathology. 2021 Feb 19;1-17. doi: \n10.1159/000512791. PMID: 33611314. IF: 1,944\n4. Lazaro Tome A, Jose Reig Cebria M, Gonzalez-Teruel A, Antonio \nCarbonell-Asins J, Canete Nicolas C, Hernandez-Viadel M. \nEfficacy of vitamin D in the treatment of depression: a systematic \nreview and meta-analysis. Actas Espanolas de Psiquiatria. 2021 \nJan;49(1):12-23. PMID: 33533015. IF: 1,196\nTHESIS\nThesis title:  Hospitalizaci\u00f3n Domiciliaria en Salud Mental: eficacia \ny viabilidad\nDoctoral candidate: Elvira Ferrando Aparicio\nDirector(s): Eduardo Jes\u00fas Aguilar Garc\u00eda Iturrospe, Francisca \nSilvestre Pascual \nDate of the defense: 07/07/2021\nGrade: Sobresaliente \u201ccum laude\u201dSELECTED PUBLICATIONS\n1. Sastre-Buades A, Ochoa S, Lorente-Rovira E, Barajas A, Grasa \nE, Lopez-Carrilero R, Luengo A, Ruiz-Delgado I, Cid J, Gonzalez-\nHigueras F, Sanchez-Alonso S, Baca-Garcia E, Barrigon M, \nSpanish Metacognition Study Grp. Jumping to conclusions \nand suicidal behavior in depression and psychosis. Journal \nof Psychiatric Research. 2021 May;137:514-520. doi: \n10.1016/j.jpsychires.2021.03.024. PMID: 33812324. IF: \n4,791\n2. Carrasco JP, Herraiz B, Sanchez LO, Luengo A, Fusalba OR, \nAguilar EJ. COVID-19 lockdown influence in the psychiatric \nemergencies: drastic reduction and increase in severe \nmental disorders. Revista de Psiquiatria y Salud Mental. \n2021;14(2):117-118. doi: 10.1016/j.rpsm.2020.11.003. \nPMID: 33248289. IF: 3,318\n3. Etxeandia-Pradera J, Martinez-Uribe D, Bellver-Pradas \nF, Gonzalez-Piqueras J, Nacher J, Aguilar E. Training \npsychiatry residents in descriptive psychopathology: a \nDepartment of Radiologic Diagnosis \nMain lines of research\n\u2022 To participate in clinical trials with Hematology and Oncology Departments by performing CT and/or biopsies to check \ninclusion of patients in new chemotherapy treatments\n\u2022 To evaluate cerebral reperfusion syndrome after treatment of carotid stenosis by stent\n\u2022 To study gastric pre-oesophagectomy conditioning to reduce the incidence of dehiscence of sutured anastomoses\n2. Ballester M, Lluch P, Gomez C, Capilla M, Tosca J, Marti-\nAguado D, Guijarro J, Minguez M. Transjugular intrahepatic \nportosystemic shunt reduces hospital care burden in patients \nwith decompensated cirrosis. Internal and Emergency \nMedicine. 2021 Sep;16(6):1519-1527. doi: 10.1007/\ns11739-020-02602-x. PMID: 33400160. IF: 3,397SELECTED PUBLICATIONS\n1. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, \nMonton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. \nRadiomics and radiogenomics in head and neck squamous \ncell carcinoma: potential contribution to patient management \nand challenges. Cancer Treatment Reviews. 2021 \nSep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: \n34343892. IF: 12,111PUBLICATIONS\nIF 5\nNumber of  \narticles22.664IF\n4.532Average0\nCorresponding  \nauthor3\nNational  \ncollaborations0\nInternational \ncollaborations219\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 43. Estebanez A, Puche-Torres M, Garcia J, Cunat A, Canales M, \nFelix M, Campos S, Canada J, Hernandez J. Characteristics \nof mucocutaneous vascular malformations drawn from \na decade of a multidisciplinary committee experience. \nDermatologic Therapy. 2021 Sep;34(5):e15074. doi: \n10.1111/dth.15074. PMID: 34338412. IF: 2,851\n4. Guillen-Climent S, Garcia-Vazquez A, Silva E, Estebanez A, \nPeredo A, Ruiz M, Monteagudo C, Quiles M. Pseudoxanthoma \nelasticum-like syndrome with coagulation deficiency \nassociated with carotid artery hypoplasia and a novel gamma-\nglutamyl carboxylase gene mutation. International Journal \nof Dermatology. 2021 Jan;60(1):e13-e15. doi: 10.1111/\nijd.15147. PMID: 32808310. IF: 2,7365. Torres-Gaya J, Bosca-Ramon A, Marques-Mateo M, \nValverde-Navarro A, Garcia-San Segundo M, Puche-Torres \nM. Temporomandibular joint arthrocentesis guided by \nultrasonography: an anatomical study. Journal of Stomatology, \nOral and Maxillofacial Surgery. 2021 Sep;122(4):e27-e31. \ndoi: 10.1016/j.jormas.2021.03.002. PMID: 33706027. IF: \n1,569\n1\nCorresponding  \nauthor0\nInternational \ncollaborationsDepartment of Radiotherapy\nPUBLICATIONS\nIF 1\nNumber of  \narticles5.923IF\n5.923Average0\nNational  \ncollaborations\nreview. International Journal of Molecular Sciences. 2021 Oct \n27;22(21):11621. doi: 10.3390/ijms222111621. PMID: \n34769050. IF: 5,923SELECTED PUBLICATIONS\n1. Rodriguez Pla M, Dualde Beltran D, Ferrer Albiach E. Immune \ncheckpoints inhibitors and SRS/SBRT synergy in metastatic \nnon-small-cell lung cancer and melanoma: a systematic \n0\nCorresponding  \nauthor0\nInternational \ncollaborationsDepartment of Rehabilitation\nPUBLICATIONS\nIF 1\nNumber of  \narticles4.342IF\n4.342Average1\nNational  \ncollaborations\non balance and functional outcome up to 1 year following \ntotal knee replacement. Knee Surgery Sports Traumatology \nArthroscopy. 2021 Mar;29(3):838-848. doi: 10.1007/\ns00167-020-06029-x. PMID: 32342139. IF: 4,342SELECTED PUBLICATIONS\n1. Dominguez-Navarro F, Silvestre Mu\u00f1oz A, Igual-Camacho C, \nDiaz-Diaz B, Torrella J, Rodrigo J, Paya Rubio A, Roig-Casasus \nS, Blasco J. A randomized controlled trial assessing the \neffects of preoperative strengthening plus balance training 220\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Department of Thoracic Surgery \nStrategic aims\n\u2022 Tracheal tissue bioengineering\nMain lines of research\n\u2022 Tracheal tissue bioengineering\n\u2022 Rare diseases\n\u2022 Endoscopic VATS resections\n\u2022 Fast track pulmonary surgery and ERAS project\n0\nCorresponding  \nauthor0\nInternational \ncollaborationsPUBLICATIONS\nIF 2\nNumber of  \narticles5.884IF\n2.922Average2\nNational  \ncollaborations\n2. Cilleruelo Ramos A, Figueroa Almanzar S, Lopez Castro R, \nMartinez Hernandez N, Mezquita Perez L, Moreno Casado P, \nZabaleta Jimenez J. Long-term follow-up for operated patients \nwith lung cancer. Spanish Society of Thoracic Surgery (SECT) \nconsensus document. Cirugia Espanola. 2021 Sep 11:S0009-\n739X(21)00250-5. doi: 10.1016/j.ciresp.2021.08.003. \nPMID: 34521509. IF: 1,653SELECTED PUBLICATIONS\n1. Roman A, de la Cruz J, Macia I, Campuzano I, Almanzar S, Roel \nM, Munoz C, Fontan E, Trueba I, Vielva L, Garcia J, Tellez E, \nGonzalez C, Lopez M, Maestre U, Poce R, Lorente D, Kindelan \nA, Pulla M. Outcomes of surgical resection after neoadjuvant \nchemoimmunotherapy in locally advanced stage IIIA non-\nsmall-cell lung cancer. European Journal of Cardio-Thoracic \nSurgery. 2021 Jul 14;60(1):81-88. doi: 10.1093/ejcts/\nezab007. PMID: 33661301. IF: 4,191\nDepartment of Traumatology and Orthopedic Surgery\nStrategic aims\n\u2022 Non-invasive image in orthopedics\n\u2022 Mechanisms of inflammation and oxidative stress in bone pathologies\n\u2022 New systems of fixation of prostheses applied to Traumatology\nMain lines of research\n\u2022 Cellular oxidative stress and its relationship with idiopathic femoral osteonecrosis\n\u2022 Sequentiality of muscle contraction: importance in early detection of lumbopelvic, cervical and shoulder girdle dysfunction\n\u2022 Diagnosis and monitoring of the diabetic foot using infrared thermography\n\u2022 Cellular mechanisms to regulate inflammatory response in chronic inflammatory diseases\n\u2022 Protection strategies against osteoarticular deterioration\n\u2022 Robotics for precission in orthopedic reconstructive surgery\n\u2022 Rehabilitation to improve outcomes after total knee arthroplasty prospective randomized study\n\u2022 Local mechanical stimulation of mesenchymal cells for osteogenic and chondrogenic differentiation in regenerative medicine221\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Department of Urology\nStrategic aims\n\u2022 Study the use of metabolics in urine and tissue in patients with prostate cancer\n\u2022 Study the use of perform biopsy liquid in bladder cancer using digital PCRPUBLICATIONS\nIF 5\nNumber of  \narticles19.6IF\n3.92Average1\nCorresponding  \nauthor3\nNational  \ncollaborations0\nInternational \ncollaborations\n5. Sancheza D, Almero L, Rey M. A solitary osteochondroma of the \nscapula: uncommon location for a common tumor. Archivos \nArgentinos de Pediatria. 2021 Oct;119(5):e562-e566. doi: \n10.5546/aap.2021.e562. PMID: 34569764. IF: 0,635\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference : DTS18/00177\nTitle: Desarrollo de un nuevo sistema de fijaci\u00f3n intramedular \npara implantes (pr\u00f3tesis, clavos para fracturas y exopr\u00f3tesis)\nPrincipal  Investigator: Antonio Silvestre Mu\u00f1oz\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal Budget: \u20ac99.500\nTitle: Evaluaci\u00f3n de la eficiencia de la metodolog\u00eda para el \nseguimiento de pacientes con pr\u00f3tesis de rodilla\nPrincipal  Investigator: Antonio Silvestre Mu\u00f1oz\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2022\nTotal Budget: \u20ac65.000SELECTED PUBLICATIONS\n1. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon \nS, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, \nPena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, \nCano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella \nGonzalez I. Ten-year assessment of a cancer fast-track \nprogramme to connect primary care with oncology: reducing \ntime from initial symptoms to diagnosis and treatment \ninitiation. ESMO Open. 2021 May 11;6(3):100148. doi: \n10.1016/j.esmoop.2021.100148. PMID: 33989988, IF: \n6,54\n2. Rodriguez-Collell J, Mifsut D, Ruiz-Sauri A, Rodriguez-Pino \nL, Gonzalez-Soler E, Valverde-Navarro A. Improving the \ncementation of the tibial component in knee arthroplasty: \na study of four techniques in the cadaver. Bone & Joint \nResearch. 2021 Aug;10(8):467-473. doi: 10.1302/2046-\n3758.108.BJR-2020-0524.R1. PMID: 34340533. IF: 5,853\n3. Dominguez-Navarro F, Silvestre Mu\u00f1oz A, Igual-Camacho C, \nDiaz-Diaz B, Torrella J, Rodrigo J, Paya Rubio A, Roig-Casasus \nS, Blasco J. A randomized controlled trial assessing the \neffects of preoperative strengthening plus balance training \non balance and functional outcome up to 1 year following \ntotal knee replacement. Knee Surgery Sports Traumatology \nArthroscopy. 2021 Mar;29(3):838-848. doi: 10.1007/\ns00167-020-06029-x. PMID: 32342139. IF: 4,342\n4. Ferrando E, Navarro J, Rojas R, Mata D, Silvestre A. \nOsteosarcoma of the Trapezium. Journal of Hand Surgery. \n2021 Aug;46(8):717.e1-717.e5. doi: 10.1016/j.\njhsa.2020.10.011. PMID: 33277099. IF: 2,23222\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4PUBLICATIONS\nIF 5\nNumber of  \narticles12.852IF\n2.57Average3\nCorresponding  \nauthor2\nNational  \ncollaborations0\nInternational \ncollaborations\nEspanoles de Urologia. 2021 Mar;74(2):265-268. PMID: \n33650543. IF: 0,436\n5. Panach-Navarrete J, Valls-Gonzalez L, Negueroles-Garcia M, \nCastello-Porcar A, Martinez-Jabaloyas J. Pediatric ureteral \nectopia: solutions for several issues. Archivos Espanoles de \nUrologia. 2021 Jul;74(6):627-632. PMID: 34219067. IF: \n0,436\nTHESIS\nThesis title: Adhesi\u00f3n a las gu\u00edas cl\u00ednicas para el screening del \nc\u00e1ncer de pr\u00f3stata en atenci\u00f3n primaria e identificaci\u00f3n de \u00e1reas \nde mejora\nDoctoral candidate: Celia Juli\u00e1 Romero \nDirector(s): Joaqu\u00edn Ulises Juan Escudero, Cristina Dom\u00e9nech \nP\u00e9rez\nDate of the defense: 15/07/2021\nGrade: Sobresaliente \u201ccum laude\u201dSELECTED PUBLICATIONS\n1. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon \nS, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, \nPena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, \nCano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella \nGonzalez I. Ten-year assessment of a cancer fast-track \nprogramme to connect primary care with oncology: reducing \ntime from initial symptoms to diagnosis and treatment \ninitiation. ESMO Open. 2021 May 11;6(3):100148. doi: \n10.1016/j.esmoop.2021.100148. PMID: 33989988. IF: \n6,54\n2. Hervas I, Valls L, Rivera-Egea R, Gil JM, Navarro-Gomezlechon \nA, Garrido N, Martinez-Jabaloyas JM. TESE-ICSI outcomes \nper couple in vasectomized males are negatively affected \nby time since the intervention, but not other comorbidities. \nReproductive Biomedicine Online. 2021 Oct;43(4):708-717. \ndoi: 10.1016/j.rbmo.2021.05.013. PMID: 34391685. IF: \n3,828\n3. Panach-Navarrete J, Valls-Gonz\u00e1lez L, Mart\u00ednez-Jabaloyas JM. \nEndoureterotomy with the Lovaco technique for treatment \nof ureterointestinal strictures: outcomes in an experienced \ncenter and factors associated with procedural success or \nfailure. Scandinavian Journal of Urology. 2021 Nov 13:1-\n7. doi: 10.1080/21681805.2021.2002401. PMID: \n34775899. IF: 1,612\n4. Lloret-Dura M, Panach-Navarrete J, Mata-Cano D, Martinez-\nJabaloyas J. Penile cancer: a case for non-lymph node disease \nfollowing a negative sentinel node exploration. Archivos Main lines of research\n\u2022 Usefulness of metabolomic analysis in the diagnosis and prognosis of prostate cancer: it involves performing a metabolomic \nanalysis of urine and prostate tissue in patients with prostate cancer. The purpose is to define a metabolomic profile that \nallows establishing a diagnostic suspicion after urinalysis, as well as evaluating the metabolomic profile of prostate tumor \ntissue. In addition to evaluating its diagnostic utility, its prognostic capacity will be evaluated in patients with prostate cancer\n\u2022 Liquid biopsy in bladder cancer. The aim is to detect the presence of a certain genetic profile in patients with bladder cancer \nand to see its diagnostic correlation, as well as the correlation with grade and stage. Preliminary analysis223\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Teaching and Dissemination of Knowledge Unit\nPUBLICATIONS\nIF 15\nNumber of  \narticles165.091IF\n11.006Average3\nCorresponding  \nauthor8\nNational  \ncollaborations7\nInternational \ncollaborations\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PI18/01937\nTitle: Desigualdades por genero derivadas de la inercia diagnostica \nen los factores m\u00e1s prevalentes de riesgo cardiovascular: un \nestudio de cohortes de base poblacional (ESCAARVAL GENERO)\nPrincipal Investigator: Jos\u00e9 Mar\u00eda Mart\u00edn Moreno\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal budget: \u20ac33.880\nTHESIS\nThesis title: Ganancia de peso gestacional: adecuaci\u00f3n de \nrecomendaciones en poblaci\u00f3n gestante de la Comunidad Valenciana\nDoctoral candidate: Mar\u00eda Faus Garc\u00eda  \nDirector(s): Jos\u00e9 Mar\u00eda Mart\u00edn Moreno, Rafael Vila Candel\nDate of the defense: 20/01/2021\nGrade: Sobresaliente \u201ccum laude\u201dSELECTED PUBLICATIONS\n1. Burgess R, Osborne R, Yongabi K, Greenhalgh T, Gurdasani \nD, Kang G, Falade A, Odone A, Busse R, Martin-Moreno \nJ, Reicher S, McKee M. The COVID-19 vaccines rush: \nparticipatory community engagement matters more than \never. Lancet. 2021 Jan 2;397(10268):8-10. doi: 10.1016/\nS0140-6736(20)32642-8. PMID: 33308484. IF: 79,321\n2. Martin-Moreno J, Lessof S. Predictions of cancer mortality in \nEurope in 2021: room for hope in the shadow of COVID-19?. \nAnnals of oncology. 2021 Apr;32(4):425-426. doi: 10.1016/j.\nannonc.2021.02.001. PMID: 33626376. IF: 32,976\n3. Mart\u00edn Moreno J, Ruiz-Segovia N, Diaz-Rubio E. Behavioural \nand structural interventions in cancer prevention: towards \nthe 2030 SDG horizon. Molecular Oncology. 2021 \nMar;15(3):801-808. doi: 10.1002/1878-0261.12805. \nPMID: 32970894. IF: 6,603\n4. Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schuz \nJ, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, \nBesse B, Cardoso F, Carneiro F, van den Eede G, Eggermont \nA, Frohling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher \nT, Jonsson B, Kallioniemi O, Kasler M, Kondorosi E, Korbel J, \nLacombe D,  Machado JC, Martin-Moreno JM, Meunier F, \nNagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, \nRicciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca \nR, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass \nE, Wilking N, Wren A, Zitvogel L. The Porto European \nCancer Research Summit 2021. Molecular Oncology. 2021 \nOct;15(10):2507-2543. doi: 10.1002/1878-0261.13078. \nPMID: 34515408. IF: 6,603\n5. Aguilera-Buenosvinos I, Fernandez-Lazaro C, Romanos-\nNanclares A, Gea A, Sanchez-Bayona R, Martin-Moreno \nJ, Martinez-Gonzalez M, Toledo E. Dairy consumption and \nincidence of breast cancer in the \u2018Seguimiento Universidad de \nNavarra\u2019 (SUN) Project. Nutrients. 2021 Feb 21;13(2):687. \ndoi: 10.3390/nu13020687. PMID: 33669972. IF: 5,717224\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.5 Other scientific contributions from scientific platforms\n4.5.1 Biobank\nACTIVITIES DEVELOPED\nIncorporation of samples in pre-existing collections within the bio-\nbank regime in 2021:\nOncological Node:\n\u2022 Collection of solid tumors: 54 new sample donations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from breast cancer (including cases of Aurk-Seom \nproject): 242 new sample donations\n\u2022 Collections of peripheral blood and derivative products in patients \nsuffering from lung cancer: 219 new sample donations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from melanoma: 5 new sample donations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from gastrointestinal cancer (including colorectal, \npancreatic and gastric cancer, and cases of TFK project): 1202 \nnew sample donations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from head and neck tumors: 279 new sample donations\n\u2022 Collections of peripheral blood and derivative products in patients \nsuffering from brain tumors: 12 new sample donations\n\u2022 Collections of peripheral blood and derivative products in patients \nsuffering from gynecological tumors (including cases of Aurk-\nSeom project): 39 new sample donations\n\u2022 Collections of peripheral blood and derivative products in patients \nsuffering from sarcoma: no new sample donations\n\u2022 Collections of peripheral blood, derivative products and urine in \npatients suffering from bladder cancer: 16 new sample donations\nImmunological Diseases Node:\n\u2022 Collection of peripheral blood and derivative products in \npatients suffering from Systemic Lupus Erythematosus or other \nautoimmune diseases: 12 new sample donations\nCardiovascular Node:\n\u2022 Collection of peripheral blood and derivative products and urine in patients suffering from Hyperaldosteronism: no new sample \ndonations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from Hypertension: no new sample donations\n\u2022 Collection of peripheral blood and derivative products and urine \nin patients suffering from Acute heart failure: 97 new sample \ndonations\n\u2022 Collection of peripheral blood and derivative products and urine \nin patients suffering from heart failure: 2 new sample donations\nEndocrinology Node: \n\u2022 Collection of peripheral blood and derivative products and urine \nin patients suffering from endocrine diseases (DM1, DM2 and \ncontrols): 69 new sample donations\nOther collections:\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from sepsis gravis and septic shock from ICU: 26 new \nsample donations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from Multiple Esclerosis: no new cases\n\u2022 Collection of peripheral blood and derivative products and urine in \nstandard population (including cases of Obenoutec subcollection): \nno new sample donations\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from COVID-19 disease: no new cases\n\u2022 Collection of peripheral blood and derivative products in patients \nsuffering from Pulmonary Emphysema disease: 263 sample \ndonations\nIncorporation of new collections within the biobank regime in \n2021:\n\u2022 Endocrine Disease Controls subcollection; peripheral blood and \nderivative products in standard population: 2 sample donations\n\u2022 Hereditary Cancer Collection: peripheral blood and derivative Technicians\nOlga Bahamonde Ponce. INCLIVA\n\u00c0ngela Ba\u00f1uls Alemany. INCLIVA\nLaura Blasco Maza. INCLIVA\nMarta Belda Moscard\u00f3. INCLIVATeam\nPI:\nAntonio Ferr\u00e1ndez Izquierdo. Hospital. University. \nCollaborating researchers:\nLorena Peir\u00f3 Chova. INCLIVAbiobanco@incliva.es225\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4products in patients suffering from this pathology: 12 sample \ndonations\n\u2022 COVID-19 Vaccinated Collection; peripheral blood mononuclear \ncells from standard population vaccinated against COVID-19  \ndisease: 428 sample donations\n\u2022 Reproductive Medicine Node, including Single Cell Cryopreserved \nHuman Endometrial Sample Collection; viable cells from endo-\nmetrial biopsy or from endometrial fluid taken from women at  \ndifferent phases of their menstrual cycle: 254 sample donations\n\u2022 COVID-19 Disease Follow-up Collection; peripheral blood and de-\nrivative products in patients who have suffered from COVID-19 \ndisease under follow-up: 69 sample donations\nIn summary, 3105 new sample donations have been received, \n13108 samples have been processed and 55421 aliquots have \nbeen stored in 2021 at INCLIVA Biobank facilities from collections \nwithin biobank regime.\nIn addition, the Biobank has surplus diagnostic samples from the \nHCUV Pathology and Hematology services that may be used in re-\nsearch provided they have the corresponding Biobank Informed Con-\nsent.\nIncorporation of samples in pre-existing collections outside the \nbiobank regime in 2021. The collections are outside the organiza-\ntional structure of the biobank and they are generated in the scope \nof projects and/or private clinical trials. The biobank manages the \nstorage and custody of the samples, as well as the processing of the \nsame in some cases.\n\u2022 Amadix Study: processing, conservation and shipment of proces-\nsed samples for the PancreaDIX study: Study for the development \nand validation of a genetic fingerprint for the diagnosis of pancrea-\ntic cancer and precursor lesions. AMD-CPA-2016-01: 19 new \nsample donations\n\u2022 Renas Study: processing, conservation and shipment of processed \nsamples for the study: Effect of CPAP on the deterioration of renal \nfunction in early stages of chronic kidney disease. 195/2015: \ncustody of 2 cryoboxes\n\u2022 Rolando Study: processing, conservation and shipment of proces-\nsed samples for translational study within the framework of the \nROLANDO trial: Multicenter and uncontrolled phase II clinical trial \nto evaluate the safety and efficacy of the combination of Olaparib \nand Pegylated Liposomal Doxorubicin (DLP) in patients with perito-\nneal carcinoma primary ovarian and resistant platinum fallopian \ntubes. GEICO-1601 ROLANDO: custody of 8 cryoboxes\n\u2022 European LEGACy Project: processing, conservation and shipment \nof processed samples for this project: 226 new sample donations\u2022 ROTATE-3 Study: processing, conservation and shipment of pro-\ncessed samples for this clinical trial: 185 new sample donations \n(Finished project)\n\u2022 ALFA\u2126MEGA/PEGASUS Study: processing, conservation and  \nshipment of processed samples for this clinical trial:  148 sample \ndonations\nIncorporation of new collections outside the biobank regime in \n2021:\n\u2022 Diabetic Nephropathy study:  processing, conservation and ship-\nment of processed samples for the study: Early detection of his-\ntological lesions in nephrectomy pieces of diabetic patients. Ana-\ntomoclinical correlation. Analysis of the expression of Klotho in \nhealthy kidney tissue vs tumor tissue:  61 sample donations\n\u2022 NIKOLE Study (GEICAM/2018-03): processing, conservation and \nshipment of processed samples for the clinical trial: Characteriza-\ntion of innate immune system in patients with luminal advanced \nbreast cancer: 11 sample donations\n\u2022 VERONA Study (RPL554-CO-302): processing, conservation and \nshipment of processed samples for the clinical trial: A Phase III \nrandomized, double-blind, placebo- controlled study to evaluate the \nefficacy and safety of ensifentrine over 24 weeks in patients with \nmoderate to severe Chronic Obstructive Pulmonary Disease: 1 \nsample donation\n\u2022 HIPRA HH-2 Study: processing, conservation and shipment of pro-\ncessed samples for the clinical trial: A phase IIb, double-blind, ran-\ndomised, active-controlled, multicentre, non-inferiority trial followed \nby a phase iii, single-arm, open-label trial to assess immunogenicity \nand safety of a booster vaccination with a recombinant protein rbd \nfusion dimer candidate (PHH-1V) against SARS-CoV-2 in adults fu-\nlly vaccinated against COVID-19: 207 sample donations\n\u2022 TRANSPAIRE Study: processing, conservation and shipment of \nprocessed samples for the study:  Radiofrequency-assisted pan-\ncreatic transection vs endostapler: 1 sample donation\n\u2022 Cytosorb Study: processing, conservation and shipment of pro-\ncessed samples for the study:  Hemoabsorption with Cytosorb \nvs usual clinical practice to analyze its effect on kidney damage \nbiomarkers in asystole donation controlled with ECMO: 4 sample \ndonations\nIIn summary, 863 new sample donations have been received in 2021 \nat INCLIVA Biobank facilities from studies outside biobank regime.226\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Transfer of samples\nProject Ref./AgencyPrincipal Researcher, \nInstitutionSamples\nBBI_12/2018 and BBI_10/2020\nIdentification and analysis of image \nand circulating biomarkers with \nprognostic value and response \npredictor in patients with head and \nneck squamous cell carcinomaNA / INCLIVAGema Bruixola, HCUV/\nINCLIVAHead and neck tumors: 206 \nplasma aliquots and 10 PBMC/\nDNA aliquots\nBBI_01/2019\nExosomal microRNA profile and its \nlong-term prognostic value in systemic \nlupus erythematosus. Association \nwith established markers of kidney \ndamagePI18/01405, ISCIII Raquel Cort\u00e9s, INCLIVASystemic Lupus Erythematosus \nand other autoimmune \ndiseases: 36 plasma aliquots, \n18 serum aliquots and 18 \nPBMC aliquots\nBBI_04/2019\nAnalysis of the role of p53-Aurora-\nkinase pathway as potential predictive \nbiomarkers and therapeutic targets \nin triple-negative breast cancerNC, Fundaci\u00f3n Mutua \nMadrile\u00f1aBego\u00f1a Pineda, INCLIVAGynecological tumors: 2 plasma \naliquots\nBBI_06/2019 and BBI_03/2020\nUsefulness of liquid biopsy and \norganoids in the management \nand treatment of pancreatic \nadenocarcinoma: towards Precission \nMedicineNA, Fundaci\u00f3n Mutua \nMadrile\u00f1aMaider Ibarrola, INCLIVAPancreatic cancer: 116 plasma \naliquots and 2 PBMC/DNA \naliquots\nBBI_09/2019\nPersonalized Medicine in patients \nwith localized colorectal cancer: \nmultiomic approach to minimal \nresidual disease in liquid biopsy and \norganoid modelsPI18/01909, ISCIIIAndr\u00e9s Cervantes, HCUV/\nINCLIVAGastrointestinal tumors: 490 \nplasma aliquots and 16 DNA \naliquots\nBBI_11/2019\nMetabolic and epigenetic \nreprogramming mediated by NNMT \nduring epithelial to mesenchymal \ntransition: molecular mechanisms and \nclinical impact in lung cancerSAF2017-85352-R,\nMinisterio de Econom\u00eda,\nIndustria y CompetitividadJuli\u00e1n Carretero Asunci\u00f3n, \nUVLung cancer: 185 serum \naliquots\nBBI_09/2020\nVariability in immune response genes \nand prediction of severe infection by \nSARSCoV-2 (INMUNGEN-CoV2 Study)202020E086 / CSIC Jordi P\u00e9rez Tur, IBV-CSICCOVID-19 Collection: 5 DNA \naliquots227\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4BBI_11/2020 and BBI_08/2021\nEpigenetic biomarkers for \nsepsis. Focus on long-term \nimmunosupression and future \ncomorbidities in survivorsPI19/00994 / ISCIIIJos\u00e9 Luis Garc\u00eda Gim\u00e9nez, \nCIBERERSepsis and Septic Shock: \n96+234 plasma aliquots and \n6+39 DNA aliquots\nBBI_12/2020 and BBI_14/2021: \nFUSOMAP: Development of \ndiagnostic and prognostic models \nbased on intratumoral infection \nby Fusobacterium and associated \nmicrobiota in localized colorectal \ncancerNA / Fundaci\u00f3n Mutua \nMadrile\u00f1aPaolo Nuciforo, VHIO\n(Susana Rosell\u00f3, HCUV/\nINCLIVA)Colorectal Cancer: slides from \n70 FFPE tissue blocks and 33 \nOCT tissue blocks\nBBI_19/2020: Characterization and \ntherapeutic impact of the ecology of \nHER2 positive breast cancer PI18/01219, ISCIII Pilar Eroles, INCLIVABreast cancer: 32 plasma \naliquots\nBBI_20/2020: Congenital errors of \nimmunity and predisposition to SARS-\nCov-2 infection and to COVID-19 \nseverity. International coordinated \naction of complete exomic \nsequencingCOV20/01334, ISCIIJos\u00e9 Carlos Rodr\u00edguez \nGallego, Hospital \nUniversitario de Gran \nCanarias Dr. Negr\u00ednCOVID-19 Collection: 39 serum \naliquots and 39 DNA aliquots\nBBI_01/2021\nImpact of oxidative stress and \ninflammation as a predictor of \nseverity in SARS-CoV-2 pneumoniaNA, INCLIVAJaime Signes-Costa, HCUV\nM\u00aa Jes\u00fas Sanz, UV\nJos\u00e9 Vi\u00f1a, UVCOVID-19 Collection: 149 \nplasma aliquots\nBBI_02/2021\nTumor-associated macrophages, \ntumor angiogenesis and resistance \nto therapies in diffuse gastric cancer \nmesenchymal phenotypePI18/01508, ISCIII \nTania Fleitas Kanonnikoff, \nHCUV/INCLIVAGastric cancer: 38 plasma \naliquots, 19 blood samples and \n3 PBMCs aliquots\nBBI_03/2021\nStudy of new genetic biomarkers \nin chronic lymphocytic leukemia B \n(CLL-B). Thesis projectNA, INCLIVABlanca Ferrer Lores, \nHCUV/INCLIVAB-cell chronic lymphocytic \nleukemia: 244 DNA aliquots and \n244 RNA aliquots\nBBI_04/2021\nChronic lymphocytic leukemia: \nclonal evolution and its molecular \nmonitoring. Thesis projectNA, INCLIVAAlicia Serrano Alcal\u00e1, \nHCUV/INCLIVAB-cell chronic lymphocytic \nleukemia: 95 DNA aliquots and \n95 RNA aliquots\nBBI_05/2021\nAnalysis of BRAF mutation in \ncirculating exosomes from melanoma \npatientsLABAE19027PEIN, AECCH\u00e9ctor Peinado Selgas, \nCNIOMelanoma: 28 plasma aliquots228\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4BBI_06/2021\nRole of the inflamatory processes in \nmetabolic diseases and associated \ncomplicationsPI19/00169, ISCIIIHerminia Gonz\u00e1lez \nNavarro, UV/INCLIVAEndocrine diseases: 71 plasma \naliquots and 70 PBMCs aliquots\nBBI_07/2021 and BBI_13_2021\nStudy of the appearance of pulmonary \nfibrotic changes associated with \nSARS-CoV-2 infectionCOV20/01209, ISCIIIJaime Signes-Costa, HCUVStandard population: 14 DNA \naliquots;\nCOVID-19 Collection: 69 DNA \naliquots\nBBI_09/2021\nDevelopment of EOSAL technology for \nits application to genetic diagnosisFDEGENT/2019/006GVAAna B\u00e1rbara Garc\u00eda \nGarc\u00eda, INCLIVAStandard population: 14 DNA \naliquots\nBBI_10/2021\nTuMiCC. TUmor MIcroenvironment-\nderived factors in localized Colon \nCancer: clinical impact and \ntherapeutic implicationsGCAEC20030CERV, AECCAndr\u00e9s Cervantes, \nHCUV/UV/INCLIVAColorectal cancer: 103 FFPE \ntissue samples and 6 PBMCs \naliquots\nBBI_11/2021_CONS62.07.2021\nEx vivo pharmacological \ncharacterization study of treatments \nin malignant blood diseases and \nsolid tumors, using the PharmaFlow \nautomated flow cytometry platformVivia-PMMH-02, Vivia \nBiotechJoan Ballesteros Nobell, \nVivia Biotech SLMyelodysplastic syndrome \n(MDS): 13 viable cells aliquots\nBBI_12/2021\nOrigins and biological consequences \nof human infertility: development of \nHuman Endometrium for Embryonic \nImplantation; and the subproject: \nMolecular and Cellular Cartography \nof Human Endometrium in Women \nwith EndometriosisP50 HD055764, \nCenter for Research, \nInnovation and Training in \nReproduction and InfertilityLinda C. Giudice, \nUCSF, San FranciscoSingle Cell Cryopreserved \nHuman Endometrial Sample \nCollection: 142 single cell \naliquots\nBBI_15/2021\nAdaptative immunity of B and T \nlymphocytes against SARS-CoV-2 \nafter vaccination of patients at risk of \nsevere COVID-19 diseasePI21/00563, ISCIIIDavid Navarro, HCUV/\nINCLIVACOVID-19 Vaccinated Collection: \nblood simples and PBMCs\nBBI_16/2021\nLinking cofilin, an actin-binding \nprotein, to calcium dysregulation: a \nprecission approach to the treatment \nof Friedreich\u2019s AtaxiaPID2020-115190RB-I00, \nMinisterio de Ciencia e \nInnovaci\u00f3nPilar Gonz\u00e1lez Cabo, \nCIBER, INCLIVA/UVStandard population: no \nsamples released yet\nIn summary, 3128 aliquots were transferred in 2021.229\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4In addition, 1168 aliquots have been processed and delivered to provide specialized technical services to the following research projects:\nSERV01/2021: Optimization of tissue simples for the development and validation of disease biomarkers: OPTIMARK Project (100 RNA \nisolations).\nSERV02/2021: Biomarkers of response to therapy in patients with lung cancer, UV (Automated aliquoting of plasma simples: 1050 \naliquots generated).\nSERV03/2021: ENOD Project Ref. C21071728 (18 DNA isolations).\nRESEARCH PROJECTS AND GRANTS FOR RESEARCH\nReference : PT20/00029\nTitle: Biobanks and Biomodels Platform\nPrincipal Investigator : Antonio Ferr\u00e1ndez Izquierdo\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de Valencia\nDuration: 2021 -2023\nTotal Budget: \u20ac265.650\nPUBLICATIONS\nNote that these are 2021 scientific publications derived from the use of samples or services provided by the biobank.\n1. Garrido-Cano I, Pla L, Santiago-Felipe S, Sim\u00f3n S, Ortega B, \nBermejo B, Lluch A, Cejalvo JM, Eroles P, Mart\u00ednez-M\u00e1\u00f1ez R. \nNanoporous anodic alumina-based sensor for miR-99a-5p \ndetection as an effective early breast cancer diagnostic tool. \nACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: 10.1021/\nacssensors.0c02222. PMID: 33599490\n2. De Dios E, Rios-Navarro C, P\u00e9rez-Sol\u00e9 N, Gavara J, Marcos-\nGarc\u00e9s V, Forteza MJ, Oltra R, Vila JM, Chorro FJ, Bodi V. \nOverexpression of genes involved in lymphocyte activation and \nregulation are associated with reduced CRM-derived cardiac \nremodelling after STEMI. International Immunopharmacology. \n2021 Jun;95:107490. doi: 10.1016/j.intimp.2021.107490. \nPMID: 33677257\n3. Adam-Artigues A, Garrido-Cano I, Sim\u00f3n S, Ortega B, \nMorag\u00f3n S, Lameirinhas A, Const\u00e2ncio V, Salta S, Burgu\u00e9s \nO, Bermejo B, Henrique R, Lluch A, Jer\u00f3nimo C, Eroles P, \nCejalvo JM. Circulating miR-30b-5p levels in plasma as a \nnovel potential biomarker for early detection of breast cancer. \nESMO Open. 2021 Feb;6(1):100039. doi: 10.1016/j.\nesmoop.2020.100039. PMID: 33477007\n4. Adam-Artigues A, Garrido-Cano I, Carbonell-Asins JA, \nLameirinhas A, Sim\u00f3n S, Ortega-Morillo B, Mart\u00ednez MT, \nHernando C, Const\u00e2ncio V, Burgues O, Bermejo B, Henrique \nR, Lluch A, Jer\u00f3nimo C, Eroles P, Cejalvo JM. Identification of \na two-MicroRNA signature in plasma as a novel biomarker for very early diagnosis of breast cancer. Cancers (Basel). 2021 \nJun 7;13(11):2848. doi: 10.3390/cancers13112848. \nPMID: 34200463\n5. Gimeno-Valiente F, Riffo-Campos \u00c1L, Torres L, Tarazona \nN, Gambardella V, Cervantes A, L\u00f3pez-Rodas G, Franco \nL, Castillo J. Epigenetic mechanisms are involved in the \noncogenic properties of znf518b in colorectal cancer. \nCancers (Basel). 2021 Mar 21;13(6):1433. doi: 10.3390/\ncancers13061433. PMID: 33801071\n6. Bosch F, Navarro B, Crespo M, Alcoceba M, S\u00e1nchez JB, \nTaz\u00f3n B, Serrano A, \u00c1lvarez MG, Serrano LG, Alonso-Torres \nP, Villanueva M, Loriente C, Abrisqueta P, Peir\u00f3 M, Garc\u00eda-\nMarco JA, Gonz\u00e1lez M, Terol MJ. Building a network of TP53 \nand IGHV testing reference centers across Spain: the Red53 \ninitiative. Annals of Hematology. 2021 Mar;100(3):825-830. \ndoi: 10.1007/s00277-020-04331-9. PMID: 33409623\n7. Frasquet M, Rojas-Garc\u00eda R, Argente-Escrig H, V\u00e1zquez-Costa \nJF, Muelas N, V\u00edlchez JJ, Sivera R, Millet E, Barreiro M, D\u00edaz-\nManera J, Turon-Sans J, Cort\u00e9s-Vicente E, Querol L, Ram\u00edrez-\nJim\u00e9nez L, Mart\u00ednez-Rubio D, S\u00e1nchez-Monteagudo A, Espin\u00f3s \nC, Sevilla T, Lupo V. Distal hereditary motor neuropathies: \nmutation spectrum and genotype-phenotype correlation. \nEuropean Journal of Neurology. 2021 Apr;28(4):1334-1343. \ndoi: 10.1111/ene.14700. PMID: 33369814230\nINCLIVA SCIENTIFIC REPORT 2021scientific activity48. Castro de Moura M, Davalos V, Planas-Serra L, Alvarez-Errico D, \nArribas C, Ruiz M, Aguilera-Albesa S, Troya J, Valencia-Ramos \nJ, V\u00e9lez-Santamaria V, Rodr\u00edguez-Palmero A, Villar-Garcia J, \nHorcajada JP, Albu S, Casasnovas C, Rull A, Reverte L, Dietl \nB, Dalmau D, Arranz MJ, Lluci\u00e0-Carol L, Planas AM, P\u00e9rez-\nTur J, Fernandez-Cadenas I, Villares P, Tenorio J, Colobran R, \nMartin-Nalda A, Soler-Palacin P, Vidal F, Pujol A, Esteller M. \nEpigenome-wide association study of COVID-19 severity with \nrespiratory failure. EBioMedicine. 2021 Apr;66:103339. doi: \n10.1016/j.ebiom.2021.103339. PMID: 33867313\n9. Beltr\u00e1n-Garc\u00eda J, Mancl\u00fas JJ, Garc\u00eda-L\u00f3pez EM, Carbonell \nN, Ferreres J, Rodr\u00edguez-Gimillo M, Garc\u00e9s C, Pallard\u00f3 FV, \nGarc\u00eda-Gim\u00e9nez JL, Montoya \u00c1, Rom\u00e1-Mateo C. Comparative \nanalysis of chromatin-delivered biomarkers in the monitoring \nof sepsis and septic shock: a pilot study. International Journal \nof Molecular Sciences. 2021 Sep 14;22(18):9935. doi: \n10.3390/ijms22189935. PMID: 34576097\n10. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona \nN, Cejalvo JM, Gonz\u00e1lez-Barrallo I, Mart\u00edn-Arana J, T\u00e9bar-\nMart\u00ednez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio \nF, Mart\u00ednez-Ciarpaglini C, Alfaro-Cervell\u00f3 C, Seda-Garc\u00eda E, \nBlesa S, Chirivella I, Castillo J, Mont\u00f3n-Bueno JV, Rosell\u00f3 S, \nHuerta M, P\u00e9rez-Fidalgo A, Mart\u00edn-Martorell P, Insa-Moll\u00e1 A, Fleitas T, Rentero-Garrido P, Z\u00fa\u00f1iga-Trejos S, Cervantes A, \nRoda D. Molecular profiling of advanced solid tumours. The \nimpact of experimental molecular-matched therapies on \ncancer patient outcomes in early-phase trials: the MAST study. \nBritish Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: \n10.1038/s41416-021-01502-x. PMID: 34493820\n11. Cortes-Mac\u00edas E, Selma-Royo M, Garc\u00eda-Mantrana I, Calatayud \nM, Gonz\u00e1lez S, Mart\u00ednez-Costa C, Collado MC. Maternal diet \nshapes the breast milk microbiota composition and diversity: \nimpact of mode of delivery and antibiotic exposure. Journal \nof Nutrition. 2021 Feb 1;151(2):330-340. doi: 10.1093/jn/\nnxaa310. PMID: 33188413\nTHESIS\nThesis title: Role of miR-99a-5p in breast cancer: translating \nmolecular findings into clinical tool\nDoctoral candidate: Iris Garrido Cano\nDirector(s): Pilar Eroles Asensio, Ram\u00f3n Mart\u00ednez M\u00e1\u00f1ez \nDate of the defense: 17/12/2021\nGrade: Sobresaliente \u201ccum laude\u201d\nQuality recognition/Award: European PhD231\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.5.2 Oncology Phase I Oncology Clinical Trials unit  \nTeam\nPI:\nAndres Cervantes Ruip\u00e9rez. Hospital. University \nMedical doctors\nAlba Viala Monle\u00f3n. Hospital\nAmelia Insa Moll\u00e1. Hospital\nBego\u00f1a Bermejo de las Heras. Hospital. University\nCristina Herrando Meli\u00e1. Hospital\nDesamparados Roda P\u00e9rez. Hospital\nGema Bruixola Campos. Hospital\nIsabel Chirivella Gonz\u00e1lez. Hospital. University\nJose A. P\u00e9rez Fidalgo. Hospital. University\nJuan Miguel Cejalvo And\u00fajar. Hospital\nMarisol Huerta \u00c1lvaro. Hospital\nPaloma Mart\u00edn Martorell. Hospital\nSusana Rosell\u00f3 Keranen. Hospital\nTania Fleitas Kanonnikoff. Hospital\nValentina Gambardella. Hospital\nNurses\nCelia Mart\u00ednez Ridaura. INCLIVA\nCristina Jord\u00e1 Guerola. INCLIVA\nGloria Corredor Agull\u00f3. INCLIVA\nInma Blasco Blasco. INCLIVA\nLuna Porta Campos. INCLIVA\nVer\u00f3nica Babiano Su\u00e1rez. INCLIVA\nVer\u00f3nica Garc\u00eda Oliver. INCLIVA\nData Managers\nAna Vercher Grau. INCLIVA\nBeatriz L\u00f3pez Montero. INCLIVA.\nGuillermo Moret Peir\u00f3. INCLIVA\nIgnacio Casta\u00f1o L\u00f3pez. INCLIVA\nM\u00aa Carmen Mart\u00ednez L\u00f3pez. INCLIVA\nSergio Romero Alcaide. INCLIVAAdministrative assistant\nHelen Manzaneda L\u00f3pez. INCLIVA\nPaula Petruskevicius Fern\u00e1ndez. INCLIVA\nINCLIVA is the only hospital in Valencia performing Phase I cancer clinical trials, and one of the few in Spain. Phase I trials are those in \nwhich a substance or product is tested in humans for the first time.\nINCLIVA is conducting, through the Oncology Department, 261 clinical trials, 146 of them related to treatment in the early stages of \ntesting (74 phase I or \u201cfirst in human\u201d and 72 phase II). INCLIVA\u2019s new facilities provide a full floor and a half specifically dedicated to host \nthe unit.\nThe unit aims to develop and select new drugs through clinical trials and to perform studies related to the pathogenesis, prognosis and \nnew experimental therapies in solid tumors232\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4FUNCTIONS\nThe unit implements early clinical trials with experimental agents \nin the field of Oncology.\nEQUIPMENTS\n\u2022 -80\u00ba C Freezer \n\u2022 -20\u00ba C Freezer\n\u2022 Refrigerated desktop centrifuge \n\u2022 Scientific refrigerator \n\u2022 Conventional fridge \n\u2022 Defibrillator \n\u2022 Electrocardiographic equipment\n\u2022 7 monitors (blood pressure, heart rate and 02 saturation)\n\u2022 7 double medication infusion pumps \n\u2022 7 heads gases (oxygen and vacuum)\nLOCATION\nThe following facilities are located on the second floor:\n\u2022 Reception and waiting room \n\u2022 2 Consulting rooms\n\u2022 Staff room \n\u2022 Meeting room\n\u2022 Therapy room\nThe third floor hosts the following facilities: \n\u2022 Clinical trials office\n\u2022 Monitoring room\n\u2022 Clinical trials archivesRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PT17/0017/0003\nTitle: Clinical Research and Trials Platform\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2017-2021\nTotal budget:  \u20ac266.475233\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4RESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference:  PT17/0005/0017\nTitle:  Innovation Platform ITEMAS-ISCIII\nPrincipal Investigator:  Josep Red\u00f3n i Mas\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2018-2021\nTotal Budget: \u20ac104.775\nReference: COV20/00279\nTitle: Detecci\u00f3n y caracterizaci\u00f3n r\u00e1pida de COVID19 y del \npaciente\nPrincipal Investigator : Javier Chaves Mart\u00ednez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER4.5.3. Innovation Platform ITEMAS\nTeam\nPI:\nJosep Red\u00f3n i Mas. Hospital. University\nCollaborating researchers:\nCarlos Guerrero Calatayud. INCLIVA\nFederico Pallard\u00f3 Calatayud. University\nMarta del Olmo Zurriaga. INCLIVA\nIndicators in 2021\nNational collaborations managed by the UAI that have been formalized through agreements 15\nInternational collaborations managed by the UAI that have been formalized through agreements 0\nTraining activities, for IIS personnel, aimed at increasing competencies for the effective transfer of research \nresults to healthcare practice1 \nExternal diffusion events 2\nActions with companies to promote the innovation portfolio of the IIS 21\nProjects requested to competitive national calls for innovation / knowledge transfer 17\nProjects awarded through competitive external calls for innovation / knowledge transfer 8 (\u20ac822.010,37)\nProjects financed by internal innovation calls 2 (\u20ac398.125,00)\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac175.000\nReference : DTS19/00128\nTitle: Desarrollo precl\u00ednico de un f\u00e1rmaco innovador para \nDistrofia Miot\u00f3nica\nPrincipal Investigator: Rub\u00e9n Artero Allepuz\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac111.100 234\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Reference: INNTA1/ 2021/27\nTitle: Agente de innovaci\u00f3n INCLIVA para la promoci\u00f3n de la \ninnovaci\u00f3n y transferencia del conocimiento\nPrincipal Investigator : Marta del Olmo Zurriaga\nFunding Body: Agencia Valenciana de Innovaci\u00f3n\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac124.193,67\nReference: INNTA1/ 2021/19\nTitle: Agente de innovaci\u00f3n INCLIVA para para la formaci\u00f3n de \nespacios de cocreaci\u00f3n hospitalarios con agentes del SVI \nPrincipal Investigator : Carlos Guerrero Calatayud\nFunding Body: Agencia Valenciana de Innovaci\u00f3n\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021-2023\nTotal Budget: \u20ac126.483,95\nReference: INNVA1/2020/85\nTitle:  Valorizaci\u00f3n, estrategia de protecci\u00f3n y transferencia de un \nm\u00e9todo de diagn\u00f3stico y pron\u00f3stico de la sepsis y el shock s\u00e9ptico\nPrincipal Investigator : Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Agencia Valenciana de Innovaci\u00f3n\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac110.670\nReference: FIPSE 3819-21\nTitle: Valorizaci\u00f3n e internacionalizaci\u00f3n de HistShock, un test IVD \npara el diagn\u00f3stico y pron\u00f3stico de la sepsis y el shock s\u00e9ptico\nPrincipal Investigator : Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Fundaci\u00f3n para la Innovaci\u00f3n y Prospectiva en \nSalud en Espa\u00f1a (FIPSE)\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2021\nTotal Budget: \u20ac30.000Title: Validaci\u00f3n de microRNAs circulantes como biomarcadores \nde pron\u00f3stico y evoluci\u00f3n cl\u00ednica en Ataxia de Friedreich. Hacia la \nmedicina de precisi\u00f3n en las Enfermedades Raras\nPrincipal Investigator : Jos\u00e9 Luis Garc\u00eda Gim\u00e9nez\nFunding Body: Federaci\u00f3n de ataxias de Espa\u00f1a (FEDAES)\nBeneficiary Institution: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2020-2021\nTotal Budget: \u20ac6.000\nFrom June 2021, INCLIVA has the status of Adhered Center of \nthe ITEMAS Platform of the IDIBELL Node. INCLIVA is part of the \nAlliance for Health Innovation and Industrialization of the Mediter -\nranean Axis (AIISEM) coordinated by the IDIBELL Foundation and \ncreated by the following institutions: IIS La Fe, FISABIO, IDIBELL, \nISABIAL, IISPV, IdISBa, IDIAP and IMIB. AIISEM nodes meet once \na month, both the Technical Commission and the Strategic Com -\nmission. The Alliance has a 3-year Action or Work Plan divided \ninto 5 key objectives.235\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Team\nPI:\nAndr\u00e9s Cervantes Ruip\u00e9rez. Hospital. University \nAssociated Members: \nJulio N\u00fa\u00f1ez Villota. Hospital. INCLIVA \nMarta Peir\u00f3 Signes. INCLIVA \nVer\u00f3nica Guillot Yacyszyn. INCLIVA \nDolores Iglesias Ferri. INCLIVA \nJos\u00e9 Enrique Mu\u00f1oz Cebri\u00e1. INCLIVA4.5.4. Spanish Clinical Research Network (SCReN), Clinical Research and Clinical \nTrials of the Clinical Trials Platform (UICEC INCLIVA)\nLuis Sabater Ort\u00ed. Hospital. INCLIVA\nEsteban Jes\u00fas Morcillo S\u00e1nchez. Hospital. INCLIVA\nJuan Antonio Carbonell Asins. Hospital. INCLIVA\nHired Members: \nLaura Silla Mira. INCLIVA \nUICEC participates in all activities related with the correct development of observational studies and clinical trials, in accordance with the \napplicable legal regulations and the standards of good clinical practice.\nCurrently, the portfolio of services includes, among others, the following activities:\n1. Methodological and regulatory advice: collaboration tasks in the drafting of the protocol, CRF, Patient Information Sheet and Informed \nConsent and all documentation necessary for the correct development of the study in accordance with applicable regulations.\n2. Start-up activities: in this phase the Unit collaborate with economic viability evaluation; identification and selection of participating sites; \nsubmission to national and local Authorities and Ethics Committee; Contract management with the participating sites; Monitoring Plan; \nMaster File creation.\n3. Development activities: Project Management activities; notifications; processing of amendments, interim analysis and reports; home \nvisits; maintenance of file and monitoring visits.\n4. Completion and closure activities: close-out visits; resolution of queries, elaboration of final reports, closure notifications to national and \nlocal Authorities and Ethics Committees.\nACTIVITIES DEVELOPED\nDuring 2021, UICEC had collaborated with the development of \nthe following clinical trials, interventional and observational studies:\nCLINICAL TRIALS /Interventional Studies\nStudy: SEVO-COVID19\nTitle:  Sevoflurane versus propofol sedation in patients with acute \nrespiratory distress syndrome caused by COVID19 infection\nEUDRACT:  2020-001379-34\nSponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario \nde Valencia\nPhase: IV (Low intervention clinical trial)\nStudy: SOLIDARITY\nTitle: An international randomised trial of additional treatments \nfor COVID-19 in hospitalised patients who are all receiving the \nlocal standard of careEUDRACT:  2020-001366-11\nSponsor:  Ministerio de Sanidad, Consumo y Bienestar Social\nPhase: IV\nStudy:  ESR-17-13447(DAPA-HF)\nTitle:  Short-term effects of Dapagliflozin on Peak VO2 in patients \nwith heart failure with reduced ejection fraction\nEUCRACT:  2018-002614-12\nSponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: IV\nStudy: BBLOQ-2017\nTitle:  Betablockers withdrawal in patients with heart failure with \npreserved ejection fraction and chronotropic incompetence: ef -\nfect on functional capacity and life quality\nEUCRACT:  2017-005077-39236\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Sponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: IV\nStudy:  ADAMPA\nTitle: Impact of self-measurement of blood pressure and self-ad-\njustment of antihypertensive medication in the control of hyper -\ntension and adherence to treatment. A pragmatic, randomized, \ncontrolled clinical trial (ADAMPA Study)\nEUCRACT: 2016-003986-25\nSponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: IV (Low intervention clinical trial)\nStudy:  CECUM\nTitle: Efficacy of high-dose corticosteroid pulses added to conven-\ntional oral corticosteroid course in comparison with monotherapy \noral corticosteroid course for moderate flares of ulcerative colitis: \na randomized multicentre clinical trial\nEUCRACT:  2016-001170-15\nSponsor:  Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y \nColitis ulcerosa (GETECCU)\nPhase: IV\nStudy:  ELECLA\nTitle:  Analysis of the effectiveness of neoadjuvant chemotherapy \nin treating colon cancer locally advanced\nEUCRACT:  2016-002970-10\nSponsor:  Jorge Arredondo Chaves, Complejo Asistencial Univer -\nsitario de Le\u00f3n \nPhase: IV (Low interventional clinical trial)\nStudy:  X16082\nTitle:  Phase Ib/II trial to evaluate safety and efficacy of oral  \nixazomib in combination with sirolimus and tacrolimus in the pro-\nphylaxis of chronic graft-versus-host disease\nEUCRACT:  2016-002503-26\nSponsor:  Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n en Salud de \nSevilla (FISEVI)\nPhase: Ib/II\nStudy: EXIT\nTitle:  Suspension of anti-tnf treatment in patients with intestinal \ninflammatory disease: multicenter, prospective and randomized \nclinical trial\nEUCRACT:  2015-001410-10\nSponsor: Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica Hospital Universi-\ntario de la Princesa\nPhase: IVStudy:  SECURE\nTitle:  Secondary prevention of cardiovascular disease in the el -\nderly\nEUCRACT: 2015-002868-17\nSponsor:  Fundaci\u00f3n Centro Nacional de Investigaciones Cardio-\nvasculares, Instituto de Salud Carlos III (CNIC)\nPhase: III\nStudy:  IGR2009/1593\nTitle:  Intergroup trial for children or adolescents with B-cell NHL \nor B-AL: evaluation of rituximab efficacy and safety in high risk pa-\ntients\nEUCRACT: 2010-019224-31\nSponsor:  Institut Gustave Roussy\nPhase: II/III\nStudy:  LINES\nTitle: European Low and Intermediate Risk Neuroblastoma\nEUCRACT: 2010-021396-81\nSponsor: Fundaci\u00f3n para la Investigaci\u00f3n Hospital Universitario y \nPolit\u00e9cnico La Fe\nPhase: III\nStudy:  RAPIDO\nTitle: Randomized Multicentre Phase III study of short \ncourse radiation therapy followed by prolonged pre-operative  \nchemotherapy and surgery in primary high risk rectal cancer \ncompared to standard chemoradiotherapy and surgery and  \noptional adjuvant chemotherapy\nEUCRACT: 2010-023957-12\nSponsor: UMCG, Groningen, The Netherlands\nPhase: III\nStudy: HaploMUDStudy\nTitle: Matched Unrelated vs. Haploidentical Donor for Allogeneic \nStem Cell Transplantation in Patients with Acute Leukemia with \nIdentical GVHD Prophylaxis \u2013 A Randomized Prospective Europe -\nan Trial\nSponsor:  University Medical Center Hamburg-Eppendorf Investi -\ngator Initiated Trial (IIT) (financial support by DKMS)\nPhase: Non Observational with no drugs study\nStudy: DIAL-COVID\nTitle:  Comparison of two types of dialysers (PMMA VS POLYSUL -\nPHONE) on cytokine extraction in haemodialysis patients with \nCOVID 19 infection. Prospective study\nSponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: Clinical trial with Medical Device237\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4Study:  PANGASBLUM\nTitle: Pancreatic anastomosis following pancreatoduodenectomy: \npancreatogastrostomy versus blumgart\u00b4s anastomosis. A ran-\ndomized, prospective, multicenter study\nSponsor: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: Non Observational with no drugs study\nStudy: MOSCA FRAIL\nTitle: Randomized comparison between the invasive and conser-\nvative strategies in elderly frail patients with non-ST elevation \nmyocardial infarction: The MOSCA-FRAIL Clinical Trial\nSponsor: Sociedad Espa\u00f1ola de Cardiolog\u00eda\nPhase: Intervention clinical trial\nStudy: CETUPANC\nTitle:  Impact of the dissemination of the circulating tumor \ncells (CTCS) during the cephal duopenopancreatomy at the \nappearance of metastasis and survival in patients with tumors of \npancreas and periampulars (CETUPANC Study)\nSponsor:  Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n en Salud de \nSevilla (FISEVI)\nPhase: Interventional study\nStudy: FAIR\nTitle:  Intravenous iron in patients with systolic heart failure and \niron deficiency to improve morbidity & mortality (FAIR-HF2)\nEUCRACT:  2016-000068-40\nSponsor:  University Medical Center Hamburg-Eppendorf Investi -\ngator Initiated Trial (IIT) (financial support by DKMS)\nPhase: IV\nStudy: COLICA\nTitle: Randomized double-blind trial to study the benefit of Colchi-\ncine in Patients with Acutely Decompensated Heart Failure (IMIB-\nCO-2020-01)\nEUCRACT: 2020-000941-15\nSponsor:  Fundaci\u00f3n para la Formaci\u00f3n e Investigaci\u00f3n Sanitarias \nde la Regi\u00f3n de Murcia (FFIS)\nPhase: III\nStudy: ECACIKAGEL\nTitle:  Ensayo Cl\u00ednico Aleatorizado triple ciego para la evaluaci\u00f3n \nde la seguridad y eficacia de CikaGel \u00ae en el tratamiento de las \n\u00falceras de pierna en pacientes sin Enfermedad Arterial Perif\u00e9rica\nSponsor: Georges Klein\nPhase: Clinical trial with Medical DeviceStudy: ASTART\u00c9\nTitle:  Temociclina vs Meropenem para el Tratamiento de la Bac -\ntiremia por Enterobacterales Resistentes a Cefalosprorinas de \nTercera Generaci\u00f3n: Ensayo Aleatorizado y Pragm\u00e1tico\nEUCRACT:  2020-000064-39\nSponsor:  Fundaci\u00f3n P\u00fablica para la Gesti\u00f3n de la Investigaci\u00f3n en \nSalud de Sevilla (FISEVI)\nPhase: III\nStudy:  CIRCULATE-SPAIN-01\nTitle:  Phase II randomized trial to assess the effect of intensive vs \nstandard adjuvant chemotherapy in localised colon cancer with \ncirculating tumor DNA\nEUDRACT: 2021-000507-20\nSponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: II\nStudy:  KEEP ON (ESR-19-20217)\nTitle: Phase III, multicenter, open-label, randomized clinical trial \nto evaluate efficacy of Sodium Zirconium Cyclosilicate (Lokelma) \ncompared to standard of care to manage hyperkalemia in pa-\ntients with chronic kidney disease (CKD) and heart failure history\nEUDRACT:  2020-003229-47\nSponsor: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: III (Low intervention clinical trial)\nStudy:  ROTATE\nTitle:  Rotation for Optimal Targeting of Albuminuria and Treat-\nment Evaluation (ROTATE-3)\nEUCRACT:  2017-004641-25\nSponsor:  University Medical Center Groningen\nPhase: III\nObservational studies\nStudy:  INC-CVD-2020-01\nTitle:  Study of the occurrence of fibrotic pulmonary changes asso -\nciated with SARS-CoV-2 infection\nSponsor:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: NO- EPA\nStudy: DNO-IBR-2018-01 \nTitle:  Virology and immunology of cytomegalovirus (CMV) infection \nin patients with hematological malignancies in the time of new \nbiotherapies238\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Sponsor: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia\nPhase: EPA-AS \nStudy:  TFK-RAM-2018-01 \nTitle:  Macrophages associated with tumor, tumor angiogenesis \nand resistance to therapies in diffuse gastric cancer mesenchy -\nmal phenotype \nSponsor: Tania Fleitas Kanonnikoff \nPhase: EPA-AS \nStudy:  JFA-ALI-2018-01 \nTitle: Study of inflammatory marker changes associated with en-\ndothelial dysfunction in patients treated with PCSK9 inhibitors\nSponsor:  Jose T. Real Collado\nPhase: EPA-AS \nStudy: OPTIM- BIOMA FIS-ANT-2017-01\nTitle: Optimization of antibiotic treatment in recipients of alloge -\nneic LIN transplantation: impact on the intestinal microbiota and \non clinical results\nSponsor: Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Inves -\ntigaci\u00f3n en Salud de Sevilla (FISEVI)\nPhase: EPA-SP\nStudy: GOLD 0 -DLCO 1\nTitle:  GOLD 0 - DLCO 1: A look beyond obstruction. Is spirometry \nsufficient in COPD screening?\nSponsor: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario de \nValencia \nPhase: No-EPA\nStudy: JSC-TAB-2015-01 \nTitle: Effectiveness of an intensive smoking treatment program \non the serious exacerbations of smoking patients with moderate \nsevere EPOC \nSponsor: Jaime Signes Costa Mi\u00f1ana\nPhase: EPA-SP\nStudy: JGT-FER-2020-01 (COCOON) \nTitle:  Efecto de la administraci\u00f3n intravenosa de hierro carboxi-\nmaltosa sobre el rendimiento f\u00edsico, la fatiga y la calidad de vida \nen pacientes con enfermedad renal cr\u00f3nica no en di\u00e1lisis y d\u00e9ficit \nde hierro\nSponsor:  Jos\u00e9 Luis G\u00f3rriz Teruel \nPhase: EPA-SPStudy: HK-01-21\nTitle: Evidencia en la vida real del uso de patiromer para el trata-\nmiento de pacientes con hiperpotasemia cr\u00f3nica en una regi\u00f3n \nde Espa\u00f1a\nSponsor: Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico Universitario \nde Valencia\nPhase: EPA-OD\nStudy: FIS-BAZ-2012-01\nTitle: Acci\u00f3n del bazedoxifeno sobre el metabolismo \u00f3seo y los \nfactores de riesgo cardiovascular\nSponsor: Antonio Cano S\u00e1nchez\nPhase: EPA-SP\nClinical trials Observational Studies2020 202110\n8\n6\n4\n2\n0New StudiesUNIT ACTIVITY DURING LAST 5 YEARS\nDuring the last five years, the unit has initiated 33 studies (21 \nclinical trials and 12 observational studies). The following table \nshows its distribution by year.\nClinical trialsObservational \nStudiesTotal\n2017 5 2 7\n2018 3 0 3\n2019 4 4 8\n2020 5 4 9\n2021 4 2 6239\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4As accumulative activity, new and ongoing studies, the Unit maintains an average of 26 active studies, per year, with a clear increasing \ntendency in the number of studies. Their distribution by type of study and year is detailed in the following table.\n2017 2018 2019 2020 2021\nPhase I 1 1 1 1 1\nPhaseII 0 0 0 0 0\nPhase III 7 7 5 3 6\nPhase IV 6 8 8 9 10\nOther Designs 2 3 4 6 6\nObservationals 5 5 8 8 9\nTotal 21 24 26 27 32\nOngoing Studies\nPhase I Phase II Phase III Phase IV Other Designs Observationals2017 2018 2019 2020 202135\n30\n25\n20\n15\n10\n5\n0\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: PT20/0100\nTitle: Spanish Clinical Research Network (SCReN)\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez \nFunding Body: Instituto de Salud Carlos III-Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2021-2023\nTotal Budget: \u20ac 199.650Reference: PT17/0017/0003 \nTitle:  Spanish Clinical Research Network (SCReN)\nPrincipal Investigator:  Andr\u00e9s Cervantes Ruip\u00e9rez \nFunding Body: Instituto de Salud Carlos III-Co-financed FEDER\nBeneficiary Institution:  Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2018-2021\nTotal Budget: \u20ac 266.475240\nINCLIVA SCIENTIFIC REPORT 2021scientific activity44.5.5. Precission medicine unit\nTeam\nPI:\nAndr\u00e9s Cervantes Ruip\u00e9rez. Hospital. University\nCoordinator:\nPilar Rentero Garrido. INCLIVA\nCollaborating researchers:\nDesamparados Roda P\u00e9rez. Hospital\nValentina Gambardella. INCLIVATechnicians:\nEnrique Seda Garc\u00eda. INCLIVA\nLaura Gonz\u00e1lez Castillo. INCLIVA\nSebasti\u00e1n Blesa Luj\u00e1n. INCLIVA\nThe Precission Medicine Unit was stablished in March 2018. Since then, the group have developed a robust and wide portfolio of services \nto support research at INCLIVA.\nTo date, the unit closely collaborates with the Oncology Phase I Clinical Trial Unit. Together we have developed an integrated screening \nsystem to support personalized patient care and hence implementing the latest techniques into the clinical practice. In addition, the unit \ncurrently collaborates in several research projects from different groups at INCLIVA.\nThe group integrates professional profiles from multiple disciplines (Medical Oncology, Molecular Biology, Bioinformatics and Biochemis-\ntry) with large professional experience in Human Genetics and Genomics.ump@incliva.es\nFUNCTIONS\nOur mission is to impulse, promote and execute quality transla -\ntional research offering support in Molecular Biology as well as in \nData Analysis techniques to the scientific community.\nLABORATORY EQUIPMENT \n\u2022 Two massive sequencers with Illumina chemistry: MiSeq and \nNextSeq550\n\u2022 iScan System to scan Illumina microarrays\n\u2022 nanoString n-Counter platform\n\u2022 Biorad ddPCR\n\u2022 Chromium Single Cell System (10X Genomics)\n\u2022 Glomax Discovery System (Promega)\n\u2022 Maxwell RSC (Promega)\n\u2022 Quantitative thermalcycler\n\u2022 Standard thermalcyclers\n\u2022 TapeStation system to visualize DNA and RNA\n\u2022 Laminar cabins, centrifuges, heat blocks, ovens, etc.\nLOCATION\n\u2022 Laboratories: Facultad de Medicina. Avenida Blasco Ib\u00e1\u00f1ez \n15, Building 2, 2nd floor, UCIM Corridor, Laboratory 1SERVICES\n 1. Next-Generation Sequencing (NGS):\n\u2022 Design, development, validation and sequencing of custom \ngene panels\n\u2022 Exome sequencing and analysis\n\u2022 Whole-genome sequencing\n\u2022 Sequencing small genomes \u201cde novo\u201d\n\u2022 RNA-sequencing (total RNA, poly(A) fraction, rRNA depleted\u2026)\n\u2022 Microtranscriptome sequencing (smallRNA/miRNA\u2026)\n 2. Microarrays:\n\u2022 Genotyping arrays \n\u2022 Methylation arrays \n 3. Digital PCR\n 4. nanoString platform\n 5. Chromium Single Cell System (10X genomics)\n 6. Other molecular biology techniques:\n\u2022 Nucleic acid isolation\n\u2022 Nucleic acid quantification (absorbance and fluorescence)\n\u2022 Luminiscence analysis\n\u2022 Uniplex and Multiplex PCR\n\u2022 Quantitative PCR241\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4 7. Additional services:\n\u2022 Advice and methodological support in writing protocols, re -\nsearch project proposals, scientific papers\n\u2022 Mentoring of bachelor, master and doctorate students\n\u2022 On demand training\n\u2022 Consulting services\nDEVELOPED ACTIVITIES\n1800 oncologic patients have been molecularly tested to select \nthe best treatment\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nReference: ICI20/00009\nTitle: Circulating Tumor DNA Based Decision for Adjuvant \nTreatment in Colon Cancer stage II-III (CIRCULANTE-SPAIN)\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2021-2024\nTotal budget:  \u20ac1.039.970\nReference: PI18/01909\nTitle:  Precission medicine in localized colorectal cancer patients: \nliquid biopsy-based multiomic approach in minimal residual \ndisease and organoids\nPrincipal Investigator: Andr\u00e9s Cervantes and Desamparados \nRoda\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac140.000 \nReference: PI18/01508\nTitle: Macrophages associated with tumor, tumor angiogenesis \nand resistance to therapies in gastric cancer diffuse mesenchymal \nphenotype\nPrincipal Investigator: Tania Fleitas Kanonnikoff\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2019-2021\nTotal budget:  \u20ac99.000Title: Whole exome sequencing of circulating tumor DNA and \ngenomic DNA to increase sensitivity in the detection of minimal \nresidual disease and open new mechanisms for personalized \nmedicine in localized colon cancer\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: SEOM\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2020-2022\nTotal budget:  \u20ac20.000\nTitle:  Molecular mechanisms and tumor heterogeneity associated \nwith primary and acquired resistance to trastuzumab treatment \nin gastric or gastroesophageal junction cancer\nPrincipal Investigator: Tania Fleitas Kanonnikoff\nFunding Body: SEOM\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2019-2021\nTitle: Patient derived organoids (PDOs) to personalize the \ntreatment of relapsed localized colon cancer (CC) by sequencing \nthe whole exome and genomic DNA\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: TTD\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2020-2022\nTotal budget:  \u20ac40.000\nTitle: Tumor microenvironment-derived factors in localized colon \ncancer: clinical impact and therapeutic implications (TUMMIC)\nPrincipal Investigator: Andr\u00e9s Cervantes Ruip\u00e9rez\nFunding Body: Fundaci\u00f3n AECC\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2020-2025\nTotal budget:  \u20ac992.996\nTitle: Colorectal carcinogenesis: the interaction of the tumor \nmicroenvironment and stem cells. Impact on personalized \ntreatment\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia 242\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Duration: 2020-2023\nTotal budget:  \u20ac130.000\nTitle:  Precission medicine in oncology: development of new \ntechnological approaches for personalized treatments in \nInmunotherapy\nPrincipal Investigator: Desamparados Roda and Sheila Z\u00fa\u00f1iga\nFunding Body: Fundaci\u00f3n FERO\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac240.000\nPUBLICATIONS\n1. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, \nCejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Marti-\nnez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, \nMartinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa \nS, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta \nM, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas \nT, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. \nMolecular profiling of advanced solid tumours. The impact of \nexperimental molecular-matched therapies on cancer patient \noutcomes in early-phase trials: the MAST study. British Jour -\nnal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/\ns41416-021-01502-x. PMID: 34493820243\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 44.5.6. Bioinformatics and Biostatistics Unit\nTeam\nCoodinator\nSheila Z\u00fa\u00f1iga Trejos. INCLIVA\nMiguel Herreros Mart\u00ednez. INCLIVATechnician\nFabi\u00e1n Robledo Yag\u00fce. INCLIVA\nJuan Carbonell Asins. INCLIVA \nPilar Natividad L\u00f3pez. INCLIVA\nThe Bioinformatics and Biostatistics Unit is a core facility created in 2013. The unit is mainly dedicated to collaborate in different research \nprojects, providing advice and support to researchers in the design, workflow implementation, development of computing strategies and \nanalysis of data.\n\u2022 Simulation techniques \n\u2022 Supervised and unsupervised analysis techniques \n\u2022 Predictive modelling\n3. Additional services:\n\u2022 Advice and methodological support to write protocols, re -\nsearch project proposals, articles, doctoral/MSc/BSc thesis \n\u2022 Data mining and exploratory analysis of databases \n\u2022 Graphical representation of research results \n\u2022 Curation and analysis of databases \n\u2022 Consulting\nRESEARCH PROJECTS AND GRANTS FOR \nRESEARCH\nTitle:  Legacy: CELAC and European consortium for a personalized \nmedicine approach to Gastric Cancer \nPrincipal investigator : Andr\u00e9s Cervantes and Tania Fleitas\nFunding Body: European Commission\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2022\nTotal Budget: \u20ac638.315\nReference: PI18/01909\nTitle:  Precission medicine in localized colorectal cancer patients: \nliquid biopsy-based multiomic approach in minimal residual \ndisease and organoids\nPrincipal Investigator: Andr\u00e9s Cervantes and Desamparados \nRoda\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de ValenciaFUNCTIONS\nOur mission is to drive, promote and execute quality translational \nresearch through methodological and analytical support.\nEQUIPMENT\nINCLIVA has a computing facility with 100 cores, 400GB of RAM \nmemory 80TB of redundant network storage and 20TB of fast \nnon-redundant local storage to the nodes for high I/O processes \nsuch as those applied to omics data analysis.\nIn addition, and as part of the Valencian biomedical research \ncommunity, we also have access to a large computing facility hos-\nted at the Centro de Investigation Pr\u00edncipe Felipe to cope with large \nprojects.\nSERVICES\n1. Bioinformatics services:\n\u2022 Analysis of Next-Generation Sequencing Data (gene panels/\nexomes and genomes to detect both germline and somatic \nvariants, RNA-Seq and smallRNA data analysis, Methyl-Seq \ndata analysis)\n\u2022 Microarray data analysis (both expression and methylation ar-\nrays)\n\u2022 Functional enrichment analysis (identification of biological func-\ntions, cellular components or molecular functions with gene \nontology terms, identification of altered metabolic pathways or \nrelated diseases) \n\u2022 Complex network data integration, analysis and visualization\n2. Biostatistics services:\n\u2022 Design of clinical and epidemiological studies \n\u2022 Sample size estimation 244\nINCLIVA SCIENTIFIC REPORT 2021scientific activity4Duration: 2019-2021\nTotal budget:  \u20ac140.000 \nReference: PI18/01508\nTitle: Macrophages associated with tumor, tumor angiogenesis \nand resistance to therapies in gastric cancer diffuse mesenchymal \nphenotype\nPrincipal Investigator: Tania Fleitas Kanonnikoff\nFunding Body: Instituto de Salud Carlos III - Co-financed FEDER\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2019-2021\nTotal budget:  \u20ac99.000\nTitle: Whole exome sequencing of circulating tumor DNA and \ngenomic DNA to increase sensitivity in the detection of minimal \nresidual disease and open new mechanisms for personalized \nmedicine in localized colon cancer\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: SEOM\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2020-2022\nTotal budget:  \u20ac20.000\nTitle:  Molecular mechanisms and tumor heterogeneity associated \nwith primary and acquired resistance to trastuzumab treatment \nin gastric or gastroesophageal junction cancer\nPrincipal Investigator: Tania Fleitas Kanonnikoff\nFunding Body: SEOM\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2019-2021\nTitle: Patient derived organoids (PDOs) to personalize the \ntreatment of relapsed localized colon cancer (CC) by sequencing \nthe whole exome and genomic DNA\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: TTD\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2020-2022\nTitle:  Precission medicine in oncology: development of new \ntechnological approaches for personalized treatments in \nInmunotherapyPrincipal Investigator: Desamparados Roda and Sheila Z\u00fa\u00f1iga\nFunding Body: Fundaci\u00f3n FERO\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia\nDuration: 2019-2021\nTotal budget:  \u20ac240.000\nTitle: Colorectal carcinogenesis: the interaction of the tumor \nmicroenvironment and stem cells. Impact on personalized \ntreatment\nPrincipal Investigator: Noelia Tarazona Llavero\nFunding Body: Fundaci\u00f3n Mutua Madrile\u00f1a\nBeneficiary Institution : Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico \nUniversitario de Valencia \nDuration: 2020-2023\nTotal budget:  \u20ac130.000\nPUBLICATIONS\n1. Moya-Herraiz AA, Dorcaratto D, Martin-Perez E, Escrig-Sos J, \nPoves-Prim I, Fabregat-Prous J, Larrea Y Olea J, Sanchez-Bue-\nno F, Botello-Martinez F, Sabater L. Non-arbitrary minimum \nthreshold of yearly performed pancreatoduodenectomies: \nnational multicentric study. Surgery. 2021 Sep;170(3):910-\n916. doi: 10.1016/j.surg.2021.03.012. PMID: 33875253\n2. Lazaro Tome A, Jose Reig Cebria M, Gonzalez-Teruel A, Anto-\nnio Carbonell-Asins J, Canete Nicolas C, Hernandez-Viadel M. \nEfficacy of vitamin D in the treatment of depression: a system -\natic review and meta-analysis. Actas Espanolas de Psiquiatria. \n2021 Jan;49(1):12-23. PMID: 33533015\n3. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, \nCejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Marti-\nnez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, \nMartinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa \nS, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta \nM, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas \nT, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. \nMolecular profiling of advanced solid tumours. The impact of \nexperimental molecular-matched therapies on cancer patient \noutcomes in early-phase trials: the MAST study. British Jour-\nnal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/\ns41416-021-01502-x. PMID: 34493820\n4. Adam-Artigues A, Garrido-Cano I, Carbonell-Asins JA, Lam -\neirinhas A, Simon S, Ortega-Morillo B, Martinez MT, Her-245\nINCLIVA SCIENTIFIC REPORT 2021scientific activity 4nando C, Constancio V, Burgues O, Bermejo B, Henrique R, \nLluch A, Jeronimo C, Eroles P, Cejalvo JM. Identification of a \nTwo-MicroRNA signature in plasma as a novel biomarker for \nvery early diagnosis of breast cancer. Cancers. 2021 Jun \n7;13(11):2848. doi: 10.3390/cancers13112848. PMID: \n34200463\n5. Pizza F, D\u2019Antonio D, Lucido F, Gambardella C, Carbonell \nAsins J, Dell\u2019isola C, Tolone S. Does antrum size matter in \nsleeve gastrectomy?. A prospective randomized Study. Sur-\ngical Endoscopy and Other Interventional Techniques. 2021 \nJul;35(7):3524-3532. doi: 10.1007/s00464-020-07811-\n1. PMID: 32691207\n6. Signes-Costa J, Nu\u00f1ez-Gil IJ, Soriano JB, Arroyo-Espliguero \nR, Eid CM, Romero R, Uribarri A, Fern\u00e1ndez-Rozas I, Aguado \nMG, Becerra-Mu\u00f1oz VM, Huang J, Pepe M, Cerrato E, Rapo-\nseiras S, Gonzalez A, Franco-Leon F, Wang L, Alfonso E, Ugo \nF, Garcia-Prieto JF, Feltes G, Abumayyaleh M, Espejo-Paeres \nC, Jativa J, Masjuan AL, Macaya C, Carbonell Asins JA, Estra-\nda V; HOPE COVID-19 investigators. Prevalence and 30-day \nmortality in hospitalized patients with covid-19 and prior lung \ndiseases. Archivos de Bronconeumologia. 2021 Apr;57:13-\n20. doi: 10.1016/j.arbres.2020.11.012. PMID: 34629634clini-cal\ntrials\nINCLIVA SCIENTIFIC REPORT 20215. Clinical trials and other studies\n 5.1 Activity of the Ethical Committee for \n  investigation with medicinal products (CEIm)\n 5.2 Clinical research activity performed by \n  Valencia Cl\u00ednico-Malvarrosa Health Department249\nINCLIVA SCIENTIFIC REPORT 2021clinical trials 5TYPES OF EVALUATED STUDIES 2021\nCLINICAL TRIALS WITH MEDICINAL PRODUCTS 13\nPhase 0 0\nPhase I 1\nPhase II 6\nPhase III 6\nPhase IV 0\nCLINICAL TRIALS WITH MEDICAL DEVICES 0\nOBSERVATIONAL STUDIES WITH MEDICINAL PRODUCTS 25\nPost-authorization Studies other Designs: EPA-OD 2\nPost-authorization Studies promoted by Health Authorities: EPA-AS and  EPA-LA 0\nNo EPA 3\nPost-authorization Studies with prospective follow-up: EPA-SP 3\nObservacional studies with medicaments 12\nOBSERVATIONAL STUDIES WITH MEDICAL DEVICES 5\nRESEARCH PROJECTS 192\nTOTAL 2305.1. Activity of the Ethical Committee for investigation with medicinal products \n(CEIm)\nThe Ethical Committee for Investigation with Medicinal Products are an independent board with a multidisciplinary composition whose \nmain purpose is to oversee the protection of the rights, safety and well-being of subjects participating in clinical studies and biomedical \nresearch projects.\nAs a result of its activity along 2021, the CEIm has processed a total of 38 studies (clinical trials and observational studies): 37 were \npositively valued, and 1 is in the process of evaluating the response to the requested clarifications.\nOf the 38 approved studies, 19 were approved in the first evaluation and 19 after requesting clarification to the promoter.\nOf the 13 clinical trials with drugs evaluated, anyone has been evaluated through the Voluntary Harmonisation Procedure (VHP) process.\nThe following table shows the number of clinical trials and other studies according to their typology.\nTYPES OF EVALUATED STUDIES\nCLINICAL TRIALS WITH \nMEDICINAL PRODUCTS  \n6%\nCLINICAL TRIALS WITH \nMEDICAL DEVICES  \n0%OBSERVATIONAL STUDIES \nWITH MEDICAL PRODUCTS \n11%\nRESEARCH PROJECTS\n83%250\nINCLIVA SCIENTIFIC REPORT 2021clinical trials5Distribution of the clinical studies depending on the department where they are performed is the following:\nCLINICAL TRIALS BY DEPARTMENT N\u00ba\nAnesthesiology and Reanimation 1\nCardiology 4\nDigestive Medicine 4\nEmergencies 1\nGeneral Surgery 1\nHaematology 5\nHospital Pharmacy 2\nNephrology 3\nNeurology 1\nNeurosurgery 2\nOncology 6\nPsychiatry 3\nRheumatology 1\nTutelage 3\nUrology 1\nTOTAL 38\nDistribution of the research projects depending on the department where they are performed is the following:\nRESEARCH PROJECTS BY DEPARTMENT N\u00ba\nAnesthesiology and Reanimation 6\nCardiology 9\nDermatology 3\nDigestive Medicine 11\nEmergencies 1\nEndocrinology and Nutrition 12\nExternal 7\nGeneral Surgery 16\nGynecology 5\nHaematology 6\nINCLIVA Research Groups 11\nIntensive Medicine 1\nInternal Medicine 6\nMicrobiology 11\nNephrology 3\nNeumology 9\nNeurology 3\nNuclear Medicine 1\nNursery 6\nOncology 10\nOphthalmology 1\nOral and maxillofacial surgery 3\nOrthopedic and Traumatology Surgery 6\nOtorhinolaryngology 1251\nINCLIVA SCIENTIFIC REPORT 2021clinical trials 5RESEARCH PROJECTS BY DEPARTMENT N\u00ba\nPathological Anatomy 7\nPediatrics 20\nPharmacy 1\nPlastic surgery 2\nPrimary Care 1\nPsychiatry 2\nPsychology 1\nPhysical Medicine and Rehabilitation 2\nPublic Health 1\nRheumatology 1\nTutelage 2\nUniversity 2\nUrology 2\nTOTAL 192\n5.2. Clinical research activity performed by Valencia Cl\u00ednico-Malvarrosa  \nHealth Department\n5.2.1. Activity during 2021\nINCLIVA Health Research Institute manages the clinical studies (trials, observational studies, and research projects) carried out by the \nHospital Cl\u00ednico Universitario de Valencia and the Valencia Cl\u00ednico-Malvarrosa Health Department researchers. \nAs a result of its activity along 2021, the INCLIVA has managed a total of 211 studies (clinical trials and observational studies).\nThe distribution of these trials by phase is: Phase I: 24, Phase II: 56; Phase III: 67, Phase IV: 3, Observational studies: 57, others: 4. The \nfollowing table shows the number of clinical trials and other studies according to their phase and department.\n Phase I Phase II Phase III Phase IV Others Observational  TOTAL\nCardiology - 2 6 1 2 12 23\nDigestive Medicine - 5 2 - 1 7 15\nHaematology 3 3 9 - - 5 20\nInternal Medicine - - 2 - - - 2\nNephrology - 4 5 - - 3 12\nNeurology - - 4 - - - 4\nOncology 20 36 30 - - 7 93\nOthers1 6 9 2 1 23 42\n TOTAL24 56 67 3 4 57 211252\nINCLIVA SCIENTIFIC REPORT 2021clinical trials5The Department of Medical Oncology leads the number of trials assested to INCLIVA. It is followed by the departments of Cardiology, \nHaematology, Neurology, Digestive Medicine and Internal Medicine. These six services make over 75 % of the total processed trials.\nPROMOTOR N\u00ba\nHOSPITAL CL\u00cdNICO UNIVERSITARIO DE VALENCIA RESEARCHERS AND INCLIVA 3\nINDEPENDENT CLINICAL RESEARCH 67\nCOMERCIAL RESEARCH 141Regarding the distribution of studies per promoter, 67 trials are considered as Independent Clinical Research (trials from associations, \ngroups, foundations, and private individuals), 3 of which have been promoted by researchers from the Hospital Cl\u00ednico Universitario de \nValencia and INCLIVA and the rest of them have been promoted by the pharmaceutical industry.Cardiology\nDigestive Medicine\nHaematology\nInternal MedicineNephrology\nNeurology\nOncology\nOthers\n934223\n15\n420\n2\n12\n    Cardiology\nDigestive Medicine\nHaematology\nInternal Medicine\nNephrology\nNeurology\nOncology\nOthers\n0                      5                     10                    15                   20                    25                   30                   35                   40              \nPhase I                          Phase II                          Phase III                        Phase IV                         Others                         Observational253\nINCLIVA SCIENTIFIC REPORT 2021clinical trials 55.2.2 Assessment activity during last 5 years\nThe table below shows the number of studies processed yearly, during 2021 the number of processed studies has increase upper two \nhundred.\nYear Processed studies\n2017 143\n2018 172\n2019 159\n2020 206\n2021 211\nOne of INCLIVA\u2019s main goals is to develop clinical research at its early stages, thus contributing to translational research that moves \nscientific knowledge from bench to bedside. With this regard, during the period 2017-2021, Phase I and Phase II trials are prioritized and \nits number remains stable as shown in the table and graph below.\nPHASE 2017 2018 2019 2020 2021\nPhase 0 - 2 - 1 -\nPhase I 13 20 17 32 24\nPhase II 31 25 43 43 56\nPhase III 46 67 43 64 67\nPhase IV 6 5 7 8 3\nObservational 43 51 42 50 57\nOthers 4 2 7 8 4\nEvolution of clinical trial distribution by phase\nPhase I Phase II Phase III Phase IV Observational Others2021 2017 2018 2019 2020250\n200\n150\n100\n50\n0254\nINCLIVA SCIENTIFIC REPORT 2021clinical trials55.2.3. Ongoing studies\nDuring 2021, 579 studies have been active. The distribution of clinical trials per department analyzed below uses a semilogarithmic scale \ndue to the great difference between the Department of Medical Oncology and the rest of the Departments.\nDEPARTMENT N\u00ba\nAnesthesiology and Reanimation 20\nCardiology 63\nDigestive Medicine 38\nEndocrinology 8\nGeneral Surgery 5\nGynecology and Obstetrics 8\nHaematology 85\nInfectious Diseases unit 7\nInternal Medicine 8\nMedical Oncology 209\nNephrology 23\nNeurology 35\nPediatrics 6\nPharmacy 6\nPrimary Health Care 1\nRespiratory Diseases 10\nUrology 5\nOthers 42\nTOTAL 579\nAnesthesiology and Reanimation\nCardiology\nDigestive Medicine\nEndocrinology\nGeneral Surgery\nGynecology and Obstetrics\nHaematology\nInfectious Diseases Unit\nInternal Medicine\nMedical Oncology\nNephrology\nNeurology\nPediatrics\nPharmacy\nPrimary Health Care\nRespiratory Diseases\nUrology\nOthers\n1                                        10                                     100                                   1000255\nINCLIVA SCIENTIFIC REPORT 2021clinical trials 5The distribution of ongoing trials and other studies according to their typology are the following:\nPHASE N\u00ba\nPhase I 64\nPhase II 124\nPhase III 210\nPhase IV 30\nObservational 139\nOther 12\nPhase I\nPhase II\nPhase III\nPhase IV\nObservational\nOther\n0            20       40           60              80              100   120       140           160            220initia-\ntives\nINCLIVA SCIENTIFIC REPORT 20216. Initiatives for research promotion   \n 6.1 Grants for external fellowships, \n  Trainee students, Outgoing and Incoming \n  Internships and new initiatives \n 6.2 Training and teaching activities259\nINCLIVA SCIENTIFIC REPORT 2021initiatives 6Ana Aliaga Chueca\nUniversity of San Francisco. California (USA)\nM\u00aa Pilar Ballester Ferr\u00e9\nUCL Medical School-Royal Free Hospital. London (United Kingdom)\nManuel Ballesteros Redondo\nHospital Universitario Ram\u00f3n y Cajal. Madrid\nSilvia Bus\u00f3 Gil\nHospital Cl\u00ednic Barcelona. Barcelona\nGuillermo Cervera Ygual\nHospital Universitario Virgen del Roc\u00edo. Sevilla\nLeopoldo Fern\u00e1ndez Domper\nHospital Universitario Ram\u00f3n y Cajal. Madrid\nAna M\u00aa G\u00e1lvez Llompart\nHospital Universitario de Gran Canaria Dr. Negr\u00edn. Gran Canaria\nFrancisco Gimeno Valiente\nUniversity College of London. London (United Kingdom)\nConcepci\u00f3n G\u00f3mez Medina\nUniversity of Pittsuburgh Medical Center. Pittsuburgh (USA)6.1. Grants for external fellowships, Trainee students, Outgoing and Incoming  \n  Internships and new initiatives\nTo allow researchers to acquire new knowledge for clinical and research techniques, every year INCLIVA sponsors its Grants for research \ninternships in centers of excellence.\nSince the establishment of this scholarship program, over 158 professionals have visited national and foreign centers. In 2021 the \nnumber of grants funded was 17.\nList of beneficiaries and destination centers of the IIS INCLIVA Training Stays Grants during 2021:\nMariola Hern\u00e1ndez Mart\u00ednez\nComplejo Quir\u00f3n Salud (HRJB y HQSJ). Madrid\nH\u00e9ctor Manuel Merenciano Gonz\u00e1lez\nHospital Universitario de Bellvitge. Barcelona\nIria Mestre D\u00edaz\nHospital Santa Cristina. Madrid\nMarina Miralles Sancho\nHospital Psiqui\u00e1trico Rom\u00e1n Alberca. Murcia\nAlejandro P\u00e9rez Mora\nHospital Universitario Santa Cristina. Madrid\nAndr\u00e9s Piolatti Luna\nHospital Universitario Infantil Ni\u00f1o Jes\u00fas. Madrid\nSerena Pisoni\nIstituto Auxologico Italiano. Milan (Italy)\nMario Rodr\u00edguez Rivas\nHospital Universitario 12 de Octubre. Madrid\nOUTGOING INTERNSHIPS\nResearchers from our IIS INCLIVA that during 2021 carried out external fellowships in foreign centers are shown in the following table:\nJuan Antonio Carbonell Asins\nUniversidad de Puerto Rico. Mayag\u00fcez (Puerto Rico)\nBlanca Alabad\u00ed Pardi\u00f1es\nZNA (Ziekenhuis NETWERK Antwerpen). Antwerpen. Belgium\nLaura Robles Rodr\u00edguez\nUniversity of Colonia. Colonia (Germany)David Mart\u00ed Aguado\nUniversity of Pittsburgh Medical Center. Pittsburgh (USA)\nC\u00e9sar R\u00edos Navarro\nUniversit\u00e4tsklinikum Essen. Essen (Germany)\nDavid Mart\u00ed Aguado\nCentro Nacional de Investigaciones Cardiovasculares (CNIC). \nMadrid\nEzequiel Monferrer Garzar\u00e1n\nCentre for the Cellular Microenvironment Universtiy of Glas-\ngow. Glasgow (United Kingdom)260\nINCLIVA SCIENTIFIC REPORT 2021initiatives6Students who benefited from the Sanec 2021 Scholarship for Dual Training program for the academic years 2020-2021 and 2021-\n2022, promoted by the Bankia Foundation and several Research Institutes, including INCLIVA. There were a total of 5 beneficiaries.34 Bachelor Degree students at the University of Valencia (including TFG students)\n23 Bachelor Degree students at the Polytechnic University of Valencia (including TFG students)\n22 Master\u2019s Degree students at the University of Valencia (including TFM students)\n6 Master\u2019s Degree students at the Polytechnic University of Valencia (including TFM students)\n7 Bachelor Degree students from other universities (including TFG students)\n8 Master\u2019s Degree students from other universities (including TFM students)\n25 Higher Vocational Qualification students of public and/or private centers of the Valencian Community  \n   (10 of them were beneficiaries of the Sanec 2020 Program y 5 of them were beneficiaries of the Sanec 2021 Program)\n1 ESO students Program for acquiring knowledge about the world of workFrancisco Lara Hern\u00e1ndez\nUniversity of Valencia\n(Genomics and Diabetes Unit)\nSelene Valero Moreno\nUniversity of Valencia\n(Research Group on Rare Respiratory Diseases (RRD))\nEstrella Christabel Porr\u00e1s N\u00fa\u00f1ez\nUniversit\u00e0 Nazionale di Piura (Per\u00fa)\n(Genomics and Diabetes Unit)Granted by Conselleria de Innovaci\u00f3n,Universidades, \nCiencia y Sociedad Digital\nJuan Jos\u00e9 Gallego Roig\nImperial College London. London (United Kingdom)\nINCOMING INTERNSHIPS\nThe incoming researchers in 2021 are shown in the following table:\nAna Garc\u00eda Gosp - Research Group on Rare Respiratory Diseases (RRD) - Mr. Francisco Das\u00ed Fern\u00e1ndez\nAlba Gallardo Asunci\u00f3n  - Genomics and Diabetes Unit - Mr. Felipe Javier Chaves Mart\u00ednez\nAdri\u00e1n P\u00e9rez Andr\u00e9s - Research Group on Neurological Impairment - Mrs. Carmina Montoliu F\u00e9lix\nAlejandra Guti\u00e9rrez P\u00e9rez  - Research Group on Lymphoproliferative Disorders - Mrs. Blanca Ferrer Lores\nMar\u00eda Fern\u00e1ndez Calduch  - Group on Translational Research in Ischemic Heart Disease - Mrs. Amparo Ruiz Saur\u00edVlad Stefan Hancig\nPolytechnic University of Valencia\n(Research Group on Hematopoietic Transplantation)\nMarcella La Noce\nUniversit\u00e0 della Campania \u201cL.Vanvitelli\u201d. Napoles (Italy) \n(Research Group of Innovative Diagnostic and Therapeutical \nDevelopments in Solid Tumors \u2013 InDeST)\nTRAINEE STUDENTS\nThere is a table attached that includes the number of students of Vocational Qualification, Degree or Master accepted during 2021 in \nINCLIVA. They have carried out training practices in different research groups:Ariadna Bargiela Sch\u00f6nbrunn\nUniversity of Oxford. Oxford (United Kingdom)261\nINCLIVA SCIENTIFIC REPORT 2021initiatives 66.2 Training and teaching activities\nCourses (14)\n\u2022 La Diabetes Tipo 2 desde la Perspectiva de la Multimor -\nbilidad\n\u2022 VII Workshop Internacional Ecograf\u00eda y Resonancia Ano-\nrrectal\n\u2022 C19_SPACE Curso de Preparaci\u00f3n de Habilidades\n\u2022 Curso te\u00f3rico pr\u00e1ctico Leucemia Linfoc\u00edtica Cr\u00f3nica-LLC\n\u2022 I Curso de Laparoscopia Experimental para Residentes de \nUrolog\u00eda\n\u2022 Estad\u00edstica Aplicada a la Medicina\n\u2022 Curso Online en Atenci\u00f3n Sanitaria Basada en Valor\n\u2022 Curso Cat\u00e9ter Venoso Central de Inserci\u00f3n Perif\u00e9rica-PICC\n\u2022 Formaci\u00f3n Progresiva Cirug\u00eda Laparosc\u00f3pica Colorrectal\n\u2022 Curso Buenas Pr\u00e1cticas Cl\u00ednicas para Investigadores\n\u2022 I Curso sobre Gesti\u00f3n de la CronicidadNEW INITIATIVES\nThe first call for applications for TFD and TFM Tutorials was opened in 2021. The call is aimed at university students enrolled in University \nDegrees and Masters in the Area of   Health and Allied Sciences.\nThe following list shows the students who are going to do their TFD or TFM:\nTFG\nMalena Parlatore - Genomics and Diabetes Unit - Mrs. Ana B\u00e1rbara Garc\u00eda Garc\u00eda\nMar\u00eda Janini Vilarrasa - Research Group on the Study of Cardiometabolic and Renal Risk - Mr. David Mart\u00ed Aguado\nAlexandre Ruix Morell - Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST - Mr. \nAndr\u00e9s Cervantes\nLaura Arias Blanco  - Research Group on Breast Cancer Biology - Mrs. Pilar Eroles Asensio\nIn\u00e9s Escobedo Camacho  - Research Group on the Study of Cardiometabolic and Renal Risk - Mrs. Raquel Cort\u00e9s Vergaz\nTFM\nVictoria Muriach P\u00e9rez - Research Group on Neurological Impairment - Mrs. Carmina Montoliu F\u00e9lix\nAdri\u00e0 L\u00f3pez Gramaje - Research Group on Neurological Impairment - Mrs. Carmina Montoliu F\u00e9lix\nCarmen Costa Gregori - Genomics and Diabetes Unit - Mrs. Ana B\u00e1rbara Garc\u00eda Garc\u00eda\nCeleste Moya Valera - Genomics and Diabetes Unit - Mr. Felipe Javier Chaves Mart\u00ednez\nAntonio P\u00e9rez-Cardona Garc\u00eda  - Research Group on the Study of Cardiometabolic and Renal Risk - Mr. Josep Red\u00f3n i Mas\nCristian Mart\u00ednez Fajardo - Research Group on Healthy Aging - Mr. Juan Gambini Buch\u00f3n\nNoelia Ruiz Alonso  - Research Group on Breast Cancer Biology - Mrs. Pilar Eroles Asensio\nAna M\u00aa Agreda Roca  - Research Group on Breast Cancer Biology - Mr. Juan Miguel Cejalvo And\u00fajar\nAna Puertes Espada - Research Group on the Study of Cardiometabolic and Renal Risk - Mrs. Raquel Cort\u00e9s Vergaz\nCarme Mar\u00eda Ortega Albiach  - Bioinformatics and Biostatistics Unit - Mrs. Sheila Z\u00fa\u00f1iga Trejos\n\u2022 Curso Aspectos B\u00e1sicos Protecci\u00f3n de Datos\n\u2022 9\u00aa Edici\u00f3n Curso de Anatom\u00eda Quir\u00fargica Aplicada HBP\n\u2022 VII Workshop Cirug\u00eda Laparosc\u00f3pica Colorrectal Avanzada\nScientific Conferences (24)\n\u2022 Jornada Personal de Enfermer\u00eda Hematolog\u00eda\n\u2022 Nueva Normativa de Estudios Observacionales con \nmedicamentos\n\u2022 Jornada Estrat\u00e9gica de Investigaci\u00f3n EERR\n\u2022 Normativa de Protecci\u00f3n de Datos en los Proyectos\n\u2022 Reuni\u00f3n Virtual THP Domiciliario-Jornada Ruta Asistencial\n\u2022 Visualizaci\u00f3n del Personal Investigador en Redes Sociales\n\u2022 Con la Igualdad Siempre Ganas 1\u00aa sesi\u00f3n\n\u2022 Requisitos para la presentaci\u00f3n de proyectos de investigaci\u00f3n262\nINCLIVA SCIENTIFIC REPORT 2021initiatives6\u2022 Proyecto Formativo para Atenci\u00f3n Primaria\n\u2022 Programa de Formaci\u00f3n en Hemopatolog\u00eda 2021\n\u2022 Proyecto Marco Polo I (3 sesiones)\n\u2022 Jornada Formativa Acceso a HC en Investigaci\u00f3n \nBiom\u00e9dica\n\u2022 Innovaci\u00f3n y Transferencia de Conocimientos\n\u2022 Nuevas tecnolog\u00edas aparatos W8\n\u2022 Jornada Enfermedades Raras en Pediatr\u00eda y Atenci\u00f3n \nPrimaria\n\u2022 Proyecto Marco Polo II (4 sesiones)\n\u2022 Post-ESMO 2021\n\u2022 Innova HUB SALUD LANZADERA\n\u2022 Con la Igualdad Siempre Ganas 2\u00aa Sesi\u00f3n\n\u2022 Formaci\u00f3n Sanitaria Especializada\n\u2022 Actualizaci\u00f3n C\u00e1ncer de Pr\u00f3stata 2021\n\u2022 Jornada Papel del m\u00e9dico residente en la lucha contra el \nVIH\n\u2022 T\u00e9cnicas de abordaje del paciente con espasticidad post \nictus\n\u2022 Jornada Formativa sobre Patolog\u00eda Hematol\u00f3gica y \nOncol\u00f3gica. Evoluci\u00f3n de Enfermer\u00eda: estudio de un casoINCLIVA Seminars / Meet the Expert  (10)\n\u2022 Los biomarcadores para la Enfermedad de Alzheimer en \nla pr\u00e1ctica cl\u00ednica\n\u2022 La Investigaci\u00f3n Biom\u00e9dica del Dolor con Perspectiva de \nG\u00e9nero\n\u2022 2\u00aa Reuni\u00f3n \u201cLos biomarcadores para la Enfermedad de \nAlzheimer\u201d\n\u2022 Mitos frente a realidades en el c\u00e1ncer de pr\u00f3stata \navanzado\n\u2022 Visitas de observaci\u00f3n \u201cShadow Visit\u201d\n\u2022 Seminarios Cient\u00edficos Deterioro Neurol\u00f3gico\n\u2022 Proyecto THP Domiciliario\n\u2022 Seminario Incliva-BIOBANCO\n\u2022 Seminario INCLIVA Dr. Batlle\n\u2022 I Reuni\u00f3n Matriz extracelular en el sistema nervioso\nSocial Dissemination Days (5)\n\u2022 D\u00eda Mundial EERR 2021\n\u2022 Encuentro on-line Club Triple Negativo\n\u2022 C3 Coloquio Visi\u00f3n de la Ciencia de Investigadoras \nValencianas\n\u2022 Celebraci\u00f3n: D\u00eda del Prematuro\n\u2022 Prevenci\u00f3n y Tratamiento de \u00dalceras por Presi\u00f3n-UPPcom-\nmuni-\ncation\nINCLIVA SCIENTIFIC REPORT 20217 . Communication \n 7.1 Highlights \n 7 .2 Communication Indicators 2021265\n265\nINCLIVA SCIENTIFIC REPORT 2021communication 7 7.1. Highlights\nJanuary\n\u2022 INCLIVA coordinates an international and multicenter study on the prevalence of coma and delirium in ICU patients with \nCOVID-19\n\u2022 INCLIVA participates in a European project to analyze and reduce energy poverty and its impact on health\n\u2022 Igenomix-INCLIVA researchers decode for the first time the cellular behavior of the human endometrium\nFebruary\n\u2022 INCLIVA participates in a project to disseminate the contributions of senior female scientists in the field of physical activity and \nhealth\n\u2022 INCLIVA analyzes the effectiveness of 3D printing in understanding neuroblastoma and other tumors\n\u2022 An INCLIVA study opens up new therapeutic possibilities in patients with Friedreich\u2019s Ataxia (FA)\n\u2022 INCLIVA ends the study of non-invasive stimulation of the vagus nerve in COVID-19 patients with respiratory symptoms\nMarch\n\u2022 INCLIVA and AVA-ASAJA initiate biomedical projects to study and disseminate the healthy properties of Valencian agricultural \nproducts\n\u2022 An INCLIVA study shows that the increase in potassium level after an episode of severe hyperkalaemia is associated with the \nrisk of death\n\u2022 INCLIVA research confirms the efficacy of circulating microRNA-30b as a diagnostic marker for breast cancer\n\u2022 An INCLIVA-CIBERFES study points to a new therapeutic target for satisfactory aging\n\u2022 An INCLIVA study identifies a molecular profile associated with the development of kidney disease in early stages in patients \nwith hypertension\nApril\n\u2022 An INCLIVA study demonstrates the importance of a new molecular target in the treatment of obesity and diabetes\n\u2022 An INCLIVA investigation opens the doors to a new DAAT study model\n\u2022 INCLIVA develops, with the support of the AVI, a test that detects early and predicts the evolution of sepsis, one of the main \ncauses of death in hospital\n\u2022 An INCLIVA study shows that stress in childhood and adolescence can modify the brain\nMay\n\u2022 INCLIVA develops a rapid detection kit for COVID-19, highly sensitive and easy to use\n\u2022 INCLIVA receives funding from FIPSE for the development of a rapid diagnostic and prognostic test for sepsis and septic shock\n\u2022 INCLIVA, UPV and CIBERBBN develop a new biosensor that helps in the early diagnosis of breast cancer\nJune\n\u2022 Professor Cervantes warns of the impact of COVID-19 on women oncologists and highlights the need for more measures to \nguarantee gender equality\n\u2022 The College of Customs Agents and ATEIA-Oltra collaborate with INCLIVA to promote research on gastric cancer\n\u2022 INCLIVA and IATA-CSIC researchers confirm the absence of COVID 19 and the presence of defenses against the virus in breast milk\n\u2022 INCLIVA participates in a pioneering clinical trial to validate the efficacy of immunotherapy in 29 types of tumors266\n266\nINCLIVA SCIENTIFIC REPORT 2021communication7July\n\u2022 INCLIVA renews its accreditation as a Health Research Institute\n\u2022 Big Data & AI: Actionable Insights Transforming European Healthcare shows the results of 12 big data and artificial intelligence \npilots that make up this BigMedilytics Project\n\u2022 II Ideas Contest to stimulate the innovative culture of the Hospital Cl\u00ednico Universitario de Valencia and its department, through \nthe INCLIVA Innovation Support Unit\n\u2022 INCLIVA and IIS La FE participate in a European clinical trial aimed at reducing infections and rejection in kidney transplant \npatients\n August\n\u2022 INCLIVA participates in a project funded by the EU to improve post-treatment in breast cancer\n\u2022 INCLIVA and CIBERONC promote a study aimed at improving the diagnosis of aggressiveness and advancing in personalized \ntherapies in uterine cancer\n\u2022 An INCLIVA study demonstrates the relationship between chronic kidney disease and heart conditions through the Rabphilin \nprotein\nSeptember\n\u2022 UV and INCLIVA researchers demonstrate for the first time the influence of pheromonal signals on memory generated in the \nhippocampus\n\u2022 An INCLIVA study shows the relevance of personalized treatments in patients with advanced tumors and specific molecular \nabnormalities\n\u2022 European researchers promote the large-scale integration of Big Data and Artificial Intelligence techniques in health\n\u2022 INCLIVA demonstrates the usefulness of cardiac magnetic resonance imaging of cardiac function in patients with acute \nmyocardial infarction\n October\n\u2022 INCLIVA demonstrates the impact of the G6PD enzyme in the prevention of frailty in the elderly\n\u2022 INCLIVA and Boehringer Ingelheim renew their collaboration to promote training and health research\n\u2022 INCLIVA, AIDIMME and IBV will bring a custom-made maxillo-mandibular prosthesis to the market in collaboration with the \n3DSolutions Group\n\u2022 An international trial shows, for the first time, that associating an immunotherapy with standard chemotherapy improves survival \nin triple-negative breast cancer\n\u2022 An INCLIVA study analyzes the potential of microRNAs as biomarkers of osteoporosis and osteoarthritis\n November\n\u2022 An INCLIVA and UV study highlights the importance of combined dietary-nutritional and physical exercise programs during \nchildhood to prevent obesity in adulthood\n\u2022 About half of the patients admitted for moderate or severe pneumonia due to COVID-19 present alterations in lung function six \nmonths after hospital discharge\n\u2022 Professor Cervantes defends a paradigm shift in oncology based on the molecular abnormalities that cause cancer rather than \non the location of the tumor in a specific organ\n December\n\u2022 INCLIVA and the International University of Valencia (VIU) sign an agreement to collaborate in training and research activities\n\u2022 Professor Cervantes conveys to the deputies and senators of the Health commissions of the Congress and Senate the challenges \nof Personalized Precission Medicine in a colloquium organized by Diariofarma\n\u2022 Fundaci\u00f3n Bancaja and INCLIVA renew the agreement to promote the Precission Medicine Unit in Oncology267\n267\nINCLIVA SCIENTIFIC REPORT 2021communication 7\nTotal press releases                 Total media appearances7.2.   Communication Indicators 2021\nPress office  \nDuring 2021, INCLIVA issued a total of 149 press releases on the Web.\n350\n300\n250\n200\n150\n100\n50\n0\njan-21          feb-21          mar-21          apr-21        may-21          jun-21           jul-21           aug-21         sep-21          oct-21          nov-21          dec-21\njan-21 feb-21 mar-21 apr-21 may-21 jun-21 jul-21 aug-21 sep-21 oct-21 nov-21 dec-21\nTotal press releases 18 16 8 12 33 18 5 9 7 6 12 5\nTotal media appearances    143 112 199 245 319 157 112 115 171 166 194 84\nSocial Media users 2021\n10.688 5.165 1.055 6.191268\n268\nINCLIVA SCIENTIFIC REPORT 2021communication7\nWebsite users\n77.163Website sessions\n153.049Website new sessions\n84,1%INCLIVA Website 2021\nOutreach 2021\n149 Issued press releases\n112 Newspieces on INCLIVA\u2019s website\n19 News on Radio\n14 News on TV\nIn may was held MedNight 2021: Nit Mediterr\u00e0nea de les in-\nvestigadores, an event associated with the European Union\u2019s No-\nche Europea de los Investigadores initiative, funded by the Marie \nSk\u0142odowska-Curie actions of the Horizon2020 European funding \nprogramme.\nIts objectives are to value science and the role of women in scien-\ntific and technological research in the Region of Murcia and the \nValencian Community for the first time jointly, and to promote scien-\ntific vocations through formats and attractive activities for all ages \nand all types of audiences like talks, workshops, virtual exhibitions \nand scientific shows.\n269social initiativessocial\ninitia-\ntives\nINCLIVA SCIENTIFIC REPORT 20218. INCLIVA social initiatives\n 8.1 Philantropic projects\n 8.2 Private philantropic donations and acknowledgments271\n271\nINCLIVA SCIENTIFIC REPORT 2021social initiatives 88. INCLIVA social initiatives\nIn 2021, the Institute of Health Research at the Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, launched an awareness campaign \non the importance of health research to guarantee first-rate assistance in the field of public health, and thus save more lives every year.\nUnder the slogan I support research, which is part of its Patronage Plan, INCLIVA underlines the essential nature of research to achieve \nmedical advances that translate into improved quality of life for all citizens.\nThese are the main highlights: \n18 March, 2021. AVA-ASAJA (Valencian association of Farmers) became an honorary ambassador of INCLIVA. The two entities signed \na framework collaboration agreement to launch biomedical research projects studying the health properties of different Valencian agricul -\ntural products and promoting them within society. This agreement shows the commitment of the agricultural and health sectors to offer -\ning consumers a healthy and balanced diet, coinciding with the Covid-19 pandemic which highlighted the importance of health in disease \nprevention.\nDecember 2020-January 2021 . The INCLIVA Health Research Institute at the Clinical Hospital of Valencia launched the campaign \n\u2018Give research as a gift this Christmas\u2019, inviting people to make donations to health research as a Christmas present. Running until 6 \nJanuary, the objective of this campaign was to raise public awareness of the importance of health research and suggest the possibility \nthat by donating, anyone can contribute individually and within their means to the advancement of science and to unravelling unsolved \nmedical problems.\nFebruary 2021 . Solidarity campaign: \u201cThe art of painting to defeat childhood cancer, neuroblastoma\u201d. The Research Group led by \nDr Rosa Noguera launched a fundraising campaign for research into neuroblastoma, the most common tumour type in childhood. \nThe campaign invited everyone making a donation to this cause to enter a competition to draw a painting by urban artist Dridali. The \nprize-winner who won the painting was the Iraila National Association, initiatives for funding childhood cancer research.\nApril 2021 . INCLIVA participates in the \u2018Make history with your story\u2019 campaign to help women with breast cancer trying to conceive. \nLaunched by the GEICAM Breast Cancer Research Group to coincide with Mother\u2019s Day, the initiative involved mothers with breast \ncancer explaining their experience and highlighting the importance of both the medical team to overcome the challenges involved, \nand of research to help other women with this disease become mothers. The aim of the campaign was to advance knowledge of the \nrelationship between breast cancer and pregnancy via the patients themselves, and help women with this disease who are trying to \nconceive by providing them with the best and most appropriate advice.\nJune 2021 . The Colegio de Agentes de Aduanas (Association of Customs \nAgents) and ATEIA-Oltra (Business Association of Freight Forwarders \nin Valencia) collaborated with INCLIVA to promote research on gastric \ncancer, allocating the proceeds from the trilogy \u2018How much do you know \nabout customs and customs duties?\u2019 to INCLIVA to further the study of \ngastric cancer immune microenvironment.\nJuly 2021. Launch of the charity campaign \u201cWhen I grow up I want to \nbe like you\u201d supporting childhood cancer research. Promoted by Mar\u00eda \nFerrer, this initiative aimed to raise funds for childhood cancer research \nby placing money collection tins in various collaborating restaurants and \nshops, mainly in the Marina Alta area. The campaign started on July 10 \nand ran until the end of the Christmas holidays. This campaign aims to \nraise awareness about childhood cancer and funds to investigate this \ndisease and give children with cancer the opportunity to grow up healthy. \nThe collection tins, prepared by hand by Mar\u00eda and her children, will raise \nlife expectancy and hope for children suffering from Neuroblastoma, the \nmost common childhood cancer. Today these children are ill, but thanks \nto research, we hope that they will become healthy adults who can enjoy \nlife and contribute their full potential to society.\nCAMPAIGNS272\n272\nINCLIVA SCIENTIFIC REPORT 2021social initiatives83 November, 2021. INCLIVA Health Research Institute at the Clinical Hospital \nof Valencia joined the \u2018ADN Mestalla Solidari\u2019 campaign of Valencia CF Foot -\nball club and Foundation, which gives visibility to the important charitable work \nof various Valencian organisations. INCLIVA has thus joined entities such as \nCruz Roja Juventud, Civil Protection, Fivan, Hogares Compartidos and Lamna \nin receiving support and promotion from Valencia CF and the VCF Foundation \nduring La Liga  matches played at Mestalla football grounds this season.\nDONATIONS\nJanuary 2021 . The Els Generals falla collaborated with INCLIVA as part of its \nEN VENA initiative. Thanks to the campaign carried out and the \u201cRemember \nthe 80s\u201d concert held before the pandemic, INCLIVA received \u20ac2,345 to sup-\nport precission medicine and liquid biopsy research in their institute.\nMarch 2021 . ASPANION (Association of Parents of Children with Cancer in \nthe Valencian Community), together with the charity initiative  Contigo por la \nBatalla, made a donation to the INCLIVA Health Research Institute towards \ndevelopment of health research in childhood cancer, from an idea put forth \nby two women from Castell\u00f3n with children affected by cancer. The donation \nof \u20ac3,009.64 was allocated specifically to the INCLIVA Pediatric Solid Tumor \nTranslational Research Group, co-directed by Drs. Samuel Navarro and Rosa \nNoguera from the CIBER Cancer group (CIBERONC), towards research into \nEwing\u2019s sarcoma, a cancer which although it can occur at any age, is more \ncommon in children and adolescents.\n15 March, 2021 . The Esperan\u00e7a de Pego Cancer Association supported \nINCLIVA with a donation of \u20ac3,000 for breast cancer research, adding to \na contribution made last year to support ovarian cancer research. This year \nfunds were raised through association member Carlos Siscar Bay. This \nathletics fan set himself the challenge of running 12 charity marathons in 12 \nmonths. Beyond raising money for this cause, he also helped raise awareness \nof the importance of continuing research and creating hope for everyone living \nwith cancer.\n21 May, 2021 . Amunt Contra el Cancer signed a collaboration agreement \nwith the INCLIVA Health Research Institute, making a donation this year of \n\u20ac12,250 euros to research projects in ovarian cancer, head cancer and neck \nand liquid biopsy. The agreement, signed by INCLIVA director Dr. Andr\u00e9s Cer -\nvantes and the president of Amunt Contra el Cancer, M\u00aa Isabel Llorca, will \nincrease resources to investigate ovarian cancer (by \u20ac4,100), head and neck \ncancer (\u20ac4,000) and liquid biopsy ( \u20ac4,150).273\n273\nINCLIVA SCIENTIFIC REPORT 2021social initiatives 8September 2021 . The Valencia-Castell\u00f3n Association of Property \nAdministrators and the Special Section Fallas Federation have awarded the \nsecond annual \u201cSpecialist Award\u201d to Dr. Ana Lluch, and have made a donation \nof \u20ac1,000 for research in breast cancer. This award, which acknowledges \nexcellence of work in art, science or sports, this year went to our researcher \nAna Lluch for her professional dedication and research effort in the fight \nagainst breast cancer. Held at the headquarters of the Association of Property \nAdministrators of Valencia-Castell\u00f3n, this emotive ceremony was attended by \nthe principal falleras of Valencia in 2021, Consuelo Llobell and Carla Gracia, \nas well as political representatives of the Consell, the Corts and Valencia City \nCouncil, the Association of Property Administrators and the Special Selection \nFallas Federation.\nOctober 2021 . The Le Cad\u00f3 Foundation donated \u20ac12,500 to INCLIVA for \nresearch into breast cancer. Founded in 2010, the foundation aims to finance \nprojects for breast cancer research, and in addition to ours, they currently \nare funding two other studies: \u201cDeciphering the genome of hereditary breast \ncancer\u201d at the Provincial Hospital of Castell\u00f3n in conjunction with La Fe Hospi-\ntal in Valencia, led by Dr Mar\u00eda Fonfr\u00eda Esparcia and Dr Eduardo Mart\u00ednez de \nDue\u00f1as, and most recently the BAFC (Benefits of Physical Activity in Cancer) \nproject, a physical exercise program directed at women with breast cancer \ncurrently under development at the UJI.\nDecember 2021 . The Bancaja Foundation and INCLIVA renewed their collab -\noration promoting our Precission Medicine Unit, which received a \u20ac22,000 \ncontribution from Bancaja on renewal of the agreement. The unit is focused \non molecular screening of cancer patients for genetic sequencing of the tu-\nmour, which enables a personalized approach through the most appropriate \ntherapy in each case and experimental therapeutic alternatives.\nDecember 2021 . The Coraz\u00f3n Solidario Association presented INCLIVA with \u20ac10,000 to be used for the NED breast cancer project, coordinated \nby Dr Juan Miguel Cejalvo of the Breast Cancer Biology Research Group. INCLIVA signed a collaboration agreement with the entity in 2020, be -\ncoming the only organisation that receives funds from this Association..July 2021 . ASPANION (Association of Parents of Children with Cancer in the Valencian Community), together with the solidarity initiative Painting \nthe way in pink made a donation to the INCLIVA Health Research Institute at the Hospital Clinical of Valencia to contribute to the development of \nhealth research in childhood cancer. Raised through charity collection tins from collaborating businesses, and donations with fundraising gifts at \ncommunions, weddings and baptisms, the final amount collected of \u20ac10,000 will be used for translational research in the field of Pediatric Non-\nHodgkin\u2019s Lymphoma (NHL).274\n274\nINCLIVA SCIENTIFIC REPORT 2021social initiatives8\n8.1 Philanthropic projects\n \nFUNDACI\u00d3N LE CAD\u00f3\nFundaci\u00f3n Le Cad\u00f3 was created in 2010 under the leadership of \nits president Elvira Monferrer Daudi. This initiative seeks to unite \nefforts and resources in supporting this kind of tumor research, \nwhich is currently the fourth leading cause of death in women.\nFundaci\u00f3n Le Cad\u00f3 collaborates with INCLIVA in funding the \nresearch project  \u201cStudy of breast cancer in young women under \n35 years\u201d, conducted by Dr. M\u00aa Teresa Mart\u00ednez Mart\u00ednez. It also \ninvolves other researchers such as Dr. Isabel Chirivella (a genetic \ndiagnosis specialist physician) and the entire team led by the \noncologists Dr. Ana Lluch and Dr. Pilar Eroles.\nFUNDACI\u00d3N NEOBLASTOMA\nThe Neuroblastoma Foundation, created in 2017, funds research \non neuroblastoma, a particularly aggressive type of childhood \ncancer that affects the nervous system. Survival figures have not \nimproved in recent years. The Neuroblastoma foundation informs \nfamilies about existing treatments, and brings together families of \nsick children, motivating them to raise funds for research through \nnumerous campaigns. The funds are destined to research projects \nand clinical trials in Spanish laboratories and hospitals, this year \nthis year the donation received has been \u20ac14.000.ASOCIACI\u00d3N NACIONAL \nDE ALPHA 1\nThe Alfa-1 Spain Association defends the interests of patients \naffected by the Deficit, their families and their caregivers, and pro-\nmotes the research and training of health personnel who treat \nthese patients. The defense of early diagnosis, access to available \nmedical treatments and the daily support of patients and newly di-\nagnosed, are its foundational tasks. This year Alfa-1 Spain Associ -\nation and INCLIVA had signed a CV. The Research Group on Rare \nRespiratory Diseases (RRD) has been awarded the 1st Amadeu \nMonteiro Research Scholarship.\nAMUNT CONTRA EL CANCER \nAmunt Contra el C\u00e0ncer is an association based in Denia, provin-\nce of Alicante, that carries out different services and actions aimed \nat improving the quality of life of cancer patients and their families. \nOrganizes informative talks, offers psychological support to pa-\ntients and promotes various activities to raise funds for research. \nThis year this year the donation received has been \u20ac12.250.\n275\n275\nINCLIVA SCIENTIFIC REPORT 2021social initiatives 8FUNDACION SANDRA IBARRA\nThe Sandra Ibarra Foundation is a non-profit organization with a \nhistory of twelve years joining efforts against cancer. During these \nyears, the Foundation has invested its time in promoting campaigns \nand financing research, awareness and prevention projects against \ncancer, as well as the development of the humanization of health. \nThis year this year the donation received has been \u20ac10.500.\nCORAZ\u00d3N SOLIDARIO\nCoraz\u00f3n Solidario is an Association born out of the joint project of \nfive colleagues, who having collaborated in various NGOs decided to \npool their work to fundraise for the fight against cancer. All profits \nof this association go to INCLIVA.\n276\n276\nINCLIVA SCIENTIFIC REPORT 2021social initiatives88.2 Private philanthropic donations and acknowledgments \nOn behalf of INCLIVA, we want to thank all the people who have helped our research through their donations, for their support and soli-\ndarity. For us, this collaboration means much more than an economic contribution: it is the encouragement we need to keep investigating \nand working in research.\nPrivate donations\nAbarca Briones, Isabel\nAguilar Aguilar, Susana\nAhullana S\u00e1nchez, Adri\u00e1n\nAmor Fuentetaja, Estrella\nAndreu Bover, Teresa\nBaviano Rodr\u00edguez, Julia\nBayarri Esteve, Gonzalo\nBlasco Garc\u00eda, Carmen\nBosch S\u00e1nchez, Susana\nBotella Aparicio, Francisco\nCambronero L\u00f3pez, Noema\nCarbonell Beltr\u00e1n, Santiago\nCasas Tar\u00edn, Iv\u00e1n\nDe Vargas Montesinos, Mar\u00eda Luisa\nDinnbier Escuder, Enriqueta\nDoria Ca\u00f1izares, Eva\nFar\u00edas Far\u00edas, Angelo Alejandro\nFemen\u00eda Cabrera, Francisca\nFont Ferrando, Natalia\nFraile Bohoyo, Silvia\nFresneda Reche, Federico\nGallego-Casilda Pastor, Valeriano\nGarc\u00eda Alca\u00f1iz, Mar\u00eda del Carmen\nGarc\u00eda Escarda, Rosana\nGarc\u00eda Garc\u00eda, Mar\u00eda del Carmen\nGarc\u00eda Mart\u00ednez, Luis\nGil Portero, Aurelia\nGimeno Gil, Ohaine\nG\u00f3mez Mansilla, Enrique\nGuardiola Huertas, Emilio\nHerreras Monz\u00f3, Enrique\nHueso Mart\u00ed, Inmaculada\nJord\u00e1 Milligan, Silvia\nL\u00e1zaro Ballester, AmparoL\u00e1zaro Romero, Cristela Asunci\u00f3n\nL\u00f3pez Bermejo, Antonio\nMadrid Reques, Gema\nMart\u00ednez Romero, Eva\nMart\u00ed Morell, Cristina\nMartinetti Mieusset, Vanessa\nMart\u00ednez Hern\u00e1ndez, Alberto\nMart\u00ednez Vaya, Cristina\nMartorell Pe\u00f1alba, \u00d3scar\nMieusset Mieusset, Yvette-Isabelle\nMiret Bernal, Francisco\nMonedero Ca\u00f1ada, Cristina\nMoreno Dur\u00e1n, In\u00e9s\nMoreno Garc\u00eda, Herminia\nMorgado G\u00f3mez, Emilia \nMoya S\u00e1nchez, Francisco\nNicol\u00e1s Garrido, Francisco\nNoguera Salv\u00e1, Inmaculada\nPascual Revert, Diego\nPavia Estrella, Laura\nPuigdengolas Rosas, Amalia\nQueralt Pesudo, Isabel\nQueralt Pesudo, Zaida\nRequena Castell\u00e0, Alba\nRodr\u00edguez Deval, M\u00aa Dolores\nRodr\u00edguez M\u00ednguez, Virginia\nRodr\u00edguez Rodr\u00edguez, Isabel Mar\u00eda\nRom\u00e1n Veiras, Lorena\nRuiz Mar\u00edn, Noem\u00ed\nS\u00e1inz Candel, Valvanera\nSales Fornes, M\u00aa Asunci\u00f3n\nS\u00e1nchez Garc\u00eda, Adri\u00e1n\nS\u00e1nchez Gonz\u00e1lez, Mar\u00eda Jos\u00e9\nS\u00e1nchez Mu\u00f1oz, Vicenta277\n277\nINCLIVA SCIENTIFIC REPORT 2021social initiatives 8Santaf\u00e9 Moreno, Francisca\nSanz Canet, F\u00e1tima\nSanz Moliner, Ana\nSarabia Navarrete, Francisca\nColegio Territorial de Administradores de \nFincas de Valencia-Castell\u00f3n\nEurol\u00edneas Personales SL\nFalla Els Generals\nFondo Solidariet\u00e0 Cavit SC\nFresenius Kabi Espa\u00f1a SA\nFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y \nHemoterapia\nFundaci\u00f3n Lecad\u00f3\nFundaci\u00f3n Sandra Ibarra de Solidaridad frente \nal C\u00e1ncer\nGE Healthcare Biosciences SA\nGlaxosmithkline SA\nIraila, Iniciativas para la Financiaci\u00f3n de la \nInvestigaci\u00f3n del C\u00e1ncer Infantil\nJunta Local Contra el C\u00e1ncer Montesa\nLaboratorios Ordesa\nLaboratorios Viiv Healthcare SL\nPaspalmarvi SL\nRaminatrans SL\nValencia Club de F\u00fatbol SAD\nVifor Fresenius Medical Care Renal Pharma \nEspa\u00f1a SLU\nVifor Pharma Espa\u00f1a SLSchulze Steinen, Otto Heinrich\nSim\u00f3n Ruvira, Rosa Mar\u00eda\nTorrecabota Gordero, Julia\nValero Mar\u00e9s, Irene\nCorporative donations\nAMUNT contra el C\u00e0ncer\nAsociaci\u00f3 Familiars i Amics Pacients amb \nNeuroblastoma\nAsociaci\u00f3n Alfa-1 de Espa\u00f1a\nAsociaci\u00f3n Coraz\u00f3n Solidario Contra el \nC\u00e1ncer\nAsociaci\u00f3n de Padres de Ni\u00f1os con C\u00e1ncer \nASPANION\nAsociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer\nAsociaci\u00f3n Local Contra el C\u00e1ncer Onil Iris\nAsociaci\u00f3n para el Estudio e Investigaci\u00f3n de \nPatolog\u00eda en Urgencias M\u00e9dicas\nAsociaci\u00f3n para el Fomento del Estudio en \nCiencias Biom\u00e9dicas (AFEMED)\nAssociaci\u00f2 Contra el C\u00e0ncer De Pego \n(Associaci\u00f2 Esperan\u00e7a)\nAssociaci\u00f3 d\u2019Alumnes del Consell Municipal \nde Formaci\u00f3 de Persones Adultes\nAssociaci\u00f3 de Dones Clara Campoamor de la \nVall D\u2019Uix\u00f3\nATEIA-Oltra Valencia\nBiomed Central Limited\nBoston Scientific Iberica SA\nCAVIT SC\nClub N\u00e1utico J\u00e1vea\nColegio Oficial de Agentes de Aduanas y \nRepresentantes Aduanerospublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslist\npublicationslistpublicationslistpublicationslistpublicationslistpubli-\nca-\ntions\nlist\nINCLIVA SCIENTIFIC REPORT 2021280\n280\nINCLIVA SCIENTIFIC REPORT 2021publication list9List of 834 scientific publications derived from the activity of the IIS\n1. Casans-Tormo I, Alcala-Lopez J, Espinet-Coll C, Pu -\nbul-Nunez V, Martinez-Rodriguez I. 18 F-FDG PET/\nCT in cardiovascular infection and inflammation. \nRevista Espanola de Medicina Nuclear e Imagen \nMolecular. 2021;40(6):397-408. doi: 10. 1016/j.\nremnie.2021.09.008. PMID: 34627726\n2. Lainez J, Ashina M, Belvis R, Diaz-Insa S, Ezpeleta D, \nGarcia-Azorin D, Gonzalez-Oria C, Guerrero A, Gui -\nllem A, Holle-Lee D, Huerta-Villanueva M, Irimia P, \nLeira R, Pascual J, Porta-Etessam J, Pozo-Rosich \nP, Rodriguez-Vico J, Sanchez del Rio M, Santos-\nLasaosa S, Silberstein S. 1st Post-European Hea -\ndache Federation Meeting: a review of the latest \ndevelopments presented at the 2020 European \nHeadache Federation Congress. Revista de Neuro -\nlogia. 2021 Jun 30;72(s02):S1-S19. doi: 10.33588/\nrn.72s02.2021155. PMID: 34180043\n3. Stergiou GS, Palatini P, Parati G, O\u2019Brien E, Janus -\nzewicz A, Lurbe E, Persu A, Mancia G, Kreutz R. \n2021 European Society of Hypertension prac -\ntice guidelines for office and out-of-office blood \npressure measurement. Journal of Hyperten -\nsion. 2021 Jul 1;39(7):1293-1302. doi: 10. 1097 /\nHJH.0000000000002843. PMID: 33710173\n4. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam \nF, Albain KS, Hayes DF, Lin UN, Perez EA, Goldstein \nLJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Dela -\nloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil \nM, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, \nBermejo B, Ramos-Vazquez M, Jung KH, Ferrero \nJM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, \nTripathy D, Pusztai L, Hortobagyi GN. 21-Gene as -\nsay to inform chemotherapy benefit in node-positi -\nve breast cancer. New England Journal of Medicine. \n2021 Dec 16;385(25):2336-2347 . doi: 10. 1056/\nNEJMoa2108873. PMID: 34914339\n5. Castro S, Nacher F, Navarro C, Bernabeu J. A \nbench evaluation of eight home-care ventilators. \nRespiratory Care. 2021 Oct;66(10):1531-1541. doi: \n10.4187 /respcare.08650. PMID: 34552013\n6. Perez-Moraga R, Fores-Martos J, Suay-Garcia B, \nDuval J, Falco A, Climent J. A COVID-19 drug repur -\nposing strategy through quantitative homological similarities using a topological data analysis-based \nframework. Pharmaceutics. 2021 Apr 2;13(4):488. \ndoi: 10.3390/pharmaceutics13040488. PMID: \n33918313\n7. Gamble L, Purgato S, Henderson M, Di Giacomo \nS, Russell A, Pigini P, Murray J, Valli E, Milazzo \nG, Giorgi F, Cowley M, Ashton L, Bhalshankar J, \nSchleiermacher G, Rihani A, Van Maerken T, Van -\ndesompele J, Speleman F, Versteeg R, Koster J, \nEggert A, Noguera R, Stallings R, Tonini G, Fong K, \nVaksman Z, Diskin S, Maris J, London W, Marshall \nG, Ziegler D, Hogarty M, Perini G, Norris M, Haber \nM. A G316A polymorphism in the ornithine decar -\nboxylase gene promoter modulates mycn-driven \nchildhood neuroblastoma. Cancers. 2021 Apr \n9;13(8):1807 . doi: 10.3390/cancers13081807 . \nPMID: 33918978\n8. Estebanez A, Verdu-Amoros J, Silva E, Velasco \nR, Cuesta A, Monteagudo C, Martin J. A hetero -\nzygous mutation in the RAG2 gene with cutaneous \nand systemic manifestations partially resembling \nOmenn syndrome. Journal der Deutschen Der -\nmatologischen Gesellschaft. 2021 Jun;19(6):906-\n908. doi: 10. 1 1 1 1/ddg. 14383. PMID: 34096685\n9. Gasso P, Rodriguez N, Martinez-Pinteno A, Mez -\nquida G, Ribeiro M, Gonzalez-Penas J, Zorrilla I, \nMartinez-Sadurni L, Rodriguez-Jimenez R, Corripio \nI, Sarro S, Ibanez A, Usall J, Lobo A, Moren C, Cues -\nta M, Parellada M, Gonzalez-Pinto A, Berrocoso E, \nBernardo M, Mas S, 2EPs Grp. A longitudinal study \nof gene expression in first-episode schizophrenia; \nexploring relapse mechanisms by co-expression \nanalysis in peripheral blood. Translational Psychia -\ntry. 2021 Oct 19;1 1(1):539. doi: 10. 1038/s41398-\n021-01645-8. PMID: 34667144\n10. Gonzalez-Ortega I, Vega P, Echeburua E, Alberich S, \nFernandez-Sevillano J, Barbeito S, Balanza-Marti -\nnez V, Vieta E, Lorente-Rovira E, Luengo A, Cerrillo \nE, Crespo J, Matute C, Gonzalez-Pinto A. A multi -\ncentre, randomised, controlled trial of a combi -\nned clinical treatment for first-episode psychosis. \nInternational Journal of Environmental Research \nand Public Health. 2021 Jul 6;18(14):7239. doi: \n10.3390/ijerph18147239. PMID: 34299697281\n281\nINCLIVA SCIENTIFIC REPORT 2021publication list 911. Lopez-Martinez S, Campo H, de Miguel-Gomez \nL, Faus A, Navarro A, Diaz A, Pellicer A, Ferrero \nH, Cervello I. A natural xenogeneic endometrial \nextracellular matrix hydrogel toward improving \ncurrent human in vitro models and future in vivo \napplications. Frontiers in Bioengineering and Bio -\ntechnology. 2021 Mar 5;9:639688. doi: 10.3389/\nfbioe.2021.639688. PMID: 33748086\n12. Pla L, Sancenon F, Martinez-Bisbal M, Banuls C, \nEstan N, Botello-Marabotto M, Aznar E, Saez \nG, Santiago-Felipe S, Martinez-Manez R. A new \n8-oxo-7 ,8-2\u2019deoxyguanosine nanoporous anodic \nalumina aptasensor for colorectal cancer diag -\nnosis in blood and urine. Nanoscale. 2021 May \n13;13(18):8648-8657 . doi: 10.1039/d0nr07948k. \nPMID: 33942038\n13. Gimenez-Garzo C, Fiorillo A, Ballester-Ferre M, \nGallego J, Casanova-Ferrer F, Urios A, Benlloch \nS, Marti-Aguado D, San-Miguel T, Tosca J, Rios M, \nMonton C, Durban L, Escudero-Garcia D, Aparicio \nL, Felipo V, Montoliu C. A new score unveils a high \nprevalence of mild cognitive impairment in pa -\ntients with nonalcoholic fatty liver disease. Journal \nof Clinical Medicine. 2021 Jun 25;10(13):2806. doi: \n10.3390/jcm10132806. PMID: 34202269\n14. Vives S, Martinez-Cuadron D, Bergua Burgues J, \nAlgarra L, Tormo M, Martinez-Sanchez M, Serrano \nJ, Herrera P, Ramos F, Salamero O, Lavilla E, Lopez-\nLorenzo J, Gil C, Vidriales B, Falantes J, Serrano A, \nLabrador J, Sayas M, Foncillas M, Amador Barcie -\nla M, Olave M, Colorado M, Gascon A, Fernandez \nM, Simiele A, Perez-Encinas M, Rodriguez-Veiga R, \nGarcia O, Martinez-Lopez J, Barragan E, Paiva B, \nSanz M, Montesinos P, PETHEMA Group. A phase \n3 trial of azacitidine versus a semi-intensive fluda -\nrabine and cytarabine schedule in older patients \nwith untreated acute myeloid leukemia. Cancer. \n2021 Jun 15;127(12):2003-2014. doi: 10. 1002/\ncncr.33403. PMID: 33626197\n15. Garc\u00eda-Garc\u00eda I, Guerra-Garc\u00eda P, Ferreras C, Bo -\nrobia A, Carcas A, Queiruga-Parada J, Vicario J, \nMirones I, Solano Vercet C, Eguizabal C, Soria B, \nP\u00e9rez-Mart\u00ednez A. A phase I/II dose-escalation \nmulti-center study to evaluate the safety of infu -\nsion of natural killer cells or memory T cells as \nadoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. Trials. \n2021 Oct 2;22(1):674. doi: 10. 1 186/s13063-021-\n05625-7 . PMID: 34600562\n16. Schmid P, Sablin M, Bergh J, Im S, Lu Y, Martinez N, \nNeven P, Lee K, Morales S, Perez-Fidalgo J, Adam -\nson D, Goncalves A, Prat A, Jerusalem G, Schlieker \nL, Espadero R, Bogenrieder T, Huang D, Crown J, \nCortes J. A phase Ib/II study of xentuzumab, an \nIGF-neutralising antibody, combined with exemes -\ntane and everolimus in hormone receptor-positi -\nve, HER2-negative locally advanced/metastatic \nbreast cancer. Breast Cancer Research. 2021 \nJan 15;23(1):8. doi: 10.1186/s13058-020-01382-\n8. PMID: 33451345\n17. Dominguez-Navarro F, Silvestre Mu\u00f1oz A, Igual-\nCamacho C, Diaz-Diaz B, Torrella J, Rodrigo J, Paya \nRubio A, Roig-Casasus S, Blasco J. A randomized \ncontrolled trial assessing the effects of preopera -\ntive strengthening plus balance training on balan -\nce and functional outcome up to 1 year following \ntotal knee replacement. Knee Surgery Sports \nTraumatology Arthroscopy. 2021 Mar;29(3):838-\n848. doi: 10. 1007 /s00167-020-06029-x. PMID: \n32342139\n18. Tejada M, Santos-Llamas A, Fernandez-Ramirez \nM, Tarin J, Cano A, Gomez R. A reassessment of \nthe therapeutic potential of a dopamine receptor \n2 Agonist (D2-AG) in endometriosis by comparison \nagainst a standardized antiangiogenic treatment. \nBiomedicines. 2021 Mar 8;9(3):269. doi: 10.3390/\nbiomedicines9030269. PMID: 33800198\n19. Gomez-Cabrero D, Walter S, Abugessaisa I, Minam -\nbres-Herraiz R, Palomares L, Butcher L, Erusalim -\nsky J, Garcia-Garcia F, Carnicero J, Hardman T, Mis -\nchak H, Zurbig P, Hackl M, Grillari J, Fiorillo E, Cucca \nF, Cesari M, Carrie I, Colpo M, Bandinelli S, Feart \nC, Peres K, Dartigues J, Helmer C, Vina J, Olaso G, \nGarcia-Palmero I, Martinez J, Jansen-Durr P, Grune \nT, Weber D, Lippi G, Bonaguri C, Sinclair A, Tegner J, \nRodriguez-Manas L. A robust machine learning fra -\nmework to identify signatures for frailty: a nested \ncase-control study in four aging European cohorts. \nGeroScience. 2021 Jun;43(3):1317-1329. doi: \n10.1007 /s11357-021-00334-0. PMID: 33599920\n20. Ni H, Haemmig S, Deng Y, Chen J, Simion V, Yang \nD, Sukhova G, Shvartz E, Wara A, Cheng H, Perez-282\n282\nINCLIVA SCIENTIFIC REPORT 2021publication list9Cremades D, Assa C, Sausen G, Zhuang R, Dai Q, \nFeinberg M. A smooth muscle cell-enriched long \nnoncoding RNA regulates cell plasticity and athe -\nrosclerosis by interacting with serum response \nfactor. Arteriosclerosis, Thrombosis, and Vascular \nBiology. 2021 Sep;41(9):2399-2416. doi: 10. 1 161/\nATVBAHA. 120.31591 1. PMID: 34289702\n21. Sancheza D, Almero L, Rey M. A solitary osteo -\nchondroma of the scapula: uncommon location for \na common tumor. Archivos Argentinos de Pedia -\ntria. 2021 Oct;1 19(5):e562-e566. doi: 10.5546/\naap.2021.e562. PMID: 34569764\n22. Martinez-Hernandez N, Mas-Estelles J, Milian-\nMedina L, Martinez-Ramos C, Ceron-Navarro J, \nGalbis-Caravajal J, Roig-Bataller A, Mata-Roig M. A \nstandardised approach to the biomechanical eva -\nluation of tracheal grafts. Biomolecules. 2021 Oct \n5;11(10):1461. doi: 10.3390/biom11101461. PMID: \n34680094\n23. Fores-Martos J, Forte A, Garcia-Martinez J, \nPerez-Ortin J. A Trans-omics comparison re -\nveals common gene expression strategies in \nfour model organisms and exposes similarities \nand differences between Them. Cells. 2021 Feb \n5;10(2):334. doi: 10.3390/cells10020334. PMID: \n33562654\n24. Lopez-Riera M, Ortega R, Hueso L, Montesinos \nMC, Gomez-Cabrera MC, Sanz MJ, Real JT, Pique -\nras L. Activation of the constitutive androstane \nreceptor inhibits leukocyte adhesiveness to dys -\nfunctional endothelium. International Journal of \nMolecular Sciences. 2021 Aug 27;22(17):9267 . \ndoi: 10.3390/ijms22179267 . PMID: 34502180\n25. Garcia-Blas S, Cordero A, Diez-Villanueva P, Marti -\nnez-Avial M, Ayesta A, Ariza-Sole A, Mateus-Porta \nG, Martinez-Selles M, Escribano D, Gabaldon-Perez \nA, Bodi V, Bonanad C. Acute coronary syndrome in \nthe older patient. Journal of Clinical Medicine. 2021 \nSep 14;10(18):4132. doi: 10.3390/jcm10184132. \nPMID: 34575243\n26. Olea B, Albert E, Torres I, Amat P, Remigia M, Go -\nzalbo-Rovira R, Rodriguez-Diaz J, Buesa J, Blasco \nM, Redon J, Signes-Costa J, Navarro D. Adaptive \nimmune responses to SARS-CoV-2 in recovered \nsevere COVID-19 patients. Journal of Clinical Vi -rology. 2021 Sep;142:104943. doi: 10. 1016/j.\njcv.2021. 104943. PMID: 34391981\n27. Tomaszewska A, Jagasia M, Beohou E, van der Werf \nS, Blaise D, Kanfer E, Milpied N, Remenyi P, Ciceri F, \nBourhis J, Chevallier P, Solano C, Socie G, Bruno B, \nRambaldi A, Castagna L, Kroger N, Corradini P, Afa -\nnasyev B, Ladetto M, Niederwieser D, Scheid C, Sen -\ngeloev H, Kroschinsky F, Yakoub-Agha I, Schoemans \nH, Koenecke C, Penack O, Peric Z, Greinix H, Duarte \nR, Basak G. Addition of rituximab in reduced inten -\nsity conditioning regimens for B-Cell malignancies \ndoes not influence transplant outcomes: EBMT re -\ngistry analyses following allogeneic stem cell trans -\nplantation for B-Cell malignancies. Frontiers in Im -\nmunology. 2021 Feb 2;11:613954. doi: 10.3389/\nfimmu.2020.613954. PMID: 33603743\n28. Tutt A, Garber J, Kaufman B, Viale G, Fumagalli \nD, Rastogi P, Gelber R, de Azambuja E, Fielding A, \nBalmana J, Domchek S, Gelmon K, Hollingsworth \nS, Korde L, Linderholm B, Bandos H, Senkus E, \nSuga J, Shao Z, Pippas A, Nowecki Z, Huzarski T, \nGanz P, Lucas P, Baker N, Loibl S, McConnell R, \nPiccart M, Schmutzler R, Steger G, Costantino J, \nArahmani A, Wolmark N, McFadden E, Karantza V, \nLakhani S, Yothers G, Campbell C, Geyer C, Olym -\npiA Clinical Trial Steering. Adjuvant olaparib for \npatients with BRCA1- or BRCA2-mutated breast \ncancer. New England Journal of Medicine. 2021 \nJun 24;384(25):2394-2405. doi: 10.1056/NEJ -\nMoa2105215. PMID: 34081848\n29. Carlos Ledesma J, Rodriguez-Arias M, Gavito \nA, Sanchez-Perez A, Vi\u00f1a Ribes J, Medina Vera \nD, Rodriguez De Fonseca F, Minarro J. Ado -\nlescent binge-ethanol accelerates cognitive \nimpairment and beta-amyloid production and \ndysregulates endocannabinoid signaling in the \nhippocampus of APP /PSE mice. Addiction Biology. \n2021 Jan;26(1):e12883. doi: 10. 1 1 1 1/adb. 12883. \nPMID: 32043730\n30. Guerreiro M, Aguilar-Gallardo C, Montoro J, Fran -\nces-Gomez C, Latorre V, Luna I, Planelles D, Carras -\nco M, Gomez M, Maria Gonzalez-Barbera E, Aguado \nC, Sempere A, Solves P, Gomez-Segui I, Balaguer-\nRosello A, Louro A, Perla A, Larrea L, Sanz J, Arbo -\nna C, de la Rubia J, Geller R, Sanz M, Sanz G, Pinana \nJ. Adoptive transfer of ex-vivo expanded SARS-CoV-283\n283\nINCLIVA SCIENTIFIC REPORT 2021publication list 92-specific cytotoxic lymphocytes: a viable strategy for \nCOVID-19 immunosuppressed patients?. Transplant In -\nfectious Disease. 2021 Mar 17;e13602. doi: 10. 1 1 1 1/\ntid.13602. PMID: 33728702\n31. Salazar J, Navarro C, Ortega A, Nava M, Morillo D, \nTorres W, Hernandez M, Cabrera M, Angarita L, Or -\ntiz R, Chacin M, D\u2019Marco L, Bermudez V. Advanced \nglycation end products: new clinical and molecular \nperspectives. International Journal of Environmental \nResearch and Public Health. 2021 Jul 6;18(14):7236. \ndoi: 10.3390/ijerph18147236. PMID: 34299683\n32. Mac\u00edas Saint-Gerons D, Sola Arnau I, De Mucio B, \nArevalo-Rodriguez I, Aleman A, Castro J, Ropero Al -\nvarez A. Adverse events associated with the use of \nrecommended vaccines during pregnancy: an over -\nview of systematic reviews. Vaccine. 2021 Jul 30;39 \nSuppl 2:B12-B26. doi: 10.1016/j.vaccine.2020.07 .048. \nPMID: 32972737\n33. Genesca E, Morgades M, Gonzalez-Gil C, Fuster-Tormo \nF, Haferlach C, Meggendorfer M, Montesinos P, Bar -\nba P, Gil C, Coll R, Moreno MJ, Martinez-Carballeira \nD, Garcia-Cadenas I, Vives S, Ribera J, Gonzalez-Cam -\npos J, Diaz-Beya M, Mercadal S, Artola MT, Cladera \nA, Tormo M, Bermudez A, Vall-Llovera F, Martinez-\nSanchez P, Amigo ML, Monsalvo S, Novo A, Cervera \nM, Garcia-Guinon A, Ciudad J, Cervera J, Hernandez-\nRivas JM, Granada I, Haferlach T, Orfao A, Sole F, \nRibera JM. Adverse prognostic impact of complex \nkaryotype (\u22653 cytogenetic alterations) in adult T-cell \nacute lymphoblastic leukemia (T-ALL). Leukemia Re -\nsearch. 2021 Jun 8;109:106612. doi: 10. 1016/j.leu -\nkres.2021.106612. PMID: 34139642\n34. Pagan LU, Gomes MJ, Damatto RL, Lima Aline RR, \nCezar MDM, Damatto FC, Reyes DRA, Campos DHS, \nCaldonazo TMM, Polegato BF, Fernandes DC, Laurin -\ndo FR, Fernandes AAH, Lloret A, Cicogna AC, Okoshi \nMP, Okoshi K. Aerobic exercise during advance sta -\nge of uncontrolled arterial hypertension. Frontiers \nin Physiology. 2021 Jun 3;12:675778. doi: 10.3389/\nfphys.2021.675778. PMID: 34149455\n35. Oliver-Ferrandiz M, Milian L, Sancho-Tello M, de Llano J, \nRoca F, Martinez-Ramos C, Carda C, Mata M. Alginate-\nagarose hydrogels improve the in vitro differentiation \nof human dental pulp stem cells in chondrocytes. A his -\ntological study. Biomedicines. 2021 Jul 17;9(7):834. doi: \n10.3390/biomedicines9070834. PMID: 3435689836. McLornan D, Boluda J, Czerw T, Cross N, \nDeeg H, Ditschkowski M, Moonim M, Polvere -\nlli N, Robin M, Aljurf M, Conneally E, Hayden P, \nYakoub-Agha I. Allogeneic haematopoietic cell \ntransplantation for myelofibrosis: proposed \ndefinitions and management strategies for \ngraft failure, poor graft function and relapse: \nbest practice recommendations of the EBMT \nChronic Malignancies Working Party. Leuke -\nmia. 2021 Sep;35(9):2445-2459. doi: 10. 1038/\ns41375-021-01294-2. PMID: 34040148\n37. Hernandez-Boluda JC, Pereira A, Kroger N, \nCornelissen JJ, Finke J, Beelen D, de Witte M, \nWilson K, Platzbecker U, Sengeloev H, Blaise D, \nEinsele H, Sockel K, Kruger W, Lenhoff S, Sala -\nroli A, Martin H, Garcia-Gutierrez V, Pavone V, \nAlvarez-Larran A, Raya JM, Zinger N, Gras L, \nHayden P, Czerw T, McLornan D, Yakoub-Agha \nI. Allogeneic hematopoietic cell transplanta -\ntion in older myelofibrosis patients: a study of \nthe Chronic Malignancies Working Party of \nEBMT and the Spanish Myelofibrosis Registry. \nAmerican Journal of Hematology. 2021 Oct \n1;96(10):1186-1194. doi: 10.1002/ajh.26279. \nPMID: 34152630\n38. Guerreiro M, Planelles D, Aguilar-Gallardo C, \nLorenzo J, Montoro J, Sanz J, Balaguer A, Go -\nmez I, Solves P, Perez A, Blanquer M, Espigado I, \nSolano C, Pinana J, Grupo Espanol de Trasplan -\nte Hematopoyetico y Terapia Celular (GETH). \nAllogeneic Hematopoietic Stem Cell Transplant \nrecipients in Spain: human leucocyte antigen \ncharacteristics and diversity by high-resolution \nanalysis. HLA. 2021 Mar;97(3):198-213. doi: \n10.1111/t a n.14179.  PMID:  33369244\n39. Bento L, Gutierrez A, Novelli S, Montoro J, Pi -\nnana J, Lopez-Corral L, Cabrero M, Martin-San -\ncho A, Gutierrez-Garcia G, Ortiz-Moscovich M, \nBastos-Oreiro M, Dorado N, Perez A, Hernani \nR, Ferra C, Parody R, Garcia-Cadenas I, Herre -\nra P, Rodriguez G, Rodriguez N, Martin C, Yanez \nL, Zanabili J, Varela M, Lopez-Godino O, Heras \nI, Espanol I, Martinez C, Perez-Simon J, Sola -\nno C, Sureda A, Sierra J, Sampol A, Caballero \nD, GETH, Grp Espanol Li. Allogeneic stem cell \ntransplantation as a curative option in relap -\nse/refractory diffuse large B cell lymphoma: 284\n284\nINCLIVA SCIENTIFIC REPORT 2021publication list9Spanish multicenter GETH/GELTAMO study. Bone \nMarrow Transplantation. 2021 Aug;56(8):1919-\n1928. doi: 10. 1038/s41409-021-01264-3. PMID: \n33767400\n40. Albert Vicent E, Ferrer Lores B, Torres Fink I, \nSerrano Alcal\u00e1 A, Alcaraz Soriana M, Buesa Go -\nmez J, Solano Vercet C, Colomina Rodr\u00edguez F, \nBueno Ferrando F, Huntley Pascual D, Olea Mi -\nguel B, Valdivia Piqueres A, Navarro Ortega D. \nAmplification of human beta-glucoronidase gene \nfor appraising the accuracy of negative SARS-\nCoV-2 RT-PCR results in upper respiratory tract \nspecimens. Journal of Medical Virology. 2021 \nJan;93(1):48-50. doi: 10. 1002/jmv.261 12. PMID: \n32484950\n41. Del Amor R, Launet L, Colomer A, Moscardo A, \nMosquera-Zamudio A, Monteagudo C, Naran -\njo V. An attention-based weakly supervised fra -\nmework for spitzoid melanocytic lesion diagno -\nsis in whole slide images. Artificial Intelligence in \nMedicine. 2021 Nov;121:102197 . doi: 10. 1016/j.\nartmed.2021.102197. PMID: 34763799\n42. Bueno F, Albert E, Gimenez E, Pinana J, Perez A, \nGomez M, Hernandez-Boluda J, Gonzalez-Barbera \nE, Montoro J, Buesa J, Guerreiro M, Balaguer-\nRosello A, Hernani R, Sanz J, Solano C, Navarro D. \nAn investigation of the potential association bet -\nween gastrointestinal viral and bacterial infection \nand development of intestinal acute graft versus \nhost disease following allogeneic hematopoietic \nstem cell transplantation. Journal of Medical Vi -\nrology. 2021 Aug;93(8):4773-4779. doi: 10. 1002/\njmv.26892. PMID: 33605457\n43. Marques P, Piqueras L, Sanz MJ. An updated over -\nview of e-cigarette impact on human health. Res -\npiratory Research. 2021 May 18;22(1):151. doi: \n10.1186/s12931-021-01737-5. PMID: 34006276\n44. Tsaousi G, Tsitsopoulos PP, Pourzitaki C, Palaska E, \nBadenes R, Bilotta F. Analgesic efficacy and safety \nof local infiltration following lumbar decompres -\nsion surgery: a systematic review of randomized \ncontrolled trials. Journal of Clinical Medicine. 2021 \nDec 17;10(24):5936. doi: 10.3390/jcm10245936. \nPMID: 34945233\n45. Pallares-Carratala V, Quesada J, Orozco-Beltran \nD, Amigo-Grau N, Lopez-Pineda A, Fernandez Gi -menez A, Gil-Guillen V, Correig X, Masana L, Mon -\nleon Salvado D, Red\u00f3n Mas J, Pascual R, Carra -\ntala-Munuera C. Analysis of LDL and HDL size \nand number by nuclear magnetic resonance in \na healthy working population: the LipoLab Study. \nInternational Journal of Clinical Practice. 2021 \nJan;75(1):e13610. doi: 10. 1 1 1 1/ijcp. 13610. PMID: \n32648987\n46. Kinyoki D, Osgood-Zimmerman A, Bhattacharjee \nN, Kassebaum N, Hay S, Local Burden Dis Anae -\nmia Collab. Anemia prevalence in women of repro -\nductive age in low- and middle-income countries \nbetween 2000 and 2018. Nature Medicine. 2021 \nOct;27(10):1761-1782. doi: 10.1038/s41591-021-\n01498-0. PMID: 34642490\n47. Marcos Garc\u00e9s V, Lorenzo Hern\u00e1ndez M, Mart\u00ed -\nnez M\u00e1s M, Parrilla Mu\u00f1oz C, Pernias Escrig V, \nBod\u00ed Peris V. Anomalous right coronary artery \nfrom the left sinus with interarterial course. Co -\nronary Artery Disease. 2021 Aug 1;32(5):475-\n477 . doi: 10. 1097 /MCA.0000000000000941. \nPMID: 32804784\n48. Piqueras P, Ballester A, Dura-Gil J, Martinez-Her -\nvas S, Redon J, Real J. Anthropometric indicators \nas a tool for diagnosis of obesity and other health \nrisk factors: a literature review. Frontiers in \nPsychology. 2021 Jul 9;12:631 179. doi: 10.3389/\nfpsyg.2021.631179. PMID: 34305707\n49. Nunez J, de la Espriella R, Minana G, Santas E, Lla -\ncer P, Nunez E, Palau P, Bodi V, Chorro F, Sanchis \nJ, Lupon J, Bayes-Genis A. Antigen carbohydrate \n125 as a biomarker in heart failure: a narrative \nreview. European Journal of Heart Failure. 2021 \nSep;23(9):1445-1457 . doi: 10.1002/ejhf.2295. \nPMID: 34241936\n50. Stromsnes K, Correas A, Lehmann J, Gambini \nJ, Olaso-Gonzalez G. Anti-inflammatory proper -\nties of diet: role in healthy aging. Biomedicines. \n2021 Jul 30;9(8):922. doi: 10.3390/biomedici -\nnes9080922. PMID: 34440125\n51. Galvez-Fernandez M, Grau-Perez M, Garcia-\nBarrera T, Ramirez-Acosta S, Gomez-Ariza J, \nPerez-Gomez B, Galan-Labaca I, Navas-Acien A, \nRedon J, Briongos-Figuero L, Duenas-Laita A, Pe -\nrez-Castrillon J, Tellez-Plaza M, Martin-Escudero \nJ. Arsenic, cadmium, and selenium exposures 285\n285\nINCLIVA SCIENTIFIC REPORT 2021publication list 9and bone mineral density-related endpoints: the \nHortega study. Free Radical Biology & Medicine. \n2021 Jan;162:392-400. doi: 10. 1016/j.freeradbio -\nmed.2020.10.318. PMID: 33137469\n52. Garcia Fadrique A, Estevan Estevan R, Sabater \nOrti L. ASO visual abstract: quality standards for \nsurgery of colorectal peritoneal metastasis after \ncytoreductive surgery and hyperthermic intra -\nperitoneal chemotherapy. Annals of Surgical On -\ncology. 2021 Dec;28(Suppl 3):647 . doi: 10. 1245/\ns10434-021-10681-z. PMID: 34432194\n53. Peixoto Vasco R, Reid J, Lopes H, Prikazsky V, Siep -\nmann I, Martin-Moreno JM, Middleton J. ASPHER \nStatement: deja vu?. Planning for the Covid-19 \nthird wave and planning for the winter 2021-22. \nInternational Journal of Public Health. 2021 Aug \n23;66:1604361. doi: 10.3389/ijph.2021.1604361. \nPMID: 34497482\n54. Albert E, Bracho M, Serrano A, Ferrer B, Gonzalez-\nCandelas F, Navarro D. Assessing the potential \nassociation between SARS-CoV-2 RNA load in the \nrespiratory tract and COVID-19 mortality. Journal \nof Medical Virology. 2021 Apr;93(4):1862-1864. \ndoi: 10. 1002/jmv.26644. PMID: 33135804\n55. Bueno F, Solano C, Vazquez L, Gimenez E, de la \nCamara R, Albert E, Rovira M, Espigado I, Martin \nCalvo C, Lopez-Jimenez J, Suarez-Lledo M, Chinea \nA, Esquirol A, Perez A, Bermudez A, Saldana R, \nHeras I, Gonzalez-Huerta AJ, Torrado T, Batlle M, \nJimenez S, Vallejo C, Barba P, Cuesta MA, Duar -\nte R, Pinana JL, Navarro D. Assessment of the \nassociation between cytomegalovirus DNAemia \nand subsequent acute Graft-versus-Host Disea -\nse in allogeneic peripheral blood stem cell trans -\nplantation: a multicenter study from the Spanish \nHematopoietic Transplantation and Cell Thera -\npy Group. Transplant Infectious Disease. 2021 \nAu g;23(4):e13627.  d o i:  10.1111/t i d.13627.  PMID: \n33908148\n56. S\u00e1nchez V, Vidal J, Prieto-Sanchez L, Ros E, Razquin \nC, Mestres C, Sorli JV, Cuenca-Royo AM, Rios A, To -\nrres-Collado L, Vaquero-Luna J, P\u00e9rez-Farin\u00f3s N, Zu -\nlet MA, Sanchez-Villegas A, Casas R, Bernal-Lopez \nMR, Santos-Lozano JM, Corbella X, Mateos D, Buil-\nCosiales P, Jim\u00e9nez-Murcia S, Fernandez-Carrion \nR, Forcano-Gamazo L, L\u00f3pez M, Sempere-Pascual MA, Moreno-Rodriguez A, Gea A, de la Torre-Fornell \nR, Salas-Salvad\u00f3 J, PREDIMED-Plus Investigators. \nAssociation between coffee consumption and total \ndietary caffeine intake with cognitive functioning: \ncross-sectional assessment in an elderly Medite -\nrranean population. European Journal of Nutrition. \n2021 Aug;60(5):2381-2396. doi: 10.1007 /s00394-\n020-02415-w. PMID: 33125576\n57. Doulatram-Gamgaram V, Valdes S, Maldonado-Ara -\nque C, Lago-Sampedro A, Badia-Guillen R, Garcia-\nEscobar E, Garcia-Serrano S, Garcia-Vivanco M, \nGarrido JL, Theobald MR, Gil V, Martin-Llorente F, Ca -\nlle-Pascual A, Bordiu E, Castano L, Delgado E, Franch-\nNadal J, Chaves FJ, Montanya E, Galan-Garcia JL, \nAguilera-Venegas G, Soriguer F, Rojo-Martinez G. As -\nsociation between long term exposure to particulate \nmatter and incident hypertension in Spain. Scienti -\nfic Reports. 2021 Oct 5;1 1(1):19702. doi: 10. 1038/\ns41598-021-99154-7. PMID: 34611240\n58. Uribarri A, Nunez-Gil I, Aparisi A, Arroyo-Espligue -\nro R, Eid C, Romero R, Becerra-Munoz V, Feltes \nG, Molina M, Garcia-Aguado M, Cerrato E, Capel-\nAstrua T, Alfonso-Rodriguez E, Castro-Mejia A, \nRaposeiras-Roubin S, Espejo C, Perez-Sole N, \nBardaji A, Marin F, Fabregat-Andres O, D\u2019ascenzo \nF, Santoro F, Akin I, Estrada V, Fernandez-Ortiz A, \nMacaya C, en representacion de los investiga -\ndores del HOPE COVID-19. Atrial fibrillation in pa -\ntients with COVID-19. Usefulness of the CHA2DS2-\nVASc score: an analysis of the international HOPE \nCOVID-19 registry. Revista Espanola de Cardio -\nlogia. 2021 Jul;74(7):608-615. doi: 10. 1016/j.re -\ncesp.2020.12.014. PMID: 33678938\n59. Marques-Sule E, Arnal-Gomez A, Cortes-Amador \nS, de la Torre M, Hernandez D, Aguilar-Rodriguez \nM. Attitudes towards learning professional ethics \nin undergraduate physiotherapy students: a STRO -\nBE compliant cross-sectional study. Nurse Educa -\ntion Today. 2021 Mar;98:104771. doi: 10. 1016/j.\nnedt.2021.104771. PMID: 33529858\n60. Bastard P, Gervais A, Le Voyer T,et al. Autoanti -\nbodies neutralizing type I IFNs are present in ~ 4% \nof uninfected individuals over 70 years old and \naccount for ~20% of COVID-19 deaths. Science \nImmunology. 2021 Aug 19;6(62):eabl4340. doi: \n10. 1126/sciimmunol.abl4340. PMID: 34413139286\n286\nINCLIVA SCIENTIFIC REPORT 2021publication list961. Perez-Pelegri M, Monmeneu J, Lopez-Lereu M, \nPerez-Pelegri L, Maceira A, Bodi V, Moratal D. \nAutomatic left ventricle volume calculation with \nexplainability through a deep learning weak-super -\nvision methodology. Computer Methods and Pro -\ngrams in Biomedicine. 2021 Sep;208:106275. doi: \n10.1016/j.cmpb.2021.106275. PMID: 34274609\n62. Torres I, Albert E, Gimenez E, Alcaraz MJ, Botija P, \nAmat P, Remigia MJ, Beltran MJ, Rodado C, Hunt -\nley D, Olea B, Navarro D. B and T cell immune res -\nponses elicited by the Comirnaty COVID-19 vaccine \nin nursing home residents. Clinical Microbiology \nand Infection. 2021 Nov;27(1 1):1672-1677 . doi: \n10.1016/j.cmi.2021.06.013. PMID: 34174397\n63. Mollar A, Marrachelli V, Nunez E, Monleon D, Bodi V, \nSanchis J, Navarro D, Nunez J. Bacterial metaboli -\ntes trimethylamine N-oxide and butyrate as surro -\ngates of small intestinal bacterial overgrowth in \npatients with a recent decompensated heart failu -\nre. Scientific Reports. 2021 Mar 17;1 1(1):61 10. doi: \n10.1038/s41598-021-85527-5. PMID: 33731747\n64. Ravel J, Moreno Gimeno I, Simon Valles C. Bac -\nterial vaginosis and its association with infer -\ntility, endometritis, and pelvic inflammatory \ndisease. American Journal of Obstetrics and Gyne -\ncology. 2021 Mar;224(3):251-257 . doi: 10. 1016/j.\najog.2020.10.019. PMID: 33091407\n65. Guillen-Climent S, Saura S, Benavent M, Garcia-Vaz -\nquez A, Martin J. BASCULE syndrome associated \nwith presyncopal episodes and first-degree atrio -\nventricular block. International Journal of Derma -\ntology. 2021 Oct;60(10):e400-e402. doi: 10. 1 1 1 1/\nijd.15568. PMID: 33797752\n66. Diez-Villanueva P, Vera A, Ariza-Sole A, Formiga F, \nMartinez-Selles M, Alegre O, Sanchis J, Marin F, Vi -\ndan M, Lopez-Palop R, Abu-Assi E, Bueno H, Alfonso \nF, LONGEVO-SCA registry investigators. Baseline \nCHA2 DS2 -VASc Score and prognosis in octoge -\nnarians with Non-ST segment Elevation Acute Co -\nronary Syndrome. International Journal of Clinical \nPractice. 2021 Jun;75(6):e14082. doi: 10. 1 1 1 1/\nijcp.14082. PMID: 33565683\n67. Dudenko D, Gomez R, Garcia-Perez M, Tarin \nJ, Cano A. Bazedoxifene increases the prolife -\nration of human arterial endothelial cells but does not affect the expression of cyclins A, \nB, and D1 and of p27(Kip1). Gynecological En -\ndocrinology. 2021 Mar;37(3):269-272. doi: \n10.1080/09513590.2021.1876653. PMID: \n33480311\n68. Mas-Bargues C, Borras C, Vina J. Bcl-xL as a modu -\nlator of senescence and aging. International Jour -\nnal of Molecular Sciences. 2021 Feb 3;22(4):1527 . \ndoi: 10.3390/ijms22041527 . PMID: 33546395\n69. Mart\u00edn Moreno J, Ruiz-Segovia N, Diaz-Rubio E. Be -\nhavioural and structural interventions in cancer \nprevention: towards the 2030 SDG horizon. Mo -\nlecular Oncology. 2021 Mar;15(3):801-808. doi: \n10.10 02/1878 - 0261.12805.  P MID :  3297089 4\n70. Fuentes-Trillo A, Monzo C, Manzano I, Santiso-Be -\nllon C, da Silva Ribeiro de Andrade J, Gozalbo-Rovi -\nra R, Garcia-Garcia AB, Rodriguez-Diaz J, Chaves \nFJ. Benchmarking different approaches for No -\nrovirus genome assembly in metagenome sam -\nples. BMC Genomics. 2021 Nov 24;22(1):849. doi: \n10.1186/s12864-021-08067-2. PMID: 34819031\n71. Castelo-Branco L, Awada A, Pentheroudakis G, \nPerez-Gracia J, Mateo J, Curigliano G, Banerjee \nS, Giuliani R, Lordick F, Cervantes A, Tabernero J, \nPeters S. Beyond the lessons learned from the \nCOVID-19 pandemic: opportunities to optimize \nclinical trial implementation in oncology. ESMO \nOpen. 2021 Jul 24;6(5):100237 . doi: 10. 1016/j.es -\nmoop.2021. 100237 . PMID: 34411971\n72. Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriu -\nso J, Bogaerts J, Calles A, Curigliano G, Gomez-\nRoca C, Kiesewetter B, Oosting S, Passaro A, \nPentheroudakis G, Piccart M, Roitberg F, Taberne -\nro J, Tarazona N, Trapani D, Wester R, Zarkavelis \nG, Zielinski C, Zygoura P, Cherny NI. Biases in stu -\ndy design, implementation, and data analysis that \ndistort the appraisal of clinical benefit and ESMO-\nMagnitude of Clinical Benefit Scale (ESMO-MCBS) \nscoring. ESMO Open. 2021 Apr 19;6(3):1001 17 . \ndoi: 10.1016/j.esmoop.2021.100117. PMID: \n33887690\n73. Garrido-Cano I, Candela-Noguera V, Herrera G, Ce -\njalvo J, Lluch A, Marcos M, Sancenon F, Eroles P, \nMartinez-Manez R. Biocompatibility and internali -\nzation assessment of bare and functionalised me -287\n287\nINCLIVA SCIENTIFIC REPORT 2021publication list 9soporous silica nanoparticles. Microporous and \nMesoporous Materials. 2021; 310:1 10593\n74. Lopez-Martinez S, Rodriguez-Eguren A, de Miguel-\nGomez L, Frances-Herrero E, Faus A, Diaz A, Pelli -\ncer A, Ferrero H, Cervello I. Bioengineered endo -\nmetrial hydrogels with growth factors promote \ntissue regeneration and restore fertility in murine \nmodels. Acta Biomaterialia. 2021 Nov;135:113-\n125. doi: 10. 1016/j.actbio.2021.08.025. PMID: \n34428563\n75. Fernandez-Garibay X, Ortega MA, Cerro-Herreros \nE, Comelles J, Martinez E, Artero R, Fernandez-\nCosta JM, Ramon-Azcon J. Bioengineered in vi -\ntro 3D model of myotonic dystrophy type 1 hu -\nman skeletal muscle. Biofabrication. 2021 Apr \n26;13(3). doi: 10. 1088/1758-5090/abf6ae. PMID: \n33836519\n76. Amat P, Lopez-Corral L, Goterris R, Perez A, Lo -\npez O, Heras I, Arbona C, Viguria MC, Hernandez-\nBoluda JC, Martinez-Ruiz F, Martinez A, Solano C. \nBiomarker profile predicts clinical efficacy of ex -\ntracorporeal photopheresis in steroid-resistant \nacute and chronic graft-vs-host disease after allo -\ngenic hematopoietic stem cell transplant. Journal \nof Clinical Apheresis. 2021 Oct;36(5):697-710. doi: \n10.1002/jca.21918. PMID: 34185332\n7 7. Serra-Ano P, Ingles M, Espi-Lopez G, Sempere-\nRubio N, Aguilar-Rodriguez M. Biomechanical and \nviscoelastic properties of the ankle muscles in \nmen with previous history of ankle sprain. Jour -\nnal of Biomechanics. 2021 Jan 22;1 15:1 10191. \ndoi: 10.1016/j.jbiomech.2020.110191. PMID: \n33385869\n78. Dualde P, Leon N, Sanchis Y, Corpas-Burgos F, \nFernandez SF, Hernandez CS, Saez G, Perez-Zafra \nE, Mora-Herranz A, Pardo O, Coscolla C, Lopez A, \nYusa V. Biomonitoring of phthalates, bisphenols \nand parabens in children: exposure, predictors \nand risk assessment. International Journal of Envi -\nronmental Research and Public Health. 2021 Aug \n24;18(17):8909. doi: 10.3390/ijerph18178909. \nPMID: 34501500\n79. Laza-Briviesca R, Cruz-Bermudez A, Nadal E, Insa \nA, Garcia-Campelo M, Huidobro G, Domine M, Ma -\njem M, Rodriguez-Abreu D, Martinez-Marti A, Car -peno J, Cobo M, Vivanco G, Del Barco E, Caro R, Vi -\nnolas N, Aranda I, Viteri S, Massuti B, Casarrubios \nM, Sierra-Rodero B, Tarin C, Garcia-Grande A, Ha -\nymaker C, Wistuba I, Romero A, Franco F, Proven -\ncio M. Blood biomarkers associated to complete \npathological response on NSCLC patients treated \nwith neoadjuvant chemoimmunotherapy included \nin NADIM clinical trial. Clinical and Translational \nMedicine. 2021 Jul;1 1(7):e491. doi: 10. 1002/\nctm2.491. PMID: 34323406\n80. Navas-Acien A, Domingo-Relloso A, Subedi P, Riffo-\nCampos A, Xia R, Gomez L, Haack K, Goldsmith J, \nHoward B, Best L, Devereux R, Tauqeer A, Zhang \nY, Fretts A, Pichler G, Levy D, Vasan R, Baccarelli \nA, Herreros-Martinez M, Tang W, Bressler J, For -\nnage M, Umans J, Tellez-Plaza M, Fallin M, Zhao J, \nCole S. Blood DNA methylation and incident coro -\nnary heart disease evidence from the strong heart \nstudy. JAMA Cardiology. 2021 Nov 1;6(1 1):1237-\n1246. doi: 10. 1001/jamacardio.2021.2704. PMID: \n34347013\n81. Sanchez-Bayona R, Sayon-Orea C, Gardeazabal I, \nLlorca J, Gea A, Santisteban M, Mart\u00edn Moreno \nJ, Toledo E. Body shape trajectories and risk of \nbreast cancer: results from the SUN (\u2018Seguimien -\nto Universidad De Navarra\u2019) Project. Public Health \nNutrition. 2021 Feb;24(3):467-475. doi: 10. 1017 /\nS1368980020004322. PMID: 33168117\n82. Herreros B, Espi A, Monton Rodriguez C, Garcia-\nGranero E, Sanchiz V, Ferriols FL, Almela P, Hernan -\ndez V, Mora F, Minguez M. Botulinum toxin injec -\ntion plus topical diltiazem for chronic anal fissure: \na randomized double-blind clinical trial and long-\nterm outcome. Diseases of the Colon and Rec -\ntum. 2021 Dec 1;64(12):1521-1530. doi: 10. 1097 /\nDCR.0000000000001983. PMID: 34747917\n83. Fernandez Garcia-Agudo L, Steixner-Kumar AA, \nCurto Y, Barnkothe N, Hassouna I, Jahne S, Butt \nUJ, Grewe K, Weber MS, Green K, Rizzoli S, Nacher \nJ, Nave KA, Ehrenreich H. Brain erythropoietin \nfine-tunes a counterbalance between neurodiffe -\nrentiation and microglia in the adult hippocampus. \nCell Reports. 2021 Aug 24;36(8):109548. doi: \n10. 1016/j.celrep.2021. 109548. PMID: 34433021\n84. Perez-Miralles F, Prefasi D, Garcia-Merino A, Ara J, \nIzquierdo G, Meca-Lallana V, Gascon-Gimenez F, Mar -288\n288\nINCLIVA SCIENTIFIC REPORT 2021publication list9tinez-Gines M, Ramio-Torrenta L, Costa-Frossard L, \nFernandez O, Moreno-Garcia S, Maurino J, Carreres-\nPolo J, Casanova B. Brain region volumes and their \nrelationship with disability progression and cognitive \nfunction in primary progressive multiple sclerosis. \nBrain and Behavior. 2021 Apr;1 1(4):e02044. doi: \n10.1002/brb3.2044. PMID: 33486890\n85. Garcia-Planells J, Frances B, Diez-Juan A. BRCA, \nbreast cancer and in vitro fertilization: how should \nwe advise our patients?. Fertility and Sterility. \n2021 Aug;1 16(2):359-360. doi: 10. 1016/j.fertns -\nt er t.2021.06.011. PMID: 34247761\n86. Cortes-Macias E, Selma-Royo M, Martinez-Costa C, \nCollado MC. Breastfeeding practices influence the \nbreast milk microbiota depending on pre-gestatio -\nnal maternal BMI and weight gain over pregnancy. \nNutrients. 2021 Apr 30;13(5):1518. doi: 10.3390/\nnu13051518. PMID: 33946343\n87. Bosch F, Navarro B, Crespo M, Alcoceba M, San -\nchez J, Tazon B, Serrano A, Alvarez M, Serrano L, \nAlonso-Torres P, Villanueva M, Loriente C, Abrisque -\nta P, Peiro M, Garcia-Marco J, Gonzalez M, Terol \nM. Building a network of TP53 and IGHV testing \nreference centers across Spain: the Red53 initia -\ntive. Annals of Hematology. 2021 Mar;100(3):825-\n830. doi: 10. 1007 /s00277-020-04331-9. PMID: \n33409623\n88. Nunez-Marin G, de la Espriella R, Santas E, Lorenzo \nM, Minana G, Nunez E, Bodi V, Gonzalez M, Gorriz \nJ, Bonanad C, Sanchis J, Bayes-Genis A, Nunez J. \nCA125 but not NT-proBNP predicts the presence of \na congestive intrarenal venous flow in patients with \nacute heart failure. European Heart Journal-Acute \nCardiovascular Care. 2021 Jun 30;10(5):475-483. \ndoi: 10.1093/ehjacc/zuab022. PMID: 33829233\n89. Teerlink J, Diaz R, Felker G, McMurray J, Metra \nM, Solomon S, Adams K, Anand I, Arias-Mendoza \nA, Biering-Sorensen T, Bohm M, Bonderman D, \nCleland J, Corbalan R, Crespo-Leiro M, Dahlstrom \nU, Echeverria L, Fang J, Filippatos G, Fonseca C, \nGoncalvesova E, Goudev A, Howlett J, Lanfear \nD, Li J, Lund M, Macdonald P, Mareev V, Momo -\nmura S, O\u2019Meara E, Parkhomenko A, Ponikowski \nP, Ramires F, Serpytis P, Sliwa K, Spinar J, Suter \nT, Tomcsanyi J, Vandekerckhove H, Vinereanu D, \nVoors A, Yilmaz M, Zannad F, Sharpsten L, Legg J, Varin C, Honarpour N, Abbasi S, Malik F, Kurtz \nC, GALACTIC-HF Investigators. Cardiac myosin \nactivation with omecamtiv mecarbil in systolic \nheart failure. New England Journal of Medicine. \n2021 Jan 14;384(2):105-1 16. doi: 10. 1056/NEJ -\nMoa2025797 . PMID: 33185990\n90. D\u2019Marco L, Puchades MJ, Panizo N, Romero-Parra \nM, Gandia L, Gimenez-Civera E, Perez-Bernat E, \nGonzalez-Rico M, Gorriz JL. Cardiorenal fat: a car -\ndiovascular risk factor with implications in chronic \nkidney disease. Frontiers in Medicine. 2021 May \n25;8:640814. doi: 10.3389/fmed.2021.640814. \nPMID: 34113631\n91. Ezzatvar Y, Izquierdo M, Nunez J, Calatayud J, \nRamirez-Velez R, Garcia-Hermoso A. Cardiores -\npiratory fitness measured with cardiopulmonary \nexercise testing and mortality in patients with \ncardiovascular disease: a systematic review \nand meta-analysis. Journal of Sport and Health \nScience. 2021 Dec;10(6):609-619. doi: 10. 1016/j.\njshs.2021.06.004. PMID: 34198003\n92. Gerstein H, Sattar N, Rosenstock J, Ramasun -\ndarahettige C, Pratley R, Lopes R, Lam C, Khur -\nmi N, Heenan L, Del Prato S, Dyal L, Branch K, \nAMPLITUDE-O Trial Investigators. Cardiovascular \nand renal outcomes with efpeglenatide in type \n2 diabetes. New England Journal of Medicine. \n2021 Sep 2;385(10):896-907 . doi: 10.1056/NEJ -\nMoa2108269. PMID: 34215025\n93. Boehm M, Schumacher H, Teo KK, Lonn EM, Lau -\nder L, Mancia G, Redon J, Schmieder RE, Sliwa K, \nMarx N, Weber MA, Williams B, Yusuf S, Mann JF, \nMahfoud F. Cardiovascular outcomes in patients \nat high cardiovascular risk with previous myo -\ncardial infarction or stroke. Journal of Hyperten -\nsion. 2021 Aug 1;39(8):1602-1610. doi: 10. 1097 /\nHJH.0000000000002822. PMID: 34188004\n94. Gorriz J, Arroyo D, D\u2019Marco L, Torra R, Tomas P, Pu -\nchades M, Panizo N, Pantoja J, Montomoli M, Llis -\nterri J, Pallares-Carratala V, Valdivielso J. Cardio -\nvascular risk factors and the impact on prognosis \nin patients with chronic kidney disease secondary \nto autosomal dominant polycystic kidney disea -\nse. BMC Nephrology. 2021 Mar 25;22(1):1 10. doi: \n10.1186/s12882-021-02313-1. PMID: 33765945289\n289\nINCLIVA SCIENTIFIC REPORT 2021publication list 995. Redon J. Cardiovascular system in the sars-\nCoV-2: impact of therapies. Journal of Hyperten -\nsion. 2021 Jul 1;39(7):1306-1308. doi: 10. 1097 /\nHJH.0000000000002860. PMID: 34074967\n96. Hernani R, Sancho A, Amat P, Hernandez-Boluda J, \nPerez A, Pinana J, Carretero C, Goterris R, Gomez \nM, Saus A, Ferrer B, Teruel A, Terol M, Solano C. CAR-\nT therapy in solid transplant recipients with post-\ntransplant lymphoproliferative disease: case report \nand literature review. Current Research in Trans -\nlational Medicine. 2021 Jul 22;69(4):103304. doi: \n10.1016/j.retram.2021.103304. PMID: 34303899\n97. Barres-Fernandez A, Piolatti-Luna A, Breton-\nMartinez J, Crehua-Gaudiza E, Quinones-Torrelo \nC, Moscardo-Navarro A, Fuertes-Latasa C, Marti -\nnez-Costa C. Case report: primary peritonitis as \nthe onset of pediatric Menetrier\u2019s disease. Fron -\ntiers in Pediatrics. 2021 Jan 13;8:589853. doi: \n10.3389/fped.2020.589853. PMID: 33520889\n98. Tosca J, Villagrasa R, Sanahuja A, Sanchez A, Tre -\njo G, Herreros B, Pascual I, Mas P, Pena A, Min -\nguez M. Caustic ingestion: development and vali -\ndation of a prognostic score. Endoscopy. 2021 \nAug;53(8):784-791. doi: 10.1055/a-1297-0333. \nPMID: 33096569\n99. Valdivia Piqueres A, Torres Fink I, Huntley Pascual \nD, Alcaraz Soriana M, Albert Vicent E, Solano de \nla Asunci\u00f3n C, Gonz\u00e1lez Padr\u00f3n C, Ferrer Dot J, \nNavarro Ortega D. Caveats in interpreting SARS-\nCoV-2 IgM positive/IgG negative antibody profile \nin asymptomatic health care workers. Journal of \nMedical Virology. 2021 Feb;93(2):634-636. doi: \n10.1002/jmv.26400. PMID: 32761912\n100.  Martinez-Rodriguez M, Monteagudo C. CCL27 \nSignaling in the tumor microenvironment. Ad -\nvances in Experimental Medicine and Biology. \n2021;1302:113-132. doi: 10.1007/978-3-030-\n62658-7_9. PMID: 34286445\n101. Longhitano Y, Iannuzzi F, Bonatti G, Zanza C, Mes -\nsina A, Godoy D, Dabrowski W, Li X, Czosnyka M, \nPelosi P, Badenes R, Robba C. Cerebral autore -\ngulation in non-brain injured patients: a syste -\nmatic review. Frontiers in Neurology. 2021 Nov \n16;12:732176. doi: 10.3389/fneur.2021.732176. \nPMID: 34899560102.  Perez-Ros P, Navarro-Flores E, Julian-Rochina I, \nMartinez-Arnau F, Cauli O. Changes in salivary \namylase and glucose in diabetes: a scoping review. \nDiagnostics. 2021 Mar 6;1 1(3):453. doi: 10.3390/\ndiagnostics11030453. PMID: 33800850\n103.  Siwicka-Gieroba D, Robba C, Poleszczuk J, De -\nbowska M, Waniewski J, Badenes R, Jaroszynski \nA, Piasek E, Kotfis K, Biernawska J, Dabrowski \nW. Changes in sub-endocardial viability ratio in \ntraumatic brain injury patients. Brain Connecti -\nvity. 2021 Jun;1 1(5):349-358. doi: 10. 1089/bra -\nin.2020.0850. PMID: 33559521\n104.  Estebanez A, Puche-Torres M, Garcia J, Cunat A, \nCanales M, Felix M, Campos S, Canada J, Hernan -\ndez J. Characteristics of mucocutaneous vascular \nmalformations drawn from a decade of a multi -\ndisciplinary committee experience. Dermatologic \nTherapy. 2021 Sep;34(5):e15074. doi: 10. 1 1 1 1/\ndth.15074. PMID: 34338412\n105.  Garcia-Bustos V, Ruiz-Sauri A, Ruiz-Gaitan A, Sigona-\nGiangreco I, Cabanero-Navalon M, Sabalza-Baztan \nO, Salavert-Lleti M, Tormo M, Peman J. Characte -\nrization of the differential pathogenicity of candida \nauris in a galleria mellonella infection model. Micro -\nbiology Spectrum. 2021 Sep 3;9(1):e0001321. doi: \n10. 1128/Spectrum.00013-21. PMID: 34106570\n106.  Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, \nDiaz-Lagares A, Jacome MA, Salguero-Aranda \nC, Garcia Ros D, Davidson B, Lopez R, Melero I, \nNavarro S, Ramon y Cajal S, de Alava E, Matias-\nGuiu X, Noguera R. Characterizing the invasive \ntumor front of aggressive uterine adenocarci -\nnoma and leiomyosarcoma. Frontiers in Cell and \nDevelopmental Biology. 2021 Jun 3;9:670185. doi: \n10.3389/fcell.2021.670185. PMID: 34150764\n10 7. Angullo-Martinez E, Carretero-Anibarro E, Barran -\ncos I, Claramunt X, Beltran D, Baile J, Loiola P, Grp \nTrabajo Diabet SemFyC. Checklist for patients with \ntype 2 diabetes mellitus for remote consultation. \nAtencion Primaria. 2021 Apr;53(4):101983. doi: \n10.1016/j.aprim.2021.101983. PMID: 33743202\n108.  Manuel Perez-Garcia J, Gebhart G, Ruiz Borrego \nM, Stradella A, Bermejo B, Schmid P, Marme F, \nEscriva-de-Romani S, Calvo L, Ribelles N, Martinez \nN, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni 290\n290\nINCLIVA SCIENTIFIC REPORT 2021publication list9M, Afonso N, Di Cosimo S, Sampayo-Cordero M, \nMalfettone A, Cortes J, Llombart-Cussac A. Che -\nmotherapy de-escalation using an F-18-FDG-PET-\nbased pathological response-adapted strategy in \npatients with HER2-positive early breast cancer \n(PHERGain): a multicentre, randomised, open-label, \nnon-comparative, phase 2 trial. Lancet Oncology. \n2021 Jun;22(6):858-871. doi: 10. 1016/S1470-\n2045(21)00122-4. PMID: 34019819\n109.  Ribera J, Morgades M, Ciudad J, Montesinos P, \nEsteve J, Genesca E, Barba P, Ribera J, Garcia \nCadenas I, Moreno M, Martinez-Carballeira D, \nTorrent A, Martinez-Sanchez P, Monsalvo S, Gil \nC, Tormo M, Artola M, Cervera M, Gonzalez-Cam -\npos J, Rodriguez-Medina C, Bermudez A, Novo \nA, Soria B, Coll R, Amigo M, Lopez A, Fernandez \nMartin R, Serrano J, Mercadal S, Cladera A, \nGimenez-Conca A, Penarrubia M, Abella E, Vall-\nLlovera F, Hernandez-Rivas J, Garcia A, Bergua \nBurgues J, de Rueda B, Sanchez-Sanchez M, Se -\nrrano A, Calbacho M, Alonso Vence N, Mendez-\nSanchez J, Garcia-Boyero R, Olivares M, Barre -\nna S, Zamora L, Granada I, Lhermitte L, Feliu E, \nOrfao A. Chemotherapy or allogeneic transplan -\ntation in high-risk Philadelphia chromosome-\nnegative adult lymphoblastic leukemia. Blood. \n2021 Apr 8;137(14):1879-1894. doi: 10. 1 182/\nblood.2020007311. PMID: 33150388\n110. Sempere-Bigorra M, Julian-Rochina I, Cauli O. \nChemotherapy-induced neuropathy and diabe -\ntes: a scoping review. Current Oncology. 2021 \nAug 19;28(4):3124-3138. doi: 10.3390/curron -\ncol28040273. PMID: 34436039\n111. Martinez-Selles M, Sanchis J, Bueno H. Chest pain \nunit: do not forget the clinical indexes. Revista \nEspanola de Cardiologia. 2021 Jan;74(1):1 13. doi: \n10.1016/j.rec.2020.04.021. PMID: 32620426\n112. Salinas P, Gonzalo N, Moreno V, Fuentes M, San -\ntos-Martinez S, Fernandez-Diaz J, Amat-Santos I, \nOjeda F, Borrego J, Cuesta J, Hernandez J, Diego-\nNieto A, Dubois D, Galeote G, Goicolea J, Gutierrez \nA, Jimenez-Fernandez M, Jimenez-Mazuecos J, \nJurado A, Lacunza J, Lee D, Lopez M, Lozano F, \nMartin-Moreiras J, Martin-Yuste V, Millan R, Mina -\nna G, Mohandes M, Morales-Ponce F, Nunez J, Oje -\nda S, Pan M, Rivero F, Robles J, Rodriguez-Leiras S, Rojas S, Rondan J, Rumiz E, Sabate M, Sanchis \nJ, Vaquerizo B, Escaned J. Choice of CTO scores \nto predict procedural success in clinical practi -\nce. A comparison of 4 different CTO PCI scores \nin a comprehensive national registry including \nexpert and learning CTO operators. PLoS One. \n2021 Apr 2;16(4):e0245898. doi: 10. 1371/journal.\npone.0245898. PMID: 33798205\n113. Salvador-Clavell R, Martin de Llano J, Milian \nL, Oliver M, Mata M, Carda C, Sancho-Tello M. \nChondrogenic potential of human dental pulp \nstem cells cultured as microtissues. Stem Cells \nInternational. 2021 Sep 7;2021:7843798. doi: \n10.1155/2021/7843798. PMID: 34539791\n114. Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, \nLozano-Asencio C, Fedele V, Cornelissen S, Edvar -\nsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-\nSeisdedos R, Falco A, Van\u2019t Veer LJ, Schmidt M, \nQuigley DA, Borresen-Dale AL, Kristensen VN, \nBalmain A, Climent J. Circadian PERformance in \nbreast cancer: a germline and somatic genetic \nstudy of PER3VNTR polymorphisms and gene \nco-expression. NPJ Breast Cancer. 2021 Sep \n10;7(1):118. doi: 10.1038/s41523-021-00329-2. \nPMID: 34508103\n115. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega \nB, Moragon S, Lameirinhas A, Constancio V, Salta \nS, Burgues O, Bermejo B, Henrique R, Lluch A, Je -\nronimo C, Eroles P, Cejalvo J. Circulating miR-30b-\n5p levels in plasma as a novel potential biomar -\nker for early detection of breast cancer. ESMO \nOpen. 2021 Jan 18;6(1):100039. doi: 10. 1016/j.\nesmoop.2020. 100039. PMID: 33477007\n116. Lupon J, Santiago-Vacas E, Cediel G, Codina P, Do -\nmingo M, Revuelta-Lopez E, Zamora E, Spitaleri G, \nSantesmases J, Nunez J, Bayes-Genis A. Circula -\nting neprilysin hypothesis: a new opportunity for \nsacubitril/valsartan in patients with heart failure \nand preserved ejection fraction?. PLoS One. 2021 \nMay 14;16(5):e0249674. doi: 10.1371/journal.\npone.0249674. PMID: 33989294\n117. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona \nN, Roda D, Gambardella V, Alfaro-Cervello C, Gar -\nces-Albir M, Cervantes A, Ibarrola-Villava M. Circu -\nlating tumor DNA detection by digital-droplet PCR \nin pancreatic ductal adenocarcinoma: a systema -291\n291\nINCLIVA SCIENTIFIC REPORT 2021publication list 9tic review. Cancers. 2021 Feb 27;13(5):994. doi: \n10.3390/cancers13050994. PMID: 33673558\n118. Rodriguez-Fernandez L, Company S, Zaragoza R, \nVina J, Garcia-Trevijano E. Cleavage and activation \nof LIM kinase 1 as a novel mechanism for cal -\npain 2-mediated regulation of nuclear dynamics. \nScientific Reports. 2021 Aug 1 1;1 1(1):16339. doi: \n10. 1038/s41598-021-95797-8. PMID: 34381117\n119. Fatmi A, Chabni N, Cernada M, Vento M, Gonzalez-\nLopez M, Aribi M, Pallardo FV, Garcia-Gimenez JL. \nClinical and immunological aspects of microRNAs \nin neonatal sepsis. Biomedicine & Pharmacothe -\nrapy. 2021 Nov 19;145:1 12444. doi: 10. 1016/j.\nbiopha.2021. 1 12444. PMID: 34808550\n120.  Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Ga -\nritaonaindia Y, Insa A, Mosquera J, Casal-Rubio \nJ, Domine M, Majem M, Rodriguez-Abreu D, \nMartinez-Marti A, De Castro Carpeno J, Cobo M, \nLopez Vivanco G, Del Barco E, Bernabe Caro R, \nVinolas N, Barneto Aranda I, Viteri S, Massuti B, \nLaza-Briviesca R, Casarrubios M, Garcia-Grande \nA, Romero A, Franco F, Provencio M. Clinical and \nmolecular parameters associated to pneumoni -\ntis development in non-small-cell lung cancer pa -\ntients receiving chemoimmunotherapy from NA -\nDIM trial. Journal for ImmunoTherapy of Cancer. \n2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-\n002804. PMID: 34446577\n121. Bover J, Aguilar A, Arana C, Molina P, Lloret MJ, \nOchoa J, Berna G, Gutierrez-Maza YG, Rodrigues \nN, D\u2019Marco L, Gorriz JL. Clinical approach to vas -\ncular calcification in patients with non-dialysis \ndependent chronic kidney disease: mineral-bone \ndisorder-related aspects. Frontiers in Medi -\ncine. 2021 May 19;8:642718. doi: 10.3389/\nfmed.2021.642718. PMID: 34095165\n122. Lambertini M, Ceppi M, Hamy A, Caron O, Poorvu \nP, Carrasco E, Grinshpun A, Punie K, Rousset-Ja -\nblonski C, Ferrari A, Paluch-Shimon S, Toss A, Se -\nnechal C, Puglisi F, Pogoda K, Perez-Fidalgo J, De \nMarchis L, Ponzone R, Livraghi L, Estevez-Diz M, \nVillarreal-Garza C, Dieci M, Clatot F, Duhoux F, Gra -\nffeo R, Teixeira L, Cordoba O, Sonnenblick A, Ferrei -\nra A, Partridge A, Di Meglio A, Saule C, Peccatori \nF, Bruzzone M, t\u2019Kint de Roodenbeke M, Ameye L, \nBalmana J, Del Mastro L, Azim H. Clinical behavior and outcomes of breast cancer in young women \nwith germline BRCA pathogenic variants. NPJ \nBreast Cancer. 2021 Feb 12;7(1):16. doi: 10. 1038/\ns41523-021-00224-w. PMID: 33579978\n123. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruipe -\nrez A, Stahel R, Eniu A, Cavalli F, Costa A. Clinical \ncase presentation and discussion during ESO-\nESMO masterclass: a 10-Year interactive educa -\ntional experience. Journal of Cancer Education. \n2021 Oct;36(5):1 124-1 128. doi: 10. 1007 /s13187-\n020-01744-y. PMID: 32303982\n124. Ferrer MD, Sanchez Barrueco A, Martinez-Bene -\nyto Y, Mateos-Moreno MV, Ausina-Marquez V, Gar -\ncia-Vazquez E, Puche-Torres M, Forner Giner MJ, \nCampos Gonzalez A, Santillan Coello JM, Alcala \nRueda I, Villacampa Auba JM, Cenjor Espanol C, Lo -\npez Velasco A, Santolaya Abad D, Garcia-Esteban \nS, Artacho A, Lopez-Labrador X, Mira A. Clinical \nevaluation of antiseptic mouth rinses to reduce \nsalivary load of SARS-CoV-2. Scientific Reports. \n2021 Dec 22;1 1(1):24392. doi: 10. 1038/s41598-\n021-03461-y. PMID: 34937855\n125. Fernandez-Cisnal A, Valero E, Garcia-Blas S, Per -\nnias V, Pozo A, Carratala A, Gonzalez J, Noceda J, \nMinana G, Nunez J, Sanchis J. Clinical history and \ndetectable troponin concentrations below the \n99th percentile for risk stratification of patients \nwith chest pain and first normal troponin. Journal \nof Clinical Medicine. 2021 Apr 20;10(8):1784. doi: \n10.3390/jcm10081784. PMID: 33923925\n126. Lam C, Giczewska A, Sliwa K, Edelmann F, Re -\nfsgaard J, Bocchi E, Ezekowitz J, Hernandez A, \nO\u2019Connor C, Roessig L, Patel M, Pieske B, Ans -\ntrom K, Armstrong P, VICTORIA Study Grp. Clinical \noutcomes and response to vericiguat according \nto index heart failure event: insights from the VIC -\nTORIA trial. JAMA Cardiology. 2021 Jun 1;6(6):706-\n712. doi: 10. 1001/jamacardio.2020.6455. PMID: \n33185650\n127. Solano C, Vazquez L, Gimenez E, de la Camara R, \nAlbert E, Rovira M, Espigado I, Calvo C, Lopez-Ji -\nmenez J, Suarez-Lledo M, Chinea A, Esquirol A, Pe -\nrez A, Bermudez A, Saldana R, Heras I, Gonzalez-\nHuerta A, Torrado T, Batlle M, Jimenez S, Vallejo C, \nBarba P, Cuesta M, Pinana J, Navarro D, Spanish \nGroup of Hematopoietic Transplantation and Cell 292\n292\nINCLIVA SCIENTIFIC REPORT 2021publication list9Therapy (GETH). Clinical outcomes of allogeneic \nhematopoietic stem cell transplant recipients de -\nveloping Cytomegalovirus DNAemia prior to en -\ngraftment. Bone Marrow Transplantation. 2021 \nJun;56(6):1281-1290. doi: 10.1038/s41409-020-\n01157-x. PMID: 33319853\n128. Pla-Gil I, Redo M, Perez-Carbonell T, Martinez-Be -\nneyto P, Alborch M, Ventura A, Monteagudo E, Ri -\nbas I, Algarra J. Clinical performance assessment \nof a new active osseointegrated implant system \nin mixed hearing loss: results from a prospec -\ntive clinical investigation. Otology & Neurotolo -\ngy. 2021 Aug 1;42(7):e905-e910. doi: 10. 1097 /\nMAO.0000000000003116. PMID: 33710155\n129. Becerra-Munoz V, Nunez-Gil I, Eid C, Aguado M, \nRomero R, Huang J, Mulet Arabi A, Ugo F, Ra -\nmetta F, Liebetrau C, Aparisi A, Fernandez-Rozas \nI, Viana-Llamas M, Feltes G, Pepe M, Moreno-Ron -\ndon L, Cerrato E, Raposeiras-Roubin S, Alfonso E, \nCarrero-Fernandez A, Buzon-Martin L, Abumayya -\nleh M, Gonzalez A, Ortiz A, Macaya C, Estrada V, \nFernandez-Perez C, Gomez-Doblas J. Clinical profile \nand predictors of in-hospital mortality among older \npatients admitted for COVID-19. Age and Ageing. \n2021 Feb 26;50(2):326-334. doi: 10. 1093/ageing/\nafaa258. PMID: 33201 181\n130.  Lapena Rodriguez M, Cassinello Fernandez N, Mar -\ntin Arevalo J, Sanchiz Soler V, Alfonso Ballester R, \nOrtega Serrano J. Clinical symptoms are correla -\nted with gastrojejunal anastomosis complications \nonly during the first year after laparoscopic Roux-\nen-Y gastric bypass. Nutricion Hospitalaria. 2021 \nOct 13;38(5):978-982. doi: 10.20960/nh.03602. \nPMID: 34036791\n131. Lorenzo M, Palau P, Llacer P, Dominguez E, Ventu -\nra B, Nunez G, Minana G, Solsona J, Santas E, De \nLa Espriella R, Bodi V, Nunez E, Sanchis J, Bayes-\nGenis A, Nunez J. Clinical utility of antigen carbohy -\ndrate 125 for planning the optimal length of stay \nin acute heart failure. European Journal of Inter -\nnal Medicine. 2021 Oct;92:94-99. doi: 10. 1016/j.\nejim.2021.05.037 . PMID: 34130879\n132. Capalbo A, Fabiani M, Caroselli S, Poli M, Girardi L, \nPatassini C, Favero F, Cimadomo D, Vaiarelli A, Si -\nmon C, Rienzi LF, Ubaldi FM. Clinical validity and utili -\nty of preconception expanded carrier screening for the management of reproductive genetic risk in \nIVF and general population. Human Reproduction. \n2021 Jun 18;36(7):2050-2061. doi: 10. 1093/\nhumrep/deab087 . PMID: 34021342\n133. Schettini F, Chic N, Braso-Maristany F, Pare L, Pas -\ncual T, Conte B, Martinez-Saez O, Adamo B, Vidal \nM, Barnadas E, Fernandez-Martinez A, Gonzalez-\nFarre B, Sanfeliu E, Cejalvo J, Perrone G, Sabarese \nG, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavila J, Ba -\nrrios C, Lluch A, Martin M, Locci M, De Placido S, \nPrat A. Clinical, pathological, and PAM50 gene ex -\npression features of HER2-low breast cancer. NPJ \nBreast Cancer. 2021 Jan 4;7(1):1. doi: 10. 1038/\ns41523-020-00208-2. PMID: 33397968\n134.  Navio Anaya M, Monrabal Bernabeu A, Pons Mo -\nrales S, Castillo Corullon S. Clinically amyopathic \ndermatomyositis with pulmonary involvement, \nexceptional pathology. Anales de Pediatria. 2021 \nJan 18;S1695-4033(20)30517-8. doi: 10. 1016/j.\nanpedi.2020.11.029. PMID: 33478851\n135. Parisi A, Porzio G, Cannita K, Venditti O, Avallone \nA, Filippi R, Salvatore L, Tortora G, Ribelli M, Ni -\ngro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, \nDell\u2019Aquila E, Claudia F, Lombardi P, Keranen S, Ai -\nmar G, Depetris I, Giampieri R, Morelli C, De Tursi \nM, Tinari N, Di Pietro F, De Galitiis F, Zanaletti N, \nTroiani T, Vitale P, Garajova I, Ghidini M, Spinelli G, \nZoratto F, Roberto M, Ierino D, Petrillo A, D\u2019Orazio \nC, Ficorella C, Cortellini A. Clinicians\u2019 attitude to \ndoublet plus Anti-EGFR versus triplet plus bevaci -\nzumab as first-line treatment in left-sided RAS and \nBRAF wild-type metastatic colorectal cancer pa -\ntients: a multicenter, \u201creal-life\u201d, case-control study. \nClinical Colorectal Cancer. 2021 Dec;20(4):318-\n325. doi: 10.1016/j.clcc.2021.07 .003. PMID: \n34380594\n136. Lapena-Luzon T, Rodriguez L, Beltran-Beltran \nV, Beneto N, Pallardo F, Gonzalez-Cabo P. Cofi -\nlin and neurodegeneration: new functions for an \nold but gold protein. Brain Sciences. 2021 Jul \n20;11(7):954. doi: 10.3390/brainsci11070954. \nPMID: 34356188\n137. Velthorst E, Mollon J, Murray R, de Haan L, Ger -\nmeys I, Glahn D, Arango C, van der Ven E, Di Forti \nM, Bernardo M, Guloksuz S, Delespaul P, Mezqui -\nda G, Amoretti S, Bobes J, Saiz P, Garcia-Portilla 293\n293\nINCLIVA SCIENTIFIC REPORT 2021publication list 9M, Santos J, Jimenez-Lopez E, Sanjuan J, Aguilar \nE, Arrojo M, Carracedo A, Lopez G, Gonzalez-Pe -\nnas J, Parellada M, Atbasoglu C, Saka M, Ucok A, \nAlptekin K, Akdede B, Binbay T, Altinyazar V, Ulas \nH, Yalincetin B, Gumus-AkaY G, Beyaz B, Soygur \nH, Cankurtaran E, Kaymak S, Maric N, Mihaljevic \nM, Petrovic S, Mirjanic T, Del-Ben C, Ferraro L, \nGayer-Anderson C, Jones P, Jongsma H, Kirkbri -\nde J, La Cascia C, Lasalvia A, Tosato S, Llorca P, \nMenezes P, Morgan C, Quattrone D, Menchetti \nM, Selten J, Szoke A, Tarricone I, Tortelli A, McGui -\nre P, Valmaggia L, Kempton M, van der Gaag M, \nRiecher-Rossler A, Bressan R, Barrantes-Vidal N, \nNelson B, McGorry P, Pantelis C, Krebs M, Ruhr -\nmann S, Sachs G, Rutten B, van Os J, Alizadeh \nB, van Amelsvoort T, Bartels-Velthuis A, Brugge -\nman R, van Beveren N, Luykx J, Cahn W, Simons \nC, Kahn R, Schirmbeck F, van Winkel R, Reichen -\nberg A, EU-GEI High Risk Study. Cognitive functio -\nning throughout adulthood and illness stages in \nindividuals with psychotic disorders and their \nunaffected siblings. Molecular Psychiatry. 2021 \nAug;26(8):4529-4543. doi: 10.1038/s41380-\n020-00969-z. PMID: 33414498\n138. Sambola A, Andrea R, Ariza A, Berga G, Cid B, Lo -\npez de Sa E, Martinez-Selles M, Moreno R, Ojeda S, \nSanchis J, Huelmos A, Jimenez Quevedo P, Juarez \nM, Martin Asenjo R, Pedreira M, Rodriguez Leor \nO, Roldan I, Romaguera R, Avanzas P, Berga Con -\ngost G, Boraita A, Bueno H, Calvo D, Campuzano \nR, Delgado V, Dos L, Ferreira-Gonzalez I, Gomez \nDoblas J, Pascual Figal D, Sambola Ayala A, Viana \nTejedor A, Luis Ferreiro J, Alfonso F. Comments on \nthe 2020 ESC guidelines for the management of \nacute coronary syndromes in patients presenting \nwithout persistent ST-segment elevation. Revista \nEspanola de Cardiologia. 2021 Jun;74(6):482-487 . \ndoi: 10.1016/j.rec.2020.12.018. PMID: 33775589\n139.  De la Puerta R, Montoro J, Aznar C, Lorenzo I, \nGonz\u00e1lez-Barber\u00e1 EM, Balaguer-Rosell\u00f3 A, Gue -\nrreiro M, Dom\u00ednguez L, Salavert M, Aguilar C, de \nla Rubia J, Sanz J, G\u00f3mez MD, Pi\u00f1ana JL. Com -\nmon seasonal respiratory virus infections in allo -\ngeneic stem cell transplant recipients during the \nSARS-COV-2 pandemic. Bone Marrow Transplan -\ntation. 2021 Sep;56(9):2212-2220. doi: 10.1038/\ns41409-021-01319-5. PMID: 33947980140.  Sanchis Fores J, Garcia Acuna J, Raposeiras S, \nBarrabes J, Cordero A, Martinez-Selles M, Bar -\ndaji A, Diez-Villanueva P, Marin F, Ruiz-Nodar J, Vi -\ncente-Ibarra N, Alonso Salinas G, Rigueiro P, Abu-\nAssi E, Formiga F, Nu\u00f1ez Villota J, Nu\u00f1ez Benito \nE, Ariza-Sole A. Comorbidity burden and revascu -\nlarization benefit in elderly patients with acute \ncoronary syndrome. Revista Espanola de Cardio -\nlogia (English ed.). 2021 Sep;74(9):765-772. doi: \n10.1016/j.rec.2020.06.015. PMID: 32778402\n141. Beltran-Garcia J, Manclus J, Garcia-Lopez E, \nCarbonell N, Ferreres J, Rodriguez-Gimillo M, \nGarces C, Pallardo F, Garcia-Gimenez J, Montoya \nA, Roma-Mateo C. Comparative analysis of chro -\nmatin-delivered biomarkers in the monitoring of \nsepsis and septic shock: a pilot study. Interna -\ntional Journal of Molecular Sciences. 2021 Sep \n14;22(18):9935. doi: 10.3390/ijms22189935. \nPMID: 34576097\n142.  Llacer P, Gallardo M, Palau Sampio P, Moreno M, \nCastillo C, Fernandez C, De La Espriella Juan R, \nMollar Fernandez A, Santas Olmeda E, Mi\u00f1ana \nEscriva G, Manzano L, Bayes-Genis A, Nu\u00f1ez Villo -\nta J. Comparison between CA125 and NT-proBNP \nfor evaluating congestion in acute heart failure. \nMedicina Clinica. 2021 Jun 25;156(12):589-594. \ndoi: 10.1016/j.medcli.2020.05.063. PMID: \n32951882\n143.  Hidalgo JJ, Llueca A, Zolfaroli I, Veiga N, Ortiz E, \nAlcazar JL. Comparison of IOTA three-step stra -\ntegy and logistic regression model LR2 for discri -\nminating between benign and malignant adnexal \nmasses. Medical Ultrasonography. 2021 May \n20;23(2):168-175. doi: 10. 1 1 152/mu-2732. PMID: \n33626112\n144.  Valencia-Peris A, Lizandra J, Moya-Mata I, Go -\nmez-Gonzalvo F, Castillo-Corullon S, Escribano A. \nComparison of physical activity and sedentary \nbehaviour between schoolchildren with cystic \nfibrosis and healthy controls: a gender analysis. \nInternational Journal of Environmental Research \nand Public Health. 2021 May 18;18(10):5375. doi: \n10.3390/ijerph18105375. PMID: 34070042\n145.  Sanchez Ramos D, Pinto Pla C, De Gracia Leon A, \nColomina Rodriguez J. Rare infectious complica -\ntion after intramuscular self-injections. Revista Es -294\n294\nINCLIVA SCIENTIFIC REPORT 2021publication list9panola de Quimioterapia. 2021 Aug;34(4):393-395. \ndoi: 10.37201/req/024.2021. PMID: 34049434\n146.  Romero A, Jantus-Lewintre E, Garcia-Pelaez B, \nRoyuela A, Insa A, Cruz P, Collazo A, Altozano \nJ, Vidal O, Diz P, Cobo M, Hernandez B, Estevez \nS, Benitez G, Guirado M, Majem M, Bernabe R, \nOrtega A, Blasco A, Bosch-Barrera J, Jurado J, \nGonzalez J, Viteri S, Giron C, Massuti B, Martin \nA, Rodriguez-Festa A, Calabuig-Farinas S, Moli -\nna-Vila M, Provencio M. Comprehensive cross-\nplatform comparison of methods for non-inva -\nsive EGFR mutation testing: results of the RING \nobservational trial. Molecular Oncology. 2021 \nJ a n ;15(1):4 3 - 56.  d o i :  10.10 02/1878 - 0261.12832. \nPMID: 33107189\n147. Gambardella V, Martinez-Ciarpaglini C, Fleitas \nT, Cervantes A. Comprehensive genomic and \ntranscriptomic analysis for guiding therapeutic \ndecisions in patients with rare cancers. ESMO \nOpen. 2021 Nov 6;6(6):100285. doi: 10. 1016/j.es -\nmoop.2021. 100285. PMID: 34752996\n148.  Simon C. Consensus vision. Fertility and Sterili -\nty. 2021 Jul;1 16(1):13-14. doi: 10. 1016/j.fertns -\ntert.2021.05.090. PMID: 34148581\n149.  Zamora-Sanchez J, Zabaleta-del-Olmo E, Gea-Caba -\nllero V, Julian-Rochina I, Perez-Tortajada G, Amblas-\nNovellas J. Convergent and discriminative validity \nof the Frail-VIG index with the EQ-5D-3L in people \ncared for in primary health care. BMC Geriatrics. \n2021 Apr 13;21(1):243. doi: 10. 1 186/s12877-021-\n02186-x. PMID: 33849481\nCORRECTION: Zamora-Sanchez J, Zabaleta-del-Olmo \nE, Gea-Caballero V, Julian-Rochina I, Perez-Tortajada G, \nAmblas-Novellas J. Correction to: Convergent and dis -\ncriminative validity of the Frail-VIG index with the EQ-\n5D-3L in people cared for in primary health care. BMC \nGeriatrics. 2021 Jul 12;21(1):424. doi: 10. 1 186/s12877-\n021-02369-6. PMID: 34253182\n150.  Ampudia-Blasco F, Artime E, Diaz S, Rubio M, Revi -\nriego J, Mitchell B, Osumili B, Peyrot M, Pokrzyw -\ninski R, Spaepen E, Snoek F. Conversations and \nReactions Around Severe Hypoglycaemia (CRASH): \nSpanish results of a global survey of people with \ntype 1 diabetes or insulin-treated type 2 diabetes \nand caregivers. Endocrinologia, Diabetes y Nutri -cion. 2021 Jan 15:S2530-0164(20)30253-6. doi: \n10.1016/j.endinu.2020.10.007 . PMID: 33461913\n151. Gabaldon-Perez A, Marcos-Garces V, Gavara J, \nRios-Navarro C, Minana G, Bayes-Genis A, Husser \nO, Sanchis J, Nunez J, Chorro F, Bodi V. Coronary \nrevascularization and long-term survivorship in \nChronic Coronary Syndrome. Journal of Clinical \nMedicine. 2021 Feb 5;10(4):610. doi: 10.3390/\njcm10040610. PMID: 33562869\n152. Camanes-Gonzalvo S, Marco-Pitarch R, Plaza-\nEspin A, Puertas-Cuesta J, Agustin-Panadero R, \nFons-Font A, Fons-Badal C, Garcia-Selva M. Corre -\nlation between polysomnographic parameters \nand tridimensional changes in the upper airway \nof obstructive sleep apnea patients treated with \nmandibular advancement devices. Journal of Cli -\nnical Medicine. 2021 Nov 1 1;10(22):5255. doi: \n10.3390/jcm10225255. PMID: 34830533\n153. Uso-Talamantes R, Gonzalez-de-Julian S, Diaz-Car -\nnicero J, Sauri-Ferrer I, Trillo-Mata J, Carrasco-Pe -\nrez M, Navarro-Perez J, Gorriz J, Vivas-Consuelo \nD, Redon J. Cost of Type 2 diabetes patients with \nchronic kidney disease based on real-world data: \nan observational population-based study in Spain. \nInternational Journal of Environmental Research \nand Public Health. 2021 Sep 18;18(18):9853. doi: \n10.3390/ijerph18189853. PMID: 34574782\n154. Ljungman P, de la Camara R, Mikulska M, Tridello \nG, Aguado B, Al Zahrani M, Apperley J, Berceanu \nA, Bofarull RM, Calbacho M, Ciceri F, Lopez-Corral \nL, Crippa C, Fox ML, Grassi A, Jimenez MJ, Demir \nSK, Kwon M, Llamas C, Lorenzo JL, Mielke S, Or -\nchard K,Porras RP, Vallisa D, Xhaard A, Knelange \nNS, Cedillo A, Kroger N, Pinana JL, Styczynski J. CO -\nVID-19 and stem cell transplantation; results from \nan EBMT and GETH multicenter prospective sur -\nvey. Leukemia. 2021 Oct;35(10):2885-2894. doi: \n10.1038/s41375-021-01302-5. PMID: 34079042\n155. El-Battrawy I, Nunez-Gil I, Abumayyaleh M, Estrada \nV, Becerra-Munoz V, Uribarri A, Fernandez-Rozas \nI, Feltes G, Arroyo-Espliguero R, Trabattoni D, Lo -\npez-Pais J, Pepe M, Romero R, Castro-Mejia A, Ce -\nrrato E, Astrua T, D\u2019Ascenzo F, Fabregat-Andres \nO, Signes-Costa J, Marin F, Buonsenso D, Bardaji \nA, Tellez M, Fernandez-Ortiz A, Macaya C, Akin I. \nCOVID-19 and the impact of arterial hypertension-295\n295\nINCLIVA SCIENTIFIC REPORT 2021publication list 9An analysis of the international HOPE COVID-19 \nRegistry (Italy-Spain-Germany). European Journal \nof Clinical Investigation. 2021 Nov;51(1 1):e13582. \nd o i:  10.1111/e c i.13582.  PMID:  34409593\n156. Rabade Castedo C, Signes-Costa J, Jimenez-Ruiz \nC. COVID-19 and tobacco. Archivos de Bronconeu -\nmologia. 2021 Jan;57 Suppl 1:5-6. doi: 10. 1016/j.\narbres.2020.07 .014. PMID: 32917432\n157. Focosi D, Navarro D, Maggi F, Roilides E, Antonelli \nG. COVID-19 infodemics: the role of mainstream \nand social media. Clinical Microbiology and Infec -\ntion. 2021 Nov;27(1 1):1568-1569. doi: 10. 1016/j.\ncmi.2021.08.003. PMID: 34375756\n158. Carrasco JP, Herraiz B, Sanchez LO, Luengo A, Fu -\nsalba OR, Aguilar EJ. COVID-19 lockdown influence \nin the psychiatric emergencies: drastic reduction \nand increase in severe mental disorders. Revis -\nta de Psiquiatria y Salud Mental. 2021;14(2):1 17-\n1 18. doi: 10. 1016/j.rpsm.2020. 1 1.003. PMID: \n33248289\n159. White TM, Cash-Gibson L, Martin-Moreno JM, \nMatesanz R, Crespo J, Alfonso-Sanchez JL, Villa -\npol S, El-Mohandes A, Lazarus JV. COVID-SCORE \nSpain: public perceptions of key government CO -\nVID-19 control measures. European Journal of \nPublic Health. 2021 Oct 26;31(5):1095-1 102. doi: \n10.1093/eurpub/ckab066. PMID: 33872348\n160.  Monteagudo C, Funez R, Sanchez-Sendra B, Gon -\nzalez-Munoz JF, Nieto G, Alfaro-Cervello C, Murgui \nA, Barr R. Cutaneous lymphadenoma is a distinct \ntrichoblastoma-like lymphoepithelial tumor with \ndiffuse androgen receptor immunoreactivity, \nnotch1 ligand in reed-sternberg-like cells, and com -\nmon EGFR somatic mutations. American Journal \nof Surgical Pathology. 2021 Oct 1;45(10):1382-\n1390. doi: 10. 1097 /PAS.0000000000001727 . \nPMID: 34232601\n161. Rodriguez-Lozano F, Lopez-Garcia S, Garcia-Ber -\nnal D, Sanz J, Lozano A, Pecci-Lloret M, Melo M, \nLopez-Gines C, Forner L. Cytocompatibility and \nbioactive properties of the new dual-curing resin-\nmodified calcium silicate-based material for vital \npulp therapy. Clinical Oral Investigations. 2021 \nAug;25(8):5009-5024. doi: 10. 1007 /s00784-021-\n03811-0. PMID: 33638052162. Solano Vercet C, Vazquez L, Gimenez Quiles E, De \nLa Camara R, Albert Vicent E, Rovira M, Espigado \nI, Calvo C, Lopez-Jimenez J, Suarez-Lledo M, Chi -\nnea A, Esquirol A, Perez Martinez A, Bermudez A, \nSaldana R, Heras I, Gonzalez-Huerta A, Torrado T, \nBautista G, Batlle M, Jimenez S, Vallejo C, Barba P, \nCuesta M, Pinana J, Navarro Ortega D. Cytomega -\nlovirus DNAemia and risk of mortality in allogeneic \nhematopoietic stem cell transplantation: analysis \nfrom the Spanish Hematopoietic Transplanta -\ntion and Cell Therapy Group. American Journal \nof Transplantation. 2021 Jan;21(1):258-271. doi: \n10.1111/a j t .16147.  PMID:  32812351\n163.  De la Asuncion C, Terol M, Saus A, Olea B, Gime -\nnez E, Albert E, Lopez-Jimenez J, Andreu R, Garcia \nD, Fox L, Remigia M, Amat P, Solano C, Navarro \nD. Cytomegalovirus-specific T-cell immunity and \nDNAemia in patients with chronic lymphocytic leu -\nkaemia undergoing treatment with ibrutinib. Bri -\ntish Journal of Haematology. 2021 Nov;195(4):637-\n641. doi: 10. 1 1 1 1/bjh. 17732. PMID: 34402042\n164.  Alvarez-Larran A, Angona A, Andrade-Campos M, \nSoledad Noya M, Teresa Gomez-Casares M, Cue -\nvas B, Caballero G, Garcia-Hernandez C, Garcia-\nGutierrez V, Palomino A, Ferrer-Marin F, Isabel \nMata-Vazquez M, Moreto A, Magro E, Murillo I, \nAlonso-Dominguez J, Maria Guerra J, Guerrero L, \nMaria Raya J, Perez-Encinas M, Carreno-Tarrago -\nna G, Fox L, Pastor Galan I, Bellosillo B, Hernandez \nBoluda J, MPN Spanish Grp Gemfin. Cytoreductive \ntreatment in patients withCALR-mutated essential \nthrombocythaemia: a study comparing indications \nand efficacy among genotypes from the Spanish \nRegistry of Essential Thrombocythaemia. British \nJournal of Haematology. 2021 Mar;192(6):988-\n996. doi: 10.1111/bjh.16988. PMID: 32745264\n165. Aguilera-Buenosvinos I, Fernandez-Lazaro C, Ro -\nmanos-Nanclares A, Gea A, Sanchez-Bayona R, \nMartin-Moreno J, Martinez-Gonzalez M, Toledo E. \nDairy consumption and incidence of breast cancer \nin the \u2018Seguimiento Universidad de Navarra\u2019 (SUN) \nProject. Nutrients. 2021 Feb 21;13(2):687 . doi: \n10.3390/nu13020687 . PMID: 33669972\n166.  O\u2019Brien J, Adashi E, Simon C. Darwin meets Men -\ndel in the reproductive medicine field: Homo \nSapiens 2.0 is inevitable. Fertility and Sterility. 296\n296\nINCLIVA SCIENTIFIC REPORT 2021publication list92021 Apr;1 15(4):850-851. doi: 10. 1016/j.fertns -\ntert.2021.01.047 . PMID: 33642062\n167. McLean K, Kamarajah S, Chaudhry D, et al. Death fo -\nllowing pulmonary complications of surgery before \nand during the SARS-CoV-2 pandemic. British Jour -\nnal of Surgery. 2021 Dec 1;108(12):1448-1464. \ndoi: 10. 1093/bjs/znab336. PMID: 34871379\n168.  Martinez-Hernandez N, Diaz-Cuevas A, Milian-Medi -\nna L, Sancho-Tello M, Rosello-Ferrando J, Morcillo-\nAixela A, Campo-Canaveral J, Roig-Bataller A, Ma -\nta-Roig M. Decellularized tracheal prelamination \nimplant: a proposed bilateral double organ techni -\nque. Artificial Organs. 2021 Dec;45(12):1491-1500. \ndoi: 10. 1111/aor. 14043. PMID: 34310703\n169.  Rodriguez-Borja E, Pozo-Giraldez A, Diaz-Gimenez \nM, Hervas-Romero A, Corchon-Peyrallo A, Vinyals-\nBellido I, Calvo A. Decision support system through \nautomatic algorithms and electronic request in \ndiagnosis of anaemia for primary care patients. \nBiochemia Medica. 2021 Jun 15;31(2):020702. doi: \n10.11613/BM.2021.020702. PMID: 33927552\n170. Bayes-Genis A, Iborra-Egea O, Spitaleri G, Domingo \nM, Revuelta-Lopez E, Codina P, Cediel G, Santiago-\nVacas E, Cserkoova A, Pascual-Figal D, Nunez J, \nLupon J. Decoding empagliflozin\u2019s molecular me -\nchanism of action in heart failure with preserved \nejection fraction using artificial intelligence. Scienti -\nfic Reports. 2021 Jun 8;1 1(1):12025. doi: 10. 1038/\ns41598-021-91546-z. PMID: 34103605\n171. Wettersten N, Horiuchi Y, van Veldhuisen D, Ix J, \nMueller C, Filippatos G, Nowak R, Hogan C, Kontos \nM, Cannon C, Mueller G, Birkhahn R, Taub P, Vilke G, \nDuff S, McDonald K, Mahon N, Nunez J, Briguori C, \nPassino C, Maisel A, Murray P. Decongestion discri -\nminates risk for one-year mortality in patients with \nimproving renal function in acute heart failure. Euro -\npean Journal of Heart Failure. 2021 Jul;23(7):1 122-\n1130. doi: 10.1002/ejhf.2179. PMID: 33788989\n172. Rapisarda A, Bargiela A, Llamusi B, Pont I, Estrada-\nTejedor R, Garcia-Espana E, Artero R, Perez-Alonso \nM. Defined d-hexapeptides bind CUG repeats and \nrescue phenotypes of myotonic dystrophy myotu -\nbes in a Drosophila model of the disease. Scientific \nReports. 2021 Sep 30;1 1(1):19417 . doi: 10. 1038/\ns41598-021-98866-0. PMID: 34593893173. Ampuero J, Aller R, Gallego-Duran R, Crespo J, \nAbad J, Gonzalez-Rodriguez A, Gomez-Camarero \nJ, Caballeria J, Lo Iacono O, Ibanez L, Garcia-Sa -\nmaniego J, Martin-Mateos R, Frances R, Fernan -\ndez-Rodriguez C, Diago M, Soriano G, Andrade RJ, \nLatorre R, Jorquera F, Morillas RM, Escudero D, \nEstevez P, Hernandez-Guerra M, Augustin S, Pare -\nja-Megia MJ, Banales JM, Aspichueta P, Benlloch \nS, Rosales JM, Salmeron J, Turnes J, Romero-\nGomez M. Definite and indeterminate nonalcoho -\nlic steatohepatitis share similar clinical features \nand prognosis: a longitudinal study of 1893 biopsy-\nproven nonalcoholic fatty liver disease subjects. Li -\nver International. 2021 Sep;41(9):2076-2086. doi: \n10.1111/liv.14898. PMID: 33896100\n174. Sanz J, Rodriguez-Lozano F, Lopez-Gines C, Mon -\nleon D, Llena C, Forner L. Dental stem cell signa -\nling pathway activation in response to hydraulic \ncalcium silicate-based endodontic cements: a \nsystematic review of in vitro studies. Dental ma -\nterials. 2021 Apr;37(4):e256-e268. doi: 10. 1016/j.\ndent al.2021.01.025. PMID: 33573840\n175. De-Madaria E, Sanchez-Marin C, Carrillo I, Vege \nS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, He -\ngyi P, Marta K, Kamal A, Lauret-Brana E, Barbu \nS, Nunes V, Ruiz-Rebollo M, Garcia-Rayado G, \nLozada-Hernandez E, Pereira J, Negoi I, Espina S, \nHollenbach M, Litvin A, Bolado-Concejo F, Vargas \nR, Pascual Moreno I, Singh V, Mira J. Design and \nvalidation of a patient-reported outcome measu -\nre scale in acute pancreatitis: the PAN-PROMISE \nstudy. Gut. 2021 Jan;70(1):139-147 . doi: 10. 1 136/\ngutjnl-2020-320729. PMID: 32245906\n176. Parravicini O, Angelina E, Spinelli R, Garibotto F, \nSiano AS, Vila L, Cabedo N, Cortes D, Enriz RD. De -\nsign, synthesis, biological evaluation and molecular \nmodelling of substituted pyrrolo [2, 1-a] isoquinoli -\nnone derivatives: discovery of potent inhibitors of \nAChE and BChE. New Journal of Chemistry. 2021; \n18. 10.1039/d1nj00345c\n17 7. Hernandez Boluda J, Pereira A, Kroeger N, Beelen \nD, Robin M, Bornhaeuser M, Angelucci E, Vitek A, \nBlau I, Niittyvuopio R, Finke J, Cornelissen J, Pas -\nsweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuc -\nkerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, \nMcLornan D, Yakoub-Agha I. Determinants of sur -297\n297\nINCLIVA SCIENTIFIC REPORT 2021publication list 9vival in myelofibrosis patients undergoing alloge -\nneic hematopoietic cell transplantation. Leukemia. \n2021 Jan;35(1):215-224. doi: 10. 1038/s41375-\n020-0815-z. PMID: 32286544\n178. Canton R, Huarte R, Morata L, Trillo-Mata J, Mu -\nnoz R, Gonzalez J, Tort M, Badia X. Determining \nthe burden of infectious diseases caused by \ncarbapenem-resistant gram-negative bacteria in \nSpain. Enfermedades Infecciosas y Microbiologia \nClinica. 2021 Apr;39(4):179-183. doi: 10. 1016/j.\neimc.2020.04.009. PMID: 32576392\n179. Lurbe E, Ingelfinger J. Developmental and early \nlife origins of cardiometabolic risk factors: novel \nfindings and implications. Hypertension. 2021 \nFeb;77(2):308-318. doi: 10.1161/HYPERTENSIO -\nNAHA. 120. 14592. PMID: 33390043\n180.  Crehua-Gaudiza E, Barres Fernandez A, Jovani Ca -\nsano C, Latorre Tejerina M, Largo Blanco E, More -\nno Ruiz M, Berghezan Suarez A, Garcia-Peris M, \nGil Piquer R, Coret Sinisterra A, Martinez-Barona \nS, Salido-Capilla C, Requena Fernandez M, Arcos-\nMachancoses J, Martinez-Costa C. Diagnosis of \nceliac disease in clinical practice: present and \nfuture. Anales de Pediatria. 2021 Apr;94(4):223-\n229. doi: 10.1016/j.anpedi.2020.07 .008. PMID: \n32891578\n181. Miron Mombiela R, Vucetic J, Monllor P, Cardenas-\nHerran JS, Taltavull de la Paz P, Borras C. Diag -\nnostic performance of muscle echo intensity and \nfractal dimension for the detection of frailty phe -\nnotype. Ultrasonic Imaging. 2021 Nov;43(6):337-\n352. doi: 10. 1 177 /0161734621 1029656. PMID: \n34238072\n182. Valdivia Piqueres A, Torres Fink I, Huntley Pascual \nD, Alcar\u00e1z Soriana M, Albert Vicent E, Gonz\u00e1lez \nPadr\u00f3n C, Colomina Rodr\u00edguez F, Navarro Orte -\nga D. Diagnostic significance of SARS-CoV-2 IgM \npositive/IgG negative antibody profile in sympto -\nmatic patients with suspected COVID-19 testing \nnegative by RT-PCR. Journal of Infection. 2021 \nJan;82(1):e15-e16. doi: 10.1016/j.jinf.2020.08.028. \nPMID: 32853600\n183.  Sempere-Bigorra M, Julian-Rochina I, Cauli O. Diffe -\nrences and similarities in neuropathy in type 1 and \n2 diabetes: a systematic review. Journal of Per -sonalized Medicine. 2021 Mar 22;1 1(3):230. doi: \n10.3390/jpm11030230. PMID: 33810048\n184.  Cabezon M, Malinverni R, Bargay J, Xicoy B, Marce \nS, Garrido A, Tormo M, Arenillas L, Coll R, Borras \nJ, Jimenez M, Hoyos M, Valcarcel D, Escoda L, Vall-\nLlovera F, Garcia A, Font L, Ramila E, Buschbeck \nM, Zamora L, CETLAM Grp. Different methylation \nsignatures at diagnosis in patients with high-risk \nmyelodysplastic syndromes and secondary acu -\nte myeloid leukemia predict azacitidine response \nand longer survival. Clinical Epigenetics. 2021 \nJan 14;13(1):9. doi: 10. 1 186/s13148-021-01002-y. \nPMID: 33446256\n185. Herreros-Pomares A, Llorens C, Soriano B, Bagan \nL, Moreno A, Calabuig-Farinas S, Jantus-Lewintre \nE, Bagan J. Differentially methylated genes in \nproliferative verrucous leukoplakia reveal poten -\ntial malignant biomarkers for oral squamous cell \ncarcinoma. Oral Oncology. 2021 May;1 16:105191. \ndoi: 10.1016/j.oraloncology.2021.105191. PMID: \n33657465\n186. Marti-Fernandez R, Cassinello-Fernan -\ndez N, Palomares-Casasus S, Gomez-\nAdrian J, Ferrandez-Izquierdo A. Diffuse li -\npomatosis of the thyroid gland. American \nSurgeon. 2021 Jun 27:3134821 1029848. \ndoi: 10. 1177 /00031348211029848. PMID: \n34180266\n187. Marti-Aguado D, Rodriguez-Ortega A, Mestre-\nAlagarda C, Bauza M, Valero-Perez E, Alfaro-Cer -\nvello C, Benlloch S, Perez-Rojas J, Ferrandez A, \nAlemany-Monraval P, Escudero-Garcia D, Monton \nC, Aguilera V, Alberich-Bayarri A, Serra M, Marti-\nBonmati L. Digital pathology: accurate technique \nfor quantitative assessment of histological fea -\ntures in metabolic-associated fatty liver disease. \nAlimentary Pharmacology & Therapeutics. 2021 \nJan;53(1):160-171. doi: 10. 1 1 1 1/apt. 16100. PMID: \n32981113\n188.  Marco-Pitarch R,  Selva-Garcia M, Plaza-Espin A, \nPuertas-Cuesta J, Agustin-Panadero R, Fernan -\ndez-Julian E, Marco-Algarra J, Fons-Font A. Dimen -\nsional analysis of the upper airway in obstructive \nsleep apnea syndrome patients treated with man -\ndibular advancement device: a bi and three-dimen -\nsional evaluation. Journal of Oral Rehabilitation. 298\n298\nINCLIVA SCIENTIFIC REPORT 2021publication list92021 Aug;48(8):927-936. doi: 10. 1 1 1 1/joor. 13176. \nPMID: 33977548\n189.  Bonanad C, Garcia-Blas S, Torres Llergo J, Fernan -\ndez-Olmo R, Diez-Villanueva P, Ariza-Sole A, Marti -\nnez-Selles M, Raposeiras S, Ayesta A, Bertomeu-\nGonzalez V, Tarazona Santabalbina F, Facila L, Vivas \nD, Gabaldon-Perez A, Bodi V, Nunez J, Cordero A. \nDirect oral anticoagulants versus warfarin in oc -\ntogenarians with nonvalvular atrial fibrillation: a \nsystematic review and meta-analysis. Journal of \nClinical Medicine. 2021 Nov 12;10(22):5268. doi: \n10.3390/jcm10225268. PMID: 34830548\n190.  Pozo-Giraldez A, Rodriguez-Borja E, Diaz-Gime -\nnez M, Carratala-Calvo A, Magro-Pose P, Perez-\nGriera J. Discordant SOX-1 antibodies results in \nparaneoplastic Lambert-Eaton syndrome diag -\nnosis by the clinical laboratory. Clinical Bioche -\nmistry. 2021 Nov;97:82-84. doi: 10. 1016/j.clinbio -\nchem.2021.08.004. PMID: 34450126\n191. Sicras-Mainar A, Rejas-Gutierrez J, Vargas-Negrin \nF, Tornero-Tornero J, Sicras-Navarro A, Lizarraga I. \nDisease burden and costs in moderate-to-severe \nchronic osteoarthritis pain refractory to stan -\ndard of care: ancillary analysis of the OPIOIDS re -\nal-world study. Rheumatology and Therapy. 2021 \nMar;8(1):303-326. doi: 10.1007/s40744-020-\n00271-y. PMID: 33411324\n192. Molina P, Molina M, Pallardo L, Torralba J, Escudero \nV, Alvarez L, Peris A, Sanchez-Perez P, Gonzalez-Ri -\nco M, Puchades M, Fernandez-Najera J, Gimenez-\nCivera E, D\u2019Marco L, Carrero J, Gorriz J. Disorders \nin bone-mineral parameters and the risk of death \nin persons with chronic kidney disease stages 4 \nand 5: the PECERA study. Journal of Nephrology. \n2021 Aug;34(4):1189-1199. doi: 10.1007 /s40620-\n020-00916-9. PMID: 33394344\n193. Garrido-Gomez T, Castillo-Marco N, Clemente-Cis -\ncar M, Cordero T, Munoz-Blat I, Amadoz A, Jimenez-\nAlmazan J, Monfort-Ortiz R, Climent R, Perales-Ma -\nrin A, Simon C. Disrupted PGR-B and ESR1 signaling \nunderlies defective decidualization linked to severe \npreeclampsia. eLife. 2021 Oct 28;10:e70753. doi: \n10.7554/eLife.70753. PMID: 34709177\n194.  Herrero-Cervera A, Espinos-Estevez C, Martin-\nVano S, Taberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, Martinez-Hervas S, Gonzalez-\nNavarro H. Dissecting abdominal aortic aneurysm \nis aggravated by genetic inactivation of LIGHT \n(TNFSF14). Biomedicines. 2021 Oct 22;9(1 1):1518. \ndoi: 10.3390/biomedicines91 1 1518. PMID: \n34829747\n195. Kaminska K, Akrap N, Staaf J, Alves C, Ehinger \nA, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, \nHarbst K, Ehmsen S, Borgquist S, Borg A, Perez-\nFidalgo A, Ditzel H, Bosch A, Honeth G. Distinct me -\nchanisms of resistance to fulvestrant treatment \ndictate level of ER independence and selective \nresponse to CDK inhibitors in metastatic breast \ncancer. Breast Cancer Research. 2021 Feb \n18;23(1):26. doi: 10.1186/s13058-021-01402-1. \nPMID: 33602273\n196.  Gimenez Quiles E, Monzo Catalu\u00f1a C, Albert Vicent \nE, Fuentes Trillo A, Seda Garc\u00eda E, Pinana J, Hernan -\ndez Boluda J, Solano Vercet C, Chaves Mart\u00ednez F, \nNavarro Ortega D. Diversity and dynamic changes \nof anelloviruses in plasma following allogeneic he -\nmatopoietic stem cell transplantation. Journal of \nMedical Virology. 2021 Aug;93(8):5167-5172. doi: \n10.1002/jmv.26661. PMID: 33174620\n197. Lorente-Pozo S, Navarrete P, Garz\u00f3n MJ, Lara-Can -\nt\u00f3n I, Beltr\u00e1n-Garc\u00eda J, Osca-Verdegal R, Mena-Mo -\nll\u00e1 S, Garc\u00eda-L\u00f3pez E, Vento M, Pallard\u00f3 FV, Garc\u00eda-\nGim\u00e9nez JL. DNA methylation analysis to unravel \naltered genetic pathways underlying early onset  \nand late onset neonatal sepsis. A pilot study. Fron -\ntiers in Immunology. 2021 Feb 15;12:622599. doi: \n10.3389/fimmu.2021.622599. PMID: 33659006\n198.  Domingo-Relloso A, Huan T, Haack K, Riffo-Campos \nA, Levy D, Fallin M, Terry M, Zhang Y, Rhoades D, \nHerreros-Martinez M, Garcia-Esquinas E, Cole S, \nTellez-Plaza M, Navas-Acien A. DNA methylation \nand cancer incidence: lymphatic-hematopoietic \nversus solid cancers in the Strong Heart Study. \nClinical Epigenetics. 2021 Feb 25;13(1):43. doi: \n10.1186/s13148-021-01030-8. PMID: 33632303\n199. Gonzalez-Oria C, Belvis R, Cuadrado M, Diaz-Insa \nS, Guerrero-Peral A, Huerta M, Irimia P, Lainez \nAndr\u00e9s J, Latorre G, Leira R, Oterino A, Pascual \nJ, Porta-Etessam J, Pozo-Rosich P, Sanchez del \nRio M, Santos-Lasaosa S. Document of revision \nand updating of medication overuse headache 299\n299\nINCLIVA SCIENTIFIC REPORT 2021publication list 9(MOH). Neurologia. 2021 Apr;36(3):229-240. doi: \n10.1016/j.nrl.2020.04.029. PMID: 32917437\n200.  Pizza F, D\u2019Antonio D, Lucido F, Gambardella C, Car -\nbonell Asins J, Dell\u2019isola C, Tolone S. Does antrum \nsize matter in sleeve gastrectomy?. A prospective \nrandomized Study. Surgical Endoscopy and Other \nInterventional Techniques. 2021 Jul;35(7):3524-\n3532. doi: 10. 1007 /s00464-020-0781 1-1. PMID: \n32691207\nCORRECTION: Pizza F, D\u2019Antonio D, Lucido F, Gambar -\ndella C, Carbonell Asins J, Dell\u2019isola C, Tolone S. Does \nantrum size matter in sleeve gastrectomy?. A pros -\npective randomized study (vol 46, pg 861, 2020). Sur -\ngical Endoscopy and Other Interventional Techniques. \n2021 Jul;35(7):3524-3532. doi: 10.1007 /s00464-\n020-07811-1. PMID: 32749614\n201. Garcia-Botello S, Martin-Arevalo J, Cozar-Lozano \nC, Benitez-Riesco A, Moro-Valdezate D, Pla-Marti \nV, Espi-Macias A. Does delaying curative surgery \nfor colorectal cancer influence long-term disease-\nfree survival? A cohort study. Langenbecks Archi -\nves of Surgery. 2021 Nov;406(7):2383-2390. doi: \n10.1007/s00423-021-02251-4. PMID: 34247257\n202.  Huerta O, Cubero I, Gutierrez A, Gonzalez M. Does \nprimary care intervention have an impact in the \nplace of death for patients in a palliative care pro -\ngram?. Atencion Primaria. 2021 Oct;53(8):102063. \ndoi: 10.1016/j.aprim.2021.102063. PMID: \n34044187\n203.  Abumayyaleh M, Nunez Gil I, El-Battrawy I, Estrada \nV, Becerra-Munoz V, Aparisi A, Fernandez-Rozas I, \nFeltes G, Arroyo-Espliguero R, Trabattoni D, Lopez-\nPais J, Pepe M, Romero R, Garcia D, Biole C, Astrua \nT, Eid C, Alfonso E, Fernandez-Presa L, Espejo C, \nBuonsenso D, Raposeiras S, Fernandez C, Macaya \nC, Akin I, HOPE COVID-19 investigators. Does there \nexist an obesity paradox in COVID-19?. Insights of \nthe International HOPE-COVID-19-registry. Obesi -\nty Research & Clinical Practice. 2021;15(3):275-\n280. doi: 10.1016/j.orcp.2021.02.008. PMID: \n33741308\n204.  Mas-Coma S, Funatsu IR, Angles R, Buchon P, Mas \nBargues C, Artigas P, Valero MA, Bargues MD. \nDomestic pig prioritized in one health action aga -\ninst fascioliasis in human endemic areas: experi -mental assessment of transmission capacity and \nepidemiological evaluation of reservoir role. One \nHealth. 2021 Apr 16;13:100249. doi: 10. 1016/j.\nonehlt.2021.100249. PMID: 33997234\n205.  Benavent M, Fernandez I, Negrete E, Gullon G, Rol -\ndan F. Double nail of the second toe: a case report \nwith sonographic and radiological correlation. Pe -\ndiatric Dermatology. 2021 Nov;38(6):1588-1589. \nd o i:  10.1111/p d e.14830.  PMID:  34647639\n206.  Civera JM, Conesa A, Villaescusa A, Nunez J. \nDrug titration by nursing professionals in heart \nfailure units. Revista Espanola de Cardiologia \n(English Ed.). 2021 Jun;74(6):561. doi: 10. 1016/j.\nrec.2020.10.013. PMID: 33342715\n2 0 7. Gargallo-Benedicto A, P\u00e9rez-Torregrosa V, \nClemente-Tom\u00e1s R, Duch-Samper AM. Dual \ncorneal involvement by endotelial and epite -\nlial corneal dystrophies in Steinert\u00b4 s disease: \na case of triple dystrophy. European Journal of \nOphthalmology. 2021 Mar;31(2):NP23-NP26. doi: \n10.1177/1120672119872374.  PMID:  31476892\n208.  Ajnakina O, Rodriguez V, Quattrone D, di Forti M, \nVassos E, Arango C, Berardi D, Bernardo M, Bo -\nbes J, de Haan L, Del-Ben CM, Gayer-Anderson \nC, Jongsma HE, Lasalvia A, Tosato S, Llorca PM, \nMenezes PR, Rutten BP, Santos JL, Sanjuan J, \nSelten JP, Szoke A, Tarricone I, D\u2019Andrea G, Ri -\nchards A, Tortelli A, Velthorst E, Jones PB, Arrojo \nRomero M, La Cascia C, Kirkbride JB, van Os J, \nO\u2019Donovan M, Murray RM. Duration of untreated \npsychosis in first-episode psychosis is not asso -\nciated with common genetic variants for major \npsychiatric conditions: results from the multi-\ncenter EU-GEI Study. Schizophrenia Bulletin. 2021 \nOct 21;47(6):1653-1662. doi: 10.1093/schbul/\nsbab055. PMID: 33963865\n209.  Monedero P, Gea A, Castro P, Candela-Toha A, Her -\nnandez-Sanz M, Arruti E, Villar J, Ferrando C, CO -\nVID-19 Spanish ICU Network. Early corticosteroids \nare associated with lower mortality in critically ill \npatients with COVID-19: a cohort study. Critical \nCare. 2021 Jan 4;25(1):2. doi: 10. 1 186/s13054-\n020-03422-3. PMID: 33397463\n210. Davo L, Segui R, Botija P, Beltran M, Albert E, To -\nrres I, Lopez-Fernandez P, Orti R, Maestre J, San -300\n300\nINCLIVA SCIENTIFIC REPORT 2021publication list9chez G, Navarro D. Early detection of SARS-CoV-2 \ninfection cases or outbreaks at nursing homes by \ntargeted wastewater tracking. Clinical Microbio -\nlogy and Infection. 2021 Jul;27(7):1061-1063. doi: \n10.1016/j.cmi.2021.02.003. PMID: 33601008\n211. Ordono Saiz M, Chacon Flocos S, Rodriguez-Ra -\nmos M, Gomez Zafra R. Early symptomatic con -\ngenital syphilis in a newborn. Anales de Pediatria. \n2021 May;94(5):341-342. doi: 10. 1016/j.anpe -\ndi.2020.05.012. PMID: 32620318\n212. De La Espriella Juan R, Nu\u00f1ez Benito E, Ll\u00e0cer P, \nGarcia Blas S, Ventura Haro S, N\u00fa\u00f1ez J, S\u00e1nchez \nR, Facila De La Esperanza R, Vaquer Santamaria J, \nBod\u00ed Peris V, Santas Olmeda E, Mi\u00f1ana Escriva G, \nMollar Fernandez A, N\u00fa\u00f1ez Mar\u00edn G, Chorro Gas -\nc\u00f3 F, G\u00f3rriz Teruel J, Sanchis Fores J, Bay\u00e9s-Genis \nA, Nu\u00f1ez Villota J. Early urinary sodium trajectory \nand risk of adverse outcomes in acute heart failu -\nre and renal dysfunction. Revista Espanola de Car -\ndiologia (English ed.). 2021 Jul;74(7):616-623. doi: \n10.1016/j.rec.2020.06.004. PMID: 32624444\n213. Pesarico A, Chagas P, Nacher J. Editorial: animal \nmodels of stress - current knowledge and poten -\ntial directions. Frontiers in Behavioral Neuros -\ncience. 2021 Feb 16;15:655214. doi: 10.3389/\nfnbeh.2021.655214. PMID: 33664658\n214. Peterson DR, Hawkins RA, Vina JR. Editorial: or -\nganization and functional properties of the blood-\nbrain Barrier. Frontiers in Physiology. 2021 Dec \n2;12:796030. doi: 10.3389/fphys.2021.796030. \nPMID: 34925076\n215. Ayesa-Arriola R, Miguel-Corredera M, de la Foz \nOrtiz-Garcia V, Neergaard KD, Correa-Ghisays P, \nSetien-Suero E, Crespo-Facorro B. Education and \nlong-term outcomes in first episode psychosis: 10-\nyear follow-up study of the PAFIP cohort. Psycho -\nlogical Medicine. 2021 May 6;1-12. doi: 10. 1017 /\nS0033291721001112.  PMID:  33952364\n216. Palau P, Seller J, Dominguez E, Sastre C, Ramon \nJM, Espriella R, Santas E, Minana G, Bodi V, San -\nchis J, Valle A, Chorro FJ, Llacer P, Bayes-Genis \nA, Nunez J. Effect of beta-blocker withdrawal on \nfunctional capacity in heart failure and preserved \nejection fraction. Journal of the American College \nof Cardiology. 2021 Nov 23;78(21):2042-2056. doi: \n10.1016/j.jacc.2021.08.073. PMID: 34794685217. COVIDSurg Collaborative. Effect of COVID-19 pan -\ndemic lockdowns on planned cancer surgery for \n15 tumour types in 61 countries: an internatio -\nnal, prospective, cohort study. Lancet. Oncology. \n2021 Nov;22(1 1):1507-1517 . doi: 10. 1016/S1470-\n2045(21)00493-9. PMID: 34624250\n218. Nunez-Gil I, Fernandez-Ortiz A, Maroud Eid C, \nHuang J, Romero R, Becerra-Munoz V, Uribarri A, \nFeltes G, Trabatoni D, Fernandez-Rozas I, Viana-\nLlamas M, Pepe M, Cerrato E, Bertaina M, Capel \nAstrua T, Alfonso E, Castro-Mejia A, Raposeiras-\nRoubin S, D\u2019Ascenzo F, Espejo Paeres C, Signes-\nCosta J, Bardaji A, Fernandez-Perez C, Marin \nF, Fabregat-Andres O, Akin I, Estrada V, Macaya \nC. Effect of empagliflozin on exercise ability and \nsymptoms in heart failure patients with redu -\nced and preserved ejection fraction, with and \nwithout type 2 diabetes. Cardiology Journal. 2021 \nFeb 11;42(6):700-710. doi: 10.1093/eurhear tj/\nehaa943. PMID: 33351892\n219. Molina-Merino A, Martinez-Rodriguez L, Cubells-\nGarcia E, Hortelano-Platero V, Estan-Capell \nJ. Effect of lockdown on the preterm births \nin a Valencian Comunity. Anales de Pediatria. \n2021 Nov;95(5):379-381. doi: 10. 1016/j.anpe -\nde.2021.07 .004. PMID: 34697000\n220.  Sancho J, Ferrer S, Bures E, Diaz JL, Torrecilla T, \nSignes-Costa J, Servera E. Effect of one-year dex -\ntromethorphan/quinidine treatment on manage -\nment of respiratory impairment in amyotrophic \nlateral sclerosis. Respiratory Medicine. 2021 Jul \n7;186:106536. doi: 10.1016/j.rmed.2021.106536. \nPMID: 34260979\n221. Szarek M, Bhatt D, Steg P, Cannon C, Leiter L, Mc -\nGuire D, Lewis J, Riddle M, Voors A, Metra M, Lund \nL, Komajda M, Testani J, Wilcox C, Ponikowski P, \nLopes R, Banks P, Tesfaye E, Ezekowitz J, Verma S, \nPitt B, SOLOIST-WHF Comm Investigators. Effect \nof sotagliflozin on total hospitalizations in patients \nwith type 2 diabetes and worsening heart failure: \na randomized trial. Annals of Internal Medicine. \n2021 Aug;174(8):1065-1072. doi: 10.7326/M21-\n0651. PMID: 34152828\n222.  Kraus-Fischer G, Alfonso Ballester R, Mora Oliver \nI, Cassinello Fern\u00e1ndez N, Ortega Serrano J. Effec -\ntiveness and efficiency of a special program to re -301\n301\nINCLIVA SCIENTIFIC REPORT 2021publication list 9duce the bariatric surgery waiting list at a tertiary \nhospital. Cirugia Espanola. 2021 Apr;99(4):276-\n281. doi: 10.1016/j.ciresp.2020.05.033. PMID: \n32674840\n223.  Chaparro M, Garre A, Iborra M, Sierra M, Barrei -\nro-de Acosta M, Fernandez-Clotet A, de Castro \nL, Bosca-Watts M, Casanova M, Lopez-Garcia A, \nLorente R, Rodriguez C, Carbajo A, Arroyo M, Gu -\ntierrez A, Hinojosa J, Martinez-Perez T, Villoria A, \nBermejo F, Busquets D, Camps B, Canete F, Man -\ncenido N, Monfort D, Navarro-Llavat M, Perez-\nCalle J, Ramos L, Rivero M, Angueira T, Camo P, \nCarpio D, Garcia-de-la-Filia I, Gonzalez-Munoza C, \nHernandez L, Huguet J, Morales V, Sicilia B, Vega \nP, Vera I, Zabana Y, Nos P, Suarez Alvarez P, Cal -\nvino-Suarez C, Ricart E, Hernandez V, Minguez M, \nMarquez L, Hervias Cruz D, Rubio Iturria S, Barrio \nJ, Gargayo-Puyuelo C, Frances R, Hinojosa E, Del \nMoral M, Calvet X, Algaba A, Aldeguer X, Guardiola \nJ, Manosa M, Pajares R, Piqueras M, Garcia-Bosch \nO, Lopez Serrano P, Castro B, Lucendo A, Monto -\nro M, Castro Ortiz E, Mesonero F, Garcia-Planella \nE, Fuentes D, Bort I, Delgado-Guillena P, Arias L, \nIglesias A, Calvo M, Esteve M, Domenech E, Gis -\nbert J. Effectiveness and safety of ustekinumab \nin ulcerative colitis: real-world evidence from the \nENEIDA registry. Journal of Crohn\u2019s & Colitis. 2021 \nNov 8;15(1 1):1846-1851. doi: 10. 1093/ecco-jcc/\njjab070. PMID: 33860795\n224.  Munoz-Gomez E, Ingles M, Serra-Ano P, Espi-Lopez \nGV. Effectiveness of a manual therapy protocol \nbased on articulatory techniques in migraine pa -\ntients. A randomized controlled trial. Musculoske -\nletal Science & Practice. 2021 Apr 30;54:102386. \ndoi: 10.1016/j.msksp.2021.102386. PMID: \n33989990\n225.  Izquierdo-Alventosa R, Ingles M, Cortes-Amador S, \nGimeno-Mallench L, Sempere-Rubio N, Serra-Ano \nP. Effectiveness of high-frequency transcranial \nmagnetic stimulation and physical exercise in wo -\nmen with fibromyalgia: a randomized controlled \ntrial. Physical Therapy & Rehabilitation Journal. \n2021 Oct 1;101(10):pzab159. doi: 10.1093/ptj/\npzab159. PMID: 34216139\n226.  Sanchis-Sanchez E, Lluch-Girbes E, Guillart-Cas -\ntells P, Georgieva S, Garcia-Molina P, Blasco J. \nEffectiveness of mechanical diagnosis and thera -py in patients with non-specific chronic low back \npain: a literature review with meta-analysis. Bra -\nzilian Journal of Physical Therapy. 2021;25(2):1 17-\n134. doi: 10.1016/j.bjpt.2020.07 .007 . PUBMED: \n32773288\n227. Gras-Valenti P, Mora-Muriel J, Chico-Sanchez P, \nAlgado-Selles N, Soler-Molina V, Hernandez-Mal -\ndonado M, Lameiras-Azevedo A, Sepulveda N, \nSotero I, Villanueva-Ruiz C, Barrenengoa-Sanudo \nJ, Fuster-Perez M, Canovas-Javega S, Cerezo-\nMilan P, Monerris-Palmer M, Llorens-Soriano P, \nMerino-Lucas E, Rodriguez-Diaz J, Gil-Carbonell \nJ, Sanchez-Martinez R, Pastor-Cesteros R, Me -\nna-Esquivias L, Galiana-Ivars M, Jaime-Sanchez \nF, Margarit-Ferri C, Gonzalez-deDios J, Lloret G, \nGarcia-Alonso M, Sanchez-Vela P, Sanchez-Paya J. \nEffectivity of a program for the control and preven -\ntion of COVID-19 healthcare-associated infections \nin a Spanish academic hospital. Journal of Patient \nSafety. 2021 Jun 1;17(4):323-330. doi: 10. 1097 /\nPTS.0000000000000852. PMID: 33994534\n228.  Gramuntell Y, Klimczak P, Coviello S, Perez-Rando \nM, Nacher J. Effects of aging on the structure \nand expression of NMDA receptors of somatos -\ntatin expressing neurons in the mouse hippocam -\npus. Frontiers in Aging Neuroscience. 2021 Dec \n23;13:782737 . doi: 10.3389/fnagi.2021.782737 . \nPMID: 35002680\n229.  Molla-Casanova S, Ingles M, Serra-Ano P. Effects of \nbalance training on functionality, ankle instability, and \ndynamic balance outcomes in people with chronic \nankle instability: systematic review and meta-analy -\nsis. Clinical Rehabilitation. 2021 Dec;35(12):1694-\n1709. doi: 10.1177 /02692155211022009. PMID: \n34058832\n230.  Neuen B, Oshima M, Perkovic V, Agarwal R, Ar -\nnott C, Bakris G, Cannon C, Charytan D, Edwards \nR, Gorriz J, Jardine M, Levin A, Neal B, De Nicola \nL, Pollock C, Rosenthal N, Wheeler D, Mahaffey \nK, Heerspink H. Effects of canagliflozin on serum \npotassium in people with diabetes and chronic kid -\nney disease: the CREDENCE trial. European Heart \nJournal. 2021 Dec 21;42(48):4891-4901. doi: \n10.1093/eur hear t j /ehab497. PMID: 34423370\n231. Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, \nHou FF, McMurray JJV, Correa-Rotter R, Rossing 302\n302\nINCLIVA SCIENTIFIC REPORT 2021publication list9P, Sjostrom CD, Stefansson BV, Langkilde AM, Whe -\neler DC, Heerspink HJL. Effects of dapagliflozin in \nstage 4 chronic kidney disease. Journal of the Ame -\nrican Society of Nephrology. 2021 Sep;32(9):2352-\n2361. doi: 10. 1681/ASN.2021020167 . PMID: \n34272327\n232.  Heerspink H, Sjostrom C, Jongs N, Chertow G, Ko -\nsiborod M, Hou F, McMurray J, Rossing P, Correa-\nRotter R, Kurlyandskaya R, Stefansson B, Toto R, \nLangkilde A, Wheeler D, DAPA-CKD Trial Comm \nInvestigators. Effects of dapagliflozin on mortali -\nty in patients with chronic kidney disease: a pre-\nspecified analysis from the DAPA-CKD randomized \ncontrolled trial. European Heart Journal. 2021 \nMar 31;42(13):1216-1227 . doi: 10. 1093/eurheartj/\nehab094. PMID: 33792669\n233.  de la Espriella R, Minana G, Santas E, Nunez G, Lo -\nrenzo M, Nunez E, Bayes-Genis A, Nunez J. Effects \nof empagliflozin on CA125 trajectory in patients with \nchronic congestive heart failure. International Jour -\nnal of Cardiology. 2021 Sep 15;339:102-105. doi: \n10.1016/j.ijcard.2021.06.045. PMID: 34216708\n234.  Carrero, A, Berenguer J, Hontanon V, Guardiola JM, \nNavarro J, von Wichmann MA, Tellez MJ, Quereda \nC, Santos I, Sanz J, Galindo MJ, Hernandez Quero \nJ, Jimenez Sousa MA, Perez Latorre L, Bellon JM, \nResino S, Esteban H, Martinez E, Gonzalez Garcia J. \nEffects of HCV eradication on bone mineral density \nin HIV/HCV coinfected patients. Clinical Infectious \nDiseases. 2021 Oct 5;73(7):e2026-e2033. doi: \n10. 1093/cid/ciaa1396. PMID: 32930720\n235.  Bushinsky D, Raggi P, Bover J, Ketteler M, Bellasi \nA, Rodriguez M, Sinha S, Garg R, Perello J, Gold A, \nChertow G, CaLIPSO Investigators. Effects of myo-\ninositol hexaphosphate (SNF472) on bone mine -\nral density in patients receiving hemodialysis: an \nanalysis of the randomized, placebo-controlled Ca -\nLIPSO study. Clinical Journal of the American Socie -\nty of Nephrology. 2021 May 8;16(5):736-745. doi: \n10.2215/CJN.16931020. PMID: 33835939\n236.  Armengot Carceller M, Gomez-Gomez M, Garcia-\nNavalon C, Domenech-Campos E, Munoz-Fernandez \nN, Miguel A, Marco Algarra J, Palop-Cervera M, Pi -\nnero A. Effects of omalizumab treatment in patients \nwith recalcitrant nasal polyposis and mild asthma: \na multicenter retrospective study. American Jour -nal of Rhinology & Allergy. 2021 Jul;35(4):516-\n524. doi: 10. 1 177 /1945892420972326. PMID: \n33153272\n237. COVIDSurg Collaborative, GlobalSurg Collabora -\ntive. Effects of pre-operative isolation on posto -\nperative pulmonary complications after elective \nsurgery: an international prospective cohort stu -\ndy. Anaesthesia. 2021 Nov;76(1 1):1454-1464. doi: \n10.1111/a n a e.15560.  PMID:  34371522\n238.  Danne T, Edelman S, Frias J, Ampudia-Blasco F, \nBanks P, Jiang W, Davies M, Sawhney S. Efficacy \nand safety of adding sotagliflozin, a dual SGLT1 \nand SGLT2 inhibitor, to optimized insulin therapy in \nadults with type 1 diabetes and baseline BMI \u226527 \nkg/m2. Diabetes, Obesity & Metabolism. 2021 \nMar ;23(3):854 - 860.  d o i:  10.1111/d o m.14271.  \nPMID: 33289297\n239.  Marconi V, Ramanan A, de Bono S, Kartman C, \nKrishnan V, Liao R, Piruzeli M, Goldman J, Alato -\nrre-Alexander J, de Cassia Pellegrini R, Estrada \nV, Som M, Cardoso A, Chakladar S, Crowe B, Reis \nP, Zhang X, Adams D, Ely E, COV-BARRIER Study \nGroup. Efficacy and safety of baricitinib for the \ntreatment of hospitalised adults with COVID-19 \n(COV-BARRIER): a randomised, double-blind, pa -\nrallel-group, placebo-controlled phase 3 trial. \nLancet Respiratory Medicine. 2021; 9(12): 1407-\n1418. doi: 10. 1016/S2213-2600(21)00331-3. \nPMID: 34480861\n240.  Civera J, de la Espriella R, Heredia R, Minana G, \nSantas E, Conesa A, Mollar A, Sastre C, Martinez \nA, Villaescusa A, Nunez J. Efficacy and safety of \nsubcutaneous infusion of non-formulated furose -\nmide in patients with worsening heart failure: a \nreal-world study. Journal of Cardiovascular Trans -\nlational Research. 2021 Oct 12. doi: 10. 1007 /\ns12265-021-10173-1. PMID: 34642870\n241. Esp\u00ed L\u00f3pez G, Aguilar Rodr\u00edguez M, Zarzoso Mu -\n\u00f1oz M, Serra A\u00f1o M, Martinez De La Fuente J, \nIngl\u00e9s De La Torre M, Marques-Sule E. Efficacy \nof a proprioceptive exercise program in patients \nwith nonspecific neck pain. A randomized contro -\nlled trial. European Journal of Physical and Re -\nhabilitation Medicine. 2021 Jun;57(3):397-405. \ndoi: 10.23736/S1973-9087 .20.06302-9. PMID: \n33047944303\n303\nINCLIVA SCIENTIFIC REPORT 2021publication list 9242.  Riudavets M, Bosch-Barrera J, Cabezon-Gutierrez \nL, Tain P, Hernandez A, Alonso M, Blanco R, Gal -\nvez E, Insa A, Mielgo X, Moran T, Ponce S, Roa D, \nSanchez J, Majem M. Efficacy of nintedanib plus \ndocetaxel in patients with refractory advanced \nepidermal growth factor receptor mutant lung \nadenocarcinoma. Clinical & Translational Onco -\nlogy. 2021 Dec;23(12):2560-2567 . doi: 10. 1007 /\ns12094-021-02661-2. PMID: 34292495\n243.  Lazaro Tome A, Jose Reig Cebria M, Gonzalez-\nTeruel A, Antonio Carbonell-Asins J, Canete Nico -\nlas C, Hernandez-Viadel M. Efficacy of vitamin D in \nthe treatment of depression: a systematic review \nand meta-analysis. Actas Espanolas de Psiquia -\ntria. 2021 Jan;49(1):12-23. PMID: 33533015\n244. Glasbey JC, Nepogodiev D, Simoes JFF, Omar O, Li E, \nVenn ML, Pgdme , Abou Chaar MK, Capizzi V, Chaud -\nhry D, Desai A, Edwards JG, Evans JP, Fiore M, Vide -\nria JF, Ford SJ, Ganly I, Griffiths EA, Gujjuri RR, Kolias \nAG, Kaafarani HMA, Minaya-Bravo A, McKay SC, Mo -\nhan HM, Roberts KJ, San Miguel-M\u00e9ndez C, Pockney \nP, Shaw R, Smart NJ, Stewart GD,  Sundar Mrcog \nS, Vidya R, Bhangu AA, COVIDSurg Collaborative. \nElective cancer surgery in COVID-19-free surgical \npathways during the SARS-CoV-2 Pandemic: an in -\nternational, multicenter, comparative cohort study. \nJournal of Clinical Oncology. 2021 Jan 1;39(1):66-78. \ndoi: 10.1200/JCO.20.01933. PMID: 33021869\n245.  Monllor P, Cervera-Ferri A, Lloret MA, Esteve D, Lo -\npez B, Leon JL, Lloret A. Electroencephalography \nas a non-invasive biomarker of alzheimer\u2019s disea -\nse: a forgotten candidate to substitute CSF mo -\nlecules? . International Journal of Molecular Scien -\nces. 2021 Oct 8;22(19):10889. doi: 10.3390/\nijms221910889. PMID: 34639229\n246.  Rubio C, Simon C. Embryo Genetics. Genes. 2021 \nJan 19;12(1):1 18. doi: 10.3390/genes120101 18. \nPMID: 33477974\n247. Fonseca-Pedrero E, Perez-Alvarez M, Al-Halabi \nS, et al. Empirically supported psychological \ntreatments for children and adolescents: state of \nthe art. Psicothema. 2021 Aug;33(3):386-398. doi: \n10.7334/psicothema2021.56. PMID: 34297668\n248.  Santamaria X, Simon C. Endometrial factor in \nunexplained infertility and recurrent implantation failure. Seminars in Reproductive Medicine. 2021 \nNov;39(5-06):227-232. doi: 10.1055/s-0041-\n1735199. PMID: 34425598\n249.  Simon C. Endometrial factor testing is a use -\nful tool in clinical infertility management. Re -\nproductive Biomedicine Online. 2021 Dec \n25;S1472-6483(21)00613-1. doi: 10. 1016/j.\nrbmo.2021.12.014. PMID: 35221254\n250.  Panach-Navarrete J, Valls-Gonz\u00e1lez L, Mart\u00ednez-\nJabaloyas JM. Endoureterotomy with the Lovaco \ntechnique for treatment of ureterointestinal stric -\ntures: outcomes in an experienced center and \nfactors associated with procedural success or \nfailure. Scandinavian Journal of Urology. 2021 Nov \n13:1-7. doi: 10.1080/21681805.2021.2002401. \nPMID: 34775899\n251. Rios-Navarro C, Gavara J, Nunez J, Revuelta-Lopez \nE, Monmeneu JV, Lopez-Lereu MP, de Dios E, Perez-\nSole N, Vila JM, Oltra R, Chorro FJ, Bayes-Genis A, \nBodi V. EpCAM and microvascular obstruction in \npatients with STEMI: a cardiac magnetic resonan -\nce study. Revista Espanola de Cardiologia (English \ned.). 2021 May 24;S1885-5857(21)00135-3. doi: \n10.1016/j.rec.2021.04.006. PMID: 34045168\n252.  de Oliveira-Tozetto S, Santiso-Bellon C, Ferrer-Chi -\nrivella J, Navarro-Lleo N, Vila-Vicent S, Rodriguez-\nDiaz J, Buesa J. Epidemiological and genetic cha -\nracterization of sapovirus in patients with acute \ngastroenteritis in Valencia (Spain). Viruses. 2021 \nJan 26;13(2):184. doi: 10.3390/v13020184. \nPMID: 33530573\n253.  Gimeno-Valiente F, Riffo-Campos A, Torres L, Tara -\nzona N, Gambardella V, Cervantes A, Lopez-Rodas \nG, Franco L, Castillo J. Epigenetic mechanisms \nare involved in the oncogenic properties of ZN -\nF518B in colorectal cancer. Cancers. 2021 Mar \n21;13(6):1433. doi: 10.3390/cancers13061433. \nPMID: 33801071\n254.  Peters S, Tabernero J, Cervantes A, Baner -\njee S, Giuliani R, Lordick F. ESMO pays tribute \nto Professor Jose Baselga. Annals of Oncolo -\ngy. 2021 Jul;32(7):823-824. doi: 10. 1016/j.an -\nnonc.2021.04.001. PMID: 34090547\n255. Peters S, Tabernero J, Cervantes A, Banerjee S, \nGiuliani R, Lordick F. ESMO pays tribute to Professor 304\n304\nINCLIVA SCIENTIFIC REPORT 2021publication list9Jose Baselga. ESMO Open. 2021 Jun;6(3):100130. doi: \n10.1016/j.esmoop.2021.100130. PMID: 34144776\n256.  Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, \nCervantes A, Cavalli F, Costa A. ESO-ESMO master -\nclass in clinical oncology: analysis and evaluation \nof the learning self-assessment test. Journal of \nCancer Education. 2021 Jun;36(3):556-560. doi: \n10.1007/s13187-019-01664-6. PMID: 31845109\n257. Borras C, Ferrando M, Ingles M, Gambini J, Lopez-\nGrueso R, Edo R, Mas-Bargues C, Pellicer A, Vina J. \nEstrogen replacement therapy induces antioxidant \nand longevity-related genes in women after medi -\ncally induced menopause. Oxidative Medicine and \nCellular Longevity. 2021 Sep 9;2021:8101615. doi: \n10.1155/2021/8101615. PMID: 34539974\n258.  Lurbe E, Fernandez-Aranda F, Wuhl E, en repre -\nsentacion del Consorcio HyperChildNET. European \nNetwork for blood pressure research in children \nand adolescents (COST Action CA 191 15). Anales \nde Pediatria. 2021 Jun;94(6):421.e1-421.e4. doi: \n10.1016/j.anpedi.2021.01.015. PMID: 33653658\n259.  Lurbe E, Fernandez-Aranda F, Wuhl E, HyperChild -\nNET Consortium. European Network for blood \npressure research in children and adolescents \n(COST Action CA 191 15). Anales de Pediatria. \n2021 Jun;94(6):421.e1-421.e4. doi: 10.1016/j.an -\npede.2021.01.003. PMID: 34090641\n260.  McLornan D, Sirait T, Hernandez-Boluda J, Czerw T, \nHayden P, Yakoub-Agha I. European wide survey on \nallogeneic haematopoietic cell transplantation prac -\ntice for myelofibrosis on behalf of the EBMT chronic \nmalignancies working party. Current Research in \nTranslational Medicine. 2021 Jan;69(1):103267 . doi: \n10.1016/j.retram.2020.08.003. PMID: 33069640\n261. Carbonell-Sahuquillo S, Lazaro-Carreno M, Ca -\nmacho J, Barres-Fernandez A, Albert E, Torres I, \nBreton-Martinez J, Martinez-Costa C, Navarro D. \nEvaluation of a rapid antigen detection test (Panbio \n(TM) COVID-19 Ag Rapid Test Device) as a point-\nof-care diagnostic tool for COVID-19 in a pediatric \nemergency department. Journal of Medical Viro -\nlogy. 2021 Dec;93(12):6803-6807 . doi: 10. 1002/\njmv.27220. PMID: 34289136\n262.  Torres I, Poujois S, Albert E, Colomina J, Navarro \nD. Evaluation of a rapid antigen test (Panbio CO -VID-19 Ag rapid test device) for SARS-CoV-2 detec -\ntion in asymptomatic close contacts of COVID-19 \npatients. Clinical Microbiology and Infection. \n2021 Apr;27(4):636.e1-636.e4. doi: 10.1016/j.\ncmi.2020.12.022. PMID: 33421573\n263.  Sanchis-Artero L, Martinez-Blanch JF, Manresa-\nVera S, Cortes-Castell E, Valls-Gandia M, Iborra \nM, Paredes-Arquiola JM, Bosca-Watts M, Huguet \nJM, Gil-Borras R, Rodriguez-Morales J, Cortes-\nRizo X. Evaluation of changes in intestinal micro -\nbiota in Crohn\u2019s disease patients after anti-TNF \nalpha treatment. Scientific Reports. 2021 May \n11;11(1):10016. doi: 10.1038/s41598-021-88823-\n2. PMID: 33976272\n264.  Garcia-Molina P, Roig Casasus S, Sanchis-Sanchez \nE, Balaguer-Lopez E, Ruescas-Lopez M, Blasco JM. \nEvaluation of interface pressure and temperatu -\nre management in five wheelchair seat cushions \nand their effects on user satisfaction. Journal \nof Tissue Viability. 2021 Aug;30(3):402-409. doi: \n10.1016/j.jtv.2021.05.004. PMID: 34052087\n265.  Ruiz-Rodriguez P, Frances-Gomez C, Chiner-Oms \nA, Lopez MG, Jimenez-Serrano S, Cancino-Munoz \nI, Ruiz-Hueso P, Torres-Puente M, Bracho MA, \nD\u2019Auria G, Martinez-Priego L, Guerreiro M, Mon -\ntero-Alonso M, Gomez MD, Pinana JL, Gonzalez-\nCandelas F, Comas I, Marina A, Geller R, Coscolla \nM. Evolutionary and phenotypic characterization \nof two spike mutations in european lineage 20E of \nSARS-CoV-2. mBio. 2021 Nov 16;12(6):e0231521. \ndoi: 10. 1 128/mBio.02315-21. PMID: 34781748\n266.  Boluda B, Martinez-Cuadron D, Algarra L, Cano \nI, Sayas M, Acuna-Cruz E, Blanco A, Marco-Ayala \nJ, DeLapuerta R, Diaz-Gonzalez A, Tormo M, Ro -\ndriguez-Veiga R, Garcia R, Pinana J, Lopez-Pavia \nM, Barragan E, Amigo M, Sargas C, Lopez A, \nSolana-Altabella A, Gil C, Megias-Vericat J, Sanz \nM, Montesinos P. Evolving patterns of care and \noutcomes in relapsed/refractory FLT3 mutated \nacute myeloid leukemia adult patients. Leuke -\nmia & Lymphoma. 2021 Nov;62(1 1):2727-2736. \ndoi: 10.1080/10428194.2021.1938031. PMID: \n34121593\n2 67. Martinez-Cuadron D, Serrano J, Gil C, Tormo M, \nMartinez-Sanchez P, Perez-Simon J, Garcia-Boyero \nR, Rodriguez-Medina C, Lopez-Pavia M, Benavente 305\n305\nINCLIVA SCIENTIFIC REPORT 2021publication list 9C, Bergua J, Lavilla-Rubira E, Amigo M, Herrera \nP, Alonso-Dominguez J, Bernal T, Colorado M, Sa -\nyas M, Algarra L, Vidriales M, Rodriguez-Macias \nG, Vives S, Perez-Encinas M, Lopez A, Noriega V, \nGarcia-Fortes M, Ramos F, Rodriguez-Gutierrez \nJ, Costilla-Barriga L, Labrador J, Boluda B, Rodri -\nguez-Veiga R, Martinez-Lopez J, Sanz M, Montesi -\nnos P. Evolving treatment patterns and outcomes \nin older patients (\u226560 years) with AML: changing \neverything to change nothing?. Leukemia. 2021 \nJun;35(6):1571-1585. doi: 10.1038/s41375-020-\n01058-4. PMID: 33077867\n268.  Perandones-Gonzalez H, Dominguez-Santas M, \nFernandez-Domper L, Agud-De D, Boixeda P. Ex \nvivo dermoscopy in demodicosis. Journal of the \nAmerican Academy of Dermatology. 2021 Jul \n27;S0190-9622(21)02180-0. doi: 10. 1016/j.\njaad.2021.07 .031 PMID: 34329644\n269.  Montoro J, Roldan E, Pinana J, Barba P, Chorao P, \nQuintero A, Hernani R, Orti G, Lorenzo J, Balaguer-\nRosello A, Salamero O, Fox L, Solves P, Gomez I, \nGuerreiro M, Boluda J, Sanz G, Solano C, Sanz \nM, Valcarcel D, Sanz J. Ex vivo T-cell depletion vs \npost-transplant cyclophosphamide, sirolimus, and \nmycophenolate mofetil as graft-vs-host disease \nprophylaxis for allogeneic hematopoietic stem \ncell transplantation. European Journal of Hae -\nma t o l o g y.  2021  Ja n;106(1):114 -125.  d o i:  10.1111/\nejh.13529. PMID: 33025625\n270.  Erzin G, Pries L, van Os J, Fusar-Poli L, Delespaul \nP, Kenis G, Luykx J, Lin B, Richards A, Akdede B, \nBinbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, \nCihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak \nS, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Ber -\nnardo M, Mezquida G, Amoretti S, Bobes J, Saiz \nP, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos \nJ, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez \nG, Gonzalez-Penas J, Parellada M, Maric N, Atba -\nsoglu C, Ucok A, Alptekin K, Saka M, Arango C, \nO\u2019Donovan M, Rutten B, Guloksuz S, Genetic Risk \nand Outcome of Psychosis (GROUP) investigators. \nExamining the association between exposome \nscore for schizophrenia and functioning in schi -\nzophrenia, siblings, and healthy controls: results \nfrom the EUGEI study. European Psychiatry. 2021 \nMar 19;64(1):e25. doi: 10. 1 192/j.eurpsy.2021. 19. \nPMID: 33736735271. Dufresne S, Gueritat J, Wong CP, Isanejad A, Ho E, \nSerna E, Gomez-Cabrera MC, Rebillard A. Exerci -\nse training as a modulator of epigenetic events in \nprostate tumors. Prostate Cancer and Prostatic \nDiseases. 2021 May 18. doi: 10. 1038/s41391-\n021-00380-x. PMID: 34007020\n272.  Casquero-Veiga M, Bueno-Fernandez C, Romero-\nMiguel D, Lamanna-Rama N, Nacher J, Desco M, \nSoto-Montenegro M. Exploratory study of the \nlong-term footprint of deep brain stimulation on \nbrain metabolism and neuroplasticity in an animal \nmodel of obesity. Scientific Reports. 2021 Mar \n10;11(1):5580. doi: 10.1038/s41598-021-82987-7. \nPMID: 33692388\n273.  Mas-Bargues C, Alique M, Barrus-Ortiz M, Borras \nC, Rodrigues-Diez R. Exploring new kingdoms: \nthe role of extracellular vesicles in oxi-inflamm-\naging related to cardiorenal syndrome. Antioxi -\ndants. 2021 Dec 29;1 1(1):78. doi: 10.3390/anti -\nox11010078. PMID: 35052582\n274. Monteagudo P, Cordellat A, Roldan A, Gomez-Ca -\nbrera M, Pesce C, Blasco-Lafarga C. Exploring po -\ntential benefits of accumulated multicomponent-\ntraining in non-active older adults: from physical \nfitness to mental health. International Journal \nof Environmental Research and Public Health. \n2021 Sep 13;18(18):9645. doi: 10.3390/ijer -\nph18189645. PMID: 34574570\n275.  Sanz-Alvarez M, Cristobal I, Luque M, Santos A, \nZazo S, Madoz-Gurpide J, Carames C, Chiang C, \nGarcia-Foncillas J, Eroles P, Albanell J, Rojo F. Ex -\npression of phosphorylated BRD4 is markedly as -\nsociated with the activation status of the PP2A \npathway and shows a strong prognostic value in \ntriple negative breast cancer patients. Cancers. \n2021 Mar 12;13(6):1246. doi: 10.3390/can -\ncers13061246. PMID: 33809005\n276.  Algaba A, Guerra I, Ricart E, Iglesias E, Manosa M, \nGisbert J, Guardiola J, Minguez P\u00e9rez M, Castro \nB, de Francisco R, Nos P, Bertoletti F, Mesonero \nF, Barrio J, Dolores Martin-Arranz M, Calvet X, \nGarcia-Lopez S, Sicilia B, Alcain G, Esteve M, Mar -\nquez L, Piqueras M, Jimenez L, Perez-Calle J, Bu -\njanda L, Garcia-Sepulcre M, Fernandez A, Moraleja \nI, Humberto Lorente R, Garcia-Bosch O, Lamban A, \nBlazquez I, Rodriguez E, Huguet J, Lucendo A, Al -306\n306\nINCLIVA SCIENTIFIC REPORT 2021publication list9mela P, Busquets D, Ramirez de la Piscina P, Perez \nM, Domenech E, Bermejo F, Spanish GETECCU Grp, \nENEIDA Project. Extraintestinal manifestations in \npatients with inflammatory bowel disease: study \nbased on the ENEIDA Registry. Digestive Disea -\nses and Sciences. 2021 Jun;66(6):2014-2023. doi: \n10. 1007 /s10620-020-06424-x. PMID: 32671587\n27 7. Rojo-Sanchis J, Soto-Penaloza D, Penarrocha-\nOltra D, Penarrocha-Diago M, Vina-Almunia J. Fa -\ncial alveolar bone thickness and modifying factors \nof anterior maxillary teeth: a systematic review \nand meta-analysis of cone-beam computed to -\nmography studies. BMC Oral Health. 2021 Mar \n22;21(1):143. doi: 10. 1 186/s12903-021-01495-2. \nPMID: 33752651\n278.  Garcia-Escobar E, Valdes S, Soriguer F, Vendrell J, \nUrrutia-Etxebarria I, Maldonado-Araque C, Ortega \nE, Ocon P, Montanya E, Menendez E, Lago-Sampe -\ndro A, Gonzalez-Frutos T, Gomis R, Goday A, Gar -\ncia-Serrano S, Galan-Garcia J, Castell C, Bordiu E, \nBadia R, Aguilera-Venegas G, Girbes J, Gaztambide \nS, Delgado E, Chaves F, Castano L, Calle-Pascual \nA, Rojo-Martinez G, Franch-Nadal J. Fatty liver in -\ndex as a predictor for type 2 diabetes in subjects \nwith normoglycemia in a nationwide cohort study. \nScientific Reports. 2021 Aug 12;1 1(1):16453. doi: \n10. 1038/s41598-021-95546-x. PMID: 34385479\n279.  Salazar J, Page B, Ripoll C. Features, state and \ncontext of narcissism in drug misuse. Subs -\ntance Use & Misuse. 2021;56(1):1 1-24. doi: \n10.1080/10826084.2020.1833923. PMID: \n33100121\n280.  Gonzalez-Timoneda A, Gonzalez-Timoneda M, Cano \nSanchez A, Ruiz Ros V. Female genital mutilation \nconsequences and healthcare received among \nmigrant women: a phenomenological qualitative \nstudy. International Journal of Environmental Re -\nsearch and Public Health. 2021 Jul 5;18(13):7195. \ndoi: 10.3390/ijerph18137195. PMID: 34281134\n281. Moragon S, Di Liello R, Bermejo B, Hernando C, \nOlcina E, Chirivella I, Lluch A, Cejalvo JM, Martinez \nMT. Fertility and breast cancer: a literature review \nof counseling, preservation options and outco -\nmes. Critical Reviews In Oncology/Hematology. \n2021 Aug 27;166:103461. doi: 10. 1016/j.critre -\nvonc.2021. 103461. PMID: 34461268282.  Albert Vicent E, Torres Fink I, Bueno Ferrando F, \nHuntley Pascual D, Molla E, Fernandez-Fuentes \nM, Mart\u00ednez L\u00f3pez M, Poujois Gisbert S, Forqu\u00e9 \nRodr\u00edguez L, Valdivia Piqueres A, Solano De La \nAsunci\u00f3n C, Ferrer Dot J, Colomina Rodr\u00edguez \nF, Navarro Ortega D. Field evaluation of a rapid \nantigen test (Panbio\u2122 COVID-19 Ag Rapid Test \nDevice) for COVID-19 diagnosis in primary health -\ncare centers. Clinical Microbiology and Infection. \n2021 Mar;27(3):472.e7-472.e10. doi: 10.1016/j.\ncmi.2020.11.004. PMID: 33189872\n283.  Dent R, Oliveira M, Isakoff S, Im S, Espie M, Blau \nS, Tan A, Saura C, Wongchenko M, Xu N, Bradley \nD, Reilly S, Mani A, Kim S, LOTUS Investigators. Fi -\nnal results of the double-blind placebo-controlled \nrandomized phase 2 LOTUS trial of first-line ipa -\ntasertib plus paclitaxel for inoperable locally ad -\nvanced/metastatic triple-negative breast cancer. \nBreast Cancer Research and Treatment. 2021 \nSep;189(2):377-386. doi: 10.1007 /s10549-021-\n06143-5. PMID: 34264439\n284.  Pernas S, Villagrasa P, Vivancos A, Scaltriti M, \nRodon J, Burgues O, Nuciforo P, Canes J, Pare L, \nDuenas M, Vidal M, Cejalvo J, Perello A, Llomm -\nbard-Cussac A, Dorca J, Montano A, Pascual T, Oli -\nveira M, Ribas G, Rapado I, Prat A, Ciruelos E. First \nnationwide molecular screening program in Spain \nfor patients with advanced breast cancer: results \nfrom the AGATA SOLTI-1301 Study. Frontiers in \nOncology. 2021 Nov 4;1 1:7441 12. doi: 10.3389/\nfonc.2021.744112. PMID: 34804931\n285.  Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez \nJM, Kondo S, Simonelli M, Cosman R, van der \nWesthuizen A, Atkinson V, Carpentier AF, Lohr \nM, Redman R, Mason W, Cervantes A, Le Rhun \nE, Ochsenreither S, Warren L, Zhao Y, Callies S, \nEstrem ST, Man M, Gandhi L, Avsar E, Melisi D. \nFirst-in-human phase I study of a next-generation, \noral, transforming growth factor-beta receptor \n1 inhibitor, LY3200882 in patients with advan -\nced cancer. Clinical Cancer Research. 2021 Dec \n15;27(24):6666-6676. doi: 10.1158/1078-0432.\nCCR-21-1504. PMID: 34548321\n286.  Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato \nA, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, \nDuran G, Sastre J, Safont M, Ferreiro R, Rivera 307\n307\nINCLIVA SCIENTIFIC REPORT 2021publication list 9F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, \nAlonso-Orduna V, Vieitez J, Yubero A, Aranda E, \nSpanish Cooperative Grp Treatment. First-line \nbiological agents plus chemotherapy in older pa -\ntients with metastatic colorectal cancer: a re -\ntrospective pooled analysis. Drugs & Aging. 2021 \nMar;38(3):219-231. doi: 10.1007 /s40266-021-\n00834-w. PMID: 33615402\n287. Moral R, Monteagudo C, Muriel J, Moreno L, \nPeiro A. Fluorescent in situ hybridization (FISH): \na useful diagnostic tool for childhood conjuncti -\nval melanoma. European Journal of Ophthal -\nmology. 2021 Jul 9:1 120672121 1030775. doi: \n10.1177/11206721211030775.  PMID:  34240653\n288.  Roca-Gines J, Alfaro-Cervello C, Sanchez-Arraez \nJ, Torres-Navarro I, Navarro-Mira MA, Montea -\ngudo C, Botella-Estrada R. Folliculotropic mycosis \nfungoides with flexural eruptive cysts and come -\ndones in a 14-year-old boy. American Journal of \nDermatopathology. 2021 Sep 1;43(9):656-658. \ndoi: 10. 1097 /DAD.0000000000001958. PMID: \n33989213\n289.  Jimenez-Perez I, Gil-Calvo M, Salvador-Palmer \nR, de Anda R, Perez-Soriano P, Priego-Quesada \nJ. Footwear outsole temperature may be more \nrelated to plantar pressure during a prolonged \nrun than foot temperatura. Physiological Measu -\nrement. 2021 Jul 28;42(7). doi: 10. 1088/1361-\n6579/ac0f be. PMID: 34186519\n290.  Dasi C, Fuentes-Dura I, Ruiz J, Navarro M. Four-\nsubtest short-form of the WAIS-IV for assessment \nof patients diagnosed with schizophrenia. Revista \nde Psiquiatria y Salud Mental. 2021;14(3):139-\n147 . doi: 10. 1016/j.rpsmen.2019. 12.003. PMID: \n34362715\n291. Dasi Vivo C, Fuentes Dura I, Ruiz J, Navarro M. Four-\nsubtest short-form of the WAIS-IV for assessment \nof patients diagnosed with schizophrenia. Revista \nde Psiquiatria y Salud Mental. 2021;14(3):139-\n147 . doi: 10. 1016/j.rpsmen.2019. 12.003. PMID: \n34362715\n292.  Sanjuan Arias J, Castro-Martinez X, Garcia Marti \nG, Gonzalez-Fernandez J, Sanz-Requena R, Haro \nJ, Meana J, Marti-Bonmati L, Nacher Rosell\u00f3 J, \nSebastia Ortega N, Gilabert Juan J, Molt\u00f3 Ruiz M. FOXP2 expression and gray matter density in \nthe male brains of patients with schizophrenia. \nBrain Imaging and Behavior. 2021 Jun;15(3):1403-\n141 1. doi: 10. 1007 /s1 1682-020-00339-x. PMID: \n32734433\n293.  Naval E, Cruz Gonzalez M, Giraldos S, Calatayud J, \nJornet M, Lluch I, Meseguer M, Ruiz Cubillan JJ, \nVina J, Tarazona-Santabalbina FJ. COPD-Journal \nof Chronic Obstructive Pulmonary Disease. Frailty \nassessment in a stable COPD cohort: is there a \nCOPD-frail phenotype?. COPD. 2021 Oct;18(5):525-\n532. doi: 10.1080/15412555.2021.1975670. \nPMID: 34503389\n294.  Alabadi B, Civera M, De la Rosa A, Martinez-\nHervas S, Gomez-Cabrera MC, Real JT. Frailty \nis associated with oxidative stress in older pa -\ntients with Type 2 Diabetes. Nutrients. 2021 Nov \n9;13(11):3983. doi: 10.3390/nu13113983. PMID: \n34836238\n295.  Garcia-Blas S, Bonanad C, Fernandez-Cisnal A, \nSastre-Arbona C, Ruescas-Nicolau M, D\u2019Gregorio \nJ, Valero E, Minana G, Palau P, Tarazona-Santa -\nbalbina F, Ros V, Nunez J, Sanchis J. Frailty sca -\nles for prognosis assessment of older adult pa -\ntients after acute myocardial infarction. Journal \nof Clinical Medicine. 2021 Sep 21;10(18):4278. doi: \n10.3390/jcm10184278. PMID: 34575389\n296.  Bellini A, Potschger U, Bernard V, Lapouble E, Bau -\nlande S, Ambros PF, Auger N, Beiske K, Bernkopf \nM, Betts DR, Bhalshankar J, Bown N, de Preter K, \nClement N, Combaret V, Font de Mora J, George \nSL, Jimenez I, Jeison M, Marques B, Martinsson T, \nMazzocco K, Morini M, Muhlethaler-Mottet A, No -\nguera R, Pierron G, Rossing M, Taschner-Mandl S, \nVan Roy N, Vicha A, Chesler L, Balwierz W, Castel \nV, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, \nPopovic-Beck M, Ash S, Delattre O, Valteau-Coua -\nnet D, Tweddle DA, Ladenstein R, Schleiermacher \nG. Frequency and prognostic impact of alk amplifi -\ncations and mutations in the European Neuroblas -\ntoma Study Group (SIOPEN) High-Risk Neuroblas -\ntoma Trial (HR-NBL 1). Journal of Clinical Oncology. \n2021 Oct 20;39(30):3377-3390. doi: 10. 1200/\nJCO.21.00086. PMID: 34115544\n297. Pallardo Calatayud F, Pagano G, Rodriguez Mel -\nguizo L, Gonz\u00e1lez Cabo P, Lyakhovich A, Trifuoggi 308\n308\nINCLIVA SCIENTIFIC REPORT 2021publication list9M. Friedreich Ataxia: current state-of-the-art, and \nfuture prospects for mitochondrial-focused thera -\npies. Translational Research. 2021 Mar;229:135-\n141. doi: 10.1016/j.trsl.2020.08.009. PMID: \n32841735\n298.  Gil-Miravet I, Melchor-Eixea I, Arias-Sandoval E, \nVasquez-Celaya L, Guarque-Chabrera J, Olucha \nBordonau F, Miquel M. From back to front: a \nfunctional model for the cerebellar modulation \nin the establishment of conditioned preferences \nfor cocaine-related cues. Addiction Biology. 2021 \nJan;26(1):e12834. doi: 10.1111/adb.12834. PMID: \n31808992\n299.  Bou G, Canton R, Martinez-Martinez L, Navarro \nOrtega D, Vila J. Fundamentals and implementa -\ntion of microbiological diagnostic stewardship pro -\ngrams. Enfermedades Infecciosas y Microbiologia \nClinica. 2021 May;39(5):248-251. doi: 10. 1016/j.\neimc.2020.02.019. PMID: 32234252\n300.  Soriano-Maldonado C, Lopez-Pineda A, Orozco-\nBeltran D, Quesada JA, Alfonso-Sanchez JL, Pa -\nllares-Carratala V, Navarro-Perez J, Gil-Guillen VF, \nMartin-Moreno JM, Carratala-Munuera C. Gen -\nder differences in the diagnosis of dyslipidemia: \nESCARVAL-GENERO. International Journal of Envi -\nronmental Research and Public Health. 2021 Nov \n25;18(23):12419. doi: 10.3390/ijerph182312419. \nPMID: 34886144\n301.  Biole C, Bianco M, Nunez-Gil IJ, Cerrato E, Spirito \nA, Raposeiras Roubin S, Viana-Llamas MC, Gonza -\nlez A, Castro-Mejia AF, Maroun Eid C, Fernandez-\nPerez C, Uribarri A, Alfonso-Rodriguez E, Ugo F, \nGuerra F, Feltes G, Akin I, Fernandez-Rozas I, Blas -\nco-Angulo N, Huang J, Garcia Aguado M, Pepe M, \nRomero R, Becerra-Munoz VM, Estrada V, Maca -\nya C. Gender differences in the presentation and \noutcomes of hospitalized patients with COVID-19. \nJournal of Hospital Medicine. 2021 Jun;16(6):349-\n352. doi: 10. 12788/jhm.3594. PMID: 34129486\n302.  Carratala-Munuera C, Lopez-Pineda A, Orozco-\nBeltran D, Quesada J, Alfonso-Sanchez J, Pallares-\nCarratala V, Soriano-Maldonado C, Navarro-Perez \nJ, Gil-Guillen V, Martin-Moreno J. Gender inequali -\nties in diagnostic inertia around the three most \nprevalent cardiovascular risk studies: protocol \nfor a population-based cohort study. International Journal of Environmental Research and Public \nHealth. 2021 Apr 12;18(8):4054. doi: 10.3390/\nijerph18084054. PMID: 33921396\n303.  Jabato F, Cordoba-Caballero J, Rojano E, Roma-\nMateo C, Sanz P, Perez B, Gallego D, Seoane \nP, Ranea J, Perkins J. Gene expression analysis \nmethod integration and co-expression module \ndetection applied to rare glucide metabolism di -\nsorders using ExpHunterSuite. Scientific Reports. \n2021 Jul 23;1 1(1):15062. doi: 10. 1038/s41598-\n021-94343-w. PMID: 34301987\n304.  Grau-Perez M, Voruganti V, Balakrishnan P, Haack \nK, Goessler W, Franceschini N, Redon J, Cole S, \nNavas-Acien A, Tellez-Plaza M. Genetic variation \nand urine cadmium levels: ABCC1 effects in the \nStrong Heart Family Study. Environmental Pollu -\ntion. 2021 Feb 1 1;276:1 16717 . doi: 10. 1016/j.env -\npol.2021. 1 16717 . PMID: 33640655\n305.  Alvarez-Larran A, Diaz-Gonzalez A, Such E, Mora E, \nAndrade-Campos M, Garcia-Hernandez C, Gomez-\nCasares M, Garcia-Gutierrez V, Carreno-Tarrago -\nna G, Garrote M, Fernandez-Ibarrondo L, Cervera \nJ, Bellosillo B, Cervantes F, Hernandez-Boluda J, \nMPN Spanish Group (GEMFIN). Genomic characte -\nrization of patients with polycythemia vera develo -\nping resistance to hydroxyurea. Leukemia. 2021 \nFeb;35(2):623-627 . doi: 10.1038/s41375-020-\n0849-2. PMID: 32372025\n306.  Ielpo B, Podda M, Pellino G, Pata E, Caruso R, Gra -\nvante G, Di Saverio S, Moro Valdezate D. Global at -\ntitudes in the management of acute appendicitis \nduring COVID-19 pandemic: ACIE Appy Study. Bri -\ntish Journal of Surgery. 2021 Jun 22;108(6):717-\n726. doi: 10. 1002/bjs. 1 1999. PMID: 34157090\n3 0 7.  Rees M, Bitzer J, Cano A, Ceausu I, Chedraui P, \nDurmusoglu F, Erkkola R, Geukes M, Godfrey A, \nGoulis DG, Griffiths A, Hardy C, Hickey M, Hirsch -\nberg AL, Hunter M, Kiesel L, Jack G, Lopes P, \nMishra G, Oosterhof H, Pines A, Riach K, Shufelt \nC, van Trotsenburg M, Weiss R, Lambrinoudaki \nI. Global consensus recommendations on me -\nnopause in the workplace: a European Meno -\npause and Andropause Society (EMAS) position \nstatement. Maturitas. 2021 Sep;151:55-62. \ndoi: 10.1016/j.maturitas.2021.06.006. PMID: \n34274202309\n309\nINCLIVA SCIENTIFIC REPORT 2021publication list 9308.  Cannon J, Bonifacio J, Bucardo F, Buesa J, Bru -\nggink L, Chan M, Fumian T, Giri S, Gonzalez M, \nHewitt J, Lin J, Mans J, Munoz C, Pan C, Pang X, \nPietsch C, Rahman M, Sakon N, Selvarangan R, \nBrowne H, Barclay L, Vinje J. Global trends in no -\nrovirus genotype distribution among children with \nacute gastroenteritis. Emerging Infectious Disea -\nses. 2021 May;27(5):1438-1445. doi: 10.3201/\neid2705.204756. PMID: 33900173\n309.  GBD 2019 Resp Tract Canc Collab. Global, regio -\nnal, and national burden of respiratory tract can -\ncers and associated risk factors from 1990 to \n2019: a systematic analysis for the Global Burden \nof Disease Study 2019. Lancet Respiratory Me -\ndicine. 2021 Sep;9(9):1030-1049. doi: 10.1016/\nS2213-2600(21)00164-8. PMID: 34411511\n310. GBD 2019 Under-5 Mortality Collaborators. Glo -\nbal, regional, and national progress towards Sus -\ntainable Development Goal 3.2 for neonatal and \nchild health: all-cause and cause-specific mortality \nfindings from the Global Burden of Disease Study \n2019. Lancet. 2021 Sep 4;398(10303):870-905. \ndoi: 10.1016/S0140-6736(21)01207-1. PMID: \n34416195\n311. Arc-Chagnaud C, Salvador-Pascual A, Garcia-Do -\nminguez E, Olaso-Gonzalez G, Correas A, Serna E, \nBrioche T, Chopard A, Fernandez-Marcos P, Serra -\nno M, Serrano A, Munoz-Canoves P, Sebastia V, \nVina J, Carmen Gomez-Cabrera M. Glucose 6-P de -\nhydrogenase delays the onset of frailty by protec -\nting against muscle damage. Journal of Cachexia \nSarcopenia and Muscle. 2021 Dec;12(6):1879-\n1896. doi: 10. 1002/jcsm. 12792. PMID: 34704386\n312. Sampedro F, Roldan A, Alonso-Solis A, Grasa E, \nPortella MJ, Aguilar EJ, Nunez-Marin F, Gomez-An -\nson B, Corripio I. Grey matter microstructural alte -\nrations in schizophrenia patients with treatment-\nresistant auditory verbal hallucinations. Journal \nof Psychiatric Research. 2021 Jun;138:130-138. \ndoi: 10.1016/j.jpsychires.2021.03.037 . PMID: \n33852993\n313. Klionsky D, Abdel-Aziz A, Abdelfatah S, et al. Guidelines \nfor the use and interpretation of assays for monitoring \nautophagy (4th edition). Autophagy. 2021 Jan;17(1):1-\n382. doi: 10.1080/15548627 .2020.1797280. PMID: \n33634751314. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, \nSpadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, \nAsnicar F, Segata N, Klaver C, Brescia P, Rossi E, An -\nselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazo -\nna N, Cervantes A, Marsoni S, Lazzari L, Jodice M, \nGiovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, \nSpinelli A, Pozzi C, Penna G, Rescigno M. Gut vascu -\nlar barrier impairment leads to intestinal bacteria \ndissemination and colorectal cancer metastasis to \nliver. Cancer Cell. 2021 May 10;39(5):708-724.e1 1. \ndoi: 10.1016/j.ccell.2021.03.004. PMID: 33798472\n315. Codina P, Lupon J, Borrellas A, Spitaleri G, Cediel G, \nDomingo M, Simpson J, Levy WC, Santiago-Vacas \nE, Zamora E, Buchaca D, Subirana I, Santesmases \nJ, Diez-Quevedo C, Troya MI, Boldo M, Altmir S, \nAlonso N, Gonzalez B, Rivas C, Nunez J, McMurray \nJ, Bayes-Genis A. Head-to-head comparison of \ncontemporary heart failure risk scores. European \nJournal of Heart Failure. 2021 Dec;23(12):2035-\n2044. doi: 10. 1002/ejhf.2352. PMID: 34558158\n316. Cabellos-Garcia A, Martinez-Sabater A, Diaz-\nHerrera M, Gea-Caballero V, Castro-Sanchez E. \nHealth literacy of patients on oral anticoagulation \ntreatment- individual and social determinants \nand effect on health and treatment outcomes. \nBMC Public Health. 2021 Jul 9;21(1):1363. doi: \n10.1186/s12889-021-11259-w. PMID: 34243749\n317. Lopez A, Alos Almi\u00f1ana M, Peris J. Health outco -\nmes and primary adherence to secondary pre -\nvention treatment after st-elevation myocardial \ninfarction: a spanish cohort study. Journal of \nCardiovascular Translational Research. 2021 \nApr;14(2):308-316. doi: 10.1007/s12265-020-\n10045-0. PMID: 32557320\n318. Tarazona-Santabalbina F, Gonzalez S, Navarro J, \nVina J. Healthcare for older adults, where are \nwe moving towards?. International Journal of En -\nvironmental Research and Public Health. 2021 \nJun 8;18(12):6219. doi: 10.3390/ijerph18126219. \nPMID: 34201289\n319. Jimenez-Ruiz C, Signes-Costa Minana J, Garcia \nRueda M. Healthcare professionals and tobacco \nindustry: making the space. Archivos de Bronco -\nneumologia. 2021 Apr 15;S0300-2896(21)00120-\n4. doi: 10. 1016/j.arbres.2021.04.002. PMID: \n33958233310\n310\nINCLIVA SCIENTIFIC REPORT 2021publication list9320.  Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ci -\nruelos E, Munoz M, Bermejo B, Margeli M, Anton \nA, Casas M, Csoszi T, Murillo L, Morales S, Calvo \nL, Lang I, Alba E, de la Haba-Rodriguez J, Ramos \nM, Lopez I, Gal-Yam E, Garcia-Palomo A, Alvarez E, \nGonzalez-Santiago S, Rodriguez C, Servitja S, Cor -\nsaro M, Rodrigalvarez G, Zielinski C, Martin M. \nHealth-related quality of life with palbociclib plus \nendocrine therapy versus capecitabine in postme -\nnopausal patients with hormone receptor-posi -\ntive metastatic breast cancer: patient-reported \noutcomes in the PEARL study. European Journal \nof Cancer. 2021 Aug 20;156:70-82. doi: 10. 1016/j.\nejca.2021.07 .004. PMID: 34425406\n321. Minana, G, Nunez J. Heart failure with preserved \nejection fraction: an urgent need for precission \nmedicine. Journal of Clinical Medicine. 2021 Apr \n21;10(9):1801. doi: 10.3390/jcm10091801. PMID: \n33918988\n322.  Simonassi F, Ball L, Badenes Quiles R, Millone \nM, Citerio G, Zona G, Pelosi P, Robba C. Hemo -\ndynamic monitoring in patients with subara -\nchnoid hemorrhage: a systematic review and \nmeta-analysis. Journal of Neurosurgical Anesthe -\nsiology. 2021 Oct 1;33(4):285-292. doi: 10. 1097 /\nANA.0000000000000679. PMID: 32011413\n323.  Quintero Garc\u00eda D, Sebasti\u00e1n Cuevas F, Crehu\u00e1 \nGaudiza E. Hepatitis C and beta-thalassemia major \nin children: experience with glecaprevir/pibren -\ntasvir. Revista Espanola de Enfermedades Diges -\ntivas. 2021 Feb;1 13(2):150-151. doi: 10. 17235/\nreed.2020.7092/2020. PMID: 33207896\n324.  NCD Risk Factor Collaboration NCD. Heteroge -\nneous contributions of change in population distri -\nbution of body mass index to change in obesity and \nunderweight. ELife. 2021 Mar 9;10:e60060. doi: \n10.7554/eLife.60060. PMID: 33685583\n325.  Barbui T, Vannucchi A, Alvarez-Larran A, Iurlo A, \nMasciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi \nG, Elli E, Andrade-Campos M, Kabat M, Kiladjian J, \nPalandri F, Benevolo G, Garcia-Gutierrez V, Fox M, \nFoncillas M, Morcillo C, Rumi E, Osorio S, Papado -\npoulos P, Bonifacio M, Cervantes K, Serrano M, \nCarreno-Tarragona G, Sobas M, Lunghi F, Patriar -\nca A, Elorza B, Angona A, Mazo E, Koschmieder S, \nRuggeri M, Cuevas B, Hernandez-Boluda J, Abadia E, Cirici B, Guglielmelli P, Garrote M, Cattaneo D, \nDaffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-\nGarcia N, Bellini M, Betti S, De Stefano V, Harrison \nC, Rambaldi A. High mortality rate in COVID-19 \npatients with myeloproliferative neoplasms after \nabrupt withdrawal of ruxolitinib. Leukemia. 2021 \nFeb;35(2):485-493. doi: 10.1038/s41375-020-\n01107-y. PMID: 33414483\n326.  Mellado-Artigas R, Ferreyro B, Angriman F, Her -\nnandez-Sanz M, Arruti E, Torres A, Villar J, Bro -\nchard L, Ferrando C, COVID-19 Spanish ICU Net -\nwork. High-flow nasal oxygen in patients with \nCOVID-19-associated acute respiratory failure. \nCritical Care. 2021 Feb 1 1;25(1):58. doi: 10. 1 186/\ns13054-021-03469-w. PMID: 33573680\n3 27. Reula A, Pitarch-Fabregat J, Milara J, Cortijo J, \nMata-Roig M, Milian L, Armengot M. High-speed \nvideo microscopy for primary ciliary dyskine -\nsia diagnosis: a study of ciliary motility varia -\ntions with time and temperature. Diagnostics. \n2021 Jul 20;1 1(7):1301. doi: 10.3390/diagnos -\ntics11071301. PMID: 34359383\n328.  Wanden-Berghe C, Virgili Casas N, Cuerda Com -\npes C, et al. Home and Ambulatory Artificial Nu -\ntrition (NADYA) Group report: home parenteral \nnutrition in Spain, 2019. Nutricion Hospitalaria. \n2021 Dec 9;38(6):1304-1309. doi: 10.20960/\nnh.03720. PMID: 34670394\n329.  Mi\u00f1ana Escriva G, Gil Cayuela C, Facila De La Es -\nperanza R, Bod\u00ed Peris V, Valero Picher E, Mollar \nFernandez A, Marco M, Garcia-Ballester T, Zo -\nrio B, Marti-Cervera J, Nu\u00f1ez Benito E, Chorro \nGasc\u00f3 F, Sanchis Fores J, Nu\u00f1ez Villota J. Ho -\nmocysteine and long-term recurrent infarction \nfollowing an acute coronary syndrome. Cardiolo -\ngy Journal. 2021;28(4):598-606. doi: 10.5603/\nCJ.a2020.0170. PMID: 33346372\n330.  Domingo O, Alberto G, Ana Maria C, Jorge N, \nVicente G, Quesada-Rico Jose A, Pomares-\nGomez Francisco J, Adriana L, Concepcion C. \nHospital admissions trends for severe hypo -\nglycemia in diabetes patients in Spain, 2005 to \n2015. Diabetes Research and Clinical Practi -\nce. 2021 Jan;171:108565. doi: 10. 1016/j.dia -\nbres.2020.108565. PMID: 33242511311\n311\nINCLIVA SCIENTIFIC REPORT 2021publication list 9331. Gonzalez M, Urizar E, Urtaran-Laresgoiti M, Nu -\nno-Solinis R, Lazaro-Perez E, Vazquez L, Pascual-\nCascon M, Solano C, Kwon M, Gallego C, Fernan -\ndez-Aviles F. Hospital and outpatient models for \nHematopoietic Stem Cell Transplantation: a sys -\ntematic review of comparative studies for health \noutcomes, experience of care and costs. PLoS \nOne. 2021 Aug 12;16(8):e0254135. doi: 10. 1371/\njournal.pone.0254135. PMID: 34383780\n332.  Sarkis-Onofre R, Catala-Lopez F, Aromataris \nE, Lockwood C. How to properly use the PRIS -\nMA Statement. Systematic Reviews. 2021 Apr \n19;10(1):1 17 . doi: 10. 1 186/s13643-021-01671-z. \nPMID: 33875004\n333.  Binia A, Lavalle L, Chen C, Austin S, Agosti M, Al-\nJashi I, Pereira A, Costeira M, Silva M, Marchini G, \nMartinez-Costa C, Stiris T, Stoicescu S, Vanpee M, \nRakza T, Billeaud C, Picaud J, Domellof M, Adams \nR, Castaneda-Gutierrez E, Sprenger N. Human \nmilk oligosaccharides, infant growth, and adiposity \nover the first 4 months of lactation. Pediatric Re -\nsearch. 2021 Sep;90(3):684-693. doi: 10. 1038/\ns41390-020-01328-y. PMID: 33446921\n334.  Cilla A, Lopez-Garcia G, Collado-Diaz V, Blanch-Ruiz \nMA, Garcia-Llatas G, Barbera R, Martinez-Cuesta \nMA, Real JT, Alvarez A, Martinez-Hervas S. Hyper -\ncholesterolemic patients have higher eryptosis \nand erythrocyte adhesion to human endothelium \nindependently of statin therapy. International Jour -\nnal of Clinical Practice. 2021 Nov;75(1 1):e14771. \nd o i:  10.1111/i j c p.14771.  PMID:  34473881\n335.  Godoy D, Badenes R, Robba C, Cabezas F. Hyper -\nventilation in severe traumatic brain injury has \nsomething changed in the last decade or uncer -\ntainty continues?. A Brief Review. Frontiers in Neu -\nrology. 2021 Mar 1 1;12:573237 . doi: 10.3389/\nfneur.2021.573237. PMID: 33776876\n336.  Gabald\u00f3n-P\u00e9rez A, Marcos-Garc\u00e9s V, Mu\u00f1oz Gil \nJ, Chorro Gasc\u00f3 FJ, Santas E. Hypoplasia of the \nposterior mitral valve leaflet: don\u2019t forget to look \nbeyond the mitral valve. Echocardiography. 2021 \nJan;38(1):142-143. doi: 10. 1 1 1 1/echo. 14910. PMID: \n33107084\n3 37. Adam-Artigues A, Garrido-Cano I, Carbonell-Asins \nJA, Lameirinhas A, Simon S, Ortega-Morillo B, Martinez MT, Hernando C, Constancio V, Burgues \nO, Bermejo B, Henrique R, Lluch A, Jeronimo C, \nEroles P, Cejalvo JM. Identification of a Two-Mi -\ncroRNA signature in plasma as a novel biomarker \nfor very early diagnosis of breast cancer. Can -\ncers. 2021 Jun 7;13(1 1):2848. doi: 10.3390/can -\ncers13112848. PMID: 34200463\n338.  Gomez-Torres F, Estupinan HY, Ruiz-Sauri A. Iden -\ntification to cardiac conduction cells in humans \nand pigs according to their zonal distribution, \nusing histological, immunohistochemical and \nmorphometric study. Research in Veterinary \nScience. 2021 Jun 9;138:137-147 . doi: 10. 1016/j.\nrvsc.2021.06.008. PMID: 34144281\n339.  Jimenez-Labaig P, Pacheco-Barcia V, Cebria A, \nGalvez F, Obispo B, Paez D, Quilez A, Quintanar T, \nRamchandani A, Remon J, Rogado J, Sanchez D, \nSanchez-Canovas M, Sanz-Garcia E, Sesma A, Ta -\nrazona N, Cotes A, Gonzalez E, Bosch-Barrera J, \nFernandez A, Felip E, Vera R, Rodriguez-Lescure \nA, Elez E. Identifying and preventing burnout in \nyoung oncologists, an overwhelming challenge \nin the COVID-19 era: a study of the Spanish So -\nciety of Medical Oncology (SEOM). ESMO Open. \n2021 Jul 26;6(4):100215. doi: 10. 1016/j.es -\nmoop.2021. 100215. PMID: 34325108\n340.  Perez A, Torregrosa I, D\u2019Marco L, Juan I, Terra -\ndez L, Solis M, Moncho F, Carda-Batalla C, Forner \nM, Gorriz J. IgA-dominant infection-associated \nglomerulonephritis following SARS-CoV-2 infec -\ntion. Viruses-Basel. 2021 Mar 31;13(4):587 . doi: \n10.3390/v13040587 . PMID: 33807151\n341. Celaya A, Rodriguez-De la Rosa L, Bermudez-\nMunoz J, Zubeldia J, Roma-Mateo C, Avendano \nC, Pallardo F, Varela-Nieto I. IGF-1 haploinsuffi -\nciency causes age-related chronic cochlear in -\nflammation and increases noise-induced hearing \nloss. Cells. 2021 Jul 3;10(7):1686. doi: 10.3390/\ncells10071686. PMID: 34359856\n342.  Rodriguez Pla M, Dualde Beltran D, Ferrer Albiach \nE. Immune checkpoints inhibitors and SRS/SBRT \nsynergy in metastatic non-small-cell lung cancer \nand melanoma: a systematic review. Interna -\ntional Journal of Molecular Sciences. 2021 Oct \n27;22(21):11621. doi: 10.3390/ijms222111621. \nPMID: 34769050312\n312\nINCLIVA SCIENTIFIC REPORT 2021publication list9343.  Llorens C, Soriano B, Trilla-Fuertes L, Bagan L, \nRamos-Ruiz R, Gamez-Pozo A, Pena C, Bagan J. \nImmune expression profile identification in a group \nof proliferative verrucous leukoplakia patients: a \npre-cancer niche for oral squamous cell carcino -\nma development. Clinical Oral Investigations. 2021 \nMay;25(5):2645-2657. doi: 10.1007/s00784-020-\n03575-z. PMID: 32918120\n344.  Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, \nChic N, Pare L, Pernas S, Munoz M, Oliveira M, Vidal \nM, Llombart-Cussac A, Cortes J, Galvan P, Bermejo \nB, Martinez N, Lopez R, Morales S, Garau I, Manso \nL, Alarcon J, Martinez E, Villagrasa P, Prat A, Nu -\nciforo P. Immune microenvironment characterisa -\ntion and dynamics during anti-HER2-based neoad -\njuvant treatment in HER2-positive breast cancer. \nNPJ Precission Oncology. 2021 Mar 19;5(1):23. doi: \n10.1038/s41698-021-00163-6. PMID: 33742063\n345.  Viana D, Marcos-Garces V, Blas S, Fores J, Romano \nJ, Baena J, Giner M, Suarez N, Chorro F, Fornas F. \nImmunoglobulin G4-related aortitis and severe aor -\ntic valve stenosis treated with transcatheter aortic \nvalve replacement and immunosuppression. Cana -\ndian Journal of Cardiology. 2021 Nov;37(1 1):1873-\n1876. doi: 10. 1016/j.cjca.2021.07 .015. PMID: \n34333027\n346.  Jimenez I, Tazon-Vega B, Abrisqueta P, Nieto JC, \nBobillo S, Palacio-Garcia C, Carabia J, Valdes-Mas \nR, Munuera M, Puigdefabregas L, Parra G, Esteve-\nCodina A, Franco-Jarava C, Iacoboni G, Terol MJ, \nGarcia-Marco JA, Crespo M, Bosch F. Immunolo -\ngical and genetic kinetics from diagnosis to clini -\ncal progression in chronic lymphocytic leukemia. \nBiomarker Research. 2021 May 20;9(1):37 . doi: \n10.1186/s40364-021-00290-z. PMID: 34016160\n3 47. Monferrer E, Sanegre S, Vieco-Marti I, Lopez-Ca -\nrrasco A, Farinas F, Villatoro A, Abanades S, Ma -\nnes S, de la Cruz-merino L, Noguera R, Naranjo T. \nImmunometabolism modulation in therapy. Biome -\ndicines. 2021 Jul 9;9(7):798. doi: 10.3390/biome -\ndicines9070798. PMID: 34356862\n348.  Jimenez-Perez I, Priego-Quesada J, Camacho-\nGarcia A, de Anda R, Perez-Soriano P. Impact \naccelerations during a prolonged run using a \nmicrowavable self-customised foot orthosis. \nSports Biomechanics. 2021 Jun 14:1-14. doi: 10.1080/14763141. 2021.1902553.  P MID :  \n34126852\n349.  Montomoli M, Taco Sanchez O, D\u2019Marco L, Gorriz \nTeruel J. Impact of an article in the social age: is \ntweeting the same as citing?. Nefrologia. 2021 \nJun 29:S0211-6995(21)00108-9. doi: 10.1016/j.\nnefro.2021.02.005. PMID: 34215420\n350.  Marce S, Xicoy B, Garcia O, Cabezon M, Estrada N, \nVelez P, Boque C, Sagues M, Angona A, Teruel-Mon -\ntoya R, Ferrer-Marin F, Amat P, Hernandez-Boluda \nJ, Ibarra M, Anguita E, Cortes M, Fernandez-Ruiz A, \nFontanals S, Zamora L, Grp Espanol Leucemia Mie -\nloide Cron. Impact of BCR-ABL 1 transcript type on \nresponse, treatment-free remission rate and sur -\nvival in chronic myeloid leukemia patients treated \nwith imatinib. Journal of Clinical Medicine. 2021 \nJul 16;10(14):3146. doi: 10.3390/jcm10143146. \nPMID: 34300312\n351. Rodriguez-Larrad A, Manas A, Labayen I, Gonzalez-\nGross M, Espin A, Aznar S, Serrano-Sanchez J, \nVera-Garcia F, Gonzalez-Lamuno D, Ara I, Carras -\nco-Paez L, Castro-Pinero J, Gomez-Cabrera M, \nMarquez S, Tur J, Gusi N, Benito P, Moliner-Urdia -\nles D, Ruiz J, Ortega F, Jimenez-Pavon D, Casajus \nJ, Irazusta J. Impact of COVID-19 confinement on \nphysical activity and sedentary behaviour in Spa -\nnish university students: role of gender. Internatio -\nnal Journal of Environmental Research and Public \nHealth. 2021 Jan 6;18(2):369. doi: 10.3390/ijer -\nph18020369. PMID: 33418907\n352.  Hirschfeld C, Shaw L, Williams M, Lahey R, Villines \nT, Dorbala S, Choi A, Shah N, Bluemke D, Berman \nD, Blankstein R, Ferencik M, Narula J, Winchester \nD, Malkovskiy E, Goebel B, Randazzo M, Lopez-\nMattei J, Parwani P, Vitola J, Cerci R, Better N, \nRaggi P, Lu B, Sergienko V, Sinitsyn V, Kudo T, Nor -\ngaard B, Maurovich-Horvat P, Cohen Y, Pascual \nT, Pynda Y, Dondi M, Paez D, Einstein A, INCAPS-\nCOVID Investigators Grp. Impact of COVID-19 on \ncardiovascular testing in the united states versus \nthe rest of the world. JACC-Cardiovascular Ima -\nging. 2021 Sep;14(9):1787-1799. doi: 10. 1016/j.\njcmg.2021.03.007 . PMID: 34147434\n353.  Esteve-Pastor M, Martin E, Alegre O, Formiga F, \nSanchis J, Lopez-Palop R, Martinez Selles M, Vidan \nM, Bueno H, Diez-Villanueva P, Abu Assi E, Ariza-313\n313\nINCLIVA SCIENTIFIC REPORT 2021publication list 9Sole A, Marin F, Castillo Dominguez J, LONGEVO-\nSCA Registry Investigators. Impact of frailty and \natrial fibrillation in elderly patients with acute co -\nronary syndromes. European Journal of Clinical In -\nvestigation. 2021 May;51(5):e13505. doi: 10. 1 1 1 1/\neci.13505. PMID: 33529346\n354.  Amarenco P, Kim JS, Labreuche J, Charles H, Gi -\nroud M, Lee BC, Lavall\u00e9e PC, Mahagne MH, Me -\nseguer E, Nighoghossian N, Steg PG, Vicaut \u00c9, \nBruckert E, Treat Stroke to Target Investigators. \nImpact of lower versus higher LDL cholesterol \ntargets on cardiovascular events after ischemic \nstroke in patients with diabetes. Diabetes. 2021 \nAug;70(8):1807-1815. doi: 10.2337 /db21-0302. \nPMID: 33980690\n355.  Kotsis V, Martinez F, Trakatelli C, Redon J. Impact \nof obesity in kidney diseases. Nutrients. 2021 Dec \n15;13(12):4482. doi: 10.3390/nu13124482. PMID: \n34960033\n356.  De Luca G, Cercek M, Jensen LO, Bushljetikj O, et al. \nImpact of renin-angiotensin system inhibitors on \nmortality during the COVID Pandemic among STE -\nMI patients undergoing mechanical reperfusion: in -\nsight from an international STEMI registry. Biome -\ndicine & Pharmacotherapy. 2021 Jun;138:1 1 1469. \ndoi: 10. 1016/j.biopha.2021. 1 1 1469. PMID: \n33740523\n3 57. De Luca G, Debel N, Cercek M, et al. Impact of \nSARS-CoV-2 positivity on clinical outcome among \nSTEMI patients undergoing mechanical reperfu -\nsion: insights from the ISACS STEMI COVID 19 re -\ngistry. Atherosclerosis. 2021 Sep;332:48-54. doi: \n10. 1016/j.atherosclerosis.2021.06.926. PMID: \n34391035\n358.  Polverelli N, Mauff K, Kroger N, Robin M, Beelen \nD, Beauvais D, Chevallier P, Mohty M, Passweg J, \nRubio M, Maertens J, Finke J, Bornhauser M, Vr -\nhovac R, Helbig G, Mear J, Castagna L, Remenyi \nP, Angelucci E, Karakasis D, Rifon J, Sirait T, Rus -\nso D, de Wreede L, Czerw T, Hernandez-Boluda J, \nHayden P, McLornan D, Yakoub-Agha I. Impact of \nspleen size and splenectomy on outcomes of allo -\ngeneic hematopoietic cell transplantation for mye -\nlofibrosis: a retrospective analysis by the chronic \nmalignancies working party on behalf of European \nSociety for Blood and Marrow Transplantation (EBMT). American Journal of Hematology. 2021 \nJan;96(1):69-79. doi: 10. 1002/ajh.26020. PMID: \n33064301\n359.  Pla Mart\u00ed V, Martin Arevalo J, Moro Valdezate D, \nGarcia Botello S, Mora Oliver I, Gadea Mateo R, \nC\u00f3zar Lozano C, Esp\u00ed Macias A. Impact of the novel \npowered circular stapler on risk of anastomotic \nleakage in colorectal anastomosis: a propensity \nscore-matched study. Techniques in Coloproc -\ntology. 2021 Mar;25(3):279-284. doi: 10. 1007 /\ns10151-020-02338-y. PMID: 32914268\n360.  Baz-Redon N, Rovira-Amigo S, Paramonov I, Casti -\nllo Corullon S, Cols Roig M, Antolin M, Garcia Arumi \nE, Torrent-Vernetta A, De Mir Messa I, Gartner S, \nIglesias Serrano I, Caballero-Rabasco M, Asensio \nDe La Cruz O, Vizmanos-Lamotte G, Martin De \nVicente C, Martinez-Colls M, Reula Martin A, Es -\ncribano Montaner A, Das\u00ed Fern\u00e1ndez F, Armengot \nCarceller M, Polverino E, Amengual Pieras E, Ama -\nro-Rodriguez R, Garrido-Pontnou M, Tizzano E, Ca -\nmats-Tarruella N, Fernandez-Cancio M, Moreno-\nGaldo A. Implementation of a gene panel for genetic \ndiagnosis of primary ciliary dyskinesia. Archivos de \nBronconeumologia. 2021 Mar;57(3):186-194. doi: \n10.1016/j.arbres.2020.02.010. PMID: 32253119\n361. Garcia-Gimenez J, Mena-Molla S, Tarazona-San -\ntabalbina F, Vina J, Gomez-Cabrera M, Pallardo F. \nImplementing precission medicine in human frail -\nty through epigenetic biomarkers. International \nJournal of Environmental Research and Public \nHealth. 2021 Feb 15;18(4):1883. doi: 10.3390/\nijerph18041883. PMID: 33672064\n362.  Mas-Bargues C, Borras C. Importance of stem cell \nculture conditions for their derived extracellular \nvesicles therapeutic effect. Free Radical Biology & \nMedicine. 2021 May 20;168:16-24. doi: 10. 1016/j.\nfreeradbiomed.2021.03.028. PMID: 33781893\n363.  Padilla M, Coll E, Fernandez-Perez C, Pont T, Ruiz \nA, Perez-Redondo M, Oliver E, Atutxa L, Mancino \nJM, Daga D, Minambres E, Moya J, Vidal B, Due -\nnas-Jurado JM, Mosteiro F, Rodriguez-Salgado A, \nFernandez-Garcia E, Lara R, Hernandez-Marrero \nD, Estebanez B, Rodriguez-Ferrero ML, Barber \nM, Garcia-Lopez F, Andres A, Santiago C, Zapate -\nro A, Badenes R, Carrizosa F, Blanco JJ, Bernal \nJL, Elola FJ, Vidal C, Terron C, Castro  P, Comas J, 314\n314\nINCLIVA SCIENTIFIC REPORT 2021publication list9Dominguez-Gil B. Improved short-term outcomes \nof kidney transplants in controlled donation after \nthe circulatory determination of death with the \nuse of normothermic regional perfusion. American \nJournal of Transplantation. 2021 Nov;21(1 1):3618-\n3628. doi: 10. 1 1 1 1/ajt. 16622. PMID: 33891793\n364.  Rodriguez-Collell J, Mifsut D, Ruiz-Sauri A, Rodri -\nguez-Pino L, Gonzalez-Soler E, Valverde-Navarro \nA. Improving the cementation of the tibial compo -\nnent in knee arthroplasty: a study of four techni -\nques in the cadaver. Bone & Joint Research. 2021 \nAug;10(8):467-473. doi: 10.1302/2046-3758.108.\nBJR-2020-0524.R1. PMID: 34340533\n365.  Martin-Martorell P, Gonzalez-Barrallo I, Gambar -\ndella V, Cejalvo J M, Cervantes A. In the literature: \nApril 2021. ESMO Open. 2021 Apr 19;6(3):1001 16. \ndoi: 10.1016/j.esmoop.2021.100116. PMID: \n33887688\n366.  Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, \nCervantes A. In the literature: August 2021. ESMO \nOpen. 2021 Aug 16;6(5):100247 . doi: 10. 1016/j.es -\nmoop.2021. 100247 . PMID: 34411970\n3 67. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cer -\nvantes A. In the literature: December 2020. ESMO \nOpen. 2021 Jan 4;6(1):100009. doi: 10. 1016/j.es -\nmoop.2020.100009. PMID: 33399075\n368.  Cejalvo J, Gambardella V, Fleitas T, Cervantes \nA. In the literature: February 2021. ESMO Open. \n2021 Feb 24;6(2):100061. doi: 10. 1016/j.es -\nmoop.2021. 100061. PMID: 33639602\n369.  Gambardella V, Candia L, Tapia M, Cejalvo JM, \nCervantes A. In the literature: June 2021. ESMO \nOpen. 2021 Jun;6(3):100186. doi: 10. 1016/j.es -\nmoop.2021. 100186. PMID: 34098228\n370.  Rumiz E, Cubillos A, Vilar J, Garcia P, Berenguer A, \nFacila L, Valero E, Vidal V, Morell S, Nunez J. Inaccu -\nracy of a non-invasive estimation of pulmonary vas -\ncular resistance assessed by cardiovascular mag -\nnetic resonance in heart failure patients. Scientific \nReports. 2021 Aug 16;1 1(1):16597 . doi: 10. 1038/\ns41598-021-95897-5. PMID: 34400680\n371. Perez-Caballero L, Carceller H, Nacher J, Teruel-\nMarti V, Pujades E, Casan-Pastor N, Berrocoso E. \nInduced dipoles and possible modulation of wire -\nless effects in implanted electrodes. Effects of im -planting insulated electrodes on an animal test to \nscreen antidepressant activity. Journal of Clinical \nMedicine. 2021 Sep 4;10(17):4003. doi: 10.3390/\njcm10174003. PMID: 34501451\n372.  Rubio-Del-Campo A, Gozalbo-Rovira R, Moya-\nGonzalvez E, Alberola J, Rodriguez-Diaz J, Yebra \nM. Infant gut microbiota modulation by human \nmilk disaccharides in humanized microbiome \nmice. Gut Microbes. 2021 Jan-Dec;13(1):1-20. \ndoi: 10. 1080/19490976.2021. 1914377 . PMID: \n33938391\n373.  Moya-Gonzalvez E, Rubio-del-Campo A, Rodriguez-\nDiaz J, Yebra M. Infant-gut associated Bifidobacte -\nrium dentium strains utilize the galactose moiety \nand release lacto-N-triose from the human milk \noligosaccharides lacto-N-tetraose and lacto-\nN-neotetraose. Scientific Reports. 2021 Dec \n2;11(1):23328. doi: 10.1038/s41598-021-02741-x. \nPMID: 34857830\n374. Valdivia A, Torres I, Latorre V, Frances-Gomez C, \nAlbert E, Gozalbo-Rovira R, Alcaraz M, Buesa J, \nRodriguez-Diaz J, Geller R, Navarro D. Inference \nof SARS-CoV-2 spike-binding neutralizing antibo -\ndy titers in sera from hospitalized COVID-19 pa -\ntients by using commercial enzyme and chemilu -\nminescent immunoassays. European Journal of \nClinical Microbiology & Infectious Diseases. 2021 \nMar;40(3):485-494. doi: 10. 1007 /s10096-020-\n04128-8. PMID: 33404891\n375.  Jorda A, Aldasoro M, Aldasoro C, Valles S. Inflam -\nmatory chemokines expression variations and \ntheir receptors in APP /PS1 mice. Journal of Al -\nzheimers Disease. 2021;83(3):1051-1060. doi: \n10.3233/ JAD-210489. PMID: 34397415\n376.  Botella Casas G, Cassinello Fernandez N, Pe -\nrez Santiago L, Alfonso Ballester R, Ortega Se -\nrrano J. Influence of carotid anatomy anomaly \nin rescue surgery due to relapse of papillary \nthyroid cancer. Cirugia espa\u00f1ola. 2021 Sep \n7;S0009-739X(21)00256-6. doi: 10. 1016/j.ci -\nresp.2021.08.006. PMID: 34507819\n37 7. Badenes R, Nato Consolato G, Pena JD, Bilotta F. \nInhaled anesthesia in neurosurgery: still a role?. \nBest Practice & Research-Clinical Anaesthe -\nsiology. 2021 Jul;35(2):231-240. doi: 10. 1016/j.\nbpa.2020.10.004. PMID: 34030807315\n315\nINCLIVA SCIENTIFIC REPORT 2021publication list 9378.  Blazquez-Bernal A, Fernandez-Costa JM, Bargiela \nA, Artero R. Inhibition of autophagy rescues mus -\ncle atrophy in a LGMDD2 Drosophila model. FASEB \nJournal. 2021 Oct;35(10):e21914. doi: 10. 1096/\nfj.202100539RR. PMID: 34547132\n379.  Costa R, Bueno F, Gimenez E, Bracho A, Albert E, \nCarretero D, de Michelena P, Martinez-Costa C, \nGonzalez-Candelas F, Navarro D. Initial viral load \nand decay kinetics of SARS-CoV-2 lineage B. 1. 1.7 in \nthe upper respiratory tract of adults and children. \nJournal of Infection. 2021 Oct;83(4):496-522. doi: \n10.1016/j.jinf.2021.08.015. PMID: 34390756\n380.  Redon J, Selma-Soriano E, Cortes R. Insights into \nglomerular filtration and albuminuria. New England \nJournal of Medicine. 2021 Jul 29;385(5):477-478. \ndoi: 10.1056/NEJMc2108129. PMID: 34320301\n381. Zorrilla-Vaca A, Stone A, Ripolles-Melchor J, et al. Ins -\ntitutional factors associated with adherence to en -\nhanced recovery protocols for colorectal surgery: \nsecondary analysis of a multicenter study. Journal \nof Clinical Anesthesia. 2021 Nov;74:1 10378. doi: \n10.1016/j.jclinane.2021.110378. PMID: 34144497\n382.  Morillas C, D\u2019Marco L, Puchades M, Sola-Izquierdo \nE, Gorriz-Zambrano C, Bermudez V, Gorriz J. Insu -\nlin withdrawal in diabetic kidney disease: what are \nwe waiting for?. International Journal of Environ -\nmental Research and Public Health. 2021 May \n18;18(10):5388. doi: 10.3390/ijerph18105388. \nPMID: 34070103\n383.  Corallo D, Zanon C, Pantile M, Tonini G, Zin A, Fran -\ncescato S, Rossi B, Trevisson E, Pinato C, Monferrer \nE, Noguera R, Alino S, Herrero M, Biffi A, Viscardi E, \nAveic S. Integrated CGH/WES analyses advance \nunderstanding of aggressive neuroblastoma evolu -\ntion: a case study. Cells. 2021 Oct 9;10(10):2695. \ndoi: 10.3390/cells10102695. PMID: 34685674\n384.  Villafranca-Faus M, Esteban Vila-Martin M, Este -\nve D, Merino E, Teruel-Sanchis A, Cervera-Ferri A, \nMartinez-Ricos J, Lloret A, Lanuza E, Teruel-Marti \nV. Integrating pheromonal and spatial informa -\ntion in the amygdalo-hippocampal network. Natu -\nre Communications. 2021 Sep 6;12(1):5286. doi: \n10. 1038/s41467-021-25442-5. PMID: 34489431\n385.  Gozalbo-Rovira R, Rubio-Del-Campo A, Santiso-Be -\nllon C, Vila-Vicent S, Buesa J, Delgado S, Molinero N, Margolles A, Yebra M, Collado M, Monedero V, \nRodriguez-Diaz J. Interaction of intestinal bacteria \nwith human rotavirus during infection in children. \nInternational Journal of Molecular Sciences. 2021 \nJan 20;22(3):1010. doi: 10.3390/ijms22031010. \nPMID: 33498321\n386.  Einstein A, Shaw L, Hirschfeld C, Williams M, Villi -\nnes T, Better N, Vitola J, Cerci R, Dorbala S, Raggi \nP, Choi A, Lu B, Sinitsyn V, Sergienko V, Kudo T, Nor -\ngaard B, Maurovich-Horvat P, Campisi R, Milan E, \nLouw L, Allam A, Bhatia M, Malkovskiy E, Goebel B, \nCohen Y, Randazzo M, Narula J, Pascual T, Pynda Y, \nDondi M, Paez D, INCAPS COVID Investigators Grp. \nInternational impact of COVID-19 on the diagnosis \nof heart disease. Journal of the American Colle -\nge of Cardiology. 2021 Jan 19;77(2):173-185. doi: \n10.1016/j.jacc.2020.10.054. PMID: 33446311\n3 87. Van Bockstal M, Francois A, Altinay S, Arnould L, \nBalkenhol M, Broeckx G, Burgues O, Colpaert C, De -\ndeurwaerdere F, Dessauvagie B, Duwel V, Floris G, \nFox S, Gerosa C, Hastir D, Jaffer S, Kurpershoek E, \nLacroix-Triki M, Laka A, Lambein K, MacGrogan G, \nMarchio C, Martinez M, Nofech-Mozes S, Peeters \nD, Ravarino A, Reisenbichler E, Resetkova E, Sana -\nti S, Schelfhout A, Schelfhout V, Shaaban A, Sinke \nR, Stanciu-Pop C, van Deurzen C, van de Vijver K, \nVan Rompuy A, Vincent-Salomon A, Wen H, Wong \nS, Bouzin C, Galant C. Interobserver variability in the \nassessment of stromal tumor-infiltrating lympho -\ncytes (sTILs) in triple-negative invasive breast car -\ncinoma influences the association with pathological \ncomplete response: the IVITA study. Modern Patho -\nlogy. 2021 Dec;34(12):2130-2140. doi: 10. 1038/\ns41379-021-00865-z. PMID: 34218258\n388.  Gallardo F, Bustamante J, Martin C, Garcia A, Feld -\nman S, Pastor F, Orellana M, Rubino P, Quesada \nV. Intra- and extradural anterior clinoidectomy: \nanatomy review and surgical technique step by \nstep. Surgical and Radiologic Anatomy. 2021 \nAug;43(8):1291-1303. doi: 10.1007/s00276-021-\n02681-1. PMID: 33495868\n389.  D\u2019 Gregorio J, Fernandez-Cisnal A, Fores J, Gar -\ncia-Blas S. Intracoronary imaging of a synergy \nmegatron stent fracture in ostial right coro -\nnary artery. Journal of Invasive Cardiology. 2021 \nAug;33(8):E674-E675. PMID: 34338659316\n316\nINCLIVA SCIENTIFIC REPORT 2021publication list9390.  Robba C, Graziano F, Rebora P, Elli F, Giussani C, \nOddo M, Meyfroidt G, Helbok R, Taccone F, Pris -\nco L, Vincent J, Suarez J, Stocchetti N, Citerio G, \nSYNAPSE-ICU Investigators. Intracranial pressure \nmonitoring in patients with acute brain injury in the \nintensive care unit (SYNAPSE-ICU): an international, \nprospective observational cohort study. Lancet \nNeurology. 2021 Jul;20(7):548-558. doi: 10. 1016/\nS1474-4422(21)00138-1. PMID: 34146513\n391. Badenes R, Qeva E, Giordano G, Romero-Garcia N, \nBilotta F. Intranasal insulin administration to pre -\nvent delayed neurocognitive recovery and postope -\nrative neurocognitive disorder: a narrative review. \nInternational Journal of Environmental Research \nand Public Health. 2021 Mar 7;18(5):2681. doi: \n10.3390/ijerph18052681. PMID: 33799976\n392.  Perez Santiago L, Cassinello Fernandez N, Alfonso \nBallester R, Diaz Exposito R, Moscardo Navarro A, \nOrtega Serrano J. Intraoperative scintigraphy with \nportable gamma camera for the localization of in -\nteraortocaval paraganglioma. Clinical Nuclear Me -\ndicine. 2021 Nov 1;46(1 1):e543-e547 . doi: 10. 1097 /\nRLU.0000000000003717 . PMID: 34183502\n393.  Lopez-Carrasco A, Berbegall A, Martin-Vano S, Blan -\nquer-Maceiras M, Castel V, Navarro S, Noguera R. \nIntra-tumour genetic heterogeneity and prognosis \nin high-risk neuroblastoma. Cancers. 2021 Oct \n15;13(20):5173. doi: 10.3390/cancers13205173. \nPMID: 34680323\n394.  Simon C, Campbell A, Gardner DK, Meseguer M, Mi -\nller KA, Montag M, Palermo GD, Cheung S, Keating \nD, Xie P, Rosenwaks Z, Rienzi L, Innocenti F, Cimado -\nmo D, Ubaldi FM, Sakkas D, Tucker MJ, Nel-Themaat \nL. Invitro fertilization and andrology laboratories \nin 2030. Fertility and Sterility. 2021 Jul;1 16(1):2-\n3. doi: 10. 1016/j.fertnstert.2021.05.089. PMID: \n34148585\n395.  Campbell A, Gardner DK, Meseguer M, Miller KA, \nMontag M, Palermo GD, Cheung S, Keating D, Xie \nP, Rosenwaks Z, Rienzi L, Innocenti F, Cimadomo \nD, Ubaldi FM, Sakkas D, Tucker MJ, Nel-Themaat \nL, Simon C. Invitro fertilization and andrology la -\nboratory in 2030: expert visions. Fertility and Ste -\nrility. 2021 Jul;1 16(1):4-12. doi: 10. 1016/j.fertns -\ntert.2021.05.088. PMID: 34148588396.  Gil-Miravet I, Manas-Ojeda A, Ros-Bernal F, Casti -\nllo-Gomez E, Albert-Gasco H, Gundlach A, Olucha-\nBordonau F. Involvement of the nucleus incertus \nand relaxin-3/RXFP3 signaling system in explicit \nand implicit memory. Frontiers in Neuroanatomy. \n2021 Mar 18;15:637922. doi: 10.3389/fna -\nna.2021.637922. PMID: 33867946\n3 97. Maldonado-Araque C, Valdes S, Badia-Guillen R, \nLago-Sampedro A, Colomo N, Garcia-Fuentes E, \nGutierrez-Repiso C, Goday-Arno A, Calle-Pascual \nA, Castano L, Castell C, Delgado Alvarez E, Menen -\ndez Torre E, Franch-Nadal J, Gaztambide S, Girbes \nJ, Chaves Mart\u00ednez F, Soriguer F, Rojo-Martinez G. \nIodine deficiency and mortality in Spanish adults. \nDi@bet.es study. Thyroid. 2021 Jan;31(1):106-1 14. \ndoi: 10.1089/thy.2020.0131. PMID: 32781944\n398.  Palau P, Llacer P, Dominguez E, Tormo J, Zakarne \nR, Mollar A, Martinez A, Minana G, Santas E, Al -\nmenar L, Facila L, de la Espriella R, Nunez E, Man -\nzano L, Bayes-Genis A, Nunez J. Iron deficiency \nand short-term adverse events in patients with \ndecompensated heart failure. Clinical Research \nin Cardiology. 2021 Aug;1 10(8):1292-1298. doi: \n10.1007/s00392-021-01832-z. PMID: 33721056\n399.  Minana G, Bayes-Genis A, Nunez J. Iron deficiency \ntesting and treatment in heart failure: the eyes \nare useless when the mind is blind. European \nJournal of Heart Failure. 2021 Nov;23(1 1):1855-\n1857 . doi: 10. 1002/ejhf.2365. PMID: 34655260\n400.  Cases A, Puchades M, de Sequera P, Quiroga B, \nMartin-Rodriguez L, Gorriz J, Portoles J, en repre -\nsentacion del Grupo de Anemia de la S.E.N. Iron re -\nplacement therapy in the management of anaemia \nin non-dialysis chronic renal failure patients: pers -\npective of the Spanish Nephrology Society Anae -\nmia Group. Nefrologia. 2021;41(2):123-136. doi: \n10.1016/j.nefro.2020.11.003. PMID: 33516607\n401.  Davison B, Senger S, Sama I, Koch G, Mebazaa A, \nDickstein K, Samani N, Metra M, Anker S, Cleland \nJ, Ng L, Mordi I, Zannad F, Filippatos G, Hillege H, \nPonikowski P, van Veldhuisen D, Lang C, van der \nMeer P, Nunez J, Bayes-Genis A, Edwards C, Voors \nA, Cotter G. Is acute heart failure a distinctive di -\nsorder?. An analysis from BIOSTAT-CHF. European \nJournal of Heart Failure. 2021 Jan;23(1):43-57 . \ndoi: 10.1002/ejhf.2077 . PMID: 33340221317\n317\nINCLIVA SCIENTIFIC REPORT 2021publication list 9402.  Bellver G, Buch E, Ripoll F, Adrianzen M, Berme -\njo B, Burgues O, Julve A, Ortega J. Is axillary as -\nsessment of ductal carcinoma in situ of the breast \nnecessary in all cases?. Journal of Surgical Re -\nsearch. 2021 Dec 10;271:145-153. doi: 10. 1016/j.\njss.2021. 10.006. PMID: 34902737\n403.  Fernandez Moreno M, P\u00e9rez Santiago L, Mart\u00ed \nFernandez R, Le\u00f3n Espinoza C, Ortega Serrano \nJ. Is laparoscopic approach still a risk factor for \npost-appendectomy intra-abdominal abscess?. \nThe Journal of Trauma and Acute Care Sur -\ngery. 2021 Jan 1;90(1):163-169. doi: 10. 1097 /\nTA.0000000000002957 . PMID: 33003018\n404.  Valero-Moreno S, Lacomba-Trejo L, Montoya-\nCastilla I, Perez-Marin M. Is mHealth a useful the -\nrapy for improving physical or emotional health \nin adolescents with cystic fibrosis?. A systema -\ntic review. Current Psychology. 2021 Nov 24;1-\n14. doi: 10.1007 /s12144-021-02452-6. PMID: \n34840486\n405.  Lloret A, Esteve D, Lloret MA, Monllor P, Lopez B, \nLeon JL, Cervera-Ferri A. Is oxidative stress the \nlink between cerebral small vessel disease, sleep \ndisruption, and oligodendrocyte dysfunction in the \nonset of Alzheimer\u2019s disease?. Frontiers in Phy -\nsiology. 2021 Aug 25;12:708061. doi: 10.3389/\nfphys.2021.708061. PMID: 34512381\n406.  Luperdi SC, Correa-Ghisays P, Vila-Frances J, Selva-\nVera G, Salazar-Fraile J, Cardoner N, Ruiz-Veguilla \nM, Livianos L, Tabares-Seisdedos R, Balanza-Mar -\ntinez. Is processing speed a valid neurocognitive \nendophenotype in bipolar disorder?. Evidence from \na longitudinal, family study. Journal of Psychiatric \nResearch. 2021 Jul 6;141:241-247 . doi: 10. 1016/j.\njpsychires.2021.07 .008. PMID: 34256275\n4 0 7. Lis-Lopez L, Bauset C, Seco-Cervera M, Cosin-\nRoger J. Is the macrophage phenotype determi -\nnant for fibrosis development? . Biomedicines. \n2021 Nov 23;9(12):1747 . doi: 10.3390/biomedici -\nnes9121747 . PMID: 34944564\n408.  Rios-Navarro C, Daugbouche-Rubio N, Gavara J, \nde Dios E, Perez N, Vila JM, Chorro FJ, Ruiz-Sauri \nA, Bodi V. Ischemia-reperfusion injury to coronary \narteries: comprehensive microscopic study after \nreperfused myocardial infarction. Annals of Ana -tomy. 2021 Nov;238:151785. doi: 10. 1016/j.aa -\nnat.2021.151785. PMID: 34144157\n409.  Carnero-Alcazar M, Maroto-Castellanos L, Her -\nnandez-Vaquero D, Lopez-Menendez J, Hornero \nSos F, Silva-Guisasola J, Cobiella-Carnicer J, Pe -\nrez-Camargo D, Alvarez-de Arcaya M, Campelos-\nFernandez P, Elvira-Martinez C. Isolated aortic \nvalve replacement in Spain: national trends in \nrisks, valve types, and mortality from 1998 to \n2017 . Revista Espanola de Cardiologia (english \nEd.). 2021 Aug;74(8):700-707 . doi: 10. 1016/j.\nrec.2020.06.008. PMID: 32800747\n410. Sastre-Buades A, Ochoa S, Lorente-Rovira E, \nBarajas A, Grasa E, Lopez-Carrilero R, Luen -\ngo A, Ruiz-Delgado I, Cid J, Gonzalez-Higueras F, \nSanchez-Alonso S, Baca-Garcia E, Barrigon M, \nSpanish Metacognition Study Grp. Jumping to \nconclusions and suicidal behavior in depression \nand psychosis. Journal of Psychiatric Research. \n2021 May;137:514-520. doi: 10. 1016/j.jpsychi -\nres.2021.03.024. PMID: 33812324\n411. Tripoli G, Quattrone D, Ferraro L, Gayer-Anderson \nC, Rodriguez V, La Cascia C, La Barbera D, Sarto -\nrio C, Seminerio F, Tarricone I, Berardi D, Szoke A, \nArango C, Tortelli A, Llorca P, de Haan L, Velthorst \nE, Bobes J, Bernardo M, Sanjuan Arias J, Santos \nJ, Arrojo M, Del-Ben C, Menezes P, Selten J, Jo -\nnes P, Jongsma H, Kirkbride J, Lasalvia A, Tosato \nS, Richards A, O\u2019Donovan M, Rutten B, Os J, Mor -\ngan C, Sham P, Murray R, Murray G, Di Forti M, \nEU-GEI WP2 Group. Jumping to conclusions, ge -\nneral intelligence, and psychosis liability: findings \nfrom the multi-centre EU-GEI case-control study. \nPsychological Medicine. 2021 Mar;51(4):623-\n633. doi: 10. 1017 /S003329171900357X. PMID: \n32327005\n412. Godoy D, Badenes R, Pelosi P, Robba C. Ketamine \nin acute phase of severe traumatic brain injury an \nold drug for new uses?. Critical Care. 2021 Jan \n6;25(1):19. doi: 10.1186/s13054-020-03452-x. \nPMID: 33407737\n413. Bover J, Bosch R, Urena P, Trinidad P, Jara A, Go -\nrriz J, Furlano M, Garcia-Trabanino R, Gelpi R, Or -\ntiz A, Restrepo C, Sanchez-Baya M, Arana C, Goi -\ncoechea M, Coll V, Segura J, Gutierrez O, Sanchez \nE, Ferreiro A, Garcia-Maset R. Kidneys also speak 318\n318\nINCLIVA SCIENTIFIC REPORT 2021publication list9Spanish. Nefrologia. 2021;41(2):225-226. doi: \n10.1016/j.nefro.2020.11.002. PMID: 33288346\n414. Corma-Gomez A, Macias J, Tellez F, Morano L, Rivero \nA, Serrano M, Rios MJ, Vera-Mendez FJ, Santos M, \nReal LM, Palacios R, Santos I, Geijo P, Imaz A, Merino \nD, Galindo MJ, Reus-Banuls S, Lopez-Ruz MA, Galera \nC, Pineda JA. Kinetics of emergence of liver com -\nplications in HCV-infected patients and advanced \nfibrosis, with and without HIV-coinfection, after SVR. \nAIDS. 2021 Nov 1;35(13):21 19-2127 . doi: 10. 1097 /\nQAD.0000000000002959. PMID: 34049354\n415. Bueno Ferrando F, Albert Vicent E, Pinana J, Perez \nMartinez A, Ubeda C, Gomez M, Hernandez Boluda \nJ, Gonzalez-Barbera E, Montoro J, Gimenez Quiles \nE, Guerreiro M, Balaguer-Rosello A, Hernani Mora -\nles R, Sanz J, Solano Vercet C, Navarro Ortega D. \nKinetics of Torque Teno virus DNA in stools may \npredict occurrence of acute intestinal graft versus \nhost disease early after allogeneic hematopoietic \nstem cell transplantation. Transplant Infectious \nDisease. 2021 Jun;23(3):e13507 . doi: 10. 1 1 1 1/\ntid.13507 . PMID: 33176050\n416. Est\u00e9banez A, Verd\u00fa-Amor\u00f3s J, Silva E, Velasco R, \nCuesta A, Monteagudo C, Mart\u00edn JM. Kutane und \nsystemische ver\u00e4nderungen mit \u00e4hnlichkeiten zum \nomenn-syndrom bei heterozygoter mutation im \nRAG2-Gen. Journal der Deutschen Dermatologis -\nchen Gesellschaft. 2021 Jun;19(6):906-908. doi: \n10.1111/d d g.14383_ g.  PMID:  34139086\n417. Waijer S, de Vries S, Busch R, Xie D, Gansevoort \nR, Hou F, Gorriz J, Laverman G, De Nicola L, Pas -\ncual J, Provenzano M, Pergola P, Tang S, Wanner C, \nZaoui P, Parving H, de Zeeuw D, Heerspink H. Large \nbetween-patient variability in EGFR decline before \nclinical trial enrollment and impact on atrasentan\u2019s \nefficacy - a post-hoc analysis from the SONAR \nTrial. Journal of the American Society of Nephro -\nlogy. 2021 Nov;32(1 1):2731-2734. doi: 10. 1681/\nASN.2021040498. PMID: 34417318\n418. Puig N, Hernandez MT, Rosinol L, Gonzalez E, de \nArriba F, Oriol A, Gonzalez-Calle V, Escalante F, de \nla Rubia J, Gironella M, Rios R, Garcia-Sanchez R, \nArguinano JM, Alegre A, Martin J, Gutierrez NC, \nCalasanz MJ, Martin ML, Couto MC, Casanova M, \nArnao M, Perez-Persona E, Garzon S, Gonzalez MS, \nMartin-Sanchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortes-Rodriguez M, Paiva \nB, Cedena MT, San-Miguel JF, Lahuerta JJ, Bla -\nde J, Niesvizky R, Mateos MV. Lenalidomide and \ndexamethasone with or without clarithromycin in \npatients with multiple myeloma ineligible for auto -\nlogous transplant: a randomized trial. Blood Can -\ncer Journal. 2021 May 21;1 1(5):101. doi: 10. 1038/\ns41408-021-00490-8. PMID: 34021 1 18\n419. Gonzalez S, Selma-Royo M, Arboleya S, Martinez-\nCosta C, Solis G, Suarez M, Fernandez N, de los \nReyes-Gavilan C, Diaz-Coto S, Martinez-Camblor P, \nCollado M, Gueimonde M. Levels of predominant \nintestinal microorganisms in 1 month-old full-term \nbabies and weight gain during the first year of life. \nNutrients. 2021 Jul 14;13(7):2412. doi: 10.3390/\nnu13072412. PMID: 34371922\n420.  Borras C, Abdelaziz KM, Diaz A, Gambini J, Jove \nM, Lopez-Grueso R, Mas-Bargues C, Monleon D, \nPamplona R, Vina J. Lifelong soya consumption in \nmales does not increase lifespan but increases \nhealth span under a metabolic stress such as \ntype 2 diabetes mellitus. Mechanisms of Ageing \nand Development. 2021 Dec;200:1 1 1596. doi: \n10.1016/j . m a d . 2021.111596.  P MID :  3 4774 60 6\n421. Cervera-Martinez J, Atienza-Carbonell B, Mota JC, \nBobes-Bascaran T, Crespo-Facorro B, Esteban C, \nGarcia-Portilla MP, Gomes-da-Costa S, Gonzalez-\nPinto A, Jaen-Moreno MJ, Sarramea F, Vieta E, \nZorrilla I, Tabares-Seisdedos R, Kapczinski F, De \nBoni RB, Balanza-Martinez V. Lifestyle changes \nand mental health during the COVID-19 pandemic: \na repeated, cross-sectional web survey. Journal of \nAffective Disorders. 2021 Aug 24;295:173-182. \ndoi: 10.1016/j.jad.2021.08.020. PMID: 34469856\n422.  Giner-Murillo M, Atienza-Carbonell B, Cervera-\nMartinez J, Bobes-Bascaran T, Crespo-Facorro B, \nDe Boni R, Esteban C, Garcia-Portilla M, Gomes-\nda-Costa S, Gonzalez-Pinto A, Jaen-Moreno M, \nKapczinski F, Ponce-Mora A, Sarramea F, Tabares-\nSeisdedos R, Vieta E, Zorrilla I, Balanza-Martinez \nV. Lifestyle in undergraduate students and de -\nmographically matched controls during the CO -\nVID-19 pandemic in Spain. International Journal of \nEnvironmental Research and Public Health. 2021 \nJul 31;18(15):8133. doi: 10.3390/ijerph18158133. \nPMID: 34360426319\n319\nINCLIVA SCIENTIFIC REPORT 2021publication list 9423.  Kreutz R, Dobrowolski P, Prejbisz A, Algharably \nEAEH, Bilo G, Creutzig F, Grassi G, Kotsis V, Lovic \nD, Lurbe E, Modesti PA, Pappaccogli M, Parati G, \nPersu A, Polonia J, Rajzer M, de Timary P, Weber T, \nWeisser B, Tsioufis K, Mancia G, Januszewicz A. Li -\nfestyle, psychological, socioeconomic and environ -\nmental factors and their impact on hypertension \nduring the coronavirus disease 2019 pandemic. \nJournal of Hypertension. 2021 Jun 1;39(6):1077-\n1089. doi: 10. 1097 /HJH.0000000000002770. \nPMID: 33395152\n424.  Escudero-Acha P, Leizaola O, Lazaro N, Cordero M, \nCossio A, Ballesteros D, Recena P, Tizon A, Palomo \nM, Misis Del Campo M, Freita S, Duerto J, Mas \nBilbao N, Vidal B, Gonzalez-Romero D, Diaz-Domin -\nguez F, Revuelto J, Blasco M, Domezain M, Pavia-\nPesquera M, Perez Ruiz M, Pobo A, Gomez-Acebo \nI, Gonzalez-Castro A, Grupo de Trabajo ADENI. Limi -\nting ICU admission from emergency services and \nwards. Medicina Clinica. 2021 Dec 10;157(1 1):524-\n529. doi: 10.1016/j.medcli.2020.08.021. PMID: \n33423823\n425.  Mas-Bargues C, Escriv\u00e1 C, Dromant M, Borr\u00e1s C, \nVi\u00f1a J. Lipid peroxidation as measured by chro -\nmatographic determination of malondialdehyde. \nHuman plasma reference values in health and \ndisease. Archives of Biochemistry and Biophy -\nsics. 2021 Sep 30;709:108941. doi: 10. 1016/j.\nabb.2021. 108941. PMID: 34097903\n426.  Goicoechea M, Alvarez V, Segarra A, Polaina M, \nMartin-Reyes G, Robles N, Escudero V, Orellana \nC, Bea Granell S, de Juan-Ribera J, Fernandez \nLucas M, Grana J, Reque J, Sanchez Hernandez \nR, Villamayor S, Gorriz J. Lipid profile of patients \ntreated with evolocumab in Spanish hospital ne -\nphrology units (RETOSS NEFRO). Nefrologia. 2021 \nAug 10;S0211-6995(21)00133-8. doi: 10.1016/j.\nnefro.2021.06.004. PMID: 34389184\n4 27. Corma Gomez A, Macias J, Morano L, Rivero A, \nTellez F, Rios MJ, Santos M, Serrano M, Palacios R, \nMerino D, Real LM, De Los Santos I, Vera Mendez \nFJ, Galindo MJ, Pineda JA. Liver stiffness-based \nstrategies predict absence of variceal bleeding in \ncirrhotic HCV-infected patients with and without \nHIV-coinfection after sustained virological res -\nponse. Clinical Infectious Diseases. 2021 Mar 1;72(5):e96-e102. doi: 10. 1093/cid/ciaa1726. \nPMID:  33211801\n428.  Bueno-Fernandez C, Perez-Rando M, Alcaide J, \nCoviello S, Sandi C, Castillo-Gomez E, Nacher J. \nLong term effects of peripubertal stress on ex -\ncitatory and inhibitory circuits in the prefrontal \ncortex of male and female mice. Neurobiology of \nStress. 2021 Apr 1;14:100322. doi: 10. 1016/j.yns -\ntr.2021.100322. PMID: 33869684\n429.  Gavara Do\u00f1ate J, Rodriguez-Palomares J, Rios Na -\nvarro C, Valente F, Monmeneu J, Lopez-Lereu M, \nFerreira-Gonzalez I, Garcia Del Blanco B, Otaegui I, \nCanoves Femenia J, De Dios Lluch E, P\u00e9rez Sol\u00e9 N, \nRacugno P, Bonanad Lozano C, Mi\u00f1ana Escriva G, \nMarcos Garc\u00e9s V, Barrabes J, Evangelista A, Mora -\ntal D, Bayes-Genis A, Nu\u00f1ez Villota J, Chorro Gasc\u00f3 \nF, Bod\u00ed Peris V. Longitudinal strain in remote non-\ninfarcted myocardium by tissue tracking CMR: cha -\nracterization, dynamics, structural and prognostic \nimplications. International Journal of Cardiovascu -\nlar Imaging. 2021 Jan;37(1):241-253. doi: 10. 1007 /\ns10554-020-01890-w. PMID: 32488452\n430.  Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi \nA, Rossi G, Harrison C, Alvarez-Larran A, Elli E, Ki -\nladjian J, Kabat M, Sanchez A, Palandri F, Andrade-\nCampos M, Vannucchi A, Carreno-Tarragona G, \nPapadopoulos P, Cervantes K, Foncillas M, Fox M, \nSerrano M, Rumi E, Osorio S, Benevolo G, Patriar -\nca A, Elorza B, Garcia-Gutierrez V, Mazo E, Lunghi \nF, Bonifacio M, De Stefano V, Hernandez-Boluda \nJ, Abadia E, Angona A, Cirici B, Ruggeri M, Kosch -\nmieder S, Sobas M, Cuevas B, Cattaneo D, Daffini \nR, Bellini M, Curto-Garcia N, Garrote M, Cavalca \nF, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, \nBetti S, Salmoiraghi S, Rambaldi A. Long-term fo -\nllow-up of recovered MPN patients with COVID-19. \nBlood Cancer Journal. 2021 Jun 16;1 1(6):1 15. doi: \n10. 1038/s41408-021-00509-0. PMID: 34135309\n431. Palomares-Casasus S, Perez-Santiago L, Marti-\nFernandez R, Gimenez-Civera E, Mata-Cano D, \nGarcia-Botello S. Long-term leg ulcers resistant \nto antibiotic therapy. Clinical and Experimental \nDermatology. 2021 Aug;46(6):1 150-1 153. doi: \n10.1111/c e d.14717.  PMID:  34120360\n432.  Garcia-Blas S, Gonzalez D\u2019 Gregorio J, Bonanad C, \nFernandez-Cisnal A, Valero E, Minana G, Mollar A, 320\n320\nINCLIVA SCIENTIFIC REPORT 2021publication list9Nunez J, Sanchis J. Long-term outcome of patients \nwith NSTEMI and nonobstructive coronary arte -\nries by different angiographic subtypes. Revista \nEspanola de Cardiologia. 2021 Nov;74(1 1):919-926. \ndoi: 10.1016/j.rec.2020.10.008. PMID: 33349589\n433.  Rodriguez-Manero M, Jorda P, Hernandez J, Munoz \nC, Grima E, Garcia-Fernandez A, Canadas-Godoy M, \nJimenez-Ramos V, Oloriz T, Basterra N, Calvo D, Pe -\nrez-Alvarez L, Arias M, Exposito V, Aleman A, Diaz-\nInfante E, Guerra-Ramos J, Fernandez-Armenta J, \nArce-Leon A, Sanchez-Gomez J, Sousa P, Garcia-\nBolao I, Baluja A, Campuzano O, Sarquella-Brugada \nG, Martinez-Sande J, Gonzalez-Juanatey J, Gimeno \nJ, Brugada J, Arbelo E. Long-term prognosis of wo -\nmen with Brugada syndrome and electrophysiolo -\ngical study. Heart Rhythm. 2021 May;18(5):664-\n671. doi: 10. 1016/j.hrthm.2020. 12.020. PMID: \n33359877\n434.  Minana G, Nunez J, Marcos-Garces V, Gavara J, \nRios-Navarro C, Bodi V. Long-term prognostic im -\nplications of revascularization in patients with \nknown or suspected chronic coronary syndromes \nwithout ischemia in vasodilator stress cardiovas -\ncular magnetic resonance. International Journal of \nCardiology. 2021 Jul 15;335:15-18. doi: 10. 1016/j.\nijcard.2021.04.037 . PMID: 33895211\n435.  Sanchis J, Bonanad C, Garcia-Blas S, Ruiz V, Fer -\nnandez-Cisnal A, Sastre C, Ruescas A, Valero E, \nGonzalez J, Mollar A, Minana G, Nunez J. Long-\nterm prognostic value of cognitive impairment on \ntop of frailty in older adults after Acute Coronary \nSyndrome. Journal of Clinical Medicine. 2021 Jan \n24;10(3):444. doi: 10.3390/jcm10030444. PMID: \n33498816\n436.  Olea B, Albert E, Torres I, Gozalbo-Rovira R, Car -\nbonell N, Ferreres J, Poujois S, Costa R, Colomina \nJ, Rodriguez J, Blasco M, Navarro D. Lower res -\npiratory tract and plasma SARS-CoV-2 RNA load \nin critically ill adult COVID-19 patients: relationship \nwith biomarkers of disease severity. Journal of In -\nfection. 2021 Sep;83(3):381-412. doi: 10. 1016/j.\njinf.2021.05.036. PMID: 34087349\n4 37. Rahman I, Collado Sanchez A, Davies J, Rzeniewicz \nK, Abukscem S, Joachim J, Hoskins Green H, Ki -\nllock D, Sanz M, Charras G, Parsons M, Ivetic A. L-\nselectin regulates human neutrophil transendothe -lial migration. Journal of Cell Science. 2021 Feb \n8;134(3):jcs250340. doi: 10. 1242/jcs.250340. \nPMID: 33408247\n438.  Domingo M, Lupon J, Girerd N, Conangla L, de An -\ntonio M, Moliner P, Santiago-Vacas E, Codina P, Ce -\ndiel G, Spitaleri G, Gonzalez B, Diaz V, Rivas C, Ve -\nlayos P, Nunez J, Bayes-Genis A. Lung ultrasound \nin outpatients with heart failure: the wet-to-dry \nHF study. ESC Heart Failure. 2021 Dec;8(6):4506-\n4516. doi: 10. 1002/ehf2. 13660. PMID: 34725962\n439.  Garrido P, Paz-Ares L, Majem M, Moran T, Trigo \nJM, Bosch-Barrera J, Garcia-Campelo R, Gonza -\nlez-Larriba JL, Sanchez-Torres JMiguel, Isla D, \nVinolas N, Camps C, Insa A, Juan O, Massuti B, \nParedes A, Artal A, Lopez-Brea M, Palacios J, Felip \nE. LungBEAM: a prospective multicenter study to \nmonitor stage IV NSCLC patients with EGFR mu -\ntations using BEAMing technology. Cancer Medi -\ncine. 2021 Sep;10(17):5878-5888. doi: 10. 1002/\ncam4.4135.PMID: 34296539\n440.  COVIDSurg Collaborative Co-authors. Machine \nlearning risk prediction of mortality for patients un -\ndergoing surgery with perioperative SARS-CoV-2: \nthe COVIDSurg mortality score. British Journal \nof Surgery. 2021 Nov 1 1;108(1 1):1274-1292. doi: \n10.1093/bjs/znab183. PMID: 34227657\n441. Gavara J, Marcos-Garces V, Lopez-Lereu, MP, \nMonmeneu JV, Rios-Navarro C, de Dios E, Perez N, \nMerenciano H, Gabaldon A, Canoves J, Racugno P, \nBonanad C, Minana G, Nunez J, Nunez E, Moratal \nD, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-\nPalomares JF, Ortiz-Perez JT, Bodi V. Magnetic re -\nsonance assessment of left ventricular ejection \nfraction at any time post-infarction for predic -\ntion of subsequent events in a large multicenter \nSTEMI Registry. Journal of Magnetic Resonance \nImaging. 2021 Jun 16. doi: 10. 1002/jmri.27789. \nPMID: 34137478\n442.  Bonanad C, Diez-Villanueva P, Garcia-Blas S, Marti -\nnez-Selles M. Main challenges of electrolyte imba -\nlance in older patients with coronavirus disease \nand risk of QT prolongation. Response. Revista \nEspanola de Cardiologia. 2021 Feb;74(2):199-200. \ndoi: 10.1016/j.recesp.2020.08.014. PMID: \n32982010321\n321\nINCLIVA SCIENTIFIC REPORT 2021publication list 9443.  Suria C, Bosca-Watts MM, Navarro P, Tosca J, \nAnton R, Sanahuja A, Revaliente M, Minguez M. \nManagement of patients with Intestinal Bowel Di -\nsease and COVID-19: a review of current evidence \nand future perspectives. Gastroenterologia y He -\npatologia. 2021 Jun 22;S0210-5705(21)00203-\nX. doi: 10. 1016/j.gastrohep.2021.06.005. PMID: \n34171421\n444.  Russo E, Caretto M, Giannini A, Bitzer J, Cano San -\nchez A, Ceausu I, Chedraui P, Durmusoglu F, Erkko -\nla R, Goulis D, Kiesel L, Lambrinoudaki I, Hirschberg \nA, Lopes P, Pines A, Rees M, van Trotsenburg M, \nSimoncini T. Management of urinary incontinence \nin postmenopausal women: an EMAS clinical guide. \nMaturitas. 2021 Jan;143:223-230. doi: 10. 1016/j.\nmaturitas.2020.09.005. PMID: 33008675\n445.  Selma-Royo M, Garc\u00eda Mantrana I, Calatayud M, Pa -\nrra-Llorca A, Martinez Costa C, Collado M. Mater -\nnal diet during pregnancy and intestinal markers \nare associated with early gut microbiota. Euro -\npean Journal of Nutrition. 2021 Apr;60(3):1429-\n1442. doi: 10. 1007 /s00394-020-02337-7 . PMID: \n32728880\n446.  Cortes-Macias E, Selma-Royo M, Garcia-Mantra -\nna I, Calatayud M, Gonzalez S, Martinez-Costa C, \nCollado M. Maternal diet shapes the breast milk \nmicrobiota composition and diversity: impact of \nmode of delivery and antibiotic exposure. Jour -\nnal of Nutrition. 2021 Feb 1;151(2):330-340. doi: \n10.1093/jn/nxaa310. PMID: 33188413\n4 47. Palau Sampio P, Reese-Petersen A, Dominguez E, \nRam\u00f3n Ferrandis J, Lopez L, Mollar Fernandez A, \nChorro Gasc\u00f3 F, Sanchis Fores J, Nu\u00f1ez Villota J. Ma -\ntrix metalloproteinase-12 cleaved fragment of titin \nas a predictor of functional capacity in patients with \nheart failure and preserved ejection fraction. Scan -\ndinavian Cardiovascular Journal. 2021 Feb;55(1):9-\n14. doi: 10.1080/14017431.2020.1831052. PMID: \n33030056\n448.  Bisbe E, Garcia-Casanovas A, Illa C, et al, MAPBM \nWorking Group. Maturity assessment model \nfor patient blood management to assist hospi -\ntals in improving patients\u2019 safety and outcomes. \nThe MAPBM project. Blood Transfusion. 2021 \nMay;19(3):205-215. doi: 10.2450/2020.0105-20. \nPMID: 32955422449.  Simoes C, Paiva B, Martinez-Cuadron D, Bergua J, \nVives S, Algarra L, Tormo M, Martinez P, Serrano \nJ, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, \nLopez J, Vidriales M, Labrador J, Falantes J, Sa -\nyas M, Ayala R, Martinez-Lopez J, Villar S, Calasanz \nM, Prosper F, San-Miguel J, Sanz M, Montesinos \nP. Measurable residual disease in elderly acute \nmyeloid leukemia: results from the PETHEMA-\nFLUGAZA phase 3 clinical trial. Blood Advances. \n2021 Feb 9;5(3):760-770. doi: 10. 1 182/bloodad -\nvances.2020003195. PMID: 33560390\n450.  Sancho Chinesta J, Bures Sales E, Ferrer Espinosa \nS, Lahosa C\u00f3rdoba C, Signes-Costa Mi\u00f1ana J, Ser -\nvera Pieras E. Mechanical insufflation-exsufflation \nwith oscillations in Amyotrophic Lateral Sclerosis \nwith home ventilation via tracheostomy. Respira -\ntory Care. 2021 Mar;66(3):378-383. doi: 10.4187 /\nrespcare.08145. PMID: 33082217\n451. Martinez Gomez M, L\u00f3pez S\u00e1iz A, Ferrer Gon -\nzalez J, Pin Arboledas G. Meckel\u2019s double di -\nverticulum. About a case. Anales de Pediatria. \n2021 Apr;94(4):268-269. doi: 10. 1016/j.anpe -\ndi.2020.06.012. PMID: 32703582\n452.  Lorenzo-Pouso A, Bagan J, Bagan L, Gandara-Vila \nP, Chamorro-Petronacci C, Castelo-Baz P, Blanco-\nCarrion A, Blanco-Fernandez M, Alvarez-Calderon \nO, Carballo J, Perez-Sayans M. Medication-rela -\nted osteonecrosis of the jaw: a critical narrative \nreview. Journal of Clinical Medicine. 2021 Sep \n24;10(19):4367. doi: 10.3390/jcm10194367. \nPMID: 34640383\n453.  Porcar Saura S, Guillen Climent S, Pinazo Cana -\nles M, Monteagudo C. Melanocytic hyperactiva -\ntion simulating an acral lentiginous melanoma \nin a patient with Parkinson disease treated by \nLevodopa. American Journal of Dermatopatho -\nlogy. 2021 Mar 1;43(3):238-241. doi: 10. 1097 /\nDAD.0000000000001807 . PMID: 33595233\n454.  Garc\u00eda Oriola G, Real Pe\u00f1a L, Pastor Escartin F, \nTalamantes Escriba F. Merkel cell carcinoma spi -\nnal metastases in a immunosuppressed patient: \nclinical case. Neurocirugia. 2021;32(1):44-48. doi: \n10.1016/j.neucir.2020.01.004. PMID: 32234286\n455.  Monferrer E, Vieco-Marti I, Lopez-Carrasco A, Fa -\nrinas F, Abanades S, de la Cruz-Merino L, Noguera 322\n322\nINCLIVA SCIENTIFIC REPORT 2021publication list9R, Alvaro Naranjo T. Metabolic classification and \nintervention opportunities for tumor energy dys -\nfunction. Metabolites. 2021 Apr 23;1 1(5):264. doi: \n10.3390/metabo11050264. PMID: 33922558\n456.  Olmedo P, Rodrigo L, Grau-Perez M, Hilpert M, \nNavas-Acien A, Tellez-Plaza M, Pla A, Gil F. Metal \nexposure and biomarker levels among e-ciga -\nrette users in Spain. Environmental Research. \n2021 Jul 10;202:1 1 1667 . doi: 10. 1016/j.en -\nv r e s.2021.111667.  PMID:  34256077\n4 57. Ruiz-Duque B, Banuls L, Reinoso-Arija R, Carrasco-\nHernandez L, Caballero-Eraso C, Dasi F, Lopez-\nCampos JL. Methodologies for the determination \nof blood Alpha1 antitrypsin levels: a systematic \nreview. Journal of Clinical Medicine. 2021 Oct \n31;10(21):5132. doi: 10.3390/jcm10215132. \nPMID: 34768650\n458.  Yang D, Haemmig S, Zhou H, Perez-Cremades D, \nSun X, Chen L, Li J, Haneo-Mejia J, Yang T, Hollan \nI, Feinberg M. Methotrexate attenuates vascular \ninflammation through an adenosine-microRNA-\ndependent pathway. Elife. 2021 Jan 8;10:e58064. \ndoi: 10.7554/eLife.58064. PMID: 33416495\n459.  Gozalbo-Rovira R, Santiso-Bellon C, Buesa J, Ru -\nbio-del-Campo A, Vila-Vicent S, Munoz C, Yebra \nM, Monedero V, Rodriguez-Diaz J. Microbiota de -\npletion promotes human rotavirus replication in \nan adult mouse model. Biomedicines. 2021 Jul \n20;9(7):846. doi: 10.3390/biomedicines9070846. \nPMID: 34356911\n460.  Morales-Rosello J, Loscalzo G, Garcia-Lopez EM, \nIbanez Cabellos JS, Garcia-Gimenez JL, Canada \nMartinez AJ, Perales Marin A. MicroRNA-185-5p: \na marker of brain-sparing in foetuses with late-\nonset growth restriction. Epigenetics. 2021 Dec \n30;1-12. doi: 10. 1080/15592294.2021.2023271. \nPMID: 34969362\n461. Estal R, Bustos B, Simo G, Farinos J, Navarro I, \nde Miquel V, Sanchez R, Marco V, Ros M, Suela \nS, Estrada R. MicroRNAs expression associated \nwith aggressive clinicopathological features and \npoor prognosis in primary cutaneous melanomas. \nMelanoma Research. 2021 Feb 1;31(1):18-26. \ndoi: 10. 1097 /CMR.0000000000000709. PMID: \n33234848462.  Llacer P, Manzano L, Fernandez C, Moreno M, \nNunez J. Mid-term prognostic implication of \nhospitalized COVID-19 patients with prior heart \nfailure diagnosis. European Journal of Internal \nMedicine. 2021 Jun;88:136-138. doi: 10. 1016/j.\nejim.2021.02.013. PMID: 33676804\n463.  Tarricone I, D\u2019Andrea G, Jongsma H, Tosato S, Ga -\nyer-Anderson C, Stilo S, Suprani F, Iyegbe C, van der \nVen E, Quattrone D, di Forti M, Velthorst E, Rossi \nMenezes P, Arango C, Parellada M, Lasalvia A, La \nCascia C, Ferraro L, Bobes J, Bernardo M, San -\njuan I, Santos J, Arrojo M, Del-Ben C, Tripoli G, Llor -\nca P, de Haan L, Selten J, Tortelli A, Szoke A, Mu -\nratori R, Rutten B, van Os J, Jones P, Kirkbride J, \nBerardi D, Murray R, Morgan C. Migration history \nand risk of psychosis: results from the multina -\ntional EU-GEI study. Psychological Medicine. 2021 \nFeb 10;1-13. doi: 10. 1017 /S003329172000495X. \nPMID: 33563347\n464.  Tarazon E, Bustos B, Estal R, Simo G, Torralba A, \nSimarro J, Suela S, Estrada R. MiR-138-5p sup -\npresses cell growth and migration in melanoma \nby targeting telomerase reverse transcriptase. \nGenes. 2021 Nov 30;12(12):1931. doi: 10.3390/\ngenes12121931. PMID: 34946880\n465.  Becker-Greene D, Li H, Perez-Cremades D, Wu W, \nBestepe F, Ozdemir D, Niosi C, Aydogan C, Orgill D, \nFeinberg M, Icli B. MiR-409-3p targets a MAP4K3-\nZEB1-PLGF signaling axis and controls brown \nadipose tissue angiogenesis and insulin resistan -\nce. Cellular and Molecular Life Sciences. 2021 \nDec;78(23):7663-7679. doi: 10.1007 /s00018-\n021-03960-1. PMID: 34698882\n466.  Pagano G, Pallardo F, Lyakhovich A, Tiano L, Tri -\nfuoggi M. Mitigating the pro-oxidant state and \nmelanogenesis of Retinitis pigmentosa: by coun -\nteracting mitochondrial dysfunction. Cellular and \nMolecular Life Sciences. 2021 Dec;78(23):7491-\n7503. doi: 10. 1007 /s00018-021-04007-1. PMID: \n34718826\n4 67. Gambini J, Gimeno-Mallench L, Olaso-Gonzalez G, \nMastaloudis A, Traber M, Monleon D, Borras C, \nVina J. Moderate red wine consumption increa -\nses the expression of longevity-associated genes \nin controlled human populations and extends \nlifespan in drosophila melanogaster. Antioxi -323\n323\nINCLIVA SCIENTIFIC REPORT 2021publication list 9dants. 2021 Feb 16;10(2):301. doi: 10.3390/anti -\nox10020301. PMID: 33669360\n468.  Gonzalez-Blanch C, Birules I, Pousa E, Barrigon M, \nLopez-Carrilero R, Lorente-Rovira E, Ayesa-Arriola \nR, Setien-Suero E, Barajas A, Grasa E, Ruiz-Delgado I, \nGonzalez-Higueras F, Cid J, Ochoa S. Moderators of \ncognitive insight outcome in metacognitive training \nfor first-episode psychosis. Journal of Psychiatric \nResearch. 2021 Sep;141:104-110. doi: 10.1016/j.\njpsychires.2021.06.040. PMID: 34186271\n469.  Machado-Lopez A, Simon C, Mas A. Molecular \nand cellular insights into the development of ute -\nrine fibroids. International Journal of Molecular \nSciences. 2021 Aug 6;22(16):8483. doi: 10.3390/\nijms22168483. PMID: 34445194\n470.  Gambardella V, Lombardi P, Carbonell-Asins JA, \nTarazona N, Cejalvo JM, Gonzalez-Barrallo I, Mar -\ntin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, \nHernando C, Blasco I, Papaccio F, Martinez-Ciar -\npaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa \nS, Chirivella I, Castillo J, Monton-Bueno JV, Rose -\nllo S, Huerta M, Perez-Fidalgo A, Martin-Marto -\nrell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, \nZuniga-Trejos S, Cervantes A, Roda D. Molecular \nprofiling of advanced solid tumours. The impact \nof experimental molecular-matched therapies on \ncancer patient outcomes in early-phase trials: \nthe MAST study. British Journal of Cancer. 2021 \nOc t;125(9):1261-1269. doi: 10.1038/s41416-021-\n01502-x. PMID: 34493820\n471. Vidal Oliver L, Lopez Montero A, Gil Hernandez I, \nGarcia Ibor F, Vela Bernal S, Duch Samper AM. Moni -\ntoring therapy in anterior necrotizing scleritis with \ninflammation with anterior segment optical cohe -\nrence tomography. European Journal of Ophthal -\nmology. 2021 Dec 6;1 120672121 1065564. doi: \n10.1177/11206721211065564.  PMID:  34866457\n472.  Garcia-Vazquez A, Guillen-Climent S, Silva E, Este -\nbanez A, Ramon Quiles MD. Morpheaform plaques \nand an infiltrated scar: answer. American Journal \nof Dermatopathology. 2021 Aug 1;43(8):595-596. \ndoi: 10. 1097 /DAD.0000000000001810. PMID: \n34276028\n473.  Garcia-Vazquez A, Guillen-Climent S, Silva E, Este -\nbanez A, Ramon Quiles MD. Morpheaform plaques and an infiltrated scar: challenge. American Jour -\nnal of Dermatopathology. 2021 Aug 1;43(8):e89-\ne90. doi: 10. 1097 /DAD.0000000000001811. \nPMID: 34276032\n474. Gomez-Torres F, Ballesteros-Acuna L, Ruiz Sauri \nA. Morphological variations of the conduction sys -\ntem in the atrioventricular zone and its clinical re -\nlationship in different species. Anatomical Scien -\nce International. 2021 Mar;96(2):212-220. doi: \n10. 1007 /s12565-020-00575-7 . PMID: 32997266\n475.  Gomez-Torres F, Estupinan H, Ruiz-Sauri A. Mor -\nphometric analysis of cardiac conduction fibers \nin horses and dogs, a comparative histological \nand immunohistochemical study with findings \nin human hearts. Research in Veterinary Scien -\nce. 2021 Mar;135:200-216. doi: 10. 1016/j.\nrvsc.2021.02.013. PMID: 33618179\n476.  Gomez-Torres F, Ruiz-Sauri A. Morphometric analy -\nsis of the His bundle (atrioventricular fascicle) in \nhumans and other animal species histological and \nimmunohistochemical study. Veterinary Research \nCommunications. 2021 Dec;45(4):319-327 . doi: \n10.1007/s11259-021-09812-4. PMID: 34244914\n47 7. Spitaleri G, Lupon J, Domingo M, Santiago-Vacas \nE, Codina P, Zamora E, Cediel G, Santesmases J, \nDiez-Quevedo C, Troya M, Boldo M, Altmir S, Alon -\nso N, Gonzalez B, Nunez J, Bayes-Genis A. Mortali -\nty trends in an ambulatory multidisciplinary heart \nfailure unit from 2001 to 2018. Scientific Reports. \n2021 Jan 12;1 1(1):732. doi: 10. 1038/s41598-020-\n79926-3. PMID: 33436787\n478.  Capalbo A, Poli M, Rienzi L, Girardi L, Patassini C, \nFabiani M, Cimadomo D, Benini F, Farcomeni A, \nCuzzi J, Rubio C, Albani E, Sacchi L, Vaiarelli A, Fi -\ngliuzzi M, Findikli N, Coban O, Boynukalin FK, Vogel \nI, Hoffmann E, Livi C, Levi-Setti PE, Ubaldi FM, Si -\nmon C. Mosaic human preimplantation embryos \nand their developmental potential in a prospecti -\nve, non-selection clinical trial. American Journal \nof Human Genetics. 2021 Dec 2;108(12):2238-\n2247 . doi: 10. 1016/j.ajhg.2021. 1 1.002. PMID: \n34798051\n479.  Cuesta M, Lecumberri P, Moreno-Izco L, Lopez-\nIlundain J, Ribeiro M, Cabada T, Lorente-Omena -\nca R, de Erausquin G, Garcia Marti G, Sanjuan 324\n324\nINCLIVA SCIENTIFIC REPORT 2021publication list9Arias J, Sanchez-Torres A, Gomez M, Peralta V. \nMotor abnormalities and basal ganglia in first-\nepisode psychosis (FEP). Psychological Medici -\nne. 2021 Jul;51(10):1625-1636. doi: 10.1017/\nS0033291720000343. PMID: 32114994\n480.  Toussaint M, Chatwin M, Goncalves M, Gonzalez-\nBermejo J, Benditt J, McKim D, Sancho J, Hov B, \nSansone V, Prigent H, Carlucci A, Wijkstra P, Ga -\nrabelli B, Escarrabill J, Pinto T, Audag N, Verweij-\nvan den Oudenrijn L, Ogna A, Hughes W, Devaux \nC, Chaulet J, Andersen T, ENMC Respiratory \nTherapy Consortium. Mouthpiece ventilation in \nneuromuscular disorders: narrative review of te -\nchnical issues important for clinical success. Res -\npiratory Medicine. 2021 Mar 24;180:106373. doi: \n10.1016/j.rmed.2021.106373. PMID: 33798870\n481. Milara J, Ballester B, Safont M, Artigues E, Escri -\nva J, Morcillo E, Cortijo J. MUC4 is overexpressed \nin idiopathic pulmonary fibrosis and collaborates \nwith transforming growth factor beta inducing \nfibrotic responses. Mucosal Immunology. 2021 \nMar;14(2):377-388. doi: 10.1038/s41385-020-\n00343-w. PMID: 32887938\n482.  Cordero A, Cid-Alvarez B, Alegria E, Fernandez-Cis -\nnal A, Escribano D, Bautista J, Juskova M, Trillo R, \nBertomeu-Gonzalez V, Ferreiro J. Multicenter and \nall-comers validation of a score to select patients \nfor manual thrombectomy, the DDTA score. Cathe -\nterization and Cardiovascular Interventions. 2021 \nSep;98(3):E342-E350. doi: 10. 1002/ccd.29689. \nPMID: 33829625\n483.  Robba C, Citerio G, Taccone F, Galimberti S, Re -\nbora P, Vargiolu A, Pelosi P, VENTIBRAIN Enlarged \nSteering Comm. Multicentre observational stu -\ndy on practice of ventilation in brain injured pa -\ntients: the VENTIBRAIN study protocol. BMJ Open. \n2021 Aug 1 1;1 1(8):e047100. doi: 10. 1 136/bmjo -\npen-2020-047100. PMID: 34380722\n484.  Soares CB, Dare LR, Lima KR, Lopes LF, Santos A, \nGarcia Dos A, Schimidt HL, Carpes FP, Lloret A, Vina \nJ, Mello-Carpes P. Multicomponent training pre -\nvents memory deficit related to amyloid-beta pro -\ntein-induced neurotoxicity. Journal of Alzheimer\u2019s \nDisease. 2021;83(1):143-154. doi: 10.3233/ JAD-\n210424. PMID: 34275902485.  Rubio T, Felipo V, Tarazona S, Pastorelli R, \nEscudero-Garcia D, Tosca J, Urios A, Conesa \nA, Montoliu C. Multi-omic analysis unveils bio -\nlogical pathways in peripheral immune system \nassociated to minimal hepatic encephalopathy \nappearance in cirrhotic patients. Scientific Re -\nports. 2021 Jan 21;1 1(1):1907 . doi: 10. 1038/\ns41598-020-80941-7 . PMID: 33479266\n486.  Lapena-Rodriguez M, Garces-Albir M, Gadea-\nMateo R, Mata-Cano D, Teruel A, Doracratto \nD, Munoz-Forner E, Ortega-Serrano J, Sabater \nL. Multiple small bowel perforations during the \ntreatment of primary intestinal extranodal na -\ntural killer/T-cell lymphoma, nasal type. British \nJournal of Haematology. 2021 Jun;193(5):e39-\ne42. doi: 10. 1 1 1 1/bjh. 17229. PMID: 33928633\n4 87. Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-\nGarcia J, Vilchez J, Artero R. Musashi-2 contri -\nbutes to myotonic dystrophy muscle dysfunction \nby promoting excessive autophagy through miR-\n7 biogenesis repression. Molecular Therapy-\nNucleic Acids. 2021 Aug 19;25:652-667 . doi: \n10.1016/j.omtn.2021.08.010. PMID: 34589284\n488.  Roman W, Pinheiro H, Pimentel M, Segales J, \nOliveira L, Garcia-Dominguez E, Gomez-Cabrera \nM, Serrano A, Gomes E, Munoz-Canoves P. Mus -\ncle repair after physiological damage relies on \nnuclear migration for cellular reconstruction. \nScience. 2021 Oct 15;374(6565):355-359. doi: \n10.1126/science.abe5620. PMID: 34648328\n489.  Martin I, Villamon E, Abellan R, Calasanz M, \nIrigoyen A, Sanz G, Such E, Mora E, Gutierrez \nM, Collado R, Garcia-Serra R, Vara M, Blanco \nM, Oiartzabal I, Alvarez S, Bernal T, Granada I, \nXicoy B, Jerez A, Calabuig M, Diez R, Gil A, Diez-\nCampelo M, Solano C, Tormo M, Spanish Grp \nMyelodysplastic Syn. Myelodysplastic syndro -\nmes with 20q deletion: incidence, prognostic \nvalue and impact on response to azacitidine of \nASXL 1 chromosomal deletion and genetic mu -\ntations. British Journal of Haematology. 2021 \nAu g;194(4):708-717.  d o i:  10.1111/b j h.17675. \nPMID: 34296432\n490.  Pascual-Gilabert M, Lopez-Castel A, Artero R. \nMyotonic dystrophy type 1 drug development: a \npipeline toward the market. Drug Discovery To -325\n325\nINCLIVA SCIENTIFIC REPORT 2021publication list 9day. 2021 Jul;26(7):1765-1772. doi: 10. 1016/j.dru -\ndis.2021.03.024. PMID: 33798646\n491. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, \nOrtega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, \nMartinez-Manez R. Nanoporous anodic alumina-\nbased sensor for miR-99a-5p detection as an \neffective early breast cancer diagnostic tool. \nACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: \n10.1021/acssensors.0c02222. PMID: 33599490\n492.  Gabaldon-Perez A, de la Espriella R, Merenciano-\nGonzalez H, Santas E, Chorro F. Native mitral valve \nendocarditis complicated with abscess and fistu -\nlas: diagnosis by three-dimensional transesopha -\ngeal echocardiography. Revista Portuguesa de \nCardiologia. 2021 Aug 30:S0870-2551(21)00345-\n0. doi: 10.1016/j.repc.2020.06.023. PMID: \n34474955\n493.  Villarroel-Vicente C, Gutierrez-Palomo S, Ferri J, \nCortes D, Cabedo N. Natural products and ana -\nlogs as preventive agents for metabolic syndrome \nvia peroxisome proliferator-activated receptors: \nan overview. European Journal of Medicinal Che -\nmistry. 2021 Oct 5;221:1 13535. doi: 10. 1016/j.\nejmech.2021.113535. PMID: 33992930\n494.  Salmeron P, Vinado B, Arando M, Alcoceba E, \nRomero B, Menendez B, Bernal S, Idigoras P, \nColomina J, Martin-Saco G, Leal-Negredo A, To -\nrreblanca A, Martinez O, Serra-Pladevall J. Neis -\nseria gonorrhoeae antimicrobial resistance in \nSpain: a prospective multicentre study. The Jour -\nnal of Antimicrobial Chemotherapy. 2021 May \n12;76(6):1523-1531. doi: 10.1093/jac/dkab037 . \nPMID: 33569588\n495.  Pascual T, Oliveira M, Villagrasa P, Ortega V, Pare \nL, Bermejo B, Morales S, Amillano K, Lopez R, Gal -\nvan P, Canes J, Salvador F, Nuciforo P, Rubio IT, \nLlombart-Cussac A, Di Cosimo S, Baselga J, Har -\nbeck N, Prat A, Cortes J. Neoadjuvant eribulin in \nHER2-negative early-stage breast cancer (SOLTI-\n1007-NeoEribulin): a multicenter, two-cohort, \nnon-randomized phase II trial. NPJ Breast Cancer. \n2021 Nov 25;7(1):145. doi: 10. 1038/s41523-021-\n00351-4. PMID: 34824288\n496.  Sargas C, Ayala R, Chillon M, Larrayoz M, Carri -\nllo-Cruz E, Bilbao C, Yebenes-Ramirez M, Llop M, Rapado I, Garcia-Sanz R, Vazquez I, Soria E, Flori -\ndo-Ortega Y, Janusz K, Botella C, Serrano J, Marti -\nnez-Cuadron D, Bergua J, Amigo M, Martinez-San -\nchez P, Tormo Diaz M, Bernal T, Herrera-Puente \nP, Garcia R, Algarra L, Sayas M, Costilla-Barriga \nL, Perez-Santolalla E, Marchante I, Lavilla-Rubira E, \nNoriega V, Alonso-Dominguez J, Sanz M, Sanchez-\nGarcia J, Gomez-Casares M, Perez-Simon J, Ca -\nlasanz M, Gonzalez-Diaz M, Martinez-Lopez J, Ba -\nrragan E, Montesinos P. Networking for advanced \nmolecular diagnosis in acute myeloid leukemia pa -\ntients is possible: the PETHEMA NGS-AML Project. \nHaematologica. 2021 Dec 1;106(12):3079-3089. \ndoi: 10.3324/haematol.2020.263806. PMID: \n33179471\n4 97. Machado I, Navarro S, Lopez-Guerrero J, Verdini L, \nPicci P, Giner F, Llombart-Bosch A. Neuroendocri -\nne differentiation in a large series of genetically-\nconfirmed Ewing\u2019s sarcoma family tumor: does it \nprovide any diagnostic or prognostic information?. \nPathology, Research and Practice. 2021 Feb \n6;219:153362. doi: 10.1016/j.prp.2021.153362. \nPMID: 33610950\n498.  Soldevila-Matias P, Schoretsanitis G, Tordesillas-\nGutierrez D, Cuesta M, de Filippis R, Ayesa-Arriola \nR, Gonzalez-Vivas C, Setien-Suero E, Verdolini N, \nSanjuan J, Radua J, Crespo-Facorro B. Neuroi -\nmaging correlates of insight in non-affective \npsychosis: a systematic review and meta-analy -\nsis. Revista de Psiquiatria y Salud Mental. 2021 \nJul 13:S1888-9891(21)00067-7 . doi: 10. 1016/j.\nrpsm.2021.07.001. PMID: 34271162\n499.  Belvis R, Irimia P, Seijo-Fernandez F, Paz J, Garcia \nMarch G, Santos-Lasaosa S, Latorre G, Gonzalez-\nOria C, Rodriguez R, Pozo-Rosich P, Lainez Andr\u00e9s \nJ. Neuromodulation in headache and craniofacial \nneuralgia: guidelines from the Spanish Society of \nNeurology and the Spanish Society of Neurosur -\ngery. Neurologia. 2021;36(1):61-79. doi: 10. 1016/j.\nnrl.2020.04.022. PMID: 32718873\n500.  Serrano A, Diaz-Cambronero O, Melchor-Ripo -\nlles J, Abad-Gurumeta A, Ramirez-Rodriguez J, \nMartinez-Ubieto J, Sanchez-Merchante M, Rodri -\nguez R, Jorda L, Gil-Trujillo S, Cabellos-Olivares M, \nBordonaba-Bosque D, Aldecoa C, POWER Group. \nNeuromuscular blockade management and posto -326\n326\nINCLIVA SCIENTIFIC REPORT 2021publication list9506.  Simon C. Noninvasive preimplantation genetic \ntesting for aneuploidy in spent blastocyst media \nwill substitute for trophectoderm biopsy. Fertility \nand Sterility. 2021 Apr;1 15(4):840. doi: 10. 1016/j.\nfertnstert.2021.02.046. PMID: 33726897\n5 0 7. Rubio C, Racowsky C, Barad D, Scott R, Simon C. \nNoninvasive preimplantation genetic testing for \naneuploidy in spent culture medium as a substitu -\nte for trophectoderm biopsy. Fertility and Sterility. \n2021 Apr;1 15(4):841-849. doi: 10. 1016/j.fertns -\ntert.2021.02.045. PMID: 33741125\n508.  Rubio C, Simon C. Noninvasive preimplantation \ngenetic testing for aneuploidy: is the glass half-\nempty or half-full?. Fertility and Sterility. 2021 \nJun;115(6):1426-1427. doi: 10.1016/j.fer tns -\ntert.2021.04.002. PMID: 34053511\n509.  Bertaina M, Nunez-Gil I, Franchin L, Rozas I, \nArroyo-Espliguero R, Viana-Llamas M, Romero \nR, Eid C, Uribarri A, Becerra-Munoz V, Huang J, \nAlfonso E, Marmol-Mosquera F, Ugo F, Cerrato \nE, Fernandez-Presa L, Roubin S, Guzman G, Gon -\nzalez A, Abumayyaleh M, Fernandez-Ortiz A, Ma -\ncaya C, Estrada V, Hope COVID-19 Investigators. \nNon-invasive ventilation for SARS-CoV-2 acute \nrespiratory failure: a subanalysis from the HOPE \nCOVID-19 registry. Emergency Medicine Journal. \n2021 May;38(5):359-365. doi: 10.1136/emer -\nmed-2020-21041 1. PMID: 33727235\n510. Cases A, Gomez P, Broseta J, Bernat E, Barrio -\nnuevo J, Portoles J, Gorriz J. Non-valvular atrial \nfibrillation in CKD: role of vitamin K antagonists \nand direct oral anticoagulants. A narrative review. \nFrontiers in Medicine. 2021 Sep 17;8:654620. doi: \n10.3389/fmed.2021.654620. PMID: 34604247\n511. Breton-Martinez J, Alcolea A, Quintero-Garcia D, \nMendez-Echevarria A, Ramos E, Bueno F, Colo -\nmina J, Mari-Lopez J, Crehua-Gaudiza E, Garcia-\nRodriguez J, Martinez-Costa C. Non-wild-type \ncryptococcosis in a child with multivisceral or -\ngan transplant who owned bird pets. Transplant \nInfectious Disease. 2021 Jun;23(3):e13558. doi: \n10.1111/tid.13558. PMID: 33386674\n512. Bove M, Monto F, Guillem-Llobat P, Ivorra M, No -\nguera M, Zambrano A, Sirerol-Piquer M, Requena \nA, Garcia-Alonso M, Tejerina T, Real J, Farinas I, perative outcomes in enhanced recovery colorec -\ntal surgery: secondary analysis of POWER trial. \nMinerva Anestesiologica. 2021 Jan;87(1):13-25. \ndoi: 10.23736/S0375-9393.20. 14589-9. PMID: \n33538417\n501. Mart\u00ednez-Chac\u00f3n G, Paredes-Barquero M, Yakhine-\nDiop SMS, Uribe-Carretero E, Bargiela A, Sabater-\nArcis M, Morales-Garc\u00eda J, Alarc\u00f3n-Gil J, Alegre-\nCort\u00e9s E, Canales-Cort\u00e9s S, Rodr\u00edguez-Arribas M, \nCamello PJ, Pedro JMB, Perez-Castillo A, Artero \nR, Gonzalez-Polo RA, Fuentes JM, Niso-Santano M. \nNeuroprotective properties of queen bee acid by \nautophagy induction. Cell Biology and Toxicology. \n2021 Aug 27 . doi: 10. 1007 /s10565-021-09625-w. \nPMID: 34448959\n502.  Reula A, Pellicer D, Castillo S, Magallon M, Armen -\ngot M, Herrera G, O\u2019Connor J, Banuls L, Navarro-\nGarcia M, Escribano A, Dasi F. New laboratory \nprotocol to determine the oxidative stress profi -\nle of human nasal epithelial cells using flow cyto -\nmetry. Journal of Clinical Medicine. 2021 Mar \n1 1;10(6):1 172. doi: 10.3390/jcm10061 172. PMID: \n33799667\n503.  Lopez-Lopez V, Gomez-Perez B, de Vicente E, Ji -\nmenez-Galanes S, Mora-Oliver I, Sabater L, Huber \nT, Lang H, Brusadin R, Lopez Conesa A, Melendez \nR, Castro Santiago MJ, Ferreras D, Crespo MJ, \nCayuela V, Robles-Campos R. Next-generation \nthree-dimensional modelling software for perso -\nnalized surgery decision-making in perihilar cholan -\ngiocarcinoma: multicentre study. British Journal \nof Surgery. 2021 Dec 1;108(12):e394-e395. doi: \n10.1093/bjs/znab320. PMID: 34542590\n504.  Vallejo L, Zapater-Fajari M, Montoliu T, Puig-Perez \nS, Nacher J, Hidalgo V, Salvador A. No effects of \nacute psychosocial stress on working memory \nin older people with type 2 Diabetes. Frontiers in \nPsychology. 2021 Jan 7;1 1:596584. doi: 10.3389/\nfpsyg.2020.596584. PMID: 33584433\n505.  Moya-Herraiz AA, Dorcaratto D, Martin-Perez E, Es -\ncrig-Sos J, Poves-Prim I, Fabregat-Prous J, Larrea Y \nOlea J, Sanchez-Bueno F, Botello-Martinez F, Sabater \nL. Non-arbitrary minimum threshold of yearly per -\nformed pancreatoduodenectomies: national multi -\ncentric study. Surgery. 2021 Sep;170(3):910-916. \ndoi: 10.1016/j.surg.2021.03.012. PMID: 33875253327\n327\nINCLIVA SCIENTIFIC REPORT 2021publication list 9of Artificial Organs. 2021 Dec;44(12):998-1012. \ndoi: 10.1177 /03913988211008912. PMID: \n33863248\n519. Giordano A, Gonzalez A, Ceballos F, Carretero-\nRibon C, Aicart-Ramos M, Valenzuela J, Alonso-\nLazaro N, Luis Martin-Lorente J, Galvez Castullo C, \nPons-Beltran V, Fernandez-Urien I, Gonzalez-Sua -\nrez B, SEED group of capsule endoscopy and ente -\nroscopy. Oral ingestion versus endoscopic delivery \nof Endoscopic Capsule in patients with previous \ngastrointestinal surgery (ORENCES study): a Spa -\nnish multicentre observational study. Gastroente -\nrologia y Hepatologia. 2021 Dec;44(10):680-686. \ndoi: 10.1016/j.gastrohep.2020.11.005. PMID: \n33259828\n520.  Herreros-Pomares A, Llorens C, Soriano B, Zhang \nF, Gallach S, Bagan L, Murillo J, Jantus-Lewintre \nE, Bagan J. Oral microbiome in proliferative ve -\nrrucous leukoplakia exhibits loss of diversity and \nenrichment of pathogens. Oral Oncology. 2021 \nSep;120:105404. doi: 10.1016/j.oraloncolo -\ngy.2021.105404. PMID: 34225130\n521. Hernando C, Ortega-Morillo B, Tapia M, Moragon \nS, Martinez M, Eroles P, Garrido-Cano I, Adam-Ar -\ntigues A, Lluch A, Bermejo B, Cejalvo J. Oral Selec -\ntive Estrogen Receptor Degraders (SERDs) as a \nnovel breast cancer therapy: present and future \nfrom a clinical perspective. International Journal \nof Molecular Sciences. 2021 Jul 22;22(15):7812. \ndoi: 10.3390/ijms22157812. PMID: 34360578\n522.  Collado A, Domingo E, Marques P, Perello E, Mar -\nt\u00ednez-Herv\u00e1s S, Piqueras L, Ascaso JF, Real JT, \nSanz MJ. Oral unsaturated fat load impairs post -\nprandial systemic inflammation in primary hyper -\ncholesterolemia patients. Frontiers in Pharma -\ncology. 2021 Apr 20;12:656244. doi: 10.3389/\nfphar.2021.656244. PMID: 33959024\n523.  Ferrando E, Navarro J, Rojas R, Mata D, Silvestre \nA. Osteosarcoma of the trapezium. Journal of \nHand Surgery. 2021 Aug;46(8):717 .e1-717 .e5. doi: \n10.1016/j.jhsa.2020.10.011. PMID: 33277099\n524.  Oddo M, Taccone F, Galimberti S, Rebora P, Citerio \nG, Orange Study Group. Outcome prognostication \nof acute brain injury using the neurological pupil \nindex (ORANGE) study: protocol for a prospective, D\u2019Ocon P. NT3/TrkC pathway modulates the ex -\npression of ucp-1 and adipocyte size in human \nand rodent adipose tissue. Frontiers in Endocri -\nnology. 2021 Mar 18;12:630097 . doi: 10.3389/\nfendo.2021.630097 . PMID: 33815288\n513. Bellver J, Marin C, Lathi RB, Murugappan G, La -\nbarta E, Vidal C, Giles J, Cabanillas S, Marzal A, Ga -\nlliano D, Ruiz-Alonso M, Simon C, Valbuena D. Obe -\nsity affects endometrial receptivity by displacing \nthe window of implantation. Reproductive Scien -\nces. 2021 Nov;28(1 1):3171-3180. doi: 10. 1007 /\ns43032-021-00631-1. PMID: 34033112\n514. Drozdz D, Alvarez-Pitti J, Wojcik M, Borghi C, Gab -\nbianelli R, Mazur A, Herceg-Cavrak V, Gonzalez \nLopez-Valcarcel B, Brzezinski M, Lurbe E, Wuehl \nE. Obesity and cardiometabolic risk factors: from \nchildhood to adulthood. Nutrients. 2021 Nov \n22;13(1 1):4176. doi: 10.3390/nu131 14176. PMID: \n34836431\n515. Stabouli S, Erdine S, Suurorg L, Jankauskiene \nA, Lurbe E. Obesity and eating disorders in chil -\ndren and adolescents: the bidirectional link. Nu -\ntrients. 2021 Nov 29;13(12):4321. doi: 10.3390/\nnu13124321. PMID: 34959873\n516. Perez-Fidalgo J, Cortes A, Guerra E, Garcia Y, Igle -\nsias M, Bohn Sarmiento U, Calvo Garcia E, Manso \nSanchez L, Santaballa A, Oaknin A, Redondo A, Ru -\nbio M, Gonzalez-Martin A. Olaparib in combination \nwith pegylated liposomal doxorubicin for platinum-\nresistant ovarian cancer regardless of BRCA sta -\ntus: a GEICO phaseII trial (ROLANDO study). ESMO \nOpen. 2021 Jul 27;6(4):100212. doi: 10. 1016/j.es -\nmoop.2021. 100212. PMID: 34329939\n517. Pizza F, D\u2019Antonio D, Asins J, Lucido F, Tolone S, \nDocimo L, Dell\u2019Isola C, Gambardella C. One anas -\ntomosis gastric bypass after sleeve gastrectomy \nfailure: does a single procedure fit for all?. Obesity \nSurgery. 2021 Apr;31(4):1722-1732. doi: 10. 1007 /\ns11695-020-05191-y. PMID: 33393001\n518. Milian L, Sancho-Tello M, Roig-Soriano J, Foschini \nG, Martinez-Hernandez NJ, Mas-Estelles J, Ruiz-\nSauri A, Zurriaga J, Carda C, Mata M. Optimiza -\ntion of a decellularization protocol of porcine \ntracheas. Long-term effects of cryopreserva -\ntion. A histological study. International Journal 328\n328\nINCLIVA SCIENTIFIC REPORT 2021publication list9529.  Hidalgo-Mora J, Tarin J, Cano A. Ovarian ste -\nroids and cancer: news on the breast, ques -\ntions on the reproductive tract. Gynecological \nEndocrinology. 2021 May;37(5):383-384. doi: \n10.1080/09513590.2021.1904871. PMID: \n33825589\n530.  de Dios E, Rios-Navarro C, Perez-Sole N, Gavara \nJ, Marcos-Garces V, Forteza M, Oltra R, Vila J, \nChorro F, Bodi V. Overexpression of genes invol -\nved in lymphocyte activation and regulation are \nassociated with reduced CRM-derived cardiac re -\nmodelling after STEMI. International Immunophar -\nmacology. 2021 Mar 4;95:107490. doi: 10. 1016/j.\nintimp.2021.107490. PMID: 33677257\n531. De la Rosa A, Gomez-Cabrera M, Vinue A, Gonza -\nlez-Navarro H, Sanchez-Andres J, Vina J. Overex -\npression of glucose 6 phosphate dehydrogenase \npreserves mouse pancreatic beta cells function \nuntil late in life. Free Radical Biology & Medicine. \n2021 Feb 20;164:149-153. doi: 10. 1016/j.freerad -\nbiomed.2020. 12.439. PMID: 33418115\n532.  Loscalzo G, Scheel J, Iba\u00f1ez-Cabellos JS, Garc\u00eda-\nLopez E, Gupta S, Garc\u00eda-Gimenez JL, Mena-Moll\u00e1 \nS, Perales-Mar\u00edn A, Morales-Rosell\u00f3 J. Overex -\npression of microRNAs miR-25-3p, miR-185-5p \nand miR-132-3p in late onset fetal growth restric -\ntion, validation of results and study of the bioche -\nmical pathways involved. International Journal of \nMolecular Sciences. 2021 Dec 28;23(1):293. doi: \n10.3390/ijms23010293. PMID: 35008715\n533.  Magallon M, Carrion A, Banuls L, Pellicer D, Cas -\ntillo S, Bondia S, Navarro-Garcia M, Gonzalez C, \nDasi F. Oxidative stress and endoplasmic reticu -\nlum stress in rare respiratory diseases. Journal \nof Clinical Medicine. 2021 Mar 18;10(6):1268. doi: \n10.3390/jcm10061268. PMID: 33803835\n534.  Roma-Mateo C, Garcia-Gimenez J. Oxidative \nstress and rare diseases: from molecular crossro -\nads to therapeutic avenues. Antioxidants. 2021 \nApr 16;10(4):617 . doi: 10.3390/antiox10040617 . \nPMID: 33923815\n535.  Tomas-Simo P, D\u2019Marco L, Romero-Parra M, Tor -\nmos-Munoz M, Saez G, Torregrosa I, Estan-Capell \nN, Miguel A, Gorriz J, Puchades M. Oxidative \nstress in non-dialysis-dependent chronic kidney observational, multicentre, international cohort \nstudy. BMJ Open. 2021 May 1 1;1 1(5):e046948. \ndoi: 10. 1 136/bmjopen-2020-046948. PMID: \n33980528\n525.  Ribera J, Morgades M, Genesca E, et al. Outcomes \nand prognostic factors of adults with refractory or \nrelapsed T-cell acute lymphoblastic leukemia inclu -\nded in measurable residual disease-oriented trials. \nHematological Oncology. 2021 Oct;39(4):529-538. \ndoi: 10.1002/hon.2910. PMID: 34405901\n526.  Nabergoj M, Mauff K, Robin M, Kroger N, Angelucci \nE, Poire X, Passweg J, Radujkovic A, Platzbecker \nU, Robinson S, Rambaldi A, Petersen S, Stolzel F, \nStelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede \nL, Koster L, Hayden P, Czerw T, Hernandez-Boluda \nJ, McLornan D, Chalandon Y, Yakoub-Agha I. Outco -\nmes following second allogeneic haematopoietic \ncell transplantation in patients with myelofibrosis: \na retrospective study of the Chronic Malignancies \nWorking Party of EBMT. Bone Marrow Transplan -\ntation. 2021 Aug;56(8):1944-1952. doi: 10. 1038/\ns41409-021-01271-4. PMID: 33824436\n5 27. Pleyer L, Leisch M, Kourakli A, Padron E, Maciejews -\nki J, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, \nPatiou P, Hunter A, Mora E, Geissler K, Dimou M, Ji -\nmenez Lorenzo M, Melchardt T, Egle A, Viniou A, Pa -\ntel B, Arnan M, Valent P, Roubakis C, Bernal Del Cas -\ntillo T, Galanopoulos A, Calabuig Munoz M, Bonadies \nN, Medina de Almeida A, Cermak J, Jerez A, Mon -\ntoro M, Cortes A, Avendano Pita A, Lopez Andrade \nB, Hellstroem-Lindberg E, Germing U, Sekeres M, \nList A, Symeonidis A, Sanz G, Larcher-Senn J, Greil \nR. Outcomes of patients with chronic myelomono -\ncytic leukaemia treated with non-curative therapies: \na retrospective cohort study. Lancet. Haematology. \n2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-\n3026(20)30374-4. PMID: 33513373\n528.  Roman A, de la Cruz J, Macia I, Campuzano I, Al -\nmanzar S, Roel M, Munoz C, Fontan E, Trueba I, \nVielva L, Garcia J, Tellez E, Gonzalez C, Lopez M, \nMaestre U, Poce R, Lorente D, Kindelan A, Pulla M. \nOutcomes of surgical resection after neoadjuvant \nchemoimmunotherapy in locally advanced stage \nIIIA non-small-cell lung cancer. European Journal of \nCardio-Thoracic Surgery. 2021 Jul 14;60(1):81-88. \ndoi: 10. 1093/ejcts/ezab007 . PMID: 33661301329\n329\nINCLIVA SCIENTIFIC REPORT 2021publication list 9logy. 2021 Dec;32(12):1496-1510. doi: 10. 1016/j.\nannonc.2021.08.1752. PMID: 34411693\n541. Porcar Saura S, Garc\u00eda V\u00e1zquez A, Ramon Quiles \nM. Paraneoplastic acrokeratosis (Bazex syndro -\nme). Medicina Clinica. 2021 Feb 12;156(3):154. doi: \n10.1016/j.medcli.2019.12.016. PMID: 32197862\n542.  Klimczak P, Rizzo A, Castillo-Gomez E, Perez-Ran -\ndo M, Gramuntell Y, Beltran M, Nacher J. Parval -\nbumin interneurons and perineuronal nets in the \nhippocampus and retrosplenial cortex of adult \nmale mice after early social isolation stress and \nperinatal NMDA receptor antagonist treatment. \nFrontiers in Synaptic Neuroscience. 2021 Sep \n22;13:733989. doi: 10.3389/fnsyn.2021.733989. \nPMID: 34630066\n543.  Torres W, Morillo V, Manzano A, Suarez M, Parra \nH, Lameda V, Nava M, D\u2019Marco L, Puchades M, Me -\ndina O, Guerra-Torres X, Bermudez V. Pathogenic \nmechanisms of SARS-CoV-2 infection and kidney \ndisease: a clinical and molecular perspective. Ana -\nles del Sistema Sanitario de Navarra. 2021 Dec \n27;44(3):445-456. doi: 10.23938/ASSN.0973. \nPMID: 34664556\n544.  Calvet X, Casellas F, Saldana R, Carpio D, Minguez \nM, Vera I, Marin L, Julia B, GETECCU G. Patient-\nevaluated quality of care is related to better in -\nflammatory bowel disease outcomes: the IQCARO \nII Project. Patient. 2021 Sep;14(5):625-634. doi: \n10. 1007 /s40271-021-00500-8. PMID: 33709214\n545.  Wilmot EG, Close KL, Jurisic-Erzen D, Bruttomes -\nso D, Ampudia-Blasco FJ, Bosnyak Z, de Climens \nAR, Bigot G, Peters AL, Renard E, Berard L, Ca -\nlliari LE, Seufert J. Patient-reported outcomes in \nadults with type 1 diabetes in global real-world \nclinical practice: the SAGE study. Diabetes, Obesi -\nty & Metabolism. 2021 Aug;23(8):1892-1901. doi: \n10.1111/d o m.14416.  PMID:  33914401\n546.  Rega D, Aiko M, Penaranda N, Urios A, Gallego J, \nGimenez-Garzo C, Casanova F, Fiorillo A, Cabrera-\nPastor A, San-Miguel T, Ipiens C, Escudero-Garcia \nD, Tosca J, Monton C, Ballester M, Ballester J, \nAparicio L, Rios M, Durban L, Mir A, Kosenko E, \nCases P, Felipo V, Montoliu C. Patients with mini -\nmal hepatic encephalopathy show altered ther -\nmal sensitivity and autonomic function. Journal disease patients. International Journal of Envi -\nronmental Research and Public Health. 2021 Jul \n23;18(15):7806. doi: 10.3390/ijerph18157806. \nPMID: 34360098\n536.  Garcia-Gimenez J, Garces C, Roma-Mateo C, Pa -\nllardo F. Oxidative stress-mediated alterations \nin histone post-translational modifications. Free \nRadical Biology & Medicine. 2021 Jul;170:6-18. \ndoi: 10.1016/j.freeradbiomed.2021.02.027 . PMID: \n33689846\n5 37. Saura S, Benavent M. Pachydermodactyly. \nJournal of Cutaneous Medicine and Sur -\ngery. 2021 Mar 28:1203475421 1003523. \ndoi: 10. 1 177 /1203475421 1003523. PMID: \n33779338\n538.  Guillen-Climent S, Garcia-Vazquez A, Benavent \nM, Saura S, Canales I, Monteagudo C. Painful cu -\ntaneous lesions on the hand palm after Takotsu -\nbo cardiomyopathy and coronary angiography. \nClinical and Experimental Dermatology. 2021 \nMar ;46(2):387- 390.  d o i:  10.1111/c e d.14475.  \nPMID:  33091167\n539.  Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, \nTurner N, Ciruelos E, Munoz M, Bermejo B, Margeli \nM, Anton A, Kahan Z, Csoszi T, Casas M, Murillo \nL, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano \nA, Calvo L, Haba-Rodriguez J, Ramos M, Alvarez I, \nGarcia-Palomo A, Bartlett C, Koehler M, Caballe -\nro R, Corsaro M, Huang X, Garcia-Saenz J, Cha -\ncon J, Swift C, Thallinger C, Gil-Gil M. Palbociclib \nin combination with endocrine therapy versus ca -\npecitabine in hormonal receptor-positive, human \nepidermal growth factor 2-negative, aromatase \ninhibitor-resistant metastatic breast cancer: a \nphase III randomised controlled trial-PEARL. An -\nnals of Oncology. 2021 Apr;32(4):488-499. doi: \n10.1016/j.annonc.2020.12.013. PMID: 33385521\n540.  Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, \nArnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, \nChee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, \nSharma A, Sun Y, Curigliano G, Bando H, Lordick \nF, Yamanaka T, Tabernero J, Baba E, Cervantes A, \nOhtsu A, Peters S, Ishioka C, Pentheroudakis G. \nPan-Asian adapted ESMO Clinical Practice Guideli -\nnes for the diagnosis treatment and follow-up of pa -\ntients with localised colon cancer. Annals of Onco -330\n330\nINCLIVA SCIENTIFIC REPORT 2021publication list9552.  Misra S, Gelaye B, Williams D, Koenen K, Borba \nC, Quattrone D, Di Forti M, Tripoli G, La Cascia C, \nLa Barbera D, Ferraro L, Tarricone I, Berardi D, \nLasalvia A, Tosato S, Szoke A, Llorca P, Arango C, \nTortelli A, de Haan L, Velthorst E, Bobes J, Bernar -\ndo M, Sanjuan J, Santos J, Arrojo M, Del-Ben C, \nMenezes P, Selten J, Jones P, Jongsma H, Kirkbri -\nde J, Rutten B, van Os J, Murray R, Gayer-Ander -\nson C, Morgan C. Perceived major experiences of \ndiscrimination, ethnic group, and risk of psycho -\nsis in a six-country case-control study. Psycho -\nlogical Medicine. 2021 Mar 2;1-9. doi: 10. 1017 /\nS0033291721000453. PMID: 33648622\n553.  Torres I, Albert E, Gimenez E, Olea B, Valdivia A, \nPascual T, Huntley D, Sanchez D, Costa RM, Pin -\nto C, Oltra R, Colomina J, Navarro D. Performan -\nce of a MALDI-TOF mass spectrometry-based \nmethod for rapid detection of third-generation \noxymino-cephalosporin-resistant Escherichia coli \nand Klebsiella spp. from blood cultures. European \nJournal of Clinical Microbiology & Infectious Di -\nseases. 2021 Sep;40(9):1925-1932. doi: 10. 1007 /\ns10096-021-04251-0. PMID: 33876385\n554.  Serra-Pastor B, Bustamante-Hernandez N, Fons-\nFont A, Fernanda Sola-Ruiz M, Revilla-Leon M, \nAgustin-Panadero R. Periodontal behavior and pa -\ntient satisfaction of anterior teeth restored with \nsingle zirconia crowns using a biologically orien -\nted preparation technique: a 6-year prospective \nclinical study. Journal of Clinical Medicine. 2021 \nAug 6;10(16):3482. doi: 10.3390/jcm10163482. \nPMID: 34441778\n555. Serra-Pastor B, Bustamante-Hernandez N, Fons-\nFont A, Sola-Ruiz M, Revilla-Leon M, Agustin-Panade -\nro R. Periodontal outcomes of anterior fixed partial \ndentures on teeth treated with the biologically orien -\nted preparation technique: a 6-year prospective cli -\nnical trial. Journal of Prosthetic Dentistry. 2021 Oct \n23:S0022-3913(21)00398-X. doi: 10. 1016/j.pros -\ndent.2021.07 .009. PMID: 34702586\n556.  Di Martino M, Primavesi F, Syn N, Dorcaratto D, \nde la Hoz Rodriguez A, Dupre A, Piardi T, Rhaiem \nR, Blanco Fernandez G, Prada Villaverde A, Rodri -\nguez Sanjuan J, Fernandez Santiago R, Fernandez-\nMoreno M, Ferret G, Lopez Ben S, Suarez Munoz \nM, Perez-Alonso A, Koh Y, Jones R, Martin-Perez of Clinical Medicine. 2021 Jan 1 1;10(2):E239. doi: \n10.3390/jcm10020239. PMID: 33440769\n5 47. Sanchez-Velazquez A, Bauer-Alonso A, Estrach \nT, Vega-Diez D, Garcia-Muret P, Haya L, Penate Y, \nAcebo E, Fernandez de Misa R, Blanes M, Suh-Oh \nHJ, Izu R, Silva-Diaz E, Sarriugarte J, Roman-Curto \nC, Botella-Estrada R, Mateu-Puchades A, Prieto-\nTorres L, Morillas V, Morillo M, Sanchez-Caminero \nP, Calzado L, Perez-Ferriols A, Perez A, Dominguez \nJD, Navedo M, Muniesa C, Combalia A, Arroyo-An -\ndres J, Descalzo MA, Garcia-Doval I, Ortiz-Romero \nPL. Patients with primary cutaneous lymphoma \nare at risk for severe COVID-19. Data from the \nSpanish Primary Cutaneous Lymphoma Registry. \nJournal of the European Academy of Dermatology \nand Venereology. 2021 Oct;35(10):e624-e626. doi: \n10.1111/j d v.17430.  PMID:  34062018\n548.  Moral L, Asensi Monzo M, Julia Benito J, Ortega \nCasanueva C, Paniagua Calzon N, Perez Garcia M, \nRodriguez Fernandez-Oliva C, Sanz Ortega J, Val -\ndesoiro Navarrete L, Valverde-Molina J. Pediatric \nasthma: the REGAP consensus. Anales de Pedia -\ntria 2021 Aug;95(2):125.e1-125.e1 1. doi: 10. 1016/j.\nanpede.2021.02.007 . PMID: 34353777\n549.  Panach-Navarrete J, Valls-Gonzalez L, Negueroles-\nGarcia M, Castello-Porcar A, Martinez-Jabaloyas \nJ. Pediatric ureteral ectopia: solutions for seve -\nral issues. Archivos Espanoles de Urologia. 2021 \nJul;74(6):627-632. PMID: 34219067\n550.  Perez-Garcia JM, Llombart-Cussac A, Cortes MG, \nCurigliano G, Lopez-Miranda E, Alonso JL, Bermejo \nB, Calvo L, Caranana V, de la Cruz Sanchez S, Vaz -\nquez RM, Prat A, Borrego MR, Sampayo-Cordero \nM, Segui-Palmer MA, Soberino J, Malfettone A, \nSchmid P, Cortes J. Pembrolizumab plus eribulin in \nhormone-receptor-positive, HER2-negative, locally \nrecurrent or metastatic breast cancer (KELLY): an \nopen-label, multicentre, single-arm, phase II trial. \nEuropean Journal of Cancer. 2021 May;148:382-\n394. doi: 10. 1016/j.ejca.2021.02.028. PMID: \n33794440\n551. Lloret-Dura M, Panach-Navarrete J, Mata-Cano \nD, Martinez-Jabaloyas J. Penile Cancer: a case for \nnon-lymph node disease following a negative senti -\nnel node exploration. Archivos Espanoles de Uro -\nlogia. 2021 Mar;74(2):265-268. PMID: 33650543331\n331\nINCLIVA SCIENTIFIC REPORT 2021publication list 9562.  Diaz E, Amezaga Menendez R, Vidal Cortes P, Es -\ncapa M, Suberviola B, Serrano Lazaro A, Marcos \nNeira P, Quintana Diaz M, Catalan Gonzalez M. \nPharmacological treatment of COVID-19: narrative \nreview of the Working Group in Infectious Disea -\nses and Sepsis (GTEIS) and the Working Groups \nin Transfusions and Blood Products (GTTH). Me -\ndicina Intensiva. 2021 Mar;45(2):104-121. doi: \n10.1016/j.medin.2020.06.017 . PMID: 32854988\n563.  Jhaveri K, Chang M, Juric D, Saura C, Gambardella \nV, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, \nBedard P, Sachdev J, Dunn L, Won H, Bond J, Jones \nS, Savage H, Scaltriti M, Wilson T, Wei M, Hyman \nD. Phase I Basket study of taselisib, an isoform-\nselective PI3K inhibitor, in patients with PIK3CA-\nmutant cancers. Clinical Cancer Research. 2021 \nJan 15;27(2):447-459. doi: 10.1158/1078-0432.\nCCR-20-2657 . PMID: 33148674\n564.  Rodriguez-Rubio E, Gil-Pena H, Chocron S, Madaria -\nga L, de la Cerda-Ojeda F, Fernandez-Fernandez M, \nde Lucas-Collantes C, Gil M, Luis-Yanes M, Vergara \nI, Gonzalez-Rodriguez J, Ferrando S, Anton-Game -\nro M, Carrasco Hidalgo-Barquero M, Fernandez-\nEscribano A, Fernandez-Maseda M, Espinosa L, \nOliet A, Vicente A, Ariceta G, Santos F, Renal Tube \nGroup. Phenotypic characterization of X-linked hy -\npophosphatemia in pediatric Spanish population. \nOrphanet Journal of Rare Diseases. 2021 Feb \n27;16(1):104. doi: 10. 1 186/s13023-021-01729-0. \nPMID: 33639975\n565.  Jimenez-Perez I, Gil-Calvo M, Aparicio I, de Anda \nR, Perez-Soriano P. Plantar pressure distribution \nduring running with a self-customized foot ortho -\nsis in a home microwave. Journal of Biomecha -\nnics. 2021 Oct 8;129:1 10791. doi: 10. 1016/j.jbio -\nmech.2021. 110791. PMID: 34634594\n566.  Cuevas-Ferrando E, Randazzo W, Perez-Cataluna \nA, Falco I, Navarro D, Martin-Latil S, Diaz-Reolid A, \nGiron-Guzman I, Allende A, Sanchez G. Platinum \nchloride-based viability RT-qPCR for SARS-CoV-2 \ndetection in complex samples. Scientific Reports. \n2021 Sep 13;1 1(1):18120. doi: 10. 1038/s41598-\n021-97700-x. PMID: 34518622\n5 67. Lazaro Salvador M, Quezada Loaiza C, Rodriguez \nPadial L, Barbera J, Lopez-Meseguer M, Lopez-\nReyes R, Sala Llinas E, Alcolea S, Blanco I, Escri -E. Perioperative chemotherapy versus surgery \nalone for resectable colorectal liver metastases: \nan international multicentre propensity score \nmatched analysis on long-term outcomes ac -\ncording to established prognostic risk scores. \nHPB. 2021 Dec;23(12):1873-1885. doi: 10. 1016/j.\nhpb.2021.04.026. PMID: 34103246\n5 57. Picetti E, Rosenstein I, Balogh Z, Catena F, Tac -\ncone F, Fornaciari A, Votta D, Badenes R, Bilotta \nF. Perioperative management of polytrauma pa -\ntients with severe traumatic brain injury under -\ngoing emergency extracranial surgery: a narrati -\nve review. Journal of Clinical Medicine. 2021 Dec \n21;11(1):18. doi: 10.3390/jcm11010018. PMID: \n35011760\n558.  Ascaso P, Palanca A, Martinez-Hervas S, Sanz MJ, \nAscaso JF, Piqueras L, Real JT. Peripheral blood \nlevels of CXCL 10 are a useful marker for diabetic \npolyneuropathy in subjects with type 2 diabetes. \nInternational Journal of Clinical Practice. 2021 \nAug;75(8):e14302. doi: 10. 1111/ijcp. 14302. PMID: \n33930221\n559.  Pellino G, Garcia-Granero E, Cervantes A. Perito -\nneal invasion and metachronous peritoneal me -\ntastases after colon cancer surgery: the role of \nhomogeneous, reliable assessment and confoun -\nders. European Journal of Surgical Oncology. 2021 \nOct;47(10):2697. doi: 10.1016/j.ejso.2021.06.031. \nPMID: 34217579\n560.  Ferrer-Quintero M, Fernandez D, Lopez-Carrilero \nR, Birules I, Barajas A, Lorente-Rovira E, Diaz-Cutra -\nro L, Verdaguer M, Garcia-Mieres H, Sevilla-Llewe -\nllyn-Jones J, Gutierrez-Zotes A, Grasa E, Pousa E, \nHuerta-Ramos E, Pelaez T, Barrigon ML, Gonzalez-\nHigueras F, Ruiz-Delgado I, Cid J, Moritz S, Ochoa S. \nPersons with first episode psychosis have distinct \nprofiles of social cognition and metacognition. NPJ \nSchizophrenia. 2021 Dec 9;7(1):61. doi: 10. 1038/\ns41537-021-00187-8. PMID: 34887442\n561. Stromsnes K, Lagzdina R, Olaso-Gonzalez G, Gi -\nmeno-Mallench L, Gambini J. Pharmacological \nproperties of polyphenols: bioavailability, mecha -\nnisms of action, and biological effects in in vitro \nstudies, animal models, and humans. Biomedici -\nnes. 2021 Aug 23;9(8):1074. doi: 10.3390/biome -\ndicines9081074. PMID: 34440278332\n332\nINCLIVA SCIENTIFIC REPORT 2021publication list9A, Jimenez-Lorenzo M, Pinana J, Montoro J, Oar -\nbeascoa G, Dorado N, Gomez-Centurion I, Munoz \nC, Martinez-Laperche C, Anguita J, Buno I, Diez-\nMartin J, Grp Espanol Trasplante Hematopoyet. \nPost-transplant cyclophosphamide for GVHD pro -\nphylaxis compared to ATG-based prophylaxis in \nunrelated donor transplantation. Annals of Hema -\ntology. 2021 Feb;100(2):541-553. doi: 10. 1007 /\ns00277-020-04317-7 . PMID: 33140137\n574. Mathur D, Mishra BK, Rout S, Lopez-Iranzo FJ, Lo -\npez-Rodas G, Vallamkondu J, Kandimalla R, Casa -\nnova B. Potential biomarkers associated with mul -\ntiple sclerosis pathology. International Journal of \nMolecular Sciences. 2021 Sep 25;22(19):10323. \ndoi: 10.3390/ijms221910323. PMID: 34638664\n575.  Pagano G, Manfredi C, Pallardo Calatayud F, \nLyakhovich A, Tiano L, Trifuoggi M. Potential ro -\nles of mitochondrial cofactors in the adjuvant \nmitigation of proinflammatory acute infections, \nas in the case of sepsis and COVID-19 pneumo -\nnia. Inflammation Research. 2021 Feb;70(2):159-\n170. doi: 10. 1007 /s0001 1-020-01423-0. PMID: \n33346851\n576.  Horiuchi Y, Wettersten N, van Veldhuisen D, \nMueller C, Filippatos G, Nowak R, Hogan C, Kon -\ntos M, Cannon C, Mueller G, Birkhahn R, Taub P, \nVilke G, Barnett O, McDonald K, Mahon N, Nu -\nnez J, Briguori C, Passino C, Maisel A, Murray P. \nPotential utility of cardio-renal biomarkers for \nprediction and prognostication of worsening re -\nnal function in acute heart failure: cardio-renal \nbiomarkers and WRF in AHF. Journal of Cardiac \nFailure. 2021 May;27(5):533-541. doi: 10. 1016/j.\ncardfail.2020.11.025. PMID: 33296713\n57 7. Dabrowski W, Siwicka-Gieroba D, Robba C, Bielacz \nM, Solek-Pastuszka J, Kotfis K, Bohatyrewicz R, \nJaroszynski A, Malbrain M, Badenes R. Potentia -\nlly detrimental effects of hyperosmolality in pa -\ntients treated for traumatic brain injury. Journal \nof Clinical Medicine. 2021 Sep 14;10(18):4141. doi: \n10.3390/jcm10184141. PMID: 34575255\n578.  Guerra-Ojeda S, Marchio P, Gimeno-Raga M, \nArias-Mutis O, San-Miguel T, Valles S, Aldasoro M, \nVila J, Zarzoso M, Mauricio M. PPARgamma as an \nindicator of vascular function in an experimental \nmodel of metabolic syndrome in rabbits. Atheros -bano Subias P, Marin Gonzalez M, REHAP investi -\ngators. Portopulmonary hypertension: prognosis \nand management in the current treatment era. \nResults from the REHAP Registry. Internal Medici -\nne Journal. 2021 Mar;51(3):355-365. doi: 10. 1 1 1 1/\nimj. 14751. PMID: 31943676\n568.  Zolfaroli I, Ortiz E, Garcia-Perez M, Hidalgo-Mora J, \nTarin J, Cano A. Positive association of high-density li -\npoprotein cholesterol with lumbar and femoral neck \nbone mineral density in postmenopausal women. \nMaturitas. 2021 May;147:41-46. doi: 10. 1016/j.ma -\nturitas.2021.03.001. PMID: 33832646\n569.  Martinez-Gimenez J, Tabares-Seisdedos R. Pos -\nsible ancestral functions of the genetic and RNA \noperational precodes and the origin of the genetic \nsystem. Origins of life and evolution of biospheres. \n2021 Jun;51(2):167-183. doi: 10.1007/s11084-\n021-09610-7. PMID: 34097191\n570.  Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore \nL, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zur -\nlo IV, Fulgenzi C, Lombardi P, Rosell\u00f3 Ker\u00e4nen S, \nDepetris I, Giampieri R, Morelli C, Di Marino P, Di \nPietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli \nGP, Zoratto F, Roberto M, Petrillo A, Aimar G, Pa -\ntruno L, D\u2019Orazio C, Ficorella C, Ferri C, Porzio G. \nPost-induction management in patients with left-\nsided  RAS  and BRAF  wild-type metastatic colorec -\ntal cancer treated with first-line anti-egfr-based \ndoublet regimens: a multicentre study. Frontiers in \nOncology. 2021 Oct 27;1 1:712053. doi: 10.3389/\nfonc.2021.712053. PMID: 34778029\n571. Lumish M, Tarazona N, Janjigian Y. Postoperati -\nve ctDNA monitoring: a canary in a coalmine. An -\nnals of Oncology. 2021 Apr;32(4):431-433. doi: \n10.1016/j.annonc.2021.01.005. PMID: 33484835\n572.  Moreno-Perez B, Benito E, Civera M, Alabadi B, \nMartinez-Hervas S, Peiro M, Gonzalez-Navarro H, \nPiqueras L, Jesus Sanz M, Ascaso J, Real J. Post -\nprandial triglyceridemia is modulated by insulin re -\nsistance but not by grade of obesity in abdominal \nand morbid obese subjects. International Journal \nof Clinical Practice. 2021 Apr;75(4):e13776. doi: \n10.1111/i j c p.13776.  PMID:  33089594\n573.  Bailen R, Kwon M, Pascual-Cascon M, Ferra C, \nSanz J, Gallardo-Morillo A, Garcia-Sola A, Torrent 333\n333\nINCLIVA SCIENTIFIC REPORT 2021publication list 9584.  Capalbo A, Poli M, Riera-Escamilla A, Shukla V, Kudo \nHoffding M, Krausz C, Hoffmann E, Simon Valles \nC. Preconception genome medicine: current sta -\nte and future perspectives to improve infertility \ndiagnosis and reproductive and health outcomes \nbased on individual genomic data. Human Repro -\nduction Update. 2021 Feb 19;27(2):254-279. doi: \n10. 1093/humupd/dmaa044. PMID: 33197264\n585.  Lacomba-Trejo L, Valero-Moreno S, Montoya-\nCastilla I, Marin M. Predicting health-related \nquality of life in Spanish adolescents with aller -\ngic rhinoconjunctivitis and bronchial asthma. \nPsychology Health & Medicine. 2021 Mar 24:1-13. \ndoi: 10.1080/13548506.2021.1904514. PMID: \n33759655\n586.  Martin-Moreno J, Lessof S. Predictions of can -\ncer mortality in Europe in 2021: room for hope \nin the shadow of COVID-19?. Annals of Oncolo -\ngy. 2021 Apr;32(4):425-426. doi: 10. 1016/j.an -\nnonc.2021.02.001. PMID: 33626376\n5 87. Vieites B, Lopez-Garcia M, Martin-Salvago M, Ra -\nmirez-Tortosa C, Rezola R, Sancho M, Lopez-Vilaro \nL, Villardell F, Burgues O, Fernandez-Rodriguez B, \nAlfaro L, Peg V. Predictive and prognostic value of \ntotal tumor load in sentinel lymph nodes in breast \ncancer patients after neoadjuvant treatment \nusing one-step nucleic acid amplification: the NEO -\nVATTL study. Clinical & Translational Oncology. \n2021 Jul;23(7):1377-1385. doi: 10.1007 /s12094-\n020-02530-4. PMID: 33517542\n588.  Valente FX, Gavara J, Gutierrez L, Rios-Navarro C, \nRello P, Maymi M, Fernandez-Galera R, Monmeneu \nJV, Sao-Aviles A, Lopez-Lereu MP, Gonzalez-Alujas \nMT, Moratal D, Cuellar H, Barrabes J, Otaegui \nIEA, Ferreira I, Bodi V, Rodriguez-Palomares J. \nPredictive value of cardiac magnetic resonance \nfeature tracking after acute myocardial infarc -\ntion: a comparison with dobutamine stress echo -\ncardiography. Journal of Clinical Medicine. 2021 \nNov 12;10(22):5261. doi: 10.3390/jcm10225261. \nPMID: 34830543\n589.  Cordero A, Rey-Ranal E, Moreno M, Escribano \nD, Moreno-Arribas J, Quintanilla M, Zuazola P, \nNunez J, Bertomeu-Gonzalez V. Predictive value \nof pro-BNP for heart failure readmission after \nan acute coronary syndrome. Journal of Clinical clerosis. 2021 Aug 5;332:16-23. doi: 10. 1016/j.\natherosclerosis.2021.08.006. PMID: 34375909\n579.  Bargiela A, Artero R. Practicing logical reaso -\nning through drosophila segmentation gene mu -\ntants. Biochemistry and Molecular Biology Edu -\ncation. 2021 Sep;49(5):729-736. doi: 10. 1002/\nbmb.21554. PMID: 34160891\n580.  Jimenez-Pastor A, Alberich-Bayarri A, Lopez-Gon -\nzalez R, Marti-Aguado D, Frana M, Bachmann R, \nMazzucco J, Marti-Bonmati L. Precise whole liver \nautomatic segmentation and quantification of \nPDFF and R2* on MR images. European Radio -\nlogy. 2021 Oct;31(10):7876-7887. doi: 10.1007/\ns00330-021-07838-5. PMID: 33768292\n581. Guardia C, Bianchini G, Arpi-LLucia O, Menendez \nS, Casadevall D, Galbardi B, Dugo M, Servitja S, \nMontero J, Soria-Jimenez L, Sabbaghi M, Pena \nR, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, \nArribas J, Pandiella A, Gianni L, Rojo F, Rovira A, \nAlbanell J. Preclinical and clinical characterization \nof fibroblast-derived neuregulin-1 on trastuzumab \nand pertuzumab activity in HER2-positive breast \ncancer. Clinical Cancer Research. 2021 Sep \n15;27(18):5096-5108. doi: 10.1158/1078-0432.\nCCR-20-2915. PMID: 34385295\n582.  Cerro-Herreros E, Gonzalez-Martinez I, Moreno N, \nEspinosa-Espinosa J, Fernandez-Costa JM, Colom-\nRodrigo A, Overby SJ, Seoane-Miraz D, Poyatos-\nGarcia J, Vilchez JJ, Lopez de Munain A, Varela \nMA, Wood MJ, Perez-Alonso M, Llamusi B, Artero \nR. Molecular Therapy. Preclinical characteriza -\ntion of antagomiR-218 as a potential treatment \nfor myotonic dystrophy. Nucleic Acids. 2021 Jul \n29;26:174-191. doi: 10.1016/j.omtn.2021.07 .017 . \nPMID: 34513303\n583.  Nunez-Badinez P, De Leo B, Laux-Biehlmann A, Hoff -\nmann A, Zollner T, Saunders P, Simitsidellis I, Cha -\nrrua A, Cruz F, Gomez R, Tejada M, McMahon S, Lo \nRe L, Barthas F, Vincent K, Birch J, Meijlink J, Hum -\nmelshoj L, Sweeney P, Armstrong J, Treede R, Nagel \nJ. Preclinical models of endometriosis and intersti -\ntial cystitis/bladder pain syndrome: an Innovative \nMedicines Initiative-PainCare initiative to improve \ntheir value for translational research in pelvic pain. \nPain. 2021 Sep 1;162(9):2349-2365. doi: 10. 1097 /j.\npain.0000000000002248. PMID: 34448751334\n334\nINCLIVA SCIENTIFIC REPORT 2021publication list9595.  Santos Garcia D, Blazquez-Estrada M, Calopa M, \nEscamilla-Sevilla F, Freire E, Garcia Ruiz P, Gran -\ndas F, Kulisevsky J, Lopez-Manzanares L, Martinez \nCastrillo J, Mir P, Pagonabarraga J, Perez-Erraz -\nquin F, Salom J, Tijero B, Valldeoriola F, Yanez R, Avi -\nles A, Luquin M. Present and future of Parkinson\u2019s \ndisease in Spain: PARKINSON-2030 Delphi Pro -\nject. Brain Sciences. 2021 Jul 31;1 1(8):1027 . doi: \n10.3390/brainsci11081027. PMID: 34439646\n596.  Berendsen S, Kapitein P, Schirmbeck F, van Tri -\ncht M, McGuire P, Morgan C, Gayer-Anderson C, \nKempton M, Valmaggia L, Quattrone D, di Forti M, \nvan der Gaag M, Kirkbride J, Jongsma H, Jones \nP, Parellada M, Arango C, Arrojo M, Bernardo M, \nSanjuan Arias J, Santos J, Szoke A, Tortelli A, Llor -\nca P, Tarricone I, Tripoli G, Ferraro L, La Cascia C, \nLasalvia A, Tosato S, Menezes P, Del-Ben C, Nel -\nson B, Riecher-Rossler A, Bressan R, Barrantes-\nVidal N, Krebs M, Nordentoft M, Ruhrmann S, \nSachs G, Rutten B, van Os J, Velthorst E, de Haan \nL, EU-GEI High Risk Study. Pre-training inter-rater \nreliability of clinical instruments in an internatio -\nnal psychosis research Project. Schizophrenia \nResearch. 2021 Apr;230:104-107. doi: 10.1016/j.\nschres.2020.08.001. PMID: 33243716\n5 97. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, \nGarcia-Campelo R, Lazaro M, Domine M, Majem \nM, Rodriguez-Abreu D, Martinez-Marti A, de Cas -\ntro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Bar -\nco E, Bernabe Caro R, Vinolas N, Barneto Aranda \nI, Viteri S, Massuti B, Barquin M, Laza-Briviesca \nR, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, \nRocha P, Kadara H, Wistuba I, Romero A, Calvo V, \nProvencio M. Pre-treatment tissue TCR repertoi -\nre evenness is associated with complete patholo -\ngical response in patients with NSCLC receiving \nneoadjuvant chemoimmunotherapy. Clinical Can -\ncer Research. 2021 Nov 1;27(21):5878-5890. \ndoi: 10.1158/1078-0432.CCR-21-1200. PMID: \n34376534\n598.  Signes-Costa J, Nunez-Gil I, Soriano J, Arroyo-Es -\npliguero R, Eid C, Romero R, Uribarri A, Fernan -\ndez-Rozas I, Aguado M, Becerra-Munoz V, Huang \nJ, Pepe M, Cerrato E, Raposeiras S, Gonzalez A, \nFranco-Leon F, Wang L, Alfonso E, Ugo F, Garcia-\nPrieto J, Feltes G, Abumayyaleh M, Espejo-Paeres \nC, Jativa J, Masjuan A, Macaya C, Carbonell Asins Medicine. 2021 Apr 13;10(8):1653. doi: 10.3390/\njcm10081653. PMID: 33924437\n590.  Loughlin G, Datino T, Arenal A, Ruiz Granell R, San -\nchez Gomez J, Perez L, Martinez-Ferrer J, Alzueta \nJ, Perez-Lorente F, Vinolas X, Fidalgo Andres M, \nFernandez de la Concha J. Predictors of adoption \nand impact of evidence-based programming on the \nincidence of implantable cardioverter-defibrillator \ntherapies. Revista Espanola de Cardiologia (english \nEd.). 2021 Apr;74(4):296-302. doi: 10. 1016/j.\nrec.2020.06.017 . PMID: 32773348\n591. Soto-Rubio A, Valero-Moreno S, Perez-Marin M. \nPredictors of complicated grief in mourners \nof sudden cardiac death. American Journal of \nEmergency Medicine. 2021 Dec;50:797-798. doi: \n10.1016/j.ajem.2021.03.028. PMID: 33741200\n592.  Mellado-Artigas R, Mujica L, Ruiz M, Ferreyro B, \nAngriman F, Arruti E, Torres A, Barbeta E, Villar J, \nFerrando C, COVID-19 Spanish ICU Network. Pre -\ndictors of failure with high-flow nasal oxygen thera -\npy in COVID-19 patients with acute respiratory fai -\nlure: a multicenter observational study. Journal of \nIntensive Care. 2021 Mar 5;9(1):23. doi: 10. 1 186/\ns40560-021-00538-8. PMID: 33673863\n593.  Espejo-Paeres C, Espliguero RA, Uribarri A, Anton-\nHuguet B, Romero R, Fernandez-Rozas I, Becerra-\nMunoz VM, Alfonso-Rodriguez E, Huang J, Ortega-\nArmas ME, Pepe M, Gonzalez A, Bertolazzi M, \nCerrato E, Quezada A, Raposeiras-Roubin S, Vedia \nO, Feltes-Guzman G, Akin I, Carrero-Fernandez \nA, Macaya C, Estrada V, Nunez-Gil IJ. Predictors \nof poor prognosis in healthy, young, individuals \nwith SARS-CoV-2 infections. Clinical Microbiology \nand Infection. 2021 Sep 30;28(2):273-278. doi: \n10.1016/j.cmi.2021.09.021. PMID: 34600119\n594.  Ramia JM, de Vicente E, Pardo F, Sabater L, Lopez \nBen S, Quijano MY, Villegas T, Blanco Fernandez \nG, Diez Valladares L, Lopez Rojo I, Martin Perez E, \nPereira F, Gonzalez AJ, Herrera J, Garcia Domin -\ngo MI, Serradilla MM. Preoperative hepatic artery \nembolization before distal pancreatectomy plus \nceliac axis resection does not improve surgical \nresults: a Spanish multicentre study. The Surgeon. \n2021 Oct;19(5):e117-e124. doi: 10.1016/j.sur -\nge.2020.08.012. PMID: 33023848335\n335\nINCLIVA SCIENTIFIC REPORT 2021publication list 9ti-Amor J, Pascual P, Molina I, Martinez-Alday J, \nRECABA Investigators. Primary results of the Spa -\nnish cryoballoon ablation registry: acute and long-\nterm outcomes of the RECABA study. Scientific \nReports. 2021 Aug 26;1 1(1):17268. doi: 10. 1038/\ns41598-021-96655-3. PMID: 34446764\n605.  Zamora-Sanchez J, Zabaleta-del-Olmo E, Fernan -\ndez-Bertolin S, Gea-Caballero V, Julian-Rochina I, \nPerez-Tortajada G, Amblas-Novellas J. Profiles of \nfrailty among older people users of a home-based \nprimary care service in an urban area of Barce -\nlona (Spain): an observational study and cluster \nanalysis. Journal of Clinical Medicine. 2021 May \n13;10(10):2106. doi: 10.3390/jcm10102106. \nPMID: 34068296\n606.  Diez-Villanueva P, Garcia-Acuna JM, Raposeiras-\nRoubin S, Barrabes JA, Cordero A, Martinez-Se -\nlles M, Bardaji A, Marin F, Ruiz-Nodar JM, Vicente-\nIbarra N, Alonso Salinas GL, Cid-Alvarez B, Abu \nAssi E, Formiga F, Nunez J, Nunez E, Ariza-Sole A, \nSanchis J. Prognosis impact of diabetes in elderly \nwomen and men with non-ST elevation acute coro -\nnary syndrome. Journal of Clinical Medicine. 2021 \nSep 26;10(19):4403. doi: 10.3390/jcm10194403. \nPMID: 34640420\n607 . Pla-Marti V, Martin-Arevalo J, Moro-Valdezate D, \nGarcia-Botello S, Perez-Santiago L, Lapena-Rodri -\nguez M, Bauza-Collado M, Huerta M, Rosello-Ke -\nranen S, Espi-Macias A. Prognostic implications \nof surgical specimen quality on the oncological \noutcomes of open and laparoscopic surgery in \nmid and low rectal cancer. Langenbeck\u2019s Archives \nof Surgery. 2021 Oct 30. doi: 10. 1007 /s00423-\n021-02351-1. PMID: 34716825\n608.  Trejo-Velasco B, Estevez-Loureiro R, Carrasco-\nChinchilla F, Fernandez-Vazquez F, Arzamendi D, \nPan M, Pascual I, Nombela-Franco L, Amat-Santos \nI, Freixa X, Hernandez-Antolin R, Trillo-Nouche R, \nIkazuriaga L, Lopez-Minguez J, Cervera D, Sanchis \nJ, Diez-Gil J, Ruiz-Quevedo V, Urbano-Carrillo C, \nBecerra-Munoz V, Benito-Gonzalez T, Li C, Mesa D, \nAvanzas P, Armijo G, Serrador-Frutos A, Sanchis L, \nLoban C, Cid-Alvarez B, Hernandez-Garcia J, Garro -\nte-Coloma C, Fernandez-Peregrina E, Romero M, \nArguero V, Cruz-Gonzalez I. Prognostic role of TAP -\nSE to PASP ratio in patients undergoing mitraclip J, Estrada V, HOPE COVID-19 investigators. Preva -\nlence and 30-day mortality in hospitalized patients \nwith COVID-19 and prior lung diseases. Archivos \nde Bronconeumologia. 2021 Apr;57:13-20. doi: \n10.1016/j.arbres.2020.11.012. PMID: 33423874\n599.  Fonfria M, Jimenez I, Tena I, Chirivella I, Richart-Az -\nnar P, Segura A, Sanchez-Heras A, Martinez-Due -\nnas E. Prevalence and clinicopathological charac -\nteristics of moderate and high-penetrance genes \nin non-BRCA1/2 breast cancer high-risk Spanish \nfamilies. Journal of Personalized Medicine. 2021 \nJun 12;1 1(6):548. doi: 10.3390/jpm1 1060548. \nPMID: 34204722 \n600.  Pun B, Badenes R, Heras La Calle G, Orun O, Chen \nW, Raman R, Simpson B, Wilson-Linville S, Hinojal \nOlmedillo B, Vallejo de la Cueva A, van der Jagt M, \nNavarro Casado R, Leal Sanz P, Orhun G, Ferrer \nGomez C, Nunez Vazquez K, Pineiro Otero P, Tac -\ncone F, Gallego Curto E, Caricato A, Woien H, La -\ncave G, O\u2019Neal H, Peterson S, Brummel N, Girard \nT, Ely E, Pandharipande P, COVID-19 Intensive Care \nInternational Study Group. Prevalence and risk \nfactors for delirium in critically ill patients with CO -\nVID-19 (COVID-D): a multicentre cohort study. Lan -\ncet. Respiratory Medicine. 2021; 9(3): 239-250. \ndoi: 10. 1016/S2213-2600(20)30552-X. PMID: \n33428871\n601. Alcala M, Bolado V, Sanchez-Vera I, Clapes S, Dasi \nF, Saez G, Carrera E, Alvarez-Gallego F, Loeken \nM, Viana M. Prevention of teratogenesis in preg -\nnancies of obese rats by vitamin E supplementa -\ntion. Antioxidants. 2021 Jul 23;10(8):1 173. doi: \n10.3390/antiox10081173. PMID: 34439421\n602.  Cortes J, Sanchez C, Pajares P. Primary care at \nhome in the framework of the COVID-19 pandemic. \nAtencion Primaria. 2021 Mar;53(3):101963. doi: \n10.1016/j.aprim.2020.12.004. PMID: 33517112\n603.  Falkner B, Lurbe E. Primary hypertension be -\nginning in childhood and risk for future cardio -\nvascular disease. Journal of Pediatrics. 2021 \nNov;238:16-25. doi: 10.1016/j.jpeds.2021.08.008. \nPMID: 34391765\n604.  Ferrero-de-Loma-Osorio A, Cozar R, Garcia-Albe -\nrola A, Valles E, Barrera A, Toquero J, Ormaetxe J, \nSanchez J, Ruiz-Granell R, Amador P, Rubio J, Mar -336\n336\nINCLIVA SCIENTIFIC REPORT 2021publication list9Pseudoxanthoma elasticum-like syndrome with \ncoagulation deficiency associated with carotid \nartery hypoplasia and a novel gamma-glutamyl \ncarboxylase gene mutation. International Jour -\nnal of Dermatology. 2021 Jan;60(1):e13-e15. doi: \n10.1111/i j d.15147.  PMID:  32808310\n615. Valero-Moreno S, Lacomba-Trejo L, Tamarit A, \nPerez-Marin M, Montoya-Castilla I. Psycho-emo -\ntional adjustment in parents of adolescents: a \ncross-sectional and longitudinal analysis of the \nimpact of the COVID pandemic. Journal of Pedia -\ntric Nursing. 2021;59:e44-e51. doi: 10. 1016/j.\npedn.2021.01.028. PMID: 33608182\n616. Del Pozo-Herce P, Garrido-Garcia R, Santolalla-\nArnedo I, Gea-Caballero V, Garcia-Molina P, Ruiz \nde Vinaspre-Hernandez R, Rodriguez-Velasco F, \nJuarez-Vela R. Psychological impact on the nur -\nsing professionals of the Rioja Health Service \n(Spain) due to the SARS-CoV-2 Virus. International \nJournal of Environmental Research and Public \nHealth. 2021 Jan 12;18(2):E580. doi: 10.3390/\nijerph18020580. PMID: 33445563\n617. Buigues C, Queralt A, De Velasco J, Salvador-Sanz \nA, Jennings C, Wood D, Trapero I. Psycho-social \nfactors in patients with cardiovascular disease \nattending a family-centred prevention and re -\nhabilitation programme: EUROACTION model in \nSpain. Life. 2021 Jan 26;1 1(2):89. doi: 10.3390/\nlife11020089. PMID: 33530575\n618. Valdivia A, Torres I, Huntley D, Alcaraz M, Albert \nE, Colomina J, Ferrer J, Carratala A, Navarro D. \nQualitative assessment of SARS-CoV-2-specific \nantibody avidity by lateral flow immunochroma -\ntographic IgG/IgM antibody assay. Journal of \nMedical Virology. 2021 Feb;93(2):1 141-1 144. doi: \n10.1002/jmv.26344. PMID: 32706420\n619. de la Espriella R, Santas E, Zegri Reiriz I, Gorriz \nJ, Cobo Marcos M, Nunez J. Quantification and \ntreatment of congestion in heart failure: a cli -\nnical and pathophysiological overview. Nefrolo -\ngia. 2021 Jul 18:S021 1-6995(21)001 14-4. doi: \n10.1016/j.nefro.2021.04.006. PMID: 34289940\n620.  Canada-Soriano M, Priego-Quesada J, Bovaira M, \nGarcia-Vitoria C, Palmer R, de Anda R, Moratal D. \nQuantitative analysis of real-time infrared thermo -procedure. Journal of Clinical Medicine. 2021 Mar \n2;10(5):1006. doi: 10.3390/jcm10051006. PMID: \n33801311\n609.  Perez Catalan I, Roig Marti C, Cubides Montenegro \nA, Cardenal Alvarez A, Guerrero Jimenez F, Albiol Vi -\nnals P, Uso Blasco J. Prognostic utility of the qSOFA \nscale in patients admitted to an Internal Medicine \nservice due to infectious diseases. Revista Chilena \nde Infectologia. 2021 Feb;38(1):31-36. doi: 10.4067 /\nS0716-10182021000100031. PMID: 33844790\n610. Clar J, Oltra MR, Benavent R, Pinto C, Ruiz A, San -\nchez MT, Noceda J, Redon J, Forner MJ. Prognostic \nvalue of diagnostic scales in community-acquired \nsepsis mortality at an emergency service. Progno -\nsis in community-adquired sepsis. BMC Emergen -\ncy Medicine. 2021 Dec 18;21(1):161. doi: 10. 1 186/\ns12873-021-00532-1. PMID: 34922448\n611. Nu\u00f1ez Villota J, Merenciano Gonz\u00e1lez H, Santas \nOlmeda E, Lopez Lereu M, Monmeneu Menadas J, \nValero Picher E. Prognostic value of indexed pulmo -\nnary artery diameter assessed by cardiac magne -\ntic resonance imaging in patients with acute heart \nfailure. Revista Espanola de Cardiologia (english \nEd.). 2021 Mar;74(3):267-269. doi: 10. 1016/j.\nrec.2020.06.039. PMID: 32978097\n612. Wernly B, Beil M, Bruno R, Binnebossel S, Kelm \nM, Sigal S, van Heerden P, Boumendil A, Artigas A, \nCecconi M, Marsh B, Moreno R, Oeyen S, Bollen \nPinto B, Szczeklik W, Leaver S, Walther S, Schefold \nJ, Joannidis M, Fjolner J, Zafeiridis T, de Lange D, \nGuidet B, Flaatten H, Jung C, VIP2 study group. \nProvision of critical care for the elderly in Europe: \na retrospective comparison of national healthca -\nre frameworks in intensive care units. BMJ Open. \n2021 Jun 3;1 1(6):e046909. doi: 10. 1 136/bmjo -\npen-2020-046909. PMID: 34083342\n613. Coviello S, Benedetti B, Jakubecova D, Belles M, \nKlimczak P, Gramuntell Y, Couillard-Despres S, Na -\ncher J. PSA Depletion induces the differentiation of \nimmature neurons in the piriform cortex of adult \nmice. International Journal of Molecular Scien -\nces. 2021 May 27;22(1 1):5733. doi: 10.3390/\nijms22115733. PMID: 34072166\n614. Guillen-Climent S, Garcia-Vazquez A, Silva E, Esteba -\nnez A, Peredo A, Ruiz M, Monteagudo C, Quiles M. 337\n337\nINCLIVA SCIENTIFIC REPORT 2021publication list 9N, van den Heuvel M, Benkouar R, Findeisen H, Al -\nhaddad I, Al Balbissi K, Barge-Caballero G, Ghazi A, \nBruckers L, Martens P, Mullens W. Rationale and \ndesign of the efficacy of a standardized diuretic \nprotocol in acute heart failure study. ESC Heart \nFailure. 2021 Dec;8(6):4685-4692. doi: 10. 1002/\nehf2.13666. PMID: 34708555\n6 27. Mu\u00f1oz Langa J, Jimenez-Fonseca P, Carmona-Ba -\nyonas A, de Castro E, Perez-Segura P, Canovas M, \nGomez D, Moran L, de Tejada M, Segui E, Lopez G, \nAdrian S, Campos M, Olmos V, Portero B, Moyano \nM, Crespo J, Sanchez L, Rebollo M, Rivas P, Alto -\nzano J, Lescure A, Munoz-Martin A. Rationale, de -\nsign and methodology of TESEO study: a registry \nof thrombosis and neoplasia of SEOM (Spanish So -\nciety of Medical Oncology). Clinical & Translational \nOncology. 2021 Apr;23(4):799-81 1. doi: 10. 1007 /\ns12094-020-02472-x. PMID: 32789772\n628.  Torres I, Qualai J, Albert E, Bueno F, Huntley D, Pou -\njois S, Gil MT, Navarro D. Real-life evaluation of a ra -\npid extraction-free SARS-CoV-2 RT-PCR assay (CO -\nVID-19 PCR Fast-L) for the diagnosis of COVID-19. \nJournal of Medical Virology. 2021 Sep;93(9):5233-\n5235. doi: 10. 1002/jmv.27039. PMID: 33913561\n629.  Abrisqueta P, Loscertales J, Terol MJ, Ramirez Pa -\nyer A, Ortiz M, Perez I, Cuellar-Garcia C, Fernandez \nde la Mata M, Rodriguez A, Lario A, Delgado J, Go -\ndoy A, Arguinano Perez JM, Berruezo MJ, Oliveira \nA, Hernandez-Rivas JA, Garcia Malo MD, Medina A, \nGarcia Martin P, Osorio S, Baltasar P, Fernandez-\nZarzoso M, Marco F, Vidal Mancenido MJ, Smu -\ncler Simonovich A, Lopez Rubio M, Jarque I, Suarez \nA, Fernandez Alvarez R, Lancharro Anchel A, Rios \nE, Losada Castillo MC, Perez Persona E, Garcia \nMunoz R, Ramos R, Yanez L, Bello JL, Loriente C, \nAcha D, Villanueva M. Real-world characteristics \nand outcome of patients treated with single-agent \nibrutinib for Chronic Lymphocytic Leukemia in \nSpain (IBRORS-LLC Study). Clinical Lymphoma, Mye -\nloma & Leukemia. 2021 Dec;21(12):e985-e999. \ndoi: 10.1016/j.clml.2021.07 .022. PMID: 34511320\n630.  Iacoboni G, Villacampa G, Martinez-Cibrian N, Bai -\nlen R, Lopez Corral L, Sanchez J, Guerreiro M, Ca -\nballero A, Mussetti A, Sancho J, Hernani Morales \nR, Abrisqueta P, Solano Vercet C, Sureda A, Brio -\nnes J, Martin Garcia-Sancho A, Kwon M, Reguera-graphy for the assessment of lumbar sympathetic \nblocks: a preliminary study. Sensors. 2021 May \n21;21(11):3573. doi: 10.3390/s21113573. PMID: \n34063768\n621. Selma-Soriano E, Casillas-Serra C, Artero R, Lla -\nmusi B, Navarro J, Redon J. Rabphilin silencing \ncauses dilated cardiomyopathy in a Drosophila \nmodel of nephrocyte damage. Scientific Reports. \n2021 Jul 27;1 1(1):15287 . doi: 10. 1038/s41598-\n021-94710-7 . PMID: 34315987\n622.  Goni-Girones E, Fuertes-Cabero S, Blanco-Saiz I, \nCasans-Tormo I, San Miguel P, Martin-Gil J, Sam -\npol-Bas C, Abreu-Sanchez P, Diaz-Exposito R, Vidal-\nSicart S. Radioguided surgery in primary hyperpa -\nrathyroidism: a review of the different available \ntechniques. Revista Espanola de Medicina Nu -\nclear e Imagen Molecular. 2021;40(1):57-66. doi: \n10.1016/j.remn.2020.11.003. PMID: 33386282\n623.  Bruixola G, Remacha E, Jimenez-Pastor A, Dualde \nD, Viala A, Monton J, Ibarrola-Villava M, Alberich-\nBayarri A, Cervantes A. Radiomics and radiogeno -\nmics in head and neck squamous cell carcinoma: \npotential contribution to patient management \nand challenges. Cancer Treatment Reviews. 2021 \nSep;99:102263. doi: 10.1016/j.ctr v.2021.102263. \nPMID: 34343892\n624.  Sanchis J, Sastre C, Ruescas A, Ruiz V, Valero E, \nBonanad C, Garcia-Blas S, Fernandez-Cisnal A, \nGonzalez J, Minana G, Nunez J. Randomized com -\nparison of exercise intervention versus usual care \nin older adult patients with frailty after acute myo -\ncardial infarction. American Journal of Medicine. \n2021 Mar;134(3):383-390.e2. doi: 10. 1016/j.amj -\nmed.2020.09.019. PMID: 33228950\n625.  Nilsson A, Cano A, Bergens O, Kadi F. Randomized \ncontrolled trial for promotion of healthy eating in \nolder adults by increasing consumption of plant-\nbased foods: effect on inflammatory biomar -\nkers. Nutrients. 2021 Oct 24;13(1 1):3753. doi: \n10.3390/nu13113753. PMID: 34836009\n626.  Dauw J, Lelonek M, Zegri-Reiriz I, Paredes-Paucar \nC, Zara C, George V, Cobo-Marcos M, Knappe D, \nShchekochikhin D, Lekhakul A, Klincheva M, Frea \nS, Miro O, Barker D, Borbely A, Nasr S, Doghmi N, \nde la Espriella R, Singh J, Bovolo V, Fialho I, Ross 338\n338\nINCLIVA SCIENTIFIC REPORT 2021publication list9resis (GEA). Recommendations for the diagnosis \nand treatment of patients with thrombotic throm -\nbocytopenic purpura. Medicina Clinica. 2021 Jul \n12;S0025-7753(21)00332-8. doi: 10.1016/j.med -\ncli.2021.03.040. PMID: 34266669\n635.  Garcia-Herraiz A, Marquez-Can Combining Tilde \nAda J, Tejerina-Botella C. Reconstruction of a lar -\nge columellar defect. Dermatologic Surgery. 2021 \nJul 30. doi: 10. 1097 /DSS.0000000000003174. \nPMID: 34334619\n636.  Bernat-Adell M, Collado-Boira E, Moles-Julio P, Pani -\nzo-Gonzalez N, Martinez-Navarro I, Hernando-Fus -\nter B, Hernando-Domingo C. Recovery of inflam -\nmation, cardiac, and muscle damage biomarkers \nafter running a marathon. Journal of Strength and \nConditioning Research. 2021 Mar 1;35(3):626-\n632. doi: 10. 1519/ JSC.0000000000003167 . \nPMID: 31045685\n6 37. Proano-Haro A, Bagan L, Bagan JV. Recurrences \nfollowing treatment of proliferative verrucous \nleukoplakia: a systematic review and meta-analy -\nsis. Journal of Oral Pathology & Medicine. 2021 \nSep;50(8):820-828. doi: 10. 1 1 1 1/jop. 13178. PMID: \n33765364\n638.  Gomez-Cabrera C, Carretero A, Millan-Domingo F, \nGarcia-Dominguez E, Correas AG, Olaso-Gonzalez \nG, Vina J. Redox-related biomarkers in physical \nexercise. Redox Biology. 2021 Jun;42:101956. doi: \n10.1016/j.redox.2021.101956. PMID: 33811000\n639.  Perez-Cremades D, Paes A, Vidal-Gomez X, Mom -\npeon A, Hermenegildo C, Novella S. Regulatory \nnetwork analysis in estradiol-treated human en -\ndothelial cells. International Journal of Molecular \nSciences. 2021 Jul 30;22(15):8193. doi: 10.3390/\nijms22158193. PMID: 34360960\n640.  Horiuchi Y, Wettersten N, van Veldhuisen D, Mue -\nller C, Filippatos G, Nowak R, Hogan C, Kontos M, \nCannon C, Mueller G, Birkhahn R, Taub P, Vilke G, \nBarnett O, McDonald K, Mahon N, Nunez J, Bri -\nguori C, Passino C, Maisel A, Murray P. Relation of \ndecongestion and time to diuretics to biomarker \nchanges and outcomes in cute heart failure. Ame -\nrican Journal of Cardiology. 2021 May 15;147:70-\n79. doi: 10.1016/j.amjcard.2021.01.040. PMID: \n33617811Ortega J, Barba P, GETH G. Real-world evidence of \ntisagenlecleucel for the treatment of relapsed or \nrefractory large B-cell lymphoma. Cancer Medi -\ncine. 2021 May;10(10):3214-3223. doi: 10.1002/\ncam4.3881. PMID: 33932100\n631. Mensa J, Barberan J, Ferrer R, Borges M, Rascado \nP, Maseda E, Oliver A, Marco F, Adalia R, Aguilar G, \nEstella A, Lopez R, Marcos M, de Molina F, Garcia R, \nSalavert M, Gomez J, Poliakova Y, Pasquau J, Azan -\nza J, Arevalo G, Mondejar P, Cardinal-Fernandez P, \nSoriano A. Recommendations for antibiotic selec -\ntion for severe nosocomial infections. Revista Es -\npa\u00f1ola de Quimioterapia. 2021 Oct;34(5):51 1-524. \ndoi: 10.37201/req/126.2021. PMID: 34693705\n632.  Gegundez-Fernandez J, Llovet-Osuna F, Fernandez-\nVigo J, del Barrio J, Pablo-Julvez L, Munoz-Negrete \nF, Zarranz-Ventura J, de la Colina J, Silva V, Jimenez-\nAlfaro I, Calonge-Cano M, Galindo-Ferreiro A, Casti -\nllo-Gomez A, Mantolan-Sarmiento C, Duch-Samper \nA, de Toledo-Elizalde J, Duch-Mestres F, Elies-Amat \nD, Ortega-Usobiaga J, Saornil-Alvarez M, Cuadra -\ndo A, Aramburu G, Carduch A, Coma J, Delpech \nS, Carceles J, Sanchez J, Sanchez P, Castano M, \nPuente A, Garcia-Layana A, Spanish Ophthalmology \nSoc. Recommendations for ophthalmologic practi -\nce during the easing of COVID-19 control measu -\nres. Acta Ophthalmologica. 2021 Nov;99(7):e973-\ne983. doi: 10. 1 1 1 1/aos. 14752. PMID: 33433050\n633.  Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-\nManrique L, de Heredia C, Fortuny-Guasch C, Gar -\ncia-Cadenas I, Garcia-Vidal C, Gonzalez-Vicent M, \nHernani R, Kwon M, Machado M, Martinez-Gomez \nX, Maldonado V, Pla C, Pinana J, Pomar V, Reguera-\nOrtega J, Salavert M, Soler-Palacin P, Vazquez-Lo -\npez L, Barba P, Ruiz-Camps I. Recommendations for \nscreening, monitoring, prevention, and prophylaxis \nof infections in adult and pediatric patients recei -\nving CAR T-cell therapy: a position paper. Infection. \n2021 Apr;49(2):215-231. doi: 10.1007/s15010-\n020-01521-5. PMID: 32979154\n634.  Mingot Castellano M, Pascual Izquierdo C, Gonza -\nlez A, Viejo Llorente A, Valcarcel Ferreiras D, Se -\nbastian E, Garcia Candel F, Sarmiento Palao H, Go -\nmez Segui I, de la Rubia J, Cid J, Martinez Nieto J, \nHernandez Mateo L, Goterris Viciedo R, Fidalgo T, \nSalinas R, Del Rio-Garma J, Grupo Espanol de Afe -339\n339\nINCLIVA SCIENTIFIC REPORT 2021publication list 9Carratala-Munuera C. Renal function and attribu -\ntable risk of death and cardiovascular hospitali -\nzation in participants with diabetes from a regis -\ntry-based cohort. Primary Care Diabetes. 2021 \nFeb;15(1):88-94. doi: 10.1016/j.pcd.2020.06.004. \nPMID: 32646765\n6 47. Bohm M, Schumacher H, Teo K, Lonn E, Mahfoud \nF, Emrich I, Mancia G, Redon J, Schmieder R, Sliwa \nK, Lehrke M, Marx N, Weber M, Williams B, Yusuf \nS, Mann J. Renal outcomes and blood pressure \npatterns in diabetic and nondiabetic individuals \nat high cardiovascular risk. Journal of Hyperten -\nsion. 2021 Apr 1;39(4):766-774. doi: 10. 1097 /\nHJH.0000000000002697 . PMID: 33560052\n648.  Nunez-Gil IJ, Olier I, Feltes G, Viana-Llamas MC, \nMaroun-Eid C, Romero R, Fernandez-Rozas I, Uri -\nbarri A, Becerra-Munoz VM, Alfonso-Rodriguez E, \nGarcia-Aguado M, Elola J, Castro-Mejia A, Pepe \nM, Garcia-Prieto JF, Gonzalez A, Ugo F, Cerrato E, \nBondia E, Raposeiras-Roubin S, Mendez JL, Espejo \nC, Lopez-Masjuan A, Marin F, Lopez-Pais J, Abuma -\nyyaleh M, Corbi-Pascual M, Liebetrau C, Ramakris -\nhna H, Estrada V, Macaya C, Fernandez-Ortiz A. \nRenin-angiotensin system inhibitors effect before \nand during hospitalization in COVID-19 outcomes: \nfinal analysis of the international HOPE COVID-19 \n(Health Outcome Predictive Evaluation for CO -\nVID-19) registry. American Heart Journal. 2021 \nJul;237:104-115. doi: 10.1016/j.ahj.2021.04.001. \nPMID: 33845032\n649.  Piolatti-Luna A, Castillo-Corrullon S. Repeated \naspiration pneumonia in a 7-year-old girl with \nundiagnosed congenital tracheoesophageal \nfistula. Archivos de Bronconeumologia. 2021 \nJun 16;S1579-2129(21)00187-7 . doi: 10. 1016/j.\narbr.2021.05.015. PMID: 34147349\n650.  Smyth EC, Gambardella V, Cervantes A, Fleitas T. \nReply to the letter to the editor: adjuvant nivolu -\nmab for the management of the pathological re -\nsidual disease in esophageal or junctional tumors: \na word of caution by P.K. Garg, R. Kumar and P. \nDixit. Annals of Oncology. 2021 Sep;32(9):1 190-\n1 191. doi: 10. 1016/j.annonc.2021.05.795. PMID: \n34033882\n651. Priego-Quesada J, Gandia-Soriano A, Pellicer-Chenoll \nM, Catala-Vilaplana I, Bermejo-Ruiz J, Encarnacion-641. Schwartz G, Szarek M, Bittner V, Bhatt D, Diaz \nR, Goodman S, Jukema J, Loy M, Manvelian G, \nPordy R, White H, Steg P, ODYSSEY OUTCOMES \nComm Investigator. Relation of Lipoprotein(a) le -\nvels to incident type 2 diabetes and modification \nby alirocumab treatment. Diabetes Care. 2021 \nMay;44(5):1219-1227. doi: 10.2337 /dc20-2842. \nPMID: 33722880\n642.  De la Serna E, Puig O, Mezquida G, Moreno-Izco L, \nMerchan-Naranjo J, Amoretti S, Ruiz P, Gonzalez-\nPinto A, Molina-Garcia M, Corripio I, Vieta E, Baeza \nI, Berge D, Penades R, Sanchez-Torres A, Cuesta \nM, Bernardo M, Castro-Fornieles J, PEPs Group. \nRelationship between cognition and age at on -\nset of first-episode psychosis: comparative study \nbetween adolescents, young adults, and adults. \nEuropean Child & Adolescent Psychiatry. 2021 \nOct 29. doi: 10. 1007 /s00787-021-01901-8. PMID: \n34714406\n643.  Vanaclocha-Ferrer C, Padilla-Fernandez B, Mar -\nquez-Sanchez M, Garcia-Sanchez M, Rodriguez-\nMartin M, Hernandez-Navarro N, Domenech-Perez \nC, Valverde-Martinez L, Flores-Fraile M, Huelamo \nM, Nieto-Barbero J, Miron-Canelo J, Garcia-Cena -\ndor M, Lorenzo-Gomez M. Relationship between \nobstetric history and recurrent urinary infections. \nScientific Reports. 2021 Sep 20;1 1(1):18621. doi: \n10.1038/s41598-021-98116-3. PMID: 34545131\n644.  Garcia-Diaz C, Gil-Miravet I, Albert-Gasco H, \nManas-Ojeda A, Ros-Bernal F, Castillo-Gomez E, \nGundlach A, Olucha-Bordonau F. Relaxin-3 inner -\nvation from the nucleus incertus to the parahip -\npocampal cortex of the rat. Frontiers in Neuroa -\nnatomy. 2021 Jun 22;15:674649. doi: 10.3389/\nfnana.2021.674649. PMID: 34239421\n645.  Bonet Mora L, Torous J, Arce D, Blanquer I, San -\njuan Arias J. ReMindCare, an app for daily clinical \npractice in patients with first episode psychosis: \na pragmatic real-world study protocol. Early Inter -\nvention in Psychiatry. 2021 Feb;15(1):183-192. doi: \n10.1111/e i p.12960.  PMID:  32253830\n646.  Ruiz-Quintero M, Red\u00f3n Mas J, Tellez-Plaza M, \nCebrian-Cuenca A, Navarro Perez J, Menendez E, \nPerez-Navarro A, Fernandez-Gimenez A, Lopez-Pi -\nneda A, Quesada J, Pallares-Carratala V, Gil-Guillen \nV, Mart\u00edn Moreno J, Bleda-Cano J, Carrascosa S, 340\n340\nINCLIVA SCIENTIFIC REPORT 2021publication list9Genis A, Nunez J. Right heart dysfunction and \nreadmission risk across left ventricular ejection \nfraction status in patients with acute heart failure. \nJournal of Cardiac Failure. 2021 Oct;27(10):1090-\n1098. doi: 10.1016/j.cardfail.2021.06.020. PMID: \n34273477\n658.  Mi\u00f1ana Escriva G, Santas Olmeda E, De La Esprie -\nlla Juan R, Nunez E, Lorenzo Hern\u00e1ndez M, N\u00fa\u00f1ez \nMar\u00edn G, Valero Picher E, Bod\u00ed Peris V, Chorro Gas -\nc\u00f3 F, Sanchis Fores J, Cohen-Solal A, Bayes-Genis \nA, Nu\u00f1ez Villota J. Right ventricular function and \niron deficiency in acute heart failure. European \nHeart Journal. Acute Cardiovascular Care. 2021 \nMay 25;10(4):406-414. doi: 10.1093/ehjacc/\nzuaa028. PMID: 33620455\n659.  Marti-Aguado D, Ballester M, Minguez M. Risk \nfactors and management strategies associa -\nted with non-response to aminosalicylates for \nmaintenance treatment in ulcerative colitis. \nRevista Espanola de Enfermedades Digesti -\nvas. 2021 Jun;1 13(6):447-453. doi: 10. 17235/\nreed.2021.7797 /2021. PMID: 33569968\n660.  Gonzalez-Barbeito M, Arribas J, Vazquez A, Carne -\nro M, Sarralde J, Cal-Purrinos N, Canovas S, Ma -\nroto L, Gutierrez F, Hornero F, Bautista-Hernan -\ndez V. Risk factors for postoperative pacemaker \nimplantation after rapid deployment aortic valve \nreplacement: results from the RADAR Regis -\ntry. Advances in therapy. 2021 Apr;38(4):1832-\n1842. doi: 10. 1007 /s12325-021-01622-z. PMID: \n33665760\n661.  Calafat M, Manosa M, Ricart E, Nos P, Iglesias-\nFlores E, Vera I, Lopez-SanRoman A, Guardiola \nJ, Taxonera C, Minguez M, Martin-Arranz MD, \nde Castro L, de Francisco R, Rivero M, Garcia-\nPlanella E, Calvet X, Garcia-Lopez S, Marquez \nL, Gomollon F, Barrio J, Esteve M, Munoz F, Gis -\nbert JP, Gutierrez A, Hinojosa J, Arguelles-Arias \nF, Busquets D, Bujanda L, Perez-Calle JL, Sicilia \nB, Merino O, Martinez P, Bermejo F, Lorente R, \nBarreiro-de Acosta M, Rodriguez C, Garcia-\nSepulcre MF, Monfort D, Canete F, Domenech \nE. Risk of immunomediated adverse events and \nloss of response to infliximab in elderly patients \nwith inflammatory bowel disease. A cohort study \nof the ENEIDA registry. Journal of Crohn\u2019s & Co -Martinez A, Salvador-Palmer R, Cibrian Ortiz de Anda \nR. Reproducibility of skin temperature response after \ncold stress test using the Game Ready System: preli -\nminary study. International Journal of Environmental \nResearch and Public Health. 2021 Aug 5;18(16):8295. \ndoi: 10.3390/ijerph18168295. PMID: 34444044\n652.  Sabater L, Padillo J. Response to the comment on \ndoes the artery-first approach improve the Rate \nof R0 resection in pancreatoduodenectomy?. A \nmulticenter, randomized, controlled trial. Reply. \nAnnals of Surgery. 2021 Dec 1;274(6):e679-e680. \ndoi: 10. 1097 /SLA.0000000000003773. PMID: \n31913869\n653.  Simon C, Gomez C, Ruiz M, Mol B, Valbuena D. \nResponse to: comments on the methodology of \nan endometrial receptivity array trial. Reproduc -\ntive Biomedicine Online. 2021 Jan;42(1):284. doi: \n10.1016/j.rbmo.2020.09.028. PMID: 33060012\n654.  Moreno C, Munoz C, Terol MJ, Hernandez-Rivas JA, \nVillanueva M. Restoration of the immune function \nas a complementary strategy to treat Chronic \nLymphocytic Leukemia effectively. Journal of Ex -\nperimental & Clinical Cancer Research. 2021 Oct \n15;40(1):321. doi: 10.1186/s13046-021-02115-1. \nPMID: 34654437\n655.  Vitale P, Zanaletti N, Famiglietti V, De Falco V, \nCervantes A, Rosell\u00f2 S, Fenocchio E, Milanesio \nM, Lombardi P, Ciardiello D, Martini G, Martinelli \nE, Ciardiello F, Troiani T, Napolitano S. Retrospec -\ntive study of regorafenib versus TAS-102 effica -\ncy and safety in chemorefractory Metastatic \nColorectal Cancer (mCRC) patients: a multi-ins -\ntitution real life clinical data. Clinical Colorectal \nCancer. 2021 Sep;20(3):227-235. doi: 10. 1016/j.\nclcc.2021.06.002. PMID: 34226142\n656.  Castelo-Branco C, Gambacciani M, Cano A, Min -\nkin M, Rachon D, Ruan X, Beer A, Schnitker J, \nHenneicke-von Zepelin H, Pickartz S. Review & \nmeta-analysis: isopropanolic black cohosh extract \niCR for menopausal symptoms - an update on the \nevidence. Climacteric. 2021 Apr;24(2):109-1 19. \ndoi: 10.1080/13697137 .2020.1820477 . PMID: \n33021111\n657. Santas E, Minana G, Palau P, De La Espriella R, \nLorenzo M, Nunez G, Sanchis J, Chorro FJ, Bayes-341\n341\nINCLIVA SCIENTIFIC REPORT 2021publication list 9nell N, Pallardo FV, Lavie CJ, Garcia Gimenez JL. \nRole of non-coding RNAs as biomarkers of dele -\nterious cardiovascular effects in sepsis. Progress \nin Cardiovascular Diseases. 2021;68:70-77 . doi: \n10.1016/j.pcad.2021.07 .005. PMID: 34265333\n669.  Ferrer S, Sancho J, Bocigas I, Bures E, Mora H, \nMonclou E, Mulet A, Quezada A, Royo P, Signes-\nCosta J. ROX index as predictor of high flow \nnasal cannula therapy success in acute respi -\nratory failure due to SARS-CoV-2. Respiratory \nMedicine. 2021 Oct 6;189:106638. doi: 10. 1016/j.\nrmed.2021. 106638. PMID: 34634500\n670.  Condorelli M, Bruzzone M, Ceppi M, Ferrari A, \nGrinshpun A, Hamy AS, de Azambuja E, Carras -\nco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, \nPoorvu PD, Venturelli M, Rousset-Jablonski C, Se -\nnechal C, Livraghi L, Ponzone R, De Marchis L, Po -\ngoda K, Sonnenblick A, Villarreal-Garza C, Cordoba \nO, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, \nPerez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, \nBlondeaux E, Peretz-Yablonski T, Caron O, Saule \nC, Ameye L, Balmana J, Partridge AH, Azim HA, \nDemeestere I, Lambertini M. Safety of assisted \nreproductive techniques in young women harbo -\nring germline pathogenic variants in BRCA1/2 \nwith a pregnancy after prior history of breast \ncancer. ESMO Open. 2021 Nov 1 1;6(6):100300. \ndoi: 10.1016/j.esmoop.2021.100300. PMID: \n34775302\n671. Lavinio A, Ercole A, Battaglini D, Magnoni S, Ba -\ndenes R, Taccone F, Helbok R, Thomas W, Pelosi \nP, Robba C. Safety profile of enhanced thrombo -\nprophylaxis strategies for critically ill COVID-19 pa -\ntients during the first wave of the pandemic: obser -\nvational report from 28 European intensive care \nunits. Critical Care. 2021 Apr 22;25(1):155. doi: \n10.1186/s13054-021-03543-3. PMID: 33888132\n672.  Viola G, Stabile G, Bandino S, Rossi L, Marrazzo N, \nPecora D, Bottoni N, Solimene F, Schillaci V, Sca -\nglione M, Ocello S, Baiocchi C, Santoro A, Donzelli \nS, De Ruvo E, Lavalle C, Sanchez-Gomez J, Pas -\ntor J, Grandio P, Ferraris F, Castro A, Rebellato \nL, Marchese P, Adao L, Primo J, Barra S, Casu G. \nSafety, efficacy, and reproducibility of cavotricus -\npid isthmus ablation guided by the ablation index: \nacute results of the FLAI study. Europace. 2021 litis. 2021 Dec 3;jjab213. doi: 10. 1093/ecco-jcc/\njjab213. PMID: 34864947\n662.  Martinez-Monte E, Gascon-Gimenez F, Dominguez-\nMoran JA, Lainez-Andres JM. Rituximab for the \ntreatment of generalised myasthenia gravis: ex -\nperience in clinical practice. Revista de Neurolo -\ngia. 2021 Nov 16;73(12):416-420. doi: 10.33588/\nrn.7312.2021166. PMID: 34877644\n663.  Guzman Morais B, Ordonez Alvarez F, Santos \nRodriguez F, Martin Ramos S, Fernandez Novo \nG. Rituximab treatment in pediatric patients \nwith steroid-dependent nephrotic syndrome: a \ntertiary hospital. Anales de Pediatria. 2021 Jan \n28;S1695-4033(20)30529-4. doi: 10.1016/j.anpe -\ndi.2020.12.010. PMID: 33518484\n664.  Perez Cabeza A, G\u00f3rriz Teruel J, Bravo Marques \nR, Chinchurreta Capote P, Lopez Tejero S, Gon -\nzalez Correa J, Mesa Prado F, Valle Alberca A, \nRuiz Mateas F. Rivaroxaban inappropriate dosa -\nge predictor factors using the Ckd-Epi equation. \nNefrologia. 2021;41(2):216-218. doi: 10.1016/j.ne -\nfro.2020.04.016. PMID: 32819726\n665.  Beltran-Beltran V, Beneto N, Lapena-Luzon T, Ro -\ndriguez LR, Pallardo FV, Gonzalez-Cabo P. Role of \nadenosine receptors in rare neurodegenerative \ndiseases with motor symptoms. Current Protein \n& Peptide Science. 2021 Dec 27;22(9):675-694. \ndoi: 10.2174/1389203722666210910110126. \nPMID: 34514988\n666.  Rios Navarro C, Hueso Soler L, Diaz Cuevas A, \nMarcos Garc\u00e9s V, Bonanad Lozano C, Ruiz Sauri \nA, Vila Salinas J, Sanz Ferrando M, Chorro Gas -\nc\u00f3 F, Piqueras Ruiz L, Bod\u00ed Peris V. Role of an -\ntiangiogenic VEGF-A165b in angiogenesis and \nsystolic function after reperfused myocardial in -\nfarction. Revista Espanola de Cardiologia (English \ned.). 2021 Feb;74(2):131-139. doi: 10. 1016/j.\nrec.2020.03.013. PMID: 32474003\n6 67. Osca-Verdegal R, Beltran-Garcia J, Pallardo FV, \nGarcia-Gimenez JL. Role of microRNAs as biomar -\nkers in sepsis-associated encephalopathy. Molecu -\nlar Neurobiology. 2021 Sep;58(9):4682-4693. doi: \n10.1007 /s12035-021-02445-3. PMID: 34160774\n668.  Beltran Garcia J, Osca Verdegal R, Nacher Sendra \nE, Cardona Monzonis A, Sanchis Gomar F, Carbo -342\n342\nINCLIVA SCIENTIFIC REPORT 2021publication list9memory T lymphocytes from COVID-19 convales -\ncent donors: identification, biobanking, and large-\nscale production for adoptive cell therapy. Fron -\ntiers in Cell and Developmental Biology. 2021 Feb \n25;9:620730. doi: 10.3389/fcell.2021.620730. \nPMID: 33718360\n679.  Abad-Garcia MF, Gonzalez-Teruel A, Bolanos-Piza -\nrro M, Lurbe I Ferrer E. Scientific mapping of the \nresearch output on hypertension in children and \nadolescents, 2010-2018. Journal of Hyperten -\nsion. 2021 Jun 1;39(6):1070-1076. doi: 10. 1097 /\nHJH.0000000000002772. PMID: 33929402\n680.  Pinana J, Xhaard A, Tridello G, Passweg J, Kozijn A, \nPolverelli N, Heras I, Perez A, Sanz J, Berghuis D, \nVazquez L, Suarez-Lledo M, Itala-Remes M, Ozce -\nlik T, Iturrate Basaran I, Karakukcu M, Al Zahrani \nM, Choi G, Cuesta Casas M, Batlle Massana M, \nViviana A, Blijlevens N, Ganser A, Kuskonmaz B, \nLabussiere-Wallet H, Shaw P, Arzu Yegin Z, Gonza -\nlez-Vicent M, Rocha V, Ferster A, Knelange N, Na -\nvarro D, Mikulska M, de la Camara R, Styczynski \nJ, Infectious Diseases Working Party of the Euro -\npean Society for Blood and, Marrow Transplanta -\ntion and Infectious Complications Subcommittee, \nSpanish Hematopoietic Stem Cell Transplantation \nand Cell Therapy Group, (GETH). Seasonal human \ncoronaviruses respiratory tract infection in re -\ncipients of allogeneic hematopoietic stem cell \ntransplantation. Journal of Infectious Diseases. \n2021 May 20;223(9):1564-1575. doi: 10. 1093/\ninfdis/jiaa553. PMID: 32860509\n681. Beisani M, Pereferrer F, Vilallonga R, Lopez O, Lo -\npez A, Dejardin D, de Gordejuela A, Lopez-Barajas \nJ, Carrasco M, Spanish Surg Assoc Collaborati -\nve G. Seeking an initial-weight-independent me -\ntric in a mediterranean cohort of gastric bypass \npatients: the %AWL revisited. Obesity Surgery. \n2021 Apr;31(4):1524-1532. doi: 10.1007/s11695-\n020-05154-3. PMID: 33398625\n682.  Alessandri F, Badenes R, Bilotta F. Seizures and \nsepsis: a narrative review. Journal of Clinical Me -\ndicine. 2021 Mar 3;10(5):1041. doi: 10.3390/\njcm10051041. PMID: 33802419\n683.  Smyth LM, Batist G, Meric-Bernstam F, Kabos P, \nSpanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, \nSchram AM, Ambrose H, Carr TH, de Bruin EC, Sa -Feb 5;23(2):264-270. doi: 10. 1093/europace/\neuaa215. PMID: 33212484\n673.  Foulk R, Sakkas D, Kayali R, Valbuena D, Simon \nC, Cuzzi J. SARS-CoV-2 immunity, infective and \nna\u00efve incidence in fertility clinics after lockdown. \nAmerican Journal of Obstetrics and Gyneco -\nlogy.2021 Jul;225(1):103-105. doi: 10.1016/j.\najog.2021.03.008. PMID: 33716073\n674. GlobalSurg Collaborative, Only G, COVIDSurg Co -\nllaborative. SARS-CoV-2 vaccination modelling for \nsafe surgery to save lives: data from an interna -\ntional prospective cohort study. British Journal of \nSurgery. 2021 Sep 27;108(9):1056-1063. PMID: \n33761533\n675.  D\u2019Marco L, Puchades MJ, Serra MA, Gandia L, Ro -\nmero-Alcaide S, Gimenez-Civera E, Molina P, Pani -\nzo N, Reque J, Gorriz JL. SARS-CoV-2 vs. Hepatitis \nvirus infection risk in the hemodialysis population: \nwhat should we expect?. International Journal of \nEnvironmental Research and Public Health. 2021 \nMay 27;18(1 1):5748. doi: 10.3390/ijerph181 15748. \nPMID: 34071948\n676.  Gimenez Quiles E, Albert Vicent E, Torres Fink I, Re -\nmigia Pellicer M, Alcar\u00e1z Soriana M, Galindo Puerto \nM, Blasco Cortes M, Solano Vercet C, Forner Giner \nM, Red\u00f3n Mas J, Signes-Costa Mi\u00f1ana J, Navarro \nOrtega D. SARS-CoV-2-reactive interferon-gamma-\nproducing CD8+ T cells in patients hospitalized \nwith Coronavirus Disease 2019. Journal of Medical \nVirology. 2021 Jan;93(1):375-382. doi: 10. 1002/\njmv.26213. PMID: 32579268\n67 7. Fernandez-Ruiz M, Olea B, Gimenez E, Laguna-Goya \nR, Trujillo H, Caravaca-Fontan F, Gutierrez E, Lopez-\nMedrano F, Remigia M, Almendro-Vazquez P, Polan -\nco N, Gonzalez E, Ruiz-Merlo T, Parra P, San Juan R, \nAndres A, Navarro D, Aguado J. SARS-CoV-2-spe -\ncific cell-mediated immunity in kidney transplant \nrecipients recovered from COVID-19. Transplanta -\ntion. 2021 Jun 1;105(6):1372-1380. doi: 10. 1097 /\nTP.0000000000003672. PMID: 33729741\n678.  Ferreras C, Pascual-Miguel B, Mestre-Duran C, \nNavarro-Zapata A, Clares-Villa L, Martin-Cortazar \nC, De Paz R, Marcos A, Vicario J, Balas A, Garcia-\nSanchez F, Eguizabal C, Solano C, Mora-Rillo M, \nSoria B, Perez-Martinez A. SARS-CoV-2-specific 343\n343\nINCLIVA SCIENTIFIC REPORT 2021publication list 9Medicine. 2021 Dec;40(6):100966. doi: 10. 1016/j.\naccpm.2021.100966. PMID: 34718184\n689.  Pertusa C, Tarin JJ, Cano A, Garcia-Perez MA, Mif -\nsut D. Serum microRNAs in osteoporotic fracture \nand osteoarthritis: a genetic and functional study. \nScientific Reports. 2021 Sep 29;1 1(1):19372. doi: \n10.1038/s41598-021-98789-w. PMID: 34588560\n690.  Esquirol A, Pascual M, Kwon M, Perez A, Paro -\ndy R, Ferra C, Cadenas I, Herruzo B, Dorado N, \nHernani R, Sanchez-Ortega I, Torrent A, Sierra \nJ, Martino R, Spanish Grp Hematopoietic Stem. \nSevere infections and infection-related mortality \nin a large series of haploidentical hematopoietic \nstem cell transplantation with post-transplant \ncyclophosphamide. Bone Marrow Transplanta -\ntion. 2021 Oct;56(10):2432-2444. doi: 10. 1038/\ns41409-021-01328-4. PMID: 34059802\n691. Herrera Castro R. Sevoflurane well-handled in \nchildren is excellent, but in the wrong hands \ncan be life-threatening. Journal of Investiga -\ntive Surgery. 2021 Feb;34(2):241-242. doi: \n10.1080/08941939.2019.1616860. PMID: \n31164021\n692.  Nunez J, Lorenzo M, Minana G, Palau P, Monme -\nneu JV, Lopez-Lereu MP, Gavara J, Marcos-Garces \nV, Rios-Navarro C, Perez N, de Dios E, Nunez E, \nSanchis J, Chorro FJ, Bayes-Genis A, Bodi V. Sex \ndifferences on new-onset heart failure in patients \nwith known or suspected coronary artery disease. \nEuropean Journal of Preventive Cardiology. 2021 \nDec 29;28(15):171 1-1719. doi: 10. 1093/eurjpc/\nzwab078. PMID: 33970216\n693.  Bahadoer R, Dijkstra E, van Etten B, Marijnen C, \nPutter H, Kranenbarg E, Roodvoets A, Nagtegaal \nI, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, \nCapdevila J, Hendriks M, Edhemovic I, Cervantes \nA, Nilsson P, Glimelius B, van de Velde C, Hospers \nG, RAPIDO collaborative investigators. Short-cour -\nse radiotherapy followed by chemotherapy before \ntotal mesorectal excision (TME) versus preope -\nrative chemoradiotherapy, TME, and optional ad -\njuvant chemotherapy in locally advanced rectal \ncancer (RAPIDO): a randomised, open-label, phase \n3 trial. Lancet. Oncology. 2021 Jan;22(1):29-42. \ndoi: 10.1016/S1470-2045(20)30555-6. PMID: \n33301740linas-Souza C, Foxley A, Hauser J, Lindemann JPO, \nMaudsley R, McEwen R, Moschetta M, Nikolaou M, \nSchiavon G, Razavi P, Banerji U, Baselga J, Hyman \nDM, Chandarlapaty S. Selective AKT kinase inhibi -\ntor capivasertib in combination with fulvestrant in \nPTEN-mutant ER-positive metastatic breast can -\ncer. NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: \n10.1038/s41523-021-00251-7 . PMID: 33863913\n684.  Ruiz-Alguero M, Hernando V, Marcos H, Gutierrez \nG, Perez-Elias M, de Quiros J, Pulido F, Gorgolas \nM, Sanz J, Suarez-Garcia I, Fernandez M, Losa J, \nPerez J, Ladrero M, Prieto M, Gonzalez G, Izquier -\ndo A, Viloria L, Lopez I, Martinez E, Castrillejo D, \nAranguren R, Belmonte M, Aranda-Garcia I, Arrai -\nza A, Diaz A, Hospital Survey Study Group. Self-\nrated health among people living with HIV in Spain \nin 2019: a cross-sectional study. BMC Infectious \nDiseases. 2021 Jan 30;21(1):129. doi: 10. 1 186/\ns12879-021-05815-3. PMID: 33516173\n685.  Alarcon M, Buch E, Julve A, Hernandorena M, \nTajahuerce M, Rodriguez H, Bermejo B, Ramirez \nJ, Burgues O, Diaz S, Alcala G, Ortega J. Sentinel \nlymph node BIOPSY after neoadjuvant therapy \nin breast cancer patients with lymph node in -\nvolvement at diagnosis. Could wire localization \nof clipped node improve our results?. Surgeon. \n2021 Dec;19(6):344-350. doi: 10. 1016/j.sur -\nge.2021.01.013. PMID: 33663946\n686.  Redondo A, Guerra E, Manso L, Martin-Lorente C, \nMartinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio \nM, Barretina-Ginesta M, Gonzalez-Martin A. SEOM \nclinical guideline in ovarian cancer (2020). Clinical \n& Translational Oncology. 2021 May;23(5):961-\n968. doi: 10. 1007 /s12094-020-02545-x. PMID: \n33515422\n6 87. Monllor P, Giraldo E, Badia M, de la Asuncion J, \nAlonso M, Lloret A, Vina J. Serum levels of cluste -\nrin, PKR, and RAGE correlate with amyloid burden \nin Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Di -\nsease. 2021;80(3):1067-1077. doi: 10.3233/JAD-\n201443. PMID: 33646167\n688.  Lorente L, Martin MM, Ruiz C, Abreu-Gonzalez P, \nRamos-Gomez L, Argueso M, Sole-Violan J, Cace -\nres JJ, Jimenez A. Serum melatonin levels in pre -\ndicting mortality in patients with severe trauma -\ntic brain injury. Anaesthesia Critical Care & Pain 344\n344\nINCLIVA SCIENTIFIC REPORT 2021publication list9700.  Jongsma H, Gayer-Anderson C, Tarricone I, \nVelthorst E, van der Ven E, Quattrone D, di For -\nti M, Menezes P, Del-Ben C, Arango C, Lasalvia \nA, Berardi D, La Cascia C, Bobes J, Bernardo M, \nSanjuan Arias J, Santos J, Arrojo M, de Haan L, \nTortelli A, Szoke A, Murray R, Rutten B, van Os \nJ, Morgan C, Jones P, Kirkbride J, EU-GEI WP2 \nGroup. Social disadvantage, linguistic distance, \nethnic minority status and first-episode psycho -\nsis: results from the EU-GEI case-control study. \nPsychological Medicine. 2021 Jul;51(9):1536-\n1548. doi: 10. 1017 /S003329172000029X. \nPMID: 32122439\n701. Benavent M, Guillen-Climent S, Martinez-Casimiro \nL, Fabra M, Castro C. Soft nodule on the heel in \nan elderly male patient: answer. American Journal \nof Dermatopathology. 2021 Sep 1;43(9):674-675. \ndoi: 10. 1097 /DAD.0000000000001882. PMID: \n34411022\n702.  Benavent M, Guillen-Climent S, Martinez-Casimiro \nL, Fabra M, Castro C. Soft nodule on the heel in \nan elderly male patient: challenge. American Jour -\nnal of Dermatopathology. 2021 Sep 1;43(9):e102-\ne103. doi: 10. 1097 /DAD.0000000000001883. \nPMID: 34411026\n703.  Machado I, Nieto Morales MG, Cruz J, Lavernia J, \nGiner F, Navarro S, Ferrandez A, Llombart-Bosch \nA. Solitary fibrous tumor: integration of clinical, \nmorphologic, immunohistochemical and molecu -\nlar findings in risk stratification and classification \nmay better predict patient outcome. Interna -\ntional Journal of Molecular Sciences. 2021 Aug \n30;22(17):9423. doi: 10.3390/ijms22179423. \nPMID: 34502329\n704.  Pascual T, Oliveira M, Ciruelos E, Ezquerra M, Saura \nC, Gavila J, Pernas S, Munoz M, Vidal M, Vila M, Ce -\njalvo J, Gonzalez-Farre B, Espinosa-Bravo M, Cruz J, \nSalvador-Bofill F, Guerra J, Barrera A, de Dios M, Es -\nker S, Fan P, Martinez-Saez O, Villacampa G, Pare L, \nFerrero-Cafiero J, Villagrasa P, Prat A. SOLTI-1805 \nTOT-HER3 study concept: a window-of-opportunity \ntrial of patritumab deruxtecan, a her3 directed \nantibody drug conjugate, in patients with early \nbreast cancer. Frontiers in Oncology. 2021 Apr \n23;11:638482. doi: 10.3389/fonc.2021.638482. \nPMID: 33968735694.  Perez-Miralles F, Prefasi D, Garcia-Merino A, Ara \nJ, Izquierdo G, Meca-Lallana V, Gascon-Gimenez F, \nMartinez-Gines M, Ramio-Torrenta L, Costa-Fros -\nsard L, Fernandez O, Moreno-Garcia S, Medrano \nN, Maurino J, Casanova B. Short-term data on \ndisease activity, cognition, mood, stigma and em -\nployment outcomes in a cohort of patients with \nprimary progressive multiple sclerosis (UPPMS \nstudy). Multiple Sclerosis and Related Disor -\nders. 2021 Feb 23;50:102860. doi: 10. 1016/j.\nmsard.2021.102860. PMID: 33647591\n695.  Ruiz-Cantero M, Gonzalez-Cano R, Tejada M, \nSantos-Caballero M, Perazzoli G, Nieto F, Cobos \nE. Sigma-1 receptor: a drug target for the mo -\ndulation of neuroimmune and neuroglial interac -\ntions during chronic pain. Pharmacological Re -\nsearch. 2021 Jan;163:105339. doi: 10. 1016/j.\nphrs.2020. 105339. PMID: 33276102\n696.  Malhi V, Budha N, Sane R, Huang J, Liederer B, \nMeng R, Patel P, Deng Y, Cervantes A, Tabernero J, \nMusib L. Single- and multiple-dose pharmacokine -\ntics, potential for CYP3A inhibition, and food effect \nin patients with cancer and healthy subjects recei -\nving ipatasertib. Cancer Chemotherapy and Phar -\nmacology. 2021 Dec;88(6):921-930. doi: 10. 1007 /\ns00280-021-04344-9. PMID: 34471960\n6 97. Vilella F, Wang W, Moreno I, Roson B, Quake S, Si -\nmon C. Single-cell RNA sequencing of SARS-CoV-2 \ncell entry factors in the preconceptional human \nendometrium. Human Reproduction. 2021 Sep \n18;36(10):2709-2719. doi: 10.1093/humrep/\ndeab183. PMID: 34329437\n698.  Martinez-Arroyo O, Selma-Soriano E, Ortega A, \nCortes R, Redon J. Small Rab GTPases in intracellu -\nlar vesicle trafficking: the case of Rab3A/Raphillin-\n3a complex in the kidney. International Journal of \nMolecular Sciences. 2021 Jul 18;22(14):7679. doi: \n10.3390/ijms22147679. PMID: 34299299\n699.  Iessa N, Sarinic V, Ghazaryan L, Romanova N, \nAlemu A, Rungapiromnan W, Jiamsuchon P, Po -\nkhagul P, Castro J, Saint-Gerons D, Ghukasyan G, \nTeferi M, Gupta M, Pal S. Smart Safety Surveillan -\nce (3S): multi-country experience of implementing \nthe 3S concepts and principles. Drug Safety. 2021 \nOct;44(10):1085-1098. doi: 10.1007/s40264-021-\n01100-z. PMID: 34331675345\n345\nINCLIVA SCIENTIFIC REPORT 2021publication list 9ker for paternal offspring autism susceptibility. Cli -\nnical Epigenetics. 2021 Jan 7;13(1):6. doi: 10. 1 186/\ns13148-020-00995-2. PMID: 33413568\n711. Garcia-Botello S, Garces-Albir M, Espi-Macias A, \nMoro-Valdezate D, Pla-Marti V, Martin-Arevalo J, \nOrtega-Serrano J. Sphincter damage during fis -\ntulotomy for perianal fistulae and its relationship \nwith faecal incontinence. Langenbecks Archives \nof Surgery. 2021 Nov;406(7):2497-2505. doi: \n10.1007 /s00423-021-02307-5. PMID: 34468863\n712. De La Espriella Juan R, Bayes-Genis A, Revuelta E, \nMi\u00f1ana Escriva G, Santas Olmeda E, Llacer P, Gar -\ncia Blas S, Fern\u00e1ndez Cisnal A, Bonanad Lozano C, \nVentura S, Sanchez R, Bod\u00ed Peris V, Cordero A, Fa -\ncila De La Esperanza R, Mollar Fernandez A, San -\nchis Fores J, Improve-Hf Investigators, Nu\u00f1ez Vi -\nllota J. sST2 and diuretic efficiency in acute heart \nfailure and concomitant renal dysfunction. Journal \nof Cardiac Failure. 2021 Apr;27(4):427-434. doi: \n10.1016/j.cardfail.2020.10.002. PMID: 33038531\n713. Vila-Candel R, Faus Garcia M, Martin Moreno JM. \nStandard international recommendations for ges -\ntational weight gain: suitability for our population. \nNutricion Hospitalaria. 2021 Apr 19;38(2):306-\n314. doi: 10.20960/nh.03340. PMID: 33371702\n714. Alvarino C, Bagan L, Murillo-Cortes J, Calvo J, \nBagan J. Stimulated whole salivary flow rate: the \nmost appropriate technique for assessing salivary \nflow in Sj\u00f6gren syndrome. Medicina Oral Patologia \nOral y Cirugia Bucal. 2021 May 1;26(3):e404-e407 . \ndoi: 10.4317 /medoral.24736. PMID: 33772564\n715. Martin. Garcia A, Mitroi C, Mazon Ramos P, Garcia \nSanz R, Virizuela J, Arenas M, Egocheaga Cabello \nI, Albert D, Anguita Sanchez M, Arrarte Esteban \nV, Ayala de la Pena F, Bonanand Lozano C, Castro \nA, Castro Fernandez A, Cordoba R, Cosin-Sales J, \nChaparro-Munoz M, Dalmau R, Drak Hernandez \nY, Deiros Bronte L, Diez-Villanueva P, Escobar Cer -\nvantes C, Fernandez Redondo C, Garcia Rodriguez \nE, Lozano T, Marco Vera P, Martinez Monzonis A, \nMesa D, Oristrell G, Palma Gamiz J, Pedreira M, \nReinoso-Barbero L, Rodriguez I, Serrano Antolin \nJ, Toral B, Torres Royo L, Velasco Del Castillo S, \nVicente-Herrero T, Zatarain-Nicolas E, Tamargo J, \nLopez Fernandez T. Stratification and management \nof cardiovascular risk in cancer patients. A consen -705.  Bhatt D, Szarek M, Pitt B, Cannon C, Leiter L, Mc -\nGuire D, Lewis J, Riddle M, Inzucchi S, Kosiborod \nM, Cherney D, Dwyer J, Scirica B, Bailey C, Diaz R, \nRay K, Udell J, Lopes R, Lapuerta P, Steg P, SCO -\nRED Investigators. Sotagliflozin in patients with \ndiabetes and chronic kidney disease. New England \nJournal of Medicine. 2021 Jan 14;384(2):129-139. \ndoi: 10.1056/NEJMoa2030186. PMID: 33200891\n706.  Bhatt D, Szarek M, Steg P, Cannon C, Leiter L, \nMcGuire D, Lewis J, Riddle M, Voors A, Metra \nM, Lund L, Komajda M, Testani J, Wilcox C, Po -\nnikowski P, Lopes R, Verma S, Lapuerta P, Pitt \nB, SOLOIST-WHF Trial Investigators. Sotagliflozin \nin patients with diabetes and recent worsening \nheart failure. New England Journal of Medicine. \n2021 Jan 14;384(2):1 17-128. doi: 10. 1056/NEJ -\nMoa2030183. PMID: 33200892\n70 7. Cebrian-Cuenca A, Mira J, Caride-Miana E, Fer -\nnandez-Jimenez A, Orozco-Beltran D. Sources \nof psychological distress among primary care \nphysicians during the COVID-19 pandemic\u2019s first \nwave in Spain: a cross-sectional study. Primary \nHealth Care Research & Development. 2021 Oct \n18;22:e55. doi: 10.1017/S1463423621000566. \nPMID: 34658322\n708.  Ramia J, de Vicente E, Pardo F, Sabater Orti L, Lo -\npez-Ben S, Quijano Y, Villegas T, Blanco-Fernandez \nG, Diez-Valladares L, Lopez-Rojo I, Martin-Perez E, \nPereira F, Gonzalez A, Herrera J, Garcia-Domingo \nM, Serradilla M. Spanish multicenter study of sur -\ngical resection of pancreatic tumors infiltrating \nthe celiac axis: does the type of pancreatectomy \naffect results?. Clinical & Translational Oncology. \n2021 Feb;23(2):318-324. doi: 10.1007 /s12094-\n020-02423-6. PMID: 32592157\n709.  Cilleruelo Ramos A, Figueroa Almanzar S, Lopez \nCastro R, Martinez Hernandez N, Mezquita Perez \nL, Moreno Casado P, Zabaleta Jimenez J. Long-\nterm follow-up for operated patients with lung can -\ncer. Spanish Society of Thoracic Surgery (SECT) \nconsensus document. Cirugia Espanola. 2021 \nSep 11:S0009-739X(21)00250-5. doi: 10. 1016/j.\nciresp.2021.08.003. PMID: 34521509\n710. Garrido N, Cruz F, Egea R, Simon C, Sadler-Riggle -\nman I, Beck D, Nilsson E, Ben Maamar M, Skinner \nM. Sperm DNA methylation epimutation biomar -346\n346\nINCLIVA SCIENTIFIC REPORT 2021publication list9Clinical Medicine. 2021 Nov 18;10(22):5374. doi: \n10.3390/jcm10225374. PMID: 34830656\n721. Fletcher-Sanfeliu D, Garcia-Granero A, Dome -\nnech Dolz A, Pellino G, Orbis F, Arroyo A, Valver -\nde-Navarro A, Orti L, Martin-Gonzalez I. Surgical \nanatomy applied to transperitoneal approaches \nof the abdominal aorta and visceral trunks. \nDynamic article. Cirugia Espanola. 2021 Feb \n2;S0009-739X(20)30425-5. doi: 10. 1016/j.ci -\nresp.2020.12.016. PMID: 33546883\n722.  Garcia-Gausi M, Garcia-Armengol J, Fernan -\ndez C, Pellino G, Roig J, Garcia-Granero A, Pla-\nMarti V, Martinez-Soriano F. Surgical anatomy \nof the rectovaginal space: does a standalone \nrectovaginal septum or denonvilliers fascia \nexist in women?. Diseases of the Colon & Rec -\ntum. 2021 May;64(5):576-582. doi: 10. 1097 /\nDCR.0000000000001912. PMID: 33939388\n723.  Mart\u00ed Fernandez R, Garces Albir M, Ballester \nFerre M, Dorcaratto D, Villagrasa Manzano R, \nMu\u00f1oz Forner E, G\u00f3mez Adri\u00e1n J, Sanchiz So -\nler V, Sabater Orti L, Ortega Serrano J. Surgi -\ncal treatment of an intraductal papillary muci -\nnous neoplasm of the biliary tract diagnosed by \nSpyGlass\u00ae. Revista Espanola de Enfermedades \nDigestivas. 2021 Jan;1 13(1):45-47 . doi: 10. 17235/\nreed.2020.7122/2020. PMID: 33054282\n724.  Lorenzo-Hernandez M, Marcos-Garces V, Lopez-\nFornas F, Valero E, Bodi V, Chorro F. Suspected \nKawasaki disease diagnosed in the adulthood. \nSevere sequelae in the coronary arteries. Coro -\nnary Artery Disease. 2021 Dec 1;32(8):741-743. \ndoi: 10. 1097 /MCA.0000000000001029. PMID: \n33587361\n725.  Garcia A, Vila L, Marin P, Bernabeu A, Villarroel-\nVicente C, Hennuyer N, Staels B, Franck X, Fi -\ngadere B, Cabedo N, Cortes D. Synthesis of \n2-prenylated alkoxylated benzopyrans by hor -\nner- wadsworth-emmons olefination with PPAR \nalpha/gamma agonist activity. ACS Medicinal \nChemistry Letters. 2021 Oct 6;12(1 1):1783-\n1786. doi: 10. 1021/acsmedchemlett. 1c00400. \nPMID: 34795868\n726.  Fernandez-Ruiz M, Olea B, Almendro-Vazquez P, \nGimenez E, Marcacuzco A, San Juan R, Justo I, sus document of the SEC, FEC, SEOM, SEOR, SEHH, \nSEMG, AEEMT, AEEC, and AECC. Revista Espa\u00f1ola de \nCardiolog\u00eda (English ed.). 2021 May;74(5):438-448. \ndoi: 10.1016/j.rec.2020.11.020. PMID: 33712348\n716. Villar J, Gonzalez-Martin JM, Ambros A, Mosteiro \nF, Martinez D, Fernandez L, Soler JA, Parra L, So -\nlano R, Soro M, Del Campo R, Gonzalez-Luengo RI, \nCivantos B, Montiel R, Pita-Garcia L, Vidal A, Anon \nJM, Ferrando C, Diaz-Dominguez FJ, Mora-Ordonez \nJM, Fernandez MM, Fernandez C, Fernandez RL, \nRodriguez-Suarez P, Steyerberg EW, Kacmarek \nRM. Stratification for Identification of Prognos -\ntic Categories In the Acute RESpiratory Distress \nSyndrome (SPIRES) Score. Critical Care Medici -\nne. 2021 Oct 1;49(10):e920-e930. doi: 10. 1097 /\nCCM.0000000000005142. PMID: 34259448\n717. Garcia-Ros R, Ruescas-Nicolau M, Cezon-Serrano \nN, Carrasco J, Perez-Alenda S, Sastre-Arbona C, \nSan Martin-Valenzuela C, Flor-Rufino C, Sanchez-\nSanchez M. Students\u2019 perceptions of instructional \nrubrics in neurological physical therapy and their \neffects on students\u2019 engagement and course satis -\nfaction. International Journal of Environmental Re -\nsearch and Public Health. 2021 May 6;18(9):4957 . \ndoi: 10.3390/ijerph18094957 . PMID: 34066623\n718. Valdivia A, Torres I, Latorre V, Frances-Gomez \nC, Ferrer J, Forque L, Costa R, de la Asuncion C, \nHuntley D, Gozalbo-Rovira R, Buesa J, Gimenez E, \nRodriguez-Diaz J, Geller R, Navarro D. Suitability \nof two rapid lateral flow immunochromatographic \nassays for predicting SARS-CoV-2 neutralizing ac -\ntivity of Sera. Journal of Medical Virology. 2021 \nApr;93(4):2301-2306. doi: 10.1002/jmv.26697 . \nPMID: 33236799\n719. Zormpas Petridis K, Noguera R, Ivankovic D, Kola -\nrevic R, Jamin Y, Yuan Y. SuperHistopath: a deep \nlearning pipeline for mapping tumor heterogenei -\nty on low-resolution whole-slide digital histopatho -\nlogy images. Frontiers in Oncology. 2021 Jan \n20;10:586292. doi: 10.3389/fonc.2020.586292. \nPMID: 33552964\n720.  Dabrowski W, Siwicka-Gieroba D, Schlegel TT, Rob -\nba C, Zaid S, Bielacz M, Jaroszynski A, Badenes R. \nSuppression of electrographic seizures is associa -\nted with amelioration of QTc interval prolongation \nin patients with traumatic brain injury. Journal of 347\n347\nINCLIVA SCIENTIFIC REPORT 2021publication list 9poral trends in postinfarction ventricular septal \nrupture: the CIVIAM Registry. Revista Espanola de \nCardiologia (English ed.). 2021 Sep;74(9):757-764. \ndoi: 10.1016/j.rec.2020.07 .010. PMID: 32883644\n732.  Torres-Gaya J, Bosca-Ramon A, Marques-Mateo \nM, Valverde-Navarro A, Garcia-San Segundo M, \nPuche-Torres M. Temporomandibular joint arthro -\ncentesis guided by ultrasonography: an anatomi -\ncal study. Journal of Stomatology, Oral and Maxi -\nllofacial Surgery. 2021 Sep;122(4):e27-e31. doi: \n10.1016/j.jormas.2021.03.002. PMID: 33706027\n733.  Martinez MT, Monton-Bueno J, Simon S, Orte -\nga B, Moragon S, Rosello S, Insa A, Navarro J, \nSanmartin A, Julve A, Buch E, Pena A, Franco J, \nMartinez-Jabaloyas J, Marco J, Forner MJ, Cano \nA, Silvestre A, Teruel A, Lluch A, Cervantes A, Chiri -\nvella Gonzalez I. Ten-year assessment of a cancer \nfast-track programme to connect primary care \nwith oncology: reducing time from initial symp -\ntoms to diagnosis and treatment initiation. ESMO \nOpen. 2021 May 1 1;6(3):100148. doi: 10. 1016/j.\nesmoop.2021.100148. PMID: 33989988\n734.  Hervas I, Valls L, Rivera-Egea R, Gil JM, Navarro-Go -\nmezlechon A, Garrido N, Martinez-Jabaloyas JM. \nTESE-ICSI outcomes per couple in vasectomized \nmales are negatively affected by time since the \nintervention, but not other comorbidities. Repro -\nductive Biomedicine Online. 2021 Oct;43(4):708-\n717 . doi: 10. 1016/j.rbmo.2021.05.013. PMID: \n34391685\n735.  Iannantuoni F, Salazar J, Martinez de Maranon \nA, Banuls C, Lopez-Domenech S, Rocha M, Hur -\ntado-Murillo F, Morillas C, Gomez-Balaguer M, \nVictor V. Testosterone administration increases \nleukocyte-endothelium interactions and inflam -\nmation in transgender men. Fertility and Sterility. \n2021 Feb;1 15(2):483-489. doi: 10. 1016/j.fertns -\ntert.2020.08.002. PMID: 33032814\n736.  Gonzalez-Cano R, Ruiz-Cantero M, Santos-Caballe -\nro M, Gomez-Navas C, Tejada M, Nieto F. Tetrodo -\ntoxin, a potential drug for neuropathic and cancer \npain relief?. Toxins. 2021 Jul 12;13(7):483. doi: \n10.3390/toxins13070483. PMID: 34357955\n737. Mazzinari G, Neto A, Hemmes S, Hedenstierna G, \nJaber S, Hiesmayr M, Hollmann M, Mills G, Melo Calvo-Pulido J, Garcia-Sesma A, Manrique A, Caso \nO, Cambra F, Talayero P, Lopez-Medrano F, Remi -\ngia MJ, Ruiz-Merlo T, Parra P, Paz-Artal E, Jimenez \nC, Loinaz C, Navarro D, Laguna-Goya R, Aguado \nJM. T cell-mediated response to SARS-CoV-2 in \nliver transplant recipients with prior COVID-19. \nAmerican Journal of Transplantation. 2021 \nAu g;21(8):2785 -2794.  d o i:  10.1111/a j t .16708.  \nPMID: 34092033\n727. Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, \nCristobal I, de la Fuente L, Minguez P, Eroles P, Rovi -\nra A, Albanell J, Madoz-Gurpide J, Rojo F. Targeted \ntherapy modulates the secretome of cancer-asso -\nciated fibroblasts to induce resistance in HER2-\npositive breast cancer. International Journal of \nMolecular Sciences. 2021 Dec 10;22(24):13297 . \ndoi: 10.3390/ijms222413297. PMID: 34948097\n728.  Duro-Castano A, Borras C, Herranz-Perez V, Blan -\nco-Gandia M, Conejos-Sanchez I, Arminan A, Mas-\nBargues C, Ingles M, Minarro J, Rodriguez-Arias \nM, Garcia-Verdugo J, Vina J, Vicent M. Targeting \nAlzheimer\u2019s disease with multimodal polypeptide-\nbased nanoconjugates. Science Advances. 2021 \nMar 26;7(13):eabf9180. doi: 10. 1 126/sciadv.\nabf9180. PMID: 33771874\n729.  Diez-Villanueva P, Bonanad C, Ariza-Sole A, Mar -\ntinez-Selles M. Telematic cardiology consultation \nin the elderly. The 5M framework can help. Revis -\nta Espanola de Cardiologia. 2021 Jan;74(1):1 16-\n117 . doi: 10.1016/j.recesp.2020.08.024. PMID: \n32994661\n730.  Sakr Y, Francois B, Sole-Violan J, Kotfis K, Jasch -\ninski U, Estella A, Leone M, Jakob S, Wittebole X, \nFontes L, Gurgel M, Midega T, Vincent J, Ranieri V, \nSOAP ICON Investigators. Temporal changes in the \nepidemiology, management, and outcome from \nacute respiratory distress syndrome in European \nintensive care units: a comparison of two large \ncohorts. Critical Care. 2021 Feb 25;25(1):87 . doi: \n10.1186/s13054-020-03455-8. PMID: 33632247\n731. Sanchez Vega J, Alonso Salinas G, Vieitez Florez J, \nAriza Sole A, Lopez de Sa E, Sanz Ruiz R, Burgos \nPalacios V, Raposeiras-Roubin S, Gomez Varela S, \nSanchis Fores J, Silva Melchor L, Martinez-Seara \nX, Malagon Lopez L, Zamorano Gomez J, Sanmar -\ntin Fernandez M, CIVIAM Study Investigators. Tem -348\n348\nINCLIVA SCIENTIFIC REPORT 2021publication list9742. Acevedo-Leon D, Monzo-Beltran L, Gomez-Abril S, \nEstan-Capell N, Camarasa-Lillo N, Perez-Ebri M, \nEscandon-Alvarez J, Alonso-Iglesias E, Santaola -\nria-Ayora M, Carbonell-Moncho A, Ventura-Gayete \nJ, Pla L, Martinez-Bisbal M, Martinez-Manez R, \nBagan-Debon L, Vina-Almunia A, Martinez-Santa -\nmaria M, Ruiz-Luque M, Alonso-Fernandez J, Ba -\nnuls C, Saez G. The Effectiveness of glutathione \nredox status as a possible tumor marker in colo -\nrectal cancer. International Journal of Molecular \nSciences. 2021 Jun 8;22(12):6183. doi: 10.3390/\nijms22126183. PMID: 34201191\n743.  Godoy D, Rovegno M, Lazaridis C, Badenes Qui -\nles R. The effects of arterial CO2 on the injured \nbrain: two faces of the same coin. Journal of Cri -\ntical Care. 2021 Feb;61:207-215. doi: 10. 1016/j.\njcrc.2020.10.028. PMID: 33186827\n744.  Torres A, Motos A, Riera J, Fernandez-Barat L, \nCeccato A, Perez-Arnal R, Garcia-Gasulla D, Pe -\nnuelas O, Lorente J, Rodriguez A, de Gonzalo-Cal -\nvol D, Almansa R, Gabarrus A, Menendez R, Ber -\nmejo-Martin J, Ferrer R, Villar R, Anon J, Barbera \nC, Barberan J, Ortiz A, Bustamante-Munguira E, \nCaballero J, Carbajales C, Carbonell N, Catalan-\nGonzalez M, Galban C, Gumucio-Sanguino V, de la \nTorre M, Diaz E, Estella A, Gallego E, Garmendia \nJ, Garnacho-Montero J, Gomez J, Huerta A, Gar -\ncia R, Loza-Vazquez A, Marin-Corral J, de la Gan -\ndara A, Varela I, Messa J, Albaiceta G, Novo M, \nPenasco Y, Pozo-Laderas J, Ricart P, Salvador-Ade \nI, Sanchez-Miralles A, chinesta S, Socias L, Sole-\nViolan J, Sipmann F, Lomas L, Trenado J, Barbe F, \nCIBERESUCICOVID Project Cov20 001 1, ISCIII. The \nevolution of the ventilatory ratio is a prognostic \nfactor in mechanically ventilated COVID-19 ARDS \npatients. Critical Care. 2021 Sep 13;25(1):331. doi: \n10.1186/s13054-021-03727-x. PMID: 34517881\n745. de Toro J, Cea-Calvo L, Garc\u00eda-Vivar ML, Pantoja \nL, Ler\u00edn-Lozano C, Garc\u00eda-D\u00edaz S, Galindo MJ, Ma -\nr\u00edn-Jim\u00e9nez I, Fern\u00e1ndez S, Mestre Y, Orozco-Bel -\ntr\u00e1n D. The experience with health care of patients \nwith inflammatory arthritis: a cross-sectional sur -\nvey using the instrument to evaluate the experien -\nce of patients with chronic diseases. Journal of \nClinical Rheumatology. 2021 Jan 1;27(1):25-30. \ndoi: 10. 1097 /RHU.0000000000001155. PMID: \n31356399M, Pearse R, Putensen C, Schmid W, Severgnini P, \nWrigge H, Cambronero O, Ball L, de Abreu M, Pe -\nlosi P, Schultz M, LAS VEGAS Study-Iinvestigators, \nPROtective VEntilation Network, European Soc \nAnaesthesiology. The Association of Intraoperati -\nve driving pressure with postoperative pulmonary \ncomplications in open versus closed abdominal \nsurgery patients - a posthoc propensity score-\nweighted cohort analysis of the LAS VEGAS study. \nBMC Anesthesiology. 2021 Mar 19;21(1):84. doi: \n10.1186/s12871-021-01268-y. PMID: 33740885\n738.  Gomez-Rubio P, Trapero Gimeno I. The beneficial \neffect of physical exercise on inflammatory makers \nin older individuals. Endocrine Metabolic & Immune \nDisorders-Drug Targets. 2021;21(6):1008-1016. \ndoi: 10.2174/1871530320666200606225357 . \nPMID: 32504508\n739.  Quattrone D, Reininghaus U, Richards A, Tripoli G, \nFerraro L, Quattrone A, Marino P, Rodriguez V, Spi -\nnazzola E, Gayer-Anderson C, Jongsma H, Jones P, \nLa Cascia C, La Barbera D, Tarricone I, Bonora E, \nTosato S, Lasalvia A, Szoke A, Arango C, Bernardo \nM, Bobes J, Del Ben C, Menezes P, Llorca P, San -\ntos J, Sanjuan J, Arrojo M, Tortelli A, Velthorst E, \nBerendsen S, de Haan L, Rutten B, Lynskey M, Fre -\neman T, Kirkbride J, Sham P, O\u2019Donovan M, Cardno \nA, Vassos E, van Os J, Morgan C, Murray R, Lewis \nC, Di Forti M, EU-GEI Collaborators. The continuity \nof effect of schizophrenia polygenic risk score and \npatterns of cannabis use on transdiagnostic symp -\ntom dimensions at first-episode psychosis: findings \nfrom the EU-GEI study. Translational Psychiatry. \n2021 Aug 10;11(1):423. doi: 10.1038/s41398-021-\n01526-0. PMID: 34376640\n740.  Cervantes A. The COVID-19 pandemic could be \na setback for gender equality in oncology-and a \nkey moment to push ahead with transformative \npolicies. ESMO Open. 2021 Jun;6(3):100169. doi: \n10.1016/j.esmoop.2021.100169. PMID: 34144777\n741. Burgess R, Osborne R, Yongabi K, Greenhalgh T, \nGurdasani D, Kang G, Falade A, Odone A, Busse \nR, Martin-Moreno J, Reicher S, McKee M. The \nCOVID-19 vaccines rush: participatory communi -\nty engagement matters more than ever. Lancet. \n2021 Jan 2;397(10268):8-10. doi: 10.1016/S0140-\n6736(20)32642-8. PMID: 33308484349\n349\nINCLIVA SCIENTIFIC REPORT 2021publication list 915;11(1):5940. doi: 10.1038/s41598-021-85490-\n1. PMID: 33723360\n752.  Ayala R, Rapado I, Onecha E, Martinez-Cuadron \nD, Carreno-Tarragona G, Bergua J, Vives S, Alga -\nrra J, Tormo M, Martinez P, Serrano J, Herrera \nP, Ramos F, Salamero O, Lavilla E, Gil C, Lorenzo J, \nVidriales M, Labrador J, Falantes J, Sayas M, Paiva \nB, Barragan E, Prosper F, Sanz M, Martinez-Lopez \nJ, Montesinos P, PETHEMA Cooperative Study Grp. \nThe mutational landscape of acute myeloid leukae -\nmia predicts responses and outcomes in elderly \npatients from the PETHEMA-FLUGAZA phase 3 cli -\nnical trial. Cancers. 2021 May 18;13(10):2458. doi: \n10.3390/cancers13102458. PMID: 34070172\n753.  Sanz-Alvarez M, Martin-Aparicio E, Luque M, Zazo \nS, Martinez-Useros J, Eroles P, Rovira A, Albanell J, \nMadoz-Gurpide J, Rojo F. The novel oral mTORC1/2 \ninhibitor TAK-228 reverses trastuzumab resistan -\nce in HER2-Positive breast cancer models. Can -\ncers. 2021 Jun 3;13(1 1):2778. doi: 10.3390/can -\nc e r s13112778\n754.  Ortega R, Hueso L, Benito E, Ortega J, Civera M, \nSanz M, Real J, Piqueras L. The nuclear retinoid-re -\nlated orphan receptor RORalpha controls adipose \ntissue inflammation in patients with morbid obesi -\nty and diabetes. International Journal of Obesity. \n2021 Jul;45(7):1369-1381. doi: 10.1038/s41366-\n021-00787-5. PMID: 33637954\n755.  Masanas M, Masia N, Suarez-Cabrera L, Olivan M, \nSoriano A, Majem B, Devis-Jauregui L, Burgos-Pa -\nnadero R, Jimenez C, Rodriguez-Sodupe P, Boloix \nA, Toledano I, Guillen G, Navarro A, Llobet-Navas D, \nVillanueva A, Sanchez de Toledo J, Roma J, Nogue -\nra R, Moreno L, Krauss R, Gallego S, Santamaria \nA, Segura M. The oral KIF1 1 inhibitor 4SC-205 ex -\nhibits antitumor activity and potentiates standard \nand targeted therapies in primary and metastatic \nneuroblastoma models. Clinical and Translational \nMedicine. 2021 Oct;11(10):e533. doi: 10.1002/\nctm2.533. PMID: 34709738\n756.  Vila-Merkle H, Gonzalez-Martinez A, Campos-Ji -\nmenez R, Martinez-Ricos J, Teruel-Marti V, Blasco-\nSerra A, Lloret A, Celada P, Cervera-Ferri A. The \noscillatory profile induced by the anxiogenic drug \nFG-7142 in the amygdala-hippocampal network \nis reversed by infralimbic deep brain stimula -746.  Lopez M, Chiner-Oms A, Garcia de Viedma D, et al. \nThe first wave of the COVID-19 epidemic in Spain \nwas associated with early introductions and fast \nspread of a dominating genetic variant. Nature Ge -\nnetics. 2021 Oct;53(10):1405-1414. doi: 10. 1038/\ns41588-021-00936-6. PMID: 34594042\n747. Vezza T, Victor VM.  The HIF1 alpha-PFKFB3 \npathway: a key player in diabetic retinopathy com -\nment. Journal of Clinical Endocrinology & Meta -\nbolism. 2021 Oct 21;106(1 1):e4778-e4780. doi: \n10.1210/clinem/dgab469. PMID: 34171101\n748.  Gallardo V, Alpuente A, Cerda-Company X, Torres-\nFerrus M, Del Rio M, Lainez J, Leira R, Trochet J, \nPozo-Rosich P. The impact of a digital platform \non migraine patient-centered outcome research. \nEvaluation of midolordecabeza.org, a headache we -\nbsite in Spanish. Headache. 2021 Oct;61(9):1403-\n1410. doi: 10. 1 1 1 1/head. 14225. PMID: 34601726\n749.  Pignon B, Lajnef M, Kirkbride JB, Peyre H, Fer -\nchiou A, Richard JR, Baudin G, Tosato S, Jongsma \nH, de Haan L, Tarricone I, Bernardo M, Velthorst \nE, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben \nCM, Di Forti M, Gayer-Anderson C, Jones PB, La \nCascia C, Lasalvia A, Menezes PR, Quattrone D, \nSanjuan J, Selten JP, Tortelli A, Llorca PM, van \nOs J, Rutten BPF, Murray RM, Morgan C, Leboyer \nM, Szoke A, Schurhoff F. The independent effects \nof psychosocial stressors on subclinical psycho -\nsis: findings from the multinational EU-GEI Study. \nSchizophrenia Bulletin. 2021 Oct 21;47(6):1674-\n1684. doi: 10.1093/schbul/sbab060. PMID: \n34009318\n750.  Alfonso-Sanchez JL, Agurto-Ramirez A, Chong-\nValbuena MA, De-Jes\u00fas-Mar\u00eda I, Juli\u00e1n-Paches P, \nL\u00f3pez-Cerrillo L, Piedrahita-Vald\u00e9s H, Gim\u00e9nez-\nAzagra M, Mart\u00edn-Moreno JM. The Influence of in -\nfection and colonization on outcomes in inpatients \nwith covid-19: are we forgetting something?. Fron -\ntiers in Public Health. 2021 Nov 10;9:747791. doi: \n10.3389/fpubh.2021.747791. PMID: 34869165\n751. Nunez J, Nunez E, Revuelta-Lopez E, Minana G, \nBarallat J, Bodi V, Sanchis J, Aimo A, Emdin M, \nLupon J, Husser O, Bayes-Genis A. The influence \nof sex and body mass index on the association \nbetween soluble neprilysin and risk of heart failu -\nre hospitalizations. Scientific Reports. 2021 Mar 350\n350\nINCLIVA SCIENTIFIC REPORT 2021publication list924;13(6):1791. doi: 10.3390/nu13061791. PMID: \n34073981\n761. Bernardo M, Amoretti S, Cuesta MJ, Parellada M, \nMezquida G, Gonzalez Pinto A, Berge D, Lobo A, \nAguilar EJ, Usall J, Corripio I, Bobes J, Rodriguez \nJimenez R, Sarro S, Contreras F, Ibanez A, Gutie -\nrrez M, Mico JA. The prevention of relapses in \nfirst episodes of schizophrenia: the 2EPs Project, \nbackground, rationale and study design. Revista \nde Psiquiatria y Salud Mental. 2021;14(3):164-\n176. doi: 10. 1016/j.rpsmen.2021.08.001. PMID: \n33020032\n762.  Bernardo M, Amoretti S, Cuesta MJ, Parellada M, \nMezquida G, Gonzalez-Pinto A, Berge D, Lobo A, \nAguilar EJ, Usall J, Corripio I, Bobes J, Rodriguez-\nJimenez R, Sarro S, Contreras F, Ibanez A, Gutie -\nrrez M, Mico JA. The prevention of relapses in \nfirst episodes of schizophrenia: the 2EPs Project, \nbackground, rationale and study design. Revista \nde Psiquiatria y Salud Mental. 2021;14(3):164-\n176. doi: 10. 1016/j.rpsmen.2021.08.001. PMID: \n34456031\n763.  Dabrowski W, Siwicka-Gieroba D, Robba C, Bade -\nnes R, Malbrain M. The prone position must ac -\ncommodate changes in IAP in traumatic brain in -\njury patients. Critical Care. 2021 Apr 7;25(1):132. \ndoi: 10. 1 186/s13054-021-03506-8. PMID: \n33827641\n764.  Monzo-Miralles A, Martin-Gonzalez V, Smith-\nBallester S, Iglesias-Miguel V, Cano A. The \nRANKL/RANK system in female reproductive \norgan tumors: a preclinical and clinical over -\nview. Advances in Clinical and Experimental Me -\ndicine. 2021 Sep;30(9):879-883. doi: 10. 17219/\nacem/140422. PMID: 34435475\n765.  Ferraro L, La Cascia C, La Barbera D, Sanchez-\nGutierrez T, Tripoli G, Seminerio F, Sartorio C, Ma -\nrrazzo G, Sideli L, Arango C, Arrojo M, Bernardo \nM, Bobes J, Del-Ben C, Gayer-Anderson C, Jongs -\nma H, Kirkbride J, Lasalvia A, Tosato S, Llorca P, \nMenezes P, Rutten B, Santos J, Sanjuan J, Sel -\nten J, Szoke A, Tarricone I, Muratori R, Tortelli A, \nVelthorst E, Rodriguez V, Quattrone A, Jones P, Van \nOs J, Vassos E, Morgan C, de Haan L, Reininghaus \nU, Cardno A, Di Forti M, Murray R, Quattrone D. \nThe relationship of symptom dimensions with tion: relevance for mood disorders. Biomedicines. \n2021 Jul 6;9(7):783. doi: 10.3390/biomedici -\nnes9070783. PMID: 34356846\n757. Rubio-San-Simon A, Alvaro R, Ribelles A, Heredia A, \nGuerra-Garcia P, Verdu-Amoros J, Andres M, Ca -\nnete A, Rives S, Perez-Martinez A, Mora J, Patino-\nGarcia A, Lassaleta A, Llort A, Ramirez M, Mata \nC, Gallego S, Martin-Broto J, Cruz O, La Madrid A, \nSolano P, Romera I, Fernandez-Teijeiro A, Bautis -\nta F, Moreno L. The paediatric cancer clinical re -\nsearch landscape in Spain: a 13-year multicentre \nexperience of the new agents group of the Spanish \nSociety of Paediatric Haematology and Oncology \n(SEHOP). Clinical & Translational Oncology. 2021 \nDec;23(12):2489-2496. doi: 10.1007 /s12094-021-\n02649-y. PMID: 34076861\n758.  Bayes-Genis A, Januzzi J, Richards A, Arfsten H, de \nBoer R, Emdin M, Gonzalez A, Jaarsma T, Jhund P, \nMueller C, Nunez J, Rossignol P, Milinkovic I, Rosa -\nno G, Coats A, Seferovic P. The \u2018Peptide for Life\u2019 Ini -\ntiative: a call for action to provide equal access to \nthe use of natriuretic peptides in the diagnosis of \nacute heart failure across Europe. European Jour -\nnal of Heart Failure. 2021 Sep;23(9):1432-1436. \ndoi: 10. 1002/ejhf.2293. PMID: 34231321\n759.  Ringborg U, Berns A, Celis JE, Heitor M, Tabernero \nJ, Schuz J, Baumann M, Henrique R, Aapro M, Basu \nP, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van \nden Eede G, Eggermont A, Frohling S, Galbraith S, \nGarralda E, Hanahan D, Hofmarcher T, Jonsson B, \nKallioniemi O, Kasler M, Kondorosi E, Korbel J, La -\ncombe D,  Machado JC, Martin-Moreno JM, Me -\nunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, \nPapatriantafyllou M, Ricciardi W, Roediger A, Ryll \nB, Schilsky R, Scocca G, Seruca R, Soares M, Stein -\ndorf K, Valentini V, Voest E, Weiderpass E, Wilking \nN, Wren A, Zitvogel L. The Porto European Can -\ncer Research Summit 2021. Molecular Oncology. \n2021 Oct;15(10):2507-2543. doi: 10.1002/1878-\n0261.13078. PMID: 34515408\n760.  Flich-Carbonell J, Alegre-Martinez A, Alfonso-\nSanchez JL, Torres-Sanchez MT, Gomez-Abril S, \nMartinez-Martinez MI, Martin-Moreno JM. The po -\ntential link between episodes of diverticulitis or he -\nmorrhoidal proctitis and diets with selected plant \nfoods: a case-control study. Nutrients. 2021 May 351\n351\nINCLIVA SCIENTIFIC REPORT 2021publication list 9771. Carcamo-Calvo R, Munoz C, Buesa J, Rodriguez-\nDiaz J, Gozalbo-Rovira R. The rotavirus vaccine \nlandscape, an update. Pathogens. 2021 Apr \n26;10(5):520. doi: 10.3390/pathogens10050520. \nPMID: 33925924\n772.  Martinez-Lopez J, Mustjoki S, Porkka K, Klisovic R, \nWolf D, Busque L, Hernandez-Boluda J, Swanink \nR, Regueira P, Lipton J. The safety and efficacy \nof dasatinib plus nivolumab in patients with pre -\nviously treated chronic myeloid leukemia: results \nfrom a phase 1b dose-escalation study. Leuke -\nmia & Lymphoma. 2021 Aug;62(8):2040-2043. \ndoi: 10.1080/10428194.2021.1889536. PMID: \n33653205\n773.  Martinez Uribe D, Etxeandia Pradera J, Bobes Gar -\ncia J, Moran-Barrios J, Ruiz De Gauna P, Saenz-He -\nrrero M, Aguilar Garcia Iturrospe E. The training \nof Psychiatry resident: summary of the discussion \ntable held during the XXII National Congress of \nPsychiatry. Spain, 2019. Revista de Psiquiatria y \nSalud Mental. 2021;14(1):74-76. doi: 10. 1016/j.\nrpsm.2020.03.001. PMID: 32389515\n774. Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, \nIm YH, Valeria Bianchi G, Galbardi B, Dugo M, De \nCecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov \nV, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier \nB, Valagussa P, Gianni L, Tagliabue E. The TRAR \ngene classifier to predict response to neoadjuvant \ntherapy in HER2-positive and ER-positive breast \ncancer patients: an explorative analysis from \nthe NeoSphere trial. Molecular Oncology. 2021 \nNov 23. doi: 10. 1002/1878-0261. 13141. PMID: \n34816585\n775.  Robba C, Cardim D, Ball L, Battaglini D, Dabrowski \nW, Bassetti M, Giacobbe D, Czosnyka M, Badenes \nR, Pelosi P, Matta B. The use of different compo -\nnents of brain oxygenation for the assessment \nof cerebral haemodynamics: a prospective ob -\nservational study on COVID-19 patients. Fron -\ntiers in Neurology. 2021 Dec 20;12:735469. doi: \n10.3389/fneur.2021.735469. PMID: 34987461\n776.  Arnaiz J, Rodrigues-Silva C, Mezquida G, Amoretti \nS, Cuesta M, Fraguas D, Lobo A, Gonzalez-Pinto A, \nDiaz-Caneja M, Corripio I, Vieta E, Baeza I, Mane \nA, Garcia-Rizo C, Bioque M, Saiz J, Bernardo M, \nMas S, Balanza Martinez V. The usefulness of premorbid adjustment and cognitive characteris -\ntics at first episode psychosis: findings from the \nEU-GEI study. Schizophrenia Research. 2021 Aug \n14;236:69-79. doi: 10. 1016/j.schres.2021.08.008. \nPMID: 34403965\n766.  Perez Encinas M, Sobas M, Gomez-Casares M, \nAbuin Blanco A, Noya Pereira M, Raya J, Andra -\nde-Campos M, Alvarez Larran A, Lewandowki K, \nLukasz S, Hernandez Boluda J, Ferrer-Marin F, \nFox M, Golos A, Gasior Kabat M, Magro Mazo E, \nCzyz A, Martin Martin A, Bellosillo Paricio B, Quin -\nteiro Garcia C, Gonzalez Martin J, Stuckey R. The \nrisk of thrombosis in essential thrombocythemia \nis associated with the type of CALR mutation: a \nmulticentre collaborative study. European Journal \nof Haematology. 2021 Mar;106(3):371-379. doi: \n10.1111/e j h.13561.  PMID:  33275803\n767. Pe\u00f1a-Gil N, Santiso-Bell\u00f3n C, Gozalbo-Rovira R, \nBuesa J, Monedero V, Rodr\u00edguez-D\u00edaz J. The role \nof host glycobiology and gut microbiota in rotavi -\nrus and norovirus infection, an update. Interna -\ntional Journal of Molecular Sciences. 2021 Dec \n15;22(24):13473. doi: 10.3390/ijms222413473. \nPMID: 34948268\n768.  Badenes R, Bogossian EG, Chisbert V, Robba C, \nOddo M, Taccone FS, Matta BF. The role of non-\ninvasive brain oximetry in adult critically ill patients \nwithout primary brain injury. Minerva Anestesiolo -\ngica. 2021 Nov;87(1 1):1226-1238. doi: 10.23736/\nS0375-9393.21.15333-7 . PMID: 33938677\n769.  Martinez MS, Manzano A, Olivar LC, Nava M, Sa -\nlazar J, D\u2019Marco L, Ortiz R, Chacin M, Guerrero-\nWyss M, Cabrera de Bravo M, Cano C, Bermudez \nV, Angarita L. The role of the alpha Cell in the patho -\ngenesis of diabetes: a world beyond the mirror. In -\nternational Journal of Molecular Sciences. 2021 \nSep 1;22(17):9504. doi: 10.3390/ijms22179504. \nPMID: 34502413\n770.  Martorell-Llobregat C, Gonzalez-Lopez P, Luna E, \nAsensio-Asensio M, Jadraque-Rodriguez R, Garcia-\nMarch G, Moreno-Lopez P. The role of vagus nerve \nstimulation in the treatment of refractory epilep -\nsy: clinical outcomes and impact on quality of life. \nNeurologia. 2021 Jun 1;S2173-5808(21)00073-\n0. doi: 10. 1016/j.nrleng.2019.04.004. PMID: \n34088638352\n352\nINCLIVA SCIENTIFIC REPORT 2021publication list9Garcia JC, Olveira G, Colomo N, Rojo-Martinez G. \nThyroid hormone resistance index and mortality \nin euthyroid subjects: Di@bet.es study. European \nJournal of Endocrinology. 2021 Dec 1;186(1):95-\n103. doi: 10. 1530/EJE-21-0640. PMID: 34735370\n784.  Bellido V, Pines-Corrales, PJ, Villar-Taibo R, \nAmpudia-Blasco FJ. Time-in-range for moni -\ntoring glucose control: Is it time for a chan -\nge?. Diabetes Research and Clinical Practi -\nce. 2021 Jun 1 1;177:108917 . doi: 10. 1016/j.\ndiabr es.2021.108917. PMID: 34126129\n785.  COVIDSurg Collaborative, GlobalSurg Collabo -\nrative. Timing of surgery following SARS-CoV-2 \ninfection: an international prospective cohort \nstudy. Anaesthesia. 2021 Jun;76(6):748-758. doi: \n10.1111/a n a e.15458.  PMID:  33690889\n786.  De Ridder D, Schlee W, Vanneste S, Londero A, \nWeisz N, Kleinjung T, Shekhawat G, Elgoyhen A, \nSong J, Andersson G, Adhia D, de Azevedo A, Ba -\nguley D, Biesinger E, Binetti A, Del Bo L, Cederroth \nC, Cima R, Eggermont J, Figueiredo R, Fuller T, Ga -\nllus S, Gilles A, Hall D, Van de Heyning P, Hoare D, \nKhedr E, Kikidis D, Kleinstaeuber M, Kreuzer P, Lai \nJ, Lainez J, Landgrebe M, Li L, Lim H, Liu T, Lopez-\nEscamez J, Mazurek B, Moller A, Neff P, Pantev C, \nPark S, Piccirillo J, Poeppl T, Rauschecker J, Salvi \nR, Sanchez T, Schecklmann M, Schiller A, Sear -\nchfield G, Tyler R, Vielsmeier V, Vlaeyen J, Zhang J, \nZheng Y, de Nora M, Langguth B. Tinnitus and tin -\nnitus disorder: theoretical and operational defini -\ntions (an international multidisciplinary proposal). \nProgress in Brain Research. 2021;260:1-25. doi: \n10.1016/bs.pbr.2020.12.002. PMID: 33637213\n787. Chaparro M, Garre A, Mesonero F, Rodriguez C, \nBarreiro-de Acosta M, Martinez-Cadilla J, Arroyo \nM, Mancenido N, Sierra-Ausin M, Vera-Mendoza I, \nCasanova M, Nos P, Gonzalez-Munoza C, Martinez \nT, Bosca Watts M, Calafat M, Busquets D, Girona \nE, Llao J, Martin-Arranz M, Piqueras M, Ramos L, \nSuris G, Bermejo F, Carbajo A, Casas-Deza D, Fer -\nnandez-Clotet A, Garcia M, Ginard D, Gutierrez-\nCasbas A, Hernandez L, Lucendo A, Marquez L, \nMerino-Ochoa O, Rancel F, Taxonera C, Lopez San -\nroman A, Rubio S, Domenech E, Gisbert J. Tofaci -\ntinib in ulcerative colitis: real-world evidence from \nthe ENEIDA Registry. Journal of Crohn\u2019s & Colitis. olanzapine plasma concentrations in monitoring \ntreatment efficacy and metabolic disturbances \nin first-episode psychosis. Psychopharmacology. \n2021 Mar;238(3):665-676. doi: 10.1007 /s00213-\n020-05715-5. PMID: 33230696\n777 . Falkner B, Lurbe E. The USPSTF call to inaction on \nblood pressure screening in children and adoles -\ncents. Pediatric Nephrology. 2021 Jun;36(6):1327-\n1329. doi: 10. 1007 /s00467-021-04926-y. PMID: \n33449211\n778.  Ampudia-Blasco F, Palanca A, Trillo J, Navarro \nJ, Real J. Therapeutic inertia in patients with \ntype 2 diabetes treated with non-insulin agents. \nJournal of Diabetes and Its Complications. \n2021 Mar;35(3):107828. doi: 10.1016/j.jdia -\ncomp.2020. 107828. PMID: 33436143\n779.  Martinez-Arroyo O, Ortega A, Redon J, Cortes R. \nTherapeutic potential of extracellular vesicles in \nhypertension-associated kidney disease. Hyperten -\nsion. 2021 Jan;77(1):28-38. doi: 10. 1 161/HYPER -\nTENSIONAHA. 120. 16064. PMID: 33222549\n780.  Aguilar-Ballester M, Hurtado-Genoves G, Taberner-\nCortes A, Herrero-Cervera A, Martinez-Hervas S, \nGonzalez-Navarro H. Therapies for the treatment \nof cardiovascular disease associated with type 2 \ndiabetes and dyslipidemia. International Journal of \nMolecular Sciences. 2021 Jan 1 1;22(2):660. doi: \n10.3390/ijms22020660. PMID: 33440821\n781. Sempere-Rubio N, Aguilar-Rodriguez M, Ingles M, \nIzquierdo-Alventosa R, Serra-Ano P. Thermal ima -\nging ruled out as a supplementary assessment in \npatients with fibromyalgia: a cross-sectional stu -\ndy. PLoS One. 2021 Jun 16;16(6):e0253281. doi: \n10.1371/journal.pone.0253281. PMID: 34133467\n782.  Pons Benavent M, Garc\u00eda V\u00e1zquez A, Guillen Cli -\nment S, Porcar Saura S, Ramon Quiles M. Thy -\nmoma-associated multiorgan autoimmunity with \nprominent muco-cutaneous involvement: two ca -\nses and review of the literature. International Jour -\nnal of Dermatology. 2021 Feb;60(2):e47-e49. doi: \n10.1111/i j d.15199.  PMID:  32989745\n783.  Alonso SP, Valdes S, Maldonado-Araque C, Lago A, \nOcon P, Calle A, Castano L, Delgado E, Menendez \nE, Franch-Nadal J, Gaztambide S, Girbes J, Chaves \nF, Garcia-Serrano S, Garcia-Escobar E, Fernandez-353\n353\nINCLIVA SCIENTIFIC REPORT 2021publication list 9gy. 2021 Feb 19;1-17 . doi: 10. 1 159/000512791. \nPMID:  33611314\n794.  Casanova-Vivas S, Mico-Esparza JL, Garcia-Abad \nI, Hevilla-Cucarella EB, Ballestar-Tarin ML, Blasco \nJM, Garcia-Molina P. Training, management, and \nquality of nursing care of vascular access in adult \npatients: the INCATIV Project. Journal of Vascu -\nlar Access. 2021 Nov 26;1 129729821 1059322. \nd o i:  10.1177/11297298211059322.  PMID:  \n34836468\n795.  Donat-Vargas C, Guerrero-Zotano A, Casas A, \nBaena-Canada J, Lope V, Antolin S, Garcia-Saenz \nJ, Bermejo B, Munoz M, Ramos M, de Juan A, San -\nchez C, Sanchez-Rovira P, Anton A, Brunet J, Gavila \nJ, Salvador J, Arellano E, Bezares S, de Larrea-Baz \nN, Perez-Gomez B, Martin M, Pollan M. Trajecto -\nries of alcohol consumption during life and the \nrisk of developing breast cancer. British Journal of \nCancer. 2021 Oct;125(8):1 168-1 176. doi: 10. 1038/\ns41416-021-01492-w. PMID: 34483338\n796.  Fores-Martos J, Boullosa C, Rodrigo-Dominguez \nD, Sanchez-Valle J, Suay-Garcia B, Climent J, Fal -\nco A, Valencia A, Puig-Butille J, Puig S, Tabares-\nSeisdedos R. Transcriptomic and genetic associa -\ntions between Alzheimer\u2019s disease, Parkinson\u2019s \ndisease, and cancer. Cancers. 2021 Jun \n15;13(12):2990. doi: 10.3390/cancers13122990. \nPMID: 34203763\n797. Correa-Ghisays P, Sanchez-Orti JV, Balanza-\nMartinez V, Selva-Vera G, Vila-Frances J, Magda -\nlena-Benedito R, Victor VM, Escribano-Lopez I, \nHernandez-Mijares A, Vivas-Lalinde J, San-Martin \nC, Crespo-Facorro B, Tabares-Seisdedos R. Trans -\ndiagnostic neurocognitive deficits in patients \nwith type 2 diabetes mellitus, major depressive \ndisorder, bipolar disorder, and schizophrenia: a \n1-year follow-up study. Journal of Affective Disor -\nders. 2021 Dec 26;300:99-108. doi: 10. 1016/j.\njad.2021.12.074. PMID: 34965401\n798.  Ballester M, Lluch P, Gomez C, Capilla M, Tosca J, \nMarti-Aguado D, Guijarro J, Minguez M. Transju -\ngular intrahepatic portosystemic shunt reduces \nhospital care burden in patients with decompen -\nsated cirrosis. Internal and Emergency Medicine. \n2021 Sep;16(6):1519-1527 . doi: 10. 1007 /s1 1739-\n020-02602-x. PMID: 334001602021 Jan 13;15(1):35-42. doi: 10. 1093/ecco-jcc/\njjaa145. PMID: 32969471\n788.  Hirschberg AL, Bitzer J, Cano A, Ceausu I, Che -\ndraui P, Durmusoglu F, Erkkola R, Goulis DG, \nKiesel L, Lopes P, Pines A, van Trotsenburg M, \nLambrinoudaki I, Rees M. Topical estrogens and \nnon-hormonal preparations for postmenopausal \nvulvovaginal atrophy: an EMAS clinical guide. Ma -\nturitas. 2021 Jun;148:55-61. doi: 10. 1016/j.matu -\nritas.2021.04.005. PMID: 33896654\n789.  Saint-Gerons Macias D, Tabares-Seisdedos R. Tor -\nsade de pointes associated with chloroquine, hy -\ndroxychloroquine, and azithromycin: a retrospec -\ntive analysis of individual case safety reports from \nVigiBase. European Journal of Clinical Pharmaco -\nlogy. 2021 Oct;77(10):1513-1521. doi: 10. 1007 /\ns00228-021-03133-w. PMID: 33938974\n790.  Wong B, Green M, Reid J, Martin-Moreno J, Davi -\ndovitch N, Chambaud L, Leighton L, Sheek-Hussein \nM, Dhonkal R, Otok R, Middleton J. Toward \u2018Vac -\ncine Internationalism\u2019: the need for an equitable \nand coordinated global vaccination approach to \neffectively combat COVID-19. International Jour -\nnal of Public Health. 2021 Apr 14;66:1604077 . \ndoi: 10.3389/ijph.2021.1604077 . PMID: \n34335150\n791. Sancho J, Ferrer S, Lahosa C, Posadas T, Bures \nE, Banuls P, Fernandez-Presa L, Royo P, Blasco M, \nSignes-Costa J. Tracheostomy in patients with \nCOVID-19: predictors and clinical features. Euro -\npean Archives of Oto-Rhino-Laryngology. 2021 \nOct;278(10):3911-3919. doi: 10.1007 /s00405-\n020-06555-x. PMID: 33386436\n792.  Global Burden Dis Hlth Financing. Tracking deve -\nlopment assistance for health and for COVID-19: \na review of development assistance, government, \nout-of-pocket, and other private spending on \nhealth for 204 countries and territories, 1990-\n2050. Lancet. 2021 Oct 9;398(10308):1317-\n1343. doi: 10.1016/S0140-6736(21)01258-7. \nPMID: 34562388\n793.  Etxeandia-Pradera J, Martinez-Uribe D, Bellver-\nPradas F, Gonzalez-Piqueras J, Nacher J, Aguilar E. \nTraining psychiatry residents in descriptive psycho -\npathology: a systematic review. Psychopatholo -354\n354\nINCLIVA SCIENTIFIC REPORT 2021publication list9805.  McLornan D, Eikema DJ, Czerw T, Kroger N, Kos -\nter L, Reinhardt HC, Angelucci E, Robin M, Born -\nhauser M, Passweg J, Clark A, Vydra J, Blau IE, \nNiittyvuopio R, Platzbecker U, Cornelissen JJ, \nChevallier P, Srour M, Stamatovic D, Martinez-Lo -\npez  J, de Wreede L, Hayden P, Hernandez-Boluda \nJC, Yakoub-Agha I. Trends in allogeneic haemato -\npoietic cell transplantation for myelofibrosis in Eu -\nrope between 1995 and 2018: a CMWP of EBMT \nretrospective analysis. Bone Marrow Transplan -\ntation. 2021 Sep;56(9):2160-2172. doi: 10. 1038/\ns41409-021-01305-x. PMID: 33911203\nCORRECTION: McLornan D, Hernandez-Boluda J, \nCzerw T, Cross N, Deeg H, Ditschkowski M, Moonim \nM, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden \nP, Yakoub-Agha I. Correction: Allogeneic haematopoie -\ntic cell transplantation for myelofibrosis: proposed \ndefinitions and management strategies for graft fai -\nlure, poor graft function and relapse: best practice \nrecommendations of the EBMT Chronic Malignancies \nWorking Party. Leukemia. 2021 Dec;35(12):3625. doi: \n10.1038/s41375-021-01395-y. PMID: 34471230\n806.  Abraham W, Lindenfeld J, Ponikowski P, Agostoni \nP, Butler J, Desai A, Filippatos G, Gniot J, Fu M, Gu -\nllestad L, Howlett J, Nicholls S, Redon J, Schenken -\nberger I, Silva-Cardoso J, Stork S, Krzysztof Wra -\nnicz J, Savarese G, Brueckmann M, Jamal W, \nNordaby M, Peil B, Ritter I, Ustyugova A, Zeller \nC, Salsali A, Anker S. Underlying heart diseases \nand acute COVID-19 outcomes. European Heart \nJournal. 2021;28(2):202-214. doi: 10.5603/\nCJ.a2020.0183. PMID: 33346365\n8 0 7. Simic G, Tkalcic M, Vukic V, Mulc D, Spanic E, \nSagud M, Olucha-Bordonau F, Vuksic M, Hof P. \nUnderstanding emotions: origins and roles of the \namygdala. Biomolecules. 2021 May 31;1 1(6):823. \ndoi: 10.3390/biom11060823. PMID: 34072960\n808.  Vilella F, Wang W, Moreno I, Quake SR, Simon C. \nUnderstanding the human endometrium in the \n21st century. American Journal of Obstetrics and \nGynecology. 2021 Jul;225(1):1-2. doi: 10. 1016/j.\najog.2021.04.224. PMID: 34023092\n809.  Guillen-Climent S, Garcia-Vazquez A, Martinez-\nCiarpaglini C. Unexpected finding of iIntravascu -\nlar large B-cell lymphoma by a skin biopsy. Me -\ndicina Clinica. 2021 Aug 13;157(3):151-152. doi: \n10.1016/j.medcli.2020.04.051. PMID: 32951879799.  Pla-Marti V, Garcia-Botello S, Perez-Santiago L, \nMartin-Arevalo J, Moro-Valdezate D, Espi-Macias \nA. Transvaginal rectocele repair reinforced with \nbiological mesh - a video vignette. Colorectal Disea -\nse. 2021 Jul;23(7):1938. doi: 10. 1 1 1 1/codi. 15664. \nPMID: 33811798\n800.  Burkhardt B, Taj M, Garnier N, Minard-Colin V, Ha -\nzar V, Mellgren K, Osumi T, Fedorova A, Myakova N, \nVerdu-Amoros J, Andres M, Kabickova E, Attarbas -\nchi A, Chiang A, Bubanska E, Donska S, Hjalgrim L, \nWachowiak J, Pieczonka A, Uyttebroeck A, Lazic J, \nLoeffen J, Buechner J, Niggli F, Csoka M, Krivan G, \nPalma J, Burke G, Beishuizen A, Koeppen K, Mueller \nS, Herbrueggen H, Woessmann W, Zimmermann \nM, Balduzzi A, Pillon M. Treatment and outcome \nanalysis of 639 relapsed non-hodgkin lympho -\nmas in children and adolescents and resulting \ntreatment recommendations. Cancers. 2021 Apr \n25;13(9):2075. doi: 10.3390/cancers13092075. \nPMID: 33923026\n801. Gamon V, Hurtado I, Salazar-Fraile J, Sanfelix-\nGimeno G. Treatment patterns and appropriate -\nness of antipsychotic prescriptions in patients \nwith schizophrenia. Scientific Reports. 2021 \nJun 29;11(1):13509. doi: 10.1038/s41598-021-\n92731-w. PMID: 34188093\n802.  Rodriguez-Bano J, Pachon J, Carratala J, et al. \nTreatment with tocilizumab or corticosteroids for \nCOVID-19 patients with hyperinflammatory state: a \nmulticentre cohort study (SAM-COVID-19). Clinical \nMicrobiology and Infection. 2021 Feb;27(2):244-252. \ndoi: 10.1016/j.cmi.2020.08.010. PMID: 32860964\n803.  Chorro, FJ, Alonso-Arroyo A, Aleixandre-Benavent \nR. Trend in Spanish cardiology research and global \ncomparative analysis of major topics. Revista Es -\npanola de Cardiologia. 2021 Nov;74(1 1):909-918. \ndoi: 10.1016/j.rec.2020.12.001. PMID: 33390334\n804.  Pellino G, Al\u00f3s R, Biondo S, Codina-Cazador A, \nEnr\u00edquez-Navascues J, Esp\u00edn-Basany E, Roig-Vila \nJ, Cervantes Ruiperez A, Carceller R, Spanish \nRectal Cancer Project collaborators. Trends and \noutcome of neoadjuvant treatment for rectal \ncancer: a retrospective  analysis and critical as -\nsessment of a 10-year prospective national regis -\ntry on behalf of the Spanish Rectal Cancer Project. \nEJSO. 2021 Feb;47(2):276-284. doi: 10. 1016/j.\nejso.2020.04.056. PMID: 32950316355\n355\nINCLIVA SCIENTIFIC REPORT 2021publication list 9816. Perez Hernandez J, Mart\u00ednez Arroyo O, Ortega \nGuti\u00e9rrez A, Galera Martos M, Solis Salguero M, \nChaves Mart\u00ednez F, Red\u00f3n Mas J, Forner Giner M, \nCort\u00e9s Vergaz R. Urinary exosomal miR-146a as a \nmarker of albuminuria, activity changes and disea -\nse flares in lupus nephritis. Journal of Nephrology. \n2021 Aug;34(4):1157-1167 . doi: 10.1007 /s40620-\n020-00832-y. PMID: 32803682\n817. Styczynski J, Tridello G, Xhaard A, Medinger M, \nMielke S, Taskinen M, Blijlevens N, Rodriguez M, \nSolano C, Nikolousis E, Biffi A, Groll A, Junghanss C, \nTsirigotis P, Lioure B, Sramek J, Holler E, Galaverna \nF, Fagioli F, Knelange N, Wendel L, Gil L, de la Cama -\nra R, Mikulska M, Ljungman P. Use of letermovir \nin off-label indications: Infectious Diseases Wor -\nking Party of European Society of Blood and Ma -\nrrow Transplantation retrospective study. Bone \nMarrow Transplantation. 2021 May;56(5):1 171-\n1 179. doi: 10. 1038/s41409-020-01 166-w. PMID: \n33288863\n818. Nichols E, Abd-Allah F, Abdoli A, et al. Use of mul -\ntidimensional item response theory methods for \ndementia prevalence prediction: an example using \nthe Health and Retirement Survey and the Aging, \nDemographics, and Memory Study. BMC Medi -\ncal Informatics and Decision Making. 2021 Aug \n11;21(1):241.  d o i:  10.1186/s12911- 021- 01590 - y.  \nPMID: 34380485\n819. Barud M, Dabrowski W, Siwicka-Gieroba D, Robba \nC, Bielacz M, Badenes R. Usefulness of cerebral \noximetry in TBI by NIRS. Journal of Clinical Medi -\ncine. 2021 Jun 30;10(13):2938. doi: 10.3390/\njcm10132938. PMID: 34209017\n820.  Bentham R, Litchfield K, Watkins T, Lim E, Ro -\nsenthal R, Martinez-Ruiz C, Hiley C, Al Bakir M, \nSalgado R, Moore D, Jamal-Hanjani M, Swanton C, \nMcGranahan N, TRACERx Consortium. Using DNA \nsequencing data to quantify T cell fraction and the -\nrapy response. Nature. 2021 Sep;597(7877):555-\n560. doi: 10.1038/s41586-021-03894-5. PMID: \n34497419\n821. Rodriguez-Manero M, Baluja A, Hernandez J, Mu -\nnoz C, Calvo D, Fernandez-Armenta J, Garcia-Fer -\nnandez A, Zorio E, Arce-Leon A, Sanchez-Gomez J, \nMosquera-Perez I, Arias M, Diaz-Infante E, Exposi -\nto V, Jimenez-Ramos V, Teijeira E, Canadas-Godoy \nM, Guerra-Ramos J, Oloriz T, Basterra N, Sousa 810. Alvarez-Larran A, Sant\u2019Antonio E, Harrison C, Kilad -\njian J, Griesshammer M, Mesa R, Ianotto J, Palan -\ndri F, Hernandez-Boluda J, Birgegard G, Nangalia J, \nKoschmieder S, Rumi E, Barbui T. Unmet clinical ne -\neds in the management of CALR-mutated essential \nthrombocythaemia: a consensus-based proposal \nfrom the European LeukemiaNet. Lancet Haema -\ntology. 2021 Sep;8(9):e658-e665. doi: 10. 1016/\nS2352-3026(21)00204-0. PMID: 34450103\n811. Burgos-Panadero R, El Moukhtari SH, Noguera I, \nRodriguez-Nogales C, Martin-Vano S, Vicente-Mu -\nnuera P, Canete A, Navarro S, Blanco-Prieto MJ, \nNoguera R. Unraveling the extracellular matrix-\ntumor cell interactions to aid better targeted the -\nrapies for neuroblastoma. International Journal \nof Pharmaceutics. 2021 Aug 28;608:121058. doi: \n10.1016/j.ijpharm.2021.121058. PMID: 34461172\n812. Rios-Navarro C, de Dios E, Forteza MJ, Bodi V. \nUnraveling the thread of uncontrolled immune \nresponse in COVID-19 and STEMI: an emerging \nneed for knowledge sharing. American Journal \nof Physiology-Heart and Circulatory Physiology. \n2021 Jun 1;320(6):H2240-H2254. doi: 10. 1 152/\najpheart.00934.2020. PMID: 33844596\n813. Vogel A, Martinelli E, ESMO Guidelines Commite. \nUpdated treatment recommendations for he -\npatocellular carcinoma (HCC) from the ESMO \nClinical Practice Guidelines. Annals of Oncolo -\ngy. 2021 Jun;32(6):801-805. doi: 10. 1016/j.an -\nnonc.2021.02.014. PMID: 33716105\n814. Costa R, Bueno F, Albert E, Torres I, Carbonell-Sahu -\nquillo S, Barres-Fernandez A, Sanchez D, Padron C, \nColomina J, Lazaro Carreno M, Breton-Martinez J, \nMartinez-Costa C, Navarro D. Upper respiratory \ntract SARS-CoV-2 RNA loads in symptomatic and \nasymptomatic children and adults. Clinical Micro -\nbiology and Infection. 2021 Dec;27(12):1858.e1-\n1858.e7 . doi: 10. 1016/j.cmi.2021.08.001. PMID: \n34384874\n815. Perez-Hernandez J, Riffo-Campos A, Ortega A, \nMartinez-Arroyo O, Perez-Gil D, Olivares D, Solaz E, \nMartinez F, Martinez-Hervas S, Chaves F, Redon J, \nCortes R. Urinary- and plasma-derived exosomes \nreveal a distinct microRNA signature associated \nwith albuminuria in hypertension. Hypertension. \n2021 Mar 3;77(3):960-971. doi: 10. 1 161/HYPER -\nTENSIONAHA.120.16598. PMID: 33486986356\n356\nINCLIVA SCIENTIFIC REPORT 2021publication list9publication list9\n9;13(12):4413. doi: 10.3390/nu13124413. PMID: \n34959965\n8 27. Garcia-Bustos V, Cabanero-Navalon M, Ruiz-Sauri \nA, Ruiz-Gaitan A, Salavert M, Tormo M, Peman \nJ. What do we know about candida auris? sta -\nte of the art, knowledge gaps, and future direc -\ntions. Microorganisms. 2021 Oct 19;9(10):2177 . \ndoi: 10.3390/microorganisms9102177 . PMID: \n34683498\n828.  Garces-Albir M, Munoz-Forner E, Dorcaratto D, \nSabater L. What does preoperative three-dimen -\nsional image contribute to complex pancreatic \nsurgery?. Cirugia Espanola. 2021 Oct;99(8):602-\n607 . doi: 10. 1016/j.cireng.2021.07 .01 1. PMID: \n34391694\n829.  Castro R. What ingredients are essential \nfor the recipe of a study?. Journal of Inves -\ntigative Surgery. 2021 Jan;34(1):89-90. doi: \n10.1080/08941939.2019.1587114. PMID: \n31514553\n830.  Pico A, Gadea M. When animals cry: the effect of \nadding tears to animal expressions on human jud -\ngment. PLoS One. 2021 May 6;16(5):e0251083. \ndoi: 10. 1371/journal.pone.0251083. PMID: \n33956813\n831. Hernandez-Beeftink T, Guillen-Guio B, Rodriguez-\nPerez H, Marcelino-Rodriguez I, Lorenzo-Salazar \nJ, Corrales A, Prieto-Gonzalez M, Rodriguez-Perez \nA, Carriedo D, Blanco J, Ambros A, Gonzalez-Hi -\ngueras E, Casanova N, Gonzalez-Garay M, Espino -\nsa E, Muriel A, Dominguez D, de Lorenzo A, Anon \nJ, Soro M, Belda J, Garcia J, Villar J, Flores C, Ge -\nnetics Sepsis GEN-SEP Network. Whole-Blood mi -\ntochondrial DNA copies are associated with the \nprognosis of acute respiratory distress syndrome \nafter sepsis. Frontiers in Immunology. 2021 Sep \n7;12:737369. doi: 10.3389/fimmu.2021.737369. \nPMID: 34557198\n832.  Lopez-Gines C, Munoz-Hidalgo L, San-Miguel T, \nMegias J, Trivino J, Calabuig S, Roldan P, Cerda-\nNicolas M, Monleon D. Whole-exome sequencing, \nEGFR amplification and infiltration patterns in hu -\nman glioblastoma. American Journal of Cancer \nResearch. 2021 Nov 15;1 1(1 1):5543-5558. PMID: \n34873478\n833.  NCD Risk Factor Collaboration. Worldwide P, Elices-Teja J, Garcia-Bolao I, Gonzalez-Juanatey \nJ, Brugada R, Gimeno J, Brugada J, Arbelo E. Va -\nlidation of multiparametric approaches for the \nprediction of sudden cardiac death in patients with \nBrugada syndrome and electrophysiological study. \nRevista Espanola de Cardiologia (english Ed.). 2021 \nAug 31:S1885-5857(21)00223-1. doi: 10. 1016/j.\nr e c . 2 0 21. 0 7. 0 0 7.  P M I D :  3 4 479 8 4 5\n822.  Harrois A, Anstey J, van der Jagt M, Taccone F, Udy \nA, Citerio G, Duranteau J, Ichai C, Badenes Quiles \nR, Prowle J, Ercole A, Oddo M, Schneider A, Wolf S, \nHelbok R, Nelson D, Cooper D, Bellomo R, TBI Co -\nllaborative. Variability in serum sodium concentra -\ntion and prognostic significance in severe trauma -\ntic brain injury: a multicenter observational study. \nNeurocritical Care. 2021 Jun;34(3):899-907 . doi: \n10. 1007 /s12028-020-01 1 18-8. PMID: 33009658\n823.  Cano-Marquina AJ, Garcia-Perez MA, Tarin JJ, \nMaceira AM, Cosin-Sales J, Cano A. Variants trans -\nlating reduced expression of the beta estrogen \nreceptor gene were associated with increased \ncarotid intima media thickness: a cross-sectional \nstudy in late postmenopausal women. Medici -\nne. 2021 Jun 1 1;100(23):e26216. doi: 10. 1097 /\nMD.0000000000026216. PMID: 34115005\n824.  D\u2019Andrea M, Mongardi L, Fuschillo D, Musio A, \nCommodaro C, Quilis-Quesada V, Tosatto L. Ver -\nmian subtentorial arteriovenous malformation \nsupplied by the artery of Wollschlaeger and \nWollschlaeger. Clinical Neurology and Neurosur -\ngery. 2021 Jul;206:106670. doi: 10. 1016/j.clineu -\nro.2021.106670. PMID: 34015698\n825.  Ferrer-Suay S, Alonso-Iglesias E, Tortajada-Girbes \nM, Carrasco-Luna J, Codoner-Franch P. Vitamin D \nreceptor gene ApaI and FokI polymorphisms and its \nassociation with inflammation and oxidative stress \nin vitamin D sufficient Caucasian Spanish children. \nTranslational Pediatrics. 2021 Jan;10(1):103-1 1 1. \ndoi: 10.21037 /tp-20-198. PMID: 33633942\n826.  Mangas-Sanchez C, Garriga-Garcia M, Serrano-\nNieto MJ, Garcia-Romero R, Alvarez-Beltran M, \nCrehua-Gaudiza E, Munoz-Codoceo R, Suarez-\nCortina L, Vicente-Santamaria S, Martinez-Costa \nC, Diaz-Martin JJ, Bousono-Garcia C, Gonzalez-\nJimenez D. Vitamin D status in pediatric and \nyoung adult cystic fibrosis patients. Are the new \nrecommendations effective?. Nutrients. 2021 Dec 357\n357\nINCLIVA SCIENTIFIC REPORT 2021publication list 9trends in hypertension prevalence and progress \nin treatment and control from 1990 to 2019: a \npooled analysis of 1201 population-representati -\nve studies with 104 million participants. Lancet. \n2021 Sep 11;398(10304):957-980. doi: 10.1016/\nS0140-6736(21)01330-1. PMID: 34450083\n834.  Asano T, Boisson B, Onodi F, et al. X-linked reces -\nsive TLR7 deficiency in ~1% of men under 60 \nyears old with life-threatening COVID-19. Science \nImmunology. 2021 Aug 19;6(62):eabl4348. doi: \n10. 1126/sciimmunol.abl4348. PMID: 34413140\nCORRECTION: Ferrando C, Suarez-Sipmann F, Mella -\ndo-Artigas R, Hernandez M, Gea A, Arruti E, Aldecoa \nC, Martinez-Palli G, Martinez-Gonzalez M, Slutsky A, \nVillar J, COVID-19 Spanish ICU Network. Correction \nto: Clinical features, ventilatory management, and \noutcome of ARDS caused by COVID-19 are similar to \nother causes of ARDS. Intensive Care Medicine. 2021 \nJan;47(1):144-146. doi: 10. 1007 /s00134-020-06251-\n8. PMID: 33263817\nCORRECTION: Nagore D, Candela A, Burge M, Mone -\ndero P, Tamayo E, Alvarez J, Murie M, Wijeysundera \nDN, Vives M, Vives M, Mendez E, Pasqualetto A, Mon \nT, Pita R, Varela MA, Esteva C, Pereira MA, Sanchez J, \nRodriguez MA, Garcia A, Carmona P, Lopez M, Pajares \nA, Vicente R, Aparicio R, Gragera I, Calderon E, Cande -\nla A, Marcos JM, Gomez L, Rodriguez JM, Matilla A, \nMedina A, Morales L, Santana L, Garcia E, Monedero \nP, Montesinos S, Munoz P, Bravo B, Alvarez J, Blanco V. \nCorrigendum to \u201cCorrigendum to Hydroxyethyl starch \nand acute kidney injury in high-risk patients undergoing \ncardiac surgery: a prospective multicenter study\u201d [J \nClin Anesth 2021 Oct;73:1 10367]. Journal of Clinical \nAnesthesia. 2021 Sep 9;75:1 10436. doi: 10. 1016/j.jcli -\nnane.2021.110436. PMID: 34509966\nCORRECTION: Kayser S, Rahme R, Martinez-Cuadron \nD, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, \nGarrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey \nN, de la Serna J, Salamero O, Lengfelder E, Levis MJ, \nFenaux P, Sanz MA, Platzbecker U, Schlenk RF, Ades \nL, Montesinos P. Outcome of older (>= 70 years) APL \npatients frontline treated with or without arsenic trio -\nxide-an International Collaborative Study (vol 34, pg \n2333, 2020). Leukemia. 2021 Dec;35(12):3631. doi: \n10.1038/s41375-021-01358-3. PMID: 34785795\nCORRECTION: Caceres M, Quesada R, Iglesias M, Real \nF, Villamonte M, de Villarreal J, Perez M, Andaluz A, Moll X, Berjano E, Dorcaratto D, Sanchez-Velazquez P, \nGrande L, Burdio F. Publisher Correction: Pancreatic \nduct ligation reduces premalignant pancreatic lesions \nin a Kras model of pancreatic adenocarcinoma in \nmice. Scientific Reports. 2021 Mar 2;1 1(1):5425. doi: \n10.1038/s41598-021-85032-9. PMID: 33654171SCIENTIFIC REPORT 2021 Fundaci\u00f3n Investigaci\u00f3n Hospital Cl\u00ednico of Valencia INCLIVA Health Research Institute2021\nSCIENTIFIC REPORT\nAvda. Men\u00e9ndez Pelayo, 4 accesorio \u00b7 46010 Valencia (Espa\u00f1a)\nTel. 34 96 197 35 17   Fax 34 96 197 35 40\nwww.incliva. es   incliva@incliva.es\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}